Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Abstract

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Description

RELATED APPLICATIONS

[0001] This application is a continuation application of U.S. patent application Ser. No. 10/162,335, filed on Jun. 3, 2002, which claims priority from Provisional Applications U.S. Ser. No. 60/295,607, filed Jun. 4, 2001; U.S. Ser. No. 60/295,661, filed Jun. 4, 2001; U.S. Ser. No. 60/296,404, filed Jun. 6, 2001; U.S. Ser. No. 60/296,418, filed Jun. 6, 2001; U.S. Ser. No. 60/297,414, filed Jun. 11, 2001; U.S. Ser. No. 60/297,567, filed Jun. 12, 2001; U.S. Ser. No. 60/298,285, filed Jun. 14, 2001; U.S. Ser. No. 60/298,556, filed Jun. 15, 2001; U.S. Ser. No. 60/299,949, filed Jun. 21, 2001; U.S. Ser. No. 60/300,883, filed Jun. 26, 2001; U.S. Ser. No. 60/301,550, filed Jun. 28, 2001; U.S. Ser. No. 60/311,972, filed Aug. 13, 2001; U.S. Ser. No. 60/315,069, filed Aug. 27, 2001; U.S. Ser. No. 60/315,071, filed Aug. 27, 2001; U.S. Ser. No. 60/315,660, filed Aug. 29, 2001; U.S. Ser. No. 60/322,293, filed Sep. 14, 2001; U.S. Ser. No. 60/322,706, filed Sep. 17, 2001; U.S. Ser. No. 60/341,186, filed Dec. 14, 2001; U.S. Ser. No. 60/361,189, filed Feb. 28, 2002; U.S. Ser. No. 60/363,673, filed Mar. 12, 2002, and U.S. Ser. No. 60/363,676, filed Mar. 12, 2002, each of which is incorporated by reference in its entirety.

FIELD OF THE INVENTION

[0002] The present invention relates to novel polypeptides, and the nucleic acids encoding them, having properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.

BACKGROUND OF THE INVENTION

[0003] Eukaryotic cells are characterized by biochemical and physiological processes, which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates or, more particularly, organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways include constituted of extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

[0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, such as two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.

[0005] Signaling processes may elicit a variety of effects on cells and tissues including, by way of nonlimiting example, induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.

[0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest.

SUMMARY OF THE INVENTION

[0007] The invention is based in part upon the discovery of isolated polypeptides including amino acid sequences selected from mature forms of the amino acid sequences selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54. The invention also is based in part upon variants of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes the amino acid sequences selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54. In another embodiment, the invention also comprises variants of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also involves fragments of any of the mature forms of the amino acid sequences selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, or any other amino acid sequence selected from this group. The invention also comprises fragments from these groups in which up to 15% of the residues are changed.

[0008] In another embodiment, the invention encompasses polypeptides that are naturally occurring allelic variants of the sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54. These allelic variants include amino acid sequences that are the translations of nucleic acid sequences differing by a single nucleotide from nucleic acid sequences selected from the group consisting of SEQ ID NOS: 2n-1, wherein n is an integer between 1 and 54. The variant polypeptide where any amino acid changed in the chosen sequence is changed to provide a conservative substitution.

[0009] In another embodiment, the invention comprises a pharmaceutical composition involving a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 and a pharmaceutically acceptable carrier. In another embodiment, the invention involves a kit, including, in one or more containers, this pharmaceutical composition.

[0010] In another embodiment, the invention includes the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease being selected from a pathology associated with a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 wherein said therapeutic is the polypeptide selected from this group.

[0011] In another embodiment, the invention comprises a method for determining the presence or amount of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 in a sample, the method involving providing the sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the polypeptide, thereby determining the presence or amount of polypeptide in the sample.

[0012] In another embodiment, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 in a first mammalian subject, the method involving measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in this sample to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0013] In another embodiment, the invention involves a method of identifying an agent that binds to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, the method including introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. The agent could be a cellular receptor or a downstream effector.

[0014] In another embodiment, the invention involves a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, the method including providing a cell expressing the polypeptide of the invention and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent.

[0015] In another embodiment, the invention involves a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, the method including administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of the invention, wherein the test animal recombinantly expresses the polypeptide of the invention; measuring the activity of the polypeptide in the test animal after administering the test compound; and comparing the activity of the protein in the test animal with the activity of the polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the polypeptide of the invention. The recombinant test animal could express a test protein transgene or express the transgene under the control of a promoter at an increased level relative to a wild-type test animal The promoter may or may not b the native gene promoter of the transgene.

[0016] In another embodiment, the invention involves a method for modulating the activity of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, the method including introducing a cell sample expressing the polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.

[0017] In another embodiment, the invention involves a method of treating or preventing a pathology associated with a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, the method including administering the polypeptide to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent the pathology in the subject. The subject could be human.

[0018] In another embodiment, the invention involves a method of treating a pathological state in a mammal, the method including administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 or a biologically active fragment thereof.

[0019] In another embodiment, the invention involves an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54; a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54; a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 or any variant of the polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and the complement of any of the nucleic acid molecules.

[0020] In another embodiment, the invention comprises an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

[0021] In another embodiment, the invention involves an isolated nucleic acid molecule including a nucleic acid sequence encoding a polypeptide having an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.

[0022] In another embodiment, the invention comprises an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 2n-1, wherein n is an integer between 1 and 54.

[0023] In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54; a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54; and a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

[0024] In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein the nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54, or a complement of the nucleotide sequence.

[0025] In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein the nucleic acid molecule has a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.

[0026] In another embodiment, the invention includes a vector involving the nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54. This vector can have a promoter operably linked to the nucleic acid molecule. This vector can be located within a cell.

[0027] In another embodiment, the invention involves a method for determining the presence or amount of a nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54 in a sample, the method including providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in the sample. The presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type. The cell type can be cancerous.

[0028] In another embodiment, the invention involves a method for determining the presence of or predisposition for a disease associated with altered levels of a nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54 in a first mammalian subject, the method including measuring the amount of the nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0030] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

[0031] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table 1 provides a summary of the NOVX nucleic acids and their encoded polypeptides. TABLE-US-00001 TABLE 1 Sequences and Corresponding SEQ ID Numbers SEQ ID SEQ ID NO NO NOVX Internal (nucleic (amino Assignment Identification acid) acid) Homology Nov1a CG100488-01 1 2 Elastase 2B like homo sapiens Nov1b CG100488-06 3 4 Elastase 2B like homo sapiens Nov1c CG100488-07 5 6 Elastase 2B like homo sapiens Nov1d CG100488-08 7 8 Elastase 2B like homo sapiens Nov1e CG100488-09 9 10 Elastase 2B like homo sapiens Nov1f 198353297 11 12 Elastase 2B like homo sapiens Nov1g 198353301 13 14 Elastase 2B like homo sapiens Nov1h 198353319 15 16 Elastase 2B like homo sapiens Nov1i 198362547 17 18 Elastase 2B like homo sapiens Nov1j 198362642 19 20 Elastase 2B like homo sapiens Nov2a CG100560-01 21 22 Leucine Rich Repeat like homo sapiens Nov2b CG100560-02 23 24 Leucine Rich Repeat like homo sapiens Nov3a CG101012-01 25 26 Gonadotrophin beta-subunit like homo sapiens Nov4a CG101584-01 27 28 odorant binding protein like homo sapiens Nov5a CG101707-01 29 30 Complement C1q Nov6a CG101836-01 31 32 Cathepsin F like homo sapiens Nov6b CG101836-02 33 34 Cathepsin F like homo sapiens Nov7a CG102221-01 35 36 netrin G1 like homo sapiens Nov8a CG102325-01 37 38 Secreted reprolysin Nov9a CG102832-01 39 40 CAC37763 like homo sapiens Nov9b CG102832-02 41 42 Ig domain-containing transmembrane protein like homo sapiens Nov9c 197195425 43 44 Ig domain-containing transmembrane protein like homo sapiens Nov9d 197192431 45 46 Ig domain-containing transmembrane protein like homo sapiens Nov9e 197192437 47 48 Ig domain-containing transmembrane protein like homo sapiens Nov9f 197192443 49 50 Ig domain-containing transmembrane protein like homo sapiens Nov9g 197192448 51 52 Ig domain-containing transmembrane protein like homo sapiens Nov10a CG102942-01 53 54 lipocalin 2 like homo sapiens Nov10b CG102942-03 55 56 Neutrophil Gelatinase- Associated lipocalin like homo sapiens Nov10c 237376776 57 58 Neutrophil Gelatinase- Associated lipocalin like homo sapiens Nov11a CG104016-01 59 60 DENN domain containing protein like homo sapiens Nov11b 197208336 61 62 DENN domain containing protein like homo sapiens Nov11c 197306179 63 64 DENN domain containing protein like homo sapiens Nov11d 219903686 65 66 DENN domain containing protein like homo sapiens Nov11e 219903690 67 68 DENN domain containing protein like homo sapiens Nov12a CG104903-01 69 70 Kininogen Precursor like homo sapiens Nov12b CG104903-02 71 73 Kininogen Precursor like homo sapiens Nov12c CG104903-03 73 74 Kininogen Precursor like homo sapiens Nov12d CG104903-05 75 76 Kininogen Precursor like homo sapiens Nov12e CG104903-06 77 78 Kininogen Precursor like homo sapiens Nov12f CG104903-07 79 80 Kininogen Precursor like homo sapiens Nov12g CG104903-08 81 82 Kininogen Precursor like homo sapiens Nov12h CG104903-09 83 84 Kininogen Precursor like homo sapiens Nov13a CG105982-01 85 86 Serine Protease-CUB Domain Protein like homo sapiens Nov14a CG107614-02 87 88 Hemopexin-like Nov15a CG109445-01 89 90 neuronal leucine-rich repeat protein like homo sapiens Nov16a CG109496-01 91 92 neuronal leucine-rich repeat protein like homo sapiens Nov17a CG109532-01 93 94 Immunoglobulin domains containing protein like homo sapiens Nov17b 207775340 95 96 Immunoglobulin domains containing protein like homo sapiens Nov17c 207775361 97 98 Immunoglobulin domains containing protein like homo sapiens Nov17d 207775365 99 100 Immunoglobulin domains containing protein like homo sapiens Nov18a CG50213-01 101 102 small inducible cytokine subfamily B member 14 (BRAK) Nov18b CG50213-02 103 104 small inducible cytokine subfamily B member 14 (BRAK) Nov18c CG50213-03 105 106 small inducible cytokine subfamily B member 14 (BRAK) Nov19a CG88912-02 107 108 BETA-NEOENDORPHIN- DYNORPHIN PRECURSOR like homo sapiens

[0032] Table 1 indicates homology of NOVX nucleic acids to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table 1 will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table 1.

[0033] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0034] Consistent with other known members of the family of proteins, identified in column 5 of Table 1, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

[0035] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table 1.

[0036] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g. a variety of cancers.

[0037] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

[0038] NOVX Clones

[0039] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0040] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

[0041] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

[0042] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

[0043] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 54; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

[0044] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

[0045] NOVX Nucleic Acids and Polypeptides

[0046] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

[0047] A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide, precursor form, or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (host cell) in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

[0048] The term "probe", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), and 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

[0049] The term "isolated" nucleic acid molecule, as used herein, is a nucleic acid which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, 0.1 kb, or less of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, culture medium, or of chemical precursors or other chemicals.

[0050] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence SEQ ID NOS: 2n-1, wherein n is an integer between 1 and 54, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2.sup.nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993).

[0051] A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0052] As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

[0053] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of A NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, is one that is sufficiently complementary to the nucleotide sequence shown SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, thereby forming a stable duplex.

[0054] As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

[0055] "Fragments" provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.

[0056] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5' direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3' direction of the disclosed sequence.

[0057] "Derivatives" are nucleic acid sequences or amino acid sequences formed from the native compounds either directly, by modification, or by partial substitution. "Analogs" are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound, e.g. they differ from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

[0058] Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins of the invention under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993, and below.

[0059] A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for A NOVX polypeptide of species other than humans, including, but not limited to vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding a human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

[0060] A NOVX polypeptide is encoded by the open reading frame ("ORF") of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

[0061] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises a substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54; or an anti-sense strand nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54; or of a naturally occurring mutant of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54.

[0062] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express A NOVX protein, such as by measuring a level of A NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

[0063] "A polypeptide having a biologically-active portion of A NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, that encodes a polypeptide having A NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.

[0064] NOVX Nucleic Acid and Polypeptide Variants

[0065] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2n, wherein n is an integer between 1 and 54.

[0066] In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding A NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

[0067] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

[0068] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.

[0069] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

[0070] As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5.degree. C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30.degree. C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60.degree. C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

[0071] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6.times.SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65.degree. C., followed by one or more washes in 0.2.times.SSC, 0.01% BSA at 50.degree. C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0072] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6.times.SSC, 5.times. Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55.degree. C., followed by one or more washes in 1.times.SSC, 0.1% SDS at 37.degree. C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

[0073] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5.times.SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40.degree. C., followed by one or more washes in 2.times.SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50.degree. C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.

[0074] Conservative Mutations

[0075] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of the NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ ID NOS:2n, wherein n is an integer between 1 and 54. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well known within the art.

[0076] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40 homologous to the amino acid sequences SEQ ID NOS:2n, wherein n is an integer between 1 and 54. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2n, wherein n is an integer between 1 and 54; more preferably at least about 70% homologous SEQ ID NOS:2n, wherein n is an integer between 1 and 54; still more preferably at least about 80% homologous to SEQ ID NOS:2n, wherein n is an integer between 1 and 54; even more preferably at least about 90% homologous to SEQ ID NOS:2n, wherein n is an integer between 1 and 54; and most preferably at least about 95% homologous to SEQ ID NOS:2n, wherein n is an integer between 1 and 54.

[0077] An isolated nucleic acid molecule encoding A NOVX protein homologous to the protein of SEQ ID NOS:2n, wherein n is an integer between 1 and 54, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

[0078] Mutations can be introduced into SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of A NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

[0079] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.

[0080] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and A NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

[0081] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

[0082] Antisense Nucleic Acids

[0083] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of A NOVX protein of SEQ ID NOS:2n, wherein n is an integer between 1 and 54, or antisense nucleic acids complementary to A NOVX nucleic acid sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, are additionally provided.

[0084] In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding A NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons, which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences, which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

[0085] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

[0086] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, beta-D-mannosylqueosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0087] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding A NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0088] In yet another embodiment, the antisense nucleic acid molecule of the invention is an .alpha.-anomeric nucleic acid molecule. A .alpha.-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual .beta.-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.

[0089] Ribozymes and PNA Moieties

[0090] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

[0091] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of A NOVX cDNA disclosed herein (i.e., SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

[0092] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.

[0093] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.

[0094] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S.sub.1 nucleases (See, Hyrup, et al., 1996 supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).

[0095] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.

[0096] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

[0097] NOVX Polypeptides

[0098] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2n, wherein n is an integer between 1 and 54. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2n, wherein n is an integer between 1 and 54, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

[0099] In general, A NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

[0100] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, A NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

[0101] An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

[0102] The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

[0103] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence shown in SEQ ID NOS:2n, wherein n is an integer between 1 and 54) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of A NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of A NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

[0104] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

[0105] In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2n, wherein n is an integer between 1 and 54. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2n, wherein n is an integer between 1 and 54, and retains the functional activity of the protein of SEQ ID NOS:2n, wherein n is an integer between 1 and 54, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2n, wherein n is an integer between 1 and 54, and retains the functional activity of the NOVX proteins of SEQ ID NOS:2n, wherein n is an integer between 1 and 54.

[0106] Determining Homology Between Two or More Sequences

[0107] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

[0108] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54.

[0109] The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

[0110] Chimeric and Fusion Proteins

[0111] The invention also provides NOVX chimeric or fusion proteins. As used herein, A NOVX "chimeric protein" or "fusion protein" comprises A NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to A NOVX protein SEQ ID NOS:2n, wherein n is an integer between 1 and 54, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within A NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of A NOVX protein. In one embodiment, A NOVX fusion protein comprises at least one biologically active portion of A NOVX protein. In another embodiment, A NOVX fusion protein comprises at least two biologically active portions of A NOVX protein. In yet another embodiment, A NOVX fusion protein comprises at least three biologically active portions of A NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

[0112] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

[0113] In another embodiment, the fusion protein is A NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

[0114] In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between A NOVX ligand and A NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of A NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with A NOVX ligand.

[0115] A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

[0116] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade, which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

[0117] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods, which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11:477.

[0118] Polypeptide Libraries

[0119] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of A NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of A NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S.sub.1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

[0120] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331.

[0121] NOVX Antibodies

[0122] The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F.sub.ab, F.sub.ab, and F.sub.(ab')2 fragments, and an F.sub.ab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG.sub.1, IgG.sub.2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

[0123] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NOs: 2n, wherein n is an integer between 1 and 54, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

[0124] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0125] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

[0126] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.

[0127] Polyclonal Antibodies

[0128] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

[0129] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

[0130] Monoclonal Antibodies

[0131] The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

[0132] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

[0133] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

[0134] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

[0135] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

[0136] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

[0137] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0138] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

[0139] Humanized Antibodies

[0140] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

[0141] Human Antibodies

[0142] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

[0143] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al, (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

[0144] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse.TM. as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

[0145] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

[0146] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

[0147] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

[0148] F.sub.ab Fragments and Single Chain Antibodies

[0149] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F.sub.(ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an F.sub.ab fragment generated by reducing the disulfide bridges of an F.sub.(ab')2 fragment; (iii) an F.sub.ab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F.sub.v fragments.

[0150] Bispecific Antibodies

[0151] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

[0152] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J. 10:3655-3659 (1991).

[0153] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0154] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0155] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab').sub.2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab').sub.2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[0156] Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab').sub.2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

[0157] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V.sub.H) connected to a light-chain variable domain (V.sub.L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V.sub.H and V.sub.L domains of one fragment are forced to pair with the complementary V.sub.L and V.sub.H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

[0158] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

[0159] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc.gamma.R), such as Fc.gamma.RI (CD64), Fc.gamma.RII (CD32) and Fc.gamma.RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

[0160] Heteroconjugate Antibodies

[0161] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.

[0162] Effector Function Engineering

[0163] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design. 3: 219-230 (1989).

[0164] Immunoconjugates

[0165] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

[0166] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include .sup.212Bi, .sup.131I, .sup.131In, .sup.90Y, and .sup.186Re.

[0167] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

[0168] In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

[0169] Immunoliposomes

[0170] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

[0171] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

[0172] Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).

[0173] An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, .beta.-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include .sup.125I, .sup.131I, .sup.35S or .sup.3H.

[0174] Antibody Therapeutics

[0175] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

[0176] Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

[0177] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

[0178] Pharmaceutical Compositions of Antibodies

[0179] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

[0180] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0181] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

[0182] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

[0183] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and .gamma. ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT.TM. (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

[0184] ELISA Assay

[0185] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., F.sub.ab or F.sub.(ab)2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and "Practice and Thory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0186] NOVX Recombinant Expression Vectors and Host Cells

[0187] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding A NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0188] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

[0189] The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

[0190] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0191] Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

[0192] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

[0193] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0194] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kuijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

[0195] Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0196] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufinan, et al., 1987. EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0197] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the .alpha.-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

[0198] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., "Antisense RNA as a molecular tool for genetic analysis," Reviews-Trends in Genetics, Vol. 1(1) 1986.

[0199] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0200] A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0201] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

[0202] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0203] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

[0204] Transgenic NOVX Animals

[0205] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0206] A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

[0207] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of A NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).

[0208] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992. Cell 69:915.

[0209] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

[0210] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0211] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmnut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G.sub.0 phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

[0212] Pharmaceutical Compositions

[0213] The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0214] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0215] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL.TM.(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0216] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., A NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0217] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0218] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0219] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0220] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0221] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0222] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0223] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

[0224] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0225] Screening and Detection Methods

[0226] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in A NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease(possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

[0227] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

[0228] Screening Assays

[0229] The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

[0230] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of A NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

[0231] A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

[0232] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

[0233] Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1-991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).

[0234] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to A NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with .sup.125I, .sup.35S, .sup.14C, or .sup.3H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with A NOVX protein, wherein determining the ability of the test compound to interact with A NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

[0235] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with A NOVX target molecule. As used herein, a "target molecule" is a molecule with which A NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses A NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or A NOVX protein or polypeptide of the invention. In one embodiment, A NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

[0236] Determining the ability of the NOVX protein to bind to or interact with A NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with A NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca.sup.2+, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising A NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

[0237] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting A NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with A NOVX protein, wherein determining the ability of the test compound to interact with A NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

[0238] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to A NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate A NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

[0239] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with A NOVX protein, wherein determining the ability of the test compound to interact with A NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of A NOVX target molecule.

[0240] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton.RTM. X-100, Triton.RTM. X-114, Thesit.RTM., Isotridecypoly(ethylene glycol ether).sub.n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

[0241] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

[0242] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

[0243] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

[0244] In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

[0245] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming A NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

[0246] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

[0247] Detection Assays

[0248] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

[0249] Chromosome Mapping

[0250] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

[0251] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

[0252] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell. hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

[0253] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

[0254] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

[0255] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

[0256] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987. Nature, 325: 783-787.

[0257] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

[0258] Tissue Typing

[0259] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Pat. No. 5,272,057).

[0260] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

[0261] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

[0262] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

[0263] Predictive Medicine

[0264] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in A NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

[0265] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.) Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.

[0266] These and other agents are described in further detail in the following sections.

[0267] Diagnostic Assays

[0268] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 54, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

[0269] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab').sub.2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0270] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0271] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

[0272] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

[0273] Prognostic Assays

[0274] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

[0275] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

[0276] The methods of the invention can also be used to detect genetic lesions in A NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding A NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from A NOVX gene; (ii) an addition of one or more nucleotides to A NOVX gene; (iii) a substitution of one or more nucleotides of A NOVX gene, (iv) a chromosomal rearrangement of A NOVX gene; (v) an alteration in the level of a messenger RNA transcript of A NOVX gene, (vi) aberrant modification of A NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of A NOVX gene, (viii) a non-wild-type level of A NOVX protein, (ix) allelic loss of A NOVX gene, and (x) inappropriate post-translational modification of A NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in A NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0277] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to A NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0278] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Q.beta.Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0279] In an alternative embodiment, mutations in A NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0280] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0281] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

[0282] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S.sub.1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

[0283] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on A NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

[0284] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.

[0285] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

[0286] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0287] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0288] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving A NOVX gene.

[0289] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0290] Pharmacogenomics

[0291] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

[0292] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0293] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome Pregnancy Zone Protein Precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0294] Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with A NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

[0295] Monitoring of Effects During Clinical Trials

[0296] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

[0297] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

[0298] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of A NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.

[0299] Methods of Treatment

[0300] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, and other diseases, disorders and conditions of the like.

[0301] These methods of treatment will be discussed more fully, below.

[0302] Diseases and Disorders

[0303] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

[0304] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

[0305] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

[0306] Prophylactic Methods

[0307] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, A NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

[0308] Therapeutic Methods

[0309] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of A NOVX protein, a peptide, A NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of A NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering A NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

[0310] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

[0311] Determination of the Biological Effect of the Therapeutic

[0312] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

[0313] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

[0314] Prophylactic and Therapeutic Uses of the Compositions of the Invention

[0315] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

[0316] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

[0317] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

[0318] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example A

Polynucleotide And Polypeptide Sequences, And Homology Data

Example 1

[0319] The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A. TABLE-US-00002 TABLE 1A NOV1 Sequence Analysis SEQ ID NO: 1 1239 bp NOV1a, AACCAGGGCCTTATCCAGGGCCACGCTTACAGAACTCCCACGGACACACCATGATTAG CG100488-01 GACCCTGCTGCTGTCCACTTTGGTGGCCCTCAGTTGTGGGGTCTCCACTTACGCGCCT DNA GATATGTCTAGGATGCTTGGAGGTGAAGAAGCGAGGCCCAACAGCTGGCCCTGGCAGG Sequence TGAGTCTGCAGTACAGCTCCAATGGCCAGTGGTACCACACCTGCGGAGGGTCCCTGAT AGCCAACAGCTGGGTCCTGACGGCTGCCCACTGCATCAGCTCCTCCGGGATCTACCGC GTGATGCTGGGCCAGCATAACCTCTACGTTGCAGAGTCCGGCTCGCTGGCCGTCAGTG TCTCTAAGATTGTGGTGCACAAGGACTGGAACTCCGACCAGGTCTCCAAAGGGAACGA CATTGCCCTGCTCAAACTGGCTAACCCCGTCTCCCTCACCGACAAGATCCAGCTGGCC TGCCTCCCTCCTGCCGGCACCATTCTACCCAACAACTACCCCTGCTACGTCACGGGCT GGGGAAGGCTGCAGAGTAACGGGGCTCTCCCTGATGACCTGAAGCAGGGCCAGTTGCT GGTTGTGGACTATGCCACCTGCTCCAGCTCTGGCTGGTGGGGCAGCACCGTGAAGACG AATATGATCTGTGCTGGGGGTGATGGCGTGATATGCACCTGCAACGGAGACTCCGGTG GGCCGCTGAACTGTCAGGCATCTGACGGCCGGTGGGAGGTGCATGGCATCGGCAGCCT CACGTCGGTCCTTGGTTGCAACTACTACTACAAGCCCTCCATCTTCACGCGGGTCTCC AACTACAACGACTGGATCAATTCGGTAAGAACCGGAGCAGCCCTGAGCCCCAAGGCAC TGACCTGCTCACCTGGCCTCGGGAGTGCCATGCCCACCTGGCGACTGAGAACCCCCTC CTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGAGGAGGCTGCAGACCTTGGCAACTG CTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGTGGGTAAAGCTGAGTGAAAAGGAAC ATGAGAGTATGGCCTTGTCCAAAGACGTTGGACACTCCTCAGGTACGTTAAGAGTGAG TTCCACAGGAATGATTTTATTTTTGTGTATTTGTGTGTGGCCCAGACTCTACCATCCA GTGCTATAAATGGGTATATGTCTGCAAAACCCAAAACCTGATACTTTGAGACCCCCAT AGCATTAATTATTGGAAATTA ORF Start: ATG at 51 ORF Stop: TAA at 1167 SEQ ID NO: 2 372 aa MW at 40287.8kD NOV1a, MIRTLLLSTLVALSCGVSTYAPDMSRMLGGEEARPNSWPWQVSLQYSSNGQWYRTCGG CG100488-01 SLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSK Protein GNDIALLKLANFVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQSNGALPDDLKQG Sequence QLLVVDYATCSSSGWWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGI GSLTSVLGCNYYYKPSIFTRVSNYNDWINSVRTGAALSPKALTCSPGLGSAMPTWRLR TPSFLLRARWEPLGGGCRPWQLLSPPWVPKISVWVKLSEKEHESMALSKDVGHSSGTL RVSSTGMILFLCICVWPRLYHPVL SEQ ID NO: 3 1188 bp NOV1b, ATGATTAGGACCCTGCTGCTGTCCACTTTGGTGGCTGGAGCCCTCAGTTGTGGGGTCT CG100488-06 CCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGAGGCCCAACAG DNA CTGGCCCTGGCAGGTGAGTCTGCAGTACAGCTCCAATGGCCAGTGGTACCACACCTGC Sequence GGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGCATCAGCTCCT CCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAGAGTCCGGCTC GCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTCCGACCAGGTC TCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCCCTCACCGACA AGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACAACTAGCCCTG CTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGATGACCTGAAG CAGGGCCAGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGCTGGTGGGGCA GCACCGTGAAGACGAATATGATCTGTGCTGGGGGTAATGGCGTGATATGCACCTGCAA CGGAGACTCTGGCGGGCCACTGAACTGTCAGGCGTCTGACGGCCGGTGGCAGGTGCAC GGCATCGTCAGCTTCGGGTCTCGCCTCGGCTGCAACTACTACCACAAGCCCTCCGTCT TCACGCGGGTCTCCAATTACATCGACTGGATCAATTCGGTAAGAACCGGACCAGCCTT GAGCCCCAAGGCACTACCCTGCTCACCTGGCCTCGGGAGTGCCATGCCCACCTGGTGA CTGAGAATCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGAGGAGGCTGCA GACCTGAGTAACTGCTGGGCCTGCCATGGGTCCCCCAAATTTCTGTGTGGATAAAGCT GAGTGAAAAGGAACATAGAGGGTGGCCTTGTCCAAAGAGGTTGGACACTCCTCAGGCA TATGAAGAGTGAGTTCCGCTGGGCGCCGTGGCTCATGCCTGTAATCCCAGCTCTTTGG GAGGCCAAGGCGGGCAGATCACGAGGTCAGAAGTTCAAGACCAGCCTGACCAACCTGG CAAAACCCCATGTCTACTAAAAAAATCC ORF Start: ATG at 1 ORF Stop: TGA at 868 SEQ ID NO: 4 289 aa MW at 30820.8kD NOV1b, MIRTLLLSTLVAGALSCGVSTYAPDMSRMLGGEEARPNSWPWQVSLQYSSNGQWYHTC CG100488-06 GGSLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQV Protein SKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGALPDDLK Sequence QGQLLVVDYATCSSSGWWGSTVKTNMICAGGNGVICTCNGDSGGPLNCQASDGRWQVH GIVSFGSRLGCNYYHKPSVFTRVSNYIDWINSVRTGPALSPKALPCSPGLGSAMPTW SEQ ID NO: 5 889 bp NOV1c, ATGATTAGGACCCTGCTGCTGTCCACTTTGGTGGCTGGAGCCCTCAGTTGTGGGGTCT CG100488-07 CCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGAGGCCCAACAG DNA CTGGCCCTGGCAGGTGAGTCTGCAGTACAGCTCCAATGGCCAGTGGTACCACACCTGC Sequence GGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGCATCAGCTCCT CCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAGAGTCCGGCTC GCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTCCGACCAGGTC TCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCCCTCACCGACA AGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACAACTACCCCTG CTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGATGACCTGAAG CAGGGCCAGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGCTGGTGGGGCA GCACCGTGAAGACGAATATGATCTGTGCTGGGGGTAATGGCGTGATATGCACCTGCAA CGGAGACTCTGGCGGGCCACTGAACTGTCAGGCGTCTGACGGCCGGTGGCAGGTGCAC GGCATCGTCAGCTTCGGGTCTCGCCTCGGCTGCAACTACTACCACAAGCCCTCCGTCT TCACGCGGGTCTCCAATTACATCGACTGGATGATTGCAAATAACTAACCAAAAGAAGT CCCTGGGACTGTTTCAGACTTGGAAAGGTCACGGAAGGAAAATAATATAATAAAGTGG CAACTATGCAAAAAAAAAA ORF Start: ATG at 1 ORF Stop: TAA at 799 SEQ ID NO: 6 266 aa MW at 28573.2kD NOV1c, MIRTLLLSTLVAGALSCGVSTYAPDMSRNLGGEEARPNSWPWQVSLQYSSNGQWYHTC CG100488-07 GGSLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQV Protein SKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGALPDDLK Sequence QGQLLVVDYATCSSSGWWGSTVKTNMICAGGNGVICTCNGDSGGPLNCQASDGRWQVH GIVSFGSRLGCNYYHKPSVFTRVSNYIDWMIANN SEQ ID NO: 7 1188 bp NOV1d, ATGATTAGGACCCTGCTGCTGTCCACTTTGGTGGCTGGAGCCCTCAGTTGTGGGGACC CG100488-08 CCACTTACCCACCTTATGTGACTAGGGTGGTTGGCGGTGAAGAAGCGAGGCCCAACAG DNA CTGGCCCTGGCAGGTGAGTCTGCAGTACAGCTCCAATGGCCAGTGGTACCACACCTGC Sequence GGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGCATCAGCTCCT CCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAGAGTCCGGCTC GCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTCCGACCAGGTC TCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCCCTCACCGACA AGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACAACTACCCCTG CTACGTCACGGGCTGGGGAAGGCTGCAGGCCAACGGGGCTCTCCCTGATGACCTGAAG CAGGGCCAGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGCTGGTGGGGCA GCACCGTGAAGACGAATATGATCTGTGCTGGGGGTAATGGCGTGATATGCACCTGCAA CGGAGACTCTGGCGGGCCACTGAACTGTCAGGCGTCTGACGGCCGGTGGCAGGTGCAC GGCATCGTCAGCTTCGGGTCTCGCCTCGGCTGCAACTACTACCACAAGCCCTCCGTCT TCACGCGGGTCTCCAATTACATCGACTGGATCAATTCGGTAAGAACCGGACCAGCCTT GAGCCCCAAGGCACTACCCTGCTCACCTGGCCTCGGGAGTGCCATGCCCACCTGGTGA CTGAGAATCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGAGGAGGCTGCA GACCTGAGTAACTGCTGGGCCTGCCATGGGTCCCCCAAATTTCTGTGTGGATAAAGCT GAGTGAAAAGGAACATAGAGGGTGGCCTTGTCCAAAGAGGTTGGACACTCCTCAGGCA TATGAAGAGTGAGTTCCGCTGGGCGCCGTGGCTCATGCCTGTAATCCCAGCTCTTTGG GAGGCCAAGGCGGGCAGATCACGAGGTCAGAAGTTCAAGACCAGCCTGACCAACCTGG CAAAACCCCATGTCTACTAAAAAAATCC ORF Start: ATG at 1 ORF Stop: TGA at 868 SEQ ID NO: 8 289 aa MW at 30826.8kD NOV1d, MIRTLLLSTLVAGALSCGDPTYPPYVTRVVGGEEARPNSWPWQVSLQYSSNGQWYHTC CG100488-08 GGSLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQV Protein SKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQANGALPDDLK Sequence QGQLLVVDYATCSSSGWWGSTVKTNMICAGGNGVICTCNGDSGGPLNCQASDGRWQVH GIVSFGSRLGCNYYHKFSVFTRVSNYIDWINSVRTGPALSPKALPCSPGLGSANPTW SEQ ID NO: 9 889 bp NOV1e, ATGATTAGGACCCTGCTGCTGTCCACTTTGGTGGCTGGAGCCCTCAGTTGTGGGGACC CG100488-09 CCACTTACCCACCTTATGTGACTAGGGTGGTTGGCGGTGAAGAAGCGAGGCCCAACAG DNA CTGGCCCTGGCAGGTGAGTCTGCAGTACAGCTCCAATGGCCAGTGGTACCACACCTGC Sequence GGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGCATCAGCTCCT CCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAGAGTCCGGCTC GCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTCCGACCAGGTC TCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCCCTCACCGACA AGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACAACTACCCCTG CTACGTCACGGGCTGGGGAAGGCTGCAGGCCAACGGGGCTCTCCCTGATGACCTGAAG CAGGGCCAGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGCTGGTGGGGCA GCACCGTGAAGACGAATATGATCTGTGCTGGGGGTAATGGCGTGATATGCACCTGCAA CGGAGACTCTGGCGGGCCACTGAACTGTCAGGCGTCTGACGGCCGGTGGCAGGTGCAC GGCATCGTCAGCTTCGGGTCTCGCCTCGGCTGCAACTACTACCACAAGCCCTCCGTCT TCACGCGGGTCTCCAATTACATCGACTGGATGATTGCAAATAACTAACCAAAAGAAGT CCCTGGGACTGTTTCAGACTTGGAAAGGTCACGGAAGGAAAATAATATAATAAAGTGG CAACTATGCAAAAAAAAAA ORF Start: ATG at 1 ORF Stop: TAA at 799 SEQ ID NO: 10 1266 aa MW at 28579.2kD NOV1e, MIRTLLLSTLVAGALSCGDFTYPPYVTRVVGGEEARPNSWPWQVSLQYSSNGQWYHTC CG100488-09 GGSLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQV Protein SKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYFCYVTGWGRLQANGALPDDLK Sequence QGQLLVVDYATCSSSGWWGSTVKTNMICAGGNGVICTCNGDSGGFLNCQASDGRWQVH GIVSFGSRLGCNYYHKPSVFTRVSNYIDWMIANN SEQ ID NO: 11 1080 bp NOV1f GGATCCGTCTCCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGA 198353297 GGCCCAACAGCTGGCCCTGGCAGATCTCCCTGCAGTACAGCTCCAATGGCCAGTGGTA DNA CCACACCTGCGGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGC Sequence ATCAGCTCCTCCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAG AGTCCGGCTCGCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTC CGACCAGGTCTCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCC CTCGCCGACAAGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACA ACTACCCCTGCTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGA TGACCTGAAGCAGGGCCGGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGC TGGTGGGGCAGCACCGTGAAGACGAATATGATCTGTGCTGGGGGTGATGGCGTGATAT GCACCTGCAACGGAGACTCCGGTGGGCCGCTGAACTGTCAGGCATCTGACGGCCGGTG GGAGGTGCATGGCATCGGCAGCCTCACGTCGGTCCTTGGTTGCAACTACTACTACAAG CCCTCCATCTTCACGCGGGTCTCCAACTACAACGACTGGATCAATTCGGTAAGAACCG GAGCAGCCCTGAGCCCCAAGGCACTGACCTGCTCACCTGGCCTCGGGAGTGCCATGCC CACCTGGCGACTGAGAACCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGA GGAGGCTGCAGACCTTGGCAACTGCTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGT GGGTAAAGCTGAGTGAAAAGGAACATGAGAGTATGGCCTTGTCCAAAGACGTTGGACA CTCCTCAGGTACGTTAAGAGTGAGTTCCACAGGAATGATTTTATTTTTGTGTATTTGT GTGTGGCCCAGACTCTACCATCCAGTGCTACTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 12 360 aa MW at 39027.2kD NOV1f, GSVSTYAPDMSRNLGGEEARPNSWPWQISLQYSSNGQWYHTCGGSLIANSWVLTAAHC 198353297 ISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSKGNDIALLKLANPVS Protein LADKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGALPDDLKQGRLLVVDYATCSSSG Sequence WWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYK PSIFTRVSNYNDWINSVRTGAALSPKALTCSPGLGSAMPTWRLRTPSFLLRARWEPLG GGCRPWQLLSPFWVPKISVWVKLSEKEHESMALSKDVGHSSGTLRVSSTGMILFLCIC VWPRLYHPVLLE SEQ ID NO: 13 1080 bp NOV1g, GGATCCGTCTCCACTTACGCGCCTGATATGTCTAGGATGCGTGGAGGTGAAGAAGCGA 198353301 GGCCCAACAGCTGGCCCTGGCAGGTCTCCCTGCAGTACAGCTCCAATGGCCAGTGGTA DNA CCACACCTGCGGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGC Sequence ATCAGCTCCTCCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAG AGTCCGGCTCGCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTC CGACCAGGTCTCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCC CTCACCGACAAGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACA ACTACCCCTGCTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGA TGACCTGAAGCAGGGCCGGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGC TGGTGGGGCAGCACCGTGAAGACGAATATGATCTGTGCTGGGGGTGATGGCGTGATAT GCACCTGCAACGGAGACTCCGGTGGGCCGCTGAACTGCCAGGCATCTGACGGCCGGTG GGAGGTGCATGGCATCGGCAGCCTCACGTCGGTCCTTGGTTGCAACTACTACTACAAG CCCTCCATCTTCACGCGGGTCTCCAACTACAACGACTGGATCAATTCGGTAAGAACCG GAGCAGCCCTGAGTCCCAAGGCACTGCCCTGCTCACCTGGCCTCGGGAGTGCCATGCC CACCTGGCGACTGAGAACCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGA GGAGGCTGCAGACCTTGGCAACTGCTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGT GGGTAAAGCTGAGTGAAAAGGAACATGAGAGTATGGCCTTGTCCAAAGACGTTGGACA CTCCTCAGGTATGTTAAGAGTGAGTTCCACAGGAATGATTTTATTTTTGTGTATTTGT GAATGGCCCAGACTCTACCATCCAGTGCTACTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 14 360 aa MW at 39142.3kD NOV1g, GSVSTYAPDMSRMRGGEEARFNSWPWQVSLQYSSNGQWYHTCGGSLIANSWVLTAAHC 198353301 ISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSKGNDIALLKLANPVS Protein LTDKIQLACLPPAGTILFNNYPCYVTGWGRLQTNGALPDDLKQGRLLVVDYATCSSSG Sequence WWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYK PSIFTRVSNYNDWINSVRTGAALSPKALPCSPGLGSANPTWRLRTPSFLLRARWEPLG GGCRPWQLLSPPWVPKISVWVKLSEKEHESMALSKDVGHSSGMLRVSSTGMILFLCIC EWFRLYHPVLLE SEQ ID NO: 15 1080 bp NOV1h, GGATCCGTCTCCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGA 198353319 GGCCCAACAGCTGGCCCTGGCAGGTCTCCCTGCAGTACAGCTCCAATGGCCAGTGGTA DNA CCACACCTGCGGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGC Sequence ATCAGCTCCTCCAGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAG AGTCCGGCTCGCTAGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTC CAACCAGGTCTCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCC CTCACCGACAAGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACA ACTACCCCTGCTACGTCACAGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGA TGACCTGAAGCAGGGCCGGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGC TGGTGGGGCAGCACCGTGAAGACGAATATGATTTGTGCTGGGGGTGATGGCGTGATAT GCACCTGCAACGGAGACTCCGGTGGGCCGCTGAACTGTCAGGCATCTGACGGCCGGTG GGAGGTGCATGGCATCGGCAGCCTCACGTCGGTCCTTGGTTGCAACTACTACTACAAG CCCTCCATCTTCACGCGGGTCTCCAACTACAACGACTGGATCAATTCGGTAAGAACCG GAGCAGCCCTGAGCCCCAAGGCACTGACCTGCTCACCTGGCCTCGGGAGTGCCATGCC CACCTGGCGACTGAGAACCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGA GGAGGCTGCAGACCTTGGCAACTGCTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGT GGGTAAAGCTGAGTGAAAAGGAACATGAGAGTATGGCCTTGTCCAAAGACGTTGGACA CTCCTCAGGTATGTTAAGAGTGAGTTCCACAGGAATGATTTTATTTTTGTGTATTTGT GTGTGGCCCAGACTCTACCATCCAGTGCTACTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 16 360 aa MW at 39171.4kD NOV1h, GSVSTYAPDMSRNLGGEEARPNSWPWQVSLQYSSNGQWYHTCGGSLIANSWVLTAAHC 198353319 ISSSRIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSNQVSKGNDIALLKLANPVS Protein LTDKIQLACLPPAGTILFNNYPCYVTGWGRLQTNGALFDDLKQGRLLVVDYATCSSSG Sequence WWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYK PSIFTRVSNYNDWINSVRTGAALSPKALTCSPGLGSAMPTWRLRTPSFLLRARWEFLG GGCRPWQLLSPPWVFKISVWVKLSEKEHESMALSKDVGHSSGMLRVSSTGMILFLCIC VWPRLYHPVLLE SEQ ID NO: 17 1081 bp NOV1i, GGATCCGTCTCCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGA

198362547 GGCCCAACAGCTGGCCCTGGCAGGTCTCCCTGCAGTACAGCTCCAATGGCCAGTGGTA DNA CCAGACCTGCGGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGC Sequence ATCAGCTCCTCCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAG AGTCCGGCTCGCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTC CGACCAGGTCTCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCC CTCACCGACAAGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACA ACTACCCCTGCTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGA TGACCTGAAGCAGGGCCGGTTGCTGGTTGTGGACTATGCCACCTGCTCCAGCTCTGGC TGGTGGGGCAGCACCGTGAAGACGAATATGATCTGTGCTGGGGGTGATGGCGTGATAT GCACCTGCAACGGAGACTCCGGTGGGCCGCTGAACTGTCAGGCATCTGACGGCCGGTG GGAGGTGCATGGCATCGGCAGCCTCACGTCGGTCCTTGGTTGCAACTACTACTACAAG CCCTCCATCTTCACGCGGGTCTCCAACTACAACGACTGGATCAATTCGGTAAGAACCG GAGCAGCCCTGAGCCCCAAGGCACTGCCCTGCTCACCTGGCCTCGGGAGTGCCATGCC CACCTGGCGACTGAGAACCCCCTCCTTCCTCTTGAGAGCTAGATGGGAACCCCTTGGA GGAGGCTGCAGACCTTGGCAACTGCTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGT GGGTAAAGCTGAGTGAAAAGGAACATGAGAGTATGGCCTTGTCCAAAGACGTTGGACA CTCCTCAGGTATGTTAAGAGTGAGTTCCACAGGAATGATTTTATTTTTGTGTATTTGT GTGTGGCCCAGACTCTACCATCCAGTGCTACTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 18 360 aa MW at 39069.3kD NOV1i, GSVSTYAPDMSRNLGGEEARPNSWPWQVSLQYSSNGQWYHTCGGSLIANSWVLTAAHC 198362547 ISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSKGNDIALLKLANPVS Protein LTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGALFDDLKQGRLLVVDYATCSSSG Sequence WWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYK PSIFTRVSNYNDWINSVRTGAALSPKALPCSFGLGSANPTWRLRTPSFLLRARWEPLG GGCRPWQLLSPPWVPKISVWVKLSEKEHESMALSKDVGHSSGMLRVSSTGMILFLCIC VWPRLYHPVLLE SEQ ID NO: 19 1023 bp NOV1j, GGATCCGTCTCCACTTACGCGCCTGATATGTCTAGGATGCTTGGAGGTGAAGAAGCGA 198362642 GGCCCAACAGCCGGCCCTGGCAGGTCTCCCTGCAGTACAGCTCCAATGGCCAGTGGTA DNA CCACACCTGCGGAGGGTCCCTGATAGCCAACAGCTGGGTCCTGACGGCTGCCCACTGC Sequence ATCAGCTCCTCCGGGATCTACCGCGTGATGCTGGGCCAGCATAACCTCTACGTTGCAG AGTCCGGCTCGCTGGCCGTCAGTGTCTCTAAGATTGTGGTGCACAAGGACTGGAACTC CGACCAGGTCTCCAAAGGGAACGACATTGCCCTGCTCAAACTGGCTAACCCCGTCTCC CTCACCGACAAGATCCAGCTGGCCTGCCTCCCTCCTGCCGGCACCATTCTACCCAACA ACTACCCCTGCTACGTCACGGGCTGGGGAAGGCTGCAGACCAACGGGGCTCTCCCTGA TGACCTGAAGCAGGGCCGGTTGCTGGTTGTGGACTATGCCACCTGCTCCAACTCTGGC TGGTGGGGCAGCACCGTGAAGACGAATATGATCTGTGCTGGGGGTGATGGCGTGATAT GCACCTGCAACGGAGACTCCGGTGGGCCGCTGAACTGTCAGGCATCTGACGGCCGGTG GGAGGTGCATGGCATCGGCAGCCTCACGTCGGTCCTTGGTTGCAACTACTACTACAAG CCCTCCATCTTCACGCGGGTCTCCAACTACAACGACTGGATCAATTCGGTAAGAACCG GAGCAGCCCTGAGCCCCAAGGCACTGACCTGCTCACCTGGCCTCGGGAGTGCCATGCC CACCTGGCGACTGAGAACCCCCTCCTTCCTCTTGAGAACTAGATGGGAACCCCTTGGA GGAGGCTGCAGACCTTGGCAACTGCTGAGTCCCCCATGGGTCCCCAAAATTTCTGTGT GGGTAAAGCTGAGTGAAAAGGAACATGAGAGTATGGCCTTGTCCAAAGACGTTGGACA CTCCTCAGGTACGTTAAGAGTGAGTTCCACACTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 20 341 aa MW at 36814.4kD NOV1j, GSVSTYAPDMSRMLGGEEARPNSRPWQVSLQYSSNGQWYHTCGGSLIANSWVLTAAHC 198362642 ISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSKGNDIALLKLANPVS Protein LTDKIQLACLPFAGTILFNNYPCYVTGWGRLQTNGALPDDLKQGRLLVVDYATCSNSG Sequence WWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYK PSIFTRVSNYNDWINSVRTGAALSPKALTCSFGLGSAMPTWRLRTPSFLLRTRWEPLG GGCRPWQLLSFPWVPKISVWVKLSEKEHESMALSKDVGHSSGTLRVSSTLE

[0320] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 1B. TABLE-US-00003 TABLE 1B Comparison of NOV1a against NOV1b through NOV1j. Protein NOV1a Residues/ Identities/Similarities for the Sequence Match Residues Matched Region NOV1b 1 . . . 287 275/289 (95%) 1 . . . 289 280/289 (96%) NOV1c 1 . . . 260 249/262 (95%) 1 . . . 262 255/262 (97%) NOV1d 1 . . . 287 267/289 (92%) 1 . . . 289 276/289 (95%) NOV1e 1 . . . 260 241/262 (91%) 1 . . . 262 251/262 (94%) NOV1f 17 . . . 372 352/356 (98%) 3 . . . 358 355/356 (98%) NOV1g 17 . . . 372 350/356 (98%) 3 . . . 358 352/356 (98%) NOV1h 17 . . . 372 351/356 (98%) 3 . . . 358 354/356 (98%) NOV1i 17 . . . 372 352/356 (98%) 3 . . . 358 354/356 (98%) NOV1j 17 . . . 353 332/337 (98%) 3 . . . 339 335/337 (98%)

[0321] Further analysis of the NOV1a protein yielded the following properties shown in Table 1C. TABLE-US-00004 TABLE 1C Protein Sequence Properties NOV1a PSort 0.5469 probability located in outside; 0.1000 probability analysis: located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in lysosome (lumen) SignalP Cleavage site between residues 17 and 18 analysis:

[0322] A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D. TABLE-US-00005 TABLE 1D Geneseq Results for NOV1a NOV1a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAM78338 Human protein SEQ ID NO 1000 - 1 . . . 277 261/279 (93%) e-156 homo sapiens, 1052 aa. 1 . . . 279 268/279 (95%) [WO200157190-A2, 09-AUG- 2001] AAP70760 Human pancreas elastase-2 - Sus 1 . . . 263 259/265 (97%) e-155 scrofa, 269 aa. [JP62000276-A, 06- 1 . . . 265 262/265 (98%) JAN-1987] AAP60059 Sequence of human pancreatic 15 . . . 263 245/249 (98%) e-149 elastase IIB - Homo sapiens, 253 1 . . . 249 248/249 (99%) aa. [EP198645-A, 22-OCT-1986] AAP60062 Sequence of human pancreatic 1 . . . 263 230/265 (86%) e-137 elastase IIA encoded on pH2E2 - 1 . . . 265 248/265 (92%) Homo sapiens, 269 aa. [EP198645- A, 22-OCT-1986] AAP61723 Human elastase II - Homo sapiens, 1 . . . 263 229/265 (86%) e-135 269 aa. [JP61192288-A, 26-AUG- 1 . . . 265 246/265 (92%) 1986]

[0323] In a BLAST search of public sequence datbases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E. TABLE-US-00006 TABLE 1E Public BLASTP Results for NOV1a NOV1a Identities/ Protein Residues/ Similarities for Accession Match the Matched Number Protein/Organism/Length Residues Portion Expect Value Q96QV5 BA265F14.3 (ELASTASE 2B) - 1 . . . 263 262/265 (98%) e-157 Homo sapiens (Human), 269 aa. 1 . . . 265 263/265 (98%) P08218 Elastase 2B precursor (EC 1 . . . 263 259/265 (97%) e-155 3.4.21.71) - Homo sapiens 1 . . . 265 262/265 (98%) (Human), 269 aa. P08217 Elastase 2A precursor (EC 1 . . . 263 230/265 (86%) e-137 3.4.21.71) - Homo sapiens 1 . . . 265 248/265 (92%) (Human), 269 aa. P08419 Elastase 2 precursor (EC 1 . . . 263 204/265 (76%) e-122 3.4.21.71) - Sus scrofa (Pig), 269 1 . . . 265 230/265 (85%) aa. Q29461 Elastase 2 precursor (EC 1 . . . 263 202/265 (76%) e-121 3.4.21.71) - Bos taurus (Bovine), 1 . . . 265 231/265 (86%) 269 aa.

[0324] PFam analysis predicts that the NOV1a protein contains the domains shown in the Table 1F. TABLE-US-00007 TABLE 1F Domain Analysis of NOV1a NOV1a Identities/ Match Similarities Pfam Domain Region for the Matched Region Expect Value trypsin 27 . . . 260 120/261 (46%) 1.3e-87 192/261 (74%)

Example 2

[0325] The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A. TABLE-US-00008 TABLE 2A NOV2 Sequence Analysis SEQ ID NO: 21 1800 bp NOV2a, GAGCCTCTCTTCACCATGTGCTTCGTCCCCCTGGTGTGCTGGGTGGTGTGTACCTGCC CG100560-01 TCCAGCAGCAGCTGGAGGGTGGGGGGCTGTTGAGACAGACGTCCAGGACCACCACTGC DNA AGTGTACATGCTCTACCTGCTGAGTCTGATGCAACCCAAGCCGGGGGCCCCGCGCCTC Sequence CAGCCCCCACCCAACCAGAGAGGGTTGTGCTCCTTGGCGGCAGATGGGCTCTGGAATC AGAAAATCCTATTTGAGGAGCAGGACCTCCGGAAGCACGGCCTAGACGGGGAAGACGT CTCTGCCTTCCTCAACATGAACATCTTCCAGAAGGACATCAACTGTGAGAGGTACTAC AGCTTCATCCACTTGAGTTTCCAGGAATTCTTTGCAGCTATGTACTATATCCTGGACG AGGGGGAGGGCGGGGCAGGCCCAGACCAGGACGTGACCAGGCTGTTGACCGAGTACGC GTTTTCTGAAAGGAGGTTCCTGGCACTCACCAGCCGCTTCCTGTTTGGACTCCTGAAC GAGGAGACCAGGAGCCACCTGGAGAAGAGTCTCTGCTGGAAGGTCTCGCCGCACATCA AGATGGACCTGTTGCAGTGGATCCAAAGCAAAGCTCAGAGCGACGGCTCCACCCTGCA GCAGGGCTCCTTGGAGTTCTTCAGCTGCTTGTACGAGATCCAGGAGGAGGAGTTTATC CAGCAGGCCCTGAGCCACTTCCAGGTGATCGTGGTCAGCAACATTGCCTCCAAGATGG AGCACATGGTCTCCTCGTTCTGTCTGAAGCGCTGCAGGAGCGCCCAGGTGCTGCACTT GTATGGCGCCACCTACAGCGCGGACGGGGAAGACCGCGCGAGGTGCTCCGCAGGAGCG CACACGCTGTTGGTGCAGCTGAGACCAGAGAGGACCGTTCTGCTGGACGCCTACAGTG AACATCTGGCAGCGGCCCTGTGCACCAATCCAAACCTGATAGAGCTGTCTCTGTACCG AAATGCCCTGGGCAGCCGGGGGGTGAAGCTGCTCTGTCAAGGACTCAGACACCCCAAC TGCAAACTTCAGAACCTGAGGAGGCTGAAGAGGTGCCGCATCTCCAGCTCAGCCTGCG AGGACCTCTCTGCAGCTCTCATAGCCAATAAGAATTTGACAAGGATGGATCTCAGTGG CAACGGCGTTGGATTCCCAGGCATGATGCTGCTTTGCGAGGGCCTGCGGCATCCCCAG TGCAGGCTGCAGATGATTCAGTTGAGGAAGTGTCAGCTGGAGTCCGGGGCTTGTCAGG AGATGGCTTCTGTGCTCGGCACCAACCCACATCTGGTTGAGTTGGACCTGACAGGAAA TGCACTGGAGGATTTGGGCCTGAGGTTACTATGCCAGGGACTGAGGCACCCAGTCTGC AGACTACGGACTTTGTGGTGCAGGCTGAAGATCTGCCGCCTCACTGCTGCTGCCTGTG ACGAGCTGGCCTCAACTCTCAGTGTGAACCAGAGCCTGAGAGAGCTGGACCTGAGCCT GAATGAGCTGGGGGACCTCGGGGTGCTGCTGCTGTGTGAGGGCCTCAGGCATCCCACG TGCAAGCTCCAGACCCTGCGGAGGTTGGGCATCTGCCGGCTGGGCTCTGCCGCCTGTG AGGGTCTTTCTGTGGTGCTCCAGGCCAACCACAACCTCCGGGAGCTGGACTTGAGTTT CAACGACCTGGGAGACTGGGGCCTGTGGTTGCTGGCTGAGGGGCTGCAACATCCCGCC TGCAGACTCCAGAAACTGTGGTGAGCATCGGGGAGTGACGGGGTGGCAGTGGTCACGT TT ORF Start: ATG at 16 ORF Stop: TGA at 1762 SEQ ID NO: 22 582aa MW at 65280.8kD NOV2a, MCFVPLVCWVVCTCLQQQLEGGGLLRQTSRTTTAVYMLYLLSLMQPKPGAPRLQPPPN CG100560-01 QRGLCSLAADGLWNQKILFEEQDLRKHGLDGEDVSAFLNMNIFQKDINCERYYSFIHL Protein SFQEFFAAMYYILDEGEGGAGPDQDVTRLLTEYAFSERSFLALTSRFLFGLLNEETRS Sequence HLEKSLCWKVSPHIKMDLLQWIQSKAQSDGSTLQQGSLEFFSCLYEIQEEEFIQQALS HFQVIVVSNIASKMEHMVSSFCLKRCRSAQVLHLYGATYSADGEDRARCSAGAHTLLV QLRPERTVLLDAYSEHLAAALCTNPNLIELSLYRNALGSRGVKLLCQGLRHPNCKLQN LRRLKRCRISSSACEDLSAALIANKNLTRMDLSGNGVGFPGMMLLCEGLRHPQCRLQM IQLRKCQLESGACQEMASVLGTNPHLVELDLTGNALEDLGLRLLCQGLRHPVCRLRTL WCRLKICRLTAAACDELASTLSVNQSLRELDLSLNELGDLGVLLLCEGLRHPTCKLQT LRRLGICRLGSAACEGLSVVLQANHNLRELDLSFNDLGDWGLWLLAEGLQHPACRLQK LW SEQ ID NO: 23 1683 bp NOV2b, GCGCGCCTCTCTTCACCATGTGCTTCGTCCCCCTGGTGTGCTGGGTGGTGTGTACCTG CG100560-02 CCTCCAGCAGCAGCTGGAGGGTGGGGGGCTGTTGAGACAGACGTCCAGGACCACCACT DNA GCAGTGTACATGCTCTACCTGCTGAGTCTGATGCAACCCAAGCCGGGGGCCCCGCGCC Sequence TCCAGCCCCCACCCAACCAGAGAGGGTTGTGCTCCTTGGCGGCAGATGGGCTCTGGAA TCAGAAAATCCTATTTGAGGAGCAGGACCTCCGGAAGCACGGCCTAGACGGGGAAGAC GTCTCTGCCTTCCTCAACATGAACATCTTCCAGAAGGACATCAACTGTGAGAGGTACT ACAGCTTCATCCACTTGAGTTTCCAGGAATTCTTTGCAGCTATGTACTATATCCTGGA CGAGGGGGAGGGCGGGGCAGGCCCAGACCAGGACGTGACCAGGCTGTTGACCGAGTAC GCGTTTTCTGAAAGGAGCTTCCTGGCACTCACCAGCCGCTTCCTGTTTGGACTCCTGA ACGAGGAGACCAGGAGCCACCTGGAGAAGAGTCTCTGCTGGAAGGTCTCGCCGCACAT CAAGATGGACCTGTTGCAGTGGATCCAAAGCAAAGCTCAGAGCGACGGCTCCACCCTG CAGCAGGGCTCCTTGGAGTTCTTCAGCTGCTTGTACGAGATCCAGGAGGAGGAGTTTA TCCAGCAGGCCCTGAGCCACTTCCAGGTGATCGTGGTCAGCAACATTGCCTCCAAGAT GGAGCACATGGTCTCCTCGTTCTGTCTGAAGCGCTGCAGGAGCGCCCAGGTGCTGCAC TTGTATGGCGCCACCTACAGCGCGGACGGGGAAGACCGCGCGAGGTGCTCCGCAGGAG CGCACACGCTGTTGGTGCAGCTCAGACCAGAGAGGACCGTTCTGCTGGACGCCTACAG TGAACATCTGGCAGCGGCCCTGTGCACCAATCCAAACCTGATAGAGCTGTCTCTGTAC CGAAATGCCCTGGGCAGCCGGGGGGTGAAGCTGCTCTGTCAAGGACTCAGACACCCCA ACTGCAAACTTCAGAACCTGAGGCTGAAGAGGTGCCGCATCTCCAGCTCAGCCTGCGA GGACCTCTCTGCAGCTCTCATAGCCAATAAGAATTTGACAAGGATGGATCTCAGTGGC AACGGCGTTGGATTCCCAGGCATGATGCTGCTTTGCGAGGGCCTGCGGCATCCCCAAT GCAGGCTGCAGATGATTCAGCTGAAGATCTGCCGCCTCACTGCTGCTGCCTGTGACGA GCTGGCCTCAACTCTCAGTGTGAACCAGAGCCTGAGAGAGCTGGACCTGAGCCTGAAT GAGCTGGGGGACCTCGGGGTGCTGCTGCTGTGTGAGGGCCTCAGGCATCCCACGTGCA AGCTCCAGACCCTGCGGTTGGGCATCTGCCGGCTGGGCTCTGCCGCCTGTGAGGGTCT TTCTGTGGTGCTCCAGGCCAACCACAACCTCCGGGAGCTGGACTTGAGTTTCAACGAC CTGGGAGACTGGGGCCTGTGGTTGCTGGCTGAGGGGCTGCAACATCCCGCCTGCAGAC TCCAGAAACTGTGGTGAGCATCGGGGAGTGACGGGGTGGCAGTGGTCACGTTTGGACA GTGGAAGCGCCTTCTCATCCTTCATTTTTCTATTTATGAACTATCCTGCTTCACTACA A ORF Start: ATG at 18 ORF Stop: TGA at 1581 SEQ ID NO: 24 521 aa MW at 58384.7kD NOV2b, MCFVPLVCWVVCTCLQQQLEGGGLLRQTSRTTTAVYMLYLLSLMQPKPGAPRLQPPPN CG100560-02 QRGLCSLAADGLWNQKILFEEQDLRKHGLDGEDVSAFLNMNIFQKDINCERYYSFIHL Protein SFQEFFAAMYYILDEGEGGAGFDQDVTRLLTEYAFSERSFLALTSRFLFGLLNEETRS Sequence HLEKSLCWKVSPHIKMDLLQWIQSKAQSDGSTLQQGSLEFFSCLYEIQEEEFIQQALS HFQVIVVSNIASKMEHMVSSFCLKRCRSAQVLHLYGATYSADGEDRARCSAGAHTLLV QLRPERTVLLDAYSEHLAAALCTNPNLIELSLYRNALGSRGVKLLCQGLRHPNCKLQN LRLKRCRISSSACEDLSAALIANKNLTPNDLSGNGVGFPGMMLLCEGLRHPQCRLQMI QLKICRLTAAACDELASTLSVNQSLRELDLSLNELGDLGVLLLCEGLRHPTCKLQTLR LGICRLGSAACEGLSVVLQANHNLRELDLSFNDLGDWGLWLLAEGLQHPACRLQKLW

[0326] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B. TABLE-US-00009 TABLE 2B Comparison of NOV2a against NOV2b. NOV2a Residues/ Identities/Similarities for the Protein Sequence Match Residues Matched Region NOV2b 1 . . . 523 450/523 (86%) 1 . . . 520 464/523 (88%)

[0327] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C. TABLE-US-00010 TABLE 2C Protein Sequence Properties NOV2a PSort 0.3700 probability located in outside; 0.1900 probability analysis: located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 50 and 51 analysis:

[0328] A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D. TABLE-US-00011 TABLE 2D Geneseq Results for NOV2a NOV2a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length [Patent Match the Matched Expect Identifier #, Date] Residues Region Value AAU01067 Human secreted protein sequence 1 . . . 581 275/602 (45%) e-143 encoded by gene #28 - Homo 1 . . . 596 380/602 (62%) sapiens, 630 aa. [WO200123402- A1, 05-APR-2001] AAE07514 Human PYRIN-1 protein - Homo 1 . . . 581 275/602 (45%) e-143 sapiens, 1034 aa. [WO200161005- 406 . . . 1001 380/602 (62%) A2, 23-AUG-2001] AAU01096 Gene 28 Human secreted protein 1 . . . 523 236/532 (44%) e-123 homologous amino acid sequence - 1 . . . 482 324/532 (60%) Homo sapiens, 484 aa. [WO200123402-A1, 05-APR-2001] AAY39778 CBDAKD01 protein sequence - 1 . . . 464 210/487 (43%) e-106 Homo sapiens, 514 aa. 1 . . . 481 298/487 (61%) [WO9946290-A1, 16-SEP-1999] ABG04570 Novel human diagnostic protein 156 . . . 324 167/169 (98%) 5e-90 #4561 - Homo sapiens, 168 aa. 1 . . . 168 167/169 (98%) [WO200175067-A2, 11-OCT-2001]

[0329] In a BLAST search of public sequence datbases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E. TABLE-US-00012 TABLE 2E Public BLASTP Results for NOV2a NOV2a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value AAH28069 HYPOTHETICAL 120.2 KDA 1 . . . 582 577/582 (99%) 0.0 PROTEIN - Homo sapiens (Human), 400 . . . 976 577/582 (99%) 1061 aa. Q96P20 Cold autoinflammatory syndrome 1 1 . . . 581 275/602 (45%) e-143 protein (Cryopyrin) (NACHT-, LRR- 406 . . . 1001 380/602 (62%) and PYD-containing protein 3) (PYRIN-containing APAF1-like protein 1) (Angiotensin/vasopressin receptor AII/AVP-like) - Homo sapiens (Human), 1034 aa. AAL78632 NALP3 LONG ISOFORM - Homo 1 . . . 581 275/602 (45%) e-143 sapiens (Human), 1036 aa. 408 . . . 1003 379/602 (62%) AAL90874 MAST CELL MATURATION 1 . . . 581 274/603 (45%) e-140 INDUCIBLE PROTEIN 1 - Mus 404 . . . 1000 372/603 (61%) musculus (Mouse), 1033 aa. AAL12498 CRYOPYRIN - Homo sapiens 1 . . . 464 220/485 (45%) e-115 (Human), 920 aa. 406 . . . 887 310/485 (63%)

[0330] PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F. TABLE-US-00013 TABLE 2F Domain Analysis of NOV2a Identities/ NOV2a Match Similarities for Pfam Domain Region the Matched Region Expect Value

Example 3

[0331] The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A. TABLE-US-00014 TABLE 3A NOV3 Sequence Analysis SEQ ID NO: 25 1481 bp NOV3a, CTTGTCTTGTTCCAGTTCTCAGAGGGAATGCTTTCAATTTTTCTCTATTCAGTATTAT CG101012-01 GTTGGCTGTGGGTTTGTCATAGATTGTGTGCCGTGAGGGAGTTTACTTTCCTGGCCAA DNA GAAGCCAGGCTGCAGGGGCCTTCGGATCACCACGGATGCCTGCTGGGGTCGCTGTGAG Sequence ACCTTCTATCTATGGGGACAGAAACCCATTCTGGAACCCCCCTATATTGAAGCCCATC ATCGAGTCTGTACCTACAACGAGACCAAACAGGTGACTGTCAAGCTGCCCAACTGTGC CCCGGGAGTCGACCCCTTCTACACCTATCCCGTGGCCATCCGCTGTGACTGCGGAGCC TGCTCCACTGCCACCACGGAGTGTGAGACCATCTGAGGCCGCTAGCTGCTCTCTGCAG ACCCACCTGTGTGAGCAGCACATGCAGTTATACTTCCTGGATGCAAGACTGTTTAATT TCGACCACACCCATGGA ORF Start: ATG at 28 ORF Stop: TGA at 382 SEQ ID NO: 26 118 aa MW at 13491.6kD NOV3a, MLSIFLYSVLCWLWVCHRLCAVREFTFLAKKPGCRGLRITTDACWGRCETFYLWGQKP CG101012-01 ILEPPYIEAHHRVCTYNETKQVTVKLPNCAPGVDPFYTYPVAIRCDCGACSTATTECE Protein TI Sequence

[0332] TABLE-US-00015 TABLE 3B Protein Sequence Properties NOV3a PSort 0.5500 probability located in endoplasmic reticulum analysis: (membrane); 0.1900 probability located in lysosome (lumen); 0.1449 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 22 and 23 analysis:

[0333] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C. TABLE-US-00016 TABLE 3C Geneseq Results for NOV3a Identities/ NOV3a Similarities Residues/ for the Geneseq Protein/Organism/Length [Patent Match Matched Expect Identifier #, Date] Residues Region Value AAU10366 Human beta-like glycoprotein 20 . . . 118 93/99 (93%) 7e-53 hormone, Beta10 - Homo sapiens, 36 . . . 130 95/99 (95%) 130 aa. [WO200173034-A2, 04- OCT-2001] AAG64065 Human anterior pituitary hormone- 20 . . . 118 93/99 (93%) 7e-53 related polypeptide #2 - Homo 12 . . . 106 95/99 (95%) sapiens, 106 aa. [WO200144475-A1, 21-JUN-2001] AAG64064 Human anterior pituitary hormone- 20 . . . 118 93/99 (93%) 7e-53 related polypeptide - Homo sapiens, 36 . . . 130 95/99 (95%) 130 aa. [WO200144475-A1, 21- JUN-2001] AAG63211 Amino acid sequence of a human 20 . . . 118 93/99 (93%) 7e-53 cystine knot polypeptide - Homo 36 . . . 130 95/99 (95%) sapiens, 130 aa. [WO200153346-A1, 26-JUL-2001] AAE09440 Human sbghGTa protein - Homo 20 . . . 118 93/99 (93%) 7e-53 sapiens, 130 aa. [WO200160850-A1, 36 . . . 130 95/99 (95%) 23-AUG-2001]

[0334] In a BLAST search of public sequence datbases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D. TABLE-US-00017 TABLE 3D Public BLASTP Results for NOV3a Identities/ NOV3a Similarities Protein Residues/ for the Accession Match Matched Expect Number Protein/Organism/Length Residues Portion Value Q9I997 FOLLICLE-STIMULATING 2 . . . 118 49/119 (41%) 8e-20 HORMONE PRECURSOR - 3 . . . 116 66/119 (55%) Acipenser baerii (Siberian sturgeon), 128 aa. Q98849 Gonadotropin beta-II chain precursor 4 . . . 115 43/117 (36%) 8e-16 (GTH-II-beta) (Luteinizing hormone- 9 . . . 120 63/117 (53%) like GTH) - Carassius auratus (Goldfish), 140 aa. Q90ZK1 FOLLICLE STIMULATING 5 . . . 115 46/112 (41%) 2e-15 HORMONE BETA SUBUNIT 1 . . . 108 59/112 (52%) PRECURSOR - Rana ridibunda (Laughing frog) (Marsh frog), 123 aa (fragment). P01235 Gonadotropin beta-II chain precursor 26 . . . 115 37/91 (40%) 2e-15 (GTH-II-beta) (Luteinizing hormone- 39 . . . 124 54/91 (58%) like GTH) - Cyprinus carpio (Common carp), 144 aa. Q98TY3 LUTEINIZING HORMONE BETA 1 . . . 115 44/118 (37%) 2e-15 SUBUNIT - Mylopharyngodon 8 . . . 120 62/118 (52%) piceus, 140 aa.

[0335] PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3E. TABLE-US-00018 TABLE 3E Domain Analysis of NOV3a Identities/ NOV3a Similarities for Pfam Domain Match Region the Matched Region Expect Value Cys_knot 29 . . . 116 36/92 (39%) 2.5e-14 62/92 (67%)

Example 4

[0336] The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A. TABLE-US-00019 TABLE 4A NOV4 Sequence Analysis SEQ ID NO: 27 682 bp NOV4a, ATGAAGACCCTGTTCCTGGGTGTCACGCTCGGCCTGGCCGCTGCCCTGTCCTTCACCC CG101584-01 TGGAGGAGGAGGATGTGCATCCAGAAGAAAATCCTGATGCGGAATGGGGGCAGGAAGC DNA TCATGTACCTGCAGGAGCTGCCCAGGAGGGACCACTACATCTTTTACTGCAAAGACCA Sequence GCACCATGGGGGCCTGCTCCACATGGGAAAGCTTGTGGGTGCTCCCTGCAGGGCCGTG CCGCTGTCCCCACGTCGGCTCACCTGGCCACCTCACCTGCAGGTAGGAATTCTGATAC CAACCGGGAGGCCCTGGAAGAATTTAAGAAATTGGTGCAGCGCAAGGGACTCTCGGAG GAGGACATTTTCACGCCCCTGCAGACGGGTGAGGATGGCTGTGCCCAGTCCCCTGTGT CCCTCTGCTGTGTCTGTCTGCTATCTCCAGTGTCCCATGACCCCCATGTCCTCCCATG TCCCCCGCATTCCCCATGTGCCCCGAGTCTCCTCGCAGGGGCTCCCGGGCCCTGTTTA GCGTCCTCCTCATTGGAGGCTCTGTGCTCTGGGCTGCGATGGGGTCTGGGGCTCCGCG CTCTGGGCTGCGATGGGGTCTGGGGCTCCGCACTCTGGGCTGCGATGGGGTCTGGGGC TCCGCGCTCTGGGCTGCGATGGGCTCTGGGGCTCTGAGCTCTGG ORF Start: ATG at 1 ORF Stop: TGA at 673 SEQ ID NO: 28 224 aa MW at 23172.1kD NOV4a, MKTLFLGVTLGLAAALSFTLEEEDVHPEENFDAEWGQEAHVPAGAAQEGPLHLLLQRP CG101584-01 AFWGPAPHGKACGCSLQGRAAVPTSAHLATSPAGRNSDTNREALEEFKKLVQRKGLSE Protein EDIFTPLQTGEDGCAQSPVSLCCVCLLSPVSHDPHVLPCPPHSPCAPSLLAGAPGPCL Sequence ASSSLEALCSGLRWGLGLRALGCDGVWGSALWAAMGSGAPRSGLRWALGL

[0337] Further analysis of the NOV4a protein yielded the following properties shown in Table 4B. TABLE-US-00020 TABLE 4B Protein Sequence Properties NOV4a PSort 0.7571 probability located in outside; 0.1000 probability analysis: located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in microbody (peroxisome) SignalP Cleavage site between residues 16 and 17 analysis:

[0338] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4C. TABLE-US-00021 TABLE 4C Geneseq Results for NOV4a NOV4a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length [Patent Match the Matched Expect Identifier #, Date] Residues Region Value AAB67741 Amino acid sequence of odorant 1 . . . 126 115/141 (81%) 1e-56 binding polypeptide OBPIIa-delta - 1 . . . 141 119/141 (83%) Homo sapiens, 147 aa. [WO200112806-A2, 22-FEB-2001] AAB67744 Amino acid sequence of odorant 1 . . . 71 70/85 (82%) 7e-33 binding polypeptide OBPIIb- 1 . . . 85 71/85 (83%) gamma - Homo sapiens, 85 aa. [WO200112806-A2, 22-FEB-2001] AAB67743 Amino acid sequence of odorant 31 . . . 71 38/41 (92%) 1e-17 binding polypeptide OBPIIb-beta - 139 . . . 179 38/41 (92%) Homo sapiens, 179 aa. [WO200112806-A2, 22-FEB-2001] ABG11867 Novel human diagnostic protein 92 . . . 154 46/74 (62%) 3e-13 #11858 - Homo sapiens, 200 aa. 130 . . . 198 47/74 (63%) [WO200175067-A2, 11-OCT-2001] ABG11867 Novel human diagnostic protein 92 . . . 154 46/74 (62%) 3e-13 #11858 - Homo sapiens, 200 aa. 130 . . . 198 47/74 (63%) [WO200175067-A2, 11-OCT-2001]

[0339] In a BLAST search of public sequence datbases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4D. TABLE-US-00022 TABLE 4D Public BLASTP Results for NOV4a NOV4a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9NY54 PUTATIVE ODORANT 1 . . . 126 115/141 (81%) 3e-56 BINDING PROTEIN AD - Homo 1 . . . 141 119/141 (83%) sapiens (Human), 147 aa. Q9NY51 PUTATIVE ODORANT 1 . . . 71 70/85 (82%) 2e-32 BINDING PROTEIN BG - Homo 1 . . . 85 71/85 (83%) sapiens (Human), 85 aa. CAC33327 SEQUENCE 11 FROM PATENT 31 . . . 71 38/41 (92%) 3e-17 WO0112806 - Homo sapiens 139 . . . 179 38/41 (92%) (Human), 179 aa (fragment). Q9NY52 PUTATIVE ODORANT- 31 . . . 71 38/41 (92%) 3e-17 BINDING PROTEIN BB - Homo 125 . . . 165 38/41 (92%) sapiens (Human), 165 aa. Q9NPH6 Odorant-binding protein 2b 92 . . . 126 35/35 (100%) 3e-12 precursor (OBPIIb) - Homo 130 . . . 164 35/35 (100%) sapiens (Human), 170 aa.

[0340] PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4E. TABLE-US-00023 TABLE 4E Domain Analysis of NOV4a Identities/ NOV4a Match Similarities for Pfam Domain Region the Matched Region Expect Value lipocalin 92 . . . 128 13/37 (35%) 0.00022 31/37 (84%)

Example 5

[0341] The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A. TABLE-US-00024 TABLE 5A NOV5 Sequence Analysis SEQ ID NO: 29 1178 bp NOV5a, GGGATG; GGAAAACTATGCCTGGGGCCGACGCTCTGCCCGGCTGCTGCCGCTGAGGAAA CG101707-01 GCCGGGACGCGGAGCCCCGCCGAGAGCTTCTTTGCTCCGGACGCCCCTGGACGTGGCG DNA GGCAGCCGCGAGGGTAACCACCATGATCCCCTGGGTGCTCCTGGCCTGTGCCCTCCCC Sequence TGTGCTGCTGACCCACTGCTTGGCGCCTTTGCTCGCAGGGACTTCCGGAAAGGCTCCC CTCAACTGGTCTGCAGCCTGCCTGGCCCCCAGGGCCCACCCGGCCCCCCAGGAGCCCC AGGGCCCTCAGGAATGATGGGACGAATGGGCTTTCCTGGCAAAGACGGCCAAGATGGA CACGACGGCGACCGGGGGGACAGCGGAGAGGAAGGTCCACCTGGCCGGACAGGTAACC GGGGAAAGCCAGGACCAAAGGGCAAAGCCGGGGCCATTGGGCGGGCTGGCCCCCGTGG CCCCAAGGGGGTCAACGGTACCCCCGGGAAGCATGGCACACCAGGCAAGAAGGGGCCC AAGGGCAAGAAGGGGGAGCCAGGCCTCCCAGGCCCCTGCAGCTGTGGCAGTGGCCATA CCAAGTCAGCTTTCTCGGTGGCAGTGACCAAGAGCTACCCACGGGAGCGGCTGCCCAT CAAGTTTGACAAGATTCTGATGAACGAGGGTGGCCACTACAATGCTTCCAGCGGCAAG TTCGTCTGCGGCGTGCCTGGGATCTACTACTTCACCTACGACATCACGCTGGCCAACA AGCACCTGGCCATCGGCCTGGTGCACAACGGCCAGTACCGCATCCGGACCTTTGATGC CAACACCGGCAACCACGATGTGGCCTCAGGCTCCACCATCCTGGCTCTCAAGCAGGGT GACGAAGTTTGGCTGCAGATCTTCTACTCAGAGCAGAACGGGCTCTTCTATGACCCTT ACTGGACAGACAGCCTCTTTACGGGCTTCCTAATCTATGCCGACCAGGATGACCCCAA CGAGGTATAGACATGCCACGGCGGTCCTCCAGGCAGGGAACAAGCTTCTGGACTTGGG CTTACAGAGCAAGACCCCACAACTGTAGGCTGGGGGTGGGGGGTCGAGTGAGCGGTTC TAGCCTCAGGCTCACCTCCTCCGCCTCTTTTTTTTCCCCTTCATTAAATCCAAACCTT TTTATTCATCCAAAAAAA ORF Start: ATG at 4 ORF Stop: TAG at 994 SEQ ID NO: 30 330 aa MW at 34833.2kD NOV5a, MGKLCLGPTLCPAAAAEESRDAEPRRELLCSGRPWTWRAAARVTTMIPWVLLACALPC CG101707-01 AADPLLGAFARRDFRKGSPQLVCSLPGPQGPPGPFGAPGPSGMMGRMGFPGKDGQDGH Protein DGDRGDSGEEGPPGRTGNRGKPGPKGKAGAIGRAGPRGPKGVNGTPGKHGTPGKKGPK Sequence GKKGEPGLPGPCSCGSGHTKSAFSVAVTKSYPRERLPIKFDKILMNEGGHYNASSGKF VCGVPGIYYFTYDITLANKHLAIGLVHNGQYRIRTFDANTGNHDVASGSTILALKQGD EVWLQIFYSEQNGLFYDPYWTDSLFTGFLIYADQDDPNEV

[0342] Further analysis of the NOV5a protein yielded the following properties shown in Table 5B. TABLE-US-00025 TABLE 5B Protein Sequence Properties NOV5a PSort 0.7900 probability located in plasma membrane; analysis: 0.4043 probability located in microbody (peroxisome); 0.3000 probability located in Golgi body; 0.2000 probability located in endoplasmic reticulum (membrane) SignalP Cleavage site between residues 61 and 62 analysis:

[0343] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5C. TABLE-US-00026 TABLE 5C Geneseq Results for NOV5a NOV5a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAU19557 Human diagnostic and therapeutic 1 . . . 330 329/330 (99%) 0.0 polypeptide (DITHP) #143 - Homo 2 . . . 331 329/330 (99%) sapiens, 331 aa. [WO200162927- A2, 30-AUG-2001] AAB50374 Human adipocyte complement 46 . . . 330 285/285 (100%) e-177 related protein homologue zacrp2 - 1 . . . 285 285/285 (100%) Homo sapiens, 285 aa. [WO200073448-A1, 07-DEC- 2000] AAY54321 A polypeptide designated 46 . . . 330 285/285 (100%) e-177 ACRP30R1L which is a 1 . . . 285 285/285 (100%) homologue of ACRP30 - Homo sapiens, 285 aa. [WO9959618-A1, 25-NOV-1999] AAB30232 Human adipocyte complement 46 . . . 330 285/285 (100%) e-177 related protein homologue zacrp2 - 1 . . . 285 285/285 (100%) Homo sapiens, 285 aa. [WO200063376-A1, 26-OCT- 2000] ABB72178 Rat protein isolated from skin cells 42 . . . 330 271/289 (93%) e-168 SEQ ID NO: 294 - Rattus sp, 294 6 . . . 294 278/289 (95%) aa. [WO200190357-A1, 29-NOV- 2001]

[0344] In a BLAST search of public sequence datbases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5D. TABLE-US-00027 TABLE 5D Public BLASTP Results for NOV5a NOV5a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9BXJ5 Complement-c1q tumor necrosis 46 . . . 330 285/285 (100%) e-177 factor-related protein 2 precursor - 1 . . . 285 285/285 (100%) Homo sapiens (Human), 285 aa. Q9D8U4 1810033K05RIK PROTEIN- 42 . . . 330 272/289 (94%) e-168 Mus musculus (Mouse), 294 aa. 6 . . . 294 279/289 (96%) CAC21967 SEQUENCE 14 FROM PATENT 76 . . . 325 160/250 (64%) 1e-96 WO0073448 - Mus musculus 29 . . . 278 191/250 (76%) (Mouse), 289 aa. CAC21966 SEQUENCE 1 FROM PATENT 76 . . . 325 159/250 (63%) 3e-96 WO0073448 - Homo sapiens 43 . . . 292 192/250 (76%) (Human), 303 aa. Q9BXJ2 Complement-c1q tumor necrosis 76 . . . 325 159/250 (63%) 3e-96 factor-related protein 7 precursor - 29 . . . 278 192/250 (76%) Homo sapiens (Human), 289 aa.

[0345] PFam analysis predicts that the NOV5a protein contains the domains shown in the Table 5E. TABLE-US-00028 TABLE 5E Domain Analysis of NOV5a Identities/ Similarities for Pfam the Matched Expect Domain NOV5a Match Region Region Value Collagen 83 . . . 141 32/60 (53%) 3.3e-05 40/60 (67%) Collagen 142 . . . 201 23/60 (38%) 0.0014 37/60 (62%) C1q 196 . . . 320 45/138 (33%) 2.3e-38 93/138 (67%)

Example 6

[0346] The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A. TABLE-US-00029 TABLE 6A NOV6 Sequence Analysis SEQ ID NO: 31 1611 bp NOV6a, GGAGCGTCTGTTGGGTCCGGGCCGCCGGCTTCGCCCTCGCCATGGCGCCCTGGCTGCA CG101836-01 GCTCCTGTCGCTGCTGGGGCTGCTCCCGGGCGCAGTGGCCGCCCCCGCCCAGCCCCGA DNA GCCGCCAGCTTTCAGGCCTGGGGGCCGCCGTCCCCGCAGCTGCTGGCGCCCACCCGCT Sequence TCGCGCTGGAGATGTTCAACCGCGGCCGGGCTGCGGGGACGCGGGCCGTGCTGGGCCT TGTGCGCGACCGTCCGCGCCTCACCTACTCCTCTCTCCAGGCGGGCCAGGGGTCGCTG TACTCCCTGGAGGCCACCCTGGAGGAGCCACCCTGCAACGACCCCATGGTGTGCCGGC TCCCCGTGTCCAAGAAAACCCTGGTGACTTTCAAAGTCCTGGATGAGCTCGGGGGGCG CGTGCTGCTGCGGAAGGACTGTGGCCCAGTGGACACCAAGGTTCCAGGTGCTGGGGAG CCCAAGTCAGCCTTCACTCAGGGCTCAGCCATGATTTCTTCTCTGTCCCAAAACCATC CAGACAACAGAAACGAGACTTTCAGCTCAGTCATTTCCCTGTTGAATGAGGATCCCCT GTCCCAGGACTTGCCTGTGAAGATGGCTTCAATCTTCAAGAACTTTGTCATTACCTAT AACCGGACATATGAGTCAAAGGAAGAAGCCCGGTGGCGCCTGTCCGTCTTTGTCAATA ACATGGTGCGAGCACAGAAGATCCAGGCCCTGGACCGTGGCACAGCTCAGTATGGAGT CACCAAGTTCAGTGATCTCACAGAGGAGGAGTTCCGCACTATCTACCTGAATACTCTC CTGAGAAAAGAGCCTGGCAACAAGATGAAGCAAGCCAAGTCTGTGGGTGACCTCGCCC CACCTGAATGGGACTGGAGGAGTAAGGGGGCTGTCACAAAAGTCAAAGACGAGGGCAT GTGTGGCTCCTGCTGGGCCTTCTCAGTCACAGGCAATGTGGAGGGCCAGTGGTTTCTC AACCAGGGGACCCTGCTCTCCCTCTCTGAACAGGAGCTCTTGGACTGTGACAAGATGG ACAAGGCCTGCATGGGCGGCTTGCCCTCCAATGCCTACTCGGCCATAAAGAATTTGGG AGGGCTGGAGACAGAGGATGACTACAGCTACCAGGGTCACATGCAGTCCTGCAACTTC TCAGCAGAGAAGGCCAAGGTCTACATCAATGACTCCGTGGAGCTGAGCCAGAACGAGC AGGAGCTGGCAGCCTGGCTGGCCAAGAGAGGCCCAATCTCCGTGGCCATCAATGCCTT TGGCATGCAGTTTTACCGCCACGGGATCTCCCGCCCTCTCCGGCCCCTCTGCAGCCCT TGCGTCATTGACCATGCGGTGTTGCTTGTGGGCTACGGAACCGTGAGTTCTGACGTTC CCTTTTGGGCCATCAAGAACAGCTGGGGCACTGACTGGGGTGAGAAGGGTTACTACTA CTTGCATCGCGGGTCCGGGGCATGTGGCGTGAACACCATGGCCAGCTCGGCGGTGGTG GACTGAAGAGGGGCCCCCAGCTCGGGACCTGGTGCTGATCAGAGTGGCTGCTGCCCCA GCCTGACATGTGTCCAGGCCCCTCCCCGGGAGGTACAGCTGGCAG ORF Start: ATG at 42 ORF Stop: TGA at 1512 SEQ ID NO: 32 490 aa MW at 53794.7kD NOV6a, MAPWLQLLSLLGLLPGAVAAPAQPRAASFQAWGPPSPQLLAPTRFALEMFNRGRAAGT CG101836-01 DELGGRVLLRKDCGPVDTKVPGAGEPKSAFTQGSANISSLSQNHPDNRNETFSSVISL Protein LNEDPLSQDLPVKMASIFKNFVITYNRTYESKEEARWRLSVFVNNMVRAQKIQALDRG Sequence TAQYGVTKFSDLTEEEFRTIYLNTLLRKEPGNKMKQAKSVGDLAPPEWDWRSKGAVTK VKDQGMCGSCWAFSVTGNVEGQWFLNQGTLLSLSEQELLDCDKMDKACMGGLPSNAYS AIKNLGGLETEDDYSYQGHMQSCNFSAEKAKVYINDSVELSQNEQELAAWLAKRGPIS VAINAFGMQFYRHGISRPLRPLCSPCVIDHAVLLVGYGTVSSDVPFWAIKNSWGTDWG EKGYYYLHRGSGACGVNTMASSAVVD SEQ ID NO: 33 1226 bp NOV6b, GCTTCGCCCTCGCCATGGCGCCCTGGCTGCAGCTCCTGTCGCTGCTGGGGCTGCTCCC CG101836-02 GGGCGCAGTGGCCGCCCCCGCCCAGCCCCAAGTCCTGGATGAGCTCGGAAGACACGTG DNA CTGCTGCGGAAGGACTGTGGCCCAGTGGACACCAAGGTTCCAGGTGCTGGGGAGCCCA Sequence AGTCAGCCTTCACTCAGGGCTCAGCCATGATTTCTTCTCTGTCCCAAAACCATCCAGA CAACAGAAACGAGACTTTCAGCTCAGTCATTTCCCTGTTGAATGAGGATCCCCTGTCC CAGGACTTGCCTGTGAAGATGGCTTCAATCTTCAAGAACTTTGTCATTACCTATAACC GGACATATGAGTCAAAGGAAGAAGCCCGGTGGCGCCTGTCCGTCTTTGTCAATAACAT GGTGCGAGCACAGAAGATCCAGGCCCTGGACCGTGGCACAGCTCAGTATGGAGTCACC AAGTTCAGTGATCTCACAGAGGAGGAGTTCCGCACTATCTACCTGAATACTCTCCTGA GGAAAGAGCCTGGCAACAAGATGAAGCAAGCCAAGTCTGTGGGTGACCTCGCCCCACC TGAATGGGACTGGAGGAGTAAGGGGGCTGTCACAAAAGTCAAAGACCAGGGCATGTGT GGCTCCTGCTGGGCCTTCTCAGTCACAGGCAATGTGGAGGGCCAGTGGTTTCTCAACC AGGGGACCCTGCTCTCCCTCTCTGAACAGGAGCTCTTGGACTGTGACAAGATGGACAA GGCCTGCATGGGCGGCTTGCCCTCCAATGCCTACTCGGCCATAAAGAATTTGGGAGGG CTGGAGACAGAGGATGACTACAGCTACCAGGGTCACATGCAGTCCTGCAACTTCTCAG CAGAGAAGGCCAAGGTCTACATCAATGACTCCGTGGAGCTGAGCCAGAACGAGCAGAA GCTGGCAGCCTGGCTGGCCAAGAGAGGCCCAATCTCCGTGGCCATCAATGCCTTTGGC ATGCAGTTTTACCGCCACGGGATCTCCCGCCCTCTCCGGCCCCTCTGCAGCCCTTGGC TCATTGACCATGCGGTGTTGCTTGTGGGCTACGGCAACCGCTCTGACGTTCCCTTTTG GGCCATCAAGAACAGCTGGGGCACTGACTGGGGTGAGAAGGGTTACTACTACTTGCAT CGCGGGTCCGGGGCCTGTGGCGTGAACACCATGGCCAGCTCGGCGGTGGTGGACTGAA GAGGGGCC ORF Start: ATG at 15 ORE Stop: TGA at 1215 SEQ ID NO: 34 400 aa MW at 44237.8kD NOV6b, MAPWLQLLSLLGLLPGAVAAPAQPQVLDELGRHVLLRKDCGPVDTKVPGAGEPKSAFT CG101836-02 QGSAMISSLSQNHPDNRNETFSSVISLLNEDPLSQDLFVKMASIFKNFVITYNRTYES Protein KEEARWRLSVFVNNMVRAQKIQALDRGTAQYGVTKFSDLTEEEFRTIYLNTLLRKEPG Sequence NKMKQAKSVGDLAPPEWDWRSKGAVTKVKDQGMCGSCWAFSVTGNVEGQWFLNQGTLL SLSEQELLDCDKMDKACMGGLPSNAYSAIKNLGGLETEDDYSYQGHMQSCNFSAEKAK VYINDSVELSQNEQKLAAWLAKRGFISVAINAFGMQFYRHGISRPLRPLCSPWLIDHA VLLVGYGNRSDVPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD

[0347] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 6B. TABLE-US-00030 TABLE 6B Comparison of NOV6a against NOV6b. Identities/ Protein NOV6a Residues/ Similarities for Sequence Match Residues the Matched Region NOV6b 117 . . . 490 366/374 (97%) 28 . . . 400 368/374 (97%)

[0348] Further analysis of the NOV6a protein yielded the following properties shown in Table 6C. TABLE-US-00031 TABLE 6C Protein Sequence Properties NOV6a PSort 0.4514 probability located in outside; 0.1900 probability analysis: located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 20 and 21 analysis:

[0349] A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D. TABLE-US-00032 TABLE 6D Geneseq Results for NOV6a Identities/ Similarities for Geneseq Protein/Organism/Length NOV6a Residues/ the Matched Expect Identifier [Patent #, Date] Match Residues Region Value AAB11960 Human cathepsin Y - 1 . . . 490 469/491 (95%) 0.0 Homo sapiens, 484 aa. 1 . . . 484 476/491 (96%) [JP2000157263-A, 13-JUN-2000] AAW53200 Human spleen-derived cysteine 99 . . . 490 381/393 (96%) 0.0 protease - Homo sapiens, 392 aa. 1 . . . 392 386/393 (97%) [JP10099084-A, 21-APR-1998] AAW37957 Amino acid sequence of human 99 . . . 490 378/393 (96%) 0.0 cathepsin polypeptide-1 - 1 . . . 392 384/393 (97%) Homo sapiens, 392 aa. [WO9813484-A1, 02-APR-1998] AAY45041 Human Apop2 protein - 152 . . . 490 333/339 (98%) 0.0 Homo sapiens, 338 aa. 1 . . . 338 335/339 (98%) [WO200007545-A2, 17-FEB-2000] AAB51802 Gene 26 human secreted protein 256 . . . 490 229/235 (97%) e-135 homologous amino acid sequence 1 . . . 234 231/235 (97%) #131 - Homo sapiens, 234 aa. [WO200061625-A1, 19-OCT-2000]

[0350] In a BLAST search of public sequence datbases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E. TABLE-US-00033 TABLE 6E Public BLASTP Results for NOV6a NOV6a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9UBX1 Cathepsin F precursor 1 . . . 490 469/491 (95%) 0.0 (EC 3.4.22.41) (CATSF) - 1 . . . 484 476/491 (96%) Homo sapiens (Human), 484 aa. Q9R013 Cathepsin F precursor 1 . . . 490 350/493 (70%) 0.0 (EC 3.4.22.41) - Mus musculus 1 . . . 462 401/493 (80%) (Mouse), 462 aa. Q9ES93 CATHEPSIN F - Mus musculus 1 . . . 490 348/493 (70%) 0.0 (Mouse), 462 aa. 1 . . . 462 399/493 (80%) T46294 hypothetical protein 166 . . . 444 276/279 (98%) e-161 DKFZp434F0610.1 - human, 308 1 . . . 279 278/279 (98%) aa (fragment). Q99KQ9 SIMILAR TO CATHEPSIN F - 188 . . . 490 249/303 (82%) e-153 Mus musculus (Mouse), 302 aa. 1 . . . 302 281/303 (92%)

[0351] PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6F. TABLE-US-00034 TABLE 6F Domain Analysis of NOV6a Identities/ Similarities for the Matched Expect Pfam Domain NOV6a Match Region Region Value gpdh 404 . . . 413 5/10 (50%) 0.35 8/10 (80%) Peptidase_C1 276 . . . 488 102/337 (30%) 1.8e-104 184/337 (55%)

Example 7

[0352] The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A. TABLE-US-00035 TABLE 7A NOV7 Sequence Analysis SEQ ID NO: 35 1704 bp NOV7a, TGGTAGATGTGGCATTTGCATGCTGAGGCCGCGAGTCCCGGCTGACCCCGTCGGTGCC CG102221-01 TCTCCAGGGCTTCTCTGGGCCGCGCCTCTGCAGACTGCGCAGCCATGCTGCATCTGCT DNA GGCGCTCTTCCTGCACTGCCTCCCTCTGGCCTCTGGGGACTATGACATCTGCAAATCC Sequence TGGGTGACCACAGATGAGGGCCCCACCTGGGAGTTCTACGCCTGCCAGCCCAAGGTGA TGCGCCTGAAGGACTACGTCAAGGTGAAGGTGGAGCCCTCAGGCATCACATGTGGAGA CCCCCCTGAGAGGTTCTGCTCCCATCCCTACCTATGCAGCAACGAGTGTGACGCCTCC AACCCGGACCTGGCCCACCCGCCCAGGCTCATGTTCGACAAGGAGGAGGAGGGCCTGG CCACCTACTGGCAGAGCATCACCTGGAGCCGCTACCCCAGCCCGCTGGAAGCCAACAT CACCCTTTCGTGGAACAAGACCGTGGAGCTGACCGACGACGTGGTGATGACCTTCGAG TACGGCCGGCCCACGGTCATGGTCCTGGAGAAGTCCCTGGACAACGGGCGCACCTGGC AGCCCTACCAGTTCTACGCCGAGGACTGCATGGAGGCCTTCGGTATGTCCGCCCGCCG GGCCCGCGACATGTCATCCTCCAGCGCGCACCGCGTGCTCTGCACCGAGGAGTACTCG CGCTGGGCAGGCTCCAAGAAGGAGAAGCACGTGCGCTTCGAGGTGCGGGACCGCTTCG CCATCTTTGCCGGCCCCGACCTGCGCAACATGGACAACCTCTACACGCGGCTGGAGAG CGCCAAGGGCCTCAAGGAGTTCTTCACCCTCACCGACCTGCGCATGCGGCTGCTGCGC CCGGCGCTGGGCGGCACCTATGTGCAGCGGGAGAACCTCTACAAGTACTTCTACGCCA TCTCCAACATCGAGGTCATCGGCAGGTGCAAGTGCAACCTGCACGCCAACCTGTGCTC CATGCGCGAGGGCAGCCTGCAGTGCGAGTGCGAGCACAACACCACCGGCCCCGACTGC GGCAAGTGCAAGAAGAATTTCCGCACCCGGTCCTGGCGGGCCGGCTCCTACCTGCCGC TGCCCCATGGCTCTCCCAACGCCTGTGACTGCGAATGCTACGGTCACTCCAACCGCTG CAGCTACATTGACTTCCTGAATGTGGTGACCTGCGTCAGCTGCAAGCACAACACGCGA GGTCAGCACTGCCAGCACTGCCGGCTGGGCTACTACCGCAACGGCTCGGCAGAGCTGG ATGATGAGAACGTCTGCATTGAGTGTAACTGCAACCAGATAGGCTCCGTGCACGACCG GTGCAACGAGACCGGCTTCTGCGAGTGCCGCGAGGGCGCGGCGGGCCCCAAGTGCGAC GACTGCCTCCCCACGCACTACTGGCGCCAGGGCTGCTACCCCAACGTGTGCGACGACG ACCAGCTGCTGTGCCAGAACGGAGGCACCTGCCTGCAGAACCAGCGCTGCGCCTGCCC GCGCGGCTACACCGGCGTGCGCTGCGAGCAGCCCCGCTGCGACCCCGCCGACGATGAC GGCGGTCTGGACTGCGACCGCGCGCCCGGGGCCGCCCCGCGCCCCGCCACCCTGCTCG GCTGCCTGCTGCTGCTGGGGCTGGCCGCCCGCCTGGGCCGCTGAGCCCCGCCCGGAGG ACGCTCCCCGCACCCGGAGGCC ORF Start: ATG at 103 ORE Stop: TGA at 1666 SEQ ID NO: 36 521 aa MW at 58964.0kD NOV7a, MLHLLALFLHCLPLASGDYDICKSWVTTDEGPTWEFYACQPKVMRLKDYVKVKVEPSG CG102221-01 ITCGDFPERFCSHPYLCSNECDASNPDLAHPPRLMFDKEEEGLATYWQSITWSRYPSP Protein LEANITLSWNKTVELTDDVVMTFEYGRPTVMVLEKSLDNGRTWQPYQFYAEDCMEAFG Sequence MSARRARDMSSSSAHRVLCTEEYSRWAGSKKEKHVRFEVRDRFAIFAGPDLRNMDNLY TRLESAKGLKEFFTLTDLRNRLLRPALGGTYVQRENLYKYFYAISNIEVIGRCKCNLH ANLCSMREGSLQCECEHNTTGPDCGKCKKNFRTRSWRAGSYLPLPHGSPNACDCECYG HSNRCSYIDFLNVVTCVSCKHNTRGQHCQHCRLGYYRNGSAELDDENVCIECNCNQIG SVHDRCNETGFCECREGAAGPKCDDCLPTHYWRQGCYPNVCDDDQLLCQNGGTCLQNQ RCACPRGYTGVRCEQPRCDPADDDGGLDCDRAPGAAPRPATLLGCLLLLGLAARLGR

[0353] Further analysis of the NOV7a protein yielded the following properties shown in Table 7B. TABLE-US-00036 TABLE 7B Protein Sequence Properties NOV7a PSort 0.7000 probability located in plasma membrane; 0.3000 analysis: probability located in microbody (peroxisome); 0.2000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in mitochondrial inner membrane SignalP Cleavage site between residues 18 and 19 analysis:

[0354] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C. TABLE-US-00037 TABLE 7C Geneseq Results for NOV7a NOV7a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value ABB53284 Human polypeptide #24 - 1 . . . 521 521/533 (97%) 0.0 Homo sapiens, 1 . . . 533 521/533 (97%) 533 aa. [WO200181363-A1, 01-NOV-2001] ABB05418 Mouse membrane bound type 17 . . . 519 308/515 (59%) 0.0 netrin protein SEQ ID NO: 8 - 28 . . . 537 379/515 (72%) Mus musculus, 539 aa. [JP2001327289-A, 27-NOV-2001] ABB53283 Human polypeptide #23 - 1 . . . 284 284/286 (99%) e-170 Homo sapiens, 286 aa. 1 . . . 286 284/286 (99%) [WO200181363-A1, 01-NOV-2001] ABB05419 Mouse membrane bound type 17 . . . 427 220/438 (50%) e-124 netrin protein SEQ ID NO: 10 - 28 . . . 461 277/438 (63%) Mus musculus, 483 aa. [JP2001327289-A, 27-NOV-2001] AAB65181 Human PRO1133 (UNQ571) protein 13 . . . 427 210/419 (50%) e-123 sequence SEQ ID NO: 129 - 24 . . . 416 274/419 (65%) Homo sapiens, 438 aa. [WO200073454-A1, 07-DEC-2000]

[0355] In a BLAST search of public sequence datbases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D. TABLE-US-00038 TABLE 7D Public BLASTP Results for NOV7a NOV7a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value BAB47486 KIAA1857 PROTEIN - 1 . . . 521 520/530 (98%) 0.0 Homo sapiens 20 . . . 549 521/530 (98%) (Human), 549 aa (fragment). Q96CW9 HYPOTHETICAL 59.8 KDA 1 . . . 521 520/530 (98%) 0.0 PROTEIN - Homo sapiens 1 . . . 530 521/530 (98%) (Human), 530 aa. Q8VIP8 NETRIN-G2A - Mus musculus 1 . . . 519 493/529 (93%) 0.0 (Mouse), 530 aa. 1 . . . 528 505/529 (95%) AAL84788 LAMINET-2A - Mus musculus 1 . . . 519 492/529 (93%) 0.0 domesticus (western European 1 . . . 528 504/529 (95%) house mouse), 530 aa. Q96JH0 KIAA1857 PROTEIN - 1 . . . 342 342/344 (99%) 0.0 Homo sapiens (Human), 438 aa 20 . . . 363 342/344 (99%) (fragment).

[0356] PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7E. TABLE-US-00039 TABLE 7E Domain Analysis of NOV7a NOV7a Identities/ Match Similarities Pfam Domain Region for the Matched Region Expect Value laminin_Nterm 39 . . . 283 79/282 (28%) 5.9e-12 134/282 (48%) laminin_EGF 285 . . . 342 15/68 (22%) 1.5e-06 38/68 (56%) laminin_EGF 344 . . . 397 18/63 (29%) 0.00013 39/63 (62%) laminin_EGF 400 . . . 442 20/59 (34%) 8.3e-09 35/59 (59%) EGF 447 . . . 477 16/47 (34%) 0.00014 22/47 (47%)

Example 8

[0357] The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A. TABLE-US-00040 TABLE 8A NOV8 Sequence Analysis SEQ ID NO: 37 910 bp NOV8a, GGTCCGGGGGGGCTGCCGGTCCCGGGTACCATGTGTGACGGCGCCCTGCTGCCTCCGC CG102325-01 TCGTCCTGCCCGTGCTGCTGCTGCTGGTTTGGGGACTGGACCCGGGCACAGCTGTCGG DNA CGACGCGGCGGCCGACGTGGAGGTGGTGCTCCCGTGGCGGGTGCGCCCCGACGACGTG Sequence CACCTGCCGCCGCTGCCCGCAGCCCCCGGGCCCCGACGGCGGCGACGCCCCCGCACGC CCCCAGCCGCCCCGCGCGCCCGGCCCGGAGAGCGCGCCCTGCTGCTGCACCTGCCGGC CTTCGGGCGCGAGCTGTACCTTCAGCTGCGCCGCGACCTGCGCTTCCTGTCCCGAGGC TTCGAGGTGGAGGAGGCGGGCGCGGCCCGGCGCCGCGGGCGCCCCGCCGAGCTGTGCT TCTACTCGGGCCGTGTGCTCGGCCACCCCGGCTCCCTCGTCTCGCTCAGCGCCTGCGG CGCCGCCGGCGGCCTGGTACTGCCCGCGCCACCTCCGGGTCGGCCCGTCCGGTCTGTT GCGACGCAGAGTGGTCGCCGTGGAGGGTGGGGGTGGGGCGCCTCTGCTGGAAGTCCAG CCTCCAGGGGAACCGGAGGGAACCCCCTGCCTTTCCACCTCTCCCCATCCCCCACCCC GGCCTTCGGTACCCTCTATAGGCAAAGGGGGTGGGAGGGGCAGCATCCCAGTCCAGCG CCTCTGCAGCCCGTGGAACCCGCGCGGAGCTGGGGTTGCGTGGGGGTATACGCCGCCC GCTCTAGGGAGCGCAGATCTGGCAGGGATGAAACTGTCAGGGCCCTGGACAGAGGCGC CTTGGCCCCAATGTAGAGAACACTGCATCTGCACCGCCGTGTCAAAGTGTATGTCACG GGAGTACCTGTGTACGTGTAGGTGTTATGTTCTTGGACTT ORF Start: ATG at 31 ORF Stop: TAG at 826 SEQ ID NO: 38 265aa MW at 28223.0kD NOV8a, MCDGALLPPLVLPVLLLLVWGLDPGTAVGDAAADVEVVLPWRVRPDDVHLPPLPAAPG CG102325-01 PRRRRRPRTPPAAPRARPGERALLLHLPAFGRDLYLQLRRDLRFLSRGFEVEEAGAAR Protein RRGRPAELCFYSGRVLGHPGSLVSLSACGAAGGLVLPAPPPGRFVRSVATQSGRRGGW Sequence GWGASAGSPASRGTGGNPLPFHLSPSPTFAFGTLYRQRGWEGQHFSPAPLQPVEPARS WGCVGVYAARSRERRSGRDETVRALDRGALAPM

[0358] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B. TABLE-US-00041 TABLE 8B Protein Sequence Properties NOV8a PSort 0.8200 probability located in outside; 0.1000 probability analysis: located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in lysosome (lumen) SignalP Cleavage site between residues 28 and 29 analysis:

[0359] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C. TABLE-US-00042 TABLE 8C Geneseq Results for NOV8a NOV8a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAE10350 Human ADAMTS-J1.4 variant 1 . . . 151 151/151 (100%) 6e-85 protein - Homo sapiens, 891 aa. 1 . . . 151 151/151 (100%) [EP1134286-A2, 19-SEP-2001] AAE10348 Human ADAMTS-J1.2 variant 1 . . . 151 151/151 (100%) 6e-85 protein - Homo sapiens, 635 aa. 1 . . . 151 151/151 (100%) [EP1134286-A2, 19-SEP-2001] AAE10347 Human ADAMTS-J1.1 variant 1 . . . 151 151/151 (100%) 6e-85 protein - Homo sapiens, 745 aa. 1 . . . 151 151/151 (100%) [EP1134286-A2, 19-SEP-2001] AAU72894 Human metalloprotease partial 27 . . . 151 125/125 (100%) 1e-68 protein sequence #6 - Homo 434 . . . 558 125/125 (100%) sapiens, 1428 aa. [WO200183782- A2, 08-NOV-2001] AAU72900 Human metalloprotease partial 51 . . . 151 52/112 (46%) 3e-15 protein sequence #12 - Homo 142 . . . 244 59/112 (52%) sapiens, 1094 aa. [WO200183782- A2, 08-NOV-2001]

[0360] In a BLAST search of public sequence datbases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D. TABLE-US-00043 TABLE 8D Public BLASTP Results for NOV8a NOV8a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value CAC86016 METALLOPROTEASE 1 . . . 151 151/151 (100%) 1e-84 DISINTEGRIN 17, WITH 1 . . . 151 151/151 (100%) THROMBOSPONDIN DOMAINS - Homo sapiens (Human), 1095 aa. CAC84565 ADAMTS-19 - Homo sapiens 51 . . . 151 51/112 (45%) 1e-14 (Human), 1207 aa. 142 . . . 244 59/112 (52%) CAC86014 METALLOPROTEASE 25 . . . 259 72/248 (29%) 5e-08 DISINTEGRIN 15 WITH 13 . . . 218 100/248 (40%) THROMBOSPONDIN DOMAINS - Homo sapiens (Human), 950 aa. Q9WUQ1 ADAMTS-1 precursor (EC 3.4.24.--) 69 . . . 149 35/90 (38%) 1e-06 (A disintegrin and metalloproteinase 66 . . . 153 46/90 (50%) with thrombospondin motifs 1) (ADAM-TS 1) (ADAM-TS1) - Rattus norvegicus (Rat), 967 aa. Q9UP79 ADAMTS-8 precursor (EC 3.4.24.--) 52 . . . 187 52/167 (31%) 3e-06 (A disintegrin and metalloproteinase 3 . . . 165 65/167 (38%) with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) (METH-8) - Homo sapiens (Human), 890 aa.

[0361] PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E. TABLE-US-00044 TABLE 8E Domain Analysis of NOV8a NOV8a Identities/ Match Similarities Expect Pfam Domain Region for the Matched Region Value Pep_M12B_propep 95 . . . 192 26/119 (22%) 0.021 60/119 (50%)

Example 9

[0362] The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A. TABLE-US-00045 TABLE 9A NOV9 Sequence Analysis SEQ ID NO: 39 958 bp NOV9a, GCAGCACCCGCAGCCAGAGCCGCGCTCGGCATGATGCCCGGGGCGCCGCTCCTGCGGC CG102832-01 TGCTGACCGCGGTCTCTGCGGCAGTGGCAGTGGCAGTGGCCGGGGCGCCCGGGACGGT DNA AATGCCCCCCACCACGGGGGACGCCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCC Sequence ATGTGGGACGAACTGATGCAGGTGATCGATGGCGCCTCGCGCATTCTGGAACGCAGTC TGAGCGGCCGCAGCCAGGCCATCGCCAACTACGCGCTGGTGCCCTTCCACGACCCAGA TATTGGCCCAGTGACCCTCACGGCGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAA CTCTACGTGCAGGGAGGTGGTGACTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTG CCGTGGAGGTTGCCAACCCCGGATCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAA AGACTATCACAAGAAGGAAGAGCTGCTGCGGCTCCTGCAGCTCAAGCAATCACAGGTG GTCTTTGTGCTGACGGGGGACTGTGGCGACCGCACCCATCCTGGCTACCTGGCTTATG AGGAGATCGCTGCCACCAGCTCTGGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGAC AGAGGTGCTGAAGTGGGTGGAGTCAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCC ACAGACCACGAGGAGGAGGGGGAGCACACATGGAGACTCCCCTTTGACCCCAGCCTGA AGGAGGTCACCATCTCATTGAGTGGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCT GGGTATGGACCACCCCGGGGCTGGCCTCCTCTTTGGCCCCAAGACTGAGGTGGAAGCC CAGGATGGGACAAAGAAAGAGACCAAGGGTGACAGGGCTTCAGACATGAGGCTCCAGG AATAGGGAAATATGGGGTGGGGGGGACACG ORF Start: ATG at 31 ORF Stop: TAG at 931 SEQ ID NO: 40 300 aa MW at 32481.5kD NOV9a, MMPGAPLLRLLTAVSAAVAVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVID CG102832-01 GASRILERSLSRRSQAIANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCP Protein EMSVGAIKAAVEVANPGSFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGD Sequence RTHPGYLAYEEIAATSSGQVFHLDKQQVTEVLKWVESAIQASKVHLLSTDHEEEGEHT WRLPFDPSLKEVTISLSGPGPEIEVQDPLGMDHFGAGLLFGPKTEVEAQDGTKKETKG DRASDMRLQE SEQ ID NO: 41 2916 bp NOV9b, GCAGCACCCGCAGCCAGAGCCGCGCTCGGCATGATGCCCGGGGCGCCGCTCCTGCGGC CG102832-02 TGCTGACCGCGGTCTCTGCGGCAGTGGCAGTGGCAGTGGCCGGGGCGCCCGGGACGGT DNA AATGCCCCCCACCACGGGGGACGCCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCC Sequence ATGTGGGACGAACTGATGCAGGTGATCGATGGCGCCTCGCGCATTCTGGAACGCAGTC TGAGCCGCCGCAGCCAGGCCATCGCCAACTACGCGCTGGTGCCCTTCCACGACCCAGA TATTGGCCCAGTGACCCTCACGGCGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAA CTCTACGTGCAGGGAGGTGGTGACTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTG CCGTGGAGGTTGCCAACCCCGGATCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAA AGACTATCACAAGAAGGAAGAGCTGCTGCGGCTCCTGCAGCTCAAGCAATCACAGGTG GTCTTTGTGCTGACGGGGGACTGTGGCGACCGCACCCATCCTGGCTACCTGGCTTATG AGGAGATCGCTGCCACCAGCTCTGGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGAC AGAGGCAGGTGCTTCCGTGTTTCCAGGCAAAATTGTGCAGGAGCACAGGATCCTTTCA GGGGCCAGCTGGGAAATGATGAACAACGCTCTCTCTGGAAAGGACAAGCACACCCATT TCCGTGGTATAAATGCTCCCACCTCGGCTGATTCCAAGTCAGAGTTGGGAAGTGACGC TGACACTCAGCTTTCCGGAGCCTACACAAGTGGCTCCCACACACCACTGGATCCCGCA CAGGCACCTCTCACCGCCAGTTGGGTTAACGAGAGCCCCTACCTGGTGCTGAAGTGGG TGGAGTCAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCCACAGACCACGAGGAGGA GGGGGAGCACACATGGAGACTCCCCTTTGACCCCAGCCTGAAGGAGGTCACCATCTCA TTGAGTGGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCTGGGTATGGACCACCCCG GGGCTGGCCTCCTCTTTGGCCCCAAGACTGAGGTGGAAGCCCAGGATGGGACAAAGAA AGAGACCAAGGGGAGGATCCTGCAGGAGGACGAGGGCCTCAACGTGCTTCTCAACATC CCTGACTCGGCCAAGGTCGTAGCCTTTAAGCCTGAGCATCCGGGGCTGTGGTCCATCA AGGTCTATAGCAGTGGCCGCCATTCAGTGAGGATCACAGGCGTCAGCAACATTGACTT CCGAGCCGGCTTCTCCACTCAGCCCTTGCTGGACCTCAACCACACCCTCGAGTGGCCC TTGCAAGGAGTCCCCATCTCCCTGGTGATCAATTCCACGGGCCTGAAGGCACCCGGCC GCCTAGACTCGGTGGAGCTGGCACAAAGCTCAGGGAAGCCCCTCCTGACTCTGCCCAC GAAGCCCCTCTCCAATGGCTCCACCCATCAGCTGTGGGGCGGGCCGCCCTTCCACACC CCCAAGGAGCGCTTCTACCTCAAGGTGAAGGGCAAGGACCATGAGGGAAACCCCCTCC TTCGTGTCTCTGGAGTGTCCTACAGTGGGGTGGCCCCAGGCGCTCCCCTCGTCAGCAT GGCCCCCAGGATCCATGGCTACCTGCACCAGCCCCTGCTGGTCTCCTGCTCGGTGCAC AGTGCCCTTCCCTTCCGGCTGCAGCTGCGGCGAGGTGAAGCCAGGCTGGGCGAAGAGA GGCACTTTCAGGAGTCGGGAAACAGCAGCTGGGAGATCCTGCGGGCCTCCAAGGCCGA GGAGGGCACGTACGAGTGCACAGCCGTCAGCAGGGCTGGGACCGGGCGAGCAAAGGCC CAGATTGTTGTCACCCTGCACCTCAGGGTGGGGTTCGGGGCAGCACCAGGGCTTGCAC GAAGACCCCCTCCCTTGCCTCAGCTCCTTGGTTCCTCCTGTGCTCATGTCCCTGCAGA CCCCCCGCCGCAGCTGGTCCCTGCTCCCAACGTGACCGTGTCCCCAGGGGAGACTGCC GTCCTATCCTGCCGGGTCCTAGGCGAGGCCCCCTACAACCTGACGTGGGTCCGGGACT GGCGAGTCCTGCCGGCCTCGACGGGCCGAGTTGCCCAGCTGGCTGACCTGTCCCTGGA GATCAGTGGCATCATCCCCACAGACGGCGGGAGGTACCAGTGTGTGGCCAGCAATGCC AATGGGGTCACAAGGGCATCCGTCTGGCTCCTGGTGCGAGAGGCCCCACAGGTCAGCA TCCACACCAGCTCCCAGCACTTCTCCCAAGGTGTGGAGGTGAAGGTCAGCTGCTCAGC CTCTGGATACCCCACACCCCACATCTCCTGGAGCCGTGAGAGCCAAGCCCTACAAGAG GACAGCAGAATCCATGTGGACGCACAGGGAACCCTGATTATTCAGGGGGTAGCCCCAG AGGATGCTGGGAATTACAGCTGCCAGGCGACTAATGAGGTTGGCACTGACCAGGAGAC GGTCACCCTCTACTACACAGACCCACCGTCGGTCTCTGCTGTAAATGCCGTGGTGCTG GTGGCCGTTGGGGAGGAGGCTGTGTTGGTGTGTGAGGCATCTGGGGTTCCCCCGCCCC GAGTCATCTGGTATCGAGGGGGTCTTGAAATGATCCTGGCCCCTGAGGGCTCCAGCTC TGGGAAGCTGCGGATCCCGGCGGCTCAGGAGAGGGATGCTGGCACCTACACCTGCCGG GCTGTCAATGAGTTGGGTGACGCCTCTGCAGAAATCCAGCTGGCGGTTGGACATGCGC CCCAGCTGACGGAGCTGCCCCGGGATGTCACTGTGGAACTGGGGAGGAGTGCCCAGCT GCGGCGTGGGACTTAA ORF Start: ATG at 31 ORF Stop: TAA at 2914 SEQ ID NO: 42 961 aa MW at 102789.2kD NOV9b, MMPGAPLLRLLTAVSAAVAVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVID CG102832-02 GASRILERSLSRRSQAIANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCP Protein EMSVGAIKAAVEVANPGSFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGD Sequence RTHPGYLAYEEIAATSSGQVFHLDKQQVTEAGASVFPGKIVQEHRILSGASWEMMNNA LSGKDKHTHFRGINAFTSADSKSELGSDADTQLSGAYTSGSHTPLDPAQAPLTASWVN ESPYLVLKWVESAIQASKVHLLSTDHEEEGEHTWRLPFDPSLKEVTISLSGPGPEIEV QDPLGMDHPGAGLLFGPKTEVEAQDGTKKETKGRILQEDEGLNVLLNIPDSAKVVAFK PEHPGLWSIKVYSSGRHSVRITGVSNIDFRAGFSTQPLLDLNHTLEWPLQGVPISLVI NSTGLKAPGRLDSVELAQSSGKPLLTLPTKPLSNGSTHQLWGGPPFHTPKERFYLKVK GKDBEGNPLLRVSGVSYSGVAPGAPLVSMAPRIHGYLHQPLLVSCSVHSALPFRLQLR RGEARLGEERHFQESGNSSWEILRASKAEEGTYECTAVSRAGTGRAKAQIVVTLHLRV GFGAAPGLARRPPPLPQLLGSSCAHVPADPPPQLVPAPNVTVSPGETAVLSCRVLGEA PYNLTWVRDWRVLFASTGRVAQLADLSLEISGIIPTDGGRYQCVASNANGVTRASVWL LVREAPQVSIHTSSQHFSQGVEVKVSCSASGYPTPHISWSRESQALQEDSRIHVDAQG TLIIQGVAPEDAGNYSCQATNEVGTDQETVTLYYTDPPSVSAVNAVVLVAVGEEAVLV CEASGVPPPRVIWYRGGLEMILAPEGSSSGKLRIPAAQERDAGTYTCRAVNELGDASA EIQLAVGHAPQLTELPRDVTVELGRSAQLRRGT SEQ ID NO: 43 1023 bp NOV9c, CTCGAGTGTGGAACTCACTCTTAACGTACCTGAGGAGTGTCCAACGTCTTTGGACAAG 197195425 GCCATACTCTCATGTTCCTTTTCACTCAGCTTTACCCACACAGAAATTTTGGGGACCC DNA ATGGGGGACTCAGCAGTTGCCAAGGTCTGCAGCCTCCTCCAAGGGGTTCCCATCTAGT Sequence TCTCAAGAGGAAGGAGGGGGTTCTCAGTCGCCAGGTGGGCATGGCACTCCCGAGGCCA GGTGAGCAGGTCAGTGCCTTGGGGCTCAGGGCTGCTCCGGTTCTTACCGAATTGATCC AGTCGTTGTAGTTGGAGACCCGCGTGAAGATGGAGGGCTTGTAGTAGTAGTTGCAACC AAGGACCGACGTGAGGCTGCCGATGCCATGCACCTCCCACCGGCCGTCAGATGCCTGA CAGTTCAGCGGCCCACCGGAGTCTCCGTTGCAGGTGCATATCACGCCATCACCCCCAG CACAGATCATATTCGTCTTCACGGTGCTGCCCCACCAGCCAGAGTTGGAGCAGGTGGC ATAGTCCACAACCAGCAACCGGCCCTGCTTCAGGTCATCAGGGAGAGCCCCGTTGGTC TGCAGCCTTCCCCAGCCCGTGACGTAGCAGGGGTAGTTGTTGGGTAGAATGGTGCCGG CAGGAGGGAGGCAGGCCAGCTGGATCTTGTCGGTGAGGGAGACGGGGTTAGCCAGTTT GAGCAGGGCAATGTCGTTCCCTTTGGAGACCTGGTCGGAGTTCCAGTCCTTGTGCACC ACAATCTTAGAGACACTGACGGCCAGCGAGCCGGACTCTGCAACGTAGAGGTTATGCT GGCCCAGCATCACGCGGTAGATCCCGGAGGAGCTGATGCAGTGGGCAGCCGTCAGGAC CCAGCTGTTGGCTATCAGGGACCCTCCGCAGGTGTGGTACCACTGGCCATTGGAGCTG TACTGCAGGGAGACCTGCCAGGGCCGGCTGTTGGGCCTCGCTTCTTCACCTCCAAGCA TCCTAGACATATCAGGCGCGTAAGTGGAGACGGATCC ORF Start: at 628 ORF Stop: end of sequence SEQ ID NO: 44 132 aa MW at 13513.0kD NOV9c, NGAGRREAGQLDLVGEGDGVSQFEQGNVVPFGDLVGVPVLVHHNLRDTDGQRAGLCNV 197195425 EVMLAQHHAVDPGGADAVGSRQDPAVGYQGPSAGVVPLAIGAVLQGDLPGPAVGPRFF Protein TSKHPRHIRRVSGDGS Sequence SEQ ID NO: 45 2058 bp NOV9d, AAGCTTGTGGCAGTGGCCGGGGCGCCCGGGACGGTAATGCCCCCCACCACGGGGGACG 197192431 CCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCCATGTGGGACGAACTGATGCAGGT DNA GATCGATGGCGCCTCGCGCATTCTGGAACGCAGTCTGAGCCGCCGCAGCCAGGCCATC Sequence GCCAACTACGCGCTGGTGCCCTTCCACGACCCAGATATTGGCCCAGTGACCCTCACGG CGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAACTCTACGTGCAGGGAGGTGGTGA CTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTGCCGTGGAGGTTGCCAACCCCGGA TCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAAAGACTATCACAAGAAGGAAGAGC TGCTGCGGCTCCTGCAGGTCAAGCAATCACAGGTGGTCTTTGTGCTGACGGGGGACTG TGGCGACCACACCCATCCTGGCTACCTGGCTTATGAGGAGATCGCTGCCACCAGCTCT GGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGACAGAGGTGCTGAAGTGGGTGGAGT CAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCCACAGACCACGAGGAGGAGGGGGA GCACACATGGAGACTCCCCTTTGACCCCAGCCTGAAGGAGGTCACCATCTCATTGAGT GGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCTGGGGAGGATCCTGCAGGAGGACG AGGGCCTCAACGTGCTTCTCAACATCCCTGACTCGGCCAAGGTCGTAGCCTTTAAGCC TGAGCATCCGGGGCTGTGGTCCATCAAGGTCTATAGCAGTGGCCGCCATTCAGTGAGG ATCACAGGCGTCAGCAACATTGACTTCCGAGCCGGCTTCTCCACTCAGCCCTTGCTGG ACCTCAACCACACCCTCGAGTGGGCCTTGCAAGGAGTCCCCATCTCCCTGGTGATCAA TTCCACGGGCCTGAAGGCACCCGGCCGCCTAGACTCGGTGGAGCTGGCACAAAGCTCA GGGAAGCCCCTCCTGACTCTGCCCACGAAGCCCCTCTCCAATGGCTCCACCCATCAGC TGTGGGGCGGGCCACCCTTCCACACCCCCAAGGAGCGCTTCTACCTCAAGGTGAAGGG CAAGGACCATGAGGGAAACCCCCTCCTTCGTGTCTCTGGAGTGTCCTACAGTGGGGTG GCCCCAGGCGCTCCCCTCGTCAGCATGGTCCCCAGGATCCATGGCTACCTGCACCAGC CCCTGCTGGTCTCCTGCTCGGTGCACAGTGCCCTTCCCTTCCGGCTGCAGCTGCGGCG AGGTGAAGCCAGGCTGGGCGAAGAGAGGCACTTTCAGGAGTCGGGAAACAGTAGCTGG GAGATCCTGCGGGCCTCCAAGGCCGAGGAGGGCACGTACGAGTGCACAGCCGTCAGCA GGGCTGGGACCGGGCGAGCAAAGGCCCAGATTGTTGTCACAGACCCCCCGCCGCAGCT GGTCCCTGCTCCCAACGTGACCGTGTCCCCAGGGGAGACTGCCGTCCTATCCTGCCGG GTCCTAGGCGAGGCCCCCTACAACCTGACGTGGGTCCGGGACTGGCGAGTCCTGCCGG CCTCGACGGGCCGAGTTGCCCAGCTGGCTGACCTGTCCCTGGAGATCAGTGGCATCAT CCCCACAGACGGCGGGAGGTACCAGTGTGTGGCCAGCAATGCCAATGGGGTCACAAGG GCATCCGTCTGGCTCCTGGTGCGAGAGGTCCCACAGGTCAGCATCCACACCAGCTCCC AGCACTTCTCCCAAGGTGTGGAGGTGAAGGTCAGCTGCTCAGCCTCTGGATACCCCAC ACCCCACATCTCCTGGAGCCGTGAGAGCCAAGCCCTACAAGAGGACAGCAGAATCCAT GTGGAGGCACAGGGAACCCTGATTATTCAGGGGGTAGCCCCAGAGGATGCTGGGAATT ACAGCTGCCAGGCGACTAATGAGGTTGGCACTGACCAGGAGACGGTCACCCTCTACTA CACAGACCCACCGTCGGTCTCTGTCGAC ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 46 686 aa MW at 74318.2kD NOV9d, KLVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVIDGASRILERSLSRRSQAI 197192431 ANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCPEMSVGAIKAAVEVANPG Protein SFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGDHTHPGYLAYEEIAATSS Sequence GQVFHLDKQQVTEVLKWVESAIQASKVHLLSTDHEEEGEHTWRLPFDPSLKEVTISLS GPGPEIEVQDPLGRILQEDEGLNVLLNIPDSAKVVAFKPEHPGLWSIKVYSSGRHSVR ITGVSNIDFRAGFSTQFLLDLNHTLEWPLQGVPISLVINSTGLKAPGRLDSVELAQSS GKPLLTLPTKPLSNGSTHQLWGGPPFHTPKERFYLKVKGKDHEGNPLLRVSGVSYSGV APGAPLVSMVPRIHGYLHQPLLVSCSVHSALPFRLQLRRGEARLGEERHFQESGNSSW EILRASKAEEGTYECTAVSRAGTGRAKAQIVVTDPFPQLVPAPNVTVSPGETAVLSCR VLGEAPYNLTWVRDWRVLPASTGRVAQLADLSLEISGIIFTDGGRYQCVASNANGVTR ASVWLLVREVFQVSIHTSSQHFSQGVEVKVSCSASGYPTFHISWSRESQALQEDSRIH VDAQGTLIIQGVAPEDAGNYSCQATNEVGTDQETVTLYYTDPPSVSVD SEQ ID NO: 47 2058 bp NOV9e, AAGCTTGTGGCAGTGGCCGGGGCGCCCGGGACGGTAATGCCCCCCACCACGGGGGACG 197192437 CCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCCATGTGGGACGAACTGATGCAGGT DNA GATCGATGGCGCCTCGCGCATTCTGGAACGCAGTCTGAGCCGCCGCAGCCAGGCCATC Sequence GCCAACTACGCGCTGGTGCCCTTCCACGACCCAGATATTGGCCCAGTGACCCTCACGG CGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAACTCTACGTGCAGGGAGGTGGTGA CTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTGCCGTGGAGGTTGCCAACCCCGGA TCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAAAGACTATCACAAGAAGGAAGAGC TGCTGCGGCTCCTGCAGCTCAAGCAATCACAGGTGGTCTTTGTGCTGACGGGGGACTG TGGCGACCACACCCATCCTGGCTACCTGGCTTATGAGGAGATCGCTGCCACCAGCTCT GGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGACAGAGGTGCTGAAGTGGGTGGAGT CAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCCACAGACCACGAGGAGGAGGGGGA GCACACATGGAGACTCCCCTTTGACCCCAGCCTGAAGGAGGTCACCATCTCATTGAGT GGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCTGGGGAGGATCCTGCAGGAGGACG AGGGCCTCAACGTGCTTCTCAACATCCCTGACTCGGCCAAGGTCGTAGCCTTTAAGCC TGAGCATCCGGGGCTGTGGTCCATCAAGGTCTATAGCAGTGGCCGCCATTCAGTGAGG ATCACAGGCGTCAGCAACATTGACTTGCGAGCCGGCTTCTCCACTCAGCCCTTGCTGG ACCTCAACCACACCCTCGAGTGGCCCTTGCAAGGAGTCCCCATCTCCCTGGTGATCAA TTCCACGGGCCTGAAGGCACCCGGCCGCCTAGACTCGGTGGAGCTGGCACAAAGCTCA GGGAAGCCCCTCCTGACTCTGCCCACGAAGCCCCTCTCCAATGGCTCCACCCATCAGC TGTGGGGCGGGCCGCCCTTCCACACCCCCAAGGAGCGCTTCTACCTCAAGGTGAAGGG CAAGGACCATGAGGGAAACCCCCTCCTTCGTGTCTCTGGAGTGTCCTACAGTGGGGTG GCCCCAGGCGCTCCCCTCGTCAGCATGGCCCCCAGGATCCATGGCTACCTGCACCAGC CCCTGCTGGTCTCCTGCTCGGTGCACAGTGCCCTTCCCTTCCGGCTGCAGCTGCGGCG AGGTGAAGCCAGGCTGGGCGAAGAGAGGCACTTTCAGGAGTCGGGAAACAGCAGCTGG GAGATCCTGCGGGCCTCCAAGGCCGAGGAGGGCACGTACGAGTGCACAGCCGTCAGCA GGGCTGGGACCGGGCGAGCAAAGGCCCAGATTGTTGTCACAGACCCCCCGCCGCAGCT GGTCCCTGCTCCCAACGTGACCGTGTCCCCAGGGGAGACTGCCGTCCTATCCTGCCGG GTCCTAGGCGAGGCCCCCTACAACCTGACGTGGGTCCGGGACTGGCGAGTCCTGCCGG CCTCGACGGGCCGAGTTGCCCAGCTGGCTGACCTGTCCCTGGAGATCAGTGGCATCAT CCCCACAGACGGCGGGAGGTACCAGTGTGTGGCCAGCAATGCCAATGGGGTCACAAGG GCATCCGTCTGGCTCCTGGTGCGAGAGGCCCCACAGGTCAGCATCCACACCAGCTCCC AGCACTTCTCCCAAGGTGTGGAGGTGAAGGTCAGCTGCTCAGCCTCTGGATACCCCAC ACCCCACATCTCCTGGAGCCGTGAGAGCCAAGCCCTACAAGAGGACAGCAGAATCCAT GTGGACGCACAGGGAACCCTGATTATTCAGGGGGTAGCCCCAGAGGATGCTGGGAATT ACAGCTGCCAGGCGACTAATGAGGTTGGCACTGACCAGGAGACGGTCACCCTCTACGA CACAGACCCACCGTCGGTCTCTGTCGAC ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 48 686 aa MW at 74214.0kD NOV9e, KLVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVIDGASRILERSLSRRSQAI 197192437 ANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCPEMSVGAIKAAVEVANPG Protein SFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGDHTHFGYLAYEEIAATSS Sequence GQVFHLDKQQVTEVLKWVESAIQASKVHLLSTDHEEEGEHTWRLFFDPSLKEVTISLS GPGPEIEVQDPLGRILQEDEGLNVLLNIPDSAKVVAFKPEHPGLWSIKVYSSGRHSVR ITGVSNIDFRAGFSTQPLLDLNHTLEWPLQGVPISLVINSTGLKAPGRLDSVELAQSS GKPLLTLPTKPLSNGSTHQLWGGPPFHTPKERFYLKVKGKDHEGNPLLRVSGVSYSGV APGAPLVSMAPRIHGYLHQPLLVSCSVHSALPFRLQLRRGEARLGEERHFQESGNSSW EILRASKAEEGTYECTAVSRAGTGRAKAQIVVTDPPPQLVPAPNVTVSPGETAVLSCR VLGEAPYNLTWVRDWRVLPASTGRVAQLADLSLEISGIIPTDGGRYQCVASNANGVTR ASVWLLVREAPQVSIHTSSQHFSQGVEVKVSCSASGYPTPHISWSRESQALQEDSRIH VDAQGTLIIQGVAPEDAGNYSCQATNEVGTDQETVTLYIJTDPPSVSVD SEQ ID NO: 49 2058 bp NOV9f, AAGCTTGTGGCAGTGGCCGGGGCGCCGGGGACGGTAATGCCCCCCACCACGGGGGACG 197192443 CCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCCATGTGGGACGAACTGATGCAGGT DNA GATCGATGGCGCCTCGCGCATTCTGGAACGCAGTCTGAGCCGCCGCAGCCAGGCCATC Sequence GCCAACTACGCGCTGGTGCCCTTCCACGACCCAGATATTGGCCCAGTGACCCTCACGG CGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAACTCTACGTGCAGGGAGGTGGTGA CTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTGCCGTGGAGGTTGCCAACCCCGGA TCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAAAGACTATCACAAGAAGGAAGAGC TGCTGCGGCTCCTGCAGCTCAAGCAATCACAGGTGGTCTTTGTGCTGACGGGGGACTG

TGGCGACCACACCCATCCTGGCTACCTGGCTTATGAGGAGATCGCTGCCACCAGCTCT GGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGACAGAGGTGCTGAAGTGGGTGGAGT CAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCCACAGACCACGAGGAGGAGGGGGA GCACACATGGAGACTCCCCTTTGACCCCAGCCTGAAGGAGGTCACCATCTCATTGAGT GGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCTGGGGAGGATCCTGCAGGAGGACG AGGGCCTCAACGTGCTTCTCAACATCCCTGACTCGGCCAAGGTCGTAGCCTTTAAGCC TGAGCATCCGGGGCTGTGGTCCATCAAGGTCTATAGCAGTGGCCGCCATTCAGTGAGG ATCACAGGCGTCAGCAACATTGACTTCCGAGCCGGCTTCTCCACTCAGCCCTTGCTGG ACCTCAACCACACCCTCGAGTGGCCCTTGCAAGGAGTCCCCATCTCCCTGGTGATCAA TTCCACGGGCCTGAAGGCACCCGGCCGCCTAGACTCGGTGGAGCTGGCACAAAGCTCA GGGAAGCCCCTCCTGACTCTGCCCACGAAGCCCCTCTCCAATGGCTCCACCCATCAGC TGTGGGGCGGGCCGCCCTTCCACACCCCCAAGGAGCGCTTCTACCTCAAGGTGAAGGG CAAGGACCATGAGGGAAACCCCCTCCTTCGTGTCTCTGGAGTGTCCTACAGTGGGGTG GCCCCAGGCGCTCCCCTCGTCAGCATGGCCCCCAGGATCCATGGCTACCTGCACCAGC CCCTGCTGGTCTCCTGCTCGGTGCACAGTGCCCTTCCCTTCCGGCTGCAGCTGCGGCG AGGTGAAGCCAGGCTGGGCGAAGAGAGGCACTTTCAGGAGTCGGGAAACAGCAGCTGG GAGATCCTGCGGGCCTCCAAGGCCGAGGAGGGCACGTACGAGTGCACAGCCGTCAGCA GGGCTGGGACCGGGCGAGCAAAGGCCCAGATTGTTGTCACAGACCCCCCGCCGCAGCT GGTCCCTGCTCCCAACGTGACCGTGTCCCCAGGGGAGGCTGCCGTCCTATCCTGCCGG GTCCTAGGCGAGGCCCCCTACAACCTGACGTGGGTCCGGGACTGGCGAGTCCTGCCGG CCTCGACGGGCCGAGTTGCCCAGCTGGCTGACCTGTCCCTGGAGATCAGTGGCATCAT CCCCACAGACGGCGGGAGGTACCAGTGTGTGGCCAGCAATGCCAATGGGGTCACAAGG GCATCCGTCTGGCTCCTGGTGCGAGAGGCCCCACAGGTCAGCATCCACACCAGCTCCC AGCACTTCTCGCAAGGTGTGGAGGTGAAGGTCAGCTGCTCAGCCTCTGGATACCCCAC ACCCCACATCTCCTGGAGCCGTGAGAGCCAAGCCCTACAAGAGGACAGCAGAATCCAT GTGGACGCACAGGGAACCCTGATTATTCAGGGGGTAGCCCCAGAGGATGCTGGGAATT ACAGCTGCCAGGCGACTAATGAGGTTGGCACTGACCAGGAGACGGTCACCCTCTACTA CACAGACCCACCGTCGGTCTCTGTCGAC ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 50 686 aa MW at 74232.1kD NOV9f, KLVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVIDGASRILERSLSRRSQAI 197192443 ANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCPEMSVGAIKAAVEVANPG Protein SFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGDHTHPGYLAYEEIAATSS Sequence GQVFHLDKQQVTEVLKWVESAIQASKVHLLSTDHEEEGEHTWRLPFDPSLKEVTISLS GPGPEIEVQDPLGRILQEDEGLNVLLNIPDSAKVVAFKPEHPGLWSIKVYSSGRHSVR ITGVSNIDFRAGFSTQPLLDLNHTLEWPLQGVPISLVINSTGLKAPGRLDSVELAQSS GKPLLTLPTKPLSNGSTHQLWGGPPFHTPKERFYLKVKGKDHEGNPLLRVSGVSYSGV APGAPLVSMAFRIBGYLHQPLLVSCSVHSALPFRLQLRRGEARLGEERHFQESGNSSW EILRASKAEEGTYECTAVSRAGTGRAKAQIVVTDFPPQLVPAPNVTVSPGEAAVLSCR VLGEAPYNLTWVRDWRVLPASTGRVAQLADLSLEISGIIFTDGGRYQCVASNANGVTR ASVWLLVREAPQVSIHTSSQHFSQGVEVKVSCSASGYPTPHISWSRESQALQEDSRIH VDAQGTLIIQGVAPEDAGNYSCQATNEVGTDQETVTLYYTDPPSVSVD SEQ ID NO: 51 2058 bp NOV9g, AAGCTTGTGGCAGTGGCCGGGGCGCCCGGGACGGTAATGCCCCCCACCACGGGGGACG 197192448 CCACCCTGGCCTTCGTCTTCGACGTCACCGGCTCCATGTGGGACGAACTGATGCAGGT DNA GATCGATGGCGCCTCGCGCATTCTGGAACGCAGTCTGAGCCGCCGCAGCCAGGCCATC Sequence GCCAACTACGCGCTGGTGCCCTTCCACGACCCAGATATTGGCCCAGTGACCCTCACGG CGGACCCCACAGTGTTTCAGAGGGAGCTGAGAGAACTCTACGTGCAGGGAGGTGGTGA CTGCCCGGAGATGAGTGTGGGGGCCATTAAGGCTGCCGTGGAGGTTGCCAACCCCGGA TCCTTCATCTACGTCTTTTCGGATGCCCGCGCCAAAGACTATCACAAGAAGGAAGAGC TGCTGCGGCTCCTGCAGCTCAAGCAATCACAGGTGGTCTTTGTGCTGACGGGGGACTG TGGCGACCACACCCATCCTGGCTACCTGGCTTATGAGGAGATCGCTGCCACCAGCTCT GGGCAGGTGTTCCACCTGGACAAGCAGCAAGTGACAGAGGTGCTGAAGTGGGTGGAGT CAGCGATCCAGGCCTCCAAGGTGCACCTGCTGTCCACAGACCACGAGGAGGAGGGGGA GCACACATGGAGACTCCCCTTTGACCCCAGCCTGAAGGAGGTCACCATCTCATTGAGT GGGCCAGGGCCTGAGATTGAAGTCCAAGATCCGCTGGGGAGGATCCTGCAGGAGGACG AGGGCCTCAACGTGCTTCTCAACATCCCTGACTCGGCCAAGGTCGTAGCCTTTAAGCC TGAGCATCCGGGGCTGTGGTCCATCAAGGTCTATAGCAGTGGCCGCCATTCAGTGAGG ATCACAGGCGTCAGCAACATTGACTTCCGAGCCGGCTTCTCCACTCAGCCCTTGCTGG ACCTCAACCACACCCTCGAGTGGCCCTTGCAAGGAGTCCCCATCTCCCTGGTGATCAA TTCCACGGGCCTGAAGGCACCCGGCCGCCTAGACTCGGTGGAGCTGGCACAAAGCTCA GGGAAGCCCCTCCTGACTCTGCCCACGAAGCCCCTCTCCAATGGCTCCACCCATCAGC TGTGGGGCGGGCCGCCCTTCCACACCCCCAAGGAGCGCTTCTACCTCAAGGTGAAGGG CAAGGACCATGAGGGAAACCCCCTCCTTCGTGTCTCTGGAGTGTCCTACAGTGGGGTG GCCCCAGGCGCTCCCCTCGTCAGCATGGCCCCCAGGATCCATGGCTACCTGCACCAGC CCCTGCTGGTCTCCTGCTCGGTGCACAGTGCCCTTCCCTTCCGGCTGCAGCTGCGGCG AGGTGAAGCCAGGCTGGGCGAAGAGAGGCACTTTCAGGAGTCGGGAAACAGCAGCTGG GAGATCCTGCGGGCCTCCAAGGCCGAGGAGGGCACGTACGAGTGCACAGCCGTCAGCA GGGCTGGGACCGGGCGAGCAAAGGCCCAGATTGTTGTCACAGACCCCCCGCCGCAGCT GGTCCCTGCTCCCAACGTGACCGTGTCCCCAGGGGAGACTGCCGTCCTATCCTGCCGG GTCCTAGGCGAGGCCCCCTACAACCTGACGTGGGTCCGGGACTGGCGAGTCCTGCCGG CCTCGACGGGCCGAGTTGCCCAGCTGGCTGACCTGTCCCTGGAGATCAGTGGCATCAT CCCCACAGACGGCGGGAGGTACCAGTGTGTGGCCAGCAATGCCAATGGGGTCACAAGG ACATCCGTCTGGCTCCTGGTGCGAGAGGCCCCACAGGTCAGCATCCACACCAGCTCCC AGCACTTCTCCCAAGGTGTGGAGGTGAAGGTCAGCTGCTCAGCCTCTGGATACCCCAC ACCCCACATCTCCTGGAGCCGTGAGAGCCAAGCCCTACAAGAGGACAGCAGAATCCAT GTGGACGCACAGGGAACCCTGATTATTCAGGGGGTAGCCCCAGAGGATGCTGGGAATT ACAGCTGCCAGGCGACTAATGAGGTTGGCACTGACCAGGAGACGGTCACCGTCTACTA CACAGACCCACCGTCGGTCTCTGTCGAC ORE Start: at 1 ORF Stop: end of sequence SEQ ID NO: 52 686 aa MW at 74292.1kD NOV9g, KLVAVAGAPGTVMPPTTGDATLAFVFDVTGSMWDELMQVIDGASRILERSLSRRSQAI 197192448 ANYALVPFHDPDIGPVTLTADPTVFQRELRELYVQGGGDCPEMSVGAIKAAVEVANPG Protein SFIYVFSDARAKDYHKKEELLRLLQLKQSQVVFVLTGDCGDHTHPGYLAYEEIAATSS Sequence GQVFHLDKQQVTEVLKWVESAIQASKVHLLSTDHEEEGEHTWRLPFDPSLKEVTISLS GPGPEIEVQDPLGRILQEDEGLNVLLNIPDSAKVVAFKPEHFGLWSIKVYSSGRHSVR ITGVSNIDFRAGFSTQPLLDLNHTLEWPLQGVPISLVINSTGLKAPGRLDSVELAQSS GKPLLTLPTKPLSNGSTHQLWGGPPFHTPKERFYLKVKGKDHEGNPLLRVSGVSYSGV AFGAPLVSMAPRIHGYLHQPLLVSCSVHSALPFRLQLRRGEARLGEERHFQESGNSSW EILRASKAEEGTYECTAVSRAGTGRAKAQIVVTDPPPQLVPAPNVTVSPGETAVLSCR VLGEAPYNLTWVRDWRVLPASTGRVAQLADLSLEISGIIPTDGGRYQCVASNANGVTR TSVWLLVREAPQVSIHTSSQHFSQGVEVKVSCSASGYFTPHISWSRESQALQEDSRIH VDAQGTLIIQGVAPEDAGNYSCQATNEVGTDQETVTLYYTDPPSVSVD

[0363] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 9B. TABLE-US-00046 TABLE 9B Comparison of NOV9a against NOV9b through NOV9g. Identities/ NOV9a Residues/ Similarities for the Protein Sequence Match Residues Matched Region NOV9b 1 . . . 204 166/204 (81%) 1 . . . 204 166/204 (81%) NOV9c 80 . . . 133 15/54 (27%) 28 . . . 71 21/54 (38%) NOV9d 20 . . . 262 217/243 (89%) 3 . . . 245 217/243 (89%) NOV9e 20 . . . 262 217/243 (89%) 3 . . . 245 217/243 (89%) NOV9f 20 . . . 262 217/243 (89%) 3 . . . 245 217/243 (89%) NOV9g 20 . . . 262 217/243 (89%) 3 . . . 245 217/243 (89%)

[0364] Further analysis of the NOV9a protein yielded the following properties shown in Table 9C. TABLE-US-00047 TABLE 9C Protein Sequence Properties NOV9a PSort 0.8200 probability located in outside; 0.1000 probability analysis: located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in lysosome (lumen) SignalP Cleavage site between residues 17 and 18 analysis:

[0365] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D. TABLE-US-00048 TABLE 9D Geneseq Results for NOV9a NOV9a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAB83147 Rat secreted factor encoded by 1 . . . 271 231/272 (84%) e-129 clone P00210D09 - Rattus sp, 275 1 . . . 272 241/272 (87%) aa. [WO200123419-A2, 05-APR- 2001] AAY53667 Sequence gi/3328186 from an 34 . . . 262 119/234 (50%) 1e-64 alignment with protein 608 - 32 . . . 265 168/234 (70%) Unidentified, 3117 aa. [WO9960164-A1, 25-NOV-1999] AAU75886 Human adhesion molecule protein 34 . . . 263 72/239 (30%) 1e-21 AD4/AAD21820.1 - Homo 311 . . . 547 119/239 (49%) sapiens, 852 aa. [WO200208423- A2, 31-JAN-2002] AAU75884 Human adhesion molecule protein 34 . . . 263 72/239 (30%) 1e-21 AD2/G7c - Homo sapiens, 536 aa. 13 . . . 249 119/239 (49%) [WO200208423-A2, 31-JAN- 2002] AAM79854 Human protein SEQ ID NO 3500 - 34 . . . 263 72/239 (30%) 1e-21 Homo sapiens, 836 aa. 311 . . . 547 119/239 (49%) [WO200157190-A2, 09-AUG- 2001]

[0366] In a BLAST search of public sequence datbases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E. TABLE-US-00049 TABLE 9E Public BLASTP Results for NOV9a NOV9a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value CAC37763 SEQUENCE 2 FROM PATENT 1 . . . 271 231/272 (84%) e-128 WO0123419 - Rattus norvegicus 1 . . . 272 241/272 (87%) (Rat), 275 aa. Q96RW7 HEMICENTIN - Homo sapiens 35 . . . 262 169/228 (74%) 3e-97 (Human), 5636 aa. 38 . . . 265 199/228 (87%) T20992 hypothetical protein F15G9.4a - 34 . . . 262 119/234 (50%) 3e-64 Caenorhabditis elegans, 5175 aa. 32 . . . 265 168/234 (70%) O76518 HEMICENTIN PRECURSOR - 34 . . . 262 119/234 (50%) 3e-64 Caenorhabditis elegans, 5198 aa. 32 . . . 265 168/234 (70%) Q96QC8 G7C PROTEIN - Homo sapiens 34 . . . 263 72/239 (30%) 3e-21 (Human), 852 aa. 311 . . . 547 119/239 (49%)

[0367] PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9F. TABLE-US-00050 TABLE 9F Domain Analysis of NOV9a Identities/ Pfam NOV9a Similarities Domain Match Region for the Matched Region Expect Value

Example 10

[0368] The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A. TABLE-US-00051 TABLE 10A NOV10 Sequence Analysis SEQ ID NO: 53 621 bp NOV10a, ATCATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCC CG102942-01 AGGCCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCT DNA GCAGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCA Sequence GGGAATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATG AGCTGAAAGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTG TGACTACTGGATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGC AACATTAAGAGTTACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACT ACAACCAGCATGCTATGGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAA GATCACCCTCTACGGTAGAACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATC CGCTTCTCCAAATCTCTGGGCCTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCG GTAATGGCCAGTCTGGATGAGGGGACGGGGACATGGGGACT ORF Start: ATG at 4 ORF Stop: TGA at 598 SEQ ID NO: 54 198 aa MW at 22456.7kD NOV10a, MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAG CG102942-01 NAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGN Protein IKSYPGLTSYLVRVVSTNYNQHANVFFKKVSQNREYFKITLYGRTKELTSELKENFIR Sequence FSKSLGLPENHIVFPVPIGNGQSG SEQ ID NO: 55 609 bp NOV10b ATCATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCC CG102942-03 AGGCCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCT DNA GCAGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCA Sequence GGGAATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATG AGCTGAAAGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTG TGACTACTGGATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGC AACATTAAGAGTTACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACT ACAACCAGCATGCTATGGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAA GATCACCCTCTACGGGAGAACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATC CGCTTCTCCAAATCTCTGGGCCTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCG GTAATGGCCAGTCTGGATGAGGGGACGGG ORF Start: ATG at 4 ORE Stop: TGA at 598 SEQ ID NO: 56 198 aa MW at 22456.7kD NOV10b, MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAG CG102942-03 NAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGN Protein IKSYPGLTSYLVRVVSTNYNQHANVFFKKVSQNREYFKITLYGRTKELTSELKENFIR Sequence FSKSLGLPENHIVFPVPIGNGQSG SEQ ID NO: 57 477bp NOV10c, CGCGGATCCCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCAATTC 237376776 TCAGAGGAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAAGA DNA CAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATC Sequence AGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGC TATGGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTAC GGGAGAACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAAT CTCTGGGCCTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGGTAATGGCCAGTC TGGACTCGAGGCG ORF Start: at 1 ORF Stop: end of sequence +TL,44 SEQ ID NO: 58 159 aa MW at 18222.8kD NOV10c, RGSQFQGKWYVVGLAGNAILRGDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWI 237376776 RTFVPGCQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHANVFFKKVSQNREYFKITLY Protein GRTKELTSELKENFIRFSKSLGLPENHIVFPVPIGNGQSGLEA Sequence

[0369] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 10B. TABLE-US-00052 TABLE 10B Comparison of NOV10a against NOV10b and NOV10c. Identities/ NOV10a Residues/ Similarities for Protein Sequence Match Residues the Matched Region NOV10b 19 . . . 198 180/180 (100%) 19 . . . 198 180/180 (100%) NOV10c 45 . . . 198 152/154 (98%) 3 . . . 156 153/154 (98%)

[0370] Further analysis of the NOV10a protein yielded the following properties shown in Table 10C. TABLE-US-00053 TABLE 10C Protein Sequence Properties NOV10a PSort 0.4658 probability located in outside; 0.1134 probability analysis: located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 21 and 22 analysis:

[0371] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D. TABLE-US-00054 TABLE 10D Geneseq Results for NOV10a NOV10a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAG74315 Human colon cancer antigen 1 . . . 192 192/192 (100%) e-110 protein SEQ ID NO: 5079 - 57 . . . 248 192/192 (100%) Homo sapiens, 254 aa. [WO200122920-A2, 05-APR-2001] AAY71470 Human neutrophil gelatinase 1 . . . 192 192/192 (100%) e-110 associated protein (NGAL) - 1 . . . 192 192/192 (100%) Homo sapiens, 198 aa. [WO200029576-A1, 25-MAY-2000] AAB43668 Human cancer associated protein 1 . . . 192 192/192 (100%) e-110 sequence SEQ ID NO: 1113 - 57 . . . 248 192/192 (100%) Homo sapiens, 254 aa. [WO200055350-A1, 21-SEP-2000] AAW49088 Human NGAL protein - Homo sapiens, 1 . . . 192 189/192 (98%) e-107 197 aa. [WO9830907-A1, 16-JUL-1998] 1 . . . 191 190/192 (98%) AAW18203 Human NGAL protein - Homo sapiens, 1 . . . 192 189/192 (98%) e-107 197 aa. [U.S. Pat. No. 5627034-A, 06-MAY-1997] 1 . . . 191 190/192 (98%)

[0372] In a BLAST search of public sequence datbases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E. TABLE-US-00055 TABLE 10E Public BLASTP Results for NOV10a NOV10a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value P80188 Neutrophil gelatinase-associated 1 . . . 192 192/192 (100%) e-110 lipocalin precursor (NGAL) (P25) 1 . . . 192 192/192 (100%) (25 kDa alpha-2-microglobulin- related subunit of MMP-9) (Lipocalin 2) (Oncogene 24p3) - Homo sapiens (Human), 198 aa. JC2339 neutrophil gelatinase-associated 1 . . . 192 189/192 (98%) e-107 lipocalin precursor - human, 197 aa. 1 . . . 191 190/192 (98%) Q9QVP7 NEU-RELATED LIPOCALIN - 1 . . . 191 121/191 (63%) 1e-66 Rattus sp, 198 aa. 1 . . . 191 150/191 (78%) P30152 Neutrophil gelatinase-associated 1 . . . 191 120/191 (62%) 1e-65 lipocalin precursor (NGAL) (P25) 1 . . . 191 148/191 (76%) (Alpha-2-microglobulin-related protein) (Alpha-2U globulin- related protein) (Lipocalin 2) - Rattus norvegicus (Rat), 198 aa. Q60842 CHROMOSOME 24P3 - Mus musculus 1 . . . 194 119/196 (60%) 3e-64 (Mouse), 283 aa (fragment). 8 . . . 203 154/196 (77%)

[0373] PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10F. TABLE-US-00056 TABLE 10F Domain Analysis of NOV10a Identities/ Pfam NOV10a Similarities for Expect Domain Match Region the Matched Region Value lipocalin 46 . . . 189 42/152 (28%) 5.4e-34 115/152 (76%)

Example 11

[0374] The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A. TABLE-US-00057 TABLE 11A NOV11 Sequence Analysis SEQ ID NO: 59 2210 bp NOV11a, ATGACAATTTTAAGAGTGTTTAACCAAGACTGTTCCTTTAAATGTGTTCTTTTGCTGC CG104016-01 TGTTTAATTATACATGTCAATTATTTACAGATCCTGTGGTATTGTGGAAATTCCCAGA DNA GGACTTTGGAGACCAGGAAATACTACAGAGTGTGCCAAAGTTCTGTTTTCCCTTTGAC Sequence GTTGAAAGGTACAGTATAAGTCAAGTTGGACAGCACTTTACCTTTGTACTGACAGACA TTGAAAGTAAACAGAGATTTGGATTCTGCAGACTGACGTCAGGAGGCACAATTTGTTT ATGCATCCTTAGTTACCTTCCCTGGTTTGAAGTGTATTACAAGCTTCTAAATACTCTT GCAGATTACTTGGCTAAGCATTCCTACTTCATTGCCCCTGATGTAACTGGACTCCCAA CAATACCCGAGAGTAGAAATCTTACAGAATATTTTGTTGCCGTGGATGTGAACAACAT GCTGCAGCTGTATGCCAGTATGCTGCATGAAAGGCGCATCGTGATTATCTCGAGCAAA TTAAGCACTTTAACTGCCTGTATCCATGGATCAGCTGCTCTTCTATACCCAATGTATT GGCAACACATATACATCCCAGTGCTTCCTCCACACCTGCTGGACTACTGCAGTGCCCC AATGCCATACCTGATTGGAATACACTCCAGCCTCATAGAGAGAGTGAAAAACAAATCA TTGGAAGATGTTGTTATGTTAAATGTTGATACAAACACATTAGAATCACCATTTAGTG ACTTGAACAACCTACCAAGTGATGTGGTAAGTGCCTTGAAAAATAAACTGAAGAAGCA GTCTACAGCTACGGGTGATGGAGTAGCTAGGGCCTTTCTTAGAGCACAGGCTGCTTTG TTTGGATCCTACAGAGATGCACTGAGATACAAACCTGGTGAGCCCATCACTTTCTGTG AGGAGAGTTTTGTAAAGCACCGCTCAAGCGTGATGAAACAGTTCCTGGAAACTGCCAT TAACCTCCAGCTTTTTAAGCAGGTATTTATCGATGGTCGACTGGCAAAACTAAATGCA GGAAGGGGTTTCTCTGATGTATTTGAAGAAGAGATCACTTCAGGTGGCTTTTGTGGAG GTAAAGACAAGTTACAATATAAATATGTTTCTGTTTTTCTTTTGCAGAAAGGAGGTGC ACTGTTCAACACAGCAATGACCAAAGCAACCCCTGCTGTACGGACAGCATATAAATTT GCAAAAAATCATGCAAAGCTGGGACTAAAGGAAGTGAAGAGTAAACTAAAACACAAGG AAAATGAAGAAGATTATGGGACCTGTTCTAGTTCTGTACAATATACACCAGTTTACAA ATTACACAATGAAAAGGGAGGAAACTCAGAAAAGCGTAAGCTTGCTCAGGCACGCTTA AAAAGGCCTCTTAAGAGCCTTGATGGTGCTCTATATGATGATGAAGATGATGATGACA TTGAAAGAGCAAGCAAGTTATCTTCTGAAGATGGTGAAGAAGCTTCTGCTTATCTCTA TGAGAGTGATGACTCTGTTGAAACAAGAGTGAAGACTCCTTACTCAGGTGAAATGGAC TTACTAGGAGAGATTCTTGATACATTGAGCACACACAGCTCAGATCAGGGGAAGCTGG CAGCTGCAAAGAGCTTGGATTTCTTTAGATCAATGGATGACATTGATTACAAACCTAC GAATAAATCTAATGCTCCTAGTGAGAATAACCTGGCTTTCCTCTGTGGTGGTTCTGGT GACCAAGCAGAGTGGAATCTTGGGCAAGACGATAGTGCCCTCCATGGCAAACACCTCC CTCCATCTCCTAGGAAGCGGGTTTCCTCTAGTGGTTTGACAGATTCTCTGTTTATCCT GAGAGAGGAAAACAGTAACAAGCACCTCGGTGCTGACAATGTGAGTGACCCTACTTCA GGACTGGATTTCCAACTCACTTCCCCTGAAGTTTCCCAGACTGATAAAGGAAAAACAG AAAAGAGGGAAACACTAAGCCAGATTTCAGATGATCTGCTTATACCCGGTCTTGGGCG GCATTCATCGACTTTTGTTCCTTGGGAGAAAGAAGGGAAAGAAGCCAAAGAGACTTCA GAAGATATTGGACTGCTCCATGAAGTAGTGTCATTATGTCATATGACATCTGACTTCC AACAAAGCTTGAACATTTCAGACAAAAACACAAATGGAAACCAAACTTAAATCTTGCA TCCAAG ORF Start: ATG at 1 ORF Stop: TAA at 2194 SEQ ID NO: 60 731 aa MW at 81769.5kD NOV11a, MTILRVFNQDCSFKCVLLLLFNYTCQLFTDPVVLWKFPEDFGDQEILQSVPKFCFFFD CG104016-01 VERYSISQVGQHFTFVLTDIESKQRFGFCRLTSGGTICLCILSYLPWFEVYYKLLNTL Protein ADYLAKHSYFIAPDVTGLPTIPESRNLTEYFVAVDVNNMLQLYASMLHERRIVIISSK Sequence LSTLTACIHGSAALLYPMYWQHIYIPVLFPHLLDYCSAPMPYLIGIHSSLIERVKNKS LEDVVMLNVDTNTLESPFSDLNNLPSDVVSALKNKLKKQSTATGDGVARAFLRAQAAL FGSYRDALRYKPGEPITFCEESFVKHRSSVMKQFLETAINLQLFKQVFIDGRLAKLNA GRGFSDVFEEEITSGGFCGGKDKLQYKYVSVFLLQKGGALFNTAMTKATPAVRTAYKF AKNHAKLGLKEVKSKLKHKENEEDYGTCSSSVQYTPVYKLHNEKGGNSEKRKLAQARL KRPLKSLDGALYDDEDDDDIERASKLSSEDGEEASAYLYESDDSVETRVKTPYSGEMD LLGEILDTLSTHSSDQGKLAAAKSLDFFRSMDDIDYKPTNKSNAPSENNLAFLCGGSG DQAEWNLGQDDSALHGKHLPPSPRKRVSSSGLTDSLFILREENSNKHLGADNVSDPTS GLDFQLTSPEVSQTDKGKTEKRETLSQISDDLLIPGLGRHSSTFVPWEKEGKEAKETS EDIGLLHEVVSLCHMTSDFQQSLNISDKNTNGNQT SEQ ID NO: 61 2256 bp NOV11b, AGATCTGATCCTGTGGTATTGTGGAAATTCCCAGAGGACTTTGGAGACCAGGAAATAC 197208336 TACAGAGTGTGCCAAAGTTCTGTTTTCCCTTTGACGTTGAAAGGGTGTCTCAGAATCA DNA AGTTGGACAGCACTTTACCTTTGTACTGACAGACATTGAAAGTAAACAGAGATTTGGA Sequence TTCTGCAGACTGACGTCAGGAGGCACAATTTGTTTATGCATCCTTAGTTACCTTCCCT GGTTTGAAGTGTATTACAAGCTTCTAAATACTCTTGCAGATTACTTGGCTAAGGAACT GGAAAATGATTTGAATGAAACTCTCAGATCACTGTATAACCACCCAGTACCAAAGGCA AATACTCCTGTAAATTTGAGTGTGAACCAAGAGATATTTATTACCTGTGAGCAAGTTC TGAAAGATCAGCCTGCTCTACTACCGCATTCCTACTTCATTGCCCCTGATGTAACTGG ACTCCCAACAATACCCGAGAGTAGAAATCTTACAGAATATTTTGTTGCCGTGGATGTG AACAACATGCTGCAGCTGTATGCCAGTATGCTGCATGAAAGGCGCATCGTGATTATCT CGAGCAAATTAAGCACTTTAACTGCCTGTATCCATGGATCAGCTGCTCTTCTATACCC AATGTATTGGCAACACATATACATCCCAGTGCTTCCTCCACACCTGCTGGACTACTGC TGTGCCCCAATGCCATACCTGATTGGAATACACTCCAGCCTCATAGAGAGAGTGAAAA ACAAATCATTGGAAGATGTTGTTATGTTAAATGTTGATACAAACACATTAGAATCACC ATTTAGTGACTTGAACAACCTACCAAGTGATGTGGTCTCGGCCTTGAAAAATAAACTG AAGAAGCAGTCTACAGCTACGGGTGATGGAGTAGCTAGGGCCTTTCTTAGAGCACAGG CTGCTTTGTTTGGATCCTACAGAGATGCACTGAGATACAAACCTGGTGAGCCCATCAC TTTCTGTGAGGAGAGTTTTGTAAAGCACCGCTCAAGCGTGATGAAACAGTTCCTGGAA ACTGCCATTAACCTCCAGCTTTTTAAGCAGTTTATCGATGGTCGACTGGCAAAACTAA ATGCAGGAAGGGGTTTCTCTGATGTATTTGAAGAAGAGATCACTTCAGGTGGCTTTTG TGGAGGGAACCCGAGGTCATATCAACAATGGGTGCATACAGTCAAGAAAGGAGGTGCA CTGTTCAACACAGCAATGACCAAAGCAACCCCTGCTGTACGGACAGCATATAAATTTG CAAAAAATCATGCAAAGCTGGGACTAAAGGAAGTGAAGAGTAAACTAAAACACAAGGA AAATGAAGAAGATTATGGGACCTGTTCTAGTTCTGTACAATATACACCAGTTTACAAA TTACACAATGAAAAGGGAGGAAACTCAGAAAAGCGTAAGCTTGCTCAGGCACGCTTAA AAAGGCCTCTTAAGAGCCTTGATGGTGCTCTATATGATGATGAAGATGATGATGACAT TGAAAGAGCAAGCAAGTTATCTTCTGAAGATGGTGAAGAAGCTTCTGCTTATCTCTAT GAGAGTGATGACTCTGTTGAAACAAGAGTGAAGACTCCTTACTCAGGTGAAATGGACT TACTAGGAGAGATTCTTGATACATTGAGCACACACAGCTCAGATCAGGGGAGGCTGGC AGCTGCAAAGAGCTTGGATTTCTTTAGATCAATGGACGACATTGATTACAAACCTACG AATAAATCTAATGCTCCTAGTGAGAATAACCTGGCTTTCCTCTGTGGTGGTTCTGGTG ACCAAGCAGAGTGGAATGTTGGGCAAGACGATAGTGCCCTCCATGGCAAACACCTCCC TCCATCTCCTAGGAAGCGGGTTTCCTCTAGTGGTTTGACAGATTCTCTGTTTATCCTG AAAGAGGAAAACAGTAACAAGCACCTCGGTGCTGACAATGTGAGTGACCCTACTTCAG GACTGGATTTCCAACTCACTTCCCCTGAAGTTTCCCAGACTGATAAAGGAAAAACAGA AAAGAGGGAAACACTAAGCCAGATTTCAGATGATCTGCTTATACCCGGTCTTGGGCGG CATTGATCGACTTTTGTTCCTTGGGAGAAAGAAGGGAAAGAAGCCAAAGAGACTTCAG AAGATATTGGACTGCTCCATGAAGTAGTGTCATTATGTCATATGACATCTGACTTCCA ACAAAGCTTGAACATTTCAGACAAAAACACAAATGGAAACCAAACTAGATCT ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 62 752 aa MW at 84005.6kD NOV11b, RSDPVVLWKFPEDFGDQEILQSVPKFCFPFDVERVSQNQVGQHFTFVLTDIESKQRFG 197208336 FCRLTSGGTICLCILSYLPWFEVYYKLLNTLADYLAKELENDLNETLRSLYNHFVPKA Protein NTPVNLSVNQEIFITCEQVLKDQPALLPHSYFIAPDVTGLPTIPESRNLTEYFVAVDV Sequence NNMLQLYASMLHERRIVIISSKLSTLTACIHGSAALLYPMYWQHIYIPVLPPHLLDYC CAPMPYLIGIHSSLIERVKNKSLEDVVMLNVDTNTLESPFSDLNNLPSDVVSALKNKL KKQSTATGDGVARAFLRAQAALFGSYRDALRYKPGEPITFCEESFVKHRSSVMKQFLE TAINLQLFKQFIDGRLAKLNAGRGFSDVFEEEITSGGFCGGNPRSYQQWVHTVKKGGA LFNTAMTKATPAVRTAYKFAKNHAKLGLKEVKSKLKHKENEEDYGTCSSSVQYTPVYK LHNEKGGNSEKRKLAQARLKRPLKSLDGALYDDEDDDDIERASKLSSEDGEEASAYLY ESDDSVETRVKTPYSGEMDLLGEILDTLSTHSSDQGRLAAAKSLDFFRSMDDIDYKPT NKSNAPSENNLAFLCGGSGDQAEWNLGQDDSALHGKHLPPSPRKRVSSSGLTDSLFIL KEENSNKHLGADNVSDPTSGLDFQLTSPEVSQTDKGKTEKRETLSQISDDLLIPGLGR HSSTFVPWEKEGKEAKETSEDIGLLHEVVSLCHMTSDFQQSLNISDKNTNGNQTRS SEQ ID NO: 63 2256 bp NOV11c, AGATCTGATCCTGTGGTATTGTGGAAATTCCCAGAGGACTTTGGAGACCAGGAAATAC 197306179 TACAGAGTGTGCCAAAGTTCTGTTTTCCCTTTGACGTTGAAAGGGTGTCTCAGAATCA DNA AGTTGGACAGCACTTTACCTTTGTACTGACAGACATTGAAAGTAAACAGAGATTTGGA Sequence TTCTGCAGACTGACGTCAGGAGGCACAATTTGTTTATGCATCCTTAGTTACCTTCCCT GGTTTGAAGTGTATTACAAGCTTCTAATACTCTTGCAGATTACCTTGGCTAAGGAACT GGAAAATGATTTGAATGAAACTCTCAGATCACTGTATAACCACCCAGTACCAAAGGCA AATACTCCTGTAAATTTGAGTGTGAACCAAGAGATATTTATTACCTGTGAGCAAGTTC TGAAAGATCAGCCTGCTCTACTACCGCATTCCTACTTCATTGCCCCTGATGTAACTGG ACTCCCAACAATACCCGAGAGTAGAAATCTTACAGAATATTTTGTTGCCGTGGATGTG AACAACATGCTGCAGCTGTATGCCAGTATGCTGCATGAAAGGCGCATCGTGATTATCT CGAGCAAATTAAGCACTTTAACTGCCTGTATCCATGGATCAGCTGCTCTTCTATACCC AATGTATTGGCAACACATATACATCCCAGTGCTTCCTCCACACCTGCTGGACTACTGC TGTGCCCCAATGCCATACCTGATTGGAATACACTCCAGCCTCATAGAGAGAGTGAAAA ACAAATCATTGGAAGATGTTGTTATGTTAAATGTTGATACAAACACATTAGAATCACC ATTTAGTGACTTGAACAACCTACCAAGTGATGTGGTCTCGGCCTTGAAAAATAAACTG AAGAAGCAGTCTACAGCTACGGGTGATGGAGTAGCTAGGGCCTTTCTTAGAGCACAGG CTGCTTTGTTTGGATCCTACAGAGATGCACTGAGATACAAACCTGGTGAGCCCATCAC TTTCTGTGAGGAGAGTTTTGTAAAGCACCGCTCAAGCGTGATGAAACAGTTCCTGGAA ACTGCCATTAACCTCCAGCTTTTTAAGCAGTTTATCGATGGTCGACTGGCAAAACTAA ATGCAGGAAGGGGTTTCTCTGATGTATTTGAAGAAGAGATCACTTCAGGTGGCTTTTG TGGAGGGAACCCGAGGTCATATCAACAATGGGTGCATACAGTCAAGAAAGGAGGTGCA CTGTTCAACACAGCAATGACCAAAGCAACCCCTGCTGTACGGACAGCATATAAATTTG CAAAAAATCATGCAAAGCTGGGACTAAAGGAAGTGAAGAGTAAACTAAAACACAAGGA AAATGAAGAAGATTATGGGACCTGTTCTAGTTCTGTACAATATACACCAGTTTACAAA TTACACAATGAAAAGGGAGGAAACTCAGAAAAGCGTAAGCTTGCTCAGGCACGCTTAA AAAGGCCTCTTAAGAGCCTTGATGGTGCTCTATATGATGATGAAGATGATGATGACAT TGAAAGAGCAAGCAAGTTATCTTCTGAAGATGGTGAAGAAGCTTCTGCTTATCTCTAT GAGAGTGATGACTCTGTTGAAACAAGAGTGAAGACTCCTTACTCAGGTGAAATGGACT TACTAGGAGAGATTCTTGATACATTGAGCACACACAGCTCAGATCAGGGGAGGCTGGC AGCTGCAAAGAGCTTGGATTTCTTTAGATCAATGGACGACATTGATTACAAACCTACG AATAAATCTAATGCTCCTAGTGAGAATAACCTGGCTTTCCTCTGTGGTGGTTCTGGTG ACCAAGCAGAGTGGAATCTTGGGCAAGACGATAGTGCCCTCCATGGCAAACACCTCCC TCCATCTCCTAGGAAGCGGGTTTCCTCTAGTGGTTTGACAGATTCTCTGTTTATCCTG AAAGAGGAAAACAGTAACAAGCACCTCGGTGCTGACAATGTGAGTGACCCTACTTCAG GACTGGATTTCCAACTCACTTCCCCTGAAGTTTCCCAGACTGATAAAGGAAAAACAGA AAAGAGGGAAACACTAAGCCAGATTTCAGATGATCTGCTTATACCCGGTCTTGGGCGG CATTCATCGACTTTTGTTCCTTGGGAGAAAGAAGGGAAAGAAGCCAAAGAGACTTCAG AAGATATTGGACTGCTCCATGAAGTAGTGTCATTATGTCATATGACATCTGACTTCCA ACAAAGCTTGAACATTTCAGACAAAAACACAAATGGAAACCAAACTAGATCT ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 64 752 aa MW at 84005.6kD NOV11c, RSDPVVLWKFPEDFGDQEILQSVPKFCFPFDVERVSQNQVGQHFTFVLTDIESKQRFG 197306179 FCRLTSGGTICLCILSYLPWFEVYYKLLNTLADYLAKELENDLNETLRSLYNHPVPKA Protein NTPVNLSVNQEIFITCEQVLKDQFALLPHSYFIAPDVTGLFTIPESRNLTEYFVAVDV Sequence NNMLQLYASMLHERRIVIISSKLSTLTACIHGSAALLYPMYWQHIYIPVLPPHLLDYC CAPMPYLIGIHSSLIERVKNKSLEDVVMLNVDTNTLESPFSDLNNLPSDVVSALKNKL KKQSTATGDGVARAFLRAQAALFGSYRDALRYKPGEPITFCEESFVKHRSSVMKQFLE TAINLQLFKQFIDGRLAKLNAGRGFSDVFEEEITSGGFCGGNPRSYQQWVHTVKKGGA LFNTAMTKATPAVRTAYKFAKNHAKLGLKEVKSKLKHKENEEDYGTCSSSVQYTPVYK LHNEKGGNSEKRKLAQARLKRPLKSLDGALYDDEDDDDIERASKLSSEDGEEASAYLY ESDDSVETRVKTPYSGEMDLLGEILDTLSTHSSDQGRLAAAKSLDFFRSMDDIDYKPT NKSNAPSENNLAFLCGGSGDQAEWNLGQDDSALHGKHLPPSPRKRVSSSGLTDSLFIL KEENSNKHLGADNVSDPTSGLDFQLTSPEVSQTDKGKTEKRETLSQISDDLLIPGLGR HSSSTFVPWEKEGKEAKETSEDIGLLHEVVSLCHMTSDFQQSLNISDKNTNGNQTRS SEQ ID NO: 65 2259 bp NOV11d, AGATCTGATCCTGTGGTATTGTGGAAATTCCCAGAGGACTTTGGAGACCAGGAAATAC 219903686 TACAGAGTGTGCCAAAGTTCTGTTTTCCCTTTGACGTTGAAAGGGTGTCTCAGAATCA DNA AGTTGGACAGCACTTTACCTTTGTACTGACAGACATTGAAAGTAAACAGAGATTTGGA Sequence TTCTGCAGACTGACGTCAGGAGGCACAATTTGTTTATGCATCCTTAGTTACCTTCCCT GGTTTGAAGTGTATTACAAGCTTCTAAATACTCTTGCAGATTACTTGGCTAAGGAACT GGAAAATGATTTGAATGAAACTCTCAGATCACTGTATAACCACCCAGTACCAAAGGCA AATACTCCTGTAAATTTGAGTGTGAACCAAGAGATATTTATTGCCTGTGAGCAAGTTC TGAAAGATCAGCCTGCTCTAGTACCGCATTCCTACTTCATTGCCCCTGATGTAACTGG ACTCCCAACAATACCCGAGAGTAGAAATCTTACAGAATATTTTGTTGCCGTGGATGTG AACAACATGCTGCAGCTGTATGCCAGTATGCTGCATGAAAGGCGCATCGTGATTATCT CGAGCAAATTAAGCACTTTAACTGCCTGTATCCATGGATCAGCTGCTCTTCTATACCC AATGTATTGGCAACACATATACATCCCAGTGCTTCCTCCACACCTGCTGGACTACTGC TGTGCCCCAATGCCATACCTGATTGGAATACACTCCAGCCTCATAGAGAGAGTGAAAA ACAAATCATTGGAAGATGTTGTTATGTTAAATGTTGATACAAACACATTAGAATCACC ATTTAGTGACTTGAACAACCTACCAAGTGATGTGGTCTCGGCCTTGAAAAATAAACTG AAGAAGCAGTCTACAGCTACGGGTGATGGAGTAGCTAGGGCCTTTCTTAGAGCACAGG CTGCTTTGTTTGGATCCTACAGAGATGCACTGAGATACAAACCTGGTGAGCCCATCAC TTTCTGTGAGGAGAGTTTTGTAAAGCACCGCTCAAGCGTGATGAAACAGTTCCTGGAA ACTGCCATTAACCTCCAGCTTTTTAAGCAGTTTATCGATGGTCGACTGGCAAAACTAA ATGCAGGAAGGGGTTTCTCTGATGTATTTGAAGAAGAGATCACTTCAGGTGGCTTTTG TGGAGGGAACCCGAGGTCATATCAACAATGGGTGCATACAGTCAAGAAAGGAGGTGCA CTGTTCAACACAGCAATGACCAAAGCAACCCCTGCTGTACGGACAGCATATAAATTTG CAAAAAATCATGCAAAGCTGGGACTAAAGGAAGTGAAGAGTAAACTAAAACACAAGGA AAATGAAGAAGATTATGGGACCTGTTCTAGTTCTGTACAATATACACCAGTTTACAAA TTACACAATGAAAAGGGAGGAAACTCAGAAAAGCGTAAGCTTGCTCAGGCACGCTTAA AAAGGCCTCTTAAGAGCCTTGATGGTGCTCTATATGATGATGAAGATGATGATGACAT TGAAAGAGCAAGCAAGTTATCTTCTGAAGATGGTGAAGAAGCTTCTGCTTATCTCTAT GAGAGTGATGACTCTGTTGAAACAAGAGTGAAGACTCCTTACTCAGGTGAAATGGACT TACTAGGAGAGATTCTTGATACATTGAGCACACACAGCTCAGATCAGGGGAAGCTGGC AGCTGCAAAGAGCTTGGATTTCTTTAGATCAATGGATGACATTGATTACAAACCTACG AATAAATCTAATGCTCCTAGTGAGAATAACCTGGCTTTCCTCTGTAGTGGTTCTGGTG ACCAAGCAGAGTGGAATCTTGGGCAAGACGATAGTGCCCTCCATGGCAAACACCTCCC TCCATCTCCTAGGAAGCGGGTTTCCTCTAGTGGTTTGACAGATTCTCTGTCTATCCTG AAAGAGGAAAACAGTAACAAGCACCTCGGTGCTGACAATGTGAGTGACCCTACTTCAG GACTGGATTTCCAACTCACTTCCCCTGAAGTTTCCCAGACTGATAAAGGAAAAACAGA AAAGAGGGAAACACTAAGCCAGATTTCAGATGATCTGCTTATACCCGGTCTTGGGCGG CATTCATCGACTTTTGTTCCTTGGGAGAAAGAAGGGAAAGAAGCCAAAGAGACTTCAG AAGATATTGGACTGCTCCATGAAGTAGTGTCATTATGTCATATGACATCTGACTTGCA AGCTAAAGCTTGGAACATTTCAGACAAAAACACAAATGGAAACCAAACTAGATCT ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 66 753 aa MW at 84031.7kD NOV11d, RSDPVVLWKFPEDFGDQEILQSVPKFCFPFDVERVSQNQVGQHFTFVLTDIESKQRFG 219903686 FCRLTSGGTICLCILSYLPWFEVYYKLLNTLADYLAKELENDLNETLRSLYNHPVPKA Protein NTPVNLSVNQEIFIACEQVLKDQPALVPHSYFIAFDVTGLFTIPESRNLTEYFVAVDV Sequence NNMLQLYASMLHERRIVIISSKLSTLTACIHGSAALLYPMYWQHIYIPVLPPHLLDYC CAPMPYLIGIHSSLIERVKNKSLEDVVMLNVDTNTLESPFSDLNNLPSDVVSALKNKL KKQSTATGDGVARAFLRAQAALFGSYRDALRYKPGEPITFCEESFVKHRSSVMKQFLE TAINLQLFKQFIDGRLAKLNAGRGFSDVFEEEITSGGFCGGNPRSYQQWVHTVKKGGA LFNTAMTKATPAVRTAYKFAKNHAKLGLKEVKSKLKHKENEEDYGTCSSSVQYTPVYK LHNEKGGNSEKRKLAQARLKRPLKSLDGALYDDEDDDDIERASKLSSEDGEEASAYLY ESDDSVETRVKTPYSGEMDLLGEILDTLSTHSSDQGKLAAAKSLDFFRSMDDIDYKPT NKSNAPSENNLAFLCSGSGDQAEWNLGQDDSALHGKHLPPSPRKRVSSSGLTDSLSIL KEENSNKHLGADNVSDPTSGLDFQLTSPEVSQTDKGKTEKRETLSQISDDLLIPGLGR HSSTFVPWEKEGKEAKETSEDIGLLHEVVSLCHMTSDFQAKAWNISDKNTNGNQTRS SEQ ID NO: 67 2256 bp NOV11e, AGATCTGATCCTGTGGTATTGTGGAAATTCCCAGAGGACTTTGGAGACCAGGAAATAC 219903690 TACAGAGTGTGCCAAAGTTCTGTTTTCCCTTTGACGTTGAAAGGGTGTCTCAGAATCA DNA AGTTGGACAGCACTTTACCTTTGTACTGACAGACATTGAAAGTAAACAGAGATTTGGA Sequence TTCTGCAGACTGACGTCAGGAGGCACAATTTGTTTATGCATCCTTAGTTACCTTCCCT GGTTTGAAGTGTATTACAAGCTTCTAAATACTCTTGCAGATTACTTGGCTAAGGAACT GGAAAATGATTTGAATGAAACTCTCAGATCACTGTATAACCACCCAGTACCAAAGGCA AATACTCCTGTAAATTTGAGTGTGAACCAAGAGATATTTATTGCCTGTGAGCAAGTTC TGAAAGATCAGCCTGCTCTAGTACCGCATTCCTACTTCATTGCCCCTGATGTAACTGG ACTCCCAACAATACCCGAGAGTAGAAATCTTACAGAATATTTTGTTGCCGTGGATGTG AACAACATGCTGCAGCTGTATGCCAGTATGCTGCATGAAAGGCGCATCGTGATTATCT CGAGCAAATTAAGCACTTTAACTGCCTGTATCCATGGATCAGCTGCTCTTCTATACCC AATGTATTGGCAACACATATACATCCCAGTGCTTCCTCCACACCTGCTGGACTACTGC TGTGCCCCAATGCCATACCTGATTGGAATACACTCCAGCCTCATAGAGAGAGTGAAAA ACAAATCATTGGAAGATGTTGTTATGTTAAATGTTGATACAAACACATTAGAATCACC

ATTTAGTGACTTGAACAACCTACCAAGTGATGTGGTCTCGGCCTTGAAAAATAAACTG AAGAAGCAGTCTACAGCTACGGGTGATGGAGTAGCTAGGGCCTTTCTTAGAGCACAGG CTGCTTTGTTTGGATCCTACAGAGATGCACTGAGATACAAACCTGGTGAGCCCATCAC TTTCTGTGAGGAGAGTTTTGTAAAGCACCGCTCAAGCGTGATGAAACAGTTCCTGGAA ACTGCCATTAACCTCCAGCTTTTTAAGCAGTTTATCGATGGTCGACTGGCAAAACTAA ATGCAGGAAGGGGTTTCTCTGATGTATTTGAAGAAGAGATCACTTCAGGTGGCTTTTG TGGAGGGAACCCGAGGTCATATCAACAATGGGTGCATACAGTCAAGAAAGGAGGTGCA CTGTTCAACACAGCAATGACCAAAGCAACCCCTGCTGTACGGACAGCATATAAATTTG CAAAAAATCATGCAAAGCTGGGACTAAAGGAAGTGAAGAGTAAACTAAAACACAAGGA AAATGAAGAAGATTATGGGACCTGTTCTAGTTCTGTACAATATACACCAGTTTACAAA TTACACAATGAAAAGGGAGGAAACTCAGAAAAGCGTAAGCTTGCTCAGGCACGCTTAA AAAGGCCTCTTAAGAGCCTTGATGGTGCTCTATATGATGATGAAGATGATGATGACAT TGAAAGAGCAAGCAAGTTATCTTCTGAAGATGGTGAAGAAGCTTCTGCTTATCTCTAT GAGAGTGATGACTCTGTTGAAACAAGAGTGAAGACTCCTTACTCAGGTGAAATGGACT TACTAGGAGAGATTCTTGATACATTGAGCACACACAGCTCAGATCAGGGGAAGCTGGC AGCTGCAAAGAGCTTGGATTTCTTTAGATCAATGGATGACATTGATTACAAACCTACG AATAAATCTAATGCTCCTAGTGAGAATAACCTGGCTTTCCTCTGTGGTGGTTCTGGTG ACCAAGCAGAGTGGAATCTTGGGCAAGACGATAGTGCCCTCCATGGCAAACACCTCCC TCCATCTCCTAGGAAGCGGGTTTCCTCTAGTGGTTTGACAGATTCTCTGTTTATCCTG AAAGAGGAAAACAGTAACAAGCACCTCGGTGCTGACAATGTGAGTGACCCTACTTCAG GACTGGATTTCCAACTCACTTCCCCTGAAGTTTCCCAGACTGATAAAGGAAAAACAGA AAAGAGGGAAACACTAAGCCAGATTTCAGATGATCTGCTTATACCCGGTCTTGGGCGG CATTCATCGACTTTTGTTCCTTGGGAGAAAGAAGGGAAAGAAGCCAAAGAGACTTCAG AAGATATTGGACTGCTCCATGAAGTAGTGTCATTATGTCATATGACATCTGACTTCCA ACAAAGCTTGAACATTTCAGACAAAAACACAAATGGAAACCAAACTAGATCT ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 68 752 aa MW at 83933.6kD NOV11e, RSDPVVLWKFPEDFGDQEILQSVPKFCFPFDVERVSQNQVGQHFTFVLTDIESKQRFG 219903690 FCRLTSGGTICLCILSYLPWFEVYYKLLNTLADYLAKELENDLNETLRSLYNHPVFKA Protein NTPVNLSVNQEIFIACEQVLKDQPALVPHSYFIAPDVTGLFTIPESRNLTEYFVAVDV Sequence NNMLQLYASMLHERRIVIISSKLSTLTACIHGSAALLYFMYWQHIYIPVLPPHLLDYC CAPMPYLIGIHSSLIERVKNKSLEDVVMLNVDTNTLESPFSDLNNLPSDVVSALKNKL KKQSTATGDGVARAFLRAQAALFGSYRDALRYKPGEPITFCEESFVKHRSSVMKQFLE TAINLQLFKQFIDGRLAKLNAGRGFSDVFEEEITSGGFCGGNPRSYQQWVHTVKKGGA LFNTAMTKATPAVRTAYKFAKNHAKLGLKEVKSKLKHKENEEDYGTCSSSVQYTPVYK LHNEKGGNSEKRKLAQARLKRPLKSLDGALYDDEDDDDIERASKLSSEDGEEASAYLY ESDDSVETRVKTPYSGEMDLLGEILDTLSTHSSDQGKLAAAKSLDFFRSMDDIDYKPT NKSNAPSENNLAFLCGGSGDQAEWNLGQDDSALHGKHLPPSPRKRVSSSGLTDSLFIL KEENSNKHLGADNVSDPTSGLDFQLTSPEVSQTDKGKTEKRETLSQISDDLLIPGLGR HSSTFVPWEKEGKEAKETSEDIGLLHEVVSLCHMTSDFQQSLNISDKNTNGNQTRS

[0375] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 11B. TABLE-US-00058 TABLE 11B Comparison of NOV11a against NOV11b through NOV11e. Identities/ NOV11a Residues/ Similarities for Protein Sequence Match Residues the Matched Region NOV11b 29 . . . 731 662/752 (88%) 2 . . . 750 671/752 (89%) NOV11c 29 . . . 731 662/752 (88%) 2 . . . 750 671/752 (89%) NOV11d 29 . . . 731 658/753 (87%) 2 . . . 751 668/753 (88%) NOV11e 29 . . . 731 663/752 (88%) 2 . . . 750 671/752 (89%)

[0376] Further analysis of the NOV11a protein yielded the following properties shown in Table 11C. TABLE-US-00059 TABLE 11C Protein Sequence Properties NOV11a PSort 0.3700 probability located in outside; 0.1900 probability analysis: located in lysosome (lumen); 0.1304 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane) SignalP Cleavage site between residues 30 and 31 analysis:

[0377] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D. TABLE-US-00060 TABLE 11D Geneseq Results for NOV11a NOV11a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAU82007 Human secreted protein SECP33 - 8 . . . 430 289/454 (63%) e-163 Homo sapiens, 559 aa. 8 . . . 457 351/454 (76%) [WO200198353-A2, 27-DEC-2001] AAM39715 Human polypeptide SEQ ID NO 2860 - 8 . . . 430 289/454 (63%) e-163 Homo sapiens, 559 aa. 8 . . . 457 351/454 (76%) [WO200153312-A1, 26-JUL-2001] AAM41501 Human polypeptide SEQ ID NO 6432 - 8 . . . 406 275/430 (63%) e-154 Homo sapiens, 545 aa. 13 . . . 438 330/430 (75%) [WO200153312-A1, 26-JUL-2001] ABG03235 Novel human diagnostic protein #3226 - 188 . . . 378 137/192 (71%) 4e-75 Homo sapiens, 196 aa. 1 . . . 190 164/192 (85%) [WO200175067-A2, 11-OCT-2001] ABG03235 Novel human diagnostic protein #3226 - 188 . . . 378 137/192 (71%) 4e-75 Homo sapiens, 196 aa. 1 . . . 190 164/192 (85%) [WO200175067-A2, 11-OCT-2001]

[0378] In a BLAST search of public sequence datbases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E. TABLE-US-00061 TABLE 11E Public BLASTP Results for NOV11a NOV11a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9NXU2 CDNA FLJ20054 FIS, CLONE 393 . . . 731 339/339 (100%) 0.0 COL00849 - Homo sapiens 1 . . . 339 339/339 (100%) (Human), 339 aa. AAH22561 HYPOTHETICAL 45.0 KDA 27 . . . 376 340/379 (89%) 0.0 PROTEIN - Homo sapiens 15 . . . 392 344/379 (90%) (Human), 396 aa. Q9D5B9 4930571B16RIK PROTEIN - 337 . . . 731 298/407 (73%) e-167 Mus musculus (Mouse), 499 aa. 96 . . . 499 337/407 (82%) AAH27786 SIMILAR TO KIAA1608 8 . . . 623 342/680 (50%) e-166 PROTEIN - Mus musculus 8 . . . 676 439/680 (64%) (Mouse), 1016 aa. Q9H796 CDNA: FLJ21129 FIS, CLONE 8 . . . 426 288/450 (64%) e-162 CAS06266 - Homo sapiens 8 . . . 453 349/450 (77%) (Human), 559 aa.

[0379] PFam analysis predicts that the NOV11a protein contains the domains shown in the Table 11F. TABLE-US-00062 TABLE 11F Domain Analysis of NOV11a Identities/ Similarities for Pfam NOV11a the Matched Expect Domain Match Region Region Value DENN 129 . . . 244 48/120 (40%) 6.4e-35 84/120 (70%)

Example 12

[0380] The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A. TABLE-US-00063 TABLE 12A NOV12 Sequence Analysis SEQ ID NO: 69 1357 bp NOV12a, ATGAAACTAATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGG CG104903-01 AATCACAGTCCGAGGAAATTGATGACTGCAATGACAAGGATTTATTTAAAGCTGTGGA DNA TGCTGCTCTGAAGAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTAC Sequence CGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGCAAAAGCAGCCACTGGAGAAT GCACAGCAACCGTGGGGAAGAGGAGCAGTACGAAATTCTCCGTGGCTACCCAGACCTG CCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCCAGTACGACTGCCTCGGCTGT GTGCATCCTATATCAACGCAGAGCCCAGACCTGGAGCCCATTCTGAGACACGGCATTC AGTACTTTAACAACAACACTCAACATTCCTCCCTCTTCACGCTTAATGAAGTAAAACG GGCCCAAAGACAGGTGGTGGCTGGATTGAACTTTCGAATTACCTACTCAATTGTGCAA ACGAATTGTTCCAAAGAGAATTTTCTGTTCTTAACTCCAGACTGCAAGTCCCTTTGGA ATGGTGATACCGGTGAATGTACAGATAATGCATACATCGATATTCAGCTACGAATTGC TTCCTTCTCACAGAACTGTGACATTTATCCAGGGAAGGATTTTGTACAACCACCTACC AAGATTTGCGTGGGCTGCCCCAGAGATATACCCACCAACAGCCCAGAGCTGGAGGAGA CACTGACTCACACCATCACAAAGCTTAATGCAGAGAATAACGCAACTTTCTATTTCAA GATTGACAATGTGAAAAAAGCAAGAGTACAGGTGGTGGCTGGCAAGAAATATTTTATT GACTTCGTGGCCAGGGAAACCACATGTTCCAAGGAAAGTAATGAAGAGTTGACCGAAA GCTGTGAGACCAAAAAACTTGGCCAAAGCCTAGATTGCAACGCTGAAGTTTATGTGGT ACCCTGGGAGAAAAAAATTTACCCTACTGTCAACTGTCAACCACTGGGAATGATCTCA CTGATGAAAAGGCCTCCAGGTTTTTCACCTTTCCGATCATCACGAATAGGGGAAATAA AAGAAGAAACAACTAGTCACCTAAGGTCCTGCGAGTACAAGGGTCGACCCCCAAAGGC AGGGGCAGAGCCAGCATCTGAGAGGGAGGTCTCTTGACCAATGGGCAGAATCTTCACT CCAGGCACATAGCCCCAACCACCTCTGCCAGCAACCTTGAGAGGAAGGACAAGAAGAA AGATGGGATAGAATTTAAATAGAGAAGAATGCCATTTTATCACTCTGCCTCTGGGTGA AATAAAGATCAGTCTTGATGTTC ORF Start: ATG at 1 ORF Stop: TGA at 1195 SEQ ID NO: 70 398 aa MW at 44684.1kD NOV12a, MKLITILFLCSRLLLSLTQESQSEEIDDCNDKDLFKAVDAALKKYNSQNQSNNQFVLY CG104903-01 RKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGC Protein VHPISTQSPDLEPILRHGIQYFNNNTQHSSLFTLNEVKRAQRQVVAGLNFRITYSIVQ Sequence TNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPPT KICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFI DFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMIS LMKRPPGFSPFRSSRIGEIKEETTSHLRSCEYKGRPPKAGAEPASEREVS SEQ ID NO: 71 1848bp NOV12b, ATGAAACTAATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGG CG104903-02 AATCACAGTCCGAGGAAATTGATGACTGCAATGACAAGGATTTATTTAAAGCTGTGGA DNA TGCTGCTCTGAAGAAATATAACAGTCAPAACCAAAGTAACAACCAGTTTGTATTGTAC Sequence CGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGCAAAAGCAGCCACTGGAGAAT GCACAGCAACCGTGGGGAAGAGGAGCAGTACGAAATTCTCCGTGGCTACCCAGACCTG CCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCCAGTACGACTGCCTCGGCTGT GTGCATCCTATATCAACGCAGAGCCCAGACCTGGAGCCCATTCTGAGACACGGCATTC AGTACTTTAACAACAACACTCAACATTCCTCCCTCTTCACGCTTAATGAAGTAAAACG GGCCCAAAGACAGGTGGTGGCTGGATTGAACTTTCGAATTACCTACTCAATTGTGCAA ACGAATTGTTCCAAAGAGAATTTTCTGTTCTTAACTCCAGACTGCAAGTCCCTTTGGA ATGGTGATACCGGTGAATGTACAGATAATGCATACATCGATATTCAGCTACGAATTGC TTCCTTCTCACAGAACTGTGACATTTATCCAGGGAAGGATTTTGTACAACCACCTACC AAGATTTGCGTGGGCTGCCCCAGAGATATACCCACCAACAGCCCAGAGCTGGAGGAGA CACTGACTCACACCATCACAAAGCTTAATGCAGAGAATAACGCAACTTTCTATTTCAA GATTGACAATGTGAAAAAAGCAAGAGTACAGGTGGTGGCTGGCAAGAAATATTTTATT GACTTCGTGGCCAGGGAAACCACATGTTCCAAGGAAAGTAATGAAGAGTTGACCGAAA GCTGTGAGACCAAAAAACTTGGCCAAAGCCTAGATTGCAACGCTGAAGTTTATGTGGT ACCCTGGGAGAAAAAAATTTACCCTACTGTCAACTGTCAACCACTGGGAATGATCTCA CTGATGAAAAGGCCTCCAGGTTTTTCACCTTTCCGATCATCACGAATAGGGGAAATAA AAGAAGAAACAACTGTAAGTCCACCCCACACTTCCATGGCACCTGCACAAGATGAAGA GCGGGATTCAGGAAAAGAACAAGGGCATACTCGTAGACATGACTGGGGCCATGAAAAA CAAAGAAAACATAATCTTGGCCATGGCCATAAACATGAACGTGACCAAGGGCATGGGC ACCAAAGAGGACATGGCCTTGGCCATGGACACGAACAACAGCATGGTCTTGGTCATGG ACATAAGTTCAAACTTGATGATGATCTTGAACACCAAGGGGGCCATGTCCTTGACCAT GGACATAAGCATAAGCATGGTCATGGCCACGGAAAACATAAAAATAAAGGCAAAAAGA ATGGAAAGCACAATGGTTGGAAAACAGAGCATTTGGCAAGCTCTTCTGAAGACAGTAC TACACCTTCTGCACAGACACAAGAGAAGACAGAAGGGCCAACACCCATCCCTTCCCTA GCCAAGCCAGGTGTAACAGTTACCTTTTCTGACTTTCAGGACTCTGATCTCATTGCAA CTATGATGCCTCCTATATCACCAGCTCCCATACAGAGTGATGACGATTGGATCCCTGA TATCCAGACAGACCCAAATGGCCTTTCATTTAACCCAATATCAGATTTTCCAGACACG ACCTCCCCAAAATGTCCTGGACGCCCCTGGAAGTCAGTTAGTGAAATTAATCCAACCA CACAAATGAAAGAATCTTATTATTTCGATCTCACTGATGGCCTTTCTTAA ORF Start: ATG at 1 ORF Stop: TAA at 1846 SEQ ID NO: 72 615 aa MW at 68746.1kD NOV12b, MKLITILFLCSRLLLSLTQESQSEEIDDCNDKDLFKAVDAALKKYNSQNQSNNQFVLY CG104903-02 RKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGC Protein VHPISTQSPDLEPILRHGIQYFNNNTQHSSLFTLNEVKRAQRQVVAGLNFRITYSIVQ Sequence TNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPFT KICVGCPRDIPTNSFELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFI DFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMIS LMKRPPGFSPFRSSRIGEIKEETTVSPPHTSMAPAQDEERDSGKEQGHTRRHDWGHEK QRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQQBGLGHGHKFKLDDDLEHQGGHVLDH GHKHKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSL AKPGVTVTFSDFQDSDLIATMMPFISPAPIQSDDDWIPDIQTDPNGLSFNPISDFPDT TSPKCPGRPWKSVSEINPTTQMKESYYFDLTDGLS SEQ ID NO: 73 1981 bp NOV12c, AATTCCGGTTGAAACCATCCCTCAGCTCCTAGAGGGAGATTGTTAGATCATGAAACTA CG104903-03 ATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGGAATCACAGT DNA CCGAGGAAATTGACTGCAATGACAAGGATTTATTTAAAGCTGTGGATGCTGCTCTGAA Sequence GAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTACCGCATAACTGAA GCCACTAAGACGGTTGGCTCTGACACGTTTTATTCCTTCAAGTACGAAATCAAGGAGG GGGATTGTCCTGTTCAAAGTGGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGC AAAAGCAGCCACTGGAGAATGCACGGCAACCGTGGGGAAGAGGAGCAGTACGAAATTC TCCGTGGCTACCCAGACCTGCCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCC AGTACGACTGCCTCGGCTGTGTGCATCCTATATCAACGCAGAGCCCAGACCTGGAGCC CATTCTGAGACACGGCATTCAGTACTTTAACAACAACACTCAACATTCCTCCCTCTTC ATGCTTAATGAAGTAAAACGGGCCCAAAGACAGGTGGTGGCTGGATTGAACTTTCGAA TTACCTACTCAATTGTGCAAACGAATTGTTCCAAAGAGAATTTTCTGTTCTTAACTCC AGACTGCAAGTCCCTTTGGAATGGTGATACCGGTGAATGTACAGATAATGCATACATC GATATTCAGCTACGAATTGCTTCCTTCTCACAGAACTGTGACATTTATCCAGGGAAGG ATTTTGTACAACCACCTACCAAGATTTGCGTGGGCTGCCCCAGAGATATACCCACCAA CAGCCCAGAGCTGGAGGAGACACTGACTCACACCATCACAAAGCTTAATGCAGAGAAT AACGCAACTTTCTATTTCAAGATTGACAATGTGAAAAAAGCAAGAGTACAGGTGGTGG CTGGCAAGAAATATTTTATTGACTTCGTGGCCAGGGAAACCACATGTTCCAAGGAAAG TAATGAAGAGTTGACCGAAAGCTGTGAGACCAAAAAAGTTGGCCAAAGCCTAGATTGC AACGCTGAAGTTTATGTGGTACCCTGGGAGAAAAAAATTTACCCTACTGTCAACTGTC AACCACTGGGAATGATCTCACTGATGAAAAGGCCTCCAGGTTTTTCACCTTTCCGATC ATCACGAATAGGGGAAATAAAAGAAGAAACAACTGTAAGTCCACCCCACACTTCCATG GCACCTGCACAAGATGAAGAGCGGGATTCAGGAAAAGAACAAGGGCATACTCGTAGAC ATGACTGGGGCCATGAAAAACAAAGAAAACATAATCTTGGCCATGGCCATAAACATGA ACGTGACCAAGGGCATGGGCACCAAAGAGGACATGGCCTTGGCCATGGACACGAACAA CAGCATGGTCTTGGTCATGGACATAAGTTCAAACTTGATGATGATCTTGAACACCAAG GGGGCCATGTCCTTGACCATGGACATAAGCATAAGCATGGTCATGGCCACGGAAAACA TAAAAATAAAGGCAAAAAGAATGGAAAGCACAATGGTTGGAAAACAGAGCATTTGGCA AGCTCTTCTGAAGACAGTACTACACCTTCTGCACAGACACAAGAGAAGACAGAAGGGC CAACACCCATCCCTTCCCTAGCCAAGCCAGGTGTAACAGTTACCTTTTCTGACTTTCA GGACTCTGATCTCATTGCAACTATGATGCCTCCTATATCAGCAGCTCCCATACAGAGT GATGACGATTGGATCCCTGATATCCAGATAGACCCAAATGGCCTTTCATTTAACCCAA TATCAGATTTTCCAGACACGACCTCCCCAAAATGTCCTGGACGCCCCTGGAAGTCAGT TAGTGAAATTAATCCAACCACACAAATGAAAGAATCTTATTATTTCGATCTCACTGAT GGCCTTTCT ORF Start: ATG at 50 ORF Stop: end of sequence SEQ ID NO: 74 644 aa MW at 71956.8kD NOV12c, MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYR GG104903-03 ITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSS Protein TKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHS Sequence SLFMLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDN AYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLN AENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQS LDCNAEVYVVPWEKKIYPTVNCQPLGMTSLMKRPPGFSPFRSSRIGEIKEETTVSPPH TSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHG HEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKBGHGHGKHKNKGKKNGKHNGWKTE HLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAP IQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESYYFD LTDGLS SEQ ID NO: 75 1297 bp NOV12d, AATTCCGGTTGAAACCATCCCTCAGCTCCTAGAGGGAGATTGTTAGATCATGAAACTA CG104903-05 ATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGGAATCACAGT DNA CCGAGGAAATTGACTGCAATGACAAGGATTTATTTAAAGCTGTGGATGCTGCTCTGAA Sequence GAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTACCGCATAACTGAA GCCACTAAGACGGTTGGCTCTGACACGTTTTATTCCTTCAAGTACGAAATCAAGGAGG GGGATTGTCCTGTTCAAAGTGGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGC AAAAGCAGCCACTGGAGAATGCACAGCAACCGTGGGGAAGAGGAGCAGTACGAAATTC TCCGTGGCTACCCAGACCTGCCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCC AGTACGACTGCCTCGGCTGTGTGCATCCTATATCAACGCAGAGCCCAGGTTTTTCACC TTTCCGATCATCACGAATAGGGGAAATAAAAGAAGAAACAACTGTAAGTCCACCCCAC ACTTCCATGGCACCTGCACAAGATGAAGAGCGGGATTCAGGAAAAGAACAAGGGCATA CTCGTAGACATGACTGGGGCCATGAAAAACAAAGAAAACATAATCTTGGCCATGGCCA TAAACATGAACGTGACCAAGGGCATGGGCACCAAAGAGGACATGGCCTTGGCCATGGA CACGAACAACAGCATGGTCTTGGTCATGGACATAAGTTCAAACTTGATGATGATCTTG AACACCAAGGGGGCCATGTCCTTGACCATGGACATAAGCATAAGCATGGTCATGGCCA CGGAAAACATAAAAATAAAGGCAAAAAGAATGGAAAGCACAATGGTTGGAAAACAGAG CATTTGGCAAGCTCTTCTGAAGACAGTACTACACCTTCTGCACAGACACAAGAGAAGA CAGAAGGGCCAACACCCATCCCTTCCCTAGCCAAGCCAGGTGTAACAGTTACCTTTTC TGACTTTCAGGACTCTGATCTCATTGCAACTATGATGCCTCCTATATCACCAGCTCCC ATACAGAGTGATGACGATTGGATCCCTGATATCCAGATAGACCCAAATGGCCTTTCAT TTAACCCAATATCAGATTTTCCAGACACGACCTCCCCAAAATGTCCTGGACGCCCCTG GAAGTCAGTTAGTGAAATTAATCCAACCACACAAATGAAAGAATCTTATTATTTCGAT CTCACTGATGGCCTTTCTTAA ORF Start: ATG at 50 ORF Stop: TAA at 1295 SEQ ID NO: 76 415 aa MW at 45897.3kD NOV12d, MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYR CG104903-05 ITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSS Protein TKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPGFSPFRSSRIGEIKEETTVS Sequence PPHTSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGL GHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGW KTEHLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPFIS PAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESY YFDLTDGLS SEQ ID NO: 77 1892 bp NOV12e, AATTCCGGTTGAAACCATCCCTCAGCTCCTAGAGGGAGATTGTTAGATCATGAAACTA CG104903-06 ATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGGAATCACAGT DNA CCGAGGAAATTGACTGCAATGACAAGGATTTATTTAAAGCTGTGGATGCTGCTCTGAA Sequence GAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTACCGCATAACTGAA GCCACTAAGACGGTTGGCTCTGACACGTTTTATTCCTTCAAGTACGAAATCAAGGAGG GGGATTGTCCTGTTCAAAGTGGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGC AAAAGCAGCCACTGGAGAATGCACAGCAACCGTGGGAAGAGGAGCAGTACGAAATTCT CCGTGGCTACCCAGACCTGGAGCCCATTCTGAGACACGGCATTCAGTACTTTAACAAC AACACTCAACATTCCTCCCTCTTCACGCTTAATGAAGTAAAACGGGCCCAAAGACAGG TGGTGGCTGGATTGAACTTTCGAATTACCTACTCAATTGTGCAAACGAATTGTTCCAA AGAGAATTTTCTGTTCTTAACTCCAGACTGCAAGTCCCTTTGGAATGGTGATACCGGT GAATGTACAGATAATGCATACATCGATATTCAGCTACGAATTGCTTGCTTCTCACAGA ACTGTGACATTTATCCAGGGAAGGATTTTGTACAACCACCTACCAAGATTTGCGTGGG CTGCCCCAGAGATATACCCACCAACAGCCCAGAGCTGGAGGAGACACTGACTCACACC ATCACAAAGCTTAATGCAGAGAATAACGCAACTTTCTATTTCAAGATTGACAATGTGA AAAAAGCAAGAGTACAGGTGGTGGCTGGCAAGAAATATTTTATTGACTTCGTGGCCAG GGAAACCACATGTTCCAAGGAAAGTAATGAAGAGTTGACCGAAAGCTGTGAGACCAAA AAACTTGGCCAAAGCCTAGATTGCAACGCTGAAGTTTATGTGGTACCCTGGGAGAAAA AAATTTACCCTACTGTCAACTGTCAACCACTGGGAATGATCTCACTGATGAAAAGGCC TCCAGGTTTTTCACCTTTCCGATCATCACGAATAGGGGAAATAAAAGAAGAAACAACT GTAAGTCCACCCCACACTTCCATGGCACCTGCACAAGATGAAGAGCGGGATTCAGGAA AAGAACAAGGGCATACTCGTAGACATGACTGGGGCCATGAAAAACAAAGAAAACATAA TCTTGGCCATGGCCATAAACATGAACGTGACCAAGGGCATGGGCACCAAAGAGGACAT GGCCTTGGCCATGGACACGAACAACAGCATGGTCTTGGTCATGGACATAAGTTCAAAC TTGATGATGATCTTGAACACCAAGGGGGCCATGTCCTTGACCATGGACATAAGCATAA GCATGGTCATGGCCACGGAAAACATAAAAATAAAGGCAAAAAGAATGGAAAGCACAAT GGTTGGAAAACAGAGCATTTGGCAAGCTCTTCTGAAGACAGTACTACACCTTCTGCAC AGACACAAGAGAAGACAGAAGGGCCAACACCCATCCCTTCCCTAGCCAAGCCAGGTGT AACAGTTACCTTTTCTGACTTTCAGGACTCTGATCTCATTGCAACTATGATGCCTCCT ATATCACCAGCTCCCATACAGAGTGATGACGATTGGATCCCTGATATCCAGATAGACC CAAATGGCCTTTCATTTAACCCAATATCAGATTTTCCAGACACGACCTCCCCAAAATG TCCTGGACGCCCCTGGAAGTCAGTTAGTGAAATTAATCCAACCACACAAATGAAAGAA TCTTATTATTTCGATCTCACTGATGGCCTTTCTTAA ORF Start: ATG at 50 ORF Stop: TAA at 458 SEQ ID NO: 78 136 aa MW at 15218.9kD NOV12e, MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYR CG104903-06 ITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGRGAV Protein RNSPWLPRPGAHSETRHSVL Sequence SEQ ID NO: 79 670 bp NOV12f, ATGAAACTAATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGG CG104903-07 AATCACAGTCCGAGGAAATTGATGACTGCAATGACAAGGATTTATTTAAAGCTGTGGA DNA TGCTGCTCTGAAGAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTAC Sequence CGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGCAAAAGCAGCCACTGGAGAAT GCACAGCAACCGTGGGGAAGAGGAGCAGTACGAAATTCTCCGTGGCTACCCAGACCTG CCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCCAGTACGACTGCCTCGGCTGT GTGCATCCTATATCAACGCAGAGCCCAGGTTTTTCACCTTTCCGATCATCACGAATAG GGGAAATAAAAGAAGAAACAACTAGTCACCTAAGGTCCTGCGAGTACAAGGGTCGACC CCCAAAGGCAGGGGCAGAGCCAGCATCTGAGAGGGAGGTCTCTTGACCAATGGGCAGA ATCTTCACTCCAGGCACATAGCCCCAACCACCTCTGCCAGCAACCTTGAGAGGAAGGA CAAGAAGAAAGATGGGATAGAATTTAAATAGAGAAGAATGCCATTTTATCACTCTGCC TCTGGGTGAAATAAAGATCAGTCTTGATGTTC ORF Start: ATG at 1 ORF Stop: TGA at 508 SEQ ID NO: 80 169 aa MW at 18654.7kD NOV12f, IMKLITILFLCSRLLLSLTQESQSEEIDDCNKDLFKAVDAALKKYNSQNQSNNQFVLY CG104903-07 RKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGC Protein VHPISTQSPGFSPFRSSRIGEIKEETTSHLRSCEYKGRPPKAGAEPASEREVS Sequence SEQ ID NO: 81 1193 bp NOV12g, ATGAAACTAATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGG CG104903-08 AATCACAGTCCGAGGAAATTGACTGCAATGACAAGGATTTATTTAAAGCTGTGGATGC DNA TGCTCTGAAGAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTACCGC Sequence ATAACTGAAGCCACTAAGACGGCCACTGGAGAATGCACGGCAACCGTGGGGAAGAGGA GCAGTACGAAATTCTCCGTGGCTACCCAGACCTGCCAGATTACTCCAGCCGAGGGCCC TGTGGTGACAGCCCAGTACGACTGCCTCGGCTGTGTGCATCCTATATCAACGCAGAGC CCAGACCTGGAGCCCATTCTGAGACACGGCATTCAGTACTTTAACAACAACACTCAAC

ATTCCTCCCTCTTCACGCTTAATGAAGTAAAACGGGCCCAAAGACAGGTGGTGGCTGG ATTGAACTTTCGAATTACCTACTCAATTGTGCAAACGAATTGTTCCAAAGAGAATTTT CTGTTCTTAACTCCAGACTGCGAGTCCCTTTGGAATGGTGATACCGGTGAATGTACAG ATAATGCATACATCGATATTCAGCTACGAATTGCTTCCTTCTCACAGAACTGTGACAT TTATCCAGGGAAGGATTTTGTACAACCACCTACCAAGATTTGCGTGGGCTGCCCCAGA GATATACCCACCAACAGCCCAGAGCTGGAGGAGACACTGACTCACACCATCACAAAGC TTAATGCAGAGAATAACGCAACTTTCTATTTCAAGATTGACAATGTGAAAAAAGCAAG AGTACAGGTGGTGGCTGGCAAGAAATATTTTATTGACTTCGTGGCCAGGGAAACCACA TGTTCCAAGGAAAGTAATGAAGAGTTGACCGAAAGCTGTGAGACCAAAAAACTTGGCC AAAGCCTAGATTGCAACGCTGAAGTTTATGTGGTACCCTGGGAGAAAAAAATTTACCC TACTGTCAACTGTCAACCACTGGGAATGATCTCACTGATGAAAAGGCCTCCAGGTTTT TCACCTTTCCGATCATCACGAATAGGGGAAATAAAAGAAGAAACAACTAGTCACCTAA GGTCCTGCGAGTACAAGGGTCGACCCCCAAAGGCAGGGGCAGAGCCAGTATCTGAGAG GGAGGTCTCTTGACCAATGGGCAGAATCTTCAC ORF Start: ATG at 1 ORF Stop: TGA at 1171 SEQ ID NO: 82 390 aa MW at 43704.0kD NOV12g, MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYR CG104903-08 ITEATKTATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQS Protein PDLEPILRHGIQYFNNNTQHSSLFTLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENF Sequence LFLTPDCESLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPR DIPTNSPELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETT CSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMKRPPGF SPFRSSRIGEIKEETTSHLRSCEYKGRPPKAGAEPVSEREVS SEQ ID NO: 83 1984 bp NOV12h, AATTCCGGTTGAAACCATCCCTCAGCTCCTAGAGGGAGATTGTTAGATCATGAAACTA CG104903-09 ATTACCATCCTTTTCCTCTGCTCCAGGCTACTACTAAGTTTAACCCAGGAATCACAGT DNA CCGAGGAAATTGACTGCAATGACAAGGATTTATTTAAAGCTGTGGATGCTGCTCTGAA Sequence GAAATATAACAGTCAAAACCAAAGTAACAACCAGTTTGTATTGTACCGCATAACTGAA GCCACTAAGACGGTTGGCTCTGACACGTTTTATTCCTTCAAGTACGAAATCAAGGAGG GGGATTGTCCTGTTCAAAGTGGCAAAACCTGGCAGGACTGTGAGTACAAGGATGCTGC AAAAGCAGCCACTGGAGAATGCACGGCAACCGTGGGGAAGAGGAGCAGTACGAAATTC TCCGTGGCTACCCAGACCTGCCAGATTACTCCAGCCGAGGGCCCTGTGGTGACAGCCC AGTACGACTGCCTCGGCTGTGTGCATCCTATATCAACGCAGAGCCCAGACCTGGAGCC CATTCTGAGACACGGCATTCAGTACTTTAACAACAACACTCAACATTCCTCCCTCTTC ATGCTTAATGAAGTAAAACGGGCCCAAAGACAGGTGGTGGCTGGATTGAACTTTCGAA TTACCTACTCAATTGTGCAAACGAATTGTTCCAAAGAGAATTTTCTGTTCTTAACTCC AGACTGCAAGTCCCTTTGGAATGGTGATACCGGTGAATGTACAGATAATGCATACATC GATATTCAGCTACGAATTGCTTCCTTCTCACAGAACTGTGACATTTATCCAGGGAAGG ATTTTGTACAACCACCTACCAAGATTTGCGTGGGCTGCCCCAGAGATATACCCACCAA CAGCCCAGAGCTGGAGGAGACACTGACTCACACCATCACAAAGCTTAATGCAGAGAAT AACGCAACTTTCTATTTCAAGATTGACAATGTGAAAAAAGCAAGAGTACAGGTGGTGG CTGGCAAGAAATATTTTATTGACTTCGTGGCCAGGGAAACCACATGTTCCAAGGAAAG TAATGAAGAGTTGACGGAAAGCTGTGAGACCAAAAAACTTGGCCAAAGCCTAGATTGC AACGCTGAAGTTTATGTGGTACCCTGGGAGAAAAAAATTTACCCTACTGTCAACTGTC AACCACTGGGAATGATCTCACTGATGAAAAGGCCTCCAGGTTTTTCACCTTTCCGATC ATCACGAATAGGGGAAATAAAAGAAGAAACAACTGTAAGTCCACCCCACACTTCCATG GCACCTGCACAAGATGAAGAGCGGGATTCAGGAAAAGAACAAGGGCATACTCGTAGAC ATGACTGGGGCCATGAAAAACAAAGAAAACATAATCTTGGCCATGGCCATAAACATGA ACGTGACCAAGGGCATGGGCACCAAAGAGGACATGGCCTTGGCCATGGACACGAACAA CAGCATGGTCTTGGTCATGGACATAAGTTCAAACTTGATGATGATCTTGAACACCAAG GGGGCCATGTCCTTGACCATGGACATAAGCATAAGCATGGTCATGGCCACGGAAAACA TAAAAATAAAGGCAAAAAGAATGGAAAGCACAATGGTTGGAAAACAGAGCATTTGGCA AGCTCTTCTGAAGACAGTACTACACCTTCTGCACAGACACAAGAGAAGACAGAAGGGC CAACACCCATCCCTTCCCTAGCCAAGCCAGGTGTAACAGTTACCTTTTCTGACTTTCA GGACTCTGATCTCATTGCAACTATGATGCCTCCTATATCACCAGCTCCCATACAGAGT GATGACGATTGGATCCCTGATATCCAGATAGACCCAAATGGCCTTTCATTTAACCCAA TATCAGATTTTCCAGACACGACCTCCCCAAAATGTCCTGGACGCCCCTGGAAGTCAGT TAGTGAAATTAATCCAACCACACAAATGAAAGAATCTTATTATTTCGATCTCACTGAT GGCCTTTCTTAA ORF Start: ATG at 50 ORF Stop: TAA at 1982 SEQ ID NO: 84 644 aa MW at 71956.8kD NOV12h, MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYR CG104903-09 ITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSS Protein TKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHS Sequence SLFMLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDN AYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLN AENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQS LDCNAEVYVVPWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIKEETTVSPPH TSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHG HEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGWKTE HLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAP IQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESYYFD LTDGLS

[0381] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 12B. TABLE-US-00064 TABLE 12B Comparison of NOV12a against NOV12b through NOV12h. NOV12a Identities/ Protein Residues/Match Similarities for Sequence Residues the Matched Region NOV12b 26 . . . 396 343/371 (92%) 26 . . . 387 344/371 (92%) NOV12c 28 . . . 396 340/399 (85%) 27 . . . 416 341/399 (85%) NOV12d 28 . . . 129 90/132 (68%) 27 . . . 158 90/132 (68%) NOV12e 28 . . . 84 47/87 (54%) 27 . . . 113 48/87 (55%) NOV12f 26 . . . 129 92/104 (88%) 26 . . . 129 92/104 (88%) NOV12g 28 . . . 398 349/371 (94%) 27 . . . 390 351/371 (94%) NOV12h 28 . . . 396 340/399 (85%) 27 . . . 416 341/399 (85%)

[0382] Further analysis of the NOV12a protein yielded the following properties shown in Table 12C. TABLE-US-00065 TABLE 12C Protein Sequence Properties NOV12a PSort 0.5135 probability located in outside; 0.1900 analysis: probability located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 24 and 25 analysis:

[0383] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D. TABLE-US-00066 TABLE 12D Geneseq Results for NOV12a NOV12a Identities/ Geneseq Protein/Organism/Length Residues/Match Similarities for Expect Identifier [Patent #, Date] Residues the Matched Region Value ABG21101 Novel human diagnostic protein 1 . . . 396 375/426 (88%) 0.0 #21092 - Homo sapiens, 644 aa. 1 . . . 416 376/426 (88%) [WO200175067-A2, 11-OCT-2001] ABG21101 Novel human diagnostic protein 1 . . . 396 375/426 (88%) 0.0 #21092 - Homo sapiens, 644 aa. 1 . . . 416 376/426 (88%) [WO200175067-A2, 11-OCT-2001] ABG21105 Novel human diagnostic protein 1 . . . 398 377/435 (86%) 0.0 #21096 - Homo sapiens, 435 aa. 2 . . . 435 380/435 (86%) [WO200175067-A2, 11-OCT-2001] ABG21105 Novel human diagnostic protein 1 . . . 398 377/435 (86%) 0.0 #21096 - Homo sapiens, 435 aa. 2 . . . 435 380/435 (86%) [WO200175067-A2, 11-OCT-2001] AAP40257 Bradykinin protein precursor: 1 . . . 398 297/428 (69%) e-174 type I (pKG13, pKG59), 436 aa. 1 . . . 426 343/428 (79%) [JP59125896-A, 20-JUL-1984]

[0384] In a BLAST search of public sequence datbases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E. TABLE-US-00067 TABLE 12E Public BLASTP Results for NOV12a Protein NOV12a Identities/ Accession Residues/Match Similarities for Expect Number Protein/Organism/Length Residues the Matched Portion Value KGHUL1 kininogen, LMW precursor 1 . . . 398 396/428 (92%) 0.0 [validated] - human, 427 aa. 1 . . . 427 396/428 (92%) P01042 Kininogen precursor 1 . . . 396 375/426 (88%) 0.0 (Alpha-2-thiol proteinase 1 . . . 416 376/426 (88%) inhibitor) [Contains: Bradykinin] - Homo sapiens (Human), 644 aa. P01046 Kininogen, LMW I precursor 1 . . . 398 297/428 (69%) e-173 (Thiol proteinase inhibitor) 1 . . . 426 343/428 (79%) [Contains: Bradykinin] - Bos taurus (Bovine), 436 aa. P01047 Kininogen, LMW II precursor 1 . . . 398 292/428 (68%) e-170 (Thiol proteinase inhibitor) 1 . . . 424 340/428 (79%) [Contains: Bradykinin] - Bos taurus (Bovine), 434 aa. P01044 Kininogen, HMW I precursor 1 . . . 375 280/405 (69%) e-161 (Thiol proteinase inhibitor) 1 . . . 403 321/405 (79%) [Contains: Bradykinin] - Bos taurus (Bovine), 621 aa.

[0385] PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12F. TABLE-US-00068 TABLE 12F Domain Analysis of NOV12a Identities/ Pfam NOV12a Similarities for Expect Domain Match Region the Matched Region Value cystatin 21 . . . 59 11/40 (28%) 1.9e-06 35/40 (88%) cystatin 60 . . . 97 14/40 (35%) 4e-07 30/40 (75%) cystatin 115 . . . 219 28/113 (25%) 5e-35 92/113 (81%) cystatin 237 . . . 341 32/113 (28%) 3.4e-39 94/113 (83%)

Example 13

[0386] The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A. TABLE-US-00069 TABLE 13A NOV13 Sequence Analysis SEQ ID NO: 85 1272 bp NOV13a, CTTCCCCAGGACTCCAGGAGACATAAAACTTGAAACGGGAGACTTCGTGCAAATCCTG CG105982-01 CTCCGGACGCTGCTGAAGCTCAGATTTCTCCCACTGCCTGCACAGGGTGCTGCCTGCT DNA GGCGAATGTGACTCTCCTCCTGTTCACCCACAAGGCTGATTTTTCCGTGTTCCTCCTC Sequence TGGAAAGAGCATTGCTTTCTCTCTTCCAGCACTTTACCTACATTCATGTCTTTCAGGT GGCTGCTTCTCTATTATGCTCTGTGCTTCTCCCTGTCAAAGGCTTCAGCCCACACCGT GGAGCTAAACAATATGTTTGGCCAGATCCAGTCGCCTGGTTATCCAGACTCCTATCCC AGTGATTCAGAGGTGACTTGGAATATCACTGTCCCAGATGGGTTTCGGATCAAGCTTT ACTTCATGCACTTCAACTTGGAATCCTCCTACCTTTGTGAATATGACTATGTGAAGGT AGAAACTGAGGACACTTCGAGAGTGCCAAATGACAAGTGGTTTGGGAGTGGGGCCCTG CTCTCTGCGTCCTGGATCCTCACAGCAGCTCATGTGCTGCGCTCCCAGCGTAGAGACA CCACGGTGATACCAGTCTCCAAGGAGCATGTCACCGTCTACCTGGGCTTGCATGATGT GCGAGACAAATCGGGGGCAGTCAACAGCTCAGCTGCCCGAGTGGTGCTCCACCCAGAC TTCAACATCCAAAACTACAACCACGATATAGCTCTGGTGCAGCTGCAGGAGCCTGTGC CCCTGGGACCCCACGTTATGCCTGTCTGCCTGCCAAGGCTTGAGCCTGAAGGCCCGGC CCCCCACATGCTGGGCCTGGTGGCCGGCTGGGGCATCTCCAATCCCAATGTGACAGTG GATGAGATCATCAGCAGTGGCACACGGACCTTGTCAGATGTCCTGCAGTATGTCAAGT TACCCGTGGTGCCTCACGCTGAGTGCAAAACTAGCTATGAGTCCCGGTCGGGCAATTA CAGCGTCACGGAGAACATGTTCTGTGCTGGCTACTACGAGGGCGGCAAAGACACGTGC CTTGGAGATAGCGGTGGGGCCTTTGTCATCTTTGATGACTTGAGCCAGCGCTGGGTGG TGCAAGGCCTGGTGTCCTGGGGGGGACCTGAAGAATGCGGCAGCAAGCAGGTCTATGG AGTCTACACAAAGGTCTCCAATTACGTGGACTGGGTGTGGGAGCAGATGGGCTTACCA CAAAGTGTTGTGGAGCCCCAGGTGGAACGGTGAGCTGACTTACTTCCTCGCGGG ORF Start: ATG at 220 ORF Stop: TGA at 1249 SEQ ID NO: 86 343 aa MW at 38275.9kD NOV13a, MSFRWLLLYYALCFSLSKASAHTVELNNMFGQIQSPGYPDSYPSDSEVTWNITVPDGF CG105982-01 RIKLYFMHFNLESSYLCEYDYVKVETEDTSRVPNDKWFGSGALLSASWILTAAHVLRS Protein QRRDTTVIPVSKEHVTVYLGLHDVRDKSGAVNSSAARVVLHPDFNIQNYNHDIALVQL Sequence QEPVPLGPHVMPVCLPRLEPEGPAPHMLGLVAGWGISNPNVTVDEIISSGTRTLSDVL QYVKLPVVPHAECKTSYESRSGNYSVTENMFCAGYYEGGKDTCLGDSGGAFVIFDDLS QRWVVQGLVSWGGPEECGSKQVYGVYTKVSNYVDWVWEQMGLPQSVVEPQVER

[0387] Further analysis of the NOV13a protein yielded the following properties shown in Table 13B. TABLE-US-00070 TABLE 13B Protein Sequence Properties NOV13a PSort 0.3700 probability located in outside; 0.1900 analysis: probability located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 22 and 23 analysis:

[0388] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C. TABLE-US-00071 TABLE 13C Geneseq Results for NOV13a NOV13a Identities/ Geneseq Protein/Organism/Length Residues/Match Similarities for Expect Identifier [Patent #, Date] Residues the Matched Region Value AAB85060 Human serine protease MASP-3 82 . . . 343 259/262 (98%) e-154 polypeptide - Homo sapiens, 728 467 . . . 728 260/262 (98%) aa. [WO200140451-A2, 07-JUN-2001] AAB47559 Protease PRTS-1 - Homo sapiens, 82 . . . 343 258/262 (98%) e-153 728 aa. [WO200171004-A2, 467 . . . 728 259/262 (98%) 27-SEP-2001] AAB84203 Amino acid sequence of a human 82 . . . 332 248/251 (98%) e-148 serine protease designated Zfaix1 - 19 . . . 269 249/251 (98%) Homo sapiens, 269 aa. [WO200138501-A2, 31-MAY-2001] AAG00221 Human secreted protein, SEQ ID 4 . . . 82 79/79 (100%) 3e-42 NO: 4302 - Homo sapiens, 97 aa. 2 . . . 80 79/79 (100%) [EP1033401-A2, 06-SEP-2000] AAB60935 Horseshoe crab recombinant Factor 92 . . . 326 90/244 (36%) 2e-37 C #2 - Carcinoscorpius 787 . . . 1015 127/244 (51%) rotundicauda, 1019 aa. [WO200127289-A2, 19-APR-2001]

[0389] In a BLAST search of public sequence datbases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13D. TABLE-US-00072 TABLE 13D Public BLASTP Results for NOV13a Protein NOV13a Identities/ Accession Residues/Match Similarities for Expect Number Protein/Organism/Length Residues the Matched Portion Value CAC42682 SEQUENCE 1 FROM PATENT 82 . . . 343 259/262 (98%) e-154 WO0140451 - Homo sapiens 467 . . . 728 260/262 (98%) (Human), 728 aa. Q96RS4 COMPLEMENT FACTOR MASP-3 - 82 . . . 343 259/262 (98%) e-154 Homo sapiens (Human), 728 aa. 467 . . . 728 260/262 (98%) CAC42545 SEQUENCE 1 FROM PATENT 82 . . . 332 248/251 (98%) e-147 WO0138501 - Homo sapiens 19 . . . 269 249/251 (98%) (Human), 269 aa (fragment). Q920S0 MBL-ASSOCIATED SERINE 82 . . . 343 236/262 (90%) e-141 PROTEASE-3 - Mus musculus 472 . . . 733 247/262 (94%) (Mouse), 733 aa. Q9PVY2 MANNOSE-BINDING LECTIN- 82 . . . 330 158/251 (62%) 9e-93 ASSOCIATED SERINE 465 . . . 714 198/251 (77%) PROTEASE - Triakis scyllium (Leopard shark) (Triakis scyllia), 719 aa.

[0390] PFam analysis predicts that the NOV13a protein contains the domains shown in the Table 13E. TABLE-US-00073 TABLE 13E Domain Analysis of NOV13a Identities/ Pfam NOV13a Similarities for Expect Domain Match Region the Matched Region Value CUB 22 . . . 134 37/127 (29%) 1.5e-05 75/127 (59%) Trypsin 94 . . . 326 86/258 (33%) 2.2e-66 192/258 (74%)

Example 14

[0391] The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A. TABLE-US-00074 TABLE 14A NOV14 Sequence Analysis SEQ ID NO: 87 861 bp NOV14a, CAGCTCAGCATGGCTAGGGTACTGGGAGCACCCGTTGCACTGGGGTTGTGGAGCCTAT CG107614-02 GCTGGTCTCTGGCCATTGCCACCCCTCTTCCTCCGACTAGTGCCCATGGGAATGTTGC DNA TGAAGGCGAGACCAAGCCAGACCCAGACGTGACTGAACGCTGCTCAGATGGCTGGAGC Sequence TTTGATGCTACCACCCTGGATGACAATGGAACCATGCTGTTTTTTAAAGGGACCCACT ACTGGCGTCTGGACACCAGCCGGGATGGCTGGCATAGCTGGCCCATTGCTCATCAGTG GCCCCAGGGTCCTTCAGCAGTGGATGCTGCCTTTTCCTGGGAAGAAAAACTCTATCTG GTCCAGGGCACCCAGGTATATGTCTTCCTGACAAAGGGAGGCTATACCCTAGTAAGCG GTTATCCGAAGCGGCTGGAGAAGGAAGTCGGGACCCCTCATGGGATTATCCTGGACTC TGTGGATGCGGCCTTTATCTGCCCTGGGTCTTCTCGGCTCCATATCATGGCAGGACGG CGGCTGTGGTGGCTGGAGCTGAAGTCAGGAGCCCAAGCCACGTGGACAGAGCTTCCTT GGCCCCATGAGAAGGTAGACGGAGCCTTGTGTATGGAAAAGTCCCTTGGCCCTAACTC ATGTTCCGCCAATGGTCCCGGCTTGTACCTCATCCATGGTCCCAATTTGTACTGCTAC AGTGATGTGGAGAAACTGAATGCAGCCAAGGCCCTTCCGCAACCCCAGAATGTGACCA GTCTCCTGGGCTGCACTCACTGAGGGGCCTTCTGACATGAGTCTGGCCTGGCCCCACC TCCTAGTTCCTCATAATAAAGACAGATTGCTTCTTCGCTTCTCACTGAG ORF Start: ATG at 10 ORF Stop: TGA at 775 SEQ ID NO: 88 255 aa MW at 27921.4kD NOV14a, MARVLGAPVALGLWSLCWSLAIATPLPPTSAHGNVAEGETKPDPDVTERCSDGWSFDA CG107614-02 TTLDDNGTMLFFKGTHYWRLDTSRDGWHSWPIAHQWPQGPSAVDAAFSWEEKLYLVQG Protein TQVYVFLTKGGYTLVSGYPKRLEKEVGTPHGIILDSVDAAFICPGSSRLHIMAGRRLW Sequence WLDLKSGAQATWTELPWPHEKVDGALCMEKSLGPNSCSANGPGLYLIHGPNLYCYSDV EKLNAAKALPQPQNVTSLLGCTH

[0392] Further analysis of the NOV14a protein yielded the following properties shown in Table 14B. TABLE-US-00075 TABLE 14B Protein Sequence Properties NOV14a PSort 0.4586 probability located in lysosome (lumen); 0.4323 analysis: probability located in outside; 0.3077 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane) SignalP Cleavage site between residues 32 and 33 analysis:

[0393] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14C. TABLE-US-00076 TABLE 14C Geneseq Results for NOV14a NOV14a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAM23933 Human EST encoded protein SEQ ID 30 . . . 255 197/226 (87%) e-116 NO: 1458 - Homo sapiens, 462 aa. 242 . . . 462 201/226 (88%) [WO200154477-A2, 02-AUG-2001] AAG00304 Human secreted protein, SEQ ID 1 . . . 77 73/77 (94%) 5e-39 NO: 4385 - Homo sapiens, 83 aa. 1 . . . 77 74/77 (95%) [EP1033401-A2, 06-SEP-2000] AAP93630 Sequence of rat transin - 43 . . . 179 45/142 (31%) 2e-08 Rattus rattus, 463 aa. 270 . . . 401 68/142 (47%) [GB2209526-A, 17-MAY-1989] AAM48977 Human matrix metalloproteinase 30 . . . 177 38/150 (25%) 4e-07 13 (collagenase 3) - Homo sapiens, 264 . . . 406 68/150 (45%) 471 aa. [WO200206294-A2, 24- JAN-2002] AAB84615 Amino acid sequence of matrix 30 . . . 177 38/150 (25%) 4e-07 metalloproteinase-13 - 264 . . . 406 68/150 (45%) Homo sapiens, 471 aa. [WO200149309-A2, 12-JUL-2001]

[0394] In a BLAST search of public sequence datbases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14D. TABLE-US-00077 TABLE 14D Public BLASTP Results for NOV14a NOV14a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value P02790 Hemopexin precursor (Beta-1B- 30 . . . 255 197/226 (87%) e-116 glycoprotein) - Homo sapiens 242 . . . 462 201/226 (88%) (Human), 462 aa. OQRB hemopexin precursor - rabbit, 28 . . . 255 167/228 (73%) e-100 459 aa. 233 . . . 459 186/228 (81%) P20058 Hemopexin precursor - 28 . . . 255 167/228 (73%) e-100 Oryctolagus cuniculus (Rabbit), 234 . . . 460 186/228 (81%) 460 aa. P20059 Hemopexin precursor - 30 . . . 254 159/225 (70%) 7e-96 Rattus norvegicus (Rat), 460 aa. 242 . . . 459 183/225 (80%) P50828 Hemopexin precursor 48 . . . 253 152/206 (73%) 2e-95 (Hyaluronidase) (EC 3.2.1.35) - 248 . . . 453 175/206 (84%) Sus scrofa (Pig), 459 aa.

[0395] PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14E. TABLE-US-00078 TABLE 14E Domain Analysis of NOV14a Identities/ Similarities for the Matched Expect Pfam Domain NOV14a Match Region Region Value hemopexin 56 . . . 99 17/50 (34%) 1.4e-09 31/50 (62%) hemopexin 101 . . . 146 14/50 (28%) 4.5e-07 37/50 (74%)

Example 15

[0396] The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A. TABLE-US-00079 TABLE 15A NOV15 Sequence Analysis SEQ ID NO: 89 2671 bp NOV15a, CCCGCCGGGCGAGCATGGGGCGCCTGGCCTCGAGGCCGCTGCTGCTGGCGCTCCTGTC CG109445-01 GTTGGCTCTTTGCCGAGGGCGTGTGGTGAGAGTCCCCACAGCGACCCTGGTTCGAGTG DNA GTGGGCACTGAGCTGGTCATCCCCTGCAACGTCAGTGACTATGATGGCCCCAGCGAGC Sequence AAAACTTTGACTGGAGCTTCTCATCTTTGGGGAGCAGCTTTGTGGAGCTTGCAAGCAC CTGGGAGGTGGGGTTCCCAGCCCAACTGTACCAGGAGCGGCTGCAGAGGGGCGAGATC CTGTTAAGGCGGACTGCCAACGACGCCGTGGAGCTCCACATAAAGAACGTCCAGCCTT CAGACCAAGGCCACTACAAATGTTCAAGCCCCAGCACAGATGCCACTGTCCAGGGAAA CTATGAGGACACAGTGCAGGTTAAAGTGCTGGCCGACTCCCTGCACGTGGGCCCCAGC GCGCGGCCCCCGCCGAGCCTGAGCCTGCGGGAGGGGGAGCCCTTCGAGCTGCGCTGCA CCGCCGCCTCCGCCTCGCCGCTGCACACGCACCTGGCGCTGCTGTGGGAGGTGCACCG CGGCCCGGCCAGGCGGAGCGTCCTCGCCCTGACCCACGAGGGCAGGTTCCACCCGGGC CTGGGGTACGAGCAGCGCTACCACAGTGGGGACGTGCGCCTCGACACCGTGGGCAGCG ACGCCTACCGCCTCTCAGTGTCCCGGGCTCTGTCTGCCGACCAGGGCTCCTACAGGTG TATCGTCAGCGAGTGGATCGCCGAGCAGGGCAACTGGCAGGAAATCCAAGAAAAGGCC GTGGAAGTTGCCACCGTGGTGATCCAGCCGACAGTTCTGCGAGCAGCCGTGCCCAAGA ATGTGTCTGTGGCTGAAGGAAAGGAACTGGACCTGACCTGTAACATCACAACAGACCG AGCCGATGACGTCCGGCCCGAGGTGACGTGGTCCTTCAGCAGGATGCCTGACAGCACC CTACCTGGCTCCCGCGTGTTGGCGCGGCTTGACCGTGATTCCCTGGTGCACAGCTCGC CTCATGTTGCTTTGAGTCATGTGGATGCACGCTCCTACCATTTACTGGTTCGGGATGT TAGCAAAGAAAACTCTGGCTACTATTACTGCCACGTGTCCCTGTGGGCACCCGGACAC AACAGGAGCTGGCACAAAGTGGCAGAGGCCGTGTCTTCCCCAGCTGGTGTGGGTGTGA CCTGGCTAGAACCAGACTACCAGGTGTACCTGAATGCTTCCAAGGTCCCCGGGTTTGC GGATGACCCCACAGAGCTGGCATGCCGGGTGGTGGACACGAAGAGTGGGGAGGCGAAT GTCCGATTCACGGTTTCGTGGTACTACAGGATGAACCGGCGCAGCGACAATGTGGTGA CCAGCGAGCTGCTTGCAGTCATGGACGGGGACTGGACGCTAAAATATGGAGAGAGGAG CAAGCAGCGGGCCCAGGATGGAGACTTTATTTTTTCTAAGGAACATACAGACACGTTC AATTTCCGGATCCAAAGGACTACAGAGGAAGACAGAGGCAATTATTACTGTGTTGTGT CTGCCTGGACCAAACAGCGGAACAACAGCTGGGTGAAAAGCAAGGATGTCTTCTCCAA GCCTGTTAACATATTTTGGGCATTAGAAGATTCCGTGCTTGTGGTGAAGGCGAGGCAG CCAAAGCCTTTCTTTGCTGCCGGAAATACATTTGAGATGACTTGCAAAGTATCTTCCA AGAATATTAAGTCGCCACGCTACTCTGTTCTCATCATGGCTGAGAAGCCTGTCGGCGA CCTCTCCAGTCCCAATGAAACGAAGTACATCATCTCTCTGGACCAGGATTCTGTGGTG AAGCTGGAGAATTGGACAGATGCATCACGGGTGGATGGCGTTGTTTTAGAAAAAGTGC AGGAGGATGAGTTCCGCTATCGAATGTACCAGACTCAGGTCTCAGACGCAGGGCTGTA CCGCTGCATGGTGACAGCCTGGTCTCCTGTCAGGGGCAGCCTTTGGCGAGAAGCAGCA ACCAGTCTCTCCAATCCTATTGAGATAGACTTCCAAACCTCAGGTCCTATATTTAATG CTTCTGTGCATTCAGACACACCATCAGTAATTCGGGGAGATCTGATCAAATTGTTCTG TATCATCACTGTCGAGGGAGCAGCACTGGATCCAGATGACATGGCCTTTGATGTGTCC TGGTTTGCGGTGCACTCTTTTGGCCTGGACAAGGCTCCTGTGCTCCTGTCTTCCCTGG ATCGGAAGGGCATCGTGACCACCTCCCGGAGGGACTGGAAGAGCGACCTCAGCCTGGA GCGCGTGAGTGTGCTGGAATTCTTGCTGCAAGTGCATGGCTCCGAGGACCAGGACTTT GGCAACTACTACTGTTCCGTGACTCCATGGGTGAAGTCACCAACAGGTTCCTGGCAGA AGGAGGCAGAGATCCACTCCAAGCCCGTTTTTATAACTGTGAAGATGGATGTGCTGAA CGCCTTCAAGTATCCCTTGCTGATCGGCGTCGGTCTGTCCACGGTCATCGGGCTCCTG TCCTGTCTCATCGGGTACTGCAGCTCCCACTGGTGTTGTAAGAAGGAGGTTCAGGAGA CACGGCGCGAGCGCCGCAGGCTCATGTCGATGGAGATGGACTAGGCTGGCCCGGGAGG GGA ORF Start: ATG at 15 ORF Stop: TAG at 2652 SEQ ID NO: 90 879 aa MW at 98569.4kD NOV15a, MGRLASRPLLLALLSLALCRGRVVRVPTATLVRVVGTELVIPCNVSDYDGPSEQNFDW CG109445-01 SFSSLGSSFVELASTWEVGFPAQLYQERLQRGETLLRRTANDAVELHIKNVQPSDQGH Protein YKCSTPSTDATVQGNYEDTVQVKVLADSLHVGPSARPPPSLSLREGEPFELRCTAASA Sequence SPLHTHLALLWEVHRGPARRSVLALTHEGRFHFGLGYEQRYHSGDVRLDTVGSDAYRL SVSRALSADQGSYRCIVSEWIAEQGNWQEIQEKAVEVATVVIQPTVLRAAVPKNVSVA EGKELDLTCNITTDRADDVRPEVTWSFSRMPDSTLPGSRVLARLDRDSLVHSSPEVAL SHVDARSYHLLVRDVSKENSGYYYCHVSLWAPGHNRSWHKVAEAVSSPAGVGVTWLEP DYQVYLNASKVPGFADDPTELACRVVDTKSGEANVRFTVSWYYRMNRRSDNVVTSELL AVMDGDWTLKYGERSKQRAQDGDFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTK QRNNSWVKSKDVFSKPVNIFWALEDSVLVVKARQPKPFFAAGNTFEMTCKVSSKNIKS PRYSVLIMAEKPVGDLSSPNETKYIISLDQDSVVKLENWTDASRVDGVVLEKVQEDEF RYRNYQTQVSDAGLYRCMVTAWSPVRGSLWREAATSLSNFIEIDFQTSGPIFNASVHS DTPSVIRGDLIKLFCIITVEGAALDPDDMAFDVSWFAVHSFGLDKAPVLLSSLDRKGI VTTSRRDWKSDLSLERVSVLEFLLQVHGSEDQDFGNYYCSVTPWVKSPTGSWQKEAEI HSKPVFITVKMDVLNAFKYPLLIGVGLSTVIGLLSCLIGYCSSHWCCKKEVQETRRER RRLMSMEMD

[0397] Further analysis of the NOV15a protein yielded the following properties shown in Table 15B. TABLE-US-00080 TABLE 15B Protein Sequence Properties NOV15a PSort 0.6800 probability located in lysosome (membrane); 0.5140 analysis: probability located in plasma membrane; 0.1760 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane) SignalP Cleavage site between residues 26 and 27 analysis:

[0398] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C. TABLE-US-00081 TABLE 15C Geneseq Results for NOV15a NOV15a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAM93277 Human polypeptide, SEQ ID NO: 1 . . . 863 862/863 (99%) 0.0 2751 - Homo sapiens, 863 aa. 1 . . . 863 862/863 (99%) [EP1130094-A2, 05-SEP-2001] ABB11196 Human PG F2a receptor regulator 236 . . . 372 131/137 (95%) 7e-70 homologue, SEQ ID NO: 1566 - 2 . . . 138 132/137 (95%) Homo sapiens, 138 aa. [WO200157188-A2, 09-AUG-2001] ABB10996 Human prostaglandin receptor 500 . . . 625 117/126 (92%) 3e-60 regulator homologue, SEQ ID NO: 1 . . . 126 118/126 (92%) 1366 - Homo sapiens, 126 aa. [WO200157188-A2, 09-AUG-2001] AAB90544 Human secreted protein, SEQ ID 6 . . . 542 163/565 (28%) 2e-59 NO: 82 - Homo sapiens, 613 aa. 12 . . . 571 260/565 (45%) [WO200121658-A1, 29-MAR-2001] AAM24248 Human EST encoded protein SEQ ID 6 . . . 542 163/565 (28%) 2e-59 NO: 1773 - Homo sapiens, 613 aa. 12 . . . 571 260/565 (45%) [WO200154477-A2, 02-AUG-2001]

[0399] In a BLAST search of public sequence datbases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D. TABLE-US-00082 TABLE 15D Public BLASTP Results for NOV15a NOV15a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9P2B2 KIAA1436 PROTEIN - 1 . . . 879 878/879 (99%) 0.0 Homo sapiens (Human), 924 46 . . . 924 879/879 (99%) aa (fragment). Q9WV91 F2 ALPHA PROSTOGLANDIN 1 . . . 879 786/879 (89%) 0.0 REGULATORY PROTEIN - 1 . . . 879 830/879 (94%) Mus musculus (Mouse), 879 aa. Q62786 Prostaglandin F2-alpha receptor 1 . . . 879 784/879 (89%) 0.0 regulatory protein precursor 1 . . . 879 834/879 (94%) (Prostaglandin F2-alpha receptor associated protein) - Rattus norvegicus (Rat), 879 aa. Q9H3U3 SMAP-6 - Homo sapiens (Human), 694 . . . 879 186/186 (100%) e-106 186 aa (fragment). 1 . . . 186 186/186 (100%) O02834 ADIPOCYTE MEMBRANE 690 . . . 879 184/190 (96%) e-105 PROTEIN - Sus scrofa (Pig), 1 . . . 190 186/190 (97%) 190 aa (fragment).

[0400] PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15E. TABLE-US-00083 TABLE 15E Domain Analysis of NOV15a Identities/ Similarities for Pfam the Matched Expect Domain NOV15a Match Region Region Value ig 36 . . . 121 15/87 (17%) 0.0013 52/87 (60%) ig 162 . . . 249 13/89 (15%) 0.00048 60/89 (67%) ig 292 . . . 375 16/85 (19%) 5.8e-07 58/85 (68%) ig 422 . . . 517 16/97 (16%) 2.3e-06 72/97 (74%) ig 564 . . . 65 7 12/97 (12%) 1.2e-05 64/97 (66%) ig 704 . . . 795 11/93 (12%) 0.19 55/93 (59%)

Example 16

[0401] The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A. TABLE-US-00084 TABLE 16A NOV16 Sequence Analysis SEQ ID NO: 91 1565bp NOV16a, GGAATGCTCTCCCGCCTGAGCCTGCTCCAGGAATTGGACCTCAGCTACAACCAGCTCT CG109496-01 CAACCCTTGAGCCTGGGGCCTTCCATGGCCTACAAAGCCTACTCACCCTGAGGCTGCA DNA GGGCAATCGGCTCAGAATCATGGGGCCTGGGGTCTTCTCAGGCCTCTCTGCTCTGACC Sequence CTGCTGGACCTCCGCCTCAACCAGATTGTTCTCTTCCTAGATGGAGCTTTTGGGGAGC TAGGCAGCCTCCAGAAGCTGGAGGTTGGGGACAACCACCTGGTATTTGTGGCTCCGGG GGCCTTTGCAGGGCTAGCCAAGTTGAGCACCCTCACCCTGGAGCGCTGCAACCTCAGC ACAGTGCCTGGCCTAGCCCTTGCCCGTCTCCCGGCACTAGTGGCCCTAAGGCTTAGAG AACTGGATATTGGGAGGCTGCCAGCTGGGGCCCTGCGGGGGCTGGGGCAGCTCAAGGA GCTGGAGATCCACCTCTGGCCATCTCTGGAGGCTCTGGACCCTGGGAGCCTGGTTGGG CTCAATCTCAGCAGCCTGGCCATCACTCGCTGCAATCTGAGCTCGGTGCCCTTCCAAG CACTGTACCACCTCAGCTTCCTCAGGGTCCTGGATCTGTCCCAGAATCCCATCTCAGC CATCCCAGCCCGAAGGCTCAGCCCCCTGGTGCGGCTCCAGGAGCTACGCCTGTCAGGG GCATGCCTCACCTCCATTGCTGCCCATGCCTTCCATGGCTTGACTGCCTTCCACCTCC TGGATGTGGCAGATAACGCCCTTCAGACACTAGAGGAAACAGCTTTCCCTTCTCCAGA CAAACTGGTCACCTTGAGGCTGTCTGGCAACCCCCTAACCTGTGACTGCCGCCTCCTC TGGCTGCTCCGGCTCCGCCGCCACCTGGACTTTGGCATGTCCCCCCCTGCCTGTGCTG GCCCCCATCATGTCCAGGGGAAGAGCCTGAAGGAGTTTTCAGACATCCTGCCTCCAGG GCACTTCACCTGCAAACCAGCCCTGATCCGAAAGTCGGGGCCTCGATGGGTCATTGCA GAGGAGGGCGGGCATGCGGTTTTCTCCTGCTCTGGAGATGGAGACCCAGCCCCCACTG TCTCCTGGATGAGGCCTCATGGGGCTTGGCTGGGCAGGGCTGGGAGAGTAAGGGTCCT AGAGGATGGGACACTGGAGATCCGCTCAGTGCAGCTACGGGACAGAGGGGCCTATGTC TGTGTGGTTAGCAATGTCGCTGGGAATGACTCCCTGAGGACCTGGCTGGAAGTCATCC AGGTGGAACCACCAAACGGCACACTTTCTGACCCCAACATCACCGTGCCAGGGATCCC AGGGCCTTTTTTTCTGGATAGCAGAGGTGTGGCCATGGTGCTGGCAGTGGGCTTCCTC CCCTTCCTCACCTCAGTGACCCTCTGCTTTGGCCTGATTGCCCTTTGGAGCAAGGGCA AAGGTCGGGTCAAACATCACATGACCTTTGACTTTGTGGCACCTCGGCCCTCTGGGGA TAAAAACTCTGGGGGTAACCGGGTCACTGCCAAGCTCTTCTGACCTTTCCTTCCCCA ORF Start: ATG at 4 ORF Stop: TGA at 1549 SEQ ID NO: 92 515 aa MW at 55659.0kD NOV16a, MLSRLSLLQELDLSYNQLSTLEPGAFHGLQSLLTLRLQGNRLRIMGPGVFSGLSALTL CG109496-01 LDLRLNQIVLFLDGAFGELGSLQKLEVGDNHLVFVAPGAFAGLAKLSTLTLERCNLST Protein VPGLALARLPALVALRLRELDIGRLPAGALRGLGQLKELEIHLWPSLEALDPGSLVGL Sequence NLSSLAITRCNLSSVPFQALYHLSFLRVLDLSQNPISAIPARRLSPLVRLQELRLSGA CLTSIAAHAFHGLTAFHLLDVADNALQTLEETAFPSPDKLVTLRLSGNPLTCDCRLLW LLRLRRHLDFGMSPPACAGPHHVQGKSLKEFSDILPPGHFTCKPALIRKSGPRWVIAE EGGHAVFSCSGDGDPAPTVSWMRPHGAWLGRAGRVRVLEDGTLEIRSVQLRDRGAYVC VVSNVAGNDSLRTWLEVIQVEPPNGTLSDPNITVPGIPGPFFLDSRGVAMVLAVGFLP FLTSVTLCFGLIALWSKGKGRVKHHMTFDFVAPRPSGDKNSGGNRVTAKLF

[0402] Further analysis of the NOV16a protein yielded the following properties shown in Table 16B. TABLE-US-00085 TABLE 16B Protein Sequence Properties NOV16a PSort 0.7000 probability located in plasma membrane; 0.5204 analysis: probability located in mitochondrial inner membrane; 0.4430 probability located in microbody (peroxisome); 0.2217 probability located in mitochondrial intermembrane space SignalP No Known Signal Sequence Predicted analysis:

[0403] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C. TABLE-US-00086 TABLE 16C Geneseq Results for NOV16a NOV16a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAW84596 Amino acid sequence of the human 8 . . . 500 229/509 (44%) e-116 Tango-79 protein - Homo sapiens, 91 . . . 596 312/509 (60%) 614 aa. [WO9906427-A1, 11-FEB- 1999] AAB74705 Human membrane associated protein 8 . . . 500 228/509 (44%) e-116 MEMAP-11 - Homo sapiens, 620 aa. 97 . . . 602 312/509 (60%) [WO2001 12662-A2, 22-FEB-2001] AAB80225 Human PRO227 protein - 8 . . . 500 227/509 (44%) e-115 Homo sapiens, 620 aa. 97 . . . 602 311/509 (60%) [WO200104311-Al, 18-JAN-2001] AAU12333 Human PRO227 polypeptide sequence - 8 . . . 500 227/509 (44%) e-115 Homo sapiens, 620 aa. 97 . . . 602 311/509 (60%) [WO200140466-A2, 07-JUN-2001] AAY13357 Amino acid sequence of protein 8 . . . 500 227/509 (44%) e-115 PRO227 - Homo sapiens, 620 aa. 97 . . . 602 311/509 (60%) [WO9914328-A2, 25-MAR-1999]

[0404] In a BLAST search of public sequence datbases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16D. TABLE-US-00087 TABLE 16D Public BLASTP Results for NOV16a NOV16a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q9N008 HYPOTHETICAL 69.2 KDA 8 . . . 500 228/509 (44%) e-115 PROTEIN - Macaca fascicularis 91 . . . 596 312/509 (60%) (Crab eating macaque) (Cynomolgus monkey), 614 aa. Q96FE5 UNKNOWN (PROTEIN FOR 8 . . . 500 228/509 (44%) e-115 MGC: 17422) - Homo sapiens 91 . . . 596 312/509 (60%) (Human), 614 aa. Q9D1T0 ADULT MALE TESTIS CDNA, 8 . . . 500 228/509 (44%) e-115 RIKEN FULL-LENGTH ENRICHED 91 . . . 596 312/509 (60%) LIBRARY, CLONE: 4930471K13, FULL INSERT SEQUENCE - Mus musculus (Mouse), 614 aa. Q9BZ20 BA438B23.1 (NEURONAL 7 . . . 501 224/507 (44%) e-113 LEUCINE-RICH REPEAT 82 . . . 588 311/507 (61%) PROTEIN) (CDNA FLJ31810 FIS, CLONE NT2RI2009289, WEAKLY SIMILAR TO CARBOXYPEPTIDASE N 83 KDA CHAIN) - Homo sapiens (Human), 606 aa. CAC34918 SEQUENCE 1 FROM PATENT 7 . . . 501 197/505 (39%) 3e-89 WO0075358 - Homo sapiens 82 . . . 530 278/505 (55%) (Human), 548 aa.

[0405] PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16E. TABLE-US-00088 TABLE 16E Domain Analysis of NOV16a NOV16a Identities/ Match Similarities Pfam Domain Region for the Matched Region Expect Value LRR 7 . . . 30 13/25 (52%) 3.8e-05 22/25 (88%) LRR 31 . . . 54 8/25 (32%) 0.64 19/25 (76%) LRR 199 . . . 222 9/25 (36%) 0.27 16/25 (64%) LRR 223 . . . 246 9/25 (36%) 0.32 19/25 (76%) LRRCT 280 . . . 333 19/58 (33%) 3.1e-07 42/58 (72%) ig 350 . . . 408 19/62 (31%) 9.1e-09 41/62 (66%)

Example 17

[0406] The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A. TABLE-US-00089 TABLE 17A NOV17 Sequence Analysis SEQ ID NO: 93 1780 bp NOV17a, CCAACCCTCTGCCCGGCCGGTGCCCATGCTTCTGTGGCTGCTGCTGCTGATCCTGACT CG109532-01 CCTGGAAGAGAACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCAATCCTCCAT DNA GGTCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATCACATTC Sequence CCTAGCCCAGGGAGACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACAT GACAAGATCCAAATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCTCCC TCAGTGATGCCGTGCATGTGGAATTTTCACCTGACTGGGTGATCCTGCAGGCTTTACA TCCTGTCTTTGAAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAAC ACTCATCAAAAGGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAG AGAAGATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTGCTTA TAGGAAGTTTTACATACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTT CAAGAGCTGTTTCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGGA GTCCCATGACCCTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCT GCAATTCTCCCTCTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCC AGACTCCAGATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGG AGACAGTGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAGAG AGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAA GGAGAAAATATGGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCT CCTGGCACAAAGAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTT GGCAGAGCTGCATGTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCA GCTGATAACGTTCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTC CGGTATGTCACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGA CCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTT TATCATGAGGATGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGCCTCCT TCAACCTCTCTCTGACTGCAGAACATTCTGGAAACTACTCCTGTGATGCAGACAATGG CCTGGGGGCCCAGCACAGTCATGGAGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGC CCCGTCCTCACCCTCAGGGCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAGC TTCACTGTGAGTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACGAGGA TGACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGGCATCCTTCAACCTCTCT CTGACTACAGAACATTCTGGAAACTACTCATGTGAGGCTGACAATGGCCTGGGGGCCC AGCACAGTAAAGTGGTGACACTCAATGTTACAGGTGTGTTAATAGTACCTGGGCTAGA GGTCACAGTTATGGTAAATAAAATAGTTATCTGACAGATT ORF Start: ATG at 26 ORE Stop: TGA at 1772 SEQ ID NO: 94 582 aa MW at 64270.5kD NOV17a, MLLWLLLLILTFGREQSGVAPKAVLLLNPPWSTAFKGEKVALICSSISHSLAQGDTYW CG109532-01 YHDEKLLKIKHDKIQITEPGNYQCKTRGSSLSDAVHVEFSPDWLILQALHPVFEGDNV Protein ILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKITVNSVSRDNSKYHCTAYRKFYILDI Sequence EVTSKPLNIQVQELFLHFVLRASSSTPIEGSPMTLTCETQLSPQRPDVQLQFSLFRDS QTLGLGWSRSPRLQIPANWTEDSGSYWCEVETVTHSIKKRSLRSQIRVQRVPVSNVNL EIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHKEGRVRSLGRKTQRSLLAELHVLTV KESDAGRYYCAADNVHSPILSTWIRVTVRIPVSHPVLTFRAPRAHTVVGDLLELHCES LRGSPPILYRFYHEDVTLGNSSAPSGGGASFNLSLTAEHSGNYSCDADNGLGAQHSHG VSLRVTVFVSRPVLTLRAPGAQAVVGDLLELHCESLRGSFPILYWFYHEDDTLGNISA HSGGGASFNLSLTTEHSGNYSCEADNGLGAQHSKVVTLNVTGVLIVPGLEVTVMVNKI VI SEQ ID NO: 95 1263 bp NOV17b, AAGCTTGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATCACATTCCCTAGCCCAGG 207775340 GAGACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACATGACAAGATCCA DNA AATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCC Sequence GTGCATGTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTG AAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCATCAAAA GGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAGAGAAGATCACA GTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTGCTTATAGGAAGTTTT ACATACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTTCAAGAGCTGTT TCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACC CTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCC TCTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGTAGGTCCCCCAGACTCCAGAT CCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGGAGACAGTGACT CACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAGAGAGTCCCTGTGT CTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAAGGAGAAAATAT GGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCTCCTGGCACAAA GAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGC ATGTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACGT TCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCGGTATCTCAC CCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGACCTGCTGGAGC TTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTTTATCATGAGGA TGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCT CTGACTGCAGAACATTCTGGAAACTACTCATGTGAGGCTCTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 96 421 aa MW at 47243.1kD NOV17b, KLGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHDKIQITEPGNYQCKTRGSSLSDA 207775340 VHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKIT Protein VNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSFMT Sequence LTCETQLSPQRPDVQLQFSLFRDSQTLGLGWSRSPRLQIPANWTEDSGSYWCEVETVT HSIKKRSLRSQIRVQRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHK EGRVRSLGRKTQRSLLAELHVLTVKESDAGRYYCAADNVHSPILSTWIRVTVRIPVSH PVLTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHEDVTLGNSSAPSGGGASFNLS LTAEHSGNYSCEALE SEQ ID NO: 97 1263 bp NOV17c, AAGCTTGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATCACATTCCCTAGCCCAGG 207775361 GAGACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACATGACAAGATCCA DNA AATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCC Sequence GTGCATGTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTG AAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCATCAAAA GGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAGAGAAGATCACA GTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTGCTTATAGGAAGTTTT ACATACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTTCAAGAGCTGTT TCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACC CTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCC TCTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGACTCCAGAT CCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGGAGACAGTGACT CACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAGAGAGTCCCTGTGT CTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAAGGAGAAAATAT GGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCTCCTGGCACAAA GAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGC ATGTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACGT TCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCGGTATCTCAC CCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGACCTGCTGGAGC TTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTTTATCATGAGGA TGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCT CTGACTGCAGAACATTCTGGAAACTACTCATGTGAGGCTCTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 98 421 aa MW at 47243.1kD NOV17c, KLGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHDKIQITEFGNYQCKTRGSSLSDA 207775361 VHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKIT Protein VNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSPMT Sequence LTCETQLSPQRPDVQLQFSLFRDSQTLGLGWSRSPRLQIPAMWTEDSGSYWCEVETVT HSIKKRSLRSQIRVQRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHK EGRVRSLGRKTQRSLLAELHVLTVKESDAGRYYCAADNVHSPILSTWIRVTVRIPVSH PVLTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHEDVTLGNSSAPSGGGASFNLS LTAEHSGNYSCEALE SEQ ID NO: 99 1263bp NOV17d, AAGCTTGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATCACATTCCCTAGCCCAGG 207775365 GAGACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACATGACAAGATCCA DNA AATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCC Sequence GTGCATGTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTG AAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCATCAAAA GGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAGAGAAGATCACA GTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTGCTTATAGGAAGTTTT ACATACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTTCAGGAGCTGTT TCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACC CTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCC TCTTCAGAGATAGCCAGACCCCCGGATTGGGCTGGAGCAGGTCCCCCAGACTCCAGAT CCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGGAGACAGTGACT CACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAGAGAGTCCCTGTGT CTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAAGGAGAAAATAT GGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCTCCTGGCACAAA GAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGC ATGTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACGT TCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCGGTATCTCAC CCTGTCCCCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGACCTGCTGGAGC TTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTTTATCATGAGGA TGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGACTCCTTCAACCTCTCT CTGACTGCAGAACATTCTGGAAACTACTCATGTGAGGCTCTCGAG ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 100 421 aa MW at 47255.0kD NOV17d, KLGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHDKIQITEPGNYQCKTRGSSLSDA 207775365 VHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKIT Protein VNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSPMT Sequence LTCETQLSPQRPDVQLQFSLFRDSQTPGLGWSRSPRLQIPAMWTEDSGSYWCEVETVT HSIKKRSLRSQIRVQRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHK EGRVRSLGRKTQRSLLAELHVLTVKESDAGRYYCAADNVHSPILSTWIRVTVRIPVSH PVPTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHEDVTLGNSSAPSGGGDSFNLS LTAEHSGNYSCEALE

[0407] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 17B. TABLE-US-00090 TABLE 17B Comparison of NOV17a against NOV17b through NOV17d. NOV17a Residues/ Identities/Similarities for the Protein Sequence Match Residues Matched Region NOV17b 37 . . . 453 404/417 (96%) 3 . . . 419 405/417 (96%) NOV17c 37 . . . 453 404/417 (96%) 3 . . . 419 405/417 (96%) NOV17d 37 . . . 453 413/417 (99%) 3 . . . 419 414/417 (99%)

[0408] Further analysis of the NOV17a protein yielded the following properties shown in Table 17C. TABLE-US-00091 TABLE 17C Protein Sequence Properties NOV17a PSort 0.5374 probability located in outside; 0.1900 probability analysis: located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 18 and 19 analysis:

[0409] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17D. TABLE-US-00092 TABLE 17D Geneseq Results for NOV17a NOV17a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length Match the Matched Expect Identifier [Patent #, Date] Residues Region Value AAB82316 Human immunoglobulin receptor 1 . . . 564 564/564 (100%) 0.0 IRTA3 protein - Homo sapiens, 1 . . . 564 564/564 (100%) 734 aa. [WO200138490-A2, 31- MAY-2001] AAB82314 Human immunoglobulin receptor 1 . . . 564 259/568 (45%) e-130 isoform IRTA2b - Homo sapiens, 1 . . . 561 334/568 (58%) 592 aa. [WO200138490-A2, 31- MAY-2001] AAB82315 Human immunoglobulin receptor 1 . . . 575 261/579 (45%) e-129 isoform IRTA2c - Homo sapiens, 1 . . . 572 338/579 (58%) 977 aa. [WO200138490-A2, 31- MAY-2001] AAB82313 Human immunoglobulin receptor 1 . . . 575 261/579 (45%) e-129 isoform IRTA2a - Homo sapiens, 1 . . . 572 338/579 (58%) 759 aa. [WO200138490-A2, 31- MAY-2001] AAB82317 Human immunoglobulin receptor 100 . . . 472 227/374 (60%) e-129 IRTA4 protein - Homo sapiens, 18 . . . 389 280/374 (74%) 508 aa. [WO200138490-A2, 31- MAY-2001]

[0410] In a BLAST search of public sequence datbases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E. TABLE-US-00093 TABLE 17E Public BLASTP Results for NOV17a NOV17a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value Q96LA4 FC RECEPTOR-LIKE PROTEIN 1 . . . 564 564/564 (100%) 0.0 3 - Homo sapiens (Human), 734 aa. 1 . . . 564 564/564 (100%) Q96P31 SH2 DOMAlN-CONTAINING 1 . . . 564 564/564 (100%) 0.0 PHOSPHATASE ANCHOR 1 . . . 564 564/564 (100%) PROTEIN 2A - Homo sapiens (Human), 734 aa. Q96P29 SH2 DOMAIN-CONTAINING 1 . . . 564 563/570 (98%) 0.0 PHOSPHATASE ANCHOR 1 . . . 570 564/570 (98%) PROTEIN 2C - Homo sapiens (Human), 740 aa. CAC05323 BA367J7.2.1 (NOVEL 1 . . . 548 548/548 (100%) 0.0 IMMUNOGLOBULIN DOMAINS 1 . . . 548 548/548 (100%) CONTAINING PROTEIN (ISOFORM 1)) - Homo sapiens (Human), 548 aa (fragment). Q96P30 SH2 DOMAlN-CONTAINING 111 . . . 564 318/457 (69%) e-167 PHOSPHATASE ANCHOR 35 . . . 469 347/457 (75%) PROTEIN 2B - Homo sapiens (Human), 639 aa.

[0411] PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17F. TABLE-US-00094 TABLE 17F Domain Analysis of NOV17a NOV17a Identities/ Match Similarities Pfam Domain Region for the Matched Region Expect Value ig 37 . . . 84 12/52 (23%) 0.84 29/52 (56%) ig 113 . . . 165 12/57 (21%) 0.52 38/57 (67%) ig 204 . . . 262 18/61 (30%) 2.3e-08 43/61 (70%) ig 302 . . . 360 15/61 (25%) 8.2e-10 46/61 (75%) ig 397 . . . 453 13/59 (22%) 0.0004 45/59 (76%) ig 490 . . . 546 13/60 (22%) 1.7e-05 43/60 (72%)

Example 18

[0412] The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A. TABLE-US-00095 TABLE 18A NOV18 Sequence Analysis SEQ ID NO: 101 360 bp NOV18a CGCTGCTCCTGCTGCTGCTGGCGCTGTACACCGCGCGTGTGGACGGGTCCAAATGCAA CG50213-01 GTGCTCCCGGAAGGGACCCAAGATCCGCTACAGCGACGTGAAGAAGCTGGAAATGAAG DNA CCAAAGTACCCGCACTGCGAGGAGAAGATGGTTATCATCACCACCAAGAGCGTGTCCA Sequence GGTACCGAGGTCAGGAGCACTGCCTGCACCCCAAGCTGCAGAGCACCAAGCGCTTCAT CAAGTGGTACAACGCCTGGAACGAGAAGCGCAGGGTCTACGAAGAATAGGGTGAAAAA CCTCAGAAGGGAAAACTCCAAACCAGTTGGGAGACTTGTGCAAAGGACTTTGCAGATT AAAAAAAAAAAA ORF Start: at 3 ORF Stop: TAG at 279 SEQ ID NO: 102 92 aa MW at 11045.0kD NOV18a, LLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTKSVSR CG50213-01 YRGQEHCLHPKLQSTKRFIKWYNAWNEKRRVYEE Protein Sequence SEQ ID NO: 103 228 bp NOV18b, AAATGCAAGTGCTCCCGGAAGGGACCCAAGATCCGCTACAGCGACGTGAAGAAGCTGG CG50213-02 AAATGAAGCCAAAGTACCCGCACTGCGAGGAGAAGATGGTTATCATCACCACCAAGAG DNA CGTGTCCAGGTACCGAGGTCAGGAGCACTGCCTGCACCCCAAGCTGCAGAGCACCAAG Sequence CGCTTCATCAAGTGGTACAACGCCTGGAACGAGAAGCGCAGGGTCTACGAAGAA ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 104 76 aa MW at 9331.9kD NOV18b, KCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTKSVSRYRGQEHCLHPKLQSTK CG50213-02 RFIKWYNAWNEKRRVYEE Protein Sequence SEQ ID NO: 105 228 bp NOV18c, AAATGCAAGTGCTCCCGGAAGGGACCCAAGATCCGCTACAGCGACGTGAAGAAGCTGG CG50213-03 AAATGAAGCCAAAGTACCCGCACTGCGAGGAGAAGATGGTTATCATCACCACCAAGAG DNA CGTGTCCAGGTACCGAGGTCAGGAGCACTGCCTGCACCCCAAGCTGCAGAGCACCAAG Sequence CGCTTCATCAAGTGGTACAACGCCTGGAACGAGAAGCGCAGGGTCTACGAAGAA ORF Start: at 1 ORF Stop: end of sequence SEQ ID NO: 106 76 aa MW at 9331.9kD NOV18c, KCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTKSVSRYRGQEHCLHPKLQSTK CG50213-03 RFIKWYNAWNEKRRVYEE Protein Sequence

[0413] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 18B. TABLE-US-00096 TABLE 18B Comparison of NOV18a against NOV18b and NOV18c. NOV18a Residues/ Identities/ Similarities for the Protein Sequence Match Residues Matched Region NOV18b 17 . . . 92 76/76 (100%) 1 . . . 76 76/76 (100%) NOV18c 17 . . . 92 76/76 (100%) 1 . . . 76 76/76 (100%)

[0414] Further analysis of the NOV18a protein yielded the following properties shown in Table 18C. TABLE-US-00097 TABLE 18C Protein Sequence Properties NOV18a PSort 0.3700 probability located in outside; 0.1800 probability analysis: located in nucleus; 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen) SignalP Cleavage site between residues 16 and 17 analysis:

[0415] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D. TABLE-US-00098 TABLE 18D Geneseq Results for NOV18a NOV18a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length [Patent Match the Matched Expect Identifier #, Date] Residues Region Value ABB72228 Human protein isolated from skin 1 . . . 92 92/92 (100%) 1e-50 cells SEQ ID NO: 344 - Homo 4 . . . 95 92/92 (100%) sapiens, 95 aa. [WO200190357-A1, 29-NOV-2001] AAB56028 Skin cell protein, SEQ ID NO: 344 - 1 . . . 92 92/92 (100%) 1e-50 Homo sapiens, 95 aa. 4 . . . 95 92/92 (100%) [WO200069884-A2, 23-NOV-2000] AAB88478 Human membrane or secretory 1 . . . 92 92/92 (100%) 1e-50 protein clone PSEC0212 - Homo 20 . . . 111 92/92 (100%) sapiens, 111 aa. [EP1067182-A2, 10-JAN-2001] AAE05371 Human huKS1 protein - Homo 1 . . . 92 92/92 (100%) 1e-50 sapiens, 95 aa. [WO200148192-A1, 4 . . . 95 92/92 (100%) 05-JUL-2001] AAY76089 Human CXC chemokine homologue 1 . . . 92 92/92 (100%) 1e-50 huKS1, SEQ ID NO: 344 - Homo 4 . . . 95 92/92 (100%) sapiens, 95 aa. [WO9955865-A1, 04-NOV-1999]

[0416] In a BLAST search of public sequence datbases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E. TABLE-US-00099 TABLE 18E Public BLASTP Results for NOV18a NOV18a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value JG0182 chemokine BRAK - human, 99 aa. 1 . . . 92 92/92 (100%) 2e-50 8 . . . 99 92/92 (100%) Q9BTR1 SMALL INDUCIBLE CYTOKINE 1 . . . 92 92/92 (100%) 2e-50 SUBFAMILY B (CYS-X-CYS), 20 . . . 111 92/92 (100%) MEMBER 14 (BRAK) - Homo sapiens (Human), 111 aa. O95715 Small inducible cytokine B14 1 . . . 92 92/92 (100%) 2e-50 precursor (Chemokine BRAK) - 8 . . . 99 92/92 (100%) Homo sapiens (Human), 99 aa. Q9NS21 CHEMOKINE MIP-2 GAMMA - 1 . . . 92 91/92 (98%) 9e-50 Homo sapiens (Human), 111 aa. 20 . . . 111 91/92 (98%) Q91V02 MIP2GAMMA - Mus musculus 1 . . . 92 87/92 (94%) 7e-48 (Mouse), 95 aa (fragment). 4 . . . 95 90/92 (97%)

[0417] PFam analysis predicts that the NOV18a protein contains the domains shown in the Table 18F. TABLE-US-00100 TABLE 18F Domain Analysis of NOV18a Identities/ NOV18a Similarities for Pfam Domain Match Region the Matched Region Expect Value

Example 19

[0418] The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A. TABLE-US-00101 TABLE 19A NOV19 Sequence Analysis SEQ ID NO: 107 619 bp NOV19a, GCTGCCTGCCTCCTCATGTTCCCCTCCACCACAGCGGACTGCCTGTCGCGGTGCTCCT CG88912-02 TGTGTGCTGTAAAGACCCAGGATGGTCCCAAACCTATCAATCCCCTGATTTGCTCCCT DNA GCAATGCCAGGCTGCCCTGCTGCCCTCTGAGGAATGGGAGAGATGCCAGAGCTTTCTG Sequence TCTTTTTTCACCCCCTCCACCCTTGGGCTCAATGACAAGGAGGACTTGGGGAGCAAGT CGGTTGGGGAAGGGCCCTACAGTGAGCTGGCCAAGCTCTCTGGGTCATTCCTGAAGGA GCTGAACGATGGTGCCATGGAGACTGGCACACTCTATCTCGCTGAGGAGGACCCCAAG GAGCAGGTCAAACGCTATGGGGGCTTTTTGCGCAAATACCCCAAGAGGAGCTCAGAGG TGGCTGGGGAGGGGGACGGGGATAGCATGGGCCATGAGGACCTGTACAAACGCTATGG GGGCTTCTTGCGGCGCATTCGTCCCAAGCTCAAGTGGGACAACCAGAAGCGCTATGGC GGTTTTCTCCGGCGCCAGTTCAAGGTGGTGACTCGGTCTCAGGAAGATCCGAATGCTT ACTCTGGAGAGCTTTTTGATGCATAAGCACTTCTTTTCA ORF Start: at 1 ORF Stop: TAA at 604 SEQ ID NO: 108 201 aa MW at 22447.1kD NOV19a, AACLLMFPSTTADCLSRCSLCAVKTQDGPKFINPLICSLQCQAALLPSEEWERCQSFL CG88912-02 SFFTPSTLGLNDKEDLGSKSVGEGPYSELAKLSGSFLKELNDGAMETGTLYLAEEDPK Protein EQVKRYGGFLRKYPKRSSEVAGEGDGDSMGHEDLYKRYGGFLRRIRPKLKWDNQKRYG Sequence GFLRRQFKVVTRSQEDPNAYSGELFDA

[0419] Further analysis of the NOV19a protein yielded the following properties shown in Table 19B. TABLE-US-00102 TABLE 19B Protein Sequence Properties NOV19a PSort 0.7562 probability located in mitochondrial matrix space; analysis: 0.4352 probability located in mitochondrial inner membrane; 0.4352 probability located in mitochondrial intermembrane space; 0.4352 probability located in mitochondrial outer membrane SignalP Cleavage site between residues 13 and 14 analysis:

[0420] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C. TABLE-US-00103 TABLE 19C Geneseq Results for NOV19qa NOV19a Identities/ Residues/ Similarities for Geneseq Protein/Organism/Length [Patent Match the Matched Expect Identifier #, Date] Residues Region Value AAM79544 Human protein SEQ ID NO 3190 - 1 . . . 201 201/246 (81%) e-110 Homo sapiens, 256 aa. 11 . . . 256 201/246 (81%) [WO200157190-A2, 09-AUG- 2001] AAM78560 Human protein SEQ ID NO 1222 - 1 . . . 201 201/246 (81%) e-110 Homo sapiens, 254 aa. 9 . . . 254 201/246 (81%) [WO200157190-A2, 09-AUG- 2001] AAM05438 Peptide #4120 encoded by probe 135 . . . 201 67/67 (100%) 2e-34 for measuring breast gene 1 . . . 67 67/67 (100%) expression - Homo sapiens, 67 aa. [WO200157270-A2, 09-AUG- 2001] AAM30301 Peptide #4338 encoded by probe 135 . . . 201 67/67 (100%) 2e-34 for measuring placental gene 1 . . . 67 67/67 (100%) expression - Homo sapiens, 67 aa. [WO200157272-A2, 09-AUG- 2001] AAM17791 Peptide #4225 encoded by probe 135 . . . 201 67/67 (100%) 2e-34 for measuring cervical gene 1 . . . 67 67/67 (100%) expression - Homo sapiens, 67 aa. [WO200157278-A2, 09-AUG- 2001]

[0421] In a BLAST search of public sequence datbases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D. TABLE-US-00104 TABLE 19D Public BLASTP Results for NOV19a NOV19a Identities/ Protein Residues/ Similarities for Accession Match the Matched Expect Number Protein/Organism/Length Residues Portion Value P01213 Beta-neoendorphin-dynorphin 1 . . . 201 201/246 (81%) e-110 precursor (Proenkephalin B) 9 . . . 254 201/246 (81%) (Preprodynorphin) [Contains: Beta- neoendorphin; Dynorphin; Leu- Enkephalin; Rimorphin; Leumorphin] - Homo sapiens (Human), 254 aa. P01214 Beta-neoendorphin-dynorphin 1 . . . 200 164/247 (66%) 2e-84 precursor (Proenkephalin B) 9 . . . 255 171/247 (68%) (Preprodynorphin) [Contains: Beta- neoendorphin; Dynorphin; Leu- Enkephalin; Rimorphin; Leumorphin] - Sus scrofa (Pig), 256 aa. Q95104 Beta-neoendorphin-dynorphin 1 . . . 200 155/249 (62%) 7e-79 precursor (Proenkephalin B) 9 . . . 257 170/249 (68%) (Preprodynorphin) [Contains: Beta- neoendorphin; Dynorphin; Leu- Enkephalin; Rimorphin; Leumorphin] - Bos taurus (Bovine), 258 aa. Q60478 Beta-neoendorphin-dynorphin 1 . . . 200 153/238 (64%) 3e-77 precursor (Proenkephalin B) 9 . . . 244 165/238 (69%) (Preprodynorphin) [Contains: Beta- neoendorphin; Dynorphin; Leu- Enkephalin; Rimorphin; Leumorphin] - Cavia porcellus (Guinea pig), 245 aa. O35852 PREPRODYNORPHIN - Mus 1 . . . 198 140/238 (58%) 4e-69 musculus (Mouse), 248 aa 9 . . . 246 157/238 (65%) (fragment).

[0422] PFam analysis predicts that the NOV19a protein contains the domains shown in the Table 19E. TABLE-US-00105 TABLE 19E Domain Analysis of NOV19a Identities/ NOV19a Similarities for the Pfam Domain Match Region Matched Region Expect Value Opiods_neuropep 1 . . . 201 145/267 (54%) 1.3e-115 197/267 (74%)

Example B

Sequencing Methodology and Identification of NOVX Clones

[0423] 1. GeneCalling.TM. Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., "Gene expression analysis by transcript profiling coupled to a gene database query" Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.

[0424] 2. SeqCalling.TM. Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

3. PathCalling.TM. Technology:

[0425] The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

[0426] The laboratory screening was performed using the methods summarized below:

[0427] cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, Calif.) were then transferred from E. coli into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).

[0428] Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

[0429] Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N.sub.1O.sub.6' and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).

[0430] 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.

[0431] 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain--amygdala, brain--cerebellum, brain--hippocampus, brain--substantia nigra, brain--thalamus, brain--whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma--Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

[0432] 6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

[0433] The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.

Example C

Quantitative Expression Analysis of Clones in Various Cells and Tissues

[0434] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM.RTM. 7700 or an ABI PRISM.RTM. 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

[0435] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[0436] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, .beta.-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

[0437] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 100 .mu.g of total RNA were performed in a volume of 20 .mu.l and incubated for 60 minutes at 42.degree. C. This reaction can be scaled up to 50 .mu.g of total RNA in a final volume of 100 .mu.l. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1.times. TaqMan.RTM. Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

[0438] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58.degree.-60.degree. C., primer optimal Tm=59.degree. C., maximum primer difference=2.degree. C., probe does not have 5'G, probe Tm must be 10.degree. C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.

[0439] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan.RTM. One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48.degree. C. for 30 minutes followed by amplification/PCR cycles as follows: 95.degree. C. 10 min, then 40 cycles of 95.degree. C. for 15 seconds, 60.degree. C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

[0440] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1.times. TaqMan.RTM. Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95.degree. C. 10 min, then 40 cycles of 95.degree. C. for 15 seconds, 60.degree. C. for 1 minute. Results were analyzed and processed as described previously.

[0441] Panels 1, 1.1, 1.2, and 1.3D

[0442] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

[0443] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used: [0444] ca.=carcinoma, [0445] *=established from metastasis, [0446] met=metastasis, [0447] s cell var=small cell variant, [0448] non-s=non-sm=non-small, [0449] squam=squamous, [0450] pl. eff=pl effusion=pleural effusion, [0451] glio=glioma, [0452] astro=astrocytoma, and [0453] neuro=neuroblastoma.

[0454] General_screening_panel_v1.4, v1.5 and v1.6

[0455] The plates for Panels 1.4, 1.5, and 1.6 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panels 1.4, 1.5, and 1.6 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, 1.5, and 1.6 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, 1.5, and 1.6 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

[0456] Panels 2D, 2.2, 2.3 and 2.4

[0457] The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.

[0458] HASS Panel v 1.0

[0459] The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls. Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, Md.) and were grown in the media and conditions recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.

[0460] Panel 3D and 3.1

[0461] The plates of Panel 3D and 3.1 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D, 3.1 and 1.3D are of the most common cell lines used in the scientific literature.

[0462] Panels 4D, 4R, and 4.1D

[0463] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDR1) (Philadelphia, Pa.).

[0464] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

[0465] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (GibcoALife Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 .mu.g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM-sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 .mu.g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2.times.10.sup.6 cells/ml in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5.times.10.sup.5M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

[0466] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 .mu.g/ml for 6 and 12-14 hours.

[0467] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and mM Hepes (Gibco) and plated at 10.sup.6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 .mu.g/ml anti-CD28 (Pharmingen) and 3 .mu.g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 add 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

[0468] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 10.sup.6 cells/ml in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 .mu.g/ml or anti-CD40 (Pharmingen) at approximately 10 .mu.g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours.

[0469] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 .mu.g/ml anti-CD28 (Pharmingen) and 2 .mu.g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 10.sup.5-10.sup.6 cells/ml in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 .mu.g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 .mu.g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 .mu.g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

[0470] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5.times.10.sup.5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5.times.10.sup.5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 .mu.g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithehal tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 .mu.M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5.times.10.sup.-5M (Gibco), and mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

[0471] For these cell lines and blood cells, RNA was prepared by lysing approximately 10.sup.7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20.degree. C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 .mu.l of RNAse-free water and 35 .mu.l buffer (Promega) 5 .mu.l DTT, 7 .mu.l RNAsin and 8 .mu.l DNAse were added. The tube was incubated at 37.degree. C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at -80.degree. C.

[0472] AI_comprehensive panel_v1.0

[0473] The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

[0474] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

[0475] Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

[0476] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

[0477] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1 anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

[0478] In the labels employed to identify tissues in the Al_comprehensive panel.sub.--v1.0 panel, the following abbreviations are used: [0479] AI=Autoimmunity [0480] Syn=Synovial [0481] Normal=No apparent disease [0482] Rep22/Rep20=individual patients [0483] RA=Rheumatoid arthritis [0484] Backus=From Backus Hospital [0485] OA=Osteoarthritis [0486] (SS)(BA)(MF)=Individual patients [0487] Adj=Adjacent tissue [0488] Match control=adjacent tissues [0489] -M=Male [0490] -F=Female [0491] COPD=Chronic obstructive pulmonary disease

[0492] Panels 5D and 5I

[0493] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

[0494] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows: [0495] Patient 2: Diabetic Hispanic, overweight, not on insulin [0496] Patient 7-9: Nondiabetic Caucasian and obese (BMI>30) [0497] Patient 10: Diabetic Hispanic, overweight, on insulin [0498] Patient 11: Nondiabetic African American and overweight [0499] Patient 12: Diabetic Hispanic on insulin

[0500] Adiocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2, 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows: [0501] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose [0502] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated [0503] Donor 2 and 3 AD: Adipose, Adipose Differentiated

[0504] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

[0505] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

[0506] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used: [0507] GO Adipose=Greater Omentum Adipose [0508] SK=Skeletal Muscle [0509] UT=Uterus [0510] PL=Placenta [0511] AD=Adipose Differentiated [0512] AM=Adipose Midway Differentiated [0513] U=Undifferentiated Stem Cells

[0514] Panel CNSD.01

[0515] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80.degree. C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[0516] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

[0517] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used: [0518] PSP=Progressive supranuclear palsy [0519] Sub Nigra=Substantia nigra [0520] Glob Palladus=Globus palladus [0521] Temp Pole=Temporal pole [0522] Cing Gyr=Cingulate gyrus [0523] BA 4=Brodman Area 4

[0524] Panel CNS_Neurodegeneration_V1.0

[0525] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80.degree. C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[0526] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

[0527] In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used: [0528] AD=Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy [0529] Control=Control brains; patient not demented, showing no neuropathology [0530] Control (Path)=Control brains; pateint not demented but showing sever AD-like pathology [0531] SupTemporal Ctx=Superior Temporal Cortex [0532] Inf Temporal Ctx=Inferior Temporal Cortex

[0533] A. NOV2A and NOV2B: LRR Protein

[0534] Expression of gene NOV2A and full length physical clone NOV2B was assessed using the primer-probe sets Ag4180, Ag6318, Ag6602, Ag6659 and Ag6702, described in Tables AA, AB, AC, AD and AE. Please note that NOV2A is recognized by primer-probe set Ag4180 only. Results of the RTQ-PCR runs are shown in Tables AF, AG, AH, AI, AJ and AK. TABLE-US-00106 TABLE AA Probe Name Ag4180 Start SEQ ID Primers Sequences Length Position No Forward 5'-tcttccagaaggacatcaactg-3' 22 1347 109 Probe TET-5'-cagcttcatccacttgagtttccagg-3'- 26 1309 110 TAMRA Reverse 5'-cccctcgtccaggatatagtac-3' 22 1271 111

[0535] TABLE-US-00107 TABLE AB Probe Name Ag6318 Start SEQ ID Primers Sequences Length Position No Forward 5'-gtagtgaagcaggatagttcataaatagaa-3' 30 3 112 Probe TET-5'-agtggaagcgccttctcatccttcat-3'- 26 35 113 TAMRA Reverse 5'-gcagtggtcacgtttgga-3' 18 62 114

[0536] TABLE-US-00108 TABLE AC Probe Name Ag6602 Start SEQ Posi- ID Primers Sequences Length tion No Forward 5'-gtgaggcggcagatcttc-3' 18 426 115 Probe TET-5'- 25 444 116 agctgaatcatctgcagcctgcatt- 3'-TAMRA Reverse 5'-attcccaggcatgatgct-3' 18 495 117

[0537] TABLE-US-00109 TABLE AD Probe Name Ag6659 Start SEQ Posi- ID Primers Sequences Length tion No Forward 5'-gtgaggcggcagatcttc-3' 18 426 118 Probe TET-5'- 25 444 119 agctgaatcatctgcagcctgcatt- 3'-TAMRA Reverse 5'-attcccaggcatgatgct-3' 18 495 120

[0538] TABLE-US-00110 TABLE AE Probe Name Ag6702 Start SEQ Posi- ID Primers Sequences Length tion No Forward 5'-gtgaggcggcagatcttc-3' 18 426 121 Probe TET-5'- 25 444 122 agctgaatcatctgcagcctgcatt- 3'-TAMRA Reverse 5'-attcccaggcatgatgct-3' 18 495 123

[0539] TABLE-US-00111 TABLE AF AI_comprehensive panel_v1.0 Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Ag6318, Run Ag6659, Run Ag6318, Run Ag6659, Run Tissue Name 275481201 275481281 Tissue Name 275481201 275481281 110967 COPD-F 5.2 0.0 112427 Match 10.5 0.0 Control Psoriasis-F 110980 COPD-F 0.5 0.0 112418 11.7 0.0 Psoriasis-M 110968 COPD-M 2.5 1.6 112723 Match 0.0 0.0 Control Psoriasis-M 110977 COPD-M 4.5 4.9 112419 10.7 5.1 Psoriasis-M 110989 5.4 2.1 112424 Match 5.2 0.0 Emphysema-F Control Psoriasis-M 110992 1.4 0.0 112420 8.4 0.0 Emphysema-F Psoriasis-M 110993 2.9 0.0 112425 Match 2.0 0.0 Emphysema-F Control Psoriasis-M 110994 6.1 0.0 104689 (MF) 3.9 18.4 Emphysema-F OA Bone- Backus 110995 2.3 0.0 104690 (MF) 5.5 5.4 Emphysema-F Adj "Normal" Bone-Backus 110996 4.2 0.0 104691 (MF) 8.9 19.3 Emphysema-F OA Synovium- Backus 110997 2.2 0.0 104692 (BA) 1.3 0.0 Asthma-M OA Cartilage- Backus 111001 4.7 2.1 104694 (BA) 6.7 4.5 Asthma-F OA Bone- Backus 111002 6.3 0.0 104695 (BA) 7.1 10.8 Asthma-F Adj "Normal" Bone-Backus 111003 Atopic 4.5 0.0 104696 (BA) 5.0 15.5 Asthma-F OA Synovium- Backus 111004 Atopic 5.4 0.0 104700 (SS) 100.0 100.0 Asthma-F OA Bone- Backus 111005 Atopic 1.3 0.0 104701 (SS) 8.5 0.0 Asthma-F Adj "Normal" Bone-Backus 111006 Atopic 0.0 0.0 104702 (SS) 7.0 3.0 Asthma-F OA Synovium- Backus 111417 1.5 0.0 117093 OA 0.8 0.0 Allergy-M Cartilage Rep7 112347 0.5 0.0 112672 OA 8.1 7.6 Allergy-M Bone5 112349 0.3 0.0 112673 OA 9.7 2.3 Normal Lung-F Synovium5 112357 6.7 10.4 112674 OA 8.2 1.9 Normal Lung-F Synovial Fluid cells5 112354 2.9 0.0 117100 OA 1.8 0.0 Normal Lung-M Cartilage Rep14 112374 9.4 3.8 112756 OA 0.2 0.0 Crohns-F Bone9 112389 Match 1.2 0.0 112757 OA 6.3 0.0 Control Synovium9 Crohns-F 112375 2.1 2.6 112758 OA 6.1 6.5 Crohns-F Synovial Fluid Cells9 112732 Match 1.3 0.0 117125 RA 2.9 0.0 Control Cartilage Crohns-F Rep2 112725 3.5 0.0 113492 Bone2 18.7 5.1 Crohns-M RA 112387 Match 0.7 0.0 113493 9.0 2.2 Control Synovium2 Crohns-M RA 112378 1.3 0.0 113494 Syn 15.5 0.0 Crohns-M Fluid Cells RA 112390 Match 5.1 0.0 113499 14.6 1.6 Control Cartilage4 RA Crohns-M 112726 0.6 0.0 113500 Bone4 16.4 0.0 Crohns-M RA 112731 Match 6.2 0.0 113501 14.0 0.0 Control Synovium4 Crohns-M RA 112380 Ulcer 0.0 0.0 113502 Syn 6.2 0.0 Col-F Fluid Cells4 RA 112734 Match 17.2 22.8 113495 16.2 2.5 Control Ulcer Cartilage3 RA Col-F 112384 Ulcer 7.2 0.0 113496 Bone3 20.0 4.3 Col-F RA 112737 Match 3.0 0.0 113497 10.4 1.6 Control Ulcer Synovium3 Col-F RA 112386 Ulcer 5.3 0.0 113498 Syn 13.9 8.3 Col-F Fluid Cells3 RA 112738 Match 0.7 0.0 117106 1.1 0.0 Control Ulcer Normal Col-F Cartilage Rep20 112381 Ulcer 0.0 0.0 113663 Bone3 0.0 0.0 Col-M Normal 112735 Match 0.5 0.0 113664 0.0 0.0 Control Ulcer Synovium3 Col-M Normal 112382 Ulcer 2.6 0.0 113665 Syn 0.9 0.0 Col-M Fluid Cells3 Normal 112394 Match 2.2 0.0 117107 0.8 0.0 Control Ulcer Normal Col-M Cartilage Rep22 112383 Ulcer 0.7 0.0 113667 Bone4 1.4 0.0 Col-M Normal 112736 Match 1.6 0.0 113668 4.4 0.0 Control Ulcer Synovium4 Col-M Normal 112423 16.7 1.9 113669 Syn 2.0 0.0 Psoriasis-F Fluid Cells4 Normal

[0540] TABLE-US-00112 TABLE AG CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Exp.(%) Ag4180, Ag4180, Run Run Tissue Name 215539679 Tissue Name 215539679 AD 1 Hippo 7.1 Control (Path) 3 0.0 Temporal Ctx AD 2 Hippo 0.0 Control (Path) 4 45.4 Temporal Ctx AD 3 Hippo 0.0 AD 1 Occipital 0.0 Ctx AD 4 Hippo 0.0 AD 2 Occipital 0.0 Ctx (Missing) AD 5 hippo 52.1 AD 3 Occipital 13.3 Ctx AD 6 Hippo 57.0 AD 4 Occipital 15.4 Ctx Control 2 Hippo 17.4 AD 5 Occipital 33.0 Ctx Control 4 Hippo 14.3 AD 6 Occipital 40.9 Ctx Control (Path) 3 14.8 Control 1 55.5 Hippo Occipital Ctx AD 1 Temporal Ctx 16.7 Control 2 0.0 Occipital Ctx AD 2 Temporal Ctx 0.0 Control 3 19.3 Occipital Ctx AD 3 Temporal Ctx 0.0 Control 4 19.1 Occipital Ctx AD 4 Temporal Ctx 0.0 Control (Path) 1 38.4 Occipital Ctx AD 5 Inf Temporal 25.0 Control (Path) 2 0.0 Ctx Occipital Ctx AD 5 SupTemporal 51.4 Control (Path) 3 0.0 Ctx Occipital Ctx AD 6 Inf Temporal 0.0 Control (Path) 4 0.0 Ctx Occipital Ctx AD 6 Sup Temporal 58.6 Control 1 Parietal 0.0 Ctx Ctx Control 1 Temporal 77.9 Control 2 Parietal 0.0 Ctx Ctx Control 2 Temporal 0.0 Control 3 Parietal 0.0 Ctx Ctx Control 3 Temporal 12.7 Control (Path) 1 19.3 Ctx Parietal Ctx Control 4 Temporal 0.0 Control (Path) 2 0.0 Ctx Parietal Ctx Control (Path) 1 16.2 Control (Path) 3 16.7 Temporal Ctx Parietal Ctx Control (Path) 2 0.0 Control (Path) 4 100.0 Temporal Ctx Parietal Ctx

[0541] TABLE-US-00113 TABLE AH General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4180, Ag4180, Run Run Tissue Name 221118503 Tissue Name 221118503 Adipose 5.1 Renal ca. TK-10 0.9 Melanoma* 0.0 Bladder 0.0 Hs688(A).T Melanoma* 0.4 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.3 Melanoma* 0.0 Colon ca. SW-948 1.2 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 3.3 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 8.0 Colon ca. HT29 0.0 Prostate ca.* (bone 1.0 Colon ca. HCT-116 1.1 met) PC-3 Prostate Pool 0.9 Colon ca. CaCo-2 36.3 Placenta 6.2 Colon cancer tissue 6.3 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 5.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 1.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 2.4 Colon Pool 3.3 OVCAR-4 Ovarian ca. 1.0 Small Intestine Pool 0.0 OVCAR-5 Ovarian ca. 1.1 Stomach Pool 2.0 IGROV-1 Ovarian ca. 1.1 Bone Marrow Pool 0.8 OVCAR-8 Ovary 2.1 Fetal Heart 3.9 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 1.8 MB-231 Breast ca. BT 549 0.9 Fetal Skeletal Muscle 0.5 Breast ca. T47D 1.3 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 1.2 Spleen Pool 18.4 Breast Pool 1.7 Thymus Pool 3.5 Trachea 0.0 CNS cancer 100.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 12.9 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.5 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.5 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 7.0 295 Lung ca. A549 1.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.7 Brain (fetal) 4.5 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 2.2 Brain (Substantia 1.0 nigra) Pool Liver 3.0 Brain (Thalamus) Pool 0.0 Fetal Liver 3.1 Brain (whole) 0.0 Liver ca. HepG2 0.0 Spinal Cord Pool 0.0 Kidney Pool 5.7 Adrenal Gland 4.1 Fetal Kidney 2.8 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.6 Renal ca. A498 0.9 Thyroid (female) 7.5 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.8 Pancreas Pool 3.0

[0542] TABLE-US-00114 TABLE AI General_screening_panel_v1.5 Rel. Exp.(%) Rel. Exp.(%) Ag6318, Ag6318, Run Run Tissue Name 259139880 Tissue Name 259139880 Adipose 0.0 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 3.1 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 2.8 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 1.0 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.5 Colon ca. CaCo-2 77.9 Placenta 1.7 Colon cancer tissue 0.4 Uterus Pool 0.7 Colon ca. SW1116 100.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 1.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 1.2 OVCAR-4 Ovarian ca. 0.0 Small Intestine Pool 0.0 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.0 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 0.0 OVCAR-8 Ovary 0.0 Fetal Heart 0.0 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 0.0 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.4 Breast ca. T47D 0.0 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 0.0 Thymus Pool 0.5 Trachea 0.0 CNS cancer 2.9 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 1.4 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 0.0 295 Lung ca. A549 0.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.5 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 1.0 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 0.0 Brain (Thalamus) Pool 0.0 Fetal Liver 0.5 Brain (whole) 0.0 Liver ca. HepG2 0.0 Spinal Cord Pool 0.4 Kidney Pool 0.5 Adrenal Gland 0.0 Fetal Kidney 1.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.9 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.0

[0543] TABLE-US-00115 TABLE AJ Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4180, Ag6318, Rel. Exp.(%) Run Run Ag6602, Run Tissue Name 173607813 259196823 274219626 Secondary Th1 act 0.0 0.0 0.0 Secondary Th2 act 0.0 0.0 0.0 Secondary Tr1 act 0.0 0.0 0.0 Secondary Th1 rest 0.0 0.0 0.0 Secondary Th2 rest 0.0 0.0 0.0 Secondary Tr1 rest 0.0 0.0 0.0 Primary Th1 act 0.0 0.0 0.0 Primary Th2 act 0.0 0.0 0.0 Primary Tr1 act 0.0 1.7 0.0 Primary Th1 rest 0.0 0.0 0.0 Primary Th2 rest 0.0 0.0 0.0 Primary Tr1 rest 0.2 0.0 0.0 CD45RA CD4 0.3 0.0 0.0 lymphocyte act CD45RO CD4 0.0 0.0 0.0 lymphocyte act CD8 lymphocyte 0.0 0.0 0.0 act Secondary CD8 0.0 0.0 0.0 lymphocyte rest Secondary CD8 0.0 0.0 0.0 lymphocyte act CD4 lymphocyte 0.0 0.0 0.0 none 2ry 0.0 0.0 0.0 Th1/Th2/Tr1_anti- CD95 CH11 LAK cells rest 4.8 3.1 0.6 LAK cells IL-2 0.0 0.0 0.0 LAK cells IL-2 + IL- 0.0 0.0 0.0 12 LAK cells IL- 0.1 0.0 0.0 2 + IFN gamma LAK cells IL-2 + IL- 0.0 0.0 0.0 18 LAK cells 1.1 1.0 0.0 PMA/ionomycin NK Cells IL-2 rest 0.3 0.0 0.0 Two Way MLR 3 0.4 1.4 0.0 day Two Way MLR 5 0.0 0.0 0.0 day Two Way MLR 7 0.0 0.0 0.0 day PBMC rest 23.7 3.1 3.3 PBMC PWM 0.0 0.0 0.0 PBMC PHA-L 0.2 0.0 0.0 Ramos (B cell) 0.0 0.0 0.0 none Ramos (B cell) 0.0 0.0 0.0 ionomycin B lymphocytes 0.0 0.0 0.0 PWM B lymphocytes 0.0 0.0 0.0 CD40L and IL-4 EOL-1 dbcAMP 5.7 2.8 0.4 EOL-1 dbcAMP 0.0 1.3 0.0 PMA/ionomycin Dendritic cells none 4.1 0.6 2.3 Dendritic cells LPS 0.3 0.0 0.0 Dendritic cells anti- 2.4 0.0 0.3 CD40 Monocytes rest 100.0 11.0 7.4 Monocytes LPS 6.4 0.0 1.4 Macrophages rest 0.9 0.0 0.0 Macrophages LPS 0.0 0.0 0.0 HUVEC none 0.0 0.0 0.0 HUVEC starved 0.0 0.0 0.0 HUVEC IL-1beta 0.0 0.0 0.0 HUVEC IFN 0.0 0.0 0.7 gamma HUVEC TNF alpha + IFN 0.0 0.0 0.0 gamma HUVEC TNF alpha + IL4 0.0 0.0 0.0 HUVEC IL-11 0.0 0.0 0.0 Lung 0.0 0.0 0.0 Microvascular EC none Lung 0.0 0.0 0.0 Microvascular EC TNF alpha + IL- 1beta Microvascular 0.0 0.0 0.0 Dermal EC none Microsvasular 0.0 0.0 0.0 Dermal EC TNF alpha + IL- 1beta Bronchial 0.0 0.0 0.0 epithelium TNF alpha + IL1beta Small airway 0.0 0.0 0.0 epithelium none Small airway 0.0 0.0 0.0 epithelium TNF alpha + IL- 1beta Coronery artery 0.0 0.0 0.0 SMC rest Coronery artery 0.3 0.0 0.0 SMC TNF alpha + IL- 1beta Astrocytes rest 0.0 0.0 0.0 Astrocytes 0.0 1.9 0.0 TNF alpha + IL- 1beta KU-812 (Basophil) 0.0 0.0 0.0 rest KU-812 (Basophil) 0.0 2.1 0.0 PMA/ionomycin CCD1106 0.0 0.0 0.0 (Keratinocytes) none CCD1106 0.0 0.0 0.0 (Keratinocytes) TNF alpha + IL- 1beta Liver cirrhosis 0.2 1.0 0.0 NCI-H292 none 0.0 0.0 0.0 NCI-H292 IL-4 0.0 0.0 0.0 NCI-H292 IL-9 0.0 2.7 0.0 NCI-H292 IL-13 0.2 0.0 0.0 NCI-H292 IFN 0.0 0.0 0.0 gamma HPAEC none 0.0 0.0 0.0 HPAEC TNF alpha + IL- 0.0 1.4 0.0 1beta Lung fibroblast 0.0 0.0 0.0 none Lung fibroblast 0.1 0.0 0.0 TNF alpha + IL-1beta Lung fibroblast IL-4 0.0 0.0 0.0 Lung fibroblast IL-9 0.0 0.0 0.0 Lung fibroblast IL- 0.0 0.0 0.0 13 Lung fibroblast IFN 0.0 0.0 0.0 gamma Dermal fibroblast 0.6 0.0 0.0 CCD1070 rest Dermal fibroblast 0.0 0.0 0.0 CCD1070 TNF alpha Dermal fibroblast 0.2 0.0 0.0 CCD1070 IL-1beta Dermal fibroblast 1.9 0.0 0.0 IFN gamma Dermal fibroblast 4.5 0.0 0.0 IL-4 Dermal Fibroblasts 1.2 0.0 0.0 rest Neutrophils 23.8 11.6 17.8 TNFa + LPS Neutrophils rest 68.8 100.0 100.0 Colon 1.0 0.0 0.0 Lung 1.0 1.4 0.0 Thymus 1.9 0.0 0.0 Kidney 17.6 1.2 0.0

[0544] TABLE-US-00116 TABLE AK General oncology screening panel_v_2.4 Rel. Exp.(%) Rel. Exp.(%) Ag4180, Ag4180, Run Run Tissue Name 268695204 Tissue Name 268695204 Colon cancer 1 46.0 Bladder cancer NAT 2 0.0 Colon cancer 9.1 Bladder cancer NAT 3 0.0 NAT 1 Colon cancer 2 55.9 Bladder cancer NAT 4 0.0 Colon cancer 11.9 Adenocarcinoma of the 0.0 NAT 2 prostate 1 Colon cancer 3 22.4 Adenocarcinoma of the 4.1 prostate 2 Colon cancer 6.7 Adenocarcinoma of the 0.0 NAT 3 prostate 3 Colon malignant 49.7 Adenocarcinoma of the 1.7 cancer 4 prostate 4 Colon normal 0.0 Prostate cancer NAT 5 0.0 adjacent tissue 4 Lung cancer 1 100.0 Adenocarcinoma of the 0.0 prostate 6 Lung NAT 1 13.8 Adenocarcinoma of the 3.5 prostate 7 Lung cancer 2 11.9 Adenocarcinoma of the 0.0 prostate 8 Lung NAT 2 5.7 Adenocarcinoma of the 16.0 prostate 9 Squamous cell 10.3 Prostate cancer NAT 0.0 carcinoma 3 10 Lung NAT 3 6.3 Kidney cancer 1 44.1 metastatic 32.8 KidneyNAT 1 3.9 melanoma 1 Melanoma 2 4.1 Kidney cancer 2 65.1 Melanoma 3 2.7 Kidney NAT 2 2.1 metastatic 48.3 Kidney cancer 3 0.0 melanoma 4 metastatic 51.8 Kidney NAT 3 0.0 melanoma 5 Bladder cancer 1 9.2 Kidney cancer 4 47.6 Bladder cancer 0.0 Kidney NAT 4 33.0 NAT 1 Bladder cancer 2 0.0

[0545] AI_comprehensive panel_v1.0 Summary: Ag6318/Ag6659 Two experiments with two different probe and primer sets that are specific to the NOV2B variant produce results that are in reasonable agreement. Highest expression of this gene is seen in bone from an OA patient (CTs=30-34). Expression levels in the other samples in the Ag6659 experiment are below the threshold of reliable detection. In the experiment using probe and primer set Ag6318, low but significant levels of expression are seen in many of the samples on this panel, including bone, synovium, synovial fluid and cartilage from OA and RA patients. These results confirm expression of this gene in samples related to the autoimmune response. Thus, therapeutic modulation of the expression or function of this gene or gene product may be useful in the treatment of OA.

[0546] CNS_neurodegeneration_v1.0 Summary: Ag4180 This panel does not show differential expression of this gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. This gene encodes a leucine-rich repeat protein. Leucine rich repeats (LRR) mediate reversible protein-protein interactions and have diverse cellular functions, including cellular adhesion and signaling. Several of these proteins, such as connectin, slit, chaoptin, and Toll have pivotal roles in neuronal development in Drosophila and may play significant but distinct roles in neural development and in the adult nervous system of humans (Battye R. (2001) J. Neurosci. 21: 4290-4298. Itoh A. (1998) Brain Res. Mol. Brain Res. 62: 175-186). In Drosophilia, the LRR region of axon guidance proteins has been shown to be critical for their function (especially in axon repulsion). Since the leucine-rich-repeat protein encoded by this gene shows high expression in the cerebral cortex, it is an excellent candidate neuronal guidance protein for axons, dendrites and/or growth cones in general. Therefore, therapeutic modulation of the levels of this protein, or possible signaling via this protein, may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease). A second experiment with Ag6318 shows low/undetectable levels of expression in all samples on this panel. (CTS>35). (Data not shown.)

[0547] General_screening_panel_v1.4 Summary: Ag4180 Highest expression of this gene is seen in a brain cancer cell line (CT=30.8). Low but significant expression is also seen in colon cancer. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Members of the leucine rich superfamily have been shown to be upregulated in some brain cancers (Almeida A, Oncogene 1998 Jun. 11; 16 (23):2997-3002) Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of brain and colon cancer.

[0548] Low but significant expression is also seen in the thyroid. The extracellular domains of receptors for glycoprotein hormones that influence the development and function of the thyroid are members of the leucine-rich repeat (LRR) protein superfamily and are responsible for the high-affinity binding. (Jiang X. (1995) Structure 3: 1341-1353.) Thus, therapeutic modulation of this gene product may aid in the treatment of metabolic and neuroendocrine disorders.

[0549] General_screening_panel_v1.5 Summary: Ag6318 This probe and primer set is specific for the NOV2B variant only and produces a different expression profile than in Panel 1.4. In this panel, expression is exclusive to colon cancer cell lines (CTs=32). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of colon cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon cancer.

[0550] General_screening_panel_v1.6 Summary: Ag6702 Expression is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)

[0551] Panel 4.1D Summary: Ag4180 Expression of this gene is highest in resting monocytes (CT=28.7). Moderate levels of expression are seen in resting PBMCs, resting neutrophils (CT=29.2), TNF-a and LPS treated neutrophils (CT=30.7), and normal kidney. Low but significant levels of expression are seen in activated dermal fibroblasts, resting LAK cells, LPS treated monocytes, eosinophils and treated dendritic cells.

[0552] Two experiments with the probe and primer sets Ag6318 and Ag6602, both specific to NOV2B, show expression in resting neutrophils only (CTs=31-32).

[0553] The expression of this transcript in LPS treated monocytes, cells that play a crucial role in linking innate immunity to adaptive immunity, suggests a role for this gene product in initiating inflammatory reactions. Therefore, modulation of the expression or activity of the NOV2A gene may reduce or prevent early stages of inflammation and reduce the severity of inflammatory diseases such as psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis and other lung inflammatory diseases.

[0554] General oncology screening panel_v.sub.--2.4 Summary: Ag4180 Highest expression of this gene is seen in lung cancer (CT=33.5). In addition, expression is higher in lung, colon and kidney cancers when compared to expression in the corresponding normal adjacent tissue. Thus, expression of this gene could be as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung, colon and kidney cancer.

[0555] B. NOV3A: Gonadotrophin Beta-Subunit

[0556] Expression of gene NOV3A was assessed using the primer-probe sets Ag338 and Ag74, described in Tables BA and BB. Results of the RTQ-PCR runs are shown in Table BC. TABLE-US-00117 TABLE BA Probe Name Ag338 Start SEQ ID Primers Sequences Length Position No Forward 5'-acaacgagaccaaacaggtgact-3' 23 248 124 Probe TET-5'-tcaagctgcccaactgtgcccc-3'- 22 272 125 TAMRA Reverse 5'-ggccacgggataggtgtaga-3' 20 308 126

[0557] TABLE-US-00118 TABLE BB Probe Name Ag74 Start SEQ ID Primers Sequences Length Position No Forward 5'-acaacgagaccaaacaggtgact-3' 23 248 127 Probe TET-5'-caactgtgccccgggagtcgac-3'- 22 282 128 TAMRA Reverse 5'-ggccacgggataggtgtaga-3' 20 308 129

[0558] TABLE-US-00119 TABLE BC Panel 1 Rel. Exp.(%) Rel. Exp.(%) Ag338, Ag74, Tissue Name Run 97805375 Run 87354633 Endothelial cells 0.0 0.0 Endothelial cells (treated) 0.0 0.0 Pancreas 0.0 0.0 Pancreatic ca. CAPAN 2 0.0 0.0 Adrenal gland 0.0 0.0 Thyroid 0.0 0.0 Salivary gland 0.0 0.0 Pituitary gland 0.0 0.0 Brain (fetal) 0.0 0.0 Brain (whole) 0.5 0.0 Brain (amygdala) 0.6 0.0 Brain (cerebellum) 0.3 24.8 Brain (hippocampus) 0.0 0.0 Brain (substantia nigra) 0.0 0.0 Brain (thalamus) 0.1 0.0 Brain (hypothalamus) 0.0 0.0 Spinal cord 0.0 0.0 glio/astro U87-MG 0.0 0.0 glio/astro U-118-MG 0.0 0.0 astrocytoma SW1783 0.0 0.0 neuro*; met SK-N-AS 0.0 0.0 astrocytoma SF-539 0.0 0.0 astrocytoma SNB-75 0.0 0.0 glioma SNB-19 0.0 0.0 glioma U251 0.0 0.0 glioma SF-295 0.0 0.0 Heart 0.0 0.0 Skeletal muscle 0.0 0.0 Bone marrow 0.0 0.0 Thymus 0.0 0.0 Spleen 0.0 0.0 Lymph node 0.0 0.0 Colon (ascending) 23.2 40.3 Stomach 0.0 0.0 Small intestine 0.0 0.0 Colon ca. SW480 0.0 0.0 Colon ca.* SW620 (SW480 met) 0.0 0.0 Colon ca. HT29 0.0 0.0 Colon ca. HCT-116 0.0 0.0 Colon ca. CaCo-2 0.0 0.0 Colon ca. HCT-15 1.7 0.0 Colon ca. HCC-2998 0.0 0.0 Gastric ca.* (liver met) NCI-N87 0.0 0.0 Bladder 0.0 0.0 Trachea 0.0 0.0 Kidney 0.0 0.0 Kidney (fetal) 0.0 0.0 Renal ca. 786-0 0.0 0.0 Renal ca. A498 0.0 0.0 Renal ca. RXF 393 0.0 0.0 Renal ca. ACHN 0.0 0.0 Renal ca. UO-31 0.0 0.0 Renal ca. TK-10 0.0 0.0 Liver 0.0 0.0 Liver (fetal) 0.0 0.0 Liver ca. (hepatoblast) HepG2 0.0 0.0 Lung 0.0 0.0 Lung (fetal) 0.0 0.0 Lung ca. (small cell) LX-1 0.0 0.0 Lung ca. (small cell) NCI-H69 8.4 4.6 Lung ca. (s. cell var.) SHP-77 0.0 0.0 Lung ca. (large cell) NCI-H460 0.0 0.0 Lung ca. (non-sm. cell) A549 0.4 0.0 Lung ca. (non-s. cell) NCI-H23 0.0 0.0 Lung ca. (non-s. cell) HOP-62 0.0 0.0 Lung ca. (non-s. cl) NCI-H522 0.0 0.0 Lung ca. (squam.) SW 900 0.0 0.0 Lung ca. (squam.) NCI-H596 1.8 0.0 Mammary gland 0.0 0.0 Breast ca.* (pl. ef) MCF-7 0.0 0.0 Breast ca.* (pl. ef) MDA-MB-231 0.0 0.0 Breast ca.* (pl. ef) T47D 1.1 18.6 Breast ca. BT-549 0.0 0.0 Breast ca. MDA-N 0.0 0.0 Ovary 0.0 0.0 Ovarian ca. OVCAR-3 0.0 0.0 Ovarian ca. OVCAR-4 0.0 0.0 Ovarian ca. OVCAR-5 10.3 4.8 Ovarian ca. OVCAR-8 0.0 0.0 Ovarian ca. IGROV-1 1.5 0.0 Ovarian ca. (ascites) SK-OV-3 0.0 0.0 Uterus 0.0 0.0 Placenta 0.0 0.0 Prostate 0.0 0.0 Prostate ca.* (bone met) PC-3 0.5 0.0 Testis 5.8 100.0 Melanoma Hs688(A).T 0.0 0.0 Melanoma* (met) Hs688(B).T 0.0 0.0 Melanoma UACC-62 0.0 0.0 Melanoma M14 0.0 1.0 Melanoma LOX IMVI 0.0 0.0 Melanoma* (met) SK-MEL-5 0.0 0.0 Melanoma SK-MEL-28 100.0 0.0

[0559] CNS_neurodegeneration_v1.0 Summary: Ag338 Results from one experiment with the NOV3A gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0560] Panel 1 Summary: Ag338 Highest expression of the NOV3A gene is detected in a melanoma SK-MEL-28 cell line (CT=27.8). Thus, expression of this gene may be used to distinguish this sample from other samples used in this panel. In addition, low to moderate expression of this gene is also seen in lung cancer, breast cancer and ovarian cancer cell lines. Therefore, therapeutic modulation of this gene product may be useful in the treatment of these cancers.

[0561] Low expression of this gene is also seen in testis and colon. Therefore, therapeutic modulation of this gene product may be useful in the treatment of diseases associated testis and colon such as fertility, hypogonadism, inflammatory bowel diseases, cancers.

[0562] Ag74 Highest expression of the NOV3A gene is detected in testis (CT=31.4). Thus, expression of this gene can be used to distinguish this sample from other samples in this panel. In addition, moderate expression of this gene is also seen in colon and brain (cerebellum). Therefore, therapeutic modulation of this gene product may be useful in the treatment of neurological disorders and diseases associated with testis and colon.

[0563] Panel 4D Summary: Ag338 Expression of the NOV3A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0564] General oncology screening panel_v.sub.--2.4 Summary: Ag338 Expression of the NOV3A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0565] C. NOV4A: Odorant Binding Protein

[0566] Expression of gene NOV4A was assessed using the primer-probe sets Ag4218 and Ag4261, described in Tables CA and CB. Results of the RTQ-PCR runs are shown in Tables CC and CD. TABLE-US-00120 TABLE CA Probe Name Ag4218 Start SEQ ID Primers Sequences Length Position No Forward 5'-actctcggaggaggacatttt3' 21 339 130 Probe TET-5'-cagtcccctgtgtccctctgctg-3'- 23 394 131 TAMRA Reverse 5'-cactggagatagcagacagaca-3' 22 417 132

[0567] TABLE-US-00121 TABLE CB Probe Name Ag4261 Start SEQ ID Primers Sequences Length Position No Forward 5'-actctcggaggaggacatttt-3' 21 339 133 Probe TET-5'-cagtcccctgtgtccctctgctg-3'- 23 394 134 TAMRA Reverse 5'-cactggagatagcagacagaca-3' 22 417 135

[0568] TABLE-US-00122 TABLE CC General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4261, Ag4261, Run Run Tissue Name 222523498 Tissue Name 222523498 Adipose 0.0 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 0.0 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 2.5 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 100.0 Melanoma* 0.0 Colon ca. SW-948 1.5 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.0 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 13.4 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 7.0 OVCAR-4 Ovarian ca. 0.0 Small Intestine Pool 5.7 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.9 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 8.4 OVCAR-8 Ovary 0.0 Fetal Heart 0.4 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 0.0 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.0 Breast ca. T47D 0.0 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 0.0 Thymus Pool 0.0 Trachea 0.0 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 2.6 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 4.2 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) 0.0 SF-295 Lung ca. A549 0.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 0.0 Brain (Thalamus) Pool 0.0 Fetal Liver 0.0 Brain (whole) 0.0 Liver ca. HepG2 0.0 Spinal Cord Pool 0.0 Kidney Pool 0.0 Adrenal Gland 0.0 Fetal Kidney 1.9 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.0

[0569] TABLE-US-00123 TABLE CD Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4218, Run Ag4218, Run Tissue Name 174261203 Tissue Name 174261203 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 1.4 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 2.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.0 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.0 Bronchial epithelium 2.3 TNF alpha + IL1beta Primary Th2 rest 0.0 Small airway epithelium 0.0 none Primary Tr1 rest 0.9 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.9 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 1.0 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 1.3 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 0.0 LAK cells IL-2 + IL-12 0.0 NCI-H292 none 2.4 LAK cells IL-2 + IFN 0.0 NCI-H292 IL-4 0.0 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-9 0.0 LAK cells 0.0 NCI-H292 IL-13 0.0 PMA/ionomycin NK Cells IL-2 rest 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 0.0 HPAEC none 0.0 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 PBMC rest 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PWM 0.0 Lung fibroblast IL-4 0.0 PBMC PHA-L 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-13 2.5 Ramos (B cell) 0.0 Lung fibroblast IFN 0.0 ionomycin gamma B lymphocytes PWM 0.0 Dermal fibroblast 0.0 CCD1070 rest B lymphocytes CD40L 0.0 Dermal fibroblast 0.0 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 CCD1070 IL-1beta EOL-1 dbcAMP 0.0 Dermal fibroblast IFN 0.0 PMA/ionomycin gamma Dendritic cells none 0.0 Dermal fibroblast IL-4 1.4 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 1.3 Dendritic cells anti- 3.4 Neutrophils TNFa + LPS 0.0 CD40 Monocytes rest 0.0 Neutrophils rest 0.0 Monocytes LPS 0.0 Colon 0.0 Macrophages rest 0.0 Lung 3.1 Macrophages LPS 0.0 Thymus 14.9 HUVEC none 0.0 Kidney 100.0 HUVEC starved 0.0

[0570] CNS_neurodegeneration_v1.0 Summary: Ag4218 Expression of the NOV4A gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0571] General_screening_panel_v1.4 Summary: Ag4218 Expression of the NOV4A gene is restricted to a sample derived from a gastric cancer cell line (CT=32). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of gastric cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of gastric cancer.

[0572] Panel 4.1D Summary: Ag4218 Expression of the NOV4A gene is limited to the kidney and thymus (CTs=30-33). Therefore, therapeutic modulation of the expression or function of this gene may modulate kidney and thymus function and be important in the treatment of inflammatory or autoimmune diseases that affect these organs, including lupus and glomerulonephritis.

[0573] General oncology screening panel_v.sub.--2.4 Summary: Ag4218 Expression of the NOV4A gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0574] D. NOV6B: Cathepsin F Precursor

[0575] Expression of gene NOV6B, representing a full-length physical clone, was assessed using the primer-probe set Ag6946, described in Table DA. Results of the RTQ-PCR runs are shown in Table DB. TABLE-US-00124 TABLE DA Probe Name Ag6946 Start SEQ ID Primers Sequences Length Position No Forward 5'-ccagccccaagtcctggat-3' 19 80 136 Probe TET-5'-aaccttggtgtccactgggccaca-3'- 24 132 137 TAMRA Reverse 5'-atcatggctgagccctgagt-3' 20 186 138

[0576] TABLE-US-00125 TABLE DB General_screening_panel_v1.6 Rel. Exp.(%) Rel. Exp.(%) Ag6946, Ag6946, Run Run Tissue Name 278388882 Tissue Name 278388882 Adipose 11.4 Renal ca. TK-10 0.0 Melanoma* 21.0 Bladder 10.2 Hs688(A).T Melanoma* 13.4 Gastric ca. (liver met.) 5.2 Hs688(B).T NCI-N87 Melanoma* M14 26.1 Gastric ca. KATO III 0.0 Melanoma* 1.4 Colon ca. SW-948 1.4 LOXIMVI Melanoma* SK- 18.7 Colon ca. SW480 0.0 MEL-5 Squamous cell 3.4 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 29.7 Colon ca. HT29 0.0 Prostate ca.* (bone 17.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 12.4 Colon ca. CaCo-2 0.0 Placenta 12.3 Colon cancer tissue 3.3 Uterus Pool 7.2 Colon ca. SW1116 0.0 Ovarian ca. 36.6 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 18.8 Colon ca. SW-48 0.1 OV-3 Ovarian ca. 2.2 Colon Pool 23.8 OVCAR-4 Ovarian ca. 7.9 Small Intestine Pool 23.0 OVCAR-5 Ovarian ca. 10.8 Stomach Pool 13.4 IGROV-1 Ovarian ca. 20.7 Bone Marrow Pool 6.8 OVCAR-8 Ovary 32.8 Fetal Heart 3.5 Breast ca. MCF-7 1.5 Heart Pool 11.1 Breast ca. MDA- 22.2 Lymph Node Pool 19.1 MB-231 Breast ca. BT 549 53.2 Fetal Skeletal Muscle 2.8 Breast ca. T47D 15.3 Skeletal Muscle Pool 4.5 Breast ca. MDA-N 26.8 Spleen Pool 6.2 Breast Pool 22.8 Thymus Pool 11.1 Trachea 14.9 CNS cancer 7.0 (glio/astro) U87-MG Lung 5.1 CNS cancer 1.2 (glio/astro) U-118-MG Fetal Lung 10.5 CNS cancer 7.4 (neuro; met) SK-N-AS Lung ca. NCI-N417 1.1 CNS cancer (astro) 1.8 SF-539 Lung ca. LX-1 0.2 CNS cancer (astro) 36.9 SNB-75 Lung ca. NCI-H146 1.4 CNS cancer (glio) 11.0 SNB-19 Lung ca. SHP-77 11.4 CNS cancer (glio) SF- 62.4 295 Lung ca. A549 15.0 Brain (Amygdala) 20.9 Pool Lung ca. NCI-H526 4.8 Brain (cerebellum) 100.0 Lung ca. NCI-H23 35.4 Brain (fetal) 17.9 Lung ca. NCI-H460 10.7 Brain (Hippocampus) 24.1 Pool Lung ca. HOP-62 30.6 Cerebral Cortex Pool 35.4 Lung ca. NCI-H522 0.0 Brain (Substantia 25.0 nigra) Pool Liver 13.6 Brain (Thalamus) Pool 33.2 Fetal Liver 4.9 Brain (whole) 26.1 Liver ca. HepG2 0.0 Spinal Cord Pool 28.1 Kidney Pool 50.0 Adrenal Gland 25.7 Fetal Kidney 11.2 Pituitary gland Pool 6.2 Renal ca. 786-0 0.0 Salivary Gland 18.4 Renal ca. A498 8.9 Thyroid (female) 12.2 Renal ca. ACHN 0.0 Pancreatic ca. 6.0 CAPAN2 Renal ca. UO-31 10.7 Pancreas Pool 4.8

[0577] General_screening_panel_v1.6 Summary: Ag6946 Highest expression of the NOV6B gene is seen in the cerebellum (CT=28.3). In addition, moderate levels of expression are also seen in all regions of the CNS examined. This gene encodes a homolog of cathepsin that has been shown to be deficient in neurodegenerative lysosomal disorder galactosialidosis, which produces nephropathy, ataxia, and premature death. Expression of cathepsin in the brain has been shown to delay the onset of the neuronal degeneration and to correct the ataxia associated with this disease. (Leimig T. Blood 2002 May 1; 99 (9):3169-78). Thus, based on the expression of this gene in the CNS and the homology that this gene shows to cathepsin, modulation of this gene could be used in the treatment of this disorder, diseases that affect the cerebellum such as autism and the ataxias, Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0578] Moderate levels of expression are also seen in cell lines derived from ovarian cancer, lung cancer and breast cancer. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0579] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0580] E. NOV7A: Netrin G1

[0581] Expression of gene NOV7A was assessed using the primer-probe set Ag4235, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB, EC, ED, EE and EF. TABLE-US-00126 TABLE EA Probe Name Ag4235 Start SEQ ID Primers Sequences Length Position No Forward 5'-ggtcatggtcctggagaagt-3' 20 537 139 Probe TET-5'-acctggcagccctaccagttctacg-3'- 25 574 140 TAMRA Reverse 5'-acataccgaaggcctccat-3' 19 610 141

[0582] TABLE-US-00127 TABLE EB CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Exp.(%) Ag4235, Run Ag4235, Run Tissue Name 224078156 230510266 AD 1 Hippo 11.7 30.1 AD 2 Hippo 26.8 47.0 AD 3 Hippo 5.0 16.8 AD 4 Hippo 4.6 17.0 AD 5 Hippo 27.5 77.9 AD 6 Hippo 16.3 68.8 Control 2 Hippo 14.3 37.6 Control 4 Hippo 14.2 51.4 Control (Path) 3 Hippo 4.5 0.0 AD 1 Temporal Ctx 7.5 9.1 AD 2 Temporal Ctx 15.0 39.2 AD 3 Temporal Ctx 4.8 12.9 AD 4 Temporal Ctx 9.2 10.8 AD 5 Inf Temporal Ctx 31.6 100.0 AD 5 Sup Temporal Ctx 22.4 89.5 AD 6 Inf Temporal Ctx 18.0 58.2 AD 6 Sup Temporal Ctx 17.7 55.1 Control 1 Temporal Ctx 7.2 13.5 Control 2 Temporal Ctx 18.6 55.5 Control 3 Temporal Ctx 8.4 29.9 Control 3 Temporal Ctx 12.7 38.2 Control (Path) 1 49.0 67.4 Temporal Ctx Control (Path) 2 14.8 50.0 Temporal Ctx Control (Path) 3 9.5 14.5 Temporal Ctx Control (Path) 4 26.4 59.9 Temporal Ctx AD 1 Occipital Ctx 6.1 15.2 AD 2 Occipital Ctx 0.0 0.0 (Missing) AD 3 Occipital Ctx 5.6 11.0 AD 4 Occipital Ctx 6.7 20.7 AD 5 Occipital Ctx 14.7 39.8 AD 6 Occipital Ctx 4.0 4.8 Control 1 Occipital Ctx 3.2 13.3 Control 2 Occipital Ctx 15.0 50.0 Control 3 Occipital Ctx 7.4 24.8 Control 4 Occipital Ctx 4.9 16.4 Control (Path) 1 33.9 81.2 Occipital Ctx Control (Path) 2 7.1 0.5 Occipital Ctx Control (Path) 3 3.2 6.6 Occipital Ctx Control (Path) 4 15.3 41.5 Occipital Ctx Control 1 Parietal Ctx 6.9 21.9 Control 2 Parietal Ctx 26.4 79.6 Control 3 Parietal Ctx 8.7 7.3 Control (Path) 1 Parietal 100.0 75.8 Ctx Control (Path) 2 Parietal 9.3 35.6 Ctx Control (Path) 3 Parietal 3.2 9.0 Ctx Control (Path) 4 Parietal 31.2 41.8 Ctx

[0583] TABLE-US-00128 TABLE EC General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4235, Ag4235, Run Run Tissue Name 221994384 Tissue Name 221994384 Adipose 0.6 Renal ca. TK-10 0.8 Melanoma* 3.4 Bladder 2.7 Hs688(A).T Melanoma* 3.6 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.2 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.2 Colon ca. SW480 0.9 MEL-5 Squamous cell 0.2 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 1.1 Colon ca. HT29 0.0 Prostate ca.* (bone 1.5 Colon ca. HCT-116 0.1 met) PC-3 Prostate Pool 6.2 Colon ca. CaCo-2 0.0 Placenta 0.4 Colon cancer tissue 3.4 Uterus Pool 0.0 Colon ca. SW1116 100.0 Ovarian ca. 0.1 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 0.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 0.4 OVCAR-4 Ovarian ca. 0.9 Small Intestine Pool 0.6 OVCAR-5 Ovarian ca. 3.4 Stomach Pool 0.3 IGROV-1 Ovarian ca. 5.1 Bone Marrow Pool 0.0 OVCAR-8 Ovary 0.2 Fetal Heart 0.0 Breast ca. MCF-7 0.0 Heart Pool 0.3 Breast ca. MDA- 6.1 Lymph Node Pool 0.6 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.2 Breast ca. T47D 1.7 Skeletal Muscle Pool 0.4 Breast ca. MDA-N 0.0 Spleen Pool 2.7 Breast Pool 0.2 Thymus Pool 0.7 Trachea 1.1 CNS cancer 6.4 (glio/astro) U87-MG Lung 0.2 CNS cancer 2.1 (glio/astro) U-118-MG Fetal Lung 0.6 CNS cancer 0.2 (neuro; met) SK-N-AS Lung ca. NCI-N417 1.3 CNS cancer (astro) 2.4 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 2.9 SNB-75 Lung ca. NCI-H146 0.4 CNS cancer (glio) 4.1 SNB-19 Lung ca. SHP-77 2.7 CNS cancer (glio) SF- 14.2 295 Lung ca. A549 1.4 Brain (Amygdala) 55.5 Pool Lung ca. NCI-H526 3.2 Brain (cerebellum) 10.6 Lung ca. NCI-H23 3.3 Brain (fetal) 21.2 Lung ca. NCI-H460 17.4 Brain (Hippocampus) 20.7 Pool Lung ca. HOP-62 5.1 Cerebral Cortex Pool 14.4 Lung ca. NCI-H522 3.2 Brain (Substantia 47.0 nigra) Pool Liver 0.0 Brain (Thalamus) Pool 36.1 Fetal Liver 0.0 Brain (whole) 18.9 Liver ca. HepG2 0.0 Spinal Cord Pool 18.8 Kidney Pool 0.2 Adrenal Gland 0.8 Fetal Kidney 0.5 Pituitary gland Pool 0.0 Renal ca. 786-0 2.0 Salivary Gland 0.2 Renal ca. A498 0.4 Thyroid (female) 0.0 Renal ca. ACHN 0.3 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.5

[0584] TABLE-US-00129 TABLE ED Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4235, Run Ag4235, Run Tissue Name 175226633 Tissue Name 175226633 Secondary Th1 act 3.0 HUVEC IL-1beta 0.0 Secondary Th2 act 9.9 HUVEC IFN gamma 0.0 Secondary Tr1 act 3.8 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 16.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 21.3 HUVEC IL-11 0.0 Secondary Tr1 rest 18.2 Lung Microvascular EC 0.0 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 5.4 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 6.0 EC TNF alpha + IL-1beta Primary Th1 rest 1.9 Bronchial epithelium 0.0 TNF alpha + IL1beta Primary Th2 rest 1.6 Small airway epithelium 2.9 none Primary Tr1 rest 5.5 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 1.2 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.0 Coronery artery SMC 2.1 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 5.8 Astrocytes rest 5.5 Secondary CD8 3.0 Astrocytes TNF alpha + IL- 13.6 lymphocyte rest 1beta Secondary CD8 26.2 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 3.8 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 24.1 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 1.3 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 19.8 Liver cirrhosis 0.0 LAK cells IL-2 + IL-12 0.0 NCI-H292 none 1.2 LAK cells IL-2 + IFN 10.2 NCI-H292 IL-4 0.0 gamma LAK cells IL-2 + IL-18 1.5 NCI-H292 IL-9 0.8 LAK cells 1.3 NCI-H292 IL-13 0.0 PMA/ionomycin NK Cells IL-2 rest 13.3 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 3.5 HPAEC none 0.0 Two Way MLR 5 day 2.0 HPAEC TNF alpha + IL- 0.0 1beta Two Way MLR 7 day 3.3 Lung fibroblast none 1.9 PBMC rest 18.8 Lung fibroblast TNF 17.7 alpha + IL-1beta PBMC PWM 4.9 Lung fibroblast IL-4 3.3 PBMC PHA-L 1.4 Lung fibroblast IL-9 3.9 Ramos (B cell) none 0.0 Lung fibroblast IL-13 4.8 Ramos (B cell) 0.0 Lung fibroblast IFN 2.6 ionomycin gamma B lymphocytes PWM 0.0 Dermal fibroblast 1.3 CCD1070 rest B lymphocytes CD40L 1.9 Dermal fibroblast 2.7 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 15.4 Dermal fibroblast 0.0 CCD1070 IL-1beta EOL-1 dbcAMP 18.8 Dermal fibroblast IFN 0.5 PMA/ionomycin gamma Dendritic cells none 0.0 Dermal fibroblast IL-4 3.8 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 0.0 Dendritic cells anti- 0.0 Neutrophils TNFa + LPS 28.9 CD40 Monocytes rest 12.9 Neutrophils rest 56.3 Monocytes LPS 0.0 Colon 5.4 Macrophages rest 5.1 Lung 10.9 Macrophages LPS 1.6 Thymus 27.0 HUVEC none 0.0 Kidney 100.0 HUVEC starved 0.0

[0585] TABLE-US-00130 TABLE EE Panel CNS_1 Rel. Exp.(%) Rel. Exp.(%) Ag4235, Ag4235, Run Run Tissue Name 181012601 Tissue Name 181012601 BA4 Control 7.1 BA17 PSP 10.3 BA4 Control2 17.3 BA17 PSP2 3.6 BA4 7.0 Sub Nigra Control 11.7 Alzheimer's2 BA4 Parkinson's 16.3 Sub Nigra Control2 7.5 BA4 64.2 Sub Nigra 4.3 Parkinson's2 Alzheimer's2 BA4 13.2 Sub Nigra 22.7 Huntington's Parkinson's2 BA4 8.2 Sub Nigra 43.5 Huntington's2 Huntington's BA4 PSP 7.1 Sub Nigra 6.5 Huntington's2 BA4 PSP2 9.0 Sub Nigra PSP2 5.6 BA4 Depression 100.0 Sub Nigra 2.7 Depression BA4 5.8 Sub Nigra 0.8 Depression2 Depression2 BA7 Control 12.2 Glob Palladus 7.6 Control BA7 Control2 22.8 Glob Palladus 6.9 Control2 BA7 3.5 Glob Palladus 4.5 Alzheimer's2 Alzheimer's BA7 Parkinson's 17.7 Glob Palladus 7.8 Alzheimer's2 BA7 27.7 Glob Palladus 54.0 Parkinson's2 Parkinson's BA7 21.6 Glob Palladus 5.5 Huntington's Parkinson's2 BA7 22.2 Glob Palladus PSP 5.4 Huntington's2 BA7 PSP 9.2 Glob Palladus PSP2 3.4 BA7 PSP2 6.7 Glob Palladus 0.5 Depression BA7 Depression 5.2 Temp Pole Control 8.5 BA9 Control 7.6 Temp Pole Control2 27.0 BA9 Control2 29.1 Temp Pole 4.6 Alzheimer's BA9 9.4 Temp Pole 5.6 Alzheimer's Alzheimer's2 BA9 4.5 Temp Pole 15.4 Alzheimer's2 Parkinson's BA9 Parkinson's 21.5 Temp Pole 24.0 Parkinson's2 BA9 17.1 Temp Pole 21.5 Parkinson's2 Huntington's BA9 14.1 Temp Pole PSP 4.0 Huntington's BA9 15.9 Temp Pole PSP2 3.9 Huntington's2 BA9 PSP 7.3 Temp Pole 13.8 Depression2 BA9 PSP2 2.2 Cing Gyr Control 15.6 BA9 Depression 5.5 Cing Gyr Control2 14.9 BA9 4.7 Cing Gyr 5.6 Depression2 Alzheimer's BA17 Control 15.7 Cing Gyr 6.6 Alzheimer's2 BA17 Control2 18.0 Cing Gyr 18.7 Parkinson's BA17 5.9 Cing Gyr 20.9 Alzheimer's2 Parkinson's2 BA17 25.9 Cing Gyr 30.4 Parkinson's Huntington's BA17 24.0 Cing Gyr 8.0 Parkinson's2 Huntington's2 BA17 17.4 Cing Gyr PSP 6.3 Huntington's BA17 14.6 Cing Gyr PSP2 0.4 Huntington's2 BA17 8.9 Cing Gyr 5.8 Depression Depression BA17 15.8 Cing Gyr 10.1 Depression2 Depression2

[0586] TABLE-US-00131 TABLE EF general oncology screening panel_v_2.4 Rel. Exp.(%) Rel. Exp.(%) Ag4235, Ag4235, Run Run Tissue Name 268624980 Tissue Name 268624980 Colon cancer 1 13.6 Bladder cancer NAT 2 0.0 Colon NAT 1 4.0 Bladder cancer NAT 3 0.0 Colon cancer 2 5.7 Bladder cancer NAT 4 12.1 Colon cancer 0.0 Adenocarcinoma of the 13.4 NAT 2 prostate 1 Colon cancer 3 4.1 Adenocarcinoma of the 29.7 prostate 2 Colon cancer 4.5 Adenocarcinoma of the 96.6 NAT 3 prostate 3 Colon malignant 9.0 Adenocarcinoma of the 5.8 cancer 4 prostate 4 Colon normal 0.0 Prostate cancer NAT 5 5.2 adjacent tissue 4 Lung cancer 1 12.4 Adenocarcinoma of the 13.2 prostate 6 Lung NAT 1 7.5 Adenocarcinoma of the 41.8 prostate 7 Lung cancer 2 3.3 Adenocarcinoma of the 12.2 prostate 8 Lung NAT 2 18.6 Adenocarcinoma of the 27.9 prostate 9 Squamous cell 9.1 Prostate cancer NAT 5.6 carcinoma 3 10 Lung NAT 3 0.0 Kidney, cancer 1 13.8 metastatic 2.3 KidneyNAT 1 7.3 Melanoma 1 Melanoma 2 0.0 Kidney cancer 2 100.0 Melanoma 3 0.0 Kidney NAT 2 9.0 metastatic 10.7 Kidney cancer 3 18.6 melanoma 4 metastatic 8.1 Kidney NAT 3 0.0 melanoma 5 Bladder cancer 1 0.0 Kidney cancer 4 52.9 Bladder cancer 0.0 Kidney NAT 4 0.0 NAT 1 Bladder cancer 2 9.5

[0587] CNS_neurodegeneration_v1.0 Summary: Ag4235 Two experiments with same probe and primer sets are in excellent agreements. These results confirm the expression of the NOV7A gene at moderate to low levels in the brain in an independent group of individuals. This gene is downregulated in the temporal cortex of Alzheimer's disease patients when compared with non-demented controls (p=0.0024; p=0.01 when analyzed by Ancova, estimate of total cDNA loaded per well used asa covariate). Thus, therapeutic modulation of this gene or its protein product, may be of use in reversing the dementia, memory loss, and neuronal death associated with this disease.

[0588] General_screening_panel_v1.4 Summary: Ag4235 Highest expression of the NOV7A gene is seen in a colon cancer cell line (CT=28.6). Moderate levels of expression are also seen in cell lines derived from brain cancer, lung cancer, ovarian cancer, breast cancer, and melanoma. Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of colon cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, brain, lung, ovarian, breast and melanoma cancers.

[0589] This gene is prominently expressed at high to moderate levels in all regions of the CNS examined, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. This gene encodes a protein with homology to netrins, a family of soluble chemotropic factors that have been implicated in axon guidance and neuron survival during development. (Llambi F. EMBO J. 20 (11):2715-22; Braisted J E, J. Neurosci. 20:5792-801) Netrin may be involved in the regenerative capacity of adult retinal ganglion cells (Ellezam B. Exp Neurol 168 (1):105-15) Therefore, therapeutic modulation of the expression or function of this gene product may be of use in enhancing or directing compensatory synatogenesis and axon/dendritic outgrowth in response to neuronal death (stroke, head trauma) neurodegeneration (Alzheiemr's, Parkinson's, Huntington's, spinocerebellar ataxia, progressive supranuclear palsy) or spinal cord injury.

[0590] Among tissues with metabolic function, this gene is expressed at low but significant levels in adipose, adrenal gland, pancreas, and skeletal muscle. This expression suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0591] Panel 4.1D Summary: Ag4235 Highest expression of the NOV7A gene is seen in the kidney (CT=31.3). Low but significant levels of expression of this gene are also seen in other samples, including resting and activated neutrophils and eosinophils, TNF-alpha and IL-1 beta activated lung fibroblasts and astrocytes, resting PBMCs, monocytes, and chronically stimulated T cells, and normal thymus and lung. This expression profile suggests that this gene product may be involved in kidney function and in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.

[0592] Panel CNS.sub.--1 Summary: Ag4235 This panel confirms the presence of the CG102221-021 gene in the brain, with highest expression in Brodman Area 4 of a patient with depression (CT=30.4). Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0593] general oncology screening panel_v.sub.--2.4 Summary: Ag4235 Highest expression of the NOV7A gene is seen in kidney cancer (CT=33.8). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of kidney cancer. This gene is also expressed at a low level in prostate cancer compared to normal prostate.

[0594] It may be used as a diagnostic marker of kidney and prostate cancer and therapeutic modulation of the activity of the protein may be useful in the treatment of these cancers.

[0595] F. NOV8A: Secreted Reprolysin

[0596] Expression of gene NOV8A was assessed using the primer-probe set Ag4236, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB, FC, FD and FE. TABLE-US-00132 TABLE FA Probe Name Ag4236 Start SEQ ID Primers Sequences Length Position No Forward 5'-ggcagggatgaaactgtca-3' 19 775 142 Probe TET-5'-ccttggccccaatgtagagaacactg-3'- 26 812 143 TAMRA Reverse 5'-ctcccgtgacatacactttgac-3' 22 853 144

[0597] TABLE-US-00133 TABLE FB General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4236, Ag4236, Run Run Tissue Name 222100995 Tissue Name 222100995 Adipose 13.7 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 21.2 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 43.8 Gastric ca. KATO III 44.1 Melanoma* 0.0 Colon ca. SW-948 12.8 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 100.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 11.9 carcinoma SCC-4 met) SW620 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone 19.2 Colon ca. HCT-116 18.2 met) PC-3 Prostate Pool 0.0 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 37.4 OVCAR-3 Ovarian ca. SK- 40.3 Colon ca. SW-48 3.3 OV-3 Ovarian ca. 4.3 Colon Pool 0.0 OVCAR-4 Ovarian ca. 12.2 Small Intestine Pool 11.6 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.0 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 7.8 OVCAR-8 Ovary 5.6 Fetal Heart 0.0 Breast ca. MCF-7 12.7 Heart Pool 0.0 Breast ca. MDA- 0.0 LymPh Node Pool 11.3 MB-231 Breast ca. BT 549 3.8 Fetal Skeletal Muscle 5.1 Breast ca. T47D 12.9 Skeletal Muscle Pool 29.3 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 9.2 Thymus Pool 20.6 Trachea 11.3 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 15.3 CNS cancer 7.9 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 13.3 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 42.6 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) 0.0 SF-295 Lung ca. A549 0.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 7.3 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 0.0 Brain (Substantia 5.4 nigra) Pool Liver 0.0 Brain (Thalamus) Pool 9.5 Fetal Liver 0.0 Brain (whole) 0.0 Liver ca. HepG2 0.0 Spinal Cord Pool 11.1 Kidney Pool 22.2 Adrenal Gland 5.8 Fetal Kidney 0.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 12.2 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 2.1 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 12.3

[0598] TABLE-US-00134 TABLE FC General_screening_panel_v1.6 Rel. Exp.(%) Rel. Ag4236, Run Exp.(%) Ag4236, Run Tissue Name 277231326 Tissue Name 277231326 Adipose 11.5 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 10.1 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 30.8 Gastric ca. KATO III 50.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 39.0 Colon ca. SW480 100.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 18.6 carcinoma SCC-4 met) SW620 Testis Pool 0.0 Colon ca. HT29 10.3 Prostate ca.* (bone 45.4 Colon ca. HCT-116 27.0 met) PC-3 Prostate Pool 5.5 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 3.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 20.9 OVCAR-3 Ovarian ca. SK- 41.8 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 5.9 Colon Pool 6.0 OVCAR-4 Ovarian ca. 26.8 Small Intestine Pool 9.6 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 24.7 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 5.5 OVCAR-8 Ovary 21.6 Fetal Heart 0.0 Breast ca. MCF-7 5.8 Heart Pool 8.6 Breast ca. MDA- 10.1 Lymph Node Pool 7.2 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.0 Breast ca. T47D 0.0 Skeletal Muscle Pool 20.9 Breast ca. MDA-N 0.0 Spleen Pool 12.4 Breast Pool 9.0 Thymus Pool 21.0 Trachea 2.9 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 17.2 CNS cancer 5.9 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) SF- 0.0 539 Lung ca. LX-1 17.3 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 14.7 CNS cancer (glio) 3.9 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 0.0 295 Lung ca. A549 10.7 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 4.4 Brain (cerebellum) 9.9 Lung ca. NCI-H23 0.0 Brain (fetal) 7.0 Lung ca. NCI-H460 7.2 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 0.0 Brain (Substantia 6.2 nigra) Pool Liver 0.0 Brain (Thalamus) Pool 4.6 Fetal Liver 0.0 Brain (whole) 9.7 Liver ca. HepG2 0.0 Spinal Cord Pool 3.9 Kidney Pool 6.2 Adrenal Gland 5.4 Fetal Kidney 5.6 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 5.3 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 18.6

[0599] TABLE-US-00135 TABLE FD Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4236, Run Ag4236, Run Tissue Name 175226753 Tissue Name 175226753 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 5.3 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 1.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 2.8 Microsvasular Dermal 0.0 EC none Primary Tr1 act 1.2 Microsvasular Dermal 0.9 EC TNF alpha + IL-1beta Primary Th1 rest 1.4 Bronchial epithelium 0.0 TNF alpha + IL1beta Primary Th2 rest 4.0 Small airway epithelium 0.0 none Primary Tr1 rest 12.5 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 1.9 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 5.1 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 1.5 LAK cells IL-2 + IL-12 0.0 NCI-H292 none 0.0 LAK cells IL-2 + IFN 1.8 NCI-H292 IL-4 0.0 gamma LAK cells IL-2 + IL-18 9.2 NCI-H292 IL-9 0.0 LAK cells 0.0 NCI-H292 IL-13 0.0 PMA/ionomycin NK Cells IL-2 rest 2.5 NCI-H292 IFN gamma 3.3 Two Way MLR 3 day 1.9 HPAEC none 0.0 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 PBMC rest 4.3 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PWM 2.3 Lung fibroblast IL-4 0.0 PBMC PHA-L 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-13 3.4 Ramos (B cell) 0.0 Lung fibroblast IFN 2.1 ionomycin gamma B lymphocytes PWM 0.0 Dermal fibroblast 0.0 CCD1070 rest B lymphocytes CD40L 0.0 Dermal fibroblast 0.0 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 CCD1070 IL-1beta EOL-1 dbcAMP 0.0 Dermal fibroblast IFN 0.0 PMA/ionomycin gamma Dendritic cells non 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 0.0 Dendritic cells anti- 0.0 Neutrophils TNFa + LPS 0.0 CD40 Monocytes rest 0.0 Neutrophils rest 3.0 Monocytes LPS 0.0 Colon 0.8 Macrophages rest 0.0 Lung 1.1 Macrophages LPS 0.0 Thymus 20.9 HUVEC none 0.0 Kidney 100.0 HUVEC starved 0.0

[0600] TABLE-US-00136 TABLE FE general oncology screening panel_v_2.4 Rel. Exp.(%) Rel. Exp.(%) Ag4236, Ag4236, Run Run Tissue Name 268664312 Tissue Name 268664312 Colon cancer 1 44.4 Bladder cancer NAT 2 0.0 Colon cancer 0.0 Bladder cancer NAT 3 0.0 NAT 1 Colon cancer 2 0.0 Bladder cancer NAT 4 0.0 Colon cancer 0.0 Adenocarcinoma of the 34.6 NAT 2 prostate 1 Colon cancer 3 0.0 Adenocarcinoma of the 0.0 prostate 2 Colon cancer 0.0 Adenocarcinoma of the 0.0 NAT 3 prostate 3 Colon malignant 0.0 Adenocarcinoma of the 0.0 cancer 4 prostate 4 Colon normal 0.0 Prostate cancer NAT 5 20.6 adjacent tissue 4 Lung cancer 1 9.0 Adenocarcinoma of the 0.0 prostate 6 Lung NAT 1 0.0 Adenocarcinoma of the 0.0 prostate 7 Lung cancer 2 39.0 Adenocarcinoma of the 0.0 prostate 8 Lung NAT 2 19.2 Adenocarcinoma of the 0.0 prostate 9 Squamous cell 0.0 Prostate cancer NAT 0.0 carcinoma 3 10 Lung NAT 3 17.2 Kidney cancer 1 0.0 metastatic 0.0 KidneyNAT 1 0.0 melanoma 1 Melanoma 2 30.8 Kidney cancer 2 100.0 Melanoma 3 24.5 Kidney NAT 2 61.1 metastatic 17.3 Kidney cancer 3 0.0 melanoma 4 metastatic 48.0 Kidney NAT 3 0.0 melanoma 5 Bladder cancer 1 0.0 Kidney cancer 4 0.0 Bladder cancer 0.0 Kidney NAT 4 9.9 NAT 1 Bladder cancer 2 0.0

[0601] CNS_neurodegeneration_v1.0 Summary: Ag4236 Expression of the NOV8A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0602] General_screening_panel_v1.4 Summary: Ag4236 Highest expression of the NOV8A gene is detected in a colon cancer SW480 cell line (CT=33). In addition, low expression of this gene is also seen in a number of cancer cell lines including colon, gastric, lung, ovarian and melanoma cancer cell lines. Therefore, expression of this gene can be used as diagnostic markers for these cancers and also, therapeutic modulation of this gene product may be beneficial in the treatment of these cancers.

[0603] Low expression of this gene is also seen in skeletal muscle. Therefore, therapeutic modulation of this gene may be useful in the treatment of muscle related diseases.

[0604] General_screening_panel_v1.6 Summary: Ag4236 Highest expression of the NOV8A gene is detected in a colon cancer cell line (CT=33), in agreement with results in Panel 1.4. In addition, low but significant levels of expression are seen in melanoma, prostate, ovarian and gastric cancer cell lines. Therefore, expression of this gene may be useful as diagnostic marker for colon cancer and therapeutic modulation of this gene product may be beneficial in the treatment of these cancers.

[0605] Panel 4.1D Summary: Ag4236 Highest expression of the NOV8A gene is detected in kidney. Therefore, expression of this gene can be used to distinguish kidney sample from other samples used in this panel. In addition, low expression of this gene is also seen in thymus and resting primary Tr1 cells. Therefore, therapeutic modulation of this gene product may be useful in the treatment of autoimmune and inflammatory diseases that affect kidney including lupus and glomerulonephritis. Expression of this gene in a second experiment (run 268719696) is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0606] General oncology screening panel_v.sub.--2.4 Summary: Ag4236 Highest expression of the NOV8A gene is detected in kidney cancer sample (CT=34.7). Therefore, expression of this gene may be useful as diagnostic marker and therapeutic modulation of this gene product may be beneficial in the treatment of kidney cancer.

[0607] G. NOV9A and NOV9B: Ig-domain Containing Transmembrane Protein

[0608] Expression of gene NOV9A and variant NOV9B was assessed using the primer-probe sets Ag4244 and Ag4324, described in Tables GA and GB. Please note that NOV9A is recognized by primer-probe set Ag4244 only. Results of the RTQ-PCR runs are shown in Tables GC and GD. TABLE-US-00137 TABLE GA Probe Name Ag4244 Start SEQ ID Primers Srquences Length Position No Forward 5'-catggagactcccctttgac-3' 20 998 145 Probe TET-5'-cctgaaggaggtcaccatctcattga-3'- 26 1023 146 TAMRA Reverse 5'-cggatcttggacttcaatctc-3' 21 1063 147

[0609] TABLE-US-00138 TABLE GB Probe Name Ag4324 Start SEQ ID Primers Sequences Length Position No Forward 5'-tgggacaaagaaagagaccaa-3' 21 1149 148 Probe TET-5'-ttgctgacgcctgtgatcctcact-3' 24 1302 149 TAMRA Reverse 5'-caagggctgagtggagaag-3' 19 1344 150

[0610] TABLE-US-00139 TABLE GC General_screening_panel_v1.4 Rel. Exp.(%) Ag4244, Run Rel. Exp.(%) Ag4244, Run Tissue Name 222018688 Tissue Name 222018688 Adipose 3.2 Renal ca. TK-10 0.2 Melanoma* 0.0 Bladder 3.2 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 10.2 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 7.5 Colon ca. CaCo-2 0.0 Placenta 1.5 Colon cancer tissue 3.4 Uterus Pool 10.8 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 0.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 39.8 OVCAR-4 Ovarian ca. 0.0 Small Intestine Pool 38.7 OVCAR-5 Ovarian ca. 0.2 Stomach Pool 18.2 IGROV-1 Ovarian ca. 0.6 Bone Marrow Pool 22.8 OVCAR-8 Ovary 2.1 Fetal Heart 6.9 Breast ca. MCF-7 0.1 Heart Pool 22.4 Breast ca. MDA- 0.0 Lymph Node Pool 55.5 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 29.1 Breast ca. T47D 0.0 Skeletal Muscle Pool 44.8 Breast ca. MDA-N 0.0 Spleen Pool 0.7 Breast Pool 29.5 Thymus Pool 18.6 Trachea 7.3 CNS cancer 0.0 (glio/astro) U87-MG Lung 6.5 CNS cancer 0.8 (glio/astro) U-118-MG Fetal Lung 26.2 CNS cancer 10.7 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) SF- 0.0 539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.7 SNB-75 Lung ca. NCI-H146 0.9 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.6 CNS cancer (glio) SF- 0.0 295 Lung ca. A549 0.0 Brain (Amygdala) 0.2 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.4 Lung ca. NCI-H23 0.0 Brain (fetal) 1.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.3 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.1 Lung ca. NCI-H522 0.0 Brain (Substantia 0.2 nigra) Pool Liver 0.3 Brain (Thalamus) Pool 0.4 Fetal Liver 2.6 Brain (whole) 0.7 Liver ca. HepG2 0.0 Spinal Cord Pool 0.6 Kidney Pool 100.0 Adrenal Gland 2.3 Fetal Kidney 2.5 Pituitary gland Pool 0.7 Renal ca. 786-0 0.1 Salivary Gland 0.9 Renal ca. A498 0.2 Thyroid (female) 3.1 Renal ca. ACHN 0.2 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 58.6

[0611] TABLE-US-00140 TABLE GD General oncology screening panel_v_2.4 Rel. Exp.(%) Rel. Exp.(%) Ag4244, Ag4244, Run Run Tissue Name 268664319 Tissue Name 268664319 Colon cancer 1 1.0 Bladder cancer NAT 2 0.0 Colon NAT 1 3.8 Bladder cancer NAT 3 0.0 Colon cancer 2 0.4 Bladder cancer NAT 4 1.0 Colon cancer 1.5 Adenocarcinoma of the 0.1 NAT 2 prostate 1 Colon cancer 3 0.6 Adenocarcinoma of the 0.2 prostate 2 Colon cancer 8.0 Adenocarcinoma of the 0.5 NAT 3 prostate 3 Colon malignant 0.2 Adenocarcinoma of the 0.3 cancer 4 prostate 4 Colon normal 0.5 Prostate cancer NAT 5 1.2 adjacent tissue 4 Lung cancer 1 0.1 Adenocarcinoma of the 0.1 prostate 6 Lung NAT 1 0.1 Adenocarcinoma of the 0.0 prostate 7 Lung cancer 2 1.8 Adenocarcinoma of the 0.1 prostate 8 Lung NAT 2 1.1 Adenocarcinoma of the 2.8 prostate 9 Squamous cell 0.9 Prostate cancer NAT 0.1 carcinoma 3 10 Lung NAT 3 0.0 Kidney cancer 1 1.4 metastatic 0.8 KidneyNAT 1 0.5 melanoma 1 Melanoma 2 0.4 Kidney cancer 2 2.0 Melanoma 3 0.3 Kidney NAT 2 100.0 metastatic 2.4 Kidney cancer 3 0.4 melanoma 4 metastatic 1.1 Kidney NAT 3 0.6 melanoma 5 Bladder cancer 1 0.1 Kidney cancer 4 0.7 Bladder cancer 0.0 Kidney NAT 4 0.3 NAT 1 Bladder cancer 2 0.1

[0612] CNS_neurodegeneration_v1.0 Summary: Ag4244/Ag4324 Expression of this gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)

[0613] General_screening_panel_v1.4 Summary: Ag4244 Highest expression of the NOV9A gene is seen in the kidney (CT=28.3). Expression in fetal kidney is significantly lower (CT=33). Thus, expression of this gene could be used to differentiate between fetal and adult kidney. Overall, this gene appears to be expressed in normal tissues and may be involved in the normal function of the kidney.

[0614] Among tissues with metabolic function, this gene is expressed at moderate to low levels in adipose, adrenal gland, pancreas, thyroid, fetal liver and adult and fetal skeletal muscle and heart. This expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0615] A second experiment with the probe and primer set Ag4324, which is specific to NOV9B, shows low/undetectable levels of expression (CTs>35). (Data not shown.)

[0616] General oncology screening panel_V.sub.--2.4 Summary: Ag4244 Highest expression of the NOV9A gene is seen in the kidney (CT=26.7). This expression is consistent with expression seen in the previous panels. Thus, expression of this gene could be used as a marker of kidney tissue.

[0617] H. NOV10A and NOV10B: Novel Lipocalin 2

[0618] Expression of gene NOV10A and variant NOV10B was assessed using the primer-probe sets Ag4254 and Ag6132, described in Tables HA and HB. Results of the RTQ-PCR runs are shown in Tables HC, HD and HE. Please note that NOV10B represents a full-length physical clone, validating the prediction of the gene sequence. TABLE-US-00141 TABLE HA Probe Name Ag4254 Start SEQ ID Primers Sequences Length Position No Forward 5'cttcatccgcttctccaaat-3' 20 516 151 Probe TET-5'-cctgaaaaccacatcgtcttccctgt-3'- 26 547 152 TAMRA Reverse 5'-ctcatccagactggccattac-3' 21 581 153

[0619] TABLE-US-00142 TABLE HB Probe Name Ag6132 Start SEQ ID Primers Sequences Length Position No Forward 5'-ggagaacttcatccgcttct-3' 20 510 154 Probe TET-5'-cctgaaaaccacatcgtcttccctgt-3'- 26 547 155 TAMRA Reverse 5'-ctcatccagactggccattac-3'21 581 156

[0620] TABLE-US-00143 TABLE HC A1_comprehensive panel_v1.0 Rel. Exp.(%) Ag6132, Run Rel. Exp.(%) Ag6132, Run Tissue Name 255326117 Tissue Name 255326117 110967 COPD-F 1.0 112427 Match Control 0.5 Psoriasis-F 110980 COPD-F 0.0 112418 Psoriasis-M 0.0 110968 COPD-M 0.0 112723 Match Control 0.0 Psoriasis-M 110977 COPD-M 1.9 112419 Psoriasis-M 0.4 110989 Emphysema-F 0.0 112424 Match Control 0.0 Psoriasis-M 110992 Emphysema-F 0.9 112420 Psoriasis-M 1.4 110993 Emphysema-F 0.0 112425 Match Control 0.8 Psoriasis-M 110994 Emphysema-F 0.0 104689 (MF) OA 0.0 Bone-Backus 110995 Emphysema-F 2.8 104690 (MF) Adj 0.0 "Normal" Bone- Backus 110996 Emphysema-F 0.0 104691 (MF) OA 0.0 Synovium-Backus 110997 Asthma-M 4.1 104692 (BA) OA 0.0 Cartilage-Backus 111001 Asthma-F 0.0 104695 (BA) OA 1.8 Bone Backus 111002 Asthma-F 0.8 104695 (BA) Adj 0.0 "Normal" Bone- Backus 111003 Atopic 0.0 104696 (BA) OA 0.0 Asthma-F Synovium-Backus 111004 Atopic 1.6 104700 (SS) OA 27.4 Asthma-F Bone-Backus 111005 Atopic 0.0 104701 (SS) Adj 1.2 Asthma-F "Normal" Bone- Backus 111006 Atopic 0.0 104702 (SS) OA 1.0 Asthma-F Synovium-Backus 111417 Allergy-M 0.0 117093 OA Cartilage 0.9 Rep7 112347 Allergy-M 0.3 112672 OA Bone5 0.0 112349 Normal 0.3 112673 OA 0.0 Lung-F Synovium5 112357 Normal 0.0 112674 OA Synovial 0.0 Lung-F Fluid cells5 112354 Normal 0.0 117100 OA Cartilage 0.0 Lung-M Rep14 112374 Crohns-F 0.0 112756 OA Bone9 0.0 112389 Match 100.0 112757 OA 0.0 Control Crohns-F Synovium9 112375 Crohns-F 0.0 112758 OA Synovial 0.0 Fluid Cells9 112732 Match 28.3 117125 RA Cartilage 0.8 Control Crohns-F Rep2 112725 Crohns-M 0.9 113492 Bone2 RA 9.6 112387 Match 0.0 113493 Synovium2 1.5 Control Crohns-M RA 112378 Crohns-M 0.4 113494 Syn Fluid 2.4 Cells RA 112390 Match 0.0 113499 Cartilage4 RA 0.0 Control Crohns-M 112726 Crohns-M 0.0 113500 Bone4 RA 0.9 112731 Match 9.0 113501 Synovium4 0.0 Control Crohns-M RA 112380 Ulcer Col-F 0.0 113502 Syn Fluid 1.0 Cells4 RA 112734 Match 98.6 113495 Cartilage3 RA 0.9 Control Ulcer Col-F 112384 Ulcer Col-F 0.5 113496 Bone3 RA 1.4 112737 Match 0.0 113497 Synovium3 2.3 Control Ulcer Col-F RA 112386 Ulcer Col-F 0.0 113498 Syn Fluid 2.9 Cells3 RA 112738 Match 16.3 117106 Normal 0.0 Control Ulcer Col-F Cartilage Rep20 112381 Ulcer Col-M 0.0 113663 Bone3 Normal 1.1 112735 Match 0.0 113664 Synovium3 0.0 Control Ulcer Col-M Normal 112382 Ulcer Col-M 16.4 113665 Syn Fluid 0.0 Cells3 Normal 112394 Match 0.0 117107 Normal 0.0 Control Ulcer Col-M Cartilage Rep22 112383 Ulcer Col-M 5.1 113667 Bone4 Normal 0.3 112736 Match 30.4 113668 Synovium4 1.2 Control Ulcer Col-M Normal 112423 Psoriasis-F 0.0 113669 Syn Fluid 5.8 Cells4 Normal

[0621] TABLE-US-00144 TABLE HD General_screening_panel_v1.6 Rel. Exp.(%) Rel. Exp.(%) Ag6132, Ag6132, Run Run Tissue Name 277231849 Tissue Name 277231849 Adipose 0.0 Renal ca. TK-10 3.7 Melanoma* 0.0 Bladder 6.1 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 100.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 4.4 Melanoma* 0.0 Colon ca. SW-948 0.2 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 1.0 MEL-5 Squamous cell 3.3 Colon ca.* (SW480 0.1 carcinoma SCC-4 met) SW620 Testis Pool 0.1 Colon ca. HT29 1.7 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.1 met) PC-3 Prostate Pool 0.1 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 30.6 Uterus Pool 0.2 Colon ca. SW1116 0.0 Ovarian ca. 0.2 Colon ca. Colo-205 0.1 OVCAR-3 Ovarian ca. SK- 0.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 0.0 OVCAR-4 Ovarian ca. 21.9 Small Intestine Pool 0.2 Renal ca. ACHN 0.0 Pancreatic ca. 14.9 CAPAN2 Renal ca. UO-31 1.7 Pancreas Pool 1.5

[0622] TABLE-US-00145 TABLE HE Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag6132, Run Ag6132, Run Tissue Name 254398390 Tissue Name 254398390 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.0 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.0 Bronchial epithelium 5.8 TNF alpha + IL1beta Primary Th2 rest 0.0 Small airway epithelium 14.2 none Primary Tr1 rest 0.0 Small airway epithelium 100.0 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 0.0 Astrocytes TNF alpha + IL- 1.9 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.5 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 3.5 LAK cells IL-2 + IL-12 0.0 NCI-H292 none 23.2 LAK cells IL-2 + IFN 0.0 NCI-H292 IL-4 15.2 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-9 29.1 LAK cells 0.0 NCI-H292 IL-13 26.4 PMA/ionomycin NK Cells IL-2 rest 0.0 NCI-H292 IFN gamma 2.9 Two Way MLR 3 day 0.0 HPAEC none 0.0 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 PBMC rest 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PWM 0.0 Lung fibroblast IL-4 0.0 PBMC PHA-L 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-13 0.0 Ramos (B cell) 0.0 Lung fibroblast IFN 0.0 ionomycin gamma B lymphocytes PWM 0.0 Dermal fibroblast 0.0 CCD1070 rest B lymphocytes CD40L 0.0 Dermal fibroblast 0.0 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.8 Dermal fibroblast 0.0 CCD1070 IL-1beta EOL-1 dbcAMP 0.0 Dermal fibroblast IFN 0.0 PMA/ionomycin gamma Dendritic cells none 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 0.0 Dendritic cells anti- 0.0 Neutrophils TNFa + LPS 0.0 CD40 Monocytes rest 0.0 Neutrophils rest 0.0 Monocytes LPS 0.0 Colon 0.0 Macrophages rest 0.0 Lung 0.0 Macrophages LPS 0.0 Thymus 0.0 HUVEC none 0.0 Kidney 0.4 HUVEC starved 0.0

[0623] AI_comprehensive_panel_v1.0 Summary: Ag6132 Highest expression of the NOV10A gene is detected in match Crohns and ulcerative colitis control samples (CTs=30.4). Interestingly, expression of this gene is higher in the matched control colon samples as compared to diseased (Crohns and ulcerative colitis) samples. Low expression of this gene is also seen in synovial fluid, bone sample from orthoarthritis and rheumatide arthritis patients. Therefore, therapeutic modulation of this gene may be beneficial in the treatment of inflammatory bowel diseases and arthritis.

[0624] The NOV10A gene codes for a variant of neutrophil gelatinase-associated lipocalin precursor (NGAL). NGAL is a 25-kDa lipocalin originally purified from human neutrophils. Besides neutrophils, NGAL is expressed in most tissues normally exposed to microorganisms, and its synthesis is induced in epithelial cells during inflammation (Kjeldsen et al., 2000, Biochim Biophys Acta 1482(1-2):272-83, PMID: 11058768). Thus, NGAL may serve an important anti-inflammatory function as a scavenger of bacterial products.

[0625] CNS_neurodegeneration_v1.0 Summary: Ag4254 Expression of the NOV10A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0626] General_screening_panel_v1.4 Summary: Ag4254 Expression of the NOV10A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0627] General_screening_panel_v1.6 Summary: Ag6132 Expression of this gene appears to be associated with cancer cell lines in this panel, with highest expression in a gastric cancer cell line (CT=26.3). Moderate levels of expression are also seen in cell lines derived from pancreatic, colon, ovarian and squamous cell cancers. Thus, expression of this gene could be used to differentiate between the gastric cancer cell line and other samples on this panel and as a marker of gastric cancer. Furthermore, therapeutic modulation of the expression or function of this protein may be effective in the treatment of gastric, pancreatic, colon, ovarian and squamous cell cancers.

[0628] Panel 4.1D Summary: Ag6132 Highest expression of the NOV10A gene is detected in TNFalpha+IL-1beta treated small airway epithelium (CTs=30.4). In addition, significant expression of this gene is also seen in resting and cytokine treated NCI-H292 cells, a human airway epithelial cell line that produces mucins and TNFalpha+IL1beta treated bronchial epithelium. Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. Therefore, therapeutics designed with the protein encoded by the gene may reduce or eliminate symptoms caused by inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema. Please see AI_comprehensive panel_v1.0 for further discussion of the potential utility of this gene.

[0629] Ag4254 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0630] General oncology screening panel_v.sub.--2.4 Summary: Ag4254 Expression of the NOV10A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0631] I. NOV11A: DENN Domain Containing Protein

[0632] Expression of gene NOV11A was assessed using the primer-probe set Ag4266, described in Table IA. Results of the RTQ-PCR runs are shown in Table IB. TABLE-US-00146 TABLE IA Probe Name Ag4266 Start SEQ ID Primers Sequences Length Position No Forward 5'-cctttgacgttgaaaggtacag-3' 22 167 157 Probe TET-5'-tcaagttggacagcactttacctttg-3'- 26 195 158 TAMRA Reverse 5'-tctgcagaatccaaatctctgt-3' 22 243 159

[0633] TABLE-US-00147 TABLE IB CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Exp.(%) Ag4266, Run Ag4266, Run Tissue Name 224076199 Tissue Name 224076199 AD 1 Hippo 0.0 Control (Path) 3 13.6 Temporal Ctx AD 2 Hippo 17.2 Control (Path) 4 25.7 Temporal Ctx AD 3 Hippo 7.8 AD 1 Occipital 9.5 Ctx AD 4 Hippo 5.8 AD 2 Occipital 0.0 Ctx (Missing) AD 5 hippo 23.2 AD 3 Occipital 12.6 Ctx AD 6 Hippo 100.0 AD 4 Occipital 13.0 Ctx Control 2 Hippo 2.3 AD 5 Occipital 33.2 Ctx Control 4 Hippo 12.2 AD 6 Occipital 6.3 Ctx Control (Path) 3 4.0 Control 1 0.0 Hippo Occipital Ctx AD 1 Temporal Ctx 10.3 Control 2 19.2 Occipital Ctx AD 2 Temporal Ctx 8.7 Control 3 7.9 Occipital Ctx AD 3 Temporal Ctx 3.9 Control 4 3.9 Occipital Ctx AD 4 Temporal Ctx 12.0 Control (Path) 1 9.2 Occipital Ctx AD 5 Inf Temporal 47.6 Control (Path) 2 5.8 Ctx Occipital Ctx AD 5 SupTemporal 21.9 Control (Path) 3 0.0 Ctx Occipital Ctx AD 6 Inf Temporal 60.7 Control (Path) 4 2.6 Ctx Occipital Ctx AD 6 Sup Temporal 60.7 Control 1 Parietal 13.1 Ctx Ctx Control 1 Temporal 0.0 Control 2 Parietal 24.3 Ctx Ctx Control 2 Temporal 2.6 Control 3 Parietal 11.0 Ctx Ctx Control 3 Temporal 15.8 Control (Path) 1 7.7 Ctx Parietal Ctx Control 4 Temporal 0.0 Control (Path) 2 18.7 Ctx Parietal Ctx Control (Path) 1 13.8 Control (Path) 3 5.0 Temporal Ctx Parietal Ctx Control (Path) 2 18.7 Control (Path) 4 23.0 Temporal Ctx Parietal Ctx

[0634] CNS_neurodegeneration_v1.0 Summary: Ag4266 This panel confirms the expression of the NOV11A gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Atzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Low expression of this gene in the brain suggests that this gene may play a role in central nervous system and therapeutic modulation of this gene product may be useful in the treatment of CNS disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0635] General_screening_panel_v1.4 Summary: Ag4266 Expression of the NOV11A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0636] Panel 4.1D Summary: Ag4266 Expression of the NOV11A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0637] J. NOV12A and NOV12F: Kininogen Precursor

[0638] Expression of gene NOV12A and variant NOV12F was assessed using the primer-probe sets Ag3374, Ag4279 and Ag5114, described in Tables JA, JB and JC. The NOV12A gene is recognized by primer-probe sets Ag3374 and Ag4279, whereas variant NOV12F is recognized by primer-probe sets Ag3374 and Ag5114. Results of the RTQ-PCR runs are shown in Tables JD, JE, JF, and JG. TABLE-US-00148 TABLE JA Probe Name Ag3374 Start SEQ ID Primers Sequences Length Position No Forward 5'gattgcaacgctgaagtttatg-3' 22 961 160 Probe TET-5'-ctgtcaactgtcaaccactgggaatg-3'- 26 1013 161 TAMRA Reverse 5'-gaggccttttcatcagtgagat-3' 22 1039 162

[0639] TABLE-US-00149 TABLE JB Probe Name Ag4279 Start SEQ ID Primers Sequences Length Position No Forward 5'-aatcttcactccaggcacatag-3' 22 1209 163 Probe TET-5'-acctctgccagcaaccttgagagg-3'- 24 1239 164 Probe TAMRA Reverse 5'-tcccatctttcttcttgtcctt-3' 22 1263 165

[0640] TABLE-US-00150 TABLE JC Probe Name Ag5114 Start SEQ ID Primers Sequences Length Position No Forward 5'-acgcagagcccaggtttt-3' 18 364 166 Probe TET-5'-tcacctttccgatcatcacgaataggg-3'- 27 382 167 TAMRA Reverse 5'-cgcaggaccttaggtgactagt-3' 22 427 168

[0641] TABLE-US-00151 TABLE JD Panel 1.3D Rel. Exp.(%) Ag3374, Run Rel. Exp.(%) Ag3374, Run Tissue Name 165678152 Tissue Name 165678152 Liver adenocarcinoma 0.0 Kidney (fetal) 6.0 Pancreas 0.0 Renal ca. 786-0 0.0 Pancreatic ca. CAPAN 2 0.0 Renal ca. A498 0.0 Adrenal gland 0.0 Renal ca. RXF 393 0.0 Thyroid 0.0 Renal ca. ACHN 0.0 Salivary gland 0.0 Renal ca. UO-31 0.0 Pituitary gland 0.0 Renal ca. TK-10 0.0 Brain (fetal) 0.0 Liver 100.0 Brain (whole) 0.1 Liver (fetal) 32.1 Brain (amygdala) 0.0 Liver ca. 0.0 (hepatoblast) HepG2 Brain (cerebellum) 0.0 Lung 0.0 Brain (hippocampus) 0.0 Lung (fetal) 0.0 Brain (substantia nigra) 0.0 Lung ca. (small cell) 0.0 LX-1 Brain (thalamus) 0.0 Lung ca. (small cell) 0.0 NCI-H69 Cerebral Cortex 0.0 Lung ca. (s. cell var.) 0.0 SHP-77 Spinal cord 0.0 Lung ca. (large 0.0 cell)NCI-H460 glio/astro U87-MG 0.0 Lung ca. (non-sm. 0.0 cell) A549 glio/astro U-118-MG 0.0 Lung ca. (non-s. cell) 0.0 NCI-H23 astrocytoma SW1783 0.0 Lung ca. (non-s. cell) 0.0 HOP-62 neuro*; met SK-N-AS 0.0 Lung ca. (non-s. cl) 0.0 NCI-H522 astrocytoma SF-539 0.0 Lung ca. (squam.) 0.0 SW 900 astrocytoma SNB-75 0.0 Lung ca. (squam.) 0.0 NCI-H596 glioma SNB-19 0.0 Mammary gland 0.0 glioma U251 0.0 Breast ca.* (pl.ef) 0.0 MCF-7 glioma SF-295 0.0 Breast ca.* (pl.ef) 0.0 MDA-MB-231 Heart (fetal) 0.0 Breast ca.* (pl.ef) 0.0 T47D Heart 0.0 Breast ca. BT-549 0.0 Skeletal muscle (fetal) 0.0 Breast ca. MDA-N 0.0 Skeletal muscle 0.0 Ovary 0.0 Bone marrow 0.0 Ovarian ca. 0.0 OVCAR-3 Thymus 0.0 Ovarian ca. 0.0 OVCAR-4 Spleen 0.0 Ovarian ca. 0.0 OVCAR-5 Lymph node 0.0 Ovarian ca. 0.0 OVCAR-8 Colorectal 0.0 Ovarian ca. IGROV-1 0.0 Stomach 0.0 Ovarian ca.* 0.0 (ascites) SK-OV-3 Small intestine 0.0 Uterus 0.0 Colon ca. SW480 0.0 Placenta 0.0 Colon ca.* 0.0 Prostate 0.0 SW620(SW480 met) Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 met)PC-3 Colon ca. HCT-116 0.0 Testis 0.0 Colon ca. CaCo-2 1.4 Melanoma 0.0 Hs688(A).T Colon ca. 0.0 Melanoma* (met) 0.0 tissue(ODO3866) Hs688(B).T Colon ca. HCC-2998 0.0 Melanoma UACC- 0.0 62 Gastric ca.* (liver met) 0.0 Melanoma M14 0.0 NCI-N87 Bladder 0.0 Melanoma LOX 0.0 IMVI Trachea 0.0 Melanoma* (met) 0.0 SK-MEL-5 Kidney 32.3 Adipose 0.0

[0642] TABLE-US-00152 TABLE JE Panel 2D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 170858346 Tissue Name 170858346 Normal Colon 0.7 Kidney Margin 4.2 8120608 CC Well to Mod Diff 0.0 Kidney Cancer 0.1 (ODO3866) 8120613 CC Margin (ODO3866) 0.0 Kidney Margin 3.1 8120614 CC Gr.2 rectosigmoid 0.0 Kidney Cancer 0.0 (ODO3868) 9010320 CC Margin (ODO3868) 0.0 Kidney Margin 4.4 9010321 CC Mod Diff 0.0 Normal Uterus 0.0 (ODO3920) CC Margin (ODO3920) 0.0 Uterus Cancer 0.1 064011 CC Gr.2 ascend colon 0.0 Normal Thyroid 0.0 (ODO3921) CC Margin (ODO3921) 0.0 Thyroid Cancer 0.0 064010 CC from Partial 6.8 Thyroid Cancer 0.0 Hepatectomy (ODO4309) Mets A302152 Liver Margin 100.0 Thyroid Margin 0.0 (ODO4309) A302153 Colon mets to lung 0.0 Normal Breast 0.0 (OD04451-01) Lung Margin 0.0 Breast Cancer 0.0 (OD04451-02) (OD04566) Normal Prostate 6546-1 0.0 Breast Cancer 0.0 (OD04590-01) Prostate Cancer 0.0 Breast Cancer Mets 0.0 (OD04410) (OD04590-03) Prostate Margin 0.0 Breast Cancer 0.0 (OD04410) Metastasis (OD04655-05) Prostate Cancer 0.0 Breast Cancer 0.3 (OD04720-01) 064006 Prostate Margin (OD04720-02) 0.0 Breast Cancer 1024 0.0 Normal Lung 061010 0.1 Breast Cancer 0.0 9100266 Lung Met to Muscle 0.0 Breast Margin 0.0 (ODO4286) 9100265 Muscle Margin 0.0 Breast Cancer 0.0 (ODO4286) A209073 Lung Malignant Cancer 0.0 Breast Margin 0.0 (OD03126) A209073 Lung Margin 0.0 Normal Liver 60.7 (OD03126) Lung Cancer (OD04404) 0.0 Liver Cancer 064003 78.5 Lung Margin 0.0 Liver Cancer 1025 42.6 (OD04404) Lung Cancer (OD04565) 0.0 Liver Cancer 1026 19.2 Lung Margin 0.0 Liver Cancer 6004-T 36.9 (OD04565) Lung Cancer (OD04237-01) 0.0 Liver Tissue 6004-N 3.6 Lung Margin 0.0 Liver Cancer 6005-T 17.1 (OD04237-02) Ocular Mel Met to Liver 0.0 Liver Tissue 6005-N 8.6 (ODO4310) Liver Margin 76.3 Normal Bladder 0.0 (ODO4310) Melanoma Mets to Lung 0.0 Bladder Cancer 1023 0.0 (OD04321) Lung Margin 0.0 Bladder Cancer 0.0 (OD04321) A302173 Normal Kidney 48.6 Bladder Cancer 0.0 (OD04718-01) Kidney Ca, Nuclear 1.6 Bladder Normal 0.0 grade 2 (OD04338) Adjacent (OD04718- 03) Kidney Margin 24.3 Normal Ovary 0.0 (OD04338) Kidney Ca Nuclear 0.0 Ovarian Cancer 0.0 grade 1/2 (OD04339) 064008 Kidney Margin 28.3 Ovarian Cancer 0.0 (OD04339) (OD04768-07) Kidney Ca, Clear cell 0.0 Ovary Margin 0.0 type (OD04340) (OD04768-08) Kidney Margin (OD04340) 26.8 Normal Stomach 0.0 Kidney Ca, Nuclear 0.0 Gastric Cancer 0.0 grade 3 (OD04348) 9060358 Kidney Margin 17.2 Stomach Margin 0.0 (OD04348) 9060359 Kidney Cancer 0.0 Gastric Cancer 0.0 (OD04622-01) 9060395 Kidney Margin 2.6 Stomach Margin 0.0 (OD04622-03) 9060394 Kidney Cancer 0.0 Gastric Cancer 0.0 (OD04450-01) 9060397 Kidney Margin 32.1 Stomach Margin 0.0 (OD04450-03) 9060396 Kidney Cancer 8120607 0.0 Gastric Cancer 0.0 064005

[0643] TABLE-US-00153 TABLE JF Panel 3D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 165039071 Tissue Name 165039071 Daoy-Medulloblastoma 0.0 Ca Ski-Cervical epidermoid 0.0 carcinoma (metastasis) TE671- 0.0 ES-2-Ovarian clear cell 0.0 Medulloblastoma carcinoma D283 Med- 0.0 Ramos-Stimulated with 2.3 Medulloblastoma PMA/ionomycin 6 h PFSK-1-Primitive 0.0 Ramos-Stimulated with 0.0 Neuroectodermal PMA/ionomycin 14 h XF-498-CNS 0.0 MEG-01-Chronic 0.0 myelogenous leukemia (megokaryoblast) SNB-78-Glioma 0.0 Raji-Burkitt's lymphoma 0.0 SF-268-Glioblastoma 0.0 Daudi-Burkitt's lymphoma 0.0 T98G-Glioblastoma 0.0 U266-B-cell plasmacytoma 0.0 SK-N-SH- 0.0 CA46-Burkitt's lymphoma 0.0 Neuroblastoma (metastasis) SF-295-Glioblastoma 0.0 RL-non-Hodgkin's B-cell 0.0 lymphoma Cerebellum 0.0 JM1-pre-B-cell lymphoma 0.0 Cerebellum 0.0 Jurkat-T cell leukemia 0.0 NCI-H292- 0.0 TF-1-Erythroleukemia 0.0 Mucoepidermoid lung carcinoma DMS-114-Small cell 0.0 HUT 78-T-cell lymphoma 0.0 lung cancer DMS-79-Small cell 0.0 U937-Histiocytic 0.0 lung cancer lymphoma NCI-H146-Small cell 0.0 KU-812-Myelogenous 0.0 lung cancer leukemia NCI-H526-Small cell 0.0 769-P-Clear cell renal 0.0 lung cancer carcinoma NCI-N417-Small cell 0.0 Caki-2-Clear cell renal 0.0 lung cancer carcinoma NCI-H82-Small cell 0.0 SW 839-Clear cell renal 0.0 lung cancer carcinoma NCI-H157-Squamous 0.0 G401-Wilms' tumor 0.0 cell lung cancer (metastasis) NCI-H1155-Large cell 0.0 Hs766T-Pancreatic 0.0 lung cancer carcinoma (LN metastasis) NCI-H1299-Large cell 0.0 CAPAN-1-Pancreatic 0.0 lung cancer adenocarcinoma (liver metastasis) NCI-H727-Lung 0.0 SU86.86-Pancreatic 0.0 carcinoid carcinoma (liver metastasis) NCI-UMC-11-Lung 0.0 BxPC-3-Pancreatic 0.0 carcinoid adenocarcinoma LX-1-Small cell lung 0.0 HPAC-Pancreatic 0.0 cancer adenocarcinoma Colo-205-Colon cancer 0.0 MIA PaCa-2-Pancreatic 0.0 carcinoma KM12-Colon cancer 0.0 CFPAC-1-Pancreatic ductal 0.0 adenocarcinoma KM20L2-Colon cancer 0.0 PANC-1-Pancreatic 0.0 epithelioid ductal carcinoma NCI-H716-Colon 0.0 T24-Bladder carcinma 0.0 cancer (transitional cell) SW-48-Colon 100.0 5637-Bladder carcinoma 0.0 adenocarcinoma SW1116-Colon 0.0 HT-1197-Bladder 0.0 adenocarcinoma carcinoma LS 174T-Colon 79.6 UM-UC-3-Bladder 0.0 adenocarcinoma carcinma (transitional cell) SW-948-Colon 0.0 A204-Rhabdomyosarcoma 0.0 adenocarcinoma SW-480-Colon 0.0 HT-1080-Fibrosarcoma 0.0 adenocarcinoma NCI-SNU-5-Gastric 0.0 MG-63-Osteosarcoma 0.0 carcinoma KATO III-Gastric 4.2 SK-LMS-1- 0.0 carcinoma Leiomyosarcoma (vulva) NCI-SNU-16-Gastric 0.0 SJRH30- 0.0 carcinoma Rhabdomyosarcoma (met to bone marrow) NCI-SNU-1-Gastric 0.0 A431-Epidermoid 0.0 carcinoma carcinoma RF-1-Gastric 0.0 WM266-4-Melanoma 0.0 adenocarcinoma RF-48-Gastric 0.0 DU 145-Prostate carcinoma 0.0 adenocarcinoma (brain metastasis) MKN-45-Gastric 0.0 MDA-MB-468-Breast 0.0 carcinoma adenocarcinoma NCI-N87-Gastric 0.0 SCC-4-Squamous cell 0.0 carcinoma carcinoma of tongue OVCAR-5-Ovarian 0.0 SCC-9-Squamous cell 0.0 carcinoma carcinoma of tongue RL95-2-Uterine 0.0 SCC-15-Squamous cell 0.0 carcinoma carcinoma of tongue HelaS3-Cervical 0.0 CAL 27-Squamous cell 0.0 adenocarcinoma carcinoma of tongue

[0644] TABLE-US-00154 TABLE JG Panel 4D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 165296618 Tissue Name 165296618 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.0 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.0 Bronchial epithelium 0.0 TNF alpha + IL1beta Primary Th2 rest 0.0 Small airway epithelium 0.0 none Primary Tr1 rest 0.0 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 0.0 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 11.6 LAK cells IL-2 + IL-12 0.0 Lupus kidney 0.7 LAK cells IL-2 + IFN 0.0 NCI-H292 none 0.0 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-4 0.0 LAK cells 0.0 NCI-H292 IL-9 0.0 PMA/ionomycin NK Cells IL-2 rest 0.0 NCI-H292 IL-13 0.0 Two Way MLR 3 day 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 5 day 0.0 HPAEC none 0.0 Two Way MLR 7 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta PBMC rest 0.0 Lung fibroblast none 0.0 PBMC PWM 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PHA-L 0.0 Lung fibroblast IL-4 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) 0.0 Lung fibroblast IL-13 0.0 ionomycin B lymphocytes PWM 0.0 Lung fibroblast IFN 0.0 gamma B lymphocytes CD40L 0.0 Dermal fibroblast 0.0 and IL-4 CCD1070 rest EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 PMA/ionomycin CCD1070 IL-1beta Dendritic cells none 0.0 Dermal fibroblast IFN 0.0 gamma Dendritic cells LPS 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells anti- 0.0 IBD Colitis 2 0.0 CD40 Monocytes rest 0.0 IBD Crohn's 0.0 Monocytes LPS 0.0 Colon 0.0 Macrophages rest 0.0 Lung 0.0 Macrophages LPS 0.0 Thymus 100.0 HUVEC none 0.0 Kidney 0.0 HUVEC starved 0.0

[0645] CNS_neurodegeneration_v1.0 Summary: Ag5114 Expression of the NOV12F gene is low/undetectable (CTs>35) in all samples on this panel (data not shown).

[0646] General_screening_panel_v1.5 Summary: Ag5114 Expression of the NOV12F gene is low/undetectable (CTs>35) in all samples on this panel (data not shown).

[0647] Panel 1.3D Summary: Ag3374 Expression of this gene is restricted to a few samples, with highest expression in liver (CT=24.1), fetal liver, and kidney. Moderate expression is seen in fetal kidney and low levels of expression are seen in a colon cancer cell line. This expression profile suggests that this gene could be used to differentiate between liver and other samples on this panel and as a marker of liver and kidney tissue.

[0648] Panel 2D Summary: Ag3374 Highest expression of this gene is seen in liver derived tissue (CT=23.9), with expression in this panel restricted to liver and kidney derived tissue. This expression is in agreement with expression seen in Panel 1.3D. In addition, this gene is more highly expressed in kidney tissue when compared to normal adjacent tissue. This gene encodes a putative kininogen, which has been shown to inhibit angiogenesis (Colman R. Blood. 95:543; Guo Y. Arterioscler Thromb Vasc Biol. September 2001, pg. 1427). The expressed protein can also be used in the treatment of kidney cancers as it is not expressed in kidney cancers compared to the adjacent normal tissues and inhibition of its activity using antibodies or small molecule drugs may be useful in treating liver cancer. Thus, therapeutic modulation of the expression or function of this gene could be effective in the treatment of liver and kidney cancers.

[0649] Panel 3D Summary: Ag3374 Expression in this panel is restricted to samples derived from colon cancer cell lines (CTs=34-35). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of colon cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon cancer. A second experiment with probe and primer set Ag4269 shows low/undetectable levels of expression (CTs>35). (Data not shown.)

[0650] Panel 4D Summary: Ag3374 This transcript is most highly expressed in the thymus (CT=24.3). The protien encoded by this gene could therefore play an important role in T cell development. Thus, therapeutic modulation of the expression or function of this gene may modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.

[0651] In addition, moderate levels of expression are seen in liver cirrhosis and lupus kidney, in agreement with previous panels that showed expression in liver and kidney derived tissues.

[0652] Panel 4.1D Summary: Ag5114 Expression of the NOV12F gene is low/undetectable (CTs>35) in all samples on this panel (data not shown).

[0653] General oncology screening panel_v.sub.--2.4 Summary: Ag5114 Expression of the NOV12F gene is low/undetectable (CTs>35) in all samples on this panel (data not shown).

[0654] K. NOV12B, NOV12C, NOV12D, NOV12E, NOV12G and CG104903-09: Kininogen Precursor

[0655] Expression of gene NOV12B and variants NOV12C, NOV12D, NOV12E, NOV12G and NOV12H was assessed using the primer-probe sets Ag3374, Ag4269, Ag5115 and Ag5116, described in Tables KA, KB, KC and KD. The correspondence of primer-probe sets to the various variants is described in Table KE. These sequences are variants of NOV12A described in the previous section (section J). Results of the RTQ-PCR runs are shown in Tables KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN and KO. Please note that NOV12G represents a full-length physical clone. In addition, NOV12H represents a full-length physical clone that validates the prediction of the NOV12C sequence. TABLE-US-00155 TABLE KA Probe Name Ag3374 Start SEQ ID Primers Sequences Length Position No Forward 5'-gattgcaacgctgaagtttatg-3' 22 1005 169 Probe TET-5'-ctgtcaactgtcaaccactgggaatg-3'- 26 1057 170 TAMRA Reverse 5'-gaggccttttcatcagtgagat-3' 22 1083 171

[0656] TABLE-US-00156 TABLE KB Probe Name Ag4269 Start SEQ ID Primers Sequences Length Position No Forward 5'-acagagcatttggcaagct-3' 19 1518 172 Probe TET-5'- cagtactacaccttctgcacagacaca-3'- 27 1547 173 TAMRA Reverse 5'-gttggcccttctgtcttctc-3' 20 1575 174

[0657] TABLE-US-00157 TABLE KC Probe Name Ag5115 Start SEQ ID Primers Sequences Length Position No Forward 5'-cagccactggagaatgca-3' 18 354 175 Probe TET-5'-agcagtacgaaattctccgtggctacc-3'- 27 391 176 TAMRA Reverse 5'-gaatgggctccaggtctg-3' 18 418 177

[0658] TABLE-US-00158 TABLE KD Probe Name Ag5116 Start SEQ ID Primers Sequences Length Position No Forward 5'-acgcagagcccaggtttt-3' 18 500 178 Probe TET-5'-cacctttccgatcatcacgaatagggg-3'- 27 519 179 TAMRA Reverse 5'-gggtggacttacagttgtttcttct-3' 25 553 180

[0659] TABLE-US-00159 TABLE KE Probe Name Ag3374 NOV12B NOV12C NOV12D NOV12E NOV12G NOV12H Ag3374 X X X X X Ag4269 X X X X Ag5115 X Ag5116 X

[0660] TABLE-US-00160 TABLE KF CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Tissue Ag4269, Run Ag5115, Run Tissue Ag4269, Run Ag5115, Run Name 217215423 226443863 Name 217215423 226443863 AD 1 Hippo 0.0 0.0 Control 0.0 0.0 (Path) 3 Temporal Ctx AD 2 Hippo 0.0 3.1 Control 13.9 11.5 (Path) 4 Temporal Ctx AD 3 Hippo 0.0 0.0 AD 1 26.8 4.9 Occipital Ctx AD 4 Hippo 39.5 0.0 AD 2 0.0 0.0 Occipital Ctx (Missing) AD 5 Hippo 100.0 100.0 AD 3 0.0 0.0 Occipital Ctx AD 6 Hippo 0.0 0.0 AD 4 8.1 9.2 Occipital Ctx Control 2 0.0 0.0 AD 5 24.8 3.6 Hippo Occipital Ctx Control 4 0.0 0.0 AD 6 0.0 98.6 Hippo Occipital Ctx Control 0.0 0.0 Control 1 0.0 0.0 (Path) 3 Occipital Hippo Ctx AD 1 0.0 0.0 Control 2 57.8 85.9 Temporal Occipital Ctx Ctx AD 2 12.9 7.9 Control 3 24.0 4.0 Temporal Occipital Ctx Ctx AD 3 0.0 0.0 Control 4 0.0 0.0 Temporal Occipital Ctx Ctx AD 4 30.4 2.9 Control 79.0 54.0 Temporal (Path) 1 Ctx Occipital Ctx AD 5 Inf 28.9 12.8 Control 42.0 5.3 Temporal (Path) 2 Ctx Occipital Ctx AD 5 Sup 0.0 0.0 Control 0.0 0.0 Temporal (Path) 3 Ctx Occipital Ctx AD 6 Inf 0.0 2.3 Control 34.6 12.4 Temporal (Path) 4 Ctx Occipital Ctx AD 6 Sup 35.1 3.8 Control 1 0.0 0.0 Temporal Parietal Ctx Ctx Control 1 0.0 0.0 Control 2 0.0 6.7 Temporal Parietal Ctx Ctx Control 2 17.6 4.0 Control 3 7.2 6.4 Temporal Parietal Ctx Ctx Control 3 14.2 0.0 Control 16.4 63.3 Temporal (Path) 1 Ctx Parietal Ctx Control 3 0.0 0.0 Control 32.8 20.0 Temporal (Path) 2 Ctx Parietal Ctx Control 27.2 13.1 Control 1.1 0.0 (Path) 1 (Path) 3 Temporal Parietal Ctx Ctx Control 26.4 12.9 Control 86.5 35.4 (Path) 2 (Path) 4 Temporal Parietal Ctx Ctx

[0661] TABLE-US-00161 TABLE KG General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4269, Run Ag4269, Run Tissue Name 217044119 Tissue Name 217044119 Adipose 0.0 Renal ca. TK-10 0.0 Melanoma* Hs688(A).T 0.0 Bladder 0.1 Melanoma* Hs688(B).T 0.0 Gastric ca. (liver met.) 0.0 NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* LOXIMVI 0.0 Colon ca. SW-948 0.0 Melanoma* SK-MEL-5 0.1 Colon ca. SW480 0.0 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.0 Colon ca. CaCo-2 5.8 Placenta 0.0 Colon cancer tissue 0.2 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK-OV-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. 0.0 Colon Pool 0.1 OVCAR-4 Ovarian ca. 0.1 Small Intestine Pool 0.0 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.1 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 0.0 OVCAR-8 Ovary 0.0 Fetal Heart 0.0 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 0.0 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.0 Breast ca. T47D 0.0 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 0.1 Thymus Pool 0.0 Trachea 0.0 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 0.8 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.1 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.0 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. A549 0.1 Brain (Amygdala) Pool 0.0 Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) Pool 0.0 Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.1 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 20.0 Brain (Thalamus) Pool 0.0 Fetal Liver 100.0 Brain (whole) 1.3 Liver ca. HepG2 0.2 Spinal Cord Pool 0.0 Kidney Pool 0.0 Adrenal Gland 0.1 Fetal Kidney 12.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.1

[0662] TABLE-US-00162 TABLE KH General_screening_panel_v1.5 Rel. Exp.(%) Rel. Exp.(%) Ag5115, Run Ag5115, Run Tissue Name 228738881 Tissue Name 228738881 Adipose 0.0 Renal ca. TK-10 0.0 Melanoma* Hs688(A).T 0.0 Bladder 0.1 Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* LOXIMVI 0.0 Colon ca. SW-948 0.0 Melanoma* SK-MEL-5 0.0 colon ca. SW480 0.0 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 0.0 met) SW620 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.0 Colon ca. CaCo-2 5.4 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK-OV-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. 0.0 Colon Pool 0.0 OVCAR-4 Ovarian ca. 0.0 Small Intestine Pool 0.0 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.0 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 0.0 OVCAR-8 Ovary 0.0 Fetal Heart 0.0 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 0.0 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.0 Breast ca. T47D 0.0 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 0.1 Thymus Pool 0.0 Trachea 0.0 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.0 (glio/astro) U-118-MG Fetal Lung 0.8 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.0 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. A549 0.0 Brain (Amygdala) Pool 0.0 Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) Pool 0.2 Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.1 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 27.7 Brain (Thalamus) Pool 0.1 Fetal Liver 100.0 Brain (whole) 1.3 Liver ca. HepG2 0.0 Spinal Cord Pool 0.0 Kidney Pool 0.0 Adrenal Gland 0.0 Fetal Kidney 13.8 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.0

[0663] TABLE-US-00163 TABLE KI Panel 1.3D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 165678152 Tissue Name 165678152 Liver adenocarcinoma 0.0 Kidney (fetal) 6.0 Pancreas 0.0 Renal ca. 786-0 0.0 Pancreatic ca. CAPAN 2 0.0 Renal ca. A498 0.0 Adrenal gland 0.0 Renal ca. RXF 393 0.0 Thyroid 0.0 Renal ca. ACHN 0.0 Salivary gland 0.0 Renal ca. UO-31 0.0 Pituitary gland 0.0 Renal ca. TK-10 0.0 Brain (fetal) 0.0 Liver 100.0 Brain (whole) 0.1 Liver (fetal) 32.1 Brain (amygdala) 0.0 Liver ca. 0.0 (hepatoblast) HepG2 Brain (cerebellum) 0.0 Lung 0.0 Brain (hippocampus) 0.0 Lung (fetal) 0.0 Brain (substantia nigra) 0.0 Lung ca. (small cell) LX-1 0.0 Brain (thalamus) 0.0 Lung ca. (small cell) NCI-H69 0.0 Cerebral Cortex 0.0 Lung ca. (s. cell var.) SHP-77 0.0 Spinal cord 0.0 Lung ca. (large 0.0 cell)NCI-H460 glio/astro U87-MG 0.0 Lung ca. (non-sm. cell) A549 0.0 glio/astro U-118-MG 0.0 Lung ca. (non-s. cell) 0.0 NCI-H23 astrocytoma SW1783 0.0 Lung ca. (non-s. cell) 0.0 HOP-62 neuro*; met SK-N-AS 0.0 Lung ca. (non-s. cl) 0.0 NCI-H522 astrocytoma SF-539 0.0 Lung ca. (squam.) 0.0 SW 900 astrocytoma SNB-75 0.0 Lung ca. (squam.) 0.0 NCI-H596 glioma SNB-19 0.0 Mammary gland 0.0 glioma U251 0.0 Breast ca.* (pl.ef) 0.0 MCF-7 glioma SF-295 0.0 Breast ca.* (pl.ef) 0.0 MDA-MB-231 Heart (fetal) 0.0 Breast ca.* (pl.ef) 0.0 T47D Heart 0.0 Breast ca. BT-549 0.0 Skeletal muscle (fetal) 0.0 Breast ca. MDA-N 0.0 Skeletal muscle 0.0 Ovary 0.0 Bone marrow 0.0 Ovarian ca. 0.0 OVCAR-3 Thymus 0.0 Ovarian ca. 0.0 OVCAR-4 Spleen 0.0 Ovarian ca. 0.0 OVCAR-5 Lymph node 0.0 Ovarian ca. 0.0 OVCAR-8 Colorectal 0.0 Ovarian ca. IGROV-1 0.0 Stomach 0.0 Ovarian ca.* 0.0 (ascites) SK-OV-3 Small intestine 0.0 Uterus 0.0 Colon ca. SW480 0.0 Placenta 0.0 Colon ca.* 0.0 Prostate 0.0 SW620(SW480 met) Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 met)PC-3 Colon ca. HCT-116 0.0 Testis 0.0 Colon ca. CaCo-2 1.4 Melanoma 0.0 Hs688(A).T Colon ca. 0.0 Melanoma* (met) 0.0 tissue(ODO3866) Hs688(B).T Colon ca. HCC-2998 0.0 Melanoma UACC-62 0.0 Gastric ca.* (liver met) 0.0 Melanoma M14 0.0 NCI-N87 Bladder 0.0 Melanoma LOX 0.0 IMVI Trachea 0.0 Malanoma* (met) 0.0 SK-MEL-5 Kidney 32.3 Adipose 0.0

[0664] TABLE-US-00164 TABLE KJ Panel 2.2 Rel. Rel. Rel. Rel. Exp.(%) Exp.(%) Exp.(%) Exp.(%) Ag3374, Run Ag3374, Run Ag3374, Run Ag3374, Run Tissue Name 176283594 184372611 Tissue Name 176283594 184372611 Normal Colon 0.2 0.3 Kidney Margin 38.4 14.2 (OD04348) Colon cancer 0.0 0.0 Kidney 0.0 0.0 (OD06064) malignant cancer (OD06204B) Colon Margin 0.0 0.0 Kidney normal 4.5 4.7 (OD06064) adjacent tissue (OD06204E) Colon cancer 0.0 0.0 Kidney Cancer 0.0 0.0 (OD06159) (OD04450-01) Colon Margin 0.0 0.0 Kidney Margin 17.9 41.2 (OD06159) (OD04450-03) Colon cancer 0.0 0.0 Kidney Cancer 0.0 0.0 (OD06297-04) 8120613 Colon Margin 0.1 0.0 Kidney Margin 2.9 1.8 (OD06297-05) 8120614 CC Gr.2 ascend 0.0 0.0 Kidney Cancer 2.4 0.0 colon 9010320 (ODO3921) CC Margin 0.0 0.0 Kidney Margin 1.3 1.8 (ODO3921) 9010321 Colon cancer 0.0 0.0 Kidney Cancer 0.0 0.0 metastasis 8120607 (OD06104) Lung Margin 0.0 0.0 Kidney Margin 2.1 2.6 (OD06104) 8120608 Colon mets to 0.0 0.0 Normal Uterus 0.0 0.0 lung (OD04451-01) Lung Margin 0.1 0.0 Uterine Cancer 0.0 0.0 (OD04451-02) 064011 Normal 0.0 0.0 Normal 0.0 0.0 Prostate Thyroid Prostate Cancer 0.0 0.0 Thyroid Cancer 0.0 0.0 (OD04410) 064010 Prostate Margin 0.0 0.0 Thyroid Cancer 0.0 0.0 (OD04410) A302152 Normal Ovary 0.0 0.0 Thyroid 0.0 0.0 Margin A302153 Ovarian cancer 0.0 0.0 Normal Breast 0.0 0.0 (OD06283-03) Ovarian Margin 0.0 0.0 Breast Cancer 1.3 0.0 (OD06283-07) (OD04566) Ovarian Cancer 1.5 0.0 Breast Cancer 1.6 0.0 064008 1024 Ovarian cancer 5.8 0.0 Breast Cancer 0.1 0.0 (OD06145) (OD04590-01) Ovarian Margin 1.4 0.0 Breast Cancer 0.0 0.0 (OD06145) Mets (OD04590-03) Ovarian cancer 0.2 0.0 Breast Cancer 0.0 0.0 (OD06455-03) Metastasis (OD04655-05) Ovarian Margin 0.0 0.0 Breast Cancer 0.1 0.3 (OD06455-07) 064006 Normal Lung 0.0 0.0 Breast Cancer 0.0 0.0 9100266 Invasive poor 0.0 0.0 Breast Margin 0.0 0.0 diff. lung adeno 9100265 (ODO4945-01 Lung Margin 0.0 0.0 Breast Cancer 0.0 0.0 (ODO4945-03) A209073 Lung Malignant 0.0 0.0 Breast Margin 0.0 0.0 Cancer A2090734 (OD03126) Lung Margin 0.0 0.0 Breast cancer 0.0 0.0 (OD03126) (OD06083) Lung Cancer 0.0 0.0 Breast cancer 0.0 0.0 (OD05014A) node metastasis (OD06083) Lung Margin 0.1 0.0 Normal Liver 57.8 94.6 (OD05014B) Lung cancer 0.0 0.0 Liver Cancer 8.1 15.1 (OD06081) 1026 Lung Margin 0.0 0.0 Liver Cancer 47.0 60.3 (OD06081) 1025 Lung Cancer 0.0 0.0 Liver Cancer 23.3 44.8 (OD04237-01) 6004-T Lung Margin 0.0 0.0 Liver Tissue 1.8 1.1 (OD04237-02) 6004-N Ocular 0.0 0.0 Liver Cancer 21.8 20.7 Melanoma 6005-T Metastasis Ocular 49.7 100.0 Liver Tissue 31.6 27.0 Melanoma 6005-N Margin (Liver) Melanoma 0.0 0.0 Liver Cancer 100.0 92.7 Metastasis 064003 Melanoma 0.0 0.0 Normal 0.0 0.0 Margin (Lung) Bladder Normal Kidney 8.8 13.6 Bladder Cancer 0.0 0.0 1023 Kidney Ca, 27.9 26.1 Bladder Cancer 0.0 0.0 Nuclear grade 2 A302173 (OD04338) Kidney Margin 0.2 1.4 Normal 0.2 0.0 (OD04338) Stomach Kidney Ca 0.4 0.0 Gastric Cancer 0.0 0.0 Nuclear grade 9060397 1/2 (OD04339) Kidney Margin 12.5 15.1 Stomach 0.0 0.0 (OD04339) Margin 9060396 Kidney Ca, 0.0 0.0 Gastric Cancer 0.0 0.0 Clear cell type 9060395 (OD04340) Kidney Margin 17.8 12.4 Stomach 0.0 0.0 (OD04340) Margin 9060394 Kidney Ca, 0.0 0.0 Gastric Cancer 0.0 0.0 Nuclear grade 3 064005 (OD04348)

[0665] TABLE-US-00165 TABLE KK Panel 2D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 170858346 Tissue Name 170858346 Normal Colon 0.7 Kidney Margin 4.2 8120608 CC Well to Mod Diff 0.0 Kidney Cancer 0.1 (ODO3866) 8120613 CC Margin (ODO3866) 0.0 Kidney Margin 3.1 8120614 CC Gr.2 rectosigmoid 0.0 Kidney Cancer 0.0 (ODO3868) 9010320 CC Margin (ODO3868) 0.0 Kidney Margin 4.4 9010321 CC Mod Diff 0.0 Normal Uterus 0.0 (ODO3920) CC Margin (ODO3920) 0.0 Uterus Cancer 0.1 064011 CC Gr.2 ascend colon 0.0 Normal Thyroid 0.0 (ODO3921) CC Margin (ODO3921) 0.0 Thyroid Cancer 0.0 064010 CC from Partial 6.8 Thyroid Cancer 0.0 Hepatectomy (ODO4309) Mets A302152 Liver Margin 100.0 Thyroid Margin 0.0 (ODO4309) A302153 Colon mets to lung 0.0 Normal Breast 0.0 (OD04451-01) Lung Margin 0.0 Breast Cancer 0.0 (OD04451-02) (OD04566) Normal Prostate 6546-1 0.0 Breast Cancer 0.0 (OD04590-01) Prostate Cancer 0.0 Breast Cancer Mets 0.0 (OD04410) (OD04590-03) Prostate Margin 0.0 Breast Cancer 0.0 (OD04410) Metastasis (OD04655-05) Prostate Cancer 0.0 Breast Cancer 0.3 (OD04720-01) 064006 Prostate Margin 0.0 Breast Cancer 1024 0.0 (OD04720-02) Normal Lung 061010 0.1 Breast Cancer 0.0 9100266 Lung Met to Muscle 0.0 Breast Margin 0.0 (ODO4286) 9100265 Muscle Margin 0.0 Breast Cancer 0.0 (ODO4286) A209073 Lung Malignant Cancer 0.0 Breast Margin 0.0 (OD03126) A209073 Lung Margin (OD03126) 0.0 Normal Liver 60.7 Lung Cancer (OD04404) 0.0 Liver Cancer 064003 78.5 Lung Margin (OD04404) 0.0 Liver Cancer 1025 42.6 Lung Cancer (OD04565) 0.0 Liver Cancer 1026 19.2 Lung Margin (OD04565) 0.0 Liver Cancer 6004-T 36.9 Lung Cancer (OD04237-01) 0.0 Liver Tissue 6004-N 3.6 Lung Margin 0.0 Liver Cancer 6005-T 17.1 (OD04237-02) Ocular Mel Met to Liver 0.0 Liver Tissue 6005-N 8.6 (ODO4310) Liver Margin (ODO4310) 76.3 Normal Bladder 0.0 Melanoma Mets to Lung 0.0 Bladder Cancer 1023 0.0 (OD04321) Lung Margin 0.0 Bladder Cancer 0.0 (OD04321) A302173 Normal Kidney 48.6 Bladder Cancer 0.0 (OD04718-01) Kidney Ca, Nuclear 1.6 Bladder Normal 0.0 grade 2(OD04338) Adjacent (OD04718-03) 0.0 Kidney Margin (OD04338) 24.3 Normal Ovary 0.0 Kidney Ca Nuclear 0.0 Ovarian Cancer 0.0 grade 1/2 (OD04339) (OD04768-07) Kidney Margin 28.3 Ovarian Cancer 0.0 (OD04339) (OD04768-07) Kidney Ca, Clear cell 0.0 Ovary Margin 0.0 type (OD04340) (OD04768-08) Kidney Margin (OD04340) 26.8 Normal Stomach 0.0 Kidney Ca, Nuclear 0.0 Gastric Cancer 0.0 grade 3 (OD04348) 9060358 Kidney Margin 17.2 Stomach Margin 0.0 (OD04348) 9060359 Kidney Cancer 0.0 Gastric Cancer 0.0 (OD04622-01) 9060395 Kidney Margin 2.6 Stomach Margin 0.0 (OD04622-03) 9060394 Kidney Cancer 0.0 Gastric Cancer 0.0 (OD04450-01) 9060397 Kidney Margin 32.1 Stomach Margin 0.0 (OD04450-03) 9060396 Kidney Cancer 8120607 0.0 Gastric Cancer 0.0 064005

[0666] TABLE-US-00166 TABLE KL Panel 3D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 165039071 Tissue Name 165039071 Daoy- 0.0 Ca Ski-Cervical epidermoid 0.0 Medulloblastoma carcinoma (metastasis) TE671- 0.0 ES-2-Ovarian clear cell 0.0 Medulloblastoma carcinoma D283 Med- 0.0 Ramos-Stimulated with 2.3 Medulloblastoma PMA/ionomycin 6 h PFSK-1-Primitive 0.0 Ramos-Stimulated with 0.0 Neuroectodermal PMA/ionomycin 14 h XF-498-CNS 0.0 MEG-01-Chronic 0.0 myelogenous leukemia (megokaryoblast) SNB-78-Giloma 0.0 Raji-Burkitt's lymphoma 0.0 SF-268-Glioblastoma 0.0 Daudi-Burkitt's lymphoma 0.0 T98G-Glioblastoma 0.0 U266-B-cell plasmacytoma 0.0 SK-N-SH 0.0 CA46-Burkitt's lymphoma 0.0 Neuroblastoma (metastasis) SF-295-Glioblastoma 0.0 RL-non-Hodgkin's B-cell 0.0 lymphoma Cerebellum 0.0 JM1-pre-B-cell lymphoma 0.0 Cerebellum 0.0 Jurkat-T cell leukemia 0.0 NCI-H292- 0.0 TF-1-Erythroleukemia 0.0 Mucoepidermoid lung carcinoma DMS-114-Small cell 0.0 HUT 78-T-cell lymphoma 0.0 lung cancer DMS-79-Small cell 0.0 U937-Histiocytic 0.0 lung cancer lymphoma NCI-H146-Small cell 0.0 KU-812-Myelogenous 0.0 lung cancer leukemia NCI-H526-Small cell 0.0 769-P-Clear cell renal 0.0 lung cancer carcinoma NCI-N417-Small cell 0.0 Caki-2-Clear cell renal 0.0 lung cancer carcinoma NCI-H82-Small cell 0.0 SW 839-Clear cell renal 0.0 lung cancer carcinoma NCI-H157-Squamous 0.0 G401-Wilms' tumor 0.0 cell lung cancer (metastasis) NCI-H1155-Large cell 0.0 Hs766T-Pancreatic 0.0 lung cancer carcinoma (LN metastasis) NCI-H1299-Large cell 0.0 CAPAN-1-Pancreatic 0.0 lung cancer adenocarcinoma (liver metastasis) NCI-H727-Lung 0.0 SU86.86-Pancreatic 0.0 carcinoid carcinoma (liver metastasis) NCI-UMC-11-Lung 0.0 BxPC-3-Pancreatic 0.0 carcinoid adenocarcinoma LX-1-Small cell lung 0.0 HPAC-Pancreatic 0.0 cancer adenocarcinoma Colo-205-Colon 0.0 MIA PaCa-2-Pancreatic 0.0 cancer carcinoma KM12-Colon cancer 0.0 CFPAC-1-Pancreatic ductal 0.0 adenocarcinoma KM20L2-Colon cancer 0.0 PANC-1-Pancreatic 0.0 epithelioid ductal carcinoma NCI-H716-Colon 0.0 T24-Bladder carcinma 0.0 cancer (transitional cell) SW-48-Colon 100.0 5637-Bladder carcinoma 0.0 adenocarcinoma SW1116-Colon 0.0 HT-1197-Bladder 0.0 adenocarcinoma carcinoma LS 174T-Colon 79.6 UM-UC-3-Bladder 0.0 adenocarcinoma carcinma (transitional cell) SW-948-Colon 0.0 A204-Rhabdomyosarcoma 0.0 adenocarcinoma SW-480-Colon 0.0 HT-1080-Fibrosarcoma 0.0 adenocarcinoma NCI-SNU-5-Gastric 0.0 MG-63-Osteosarcoma 0.0 carcinoma KATO III-Gastric 4.2 SK-LMS-1- 0.0 carcinoma Leiomyosarcoma (vulva) NCI-SNU-16-Gastric 0.0 SJRH30- 0.0 carcinoma Rhabdomyosarcoma (met to bone marrow) NCI-SNU-1-Gastric 0.0 A431-Epidermoid 0.0 carcinoma carcinoma RF-1-Gastric 0.0 WM266-4-Melanoma 0.0 adenocarcinoma RF-48-Gastric 0.0 DU 145-Prostate carcinoma 0.0 adenocarcinoma (brain metastasis) MKN-45-Gastric 0.0 MDA-MB-468-Breast 0.0 carcinoma adenocarcinoma NCI-N87-Gastric 0.0 SCC-4-Squamous cell 0.0 carcinoma carcinoma of tongue OVCAR-5-Ovarian 0.0 SCC-9-Squamous cell 0.0 carcinoma carcinoma of tongue RL95-2-Uterine 0.0 SCC-15-Squamous cell 0.0 carcinoma carcinoma of tongue HelaS3-Cervical 0.0 CAL 27-Squamous cell 0.0 adenocarcinoma carcinoma of tongue

[0667] TABLE-US-00167 TABLE KM Panel 4.1D Rel. Rel. Rel. Rel. Exp.(%) Exp.(%) Exp.(%) Exp.(%) Ag4269, Ag5115, Ag4269, Ag5115, Run Run Run Run Tissue Name 182243380 226444771 Tissue Name 182243380 226444771 Secondary Th1 act 0.4 0.0 HUVEC IL-1beta 0.0 0.0 Secondary Th2 act 0.4 0.0 HUVEC IFN 0.1 0.0 gamma Secondary Tr1 act 0.0 0.0 HUVEC TNF 0.0 0.0 alpha + IFN gamma Secondary Th1 rest 0.0 0.0 HUVEC TNF 0.0 0.0 alpha + IL4 Secondary Th2 rest 0.1 0.0 HUVEC IL-11 0.2 0.0 Secondary Tr1 rest 0.2 0.0 Lung 0.2 0.0 Microvascular EC none Primary Th1 act 0.3 0.0 Lung 0.0 0.0 Microvascular EC TNF alpha + IL- 1beta Primary Th2 act 0.3 0.0 Microvascular 0.1 0.0 Dermal EC none Primary Tr1 act 0.1 0.0 Microvascular 0.0 0.0 Dermal EC TNF alPha + IL- 1beta Primary Th1 rest 0.1 0.0 Bronchial 0.0 0.0 epithelium TNF alpha + IL1beta Primary Th2 rest 0.1 0.0 Small airway 0.0 0.0 epithelium none Primary Tr1 rest 0.2 0.0 Small airway 0.0 0.0 epithelium TNF alpha + IL- 1beta CD45RA CD4 0.0 0.0 Coronery artery 0.1 0.0 lymphocyte act SMC rest CD45RO CD4 0.5 0.0 Coronery artery 0.0 0.0 lymphocyte act SMC TNF alpha + IL- 1beta CD8 lymphocyte 0.4 0.0 Astrocytes rest 0.0 0.0 act Secondary CD8 0.5 0.0 Astrocytes 0.0 0.0 lymphocyte rest TNF alpha + IL- 1beta Secondary CD8 1.1 0.0 KU-812 0.0 0.0 lymphocyte act (Basophil) rest CD4 lymphocyte 0.1 0.0 KU-812 0.0 0.0 none (Basophil) PMA/ionomycin 2ry 0.0 0.0 CCD1106 0.0 0.0 Th1/Th2/Tr1_anti- (Keratinocytes) CD95 CH11 none LAK cells rest 0.1 0.0 CCD1106 0.0 0.0 (Keratinocytes) TNF alpha + IL- 1beta LAK cells IL-2 0.4 0.0 Liver cirrhosis 26.4 20.3 LAK cells IL- 0.2 0.0 NCI-H292 none 0.0 0.0 2 + IL-12 LAK cells IL- 0.3 0.0 NCI-H292 IL-4 0.0 0.0 2 + IFN gamma LAK cells IL-2 + IL- 0.4 0.0 NCI-H292 IL-9 0.1 0.0 18 LAK cells 0.5 0.0 NCI-H292 IL-13 0.0 0.0 PMA/ionomycin NK Cells IL-2 rest 0.4 0.0 NCI-H292 IFN 0.0 0.0 gamma Two Way MLR 3 0.0 0.0 HPAEC none 0.0 0.0 day Two way MLR 5 0.1 0.0 HPAEC TNF 0.0 0.0 day alpha + IL-1beta Two Way MLR 7 0.1 0.0 Lung fibroblast 0.1 0.0 day none PBMC rest 0.0 0.0 Lung fibroblast 0.3 0.1 TNF alpha + IL- 1beta PBMC PWM 0.5 0.0 Lung fibroblast 0.0 0.0 IL-4 PBMC PHA-L 0.4 0.0 Lung fibroblast 0.1 0.1 IL-9 Ramos (B cell) 0.3 0.0 Lung fibroblast 0.1 0.1 none IL-13 Ramos (B cell) 0.0 0.0 Lung fibroblast 0.1 0.0 ionomycin IFN gamma B lymphocytes 0.5 0.0 Dermal fibroblast 0.0 0.0 PWM CCD1070 rest B lymphocytes 0.0 0.0 Dermal fibroblast 0.3 0.0 CD40L and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.1 0.0 Dermal fibroblast 0.0 0.0 CCD1070 IL- 1beta EOL-1 dbcAMP 0.0 0.0 Dermal fibroblast 0.6 0.2 PMA/ionomycin IFN gamma Dendritic cells 0.0 0.0 Dermal fibroblast 0.1 0.1 none IL-4 Dendritic cells LPS 0.0 0.0 Dermal 0.9 0.4 Fibroblasts rest Dendritic cells 0.0 0.0 Neutrophils 0.5 0.1 anti-CD40 TNFa + LPS Monocytes rest 0.0 0.0 Neutrophils rest 0.3 0.4 Monocytes LPS 0.0 0.0 Colon 0.8 0.5 Macrophages rest 0.0 0.0 Lung 1.8 1.1 Macrophages LPS 0.0 0.0 Thymus 8.8 8.1 HUVEC none 0.0 0.0 Kidney 100.0 100.0 HUVEC starved 0.0 0.0

[0668] TABLE-US-00168 TABLE KN Panel 4D Rel. Exp.(%) Rel. Exp.(%) Ag3374, Run Ag3374, Run Tissue Name 165296618 Tissue Name 165296618 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.0 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.0 Bronchial epithelium 0.0 TNF alpha + IL1beta Primary Th2 rest 0.0 Small airway epithelium 0.0 none Primary Tr1 rest 0.0 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 0.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 0.0 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 11.6 LAK cells IL-2 + IL-12 0.0 Lupus kidney 0.7 LAK cells IL-2 + IFN 0.0 NCI-H292 none 0.0 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-4 0.0 LAK cells 0.0 NCI-H292 IL-9 0.0 PMA/ionomycin NK Cells IL-2 rest 0.0 NCI-H292 IL-13 0.0 Two Way MLR 3 day 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 5 day 0.0 HPAEC none 0.0 Two Way MLR 7 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta PBMC rest 0.0 Lung fibroblast none 0.0 PBMC PWM 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PHA-L 0.0 Lung fibroblast IL-4 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) 0.0 Lung fibroblast IL-13 0.0 ionomycin B lymphocytes PWM 0.0 Lung fibroblast IFN 0.0 gamma B lymphocytes CD40L 0.0 Dermal fibroblast 0.0 and IL-4 CCD1070 rest EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 PMA/ionomycin CCD1070 IL-1beta Dendritic cells none 0.0 Dermal fibroblast IFN 0.0 gamma Dendritic cells LPS 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells anti- 0.0 IBD Colitis 2 0.0 CD40 Monocytes rest 0.0 IBD Crohn's 0.0 Monocytes LPS 0.0 Colon 0.0 Macrophages rest 0.0 Lung 0.0 Macrophages LPS 0.0 Thymus 100.0 HUVEC none 0.0 Kidney 0.0 HUVEC starved 0.0

[0669] TABLE-US-00169 TABLE KO General oncology screening panel_v_2.4 Rel. Rel. Exp.(%) Exp.(%) Ag5115, Ag5115, Run Run Tissue Name 260280407 Tissue Name 260280407 Colon cancer 1 0.0 Bladder cancer NAT 2 0.0 Colon cancer 0.0 Bladder cancer NAT 3 0.0 NAT 1 Colon cancer 2 0.0 Bladder cancer NAT 4 0.0 Colon cancer 0.0 Adenocarcinoma of the 0.0 NAT 2 prostate 1 Colon cancer 3 0.1 Adenocarcinoma of the 0.0 prostate 1 Colon cancer 0.1 Adenocarcinoma of the 0.0 NAT 3 prostate 3 Colon malignant 0.0 Adenocarcinoma of the 0.0 cancer 4 prostate 4 Colon normal 0.0 Prostate cancer NAT 5 0.0 adjacent tissue 4 Lung cancer 1 0.0 Adenocarcinoma of the 0.0 prostate 6 Lung NAT 1 0.0 Adenocarcinoma of the 0.0 prostate 7 Lung cancer 2 0.0 Adenocarcinoma of the 0.0 prostate 8 Lung NAT 2 0.0 Adenocarcinoma of the 0.0 prostate 9 Squamous cell 0.0 Prostate cancer NAT 0.0 carcinoma 3 10 Lung NAT 3 0.0 Kidney cancer 1 0.0 metastatic 0.0 KidneyNAT 1 4.4 melanoma 1 Melanoma 2 0.0 Kidney cancer 2 2.0 Melanoma 3 0.0 Kidney NAT 2 100.0 metastatic 0.0 Kidney cancer 3 0.0 melanoma 4 metastatic 0.0 Kidney NAT 3 24.3 melanoma 5 Bladder cancer 1 0.0 Kidney cancer 4 0.0 Bladder cancer 0.0 Kidney NAT 4 12.9 NAT 1 Bladder cancer 2 0.0

[0670] CNS_neurodegeneration_v1.0 Summary: Ag4269/Ag5115 These panels do not show differential expression of this gene in Alzheimer's disease. However, this expression profile shows that this gene is expressed at low levels in the CNS, including the hippocampus and cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

[0671] General_screening panel_v1.4 Summary: Ag4269 Highest expression is seen in fetal liver (CT=25). Moderate to low levels of expression are seen in liver, fetal kidney, and cell lines derived from colon and liver cancer. This expression is in agreement with expression in Panel 1.3D, where expression is seen in kidney and liver derived tissues. Thus, expression of this gene could be used as a marker of these tissues.

[0672] General_screening_panel_v1.5 Summary: Ag5115 Highest expression of the NOV12E gene is seen in fetal liver (CT=25.2) and liver. Moderate levels of expression are seen in the whole brain, a colon cancer cell line and fetal kidney. Low but significant levels of expression are seen in the hippocampus and fetal lung. This expression is in agreement with expression seen in other panels. However, the NOV12E gene is also detected in fetal lung. Ag5116 This experiment shows low/undetectable levels (CTs>35) of expression in all samples on this panel (data not shown).

[0673] Panel 1.3D Summary: Ag3374 Expression of this gene is restricted to a few samples, with highest expression in liver (CT=24.1), fetal liver, and kidney. Moderate expression is seen in fetal kidney and low levels of expression are seen in a colon cancer cell line. This expression profile suggests that this gene could be used to differentiate between liver and other samples on this panel and as a marker of liver and kidney tissue.

[0674] Panel 2.2 Summary: See Panel 2D for discussion. Panel 2.2 confirms the results in 2D.

[0675] Panel 2D Summary: Ag3374 Highest expression of this gene is seen in liver derived tissue (CT=23.9), with expression in this panel restricted to liver and kidney derived tissue. This expression is in agreement with expression seen in Panel 1.3D. In addition, this gene is more highly expressed in kidney tissue when compared to normal adjacent tissue. This gene encodes a putative kininogen, which has been shown to inhibit angiogenesis (Colman R. Blood. 95:543; Guo Y. Arterioscler Thromb Vasc Biol. September 2001, pg. 1427). The expressed protein can also be used in the treatment of kidney cancers as it is not expressed in kidney cancers compared to the adjacent normal tissues and inhibition of its activity using antibodies or small molecule drugs may be useful in treating liver cancer. Thus, therapeutic modulation of the expression or function of this gene could be effective in the treatment of liver and kidney cancers.

[0676] Panel 3D Summary: Ag3374 Expression in this panel is restricted to samples derived from colon cancer cell lines (CTs=34-35). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of colon cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon cancer. A second experiment with probe and primer set Ag4269 shows low/undetectable levels of expression (CTs>35). (Data not shown.)

[0677] Panel 4.1D Summary: Ag5115/Ag4269 Two experiments with two different probe and primer sets are in good agreement with highest expression of the NOV12E in the kidney (CTs=27). In addition, moderate levels of expression of this gene are also seen in thymus, lung and colon. The probe and primer sets for Ag5115 are specific to NOV12E. In a second experiment with Ag4269 low levels of expression of this gene is also seen in selected samples, including T cells, neutrophils, and activated dermal fibroblasts.

[0678] Panel 4D Summary: Ag3374 This transcript is most highly expressed in the thymus (CT=24.3). The protein encoded by this gene could therefore play an important role in T cell development. Thus, therapeutic modulation of the expression or function of this gene may modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.

[0679] In addition, moderate levels of expression are seen in liver cirrhosis and lupus kidney, in agreement with previous panels that showed expression in liver and kidney derived tissues.

[0680] General oncology screening panel_v.sub.--2.4 Summary: Ag5115 Expression of the NOV12E is restricted to kidney-derived tissue (highest CT=26). In addition, expression is higher in normal tissue than in adjacent tumor. Thus, expression of this gene could be used as a marker of kidney tissue. Furthermore, therapeutic modulation of this putative kininogen may be effective in the treatment of kidney cancer as a protein therapeutic. Ag5116 This experiment shows low/undetectable levels (CTs>35) of expression in all samples on this panel (data not shown).

[0681] L. NOV13A: Serine Protease-CUB Domain Protein

[0682] Expression of gene NOV13A, representing a full-length physical clone, was assessed using the primer-probe set Ag6855, described in Table LA. Results of the RTQ-PCR runs are shown in Table LB. TABLE-US-00170 TABLE LA Probe Name Ag6855 Start SEQ ID Primers Sequences Length Position No Forward 5'-ctttacttcatgcacttcaacttg-3' 24 403 181 Probe TET-5'-cctcctacctttgtgaatatgactatgtga- 30 431 182 3'-TAMRA Reverse 5'-actctcgaagtgtcctcagtttc-3' 23 466 183

[0683] TABLE-US-00171 TABLE LB General_screening_panel_v1.6 Rel. Exp.(%) Rel. Exp.(%) Ag6855, Ag6855, Run Run Tissue Name 278020605 Tissue Name 278020605 Adipose 0.0 Renal ca. TK-10 10.6 Melanoma* 23.3 Bladder 0.0 Hs688(A).T Melanoma* 22.7 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 7.0 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 27.4 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 0.0 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 37.1 OVCAR-4 Ovarian ca. 0.0 Small Intestine Pool 77.9 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 16.0 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 23.0 OVCAR-8 Ovary 5.8 Fetal Heart 73.2 Breast ca. MCF-7 0.0 Heart Pool 43.8 Breast ca. MDA- 0.0 Lymph Node Pool 41.5 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 11.5 Breast ca. T47D 0.0 Skeletal Muscle Pool 9.5 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 27.5 Thymus Pool 22.7 Trachea 9.9 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 47.3 (glio/astro) U-118-MG Fetal Lung 8.8 CNS cancer 0.0 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 32.1 295 Lung ca. A549 0.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 21.3 Lung ca. NCI-H23 0.0 Brain (fetal) 46.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 14.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 4.9 Lung ca. NCI-H522 0.0 Brain (Substantia 6.3 nigra) Pool Liver 94.0 Brain (Thalamus) pool 7.2 Fetal Liver 100.0 Brain (whole) 9.9 Liver ca. HepG2 25.7 Spinal Cord Pool 46.7 Kidney Pool 86.5 Adrenal Gland 10.9 Fetal Kidney 0.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.0

[0684] General_screening panel_v1.6 Summary: Ag6855 Expression of the NOV13A gene is limited to the fetal liver (CT=34.9). Thus, expression of this gene may be used as a marker of this tissue.

[0685] M. NOV14A: Hemopexin

[0686] Expression of gene NOV14A, representing a full-length physical clone, was assessed using the primer-probe set Ag6949, described in Table MA. Results of the RTQ-PCR runs are shown in Table MB. TABLE-US-00172 TABLE MA Probe Name Ag6949 Start SEQ ID Primers Sequences Length Position No Forward 5'-ttttaaagggacccactactgg-3' 22 625 184 Probe TET-5'-ctggcatagctggcccattgctcat-3'- 25 577 185 TAMRA Reverse 5'-gaaaaggcagcatccactg-3' 19 536 186

[0687] TABLE-US-00173 TABLE MB General_screening_panel_v1.6 Rel. Exp.(%) Rel. Exp.(%) Ag6949, Ag6949, Run Run Tissue Name 279032765 Tissue Name 279032765 Adipose 0.0 Renal ca. TK-10 0.2 Melanoma* 0.0 Bladder 0.2 Hs688(A).T Melanoma* 0.1 Gastric ca. (liver met.) 0.1 Hs688(B).T NCI-N87 Melanoma* M14 0.1 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.0 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.1 carcinoma SCC-4 met) SW620 Testis Pool 0.1 Colon ca. HT29 0.0 Prostate ca.* (bone 0.1 Colon ca. HCT-116 0.2 met) PC-3 Prostate Pool 0.1 Colon ca. CaCo-2 3.3 Placenta 0.0 Colon cancer tissue 0.1 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.1 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 0.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 0.1 OVCAR-4 Ovarian ca. 0.5 Small Intestine Pool 0.1 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 0.1 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 0.0 OVCAR-8 Ovary 0.1 Fetal Heart 0.1 Breast ca. MCF-7 0.3 Heart Pool 0.0 Breast ca. MDA- 0.0 Lymph Node Pool 0.1 MB-231 Breast ca. BT 549 0.1 Fetal Skeletal Muscle 0.0 Breast ca. T47D 0.2 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 Breast Pool 0.1 Thymus Pool 0.1 Trachea 0.1 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.1 CNS cancer 0.1 (glio/astro) U-118-MG Fetal Lung 0.4 CNS cancer 0.1 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.2 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 0.2 295 Lung ca. A549 0.1 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.4 Lung ca. NCI-H23 0.1 Brain (fetal) 0.4 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.1 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 100.0 Brain (Thalamus) pool 0.0 Fetal Liver 87.7 Brain (whole) 1.7 Liver ca. HepG2 0.2 Spinal Cord Pool 0.0 Kidney Pool 0.2 Adrenal Gland 0.0 Fetal Kidney 0.1 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.1 Pancreas Pool 0.0

[0688] General_screening_panel_v1.6 Summary: Ag6949 Highest expression of the NOV14A gene is seen in the liver (CT=23). This gene encodes a homolog of hemopexin, a heme binding glycoprotein synthesized in the liver that has been implicated in the transport of heme into liver cells. Thus, expression of this gene could be used as a marker of liver tissue and to differentiate these liver derived samples from other samples on this panel.

[0689] Orthologues of hemopexin appear to be upregulated in hepatocellular carcinoma cells infected with woodchuck hepatitis B (Darabi A. Cancer Lett 1995 Aug. 16;95(1-2): 153-9). Thus, based on the preferential expression of this gene in liver and the homology of this gene to hemopexin, therapeutic modulation of the expression or function of this gene may be effective in the treatment of liver cancer.

[0690] N. NOV15A: F2 Alpha Prostoglandin Regulatory PROTEIN

[0691] Expression of gene NOV15A was assessed using the primer-probe set Ag4383, described in Table NA. Results of the RTQ-PCR runs are shown in Tables NB, NC, ND and NE. TABLE-US-00174 TABLE NA Probe Name Ag4383 Start SEQ ID Primers Sequences Length Position No Forward 5'-agaccaaggccactacaaatgt-3' 22 350 187 Probe TET-5'-cacagatgccactgtccagggaa-3'- 23 383 188 TAMRA Reverse 5'-acctgcactgtgtcctcatagt-3' 22 406 189

[0692] TABLE-US-00175 TABLE NB CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Exp.(%) Ag4383, Ag4383, Run Run Tissue Name 224502235 Tissue Name 224502235 AD 1 Hippo 12.9 Control (Path) 3 7.0 Temporal Ctx AD 2 Hippo 23.8 Control (Path) 4 34.9 Temporal Ctx AD 3 Hippo 3.4 AD 1 Occipital Ctx 7.4 AD 4 Hippo 6.1 AD 2 Occipital Ctx 0.0 (Missing) AD 5 Hippo 67.4 AD 3 Occipital Ctx 2.7 AD 6 Hippo 41.8 AD 4 Occipital Ctx 19.5 Control 2 Hippo 22.8 AD 5 Occipital Ctx 46.7 Control 4 Hippo 16.5 AD 6 Occipital Ctx 9.7 Control (Path) 3 6.7 Control 1 Occipital 3.7 Hippo Ctx AD 1 Temporal 16.0 Control 2 Occipital 46.3 Ctx Ctx AD 2 Temporal 17.0 Control 3 Occipital 12.8 Ctx Ctx AD 3 Temporal 5.8 Control 4 Occipital 8.2 Ctx Ctx AD 4 Temporal 19.5 Control (Path) 1 83.5 Ctx Occipital Ctx AD 5 Inf Temporal 72.7 Control (Path) 2 7.1 Ctx Occipital Ctx AD 5 Sup 31.2 Control (Path) 3 1.6 Temporal Ctx Occipital Ctx AD 6 Inf Temporal 38.2 Control (Path) 4 10.8 Ctx Occipital Ctx AD 6 Sup 47.6 Control 1 Parietal 8.7 Temporal Ctx Ctx Control 1 9.8 Control 2 Parietal 36.9 Temporal Ctx Ctx Control 2 59.5 Control 3 Parietal 15.8 Temporal Ctx Ctx Control 3 9.7 Control (Path) 1 100.0 Temporal Ctx Parietal Ctx Control 3 16.3 Control (Path) 2 18.3 Temporal Ctx Parietal Ctx Control (Path) 1 67.8 Control (Path) 3 5.5 Temporal Ctx Parietal Ctx Control (Path) 2 44.1 Control (Path) 4 45.1 Temporal Ctx Parietal Ctx

[0693] TABLE-US-00176 TABLE NC General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4383, Ag4383, Run Run Tissue Name 222567780 Tissue Name 222567780 Adipose 1.0 Renal ca. TK-10 12.2 Melanoma* 10.4 Bladder 4.8 Hs688(A).T Melanoma* 11.9 Gastric ca. (liver met.) 7.3 Hs688(B).T NCI-N87 Melanoma* M14 31.6 Gastric ca. KATO III 24.8 Melanoma* 0.0 Colon ca. SW-948 5.5 LOXIMVI Melanoma* SK- 4.1 Colon ca. SW480 11.3 MEL-5 Squamous cell 16.4 Colon ca.* (SW480 3.9 carcinoma SCC-4 met) SW620 Testis Pool 2.0 Colon ca. HT29 3.4 Prostate ca.* (bone 1.3 Colon ca. HCT-116 16.4 met) PC-3 Prostate Pool 1.7 Colon ca. CaCo-2 2.8 Placenta 5.3 Colon cancer tissue 8.2 Uterus Pool 1.7 Colon ca. SW1116 3.7 Ovarian ca. 10.2 Colon ca. Colo-205 3.0 OVCAR-3 Ovarian ca. SK- 9.0 Colon ca. SW-48 6.9 OV-3 Ovarian ca. 3.4 Colon Pool 8.0 OVCAR-4 Ovarian ca. 15.8 Small Intestine Pool 7.5 OVCAR-5 Ovarian ca. 10.2 Stomach Pool 4.1 IGROV-1 Ovarian ca. 10.0 Bone Marrow Pool 2.5 OVCAR-8 Ovary 5.1 Fetal Heart 3.7 Breast ca. MCF-7 3.7 Heart Pool 5.0 Breast ca. MDA- 0.4 Lymph Node Pool 11.3 MB-231 Breast ca. BT 549 0.3 Fetal Skeletal Muscle 2.8 Breast ca. T47D 30.8 Skeletal Muscle Pool 0.7 Breast ca. MDA-N 6.0 Spleen Pool 0.9 Breast Pool 9.0 Thymus Pool 3.5 Trachea 5.4 CNS cancer 20.7 (glio/astro) U87-MG Lung 0.2 CNS cancer 12.9 (glio/astro) U-118-MG Fetal Lung 5.3 CNS cancer 6.8 (neuro; met) SK-N-AS Lung ca. NCI-N417 4.7 CNS cancer (astro) 17.1 SF-539 Lung ca. LX-1 7.3 CNS cancer (astro) 100.0 SNB-75 Lung ca. NCI-H146 2.4 CNS cancer (glio) 8.7 SNB-19 Lung ca. SHP-77 6.9 CNS cancer (glio) SF- 13.9 295 Lung ca. A549 9.3 Brain (Amygdala) 0.9 Pool Lung ca. NCI-H526 6.3 Brain (cerebellum) 0.9 Lung ca. NCI-H23 1.9 Brain (fetal) 6.7 Lung ca. NCI-H460 6.3 Brain (Hippocampus) 1.0 Pool Lung ca. HOP-62 1.7 Cerebral Cortex Pool 1.6 Lung ca. NCI-H522 0.6 Brain (Substantia 1.6 nigra) Pool Liver 0.3 Brain (Thalamus) Pool 2.0 Fetal Liver 1.8 Brain (whole) 1.9 Liver ca. HepG2 3.4 Spinal Cord Pool 0.8 Kidney Pool 15.3 Adrenal Gland 6.2 Fetal Kidney 1.5 Pituitary gland Pool 0.4 Renal ca. 786-0 34.4 Salivary Gland 3.3 Renal ca. A498 7.7 Thyroid (female) 1.4 Renal ca. ACHN 3.2 Pancreatic ca. 1.5 CAPAN2 Renal ca. UO-31 15.6 Pancreas Pool 10.1

[0694] TABLE-US-00177 TABLE ND Panel CNS_1 Rel. Exp.(%) Rel. Ag4383, Exp.(%) Ag4383, Run Run Tissue Name 190323005 Tissue Name 190323005 BA4 Control 34.2 BA17 PSP 4.4 BA4 Control2 28.9 BA17 PSP2 10.9 BA4 0.0 Sub Nigra Control 21.5 Alzheimer's2 BA4 Parkinson's 22.7 Sub Nigra Control2 24.5 BA4 50.0 Sub Nigra 6.8 Parkinson's2 Alzheimer's2 BA4 11.9 Sub Nigra 29.7 Huntington's Parkinson's2 BA4 12.4 Sub Nigra 42.3 Huntington's2 Huntington's BA4 PSP 3.3 Sub Nigra 23.3 Huntington's2 BA4 PSP2 18.6 Sub Nigra PSP2 3.1 BA4 Depression 12.3 Sub Nigra 0.0 Depression BA4 3.4 Sub Nigra 10.6 Depression2 Depression2 BA7 Control 33.4 Glob Palladus 9.2 Control BA7 Control2 45.4 Glob Palladus 3.4 Control2 BA7 3.1 Glob Palladus 20.7 Alzheimer's2 Alzheimer's BA7 Parkinson's 14.8 Glob Palladus 3.0 Alzheimer's2 BA7 33.2 Glob Palladus 40.1 Parkinson's2 Parkinson's BA7 30.8 Glob Palladus 11.6 Huntington's Parkinson's2 BA7 73.2 Glob Palladus PSP 1.5 Huntington's2 BA7 PSP 12.0 Glob Palladus PSP2 6.5 BA7 PSP2 20.6 Glob Palladus 0.0 Depression BA7 Depression 0.0 Temp Pole Control 17.9 BA9 Control 20.0 Temp Pole Control2 48.0 BA9 Control2 43.2 Temp Pole 0.0 Alzheimer's BA9 3.1 Temp Pole 2.7 Alzheimer's Alzheimer's2 BA9 9.2 Temp Pole 13.6 Alzheimer's2 Parkinson's BA9 Parkinson's 3.8 Temp Pole 36.9 Parkinson's2 BA9 41.2 Temp Pole 33.4 Parkinson's2 Huntington's BA9 36.6 Temp Pole PSP 0.0 Huntington's BA9 11.2 Temp Pole PSP2 0.0 Huntington's2 BA9 PSP 10.7 Temp Pole 3.2 Depression2 BA9 PSP2 8.0 Cing Gyr Control 100.0 BA9 Depression 2.2 Cing Gyr Control2 31.0 BA9 9.6 Cing Gyr 31.2 Depression2 Alzheimer's BA17 Control 32.5 Cing Gyr 3.5 Alzheimer's2 BA17 Control2 41.5 Cing Gyr 40.3 Parkinson's BA17 10.8 Cing Gyr 24.8 Alzheimer's2 Parkinson's2 BA17 8.7 Cing Gyr 47.6 Parkinson's Huntington's BA17 25.9 Cing Gyr 22.2 Parkinson's2 Huntington's2 BA17 37.4 Cing Gyr PSP 0.0 Huntington's BA17 16.7 Cing Gyr PSP2 0.0 Huntington's2 BA17 5.2 Cing Gyr 6.8 Depression Depression BA17 12.1 Cing Gyr 6.4 Depression2 Depression2

[0695] TABLE-US-00178 TABLE NE Panel CNS_1.1 Rel. Exp.(%) Rel. Ag4383, Exp.(%) Ag4383, Run Run Tissue Name 190028010 Tissue Name 190028010 Cing Gyr 7.8 BA17 PSP2 4.2 Depression2 Cing Gyr 0.0 BA17 PSP 15.8 Depression Cing Gyr PSP2 3.9 BA17 2.3 Huntington's2 Cing Gyr PSP 16.8 BA17 30.8 Huntington's Cing Gyr 14.6 BA17 43.5 Huntington's2 Parkinson's2 Cing Gyr 46.7 BA17 11.4 Huntington's Parkinson's Cing Gyr 26.1 BA17 8.3 Parkinson's2 Alzheimer's2 Cing Gyr 26.4 BA17 Control2 60.7 Parkinson's Cing Gyr 29.9 BA17 Control 35.1 Alzheimer's2 Cing Gyr 12.2 BA9 0.0 Alzheimer's Depression2 Cing Gyr Control2 20.0 BA9 Depression 15.5 Cing Gyr Control 92.0 BA9 PSP2 3.5 Temp Pole 14.3 BA9 PSP 7.9 Depression2 Temp Pole PSP2 6.0 BA9 52.1 Huntington's2 Temp Pole PSP 2.3 BA9 65.1 Huntington's Temp Pole 57.8 BA9 100.0 Huntington's Parkinson's2 Temp Pole 50.3 BA9 Parkinson's 51.4 Parkinson's2 Temp Pole 44.8 BA9 12.0 Parkinson's Alzheimer's2 Temp Pole 7.5 BA9 3.8 Alzheimer's2 Alzheimer's Temp Pole 3.8 BA9 Control2 91.4 Alzheimer's Temp Pole Control2 48.6 BA9 Control 7.7 Temp Pole Control 22.8 BA7 Depression 4.1 Glob Palladus 0.0 BA7 PSP2 24.0 Depression Glob Palladus PSP2 0.0 BA7 PSP 21.5 Glob Palladus PSP 0.0 BA7 54.3 Huntington's2 Glob Palladus 3.5 BA7 82.9 Parkinson's2 Huntington's Glob Palladus 83.5 BA7 42.6 Parkinson's Parkinson's2 Glob Palladus 6.5 BA7 Parkinson's 31.0 Alzheimer's2 Glob Palladus 8.5 BA7 4.1 Alzheimer's Alzheimer's2 Glob Palladus 4.0 BA7 Control2 46.3 Control2 Glob Palladus 3.5 BA7 Control 48.3 Control Sub Nigra 3.6 BA4 0.0 Depression2 Depression2 0.0 Sub Nigra 0.0 BA4 Depression 0.0 Depression Sub Nigra PSP2 6.1 BA4 PSP2 32.8 Sub Nigra 30.4 BA4 PSP 7.4 Huntington's2 Sub Nigra 59.5 BA4 1.6 Huntington's Huntington's2 Sub Nigra 36.9 BA4 30.6 Parkinson's2 Huntington's Sub Nigra 0.0 BA4 59.5 Alzheimer's2 Parkinson's2 Sub Nigra Control2 10.4 BA4 Parkinson's 62.0 Sub Nigra Control 40.6 BA4 11.0 Alzheimer's2 BA17 Depression2 6.0 BA4 Control2 32.5 BA17 Depression 12.1 BA4 Control 28.9

[0696] CNS_neurodegeneration_v1.0 Summary: Ag4383 This panel confirms the expression of the NOV15A gene at low levels in the brains of an independent group of individuals. This gene is found to be slightly down-regulated in the temporal cortex of Alzheimer's disease patients when analyzed by ANCOVA (p=0.0087). Therefore, treatment with antagonists or agonists may prevent or delay the onset of AD.

[0697] General_screening_panel_v1.4 Summary: Ag4383 Highest expression of the NOV15A gene is detected in a CNS cancer cell line (CT=24.5). In addition, significant expression of this gene is seen in cluster of cancer cell lines including CNS, pancreatic, colon, gastric, renal, lung, breast, ovarian, squamous cell carcinoma and melanoma cancer cell lines. Therefore, therapeutic modulation of this gene product may be beneficial in the treatment of these cancers.

[0698] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0699] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0700] The NOV15A gene codes for a homologue of mouse F2 alpha prostaglandin regulatory protein (FPRP). FPRP, a cell-surface Ig superfamily protein, associates specifically with CD81 or with CD81 and CD9, but not with integrins or other TM4SF proteins (Stipp et al., 2001, J Biol Chem 276(7):4853-62, PMID: 11087758). CD81 is a critical regulator of neuron-induced astrocytic differentiation (Kelic et al., 2001, Mol Cell Neurosci 17(3):551-60, PMID: 11273649). Therefore, FPRP encoded by this gene may play a role in astrocyte differentiation and brain development.

[0701] Panel 4.1D Summary: Ag4383 Results from one experiment with the NOV15A gene are not included. The amp plot indicates that there were experimental difficulties with this run (data not shown).

[0702] Panel CNS.sub.--1 Summary: Ag4383 This panel confirms the expression of the NOV15A gene at low levels in the brains of an independent group of individuals. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0703] Panel CNS.sub.--1.1 Summary: Ag4383 This panel confirms the expression of the NOV15A gene at low levels in the brains of an independent group of individuals. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0704] O. NOV16A: Neuronal Leucine-Rich Repeat Protein

[0705] Expression of gene NOV16A was assessed using the primer-probe sets Ag4386 and Ag6885, described in Tables OA and OB. Results of the RTQ-PCR runs are shown in Tables OC, OD, OE and OF. TABLE-US-00179 TABLE OA Probe Name Ag4386 Start SEQ ID Primers Sequences Length Position No Forward 5'-tcacatgacctttgactttgtg-3' 22 1467 190 Probe TET-5'-acctggccctctggggataaaa-3'- 23 1491 191 TAMRA Reverse 5'-gaaggaaaggtcagaagagctt-3' 22 1540 192

[0706] TABLE-US-00180 TABLE OB Probe Name Ag6885 Start SEQ ID Primers Sequences Length Position No Forward 5'-cctcaaggtgaccagtttgtc-3' 21 811 193 Probe TET-5'-cgcccttcagacactagaggaaacag-3'- 26 771 194 TAMRA Reverse 5'-ctcctggatgtggcagataa-3' 20 751 195

[0707] TABLE-US-00181 TABLE OC CNS_neurodegeneration_v1.0 Rel. Exp.(%) Rel. Ag4386, Exp.(%) Ag4386, Run Run Tissue Name 224502238 Tissue Name 224502238 AD 1 Hippo 6.8 Control (Path) 3 0.0 Temporal Ctx AD 2 Hippo 11.4 Control (Path) 4 11.7 Temporal Ctx AD 3 Hippo 6.3 AD 1 Occipital 11.3 Ctx AD 4 Hippo 0.0 AD 2 Occipital 0.0 Ctx (Missing) AD 5 hippo 100.0 AD 3 Occipital 3.0 Ctx AD 6 Hippo 24.5 AD 4 Occipital 7.7 Ctx Control 2 Hippo 10.8 AD 5 Occipital 7.2 Ctx Control 4 Hippo 0.0 AD 6 Occipital 7.8 Ctx Control (Path) 3 0.0 Control 1 0.0 Hippo Occipital Ctx AD 1 Temporal Ctx 12.3 Control 2 33.4 Occipital Ctx AD 2 Temporal Ctx 6.3 Control 3 13.6 Occipital Ctx AD 3 Temporal Ctx 0.0 Control 4 0.0 Occipital Ctx AD 4 Temporal Ctx 5.8 Control (Path) 1 21.3 Occipital Ctx AD 5 Inf Temporal 37.9 Control (Path) 2 3.8 Ctx Occipital Ctx AD 5 SupTemporal 25.9 Control (Path) 3 0.0 Ctx Occipital Ctx AD 6 Inf Temporal 19.9 Control (Path) 4 4.4 Ctx Occipital Ctx AD 6 Sup Temporal 18.0 Control 1 Parietal 8.1 Ctx Ctx Control 1 Temporal 0.0 Control 2 Parietal 8.7 Ctx Ctx Control 2 Temporal 5.9 Control 3 Parietal 5.6 Ctx Ctx Control 3 Temporal 0.0 Control (Path) 1 8.9 Ctx Parietal Ctx Control 4 Temporal 0.0 Control (Path) 2 0.0 Ctx Parietal Ctx Control (Path) 1 7.9 Control (Path) 3 0.0 Temporal Ctx Parietal Ctx Control (Path) 2 12.4 Control (Path) 4 11.3 Temporal Ctx Parietal Ctx

[0708] TABLE-US-00182 TABLE OD General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4386, Ag4386, Run Run Tissue Name 222567010 Tissue Name 222567010 Adipose 0.1 Renal ca. TK-10 0.2 Melanoma* 0.0 Bladder 1.0 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.4 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.3 MEL-5 squamous cell 0.0 Colon ca.* (SW480 0.3 carcinoma SCC-4 met) SW620 Testis Pool 1.7 Colon ca. HT29 0.1 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.5 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.1 OVCAR-3 Ovarian ca. SK- 0.0 Colon ca. SW-48 0.3 OV-3 Ovarian ca. 0.0 Colon Pool 0.1 OVCAR-4 Ovarian ca. 1.5 Small Intestine Pool 0.2 OVCAR-5 Ovarian ca. 0.1 Stomach Pool 0.1 IGROV-1 Ovarian ca. 0.2 Bone Marrow Pool 0.1 OVCAR-8 Ovary 0.0 Fetal Heart 0.0 Breast ca. MCF-7 1.8 Heart Pool 0.1 Breast ca. MDA- 0.3 Lymph Node Pool 0.2 MB-231 Breast ca. BT 549 0.1 Fetal Skeletal Muscle 0.9 Breast ca. T47D 2.4 Skeletal Muscle Pool 22.5 Breast ca. MDA-N 0.0 Spleen Pool 0.4 Breast Pool 0.1 Thymus Pool 0.7 Trachea 0.9 CNS cancer 0.1 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.1 (glio/astro) U-118-MG Fetal Lung 1.6 CNS cancer 0.3 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.4 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.2 CNS cancer (glio) SF- 0.0 295 Lung ca. A549 0.0 Brain (Amygdala) 0.3 Pool Lung ca. NCI-H526 0.1 Brain (cerebellum) 100.0 Lung ca. NCI-H23 0.1 Brain (fetal) 0.1 Lung ca. NCI-H460 0.1 Brain (Hippocampus) 0.1 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.0 Lung ca. NCI-H522 0.0 Brain (Substantia 0.1 nigra) Pool Liver 0.7 Brain (Thalamus) Pool 1.1 Fetal Liver 0.2 Brain (whole) 1.6 Liver ca. HepG2 0.0 Spinal Cord Pool 4.2 Kidney Pool 0.2 Adrenal Gland 1.4 Fetal Kidney 0.1 Pituitary gland Pool 0.9 Renal ca. 786-0 0.2 Salivary Gland 1.3 Renal ca. A498 0.0 Thyroid (female) 0.7 Renal ca. ACHN 0.1 Pancreatic ca. 0.1 CAPAN2 Renal ca. UO-31 0.1 Pancreas Pool 0.9

[0709] TABLE-US-00183 TABLE OE General_screening_panel_v1.6 Rel. Exp.(%) Rel. Exp.(%) Ag6885, Ag6885, Run Run Tissue Name 278388126 Tissue Name 278388126 Adipose 0.5 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 0.7 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 1.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.3 LOXIMVI Melanoma* SK- 0.0 Colon ca. SW480 0.6 MEL-5 Squamous cell 0.0 Colon ca.* (SW480 0.1 carcinoma SCC-4 met) SW620 Testis Pool 2.8 Colon ca. HT29 0.1 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.7 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 0.0 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca. 0.1 Colon ca. Colo-205 0.1 OVCAR-3 Ovarian ca. SK- 0.1 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.1 Colon Pool 0.1 OVCAR-4 Ovarian ca. 0.8 Small Intestine Pool 0.3 OVCAR-5 OVarian ca. 0.0 Stomach Pool 0.4 IGROV-1 Ovarian ca. 0.1 Bone Marrow Pool 0.3 OVCAR-8 Ovary 0.1 Fetal Heart 0.2 Breast ca. MCF-7 0.9 Heart Pool 0.5 Breast ca. MDA- 0.0 Lymph Node Pool 0.1 MB-231 Breast ca. BT 549 0.1 Fetal Skeletal Muscle 1.1 Breast ca. T47D 1.0 Skeletal Muscle Pool 8.2 Breast ca. MDA-N 0.0 Spleen Pool 0.5 Breast Pool 0.2 Thymus Pool 1.5 Trachea 1.0 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.2 (glio/astro) U-118-MG Fetal Lung 1.2 CNS cancer 0.5 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.1 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 1.3 CNS cancer (astro) 0.1 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.1 CNS cancer (glio) SF- 0.1 295 Lung ca. A549 0.1 Brain (Amygdala) 0.1 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 100.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.1 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.3 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.3 Lung ca. NCI-H522 0.1 Brain (Substantia 0.3 nigra) Pool Liver 1.0 Brain (Thalamus) Pool 0.5 Fetal Liver 0.0 Brain (whole) 1.7 Liver ca. HepG2 0.0 Spinal Cord Pool 3.8 Kidney Pool 0.2 Adrenal Gland 2.6 Fetal Kidney 0.5 Pituitary gland Pool 1.6 Renal ca. 786-0 0.0 Salivary Gland 2.2 Renal ca. A498 0.1 Thyroid (female) 2.4 Renal ca. ACHN 0.1 Pancreatic ca. 0.1 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.6

[0710] TABLE-US-00184 TABLE OF Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4386, Run Ag4386, Run Tissue Name 186506628 Tissue Name 186506628 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 1.3 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.4 Secondary Th2 rest 0.5 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.5 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.8 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.8 Bronchial epithelium 1.0 TNF alpha + IL1beta Primary Th2 rest 0.6 Small airway epithelium 0.0 none Primary Tr1 rest 0.0 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 1.0 Coronery artery SMC 0.5 lymphocyte act rest CD45RO CD4 4.8 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 2.0 Astrocytes rest 1.0 Secondary CD8 4.7 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 0.4 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.5 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 0.5 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 1.0 LAK cells IL-2 + IL-12 0.0 NCI-H292 none 1.9 LAK cells IL-2 + IFN 2.4 NCI-H292 IL-4 0.7 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-9 0.6 LAK cells 3.6 NCI-H292 IL-13 0.0 PMA/ionomycin NK Cells IL-2 rest 3.7 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 1.2 HPAEC none 0.0 Two Way MLR 5 day 0.5 HPAEC TNF alpha + IL- 0.7 1beta Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 PBMC rest 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PWM 14.9 Lung fibroblast IL-4 0.0 PBMC PHA-L 5.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-13 0.0 Ramos (B cell) 0.5 Lung fibroblast IFN 0.0 ionomycin gamma B lymphocytes PWM 1.5 Dermal fibroblast 0.0 CCD1070 rest B lymphocytes CD40L 0.4 Dermal fibroblast 0.0 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.5 CCD1070 IL-1beta EOL-1 dbcAMP 0.0 Dermal fibroblast IFN 1.0 PMA/ionomycin gamma Dendritic cells none 0.0 Dermal fibroblast IL-4 0.3 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 1.3 Dendritic cells anti- 0.0 Neutrophils TNFa + LPS 0.0 CD40 Monocytes rest 0.0 Neutrophils rest 0.0 Monocytes LPS 0.0 Colon 2.4 Macrophages rest 0.0 Lung 5.8 Macrophages LPS 0.0 Thymus 15.2 HUVEC none 0.0 Kidney 100.0 HUVEC starved 0.0

[0711] CNS_neurodegeneration_v1.0 Summary: Ag4386 This panel confirms the expression of the NOV16A gene at low levels in the brains with highest expression in hippocampus of an Alzheimer patient (CT=34.6). Therefore, therapeutic modulation of this gene may be beneficial in the treatment of Alzheimer's disease.

[0712] General_screening_panel_v1.4 Summary: Ag4386 Highest expression of the NOV16A gene is detected in brain (cerebellum) (CT=27.4). In addition, moderate expression of this gene is also detected thalamus, whole brain and spinal cord. Therefore, therapeutic modulation of this gene product may be beneficial in the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0713] The NOV16A gene encodes a homolog of neuronal leucine rich repeat protein (NLRR). In zebra fish the NLRR functions as a neuronal-specific adhesion molecule or soluble ligand binding receptor, primarily during restoration of the nervous system after injury (Bormann et al., 1999, Mol Cell Neurosci 13 (3):167-79, PMID: 10328879). Thus, NLRR encoded by this gene may also play similar role in restoration of nervous system after injury.

[0714] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adrenal gland, thyroid, pituitary gland, skeletal muscle, and liver. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0715] Interestingly, this gene is expressed at much higher levels in adult (CT=29.5) when compared to fetal skeletal muscle (CT=34.3). This observation suggests that expression of this gene can be used to distinguish fetal from adult skeletal muscle.

[0716] General_screening_panel_v1.6 Summary: Ag4386 Highest expression of this gene is seen in the cerebellum (CT=26.7). This is in agreement with expression seen in Panel 1.4. Overall, expression in this panel is in agreement with expression in Panel 1.5. Please see that panel for further description and utility of this gene in metabolic and CNS disorders.

[0717] Panel 4.1D Summary: Ag4386 Highest expression of the NOV16A gene is detected in kidney (CT=30.7). Thus, expression of this gene may be used to distinguish kidney sample from other samples in this panel. In addition, low expression of this gene is also seen in lung, thymus and PWM treated PBMC cells. Therefore, therapeutic modulation of this gene product may be useful in the treatment of inflammatory and autoimmune diseases affecting kidney and lung such as lupus, glomerulonephritis, asthma, allergy, and COPD.

[0718] P. NOV17A: Immunoglobulin Domains Containing Protein

[0719] Expression of gene NOV17A was assessed using the primer-probe set Ag4389, described in Table PA. Results of the RTQ-PCR runs are shown in Tables PB, PC and PD. TABLE-US-00185 TABLE PA Probe Name Ag4389 Start SEQ ID Primers Sequences Length Positions No Forward 5'-agagcctggaaattaccaatgt-3' 22 250 196 Probe TET-5'-agacccgaggatcctccctcagtgat-3'- 26 273 197 TAMRA Reverse 5'-cagtcaggtgaaaattccacat-3' 22 306 198

[0720] TABLE-US-00186 TABLE PB General_screening_panel_v1.4 Rel. Exp.(%) Rel. Exp.(%) Ag4389, Ag4389, Run Run Tissue Name 222641235 Tissue Name 222641235 Adipose 6.3 Renal ca. TK-10 0.0 Melanoma* 0.0 Bladder 4.0 Hs688(A).T Melanoma* 0.0 Gastric ca. (liver met.) 0.0 Hs688(B).T NCI-N87 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* 0.0 Colon ca. SW-948 0.0 LOXIMVI Melanoma* SK- 0.5 Colon ca. SW480 0.0 MEL-5 Squamous cell 0.2 Colon ca.* (SW480 0.0 carcinoma SCC-4 met) SW620 Testis Pool 0.9 Colon ca. HT29 0.0 Prostate ca.* (bone 0.0 Colon ca. HCT-116 0.0 met) PC-3 Prostate Pool 0.7 Colon ca. CaCo-2 0.0 Placenta 1.0 Colon cancer tissue 1.4 Uterus Pool 0.6 Colon ca. SW1116 0.0 Ovarian ca. 0.0 Colon ca. Colo-205 0.0 OVCAR-3 Ovarian ca. SK- 0.0 Colon ca. SW-48 0.0 OV-3 Ovarian ca. 0.0 Colon Pool 0.5 OVCAR-4 Ovarian ca. 1.7 Small Intestine Pool 1.0 OVCAR-5 Ovarian ca. 0.0 Stomach Pool 1.5 IGROV-1 Ovarian ca. 0.0 Bone Marrow Pool 0.7 OVCAR-8 Ovary 0.0 Fetal Heart 0.2 Breast ca. MCF-7 0.0 Heart Pool 0.2 Breast ca. MDA- 0.0 Lymph Node Pool 1.2 MB-231 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 0.0 Breast ca. T47D 2.0 Skeletal Muscle Pool 0.3 Breast ca. MDA-N 0.0 Spleen Pool 100.0 Breast Pool 0.4 Thymus Pool 14.9 Trachea 6.8 CNS cancer 0.0 (glio/astro) U87-MG Lung 0.0 CNS cancer 0.2 (glio/astro) U-118-MG Fetal Lung 8.5 CNS cancer 0.4 (neuro; met) SK-N-AS Lung ca. NCI-N417 0.0 CNS cancer (astro) 0.0 SF-539 Lung ca. LX-1 0.0 CNS cancer (astro) 0.0 SNB-75 Lung ca. NCI-H146 0.0 CNS cancer (glio) 0.0 SNB-19 Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 0.0 295 Lung ca. A549 0.0 Brain (Amygdala) 0.0 Pool Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.7 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 0.0 Pool Lung ca. HOP-62 0.0 Cerebral Cortex Pool 0.2 Lung ca. NCI-H522 0.0 Brain (Substantia 0.0 nigra) Pool Liver 0.7 Brain (Thalamus) Pool 0.5 Fetal Liver 2.0 Brain (whole) 0.5 Liver ca. HepG2 0.0 Spinal Cord Pool 0.0 Kidney Pool 1.4 Adrenal Gland 0.6 Fetal Kidney 0.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 1.5 Renal ca. A498 0.0 Thyroid (female) 0.2 Renal ca. ACHN 0.0 Pancreatic ca. 0.0 CAPAN2 Renal ca. UO-31 0.0 Pancreas Pool 0.5

[0721] TABLE-US-00187 TABLE PC Panel 4.1D Rel. Exp.(%) Rel. Exp.(%) Ag4389, Run Ag4389, Run Tissue Name 186502087 Tissue Name 186502087 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.1 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.1 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.7 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 5.5 HUVEC IL-11 0.5 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 1.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 4.5 Microvascular Dermal 0.1 EC none Primary Tr1 act 0.5 Microsvasular Dermal 0.1 EC TNF alpha + IL-1beta Primary Th1 rest 0.3 Bronchial epithelium 0.0 TNF alpha + IL1beta Primary Th2 rest 1.5 Small airway epithelium 0.0 none Primary Tr1 rest 0.0 Small airway epithelium 0.0 TNF alpha + IL-1beta CD45RA CD4 3.8 Coronery artery SMC 0.0 lymphocyte act rest CD45RO CD4 7.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 14.4 Astrocytes rest 0.0 Secondary CD8 2.3 Astrocytes TNF alpha + IL- 0.0 lymphocyte rest 1beta Secondary CD8 5.9 KU-812 (Basophil) rest 0.0 lymphocyte act CD4 lymphocyte none 6.9 KU-812 (Basophil) 0.0 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 1.4 CCD1106 0.0 CD95 CH11 (Keratinocytes) none LAK cells rest 15.1 CCD1106 0.0 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 26.8 Liver cirrhosis 1.0 LAK cells IL-2 + IL-12 12.2 NCI-H292 none 0.0 LAK cells IL-2 + IFN 16.0 NCI-H292 IL-4 0.0 gamma LAK cells IL-2 + IL-18 15.9 NCI-H292 IL-9 0.0 LAK cells 26.8 NCI-H292 IL-13 0.0 PMA/ionomycin NK Cells IL-2 rest 59.5 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 31.2 HPAEC none 0.1 Two Way MLR 5 day 8.4 HPAEC TNF alpha + IL- 0.0 1beta Two Way MLR 7 day 5.6 Lung fibroblast none 0.0 PBMC rest 17.1 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PWM 5.5 Lung fibroblast IL-4 0.0 PBMC PHA-L 2.5 Lung fibroblast IL-9 0.0 Ramos (B cell) none 1.8 Lung fibroblast IL-13 0.0 Ramos (B cell) 4.0 Lung fibroblast IFN 0.0 ionomycin gamma B lymphocytes PWM 8.5 Dermal fibroblast 0.6 CCD1070 rest B lymphocytes CD40L 100.0 Dermal fibroblast 0.7 and IL-4 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.0 CCD1070 IL-1beta EOL-1 dbcAMP 0.1 Dermal fibroblast IFN 0.5 PMA/ionomycin gamma Dendritic cells none 7.3 Dermal fibroblast IL-4 0.0 Dendritic cells LPS 1.0 Dermal Fibroblasts rest 0.0 Dendritic cells anti- 0.2 Neutrophils TNFa + LPS 1.4 CD40 Monocytes rest 2.8 Neutrophils rest 2.0 Monocytes LPS 3.7 Colon 8.0 Macrophages rest 19.1 Lung 1.4 Macrophages LPS 0.3 Thymus 7.3 HUVEC none 0.0 Kidney 25.9 HUVEC starved 0.0

[0722] TABLE-US-00188 TABLE PD Panel CNS_1.1 Rel. Exp.(%) Rel. Exp.(%) Ag4389, Ag4389, Run Run Tissue Name 190028469 Tissue Name 190028469 Cing Gyr 0.0 BA17 PSP2 0.0 Depression2 Cing Gyr 0.0 BA17 PSP 0.0 Depression Cing Gyr PSP2 0.0 BA17 0.0 Huntington's2 Cing Gyr PSP 0.0 BA17 1.2 Huntington's Cing Gyr 0.0 BA17 0.0 Huntington's2 Parkinson's2 Cing Gyr 0.0 BA17 0.0 Huntington's Parkinson's Cing Gyr 0.0 BA17 4.2 Parkinson's2 Alzheimer's2 Cing Gyr 0.0 BA17 Control2 0.0 Parkinson's Cing Gyr 0.0 BA17 Control 0.0 Alzheimer's2 Cing Gyr 0.0 BA9 0.0 Alzheimer's Depression2 Cing Gyr Control2 0.0 BA9 Depression 0.0 Cing Gyr Control 0.0 BA9 PSP2 0.0 Temp Pole 0.0 BA9 PSP 0.0 Depression2 Temp Pole PSP2 0.0 BA9 6.0 Huntington's2 Temp Pole PSP 0.0 BA9 0.0 Huntington's Temp Pole 0.0 BA9 0.0 Huntington's Parkinson's2 Temp Pole 0.0 BA9 Parkinson's 0.0 Parkinson's2 Temp Pole 0.0 BA9 0.0 Parkinson's Alzheimer's2 Temp Pole 0.0 BA9 0.0 Alzheimer's2 Alzheimer's Temp Pole 0.0 BA9 Control2 5.4 Alzheimer's Temp Pole Control2 0.0 BA9 Control 0.0 Temp Pole Control 0.0 BA7 Depression 0.0 Glob Palladus 0.0 BA7 PSP2 0.0 Depression Glob Palladus PSP2 0.0 BA7 PSP 0.0 Glob Palladus PSP 0.0 BA7 0.0 Huntington's2 Glob Palladus 0.0 BA7 0.0 Parkinson's2 Huntington's Glob Palladus 0.0 BA7 0.0 Parkinson's Parkinson's2 Glob Palladus 0.0 BA7 Parkinson's 100.0 Alzheimer's2 Glob Palladus 0.0 BA7 0.0 Alzheimer's Alzheimer's2 Glob Palladus 0.0 BA7 Control2 0.0 Control2 Glob Palladus 0.0 BA7 Control 0.0 Control Sub Nigra 0.0 BA4 0.0 Depression2 Depression2 Sub Nigra 0.0 BA4 Depression 0.0 Depression Sub Nigra PSP2 0.0 BA4 PSP2 0.0 Sub Nigra 0.0 BA4 PSP 0.0 Huntington's2 Sub Nigra 0.0 BA4 0.0 Huntington's Huntington's2 Sub Nigra 0.0 BA4 0.0 Parkinson's2 Huntington's Sub Nigra 0.0 BA4 0.0 Alzheimer's2 Parkinson's2 Sub Nigra Control2 0.0 BA4 Parkinson's 0.0 Sub Nigra Control 0.0 BA4 0.0 Alzheimer's2 BA17 Depression2 0.0 BA4 Control2 0.0 BA17 Depression 0.0 BA4 Control 0.0

[0723] CNS_neurodegeneration_v1.0 Summary: Ag4389 Expression of the NOV17A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0724] General_screening_panel_v1.4 Summary: Ag4389 Highest expression of the NOV17A gene is detected in spleen (CT=29). Moderate expression of this gene is also detected in thymus. The NOV17A gene encodes a protein similar to the immunoglobulin receptor translocation associated (IRTA) protein. IRTA proteins are immunoreceptors implicated in B cell development and lymphomagenesis (Hatzivassiliou et al., 2001, Immunity 14 (3):277-89, PMID: 11290337). Therefore, therapeutic modulation of IRTA-like protein encoded by this gene may be beneficial in the treatment of diseases associated with B cells including B-cell non-Hodgkin lymphoma and multiple myeloma.

[0725] In addition, low expression of this gene is also seen in adipose, and fetal liver. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0726] Significant expression of this gene is also detected in fetal lung (CT=32.6). Interestingly, this gene is expressed at much higher levels in fetal when compared to adult lung (CT=40). This observation suggests that expression of this gene can be used to distinguish fetal from adult lung. In addition, the relative overexpression of this gene in fetal lung suggests that the protein product may enhance lung growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung related diseases.

[0727] Panel 4.1D Summary: Ag4389 Highest expression of the NOV17A gene is detected in CD40L and IL-4 treated B lymphocytes (CT=28.5). In addition, significant expression of this gene is also seen in monocytes, resting macrophages, PWM treated B lymphocytes, Ramos B cells, LAK cells, Two Way MLR cells, IL2 treated NK cells, PWM/PHA treated and resting PBMC cells, CD4 and CD8 lymphocytes, primary and secondary Th2 cells and in normal tissues represented by colon, lung, thymus and kidney. Therefore, therapeutic modulation of this gene product may be beneficial in the treatment of autoimmune and inflammatory diseases in which B and Th2 cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.

[0728] Panel CNS.sub.--1 Summary: Ag4389 Expression of the NOV17A gene is low/undetectable (CTs>35) across all of the samples on this panel (data not shown).

[0729] Panel CNS.sub.--1.1 Summary: Ag4389 This panel confirms the expression of the NOV17A gene at very low levels in the brain of an independent group of individuals, with highest expression in a sample from Parkinson's patient. Therefore, therapeutic modulation of this gene product may be beneficial in the treatment of Parkinson's disease.

[0730] Q. NOV18A, NOV18B and NOV18C: Small Inducible Cytokine B14 Precursor (Chemokine BRAK)

[0731] Expression of gene NOV18A and variants NOV18B and NOV18C was assessed using the primer-probe set Ag953, described in Table QA. Results of the RTQ-PCR runs are shown in Tables QB, QC, QD and QE. Please note that NOV18A and NOV18C represent full-length physical clones. TABLE-US-00189 TABLE QA Probe Name Ag953 Start SEQ ID Primers Sequences Length Position No Forward 5'-ccaagagcgtgtccaggta-3' 19 110 199 Probe TET-5'-agagcaccaagcgcttcatcaagtg-3'- 25 164 200 TAMRA Reverse 5'-ctcgttccaggcgttgtac-3' 19 189 201

[0732] TABLE-US-00190 TABLE QB A1_comprehensive panel_v1.0 Rel. Exp.(%) Rel. Exp.(%) Ag953, Run Ag953, Run Tissue Name 247834379 Tissue Name 247834379 110967 COPD-F 0.0 112427 Match Control 0.2 Psoriasis-F 110980 COPD-F 0.2 112418 Psoriasis-M 0.1 110968 COPD-M 0.0 112723 Match Control 0.0 Psoriasis-M 110977 COPD-M 0.2 112419 Psoriasis-M 0.1 110989 0.1 112424 Match Control 0.2 Emphysema-F Psoriasis-M 110992 42.3 112420 Psoriasis-M 1.1 Emphysema-F 110993 0.1 112425 Match Control 0.1 Emphysema-F Psoriasis-M 110994 0.1 104689 (MF) OA 5.0 Emphysema-F Bone-Backus 110995 100.0 104690 (MF) Adj 4.4 Emphysema-F "Normal" Bone- Backus 110996 22.7 104691 (MF) OA 12.1 Emphysema-F Synovium-Backus 110997 Asthma-M 6.8 104692 (BA) OA 2.5 Cartilage-Backus 111001 Asthma-F 0.5 104694 (BA) OA 3.9 Bone-Backus 111002 Asthma-F 0.4 104695 (BA) Adj 1.0 "Normal" Bone- Backus 111003 Atopic 0.2 104696 (BA) OA 31.6 Asthma-F Synovium-Backus 111004 Atopic 0.3 104700 (SS) OA 2.6 Asthma-F Bone-Backus 111005 Atopic 0.2 104701 (SS) Adj 4.0 Asthma-F "Normal" Bone- Backus 111006 Atopic 0.0 104702 (SS) OA 14.2 Asthma-F Synovium-Backus 111417 Allergy-M 0.1 117093 OA Cartilage 0.6 Rep7 112347 Allergy-M 0.1 112672 OA Bone5 0.1 112349 Normal 0.2 112673 OA 0.0 Lung-F Synovium5 112357 Normal 0.1 112674 OA Synovial 0.0 Lung-F Fluid cells5 112354 Normal 0.7 117100 OA Cartilage 0.1 Lung-M Rep14 112374 Crohns-F 1.5 112756 OA Bone9 0.0 112389 Match 15.3 112757 OA 3.1 Control Crohns-F Synovium9 112375 Crohns-F 1.2 112758 OA Synovial 1.3 Fluid Cells9 112732 Match 2.6 117125 RA Cartilage 0.1 Control Crohns-F Rep2 112725 Crohns-M 0.1 113492 Bone2 RA 0.6 112387 Match 0.9 113493 Synovium2 0.4 Control Crohns-M RA 112378 Crohns-M 0.2 113494 Syn Fluid 0.6 Cells RA 112390 Match 0.2 113499 Cartilage4 RA 0.2 Control Crohns-M 112726 Crohns-M 2.5 113500 Bone4 RA 0.2 112731 Match 3.0 113501 Synovium4 0.1 Control Crohns-M RA 112380 Ulcer Col-F 0.1 113502 Syn Fluid 0.1 Cells4 RA 112734 Match 7.1 113495 Cartilage3 RA 0.1 Control Ulcer Col-F 112384 Ulcer Col-F 48.3 113496 Bone3 RA 0.1 112737 Match 2.2 113497 Synovium3 0.0 Control Ulcer Col-F RA 112386 Ulcer Col-F 1.1 113498 Syn Fluid 0.1 Cells3 RA 112738 Match 1.3 117106 Normal 0.0 Control Ulcer Col-F Cartilage Rep20 112381 Ulcer Col- 1.0 113663 Bone3 Normal 0.1 M 112735 Match 0.8 113664 Synovium3 0.0 Control Ulcer Col- Normal M 112382 Ulcer Col- 11.5 113665 Syn Fluid 0.0 M Cells3 Normal 112394 Match 1.0 117107 Normal 0.2 Control Ulcer Col- Cartilage Rep22 M 112383 Ulcer Col- 35.4 113667 Bone4 Normal 0.5 M 112736 Match 8.4 113668 Synovium4 0.7 Control Ulcer Col- Normal M 112423 Psoriasis-F 0.3 113669 Syn Fluid 0.7 Cells4 Normal

[0733] TABLE-US-00191 TABLE QC Panel 2D Rel. Exp.(%) Rel. Exp.(%) Ag953, Run Ag953, Run Tissue Name 170849612 Tissue Name 170849612 Normal Colon 36.6 Kidney Margin 43.8 8120608 CC Well to Mod Diff 0.4 Kidney Cancer 0.1 (ODO3866) 8120613 CC Margin 8.3 Kidney Margin 43.8 (ODO3866) 8120614 CC Gr.2 rectosigmoid 1.3 Kidney Cancer 3.1 (ODO3868) 9010320 CC Margin 0.3 Kidney Margin 81.2 (ODO3868) 9010321 CC Mod Diff 4.4 Normal Uterus 0.1 (ODO3920) CC Margin 1.6 Uterus Cancer 2.2 (ODO3920) 064011 CC Gr.2 ascend colon 28.3 Normal Thyroid 3.7 (ODO3921) CC Margin 4.3 Thyroid Cancer 0.1 (ODO3921) 064010 CC from Partial 2.3 Thyroid Cancer 1.1 Hepatectomy A302152 (ODO4309) Mets Liver Margin 3.1 Thyroid Margin 1.6 (ODO4309) A302153 Colon mets to lung 0.2 Normal Breast 17.2 (OD04451-01) Lung Margin 0.0 Breast Cancer 43.8 (OD04451-02) (OD04566) Normal Prostate 2.8 Breast Cancer 9.0 6546-1 (OD04590-01) Prostate Cancer 8.7 Breast Cancer Mets 14.9 (OD04410) (OD04590-03) Prostate Margin 0.5 Breast Cancer 4.1 (OD04410) Metastasis (OD04655-05) Prostate Cancer 3.0 Breast Cancer 28.7 (OD04720-01) 064006 Prostate Margin 1.8 Breast Cancer 1024 14.4 (OD04720-02) Normal Lung 061010 5.2 Breast Cancer 16.5 9100266 Lung Met to Muscle 0.1 Breast Margin 20.7 (ODO4286) 9100265 Muscle Margin 22.8 Breast Cancer 10.5 (ODO4286) A209073 Lung Malignant 3.9 Breast Margin 10.4 Cancer (OD03126) A209073 Lung Margin 0.5 Normal Liver 4.6 (OD03126) Lung Cancer 27.4 Liver Cancer 0.1 (OD04404) 064003 Lung Margin 3.0 Liver Cancer 1025 3.5 (OD04404) Lung Cancer 27.2 Liver Cancer 1026 0.7 (OD04565) Lung Margin 0.0 Liver Cancer 4.5 (OD04565) 6004-T Lung Cancer 7.5 Liver Tissue 0.3 (OD04237-01) 6004-N Lung Margin 0.2 Liver Cancer 0.5 (OD04237-02) 6005-T Ocular Mel Met to 0.0 Liver Tissue 1.2 Liver (ODO4310) 6005-N Liver Margin 2.5 Normal Bladder 2.8 (ODO4310) Melanoma Mets to 0.2 Bladder Cancer 1.6 Lung (OD04321) 1023 Lung Margin 0.5 Bladder Cancer 45.4 (OD04321) A302173 Normal Kidney 63.3 Bladder Cancer 0.1 (OD04718-01) Kidney Ca, Nuclear 23.2 Bladder Normal 12.3 grade 2 (OD04338) Adjacent (OD04718-03) Kidney Margin 22.2 Normal Ovary 0.2 (OD04338) Kidney Ca Nuclear 20.4 Ovarian Cancer 21.5 grade 1/2 (OD04339) 064008 Kidney Margin 100.0 Ovarian Cancer 0.0 (OD04339) (OD04768-07) Kidney Ca, Clear cell 39.8 Ovary Margin 2.3 type (OD04340) (OD04768-08) Kidney Margin 26.6 Normal Stomach 8.9 (OD04340) Kidney Ca, Nuclear 1.0 Gastric Cancer 3.5 grade 3 (OD04348) 9060358 Kidney Margin 12.1 Stomach Margin 10.6 (OD04348) 9060359 Kidney Cancer 32.1 Gastric Cancer 3.1 (OD04622-01) 9060395 Kidney Margin 6.3 Stomach Margin 11.4 (OD04622-03) 9060394 Kidney Cancer 9.0 Gastric Cancer 12.9 (OD04450-01) 9060397 Kidney Margin 31.6 Stomach Margin 4.0 (OD04450-03) 9060396 Kidney Cancer 1.2 Gastric Cancer 6.3 8120607 064005

[0734] TABLE-US-00192 TABLE QD Panel 3D Rel. Exp.(%) Rel. Exp.(%) Ag953, Ag953, Tissue Name Run 168032587 Tissue Name Run 168032587 Daoy-Medulloblastoma 0.7 Ca Ski-Cervical epidermoid 0.0 carcinoma (metastasis) TE671- 0.0 ES-2-Ovarian clear cell 0.0 Medulloblastoma carcinoma D283 Med- 0.0 Ramos-Stimulated with 0.0 Medulloblastoma PMA/ionomycin 6 h PFSK-1-Primitive 0.0 Ramos-Stimulated with 0.0 Neuroectodermal PMA/ionomycin 14 h XF-498-CNS 0.5 MEG-01-Chronic 1.6 myelogenous leukemia (megokaryoblast) SNB-78-Glioma 0.0 Raji-Burkitt's lymphoma 0.0 SF-268-Glioblastoma 0.0 Daudi-Burkitt's lymphoma 0.0 T98G-Glioblastoma 4.0 U266-B-cell plasmacytoma 0.0 SK-N-SH- 0.0 CA46-Burkitt's lymphoma 0.1 Neuroblastoma (metastasis) SF-295-Glioblastoma 0.0 RL-non-Hodgkin's B-cell 0.0 lymphoma Cerebellum 2.6 JM1-pre-B-cell lymphoma 0.0 Cerebellum 2.4 Jurkat-T cell leukemia 0.0 NCI-H292- 0.0 TF-1-Erythroleukemia 1.7 Mucoepidermoid lung carcinoma DMS-114-Small cell 0.0 HUT 78-T-cell lymphoma 0.1 lung cancer DMS-79-Small cell 1.2 U937-Histiocytic lymphoma 0.1 lung cancer NCI-H146-Small cell 9.7 KU-812-Myelogenous 1.9 lung cancer leukemia NCI-H526-Small cell 0.4 769-P-Clear cell renal 0.3 lung cancer carcinoma NCI-N417-Small cell 0.5 Caki-2-Clear cell renal 0.0 lung cancer carcinoma NCI-H82-Small cell 0.2 SW 839-Clear cell renal 0.1 lung cancer carcinoma NCI-H157-Squamous 0.0 G401-Wilms' tumor 0.0 cell lung cancer (metastasis) NCI-H1155-Large cell 0.0 Hs766T-Pancreatic 0.0 lung cancer carcinoma (LN metastasis) NCI-H1299-Large cell 0.0 CAPAN-1-Pancreatic 0.0 lung cancer adenocarcinoma (liver metastasis) NCI-H727-Lung 0.0 SU86.86-Pancreatic 0.1 carcinoid carcinoma (liver metastasis) NCI-UMC-11-Lung 0.0 BxPC-3-Pancreatic 4.1 carcinoid adenocarcinoma LX-1-Small cell lung 0.0 HPAC-Pancreatic 100.0 cancer adenocarcinoma Colo-205-Colon cancer 0.0 MIA PaCa-2-Pancreatic 0.1 carcinoma KM12-Colon cancer 0.0 CFPAC-1-Pancreatic ductal 74.2 adenocarcinoma KM20L2-Colon cancer 0.0 PANC-1-Pancreatic 0.0 epithelioid ductal carcinoma NCI-H716-Colon 0.0 T24-Bladder carcinma 0.0 cancer (transitional cell) SW-48-Colon 11.2 5637-Bladder carcinoma 0.0 adenocarcinoma SW1116-Colon 0.0 HT-1197-Bladder 0.0 adenocarcinoma carcinoma LS 174T-Colon 76.3 UM-UC-3-Bladder 0.0 adenocarcinoma carcinma (transitional cell) SW-948-Colon 0.0 A204-Rhabdomyosarcoma 0.0 adenocarcinoma SW-480-Colon 0.0 HT-1080-Fibrosarcoma 0.0 adenocarcinoma NCI-SNU-5-Gastric 0.9 MG-63-Osteosarcoma 0.7 carcinoma KATO III-Gastric 0.0 SK-LMS-1- 0.0 carcinoma Leiomyosarcoma (vulva) NCI-SNU-16-Gastric 0.0 SJRH30- 0.0 carcinoma Rhabdomyosarcoma (met to bone marrow) NCI-SNU-1-Gastric 0.0 A431-Epidermoid 0.0 carcinoma carcinoma RF-1-Gastric 0.0 WM266-4-Melanoma 0.3 adenocarcinoma RF-48-Gastric 0.0 DU 145-Prostate carcinoma 0.0 adenocarcinoma (brain metastasis) MKN-45-Gastric 0.0 MDA-MB-468-Breast 0.0 carcinoma adenocarcinoma NCI-N87-Gastric 0.8 SCC-4-Squamous cell 0.0 carcinoma carcinoma of tongue OVCAR-5-Ovarian 0.0 SCC-9-Squamous cell 0.0 carcinoma carcinoma of tongue RL95-2-Uterine 0.0 SCC-15-Squamous cell 0.0 carcinoma carcinoma of tongue HelaS3-Cervical 0.0 CAL 27-Squamous cell 0.4 adenocarcinoma carcinoma of tongue

[0735] TABLE-US-00193 TABLE QE Panel 4D Rel. Exp.(%) Rel. Exp.(%) Ag953, Ag953, Tissue Name Run 168033522 Tissue Name Run 168033522 Secondary Th1 act 0.0 HUVEC IL-1beta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Tr1 act 0.0 HUVEC TNF alpha + IFN 0.0 gamma Secondary Th1 rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Tr1 rest 0.0 Lung Microvascular EC 0.0 none Primary Th1 act 0.0 Lung Microvascular EC 0.0 TNF alpha + IL-1beta Primary Th2 act 0.0 Microvascular Dermal 0.0 EC none Primary Tr1 act 0.0 Microsvasular Dermal 0.0 EC TNF alpha + IL-1beta Primary Th1 rest 0.0 Bronchial epithelium 5.4 TNF alpha + IL1beta Primary Th2 rest 0.0 Small airway epithelium 1.9 none Primary Tr1 rest 0.0 Small airway epithelium 10.2 TNF alpha + IL-1beta CD45RA CD4 0.0 Coronery artery SMC rest 0.0 lymphocyte act CD45RO CD4 0.0 Coronery artery SMC 0.0 lymphocyte act TNF alpha + IL-1beta CD8 lymphocyte act 0.0 Astrocytes rest 1.7 Secondary CD8 0.0 Astrocytes TNF alpha + IL- 0.4 lymphocyte rest 1beta Secondary CD8 0.0 KU-812 (Basophil) rest 0.4 lymphocyte act CD4 lymphocyte none 0.0 KU-812 (Basophil) 0.4 PMA/ionomycin 2ry Th1/Th2/Tr1_anti- 0.0 CCD1106 0.1 CD95 CH11 (Keratinocytes) none LAK cells rest 0.0 CCD1106 0.3 (Keratinocytes) TNF alpha + IL-1beta LAK cells IL-2 0.0 Liver cirrhosis 0.8 LAK cells IL-2 + IL-12 0.0 Lupus kidney 5.1 LAK cells IL-2 + IFN 0.0 NCI-H292 none 0.0 gamma LAK cells IL-2 + IL-18 0.0 NCI-H292 IL-4 0.0 LAK cells 0.0 NCI-H292 IL-9 0.0 PMA/ionomycin NK Cells IL-2 rest 0.0 NCI-H292 IL-13 0.0 Two Way MLR 3 day 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 5 day 0.0 HPAEC none 0.0 Two Way MLR 7 day 0.0 HPAEC TNF alpha + IL- 0.0 1beta PBMC rest 0.0 Lung fibroblast none 0.0 PBMC PWM 0.0 Lung fibroblast TNF 0.0 alpha + IL-1beta PBMC PHA-L 0.0 Lung fibroblast IL-4 0.1 Ramos (B cell) none 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) 0.0 Lung fibroblast IL-13 0.0 ionomycin B lymphocytes PWM 0.0 Lung fibroblast IFN 0.0 gamma B lymphocytes CD40L 0.0 Dermal fibroblast 0.9 and IL-4 CCD1070 rest EOL-1 dbcAMP 0.0 Dermal fibroblast 0.6 CCD1070 TNF alpha EOL-1 dbcAMP 0.0 Dermal fibroblast 0.3 PMA/ionomycin CCD1070 IL-1beta Dendritic cells none 0.0 Dermal fibroblast IFN 0.0 gamma Dendritic cells LPs 0.0 Dermal fibroblast IL-4 0.1 Dendritic cells anti- 0.0 IBD Colitis 2 1.4 CD40 Monocytes rest 0.0 IBD Crohn's 1.1 Monocytes LPS 0.0 Colon 21.0 Macrophages rest 0.0 Lung 1.3 Macrophages LPS 0.0 Thymus 100.0 HUVEC none 0.0 Kidney 5.0 HUVEC starved 0.0

[0736] AI_comprehensive_panel_v1.0 Summary: Ag953 Highest expression of the NOV18B gene is seen in emphysema (CT=23). Moderate levels of expression are seen in many of the samples on this panel suggesting a role for this protein product in the immune system. Please see Panel 4D for disscussion of utility of this gene in autoimmunity.

[0737] Panel 1.3D Summary: Ag953 Results from one experiment with the CG56003-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run (data not shown).

[0738] Panel 2D Summary: Ag953 Highest expression of the CG51213-02 gene is seen in normal kidney adjacent to a tumor (CT=24.8). In addition, this gene appears to be overexpressed in normal kidney when compared to expression in adjacent tumor. In contrast, expression of this gene appears to be higher in lung and colon cancer than in the adjacent tissue. High levels of expression are also seen in bladder and ovarian cancers. This gene encodes a protein with homology to cytokines which are molecular growth factors involved in the regulation of cell proliferation. Thus, this gene product may potentially be involved in the growth regulation of cancer cells. Since blockade of the action of this factor may interfere with cancer cell proliferation, therapeutic targeting with a human monoclonal antibody may be beneficial especially in those cancers where the gene is overexpressed in the tumor compared to the normal adjacent tissue. Additionally, application of the protein encoded by this gene may be useful as a therapeutic for cancers where the gene is overexpressed in the normal adjacent tissue compared to the tumor.

[0739] Panel 3D Summary: Ag953 Highest expression of the CG51213-02 gene is seen in a pancreatic cancer cell line (CT=28.1). Moderate levels of expression are also seen in a colon cancer and a lung cell line. Thus, expression of this gene could be used to differentiate these samples from other samples on this panel.

[0740] Panel 4D Summary: Ag953 High expression of the CG51213-02 gene is seen the thymus (CT=25) and colon. Moderate levels of expression are seen in kidney, lung, Crohn's, colitis, resting dermal fibroblasts, lupus kidney, resting astrocytes, activated bronchial epithelium, and treated and untreated small airway epithelium. Low but significant levels of expression are seen in activated dermal fibroblasts and astrocytes, and treated and untreated basophils and keratinocytes. The high levels of expression in the thymus suggest that expression of this could be used to differentiate this sample from other samples and as a marker of thymic tissue. Therapeutic modulation of the protein encoded by this gene could potentially be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.

Example D

Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences

[0741] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

[0742] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

[0743] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fiagment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools.TM. program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

[0744] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderbom et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).

[0745] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

NOV3a SNP Data:

[0746] NOV3a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:25 and 26, respectively. The nucleotide sequence of the NOV3a variant differs as shown in Table 20A. TABLE-US-00194 TABLE 20A data for NOV3a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379134 370 T C 115 Cys Arg

NOV5a SNP Data:

[0747] NOV5a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:29 and 30, respectively. The nucleotide sequence of the NOV5a variant differs as shown in Table 20B. TABLE-US-00195 TABLE 20B data for NOV5a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379138 534 G A 177 Lys Lys 13379139 560 G T 186 Cys Phe 13379140 1124 C T 0

NOV10a SNP Data:

[0748] NOV10a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:53 and 54, respectively. The nucleotide sequence of the NOV10a variant differs as shown in Table 20C. TABLE-US-00196 TABLE 20C data for NOV10a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379143 172 G C 57 Ala Pro 13379142 197 A G 65 Asp Gly 13379141 398 G A 132 Ser Asn

NOV12a SNP Data:

[0749] NOV12a has seven SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:69 and 70, respectively. The nucleotide sequence of the NOV12a variant differs as shown in Table 20D. TABLE-US-00197 TABLE 20D data for NOV12a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379160 237 A G 79 Thr Thr 13379161 446 C T 149 Thr Met 13376279 636 T G 212 Ile Met 13379162 710 G A 237 Gly Asp 13376278 893 C T 298 Thr Ile 13375449 1177 T C 393 Ser Pro 13379150 1194 T C 398 Ser Ser

NOV13a SNP Data:

[0750] NOV13a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:85 and 86, respectively. The nucleotide sequence of the NOV13a variant differs as shown in Table 20E. TABLE-US-00198 TABLE 20E data for NOV13a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379144 915 G A 232 Leu Leu

NOV14a SNP Data:

[0751] NOV14a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:87 and 88, respectively. The nucleotide sequence of the NOV14a variant differs as shown in Table 20F. TABLE-US-00199 TABLE 20F data for NOV14a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379164 33 C T 8 Pro Pro 13379165 117 T C 36 Ala Ala 13379167 575 T C 189 Leu Pro 13379168 686 T C 226 Leu Ser

NOV17a SNP Data:

[0752] NOV17a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:93 and 94, respectively. The nucleotide sequence of the NOV17a variant differs as shown in Table 20G. TABLE-US-00200 TABLE 20G data for NOV17a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13377348 521 T C 166 Tyr His 13377349 1731 C A 569 Pro His

NOV18b SNP Data:

[0753] NOV18b has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:93 and 94, respectively. The nucleotide sequence of the NOV18b variant differs as shown in Table 20H. TABLE-US-00201 TABLE 20H data for NOV18b Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379152 114 G T 38 Lys Asn 13379151 222 C T 74 Tyr Tyr

NOV19a SNP Data:

[0754] NOV19a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:107 and 108, respectively. The nucleotide sequence of the NOV19a variant differs as shown in Table 201. TABLE-US-00202 TABLE 20I data for NOV19a Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379148 441 T C 147 His His

OTHER EMBODIMENTS

[0755] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.

Sequence CWU 1

1

201 1 1239 DNA Homo sapiens CDS (51)..(1167) 1 aaccagggcc ttatccaggg ccacgcttac agaactccca cggacacacc atg att 56 Met Ile 1 agg acc ctg ctg ctg tcc act ttg gtg gcc ctc agt tgt ggg gtc tcc 104 Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Leu Ser Cys Gly Val Ser 5 10 15 act tac gcg cct gat atg tct agg atg ctt gga ggt gaa gaa gcg agg 152 Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly Glu Glu Ala Arg 20 25 30 ccc aac agc tgg ccc tgg cag gtg agt ctg cag tac agc tcc aat ggc 200 Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr Ser Ser Asn Gly 35 40 45 50 cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc aac agc tgg gtc 248 Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala Asn Ser Trp Val 55 60 65 ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc tac cgc gtg atg 296 Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile Tyr Arg Val Met 70 75 80 ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc tcg ctg gcc gtc 344 Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly Ser Leu Ala Val 85 90 95 agt gtc tct aag att gtg gtg cac aag gac tgg aac tcc gac cag gtc 392 Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn Ser Asp Gln Val 100 105 110 tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct aac ccc gtc tcc 440 Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala Asn Pro Val Ser 115 120 125 130 ctc acc gac aag atc cag ctg gcc tgc ctc cct cct gcc ggc acc att 488 Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro Ala Gly Thr Ile 135 140 145 cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg gga agg ctg cag 536 Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp Gly Arg Leu Gln 150 155 160 agt aac ggg gct ctc cct gat gac ctg aag cag ggc cag ttg ctg gtt 584 Ser Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly Gln Leu Leu Val 165 170 175 gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg ggc agc acc gtg 632 Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp Gly Ser Thr Val 180 185 190 aag acg aat atg atc tgt gct ggg ggt gat ggc gtg ata tgc acc tgc 680 Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val Ile Cys Thr Cys 195 200 205 210 aac gga gac tcc ggt ggg ccg ctg aac tgt cag gca tct gac ggc cgg 728 Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala Ser Asp Gly Arg 215 220 225 tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc ctt ggt tgc aac 776 Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val Leu Gly Cys Asn 230 235 240 tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc aac tac aac gac 824 Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser Asn Tyr Asn Asp 245 250 255 tgg atc aat tcg gta aga acc gga gca gcc ctg agc ccc aag gca ctg 872 Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser Pro Lys Ala Leu 260 265 270 acc tgc tca cct ggc ctc ggg agt gcc atg ccc acc tgg cga ctg aga 920 Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr Trp Arg Leu Arg 275 280 285 290 acc ccc tcc ttc ctc ttg aga gct aga tgg gaa ccc ctt gga gga ggc 968 Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro Leu Gly Gly Gly 295 300 305 tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc ccc aaa att tct 1016 Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val Pro Lys Ile Ser 310 315 320 gtg tgg gta aag ctg agt gaa aag gaa cat gag agt atg gcc ttg tcc 1064 Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser Met Ala Leu Ser 325 330 335 aaa gac gtt gga cac tcc tca ggt acg tta aga gtg agt tcc aca gga 1112 Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val Ser Ser Thr Gly 340 345 350 atg att tta ttt ttg tgt att tgt gtg tgg ccc aga ctc tac cat cca 1160 Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg Leu Tyr His Pro 355 360 365 370 gtg cta taaatgggta tatgtctgca aaacccaaaa cctgatactt tgagaccccc 1216 Val Leu atagcattaa ttattggaaa tta 1239 2 372 PRT Homo sapiens 2 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Leu Ser Cys Gly 1 5 10 15 Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly Glu Glu 20 25 30 Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr Ser Ser 35 40 45 Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala Asn Ser 50 55 60 Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile Tyr Arg 65 70 75 80 Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly Ser Leu 85 90 95 Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn Ser Asp 100 105 110 Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala Asn Pro 115 120 125 Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro Ala Gly 130 135 140 Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp Gly Arg 145 150 155 160 Leu Gln Ser Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly Gln Leu 165 170 175 Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp Gly Ser 180 185 190 Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val Ile Cys 195 200 205 Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala Ser Asp 210 215 220 Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val Leu Gly 225 230 235 240 Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser Asn Tyr 245 250 255 Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser Pro Lys 260 265 270 Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr Trp Arg 275 280 285 Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro Leu Gly 290 295 300 Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val Pro Lys 305 310 315 320 Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser Met Ala 325 330 335 Leu Ser Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val Ser Ser 340 345 350 Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg Leu Tyr 355 360 365 His Pro Val Leu 370 3 1188 DNA Homo sapiens CDS (1)..(868) 3 atg att agg acc ctg ctg ctg tcc act ttg gtg gct gga gcc ctc agt 48 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 tgt ggg gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 96 Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 20 25 30 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtg agt ctg cag tac 144 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 192 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 240 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 288 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 336 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 384 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 432 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 480 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 528 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 cag ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 576 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt aat ggc gtg 624 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 ata tgc acc tgc aac gga gac tct ggc ggg cca ctg aac tgt cag gcg 672 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 tct gac ggc cgg tgg cag gtg cac ggc atc gtc agc ttc ggg tct cgc 720 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 ctc ggc tgc aac tac tac cac aag ccc tcc gtc ttc acg cgg gtc tcc 768 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 aat tac atc gac tgg atc aat tcg gta aga acc gga cca gcc ttg agc 816 Asn Tyr Ile Asp Trp Ile Asn Ser Val Arg Thr Gly Pro Ala Leu Ser 260 265 270 ccc aag gca cta ccc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 864 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 275 280 285 tgg tgactgagaa tcccctcctt cctcttgaga gctagatggg aaccccttgg 917 Trp aggaggctgc agacctgagt aactgctggg cctgccatgg gtcccccaaa 967 tttctgtgtg gataaagctg agtgaaaagg aacatagagg gtggccttgt 1017 ccaaagaggt tggacactcc tcaggcatat gaagagtgag ttccgctggg 1067 cgccgtggct catgcctgta atcccagctc tttgggaggc caaggcgggc 1117 agatcacgag gtcagaagtt caagaccagc ctgaccaacc tggcaaaacc 1167 ccatgtctac taaaaaaatc c 1188 4 289 PRT Homo sapiens 4 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 20 25 30 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 Asn Tyr Ile Asp Trp Ile Asn Ser Val Arg Thr Gly Pro Ala Leu Ser 260 265 270 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 275 280 285 Trp 5 889 DNA Homo sapiens CDS (1)..(799) 5 atg att agg acc ctg ctg ctg tcc act ttg gtg gct gga gcc ctc agt 48 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 tgt ggg gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 96 Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 20 25 30 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtg agt ctg cag tac 144 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 192 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 240 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 288 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 336 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 384 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 432 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 480 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 528 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 cag ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 576 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt aat ggc gtg 624 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 ata tgc acc tgc aac gga gac tct ggc ggg cca ctg aac tgt cag gcg 672 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 tct gac ggc cgg tgg cag gtg cac ggc atc gtc agc ttc ggg tct cgc 720 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 ctc ggc tgc aac tac tac cac aag ccc tcc gtc ttc acg cgg gtc tcc 768 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 aat tac atc gac tgg atg att gca aat aac taaccaaaag aagtccctgg 818 Asn Tyr Ile Asp Trp Met Ile Ala Asn Asn 260 265 gactgtttca gacttggaaa ggtcacggaa ggaaaataat ataataaagt 868 ggcaactatg caaaaaaaaa a 889 6 266 PRT Homo sapiens 6 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 Cys Gly Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 20 25 30 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135

140 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 Asn Tyr Ile Asp Trp Met Ile Ala Asn Asn 260 265 7 1188 DNA Homo sapiens CDS (1)..(868) 7 atg att agg acc ctg ctg ctg tcc act ttg gtg gct gga gcc ctc agt 48 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 tgt ggg gac ccc act tac cca cct tat gtg act agg gtg gtt ggc ggt 96 Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly 20 25 30 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtg agt ctg cag tac 144 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 192 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 240 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 288 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 336 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 384 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 432 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 480 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 gga agg ctg cag gcc aac ggg gct ctc cct gat gac ctg aag cag ggc 528 Gly Arg Leu Gln Ala Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 cag ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 576 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt aat ggc gtg 624 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 ata tgc acc tgc aac gga gac tct ggc ggg cca ctg aac tgt cag gcg 672 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 tct gac ggc cgg tgg cag gtg cac ggc atc gtc agc ttc ggg tct cgc 720 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 ctc ggc tgc aac tac tac cac aag ccc tcc gtc ttc acg cgg gtc tcc 768 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 aat tac atc gac tgg atc aat tcg gta aga acc gga cca gcc ttg agc 816 Asn Tyr Ile Asp Trp Ile Asn Ser Val Arg Thr Gly Pro Ala Leu Ser 260 265 270 ccc aag gca cta ccc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 864 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 275 280 285 tgg tgactgagaa tcccctcctt cctcttgaga gctagatggg aaccccttgg 917 Trp aggaggctgc agacctgagt aactgctggg cctgccatgg gtcccccaaa 967 tttctgtgtg gataaagctg agtgaaaagg aacatagagg gtggccttgt 1017 ccaaagaggt tggacactcc tcaggcatat gaagagtgag ttccgctggg 1067 cgccgtggct catgcctgta atcccagctc tttgggaggc caaggcgggc 1117 agatcacgag gtcagaagtt caagaccagc ctgaccaacc tggcaaaacc 1167 ccatgtctac taaaaaaatc c 1188 8 289 PRT Homo sapiens 8 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly 20 25 30 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 Gly Arg Leu Gln Ala Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 Asn Tyr Ile Asp Trp Ile Asn Ser Val Arg Thr Gly Pro Ala Leu Ser 260 265 270 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 275 280 285 Trp 9 889 DNA Homo sapiens CDS (1)..(799) 9 atg att agg acc ctg ctg ctg tcc act ttg gtg gct gga gcc ctc agt 48 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 tgt ggg gac ccc act tac cca cct tat gtg act agg gtg gtt ggc ggt 96 Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly 20 25 30 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtg agt ctg cag tac 144 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 192 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 240 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 288 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 336 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 384 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 432 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 480 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 gga agg ctg cag gcc aac ggg gct ctc cct gat gac ctg aag cag ggc 528 Gly Arg Leu Gln Ala Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 cag ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 576 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt aat ggc gtg 624 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 ata tgc acc tgc aac gga gac tct ggc ggg cca ctg aac tgt cag gcg 672 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 tct gac ggc cgg tgg cag gtg cac ggc atc gtc agc ttc ggg tct cgc 720 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 ctc ggc tgc aac tac tac cac aag ccc tcc gtc ttc acg cgg gtc tcc 768 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 aat tac atc gac tgg atg att gca aat aac taaccaaaag aagtccctgg 818 Asn Tyr Ile Asp Trp Met Ile Ala Asn Asn 260 265 gactgtttca gacttggaaa ggtcacggaa ggaaaataat ataataaagt 868 ggcaactatg caaaaaaaaa a 889 10 266 PRT Homo sapiens 10 Met Ile Arg Thr Leu Leu Leu Ser Thr Leu Val Ala Gly Ala Leu Ser 1 5 10 15 Cys Gly Asp Pro Thr Tyr Pro Pro Tyr Val Thr Arg Val Val Gly Gly 20 25 30 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 35 40 45 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 50 55 60 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 65 70 75 80 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 85 90 95 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 100 105 110 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 115 120 125 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 130 135 140 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 145 150 155 160 Gly Arg Leu Gln Ala Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 165 170 175 Gln Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 180 185 190 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asn Gly Val 195 200 205 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 210 215 220 Ser Asp Gly Arg Trp Gln Val His Gly Ile Val Ser Phe Gly Ser Arg 225 230 235 240 Leu Gly Cys Asn Tyr Tyr His Lys Pro Ser Val Phe Thr Arg Val Ser 245 250 255 Asn Tyr Ile Asp Trp Met Ile Ala Asn Asn 260 265 11 1080 DNA Homo sapiens CDS (1)..(1080) 11 gga tcc gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 48 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag atc tcc ctg cag tac 96 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Ile Ser Leu Gln Tyr 20 25 30 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 144 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 192 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 240 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 288 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 336 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 aac ccc gtc tcc ctc gcc gac aag atc cag ctg gcc tgc ctc cct cct 384 Asn Pro Val Ser Leu Ala Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 432 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 480 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 cgg ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 528 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt gat ggc gtg 576 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 ata tgc acc tgc aac gga gac tcc ggt ggg ccg ctg aac tgt cag gca 624 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 tct gac ggc cgg tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc 672 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 ctt ggt tgc aac tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc 720 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 aac tac aac gac tgg atc aat tcg gta aga acc gga gca gcc ctg agc 768 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 ccc aag gca ctg acc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 816 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 tgg cga ctg aga acc ccc tcc ttc ctc ttg aga gct aga tgg gaa ccc 864 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 ctt gga gga ggc tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc 912 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 ccc aaa att tct gtg tgg gta aag ctg agt gaa aag gaa cat gag agt 960 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 atg gcc ttg tcc aaa gac gtt gga cac tcc tca ggt acg tta aga gtg 1008 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val 325 330 335 agt tcc aca gga atg att tta ttt ttg tgt att tgt gtg tgg ccc aga 1056 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 ctc tac cat cca gtg cta ctc gag 1080 Leu Tyr His Pro Val Leu Leu Glu 355 360 12 360 PRT Homo sapiens 12 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Ile Ser Leu Gln Tyr 20 25 30 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 Asn Pro Val Ser Leu Ala Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly

Trp Trp 165 170 175 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val 325 330 335 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 Leu Tyr His Pro Val Leu Leu Glu 355 360 13 1080 DNA Homo sapiens CDS (1)..(1080) 13 gga tcc gtc tcc act tac gcg cct gat atg tct agg atg cgt gga ggt 48 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Arg Gly Gly 1 5 10 15 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtc tcc ctg cag tac 96 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 144 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 192 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 240 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 288 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 336 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 384 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 432 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 480 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 cgg ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 528 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt gat ggc gtg 576 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 ata tgc acc tgc aac gga gac tcc ggt ggg ccg ctg aac tgc cag gca 624 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 tct gac ggc cgg tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc 672 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 ctt ggt tgc aac tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc 720 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 aac tac aac gac tgg atc aat tcg gta aga acc gga gca gcc ctg agt 768 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 ccc aag gca ctg ccc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 816 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 tgg cga ctg aga acc ccc tcc ttc ctc ttg aga gct aga tgg gaa ccc 864 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 ctt gga gga ggc tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc 912 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 ccc aaa att tct gtg tgg gta aag ctg agt gaa aag gaa cat gag agt 960 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 atg gcc ttg tcc aaa gac gtt gga cac tcc tca ggt atg tta aga gtg 1008 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 agt tcc aca gga atg att tta ttt ttg tgt att tgt gaa tgg ccc aga 1056 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Glu Trp Pro Arg 340 345 350 ctc tac cat cca gtg cta ctc gag 1080 Leu Tyr His Pro Val Leu Leu Glu 355 360 14 360 PRT Homo sapiens 14 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Arg Gly Gly 1 5 10 15 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Glu Trp Pro Arg 340 345 350 Leu Tyr His Pro Val Leu Leu Glu 355 360 15 1080 DNA Homo sapiens CDS (1)..(1080) 15 gga tcc gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 48 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtc tcc ctg cag tac 96 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 144 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc agg atc 192 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Arg Ile 50 55 60 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 240 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 tcg cta gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 288 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 tcc aac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 336 Ser Asn Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 384 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc aca ggc tgg 432 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 480 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 cgg ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 528 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 ggc agc acc gtg aag acg aat atg att tgt gct ggg ggt gat ggc gtg 576 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 ata tgc acc tgc aac gga gac tcc ggt ggg ccg ctg aac tgt cag gca 624 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 tct gac ggc cgg tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc 672 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 ctt ggt tgc aac tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc 720 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 aac tac aac gac tgg atc aat tcg gta aga acc gga gca gcc ctg agc 768 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 ccc aag gca ctg acc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 816 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 tgg cga ctg aga acc ccc tcc ttc ctc ttg aga gct aga tgg gaa ccc 864 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 ctt gga gga ggc tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc 912 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 ccc aaa att tct gtg tgg gta aag ctg agt gaa aag gaa cat gag agt 960 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 atg gcc ttg tcc aaa gac gtt gga cac tcc tca ggt atg tta aga gtg 1008 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 agt tcc aca gga atg att tta ttt ttg tgt att tgt gtg tgg ccc aga 1056 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 ctc tac cat cca gtg cta ctc gag 1080 Leu Tyr His Pro Val Leu Leu Glu 355 360 16 360 PRT Homo sapiens 16 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Arg Ile 50 55 60 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 Ser Asn Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 Leu Tyr His Pro Val Leu Leu Glu 355 360 17 1080 DNA Homo sapiens CDS (1)..(1080) 17 gga tcc gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 48 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 gaa gaa gcg agg ccc aac agc tgg ccc tgg cag gtc tcc ctg cag tac 96 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 144 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 192 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 240 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 288 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 336 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 384 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 432 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 480 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 cgg ttg ctg gtt gtg gac tat gcc acc tgc tcc agc tct ggc tgg tgg 528 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt gat ggc gtg 576 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 ata tgc acc tgc aac gga gac tcc ggt ggg ccg ctg aac tgt cag gca 624 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 tct gac ggc

cgg tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc 672 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 ctt ggt tgc aac tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc 720 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 aac tac aac gac tgg atc aat tcg gta aga acc gga gca gcc ctg agc 768 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 ccc aag gca ctg ccc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 816 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 tgg cga ctg aga acc ccc tcc ttc ctc ttg aga gct aga tgg gaa ccc 864 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 ctt gga gga ggc tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc 912 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 ccc aaa att tct gtg tgg gta aag ctg agt gaa aag gaa cat gag agt 960 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 atg gcc ttg tcc aaa gac gtt gga cac tcc tca ggt atg tta aga gtg 1008 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 agt tcc aca gga atg att tta ttt ttg tgt att tgt gtg tgg ccc aga 1056 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 ctc tac cat cca gtg cta ctc gag 1080 Leu Tyr His Pro Val Leu Leu Glu 355 360 18 360 PRT Homo sapiens 18 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 Glu Glu Ala Arg Pro Asn Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Ser Ser Gly Trp Trp 165 170 175 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 Pro Lys Ala Leu Pro Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Ala Arg Trp Glu Pro 275 280 285 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Met Leu Arg Val 325 330 335 Ser Ser Thr Gly Met Ile Leu Phe Leu Cys Ile Cys Val Trp Pro Arg 340 345 350 Leu Tyr His Pro Val Leu Leu Glu 355 360 19 1023 DNA Homo sapiens CDS (1)..(1023) 19 gga tcc gtc tcc act tac gcg cct gat atg tct agg atg ctt gga ggt 48 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 gaa gaa gcg agg ccc aac agc cgg ccc tgg cag gtc tcc ctg cag tac 96 Glu Glu Ala Arg Pro Asn Ser Arg Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 agc tcc aat ggc cag tgg tac cac acc tgc gga ggg tcc ctg ata gcc 144 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 aac agc tgg gtc ctg acg gct gcc cac tgc atc agc tcc tcc ggg atc 192 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 tac cgc gtg atg ctg ggc cag cat aac ctc tac gtt gca gag tcc ggc 240 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 tcg ctg gcc gtc agt gtc tct aag att gtg gtg cac aag gac tgg aac 288 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 tcc gac cag gtc tcc aaa ggg aac gac att gcc ctg ctc aaa ctg gct 336 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 aac ccc gtc tcc ctc acc gac aag atc cag ctg gcc tgc ctc cct cct 384 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 gcc ggc acc att cta ccc aac aac tac ccc tgc tac gtc acg ggc tgg 432 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 gga agg ctg cag acc aac ggg gct ctc cct gat gac ctg aag cag ggc 480 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 cgg ttg ctg gtt gtg gac tat gcc acc tgc tcc aac tct ggc tgg tgg 528 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Asn Ser Gly Trp Trp 165 170 175 ggc agc acc gtg aag acg aat atg atc tgt gct ggg ggt gat ggc gtg 576 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 ata tgc acc tgc aac gga gac tcc ggt ggg ccg ctg aac tgt cag gca 624 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 tct gac ggc cgg tgg gag gtg cat ggc atc ggc agc ctc acg tcg gtc 672 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 ctt ggt tgc aac tac tac tac aag ccc tcc atc ttc acg cgg gtc tcc 720 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 aac tac aac gac tgg atc aat tcg gta aga acc gga gca gcc ctg agc 768 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 ccc aag gca ctg acc tgc tca cct ggc ctc ggg agt gcc atg ccc acc 816 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 tgg cga ctg aga acc ccc tcc ttc ctc ttg aga act aga tgg gaa ccc 864 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Thr Arg Trp Glu Pro 275 280 285 ctt gga gga ggc tgc aga cct tgg caa ctg ctg agt ccc cca tgg gtc 912 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 ccc aaa att tct gtg tgg gta aag ctg agt gaa aag gaa cat gag agt 960 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 atg gcc ttg tcc aaa gac gtt gga cac tcc tca ggt acg tta aga gtg 1008 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val 325 330 335 agt tcc aca ctc gag 1023 Ser Ser Thr Leu Glu 340 20 341 PRT Homo sapiens 20 Gly Ser Val Ser Thr Tyr Ala Pro Asp Met Ser Arg Met Leu Gly Gly 1 5 10 15 Glu Glu Ala Arg Pro Asn Ser Arg Pro Trp Gln Val Ser Leu Gln Tyr 20 25 30 Ser Ser Asn Gly Gln Trp Tyr His Thr Cys Gly Gly Ser Leu Ile Ala 35 40 45 Asn Ser Trp Val Leu Thr Ala Ala His Cys Ile Ser Ser Ser Gly Ile 50 55 60 Tyr Arg Val Met Leu Gly Gln His Asn Leu Tyr Val Ala Glu Ser Gly 65 70 75 80 Ser Leu Ala Val Ser Val Ser Lys Ile Val Val His Lys Asp Trp Asn 85 90 95 Ser Asp Gln Val Ser Lys Gly Asn Asp Ile Ala Leu Leu Lys Leu Ala 100 105 110 Asn Pro Val Ser Leu Thr Asp Lys Ile Gln Leu Ala Cys Leu Pro Pro 115 120 125 Ala Gly Thr Ile Leu Pro Asn Asn Tyr Pro Cys Tyr Val Thr Gly Trp 130 135 140 Gly Arg Leu Gln Thr Asn Gly Ala Leu Pro Asp Asp Leu Lys Gln Gly 145 150 155 160 Arg Leu Leu Val Val Asp Tyr Ala Thr Cys Ser Asn Ser Gly Trp Trp 165 170 175 Gly Ser Thr Val Lys Thr Asn Met Ile Cys Ala Gly Gly Asp Gly Val 180 185 190 Ile Cys Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Gln Ala 195 200 205 Ser Asp Gly Arg Trp Glu Val His Gly Ile Gly Ser Leu Thr Ser Val 210 215 220 Leu Gly Cys Asn Tyr Tyr Tyr Lys Pro Ser Ile Phe Thr Arg Val Ser 225 230 235 240 Asn Tyr Asn Asp Trp Ile Asn Ser Val Arg Thr Gly Ala Ala Leu Ser 245 250 255 Pro Lys Ala Leu Thr Cys Ser Pro Gly Leu Gly Ser Ala Met Pro Thr 260 265 270 Trp Arg Leu Arg Thr Pro Ser Phe Leu Leu Arg Thr Arg Trp Glu Pro 275 280 285 Leu Gly Gly Gly Cys Arg Pro Trp Gln Leu Leu Ser Pro Pro Trp Val 290 295 300 Pro Lys Ile Ser Val Trp Val Lys Leu Ser Glu Lys Glu His Glu Ser 305 310 315 320 Met Ala Leu Ser Lys Asp Val Gly His Ser Ser Gly Thr Leu Arg Val 325 330 335 Ser Ser Thr Leu Glu 340 21 1800 DNA Homo sapiens CDS (16)..(1762) 21 gagcctctct tcacc atg tgc ttc gtc ccc ctg gtg tgc tgg gtg gtg 48 Met Cys Phe Val Pro Leu Val Cys Trp Val Val 1 5 10 tgt acc tgc ctc cag cag cag ctg gag ggt ggg ggg ctg ttg aga cag 96 Cys Thr Cys Leu Gln Gln Gln Leu Glu Gly Gly Gly Leu Leu Arg Gln 15 20 25 acg tcc agg acc acc act gca gtg tac atg ctc tac ctg ctg agt ctg 144 Thr Ser Arg Thr Thr Thr Ala Val Tyr Met Leu Tyr Leu Leu Ser Leu 30 35 40 atg caa ccc aag ccg ggg gcc ccg cgc ctc cag ccc cca ccc aac cag 192 Met Gln Pro Lys Pro Gly Ala Pro Arg Leu Gln Pro Pro Pro Asn Gln 45 50 55 aga ggg ttg tgc tcc ttg gcg gca gat ggg ctc tgg aat cag aaa atc 240 Arg Gly Leu Cys Ser Leu Ala Ala Asp Gly Leu Trp Asn Gln Lys Ile 60 65 70 75 cta ttt gag gag cag gac ctc cgg aag cac ggc cta gac ggg gaa gac 288 Leu Phe Glu Glu Gln Asp Leu Arg Lys His Gly Leu Asp Gly Glu Asp 80 85 90 gtc tct gcc ttc ctc aac atg aac atc ttc cag aag gac atc aac tgt 336 Val Ser Ala Phe Leu Asn Met Asn Ile Phe Gln Lys Asp Ile Asn Cys 95 100 105 gag agg tac tac agc ttc atc cac ttg agt ttc cag gaa ttc ttt gca 384 Glu Arg Tyr Tyr Ser Phe Ile His Leu Ser Phe Gln Glu Phe Phe Ala 110 115 120 gct atg tac tat atc ctg gac gag ggg gag ggc ggg gca ggc cca gac 432 Ala Met Tyr Tyr Ile Leu Asp Glu Gly Glu Gly Gly Ala Gly Pro Asp 125 130 135 cag gac gtg acc agg ctg ttg acc gag tac gcg ttt tct gaa agg agc 480 Gln Asp Val Thr Arg Leu Leu Thr Glu Tyr Ala Phe Ser Glu Arg Ser 140 145 150 155 ttc ctg gca ctc acc agc cgc ttc ctg ttt gga ctc ctg aac gag gag 528 Phe Leu Ala Leu Thr Ser Arg Phe Leu Phe Gly Leu Leu Asn Glu Glu 160 165 170 acc agg agc cac ctg gag aag agt ctc tgc tgg aag gtc tcg ccg cac 576 Thr Arg Ser His Leu Glu Lys Ser Leu Cys Trp Lys Val Ser Pro His 175 180 185 atc aag atg gac ctg ttg cag tgg atc caa agc aaa gct cag agc gac 624 Ile Lys Met Asp Leu Leu Gln Trp Ile Gln Ser Lys Ala Gln Ser Asp 190 195 200 ggc tcc acc ctg cag cag ggc tcc ttg gag ttc ttc agc tgc ttg tac 672 Gly Ser Thr Leu Gln Gln Gly Ser Leu Glu Phe Phe Ser Cys Leu Tyr 205 210 215 gag atc cag gag gag gag ttt atc cag cag gcc ctg agc cac ttc cag 720 Glu Ile Gln Glu Glu Glu Phe Ile Gln Gln Ala Leu Ser His Phe Gln 220 225 230 235 gtg atc gtg gtc agc aac att gcc tcc aag atg gag cac atg gtc tcc 768 Val Ile Val Val Ser Asn Ile Ala Ser Lys Met Glu His Met Val Ser 240 245 250 tcg ttc tgt ctg aag cgc tgc agg agc gcc cag gtg ctg cac ttg tat 816 Ser Phe Cys Leu Lys Arg Cys Arg Ser Ala Gln Val Leu His Leu Tyr 255 260 265 ggc gcc acc tac agc gcg gac ggg gaa gac cgc gcg agg tgc tcc gca 864 Gly Ala Thr Tyr Ser Ala Asp Gly Glu Asp Arg Ala Arg Cys Ser Ala 270 275 280 gga gcg cac acg ctg ttg gtg cag ctg aga cca gag agg acc gtt ctg 912 Gly Ala His Thr Leu Leu Val Gln Leu Arg Pro Glu Arg Thr Val Leu 285 290 295 ctg gac gcc tac agt gaa cat ctg gca gcg gcc ctg tgc acc aat cca 960 Leu Asp Ala Tyr Ser Glu His Leu Ala Ala Ala Leu Cys Thr Asn Pro 300 305 310 315 aac ctg ata gag ctg tct ctg tac cga aat gcc ctg ggc agc cgg ggg 1008 Asn Leu Ile Glu Leu Ser Leu Tyr Arg Asn Ala Leu Gly Ser Arg Gly 320 325 330 gtg aag ctg ctc tgt caa gga ctc aga cac ccc aac tgc aaa ctt cag 1056 Val Lys Leu Leu Cys Gln Gly Leu Arg His Pro Asn Cys Lys Leu Gln 335 340 345 aac ctg agg agg ctg aag agg tgc cgc atc tcc agc tca gcc tgc gag 1104 Asn Leu Arg Arg Leu Lys Arg Cys Arg Ile Ser Ser Ser Ala Cys Glu 350 355 360 gac ctc tct gca gct ctc ata gcc aat aag aat ttg aca agg atg gat 1152 Asp Leu Ser Ala Ala Leu Ile Ala Asn Lys Asn Leu Thr Arg Met Asp 365 370 375 ctc agt ggc aac ggc gtt gga ttc cca ggc atg atg ctg ctt tgc gag 1200 Leu Ser Gly Asn Gly Val Gly Phe Pro Gly Met Met Leu Leu Cys Glu 380 385 390 395 ggc ctg cgg cat ccc cag tgc agg ctg cag atg att cag ttg agg aag 1248 Gly Leu Arg His Pro Gln Cys Arg Leu Gln Met Ile Gln Leu Arg Lys 400 405 410 tgt cag ctg gag tcc ggg gct tgt cag gag atg gct tct gtg ctc ggc 1296 Cys Gln Leu Glu Ser Gly Ala Cys Gln Glu Met Ala Ser Val Leu Gly 415 420 425 acc aac cca cat ctg gtt gag ttg gac ctg aca gga aat gca ctg gag 1344 Thr Asn Pro His Leu Val Glu Leu Asp Leu Thr Gly Asn Ala Leu Glu 430 435 440 gat ttg ggc ctg agg tta cta tgc cag gga ctg agg cac cca gtc tgc 1392 Asp Leu Gly Leu Arg Leu Leu Cys Gln Gly Leu Arg His Pro Val Cys 445 450 455 aga cta cgg act ttg tgg tgc agg ctg aag atc tgc cgc ctc act gct 1440 Arg Leu Arg Thr Leu Trp Cys Arg Leu Lys Ile Cys Arg Leu Thr Ala 460 465 470 475 gct gcc tgt gac gag ctg gcc tca act ctc agt gtg aac cag agc ctg 1488 Ala Ala Cys Asp Glu Leu Ala Ser Thr Leu Ser Val Asn Gln Ser Leu 480 485 490 aga gag ctg gac ctg agc ctg aat gag ctg ggg gac ctc ggg gtg ctg 1536 Arg Glu Leu Asp Leu Ser Leu Asn Glu Leu Gly Asp Leu Gly Val Leu 495 500 505 ctg ctg tgt gag ggc ctc agg cat ccc acg tgc aag ctc cag acc ctg 1584 Leu Leu Cys Glu Gly Leu Arg His Pro Thr Cys Lys Leu Gln Thr Leu 510 515 520 cgg agg ttg ggc atc tgc cgg ctg ggc tct gcc gcc tgt gag ggt ctt 1632 Arg Arg Leu Gly Ile Cys Arg Leu Gly Ser Ala Ala Cys Glu Gly Leu 525 530 535 tct gtg gtg ctc cag gcc aac cac aac ctc cgg gag ctg gac ttg agt 1680 Ser Val Val Leu Gln Ala Asn His Asn Leu Arg Glu Leu Asp Leu Ser 540 545 550 555 ttc aac gac ctg gga gac tgg ggc ctg tgg ttg ctg gct gag ggg ctg 1728 Phe Asn Asp Leu Gly Asp Trp Gly Leu Trp Leu Leu Ala Glu Gly Leu 560

565 570 caa cat ccc gcc tgc aga ctc cag aaa ctg tgg tgagcatcgg 1771 Gln His Pro Ala Cys Arg Leu Gln Lys Leu Trp 575 580 ggagtgacgg ggtggcagtg gtcacgttt 1800 22 582 PRT Homo sapiens 22 Met Cys Phe Val Pro Leu Val Cys Trp Val Val Cys Thr Cys Leu Gln 1 5 10 15 Gln Gln Leu Glu Gly Gly Gly Leu Leu Arg Gln Thr Ser Arg Thr Thr 20 25 30 Thr Ala Val Tyr Met Leu Tyr Leu Leu Ser Leu Met Gln Pro Lys Pro 35 40 45 Gly Ala Pro Arg Leu Gln Pro Pro Pro Asn Gln Arg Gly Leu Cys Ser 50 55 60 Leu Ala Ala Asp Gly Leu Trp Asn Gln Lys Ile Leu Phe Glu Glu Gln 65 70 75 80 Asp Leu Arg Lys His Gly Leu Asp Gly Glu Asp Val Ser Ala Phe Leu 85 90 95 Asn Met Asn Ile Phe Gln Lys Asp Ile Asn Cys Glu Arg Tyr Tyr Ser 100 105 110 Phe Ile His Leu Ser Phe Gln Glu Phe Phe Ala Ala Met Tyr Tyr Ile 115 120 125 Leu Asp Glu Gly Glu Gly Gly Ala Gly Pro Asp Gln Asp Val Thr Arg 130 135 140 Leu Leu Thr Glu Tyr Ala Phe Ser Glu Arg Ser Phe Leu Ala Leu Thr 145 150 155 160 Ser Arg Phe Leu Phe Gly Leu Leu Asn Glu Glu Thr Arg Ser His Leu 165 170 175 Glu Lys Ser Leu Cys Trp Lys Val Ser Pro His Ile Lys Met Asp Leu 180 185 190 Leu Gln Trp Ile Gln Ser Lys Ala Gln Ser Asp Gly Ser Thr Leu Gln 195 200 205 Gln Gly Ser Leu Glu Phe Phe Ser Cys Leu Tyr Glu Ile Gln Glu Glu 210 215 220 Glu Phe Ile Gln Gln Ala Leu Ser His Phe Gln Val Ile Val Val Ser 225 230 235 240 Asn Ile Ala Ser Lys Met Glu His Met Val Ser Ser Phe Cys Leu Lys 245 250 255 Arg Cys Arg Ser Ala Gln Val Leu His Leu Tyr Gly Ala Thr Tyr Ser 260 265 270 Ala Asp Gly Glu Asp Arg Ala Arg Cys Ser Ala Gly Ala His Thr Leu 275 280 285 Leu Val Gln Leu Arg Pro Glu Arg Thr Val Leu Leu Asp Ala Tyr Ser 290 295 300 Glu His Leu Ala Ala Ala Leu Cys Thr Asn Pro Asn Leu Ile Glu Leu 305 310 315 320 Ser Leu Tyr Arg Asn Ala Leu Gly Ser Arg Gly Val Lys Leu Leu Cys 325 330 335 Gln Gly Leu Arg His Pro Asn Cys Lys Leu Gln Asn Leu Arg Arg Leu 340 345 350 Lys Arg Cys Arg Ile Ser Ser Ser Ala Cys Glu Asp Leu Ser Ala Ala 355 360 365 Leu Ile Ala Asn Lys Asn Leu Thr Arg Met Asp Leu Ser Gly Asn Gly 370 375 380 Val Gly Phe Pro Gly Met Met Leu Leu Cys Glu Gly Leu Arg His Pro 385 390 395 400 Gln Cys Arg Leu Gln Met Ile Gln Leu Arg Lys Cys Gln Leu Glu Ser 405 410 415 Gly Ala Cys Gln Glu Met Ala Ser Val Leu Gly Thr Asn Pro His Leu 420 425 430 Val Glu Leu Asp Leu Thr Gly Asn Ala Leu Glu Asp Leu Gly Leu Arg 435 440 445 Leu Leu Cys Gln Gly Leu Arg His Pro Val Cys Arg Leu Arg Thr Leu 450 455 460 Trp Cys Arg Leu Lys Ile Cys Arg Leu Thr Ala Ala Ala Cys Asp Glu 465 470 475 480 Leu Ala Ser Thr Leu Ser Val Asn Gln Ser Leu Arg Glu Leu Asp Leu 485 490 495 Ser Leu Asn Glu Leu Gly Asp Leu Gly Val Leu Leu Leu Cys Glu Gly 500 505 510 Leu Arg His Pro Thr Cys Lys Leu Gln Thr Leu Arg Arg Leu Gly Ile 515 520 525 Cys Arg Leu Gly Ser Ala Ala Cys Glu Gly Leu Ser Val Val Leu Gln 530 535 540 Ala Asn His Asn Leu Arg Glu Leu Asp Leu Ser Phe Asn Asp Leu Gly 545 550 555 560 Asp Trp Gly Leu Trp Leu Leu Ala Glu Gly Leu Gln His Pro Ala Cys 565 570 575 Arg Leu Gln Lys Leu Trp 580 23 1683 DNA Homo sapiens CDS (18)..(1581) 23 gcgcgcctct cttcacc atg tgc ttc gtc ccc ctg gtg tgc tgg gtg gtg 50 Met Cys Phe Val Pro Leu Val Cys Trp Val Val 1 5 10 tgt acc tgc ctc cag cag cag ctg gag ggt ggg ggg ctg ttg aga cag 98 Cys Thr Cys Leu Gln Gln Gln Leu Glu Gly Gly Gly Leu Leu Arg Gln 15 20 25 acg tcc agg acc acc act gca gtg tac atg ctc tac ctg ctg agt ctg 146 Thr Ser Arg Thr Thr Thr Ala Val Tyr Met Leu Tyr Leu Leu Ser Leu 30 35 40 atg caa ccc aag ccg ggg gcc ccg cgc ctc cag ccc cca ccc aac cag 194 Met Gln Pro Lys Pro Gly Ala Pro Arg Leu Gln Pro Pro Pro Asn Gln 45 50 55 aga ggg ttg tgc tcc ttg gcg gca gat ggg ctc tgg aat cag aaa atc 242 Arg Gly Leu Cys Ser Leu Ala Ala Asp Gly Leu Trp Asn Gln Lys Ile 60 65 70 75 cta ttt gag gag cag gac ctc cgg aag cac ggc cta gac ggg gaa gac 290 Leu Phe Glu Glu Gln Asp Leu Arg Lys His Gly Leu Asp Gly Glu Asp 80 85 90 gtc tct gcc ttc ctc aac atg aac atc ttc cag aag gac atc aac tgt 338 Val Ser Ala Phe Leu Asn Met Asn Ile Phe Gln Lys Asp Ile Asn Cys 95 100 105 gag agg tac tac agc ttc atc cac ttg agt ttc cag gaa ttc ttt gca 386 Glu Arg Tyr Tyr Ser Phe Ile His Leu Ser Phe Gln Glu Phe Phe Ala 110 115 120 gct atg tac tat atc ctg gac gag ggg gag ggc ggg gca ggc cca gac 434 Ala Met Tyr Tyr Ile Leu Asp Glu Gly Glu Gly Gly Ala Gly Pro Asp 125 130 135 cag gac gtg acc agg ctg ttg acc gag tac gcg ttt tct gaa agg agc 482 Gln Asp Val Thr Arg Leu Leu Thr Glu Tyr Ala Phe Ser Glu Arg Ser 140 145 150 155 ttc ctg gca ctc acc agc cgc ttc ctg ttt gga ctc ctg aac gag gag 530 Phe Leu Ala Leu Thr Ser Arg Phe Leu Phe Gly Leu Leu Asn Glu Glu 160 165 170 acc agg agc cac ctg gag aag agt ctc tgc tgg aag gtc tcg ccg cac 578 Thr Arg Ser His Leu Glu Lys Ser Leu Cys Trp Lys Val Ser Pro His 175 180 185 atc aag atg gac ctg ttg cag tgg atc caa agc aaa gct cag agc gac 626 Ile Lys Met Asp Leu Leu Gln Trp Ile Gln Ser Lys Ala Gln Ser Asp 190 195 200 ggc tcc acc ctg cag cag ggc tcc ttg gag ttc ttc agc tgc ttg tac 674 Gly Ser Thr Leu Gln Gln Gly Ser Leu Glu Phe Phe Ser Cys Leu Tyr 205 210 215 gag atc cag gag gag gag ttt atc cag cag gcc ctg agc cac ttc cag 722 Glu Ile Gln Glu Glu Glu Phe Ile Gln Gln Ala Leu Ser His Phe Gln 220 225 230 235 gtg atc gtg gtc agc aac att gcc tcc aag atg gag cac atg gtc tcc 770 Val Ile Val Val Ser Asn Ile Ala Ser Lys Met Glu His Met Val Ser 240 245 250 tcg ttc tgt ctg aag cgc tgc agg agc gcc cag gtg ctg cac ttg tat 818 Ser Phe Cys Leu Lys Arg Cys Arg Ser Ala Gln Val Leu His Leu Tyr 255 260 265 ggc gcc acc tac agc gcg gac ggg gaa gac cgc gcg agg tgc tcc gca 866 Gly Ala Thr Tyr Ser Ala Asp Gly Glu Asp Arg Ala Arg Cys Ser Ala 270 275 280 gga gcg cac acg ctg ttg gtg cag ctc aga cca gag agg acc gtt ctg 914 Gly Ala His Thr Leu Leu Val Gln Leu Arg Pro Glu Arg Thr Val Leu 285 290 295 ctg gac gcc tac agt gaa cat ctg gca gcg gcc ctg tgc acc aat cca 962 Leu Asp Ala Tyr Ser Glu His Leu Ala Ala Ala Leu Cys Thr Asn Pro 300 305 310 315 aac ctg ata gag ctg tct ctg tac cga aat gcc ctg ggc agc cgg ggg 1010 Asn Leu Ile Glu Leu Ser Leu Tyr Arg Asn Ala Leu Gly Ser Arg Gly 320 325 330 gtg aag ctg ctc tgt caa gga ctc aga cac ccc aac tgc aaa ctt cag 1058 Val Lys Leu Leu Cys Gln Gly Leu Arg His Pro Asn Cys Lys Leu Gln 335 340 345 aac ctg agg ctg aag agg tgc cgc atc tcc agc tca gcc tgc gag gac 1106 Asn Leu Arg Leu Lys Arg Cys Arg Ile Ser Ser Ser Ala Cys Glu Asp 350 355 360 ctc tct gca gct ctc ata gcc aat aag aat ttg aca agg atg gat ctc 1154 Leu Ser Ala Ala Leu Ile Ala Asn Lys Asn Leu Thr Arg Met Asp Leu 365 370 375 agt ggc aac ggc gtt gga ttc cca ggc atg atg ctg ctt tgc gag ggc 1202 Ser Gly Asn Gly Val Gly Phe Pro Gly Met Met Leu Leu Cys Glu Gly 380 385 390 395 ctg cgg cat ccc caa tgc agg ctg cag atg att cag ctg aag atc tgc 1250 Leu Arg His Pro Gln Cys Arg Leu Gln Met Ile Gln Leu Lys Ile Cys 400 405 410 cgc ctc act gct gct gcc tgt gac gag ctg gcc tca act ctc agt gtg 1298 Arg Leu Thr Ala Ala Ala Cys Asp Glu Leu Ala Ser Thr Leu Ser Val 415 420 425 aac cag agc ctg aga gag ctg gac ctg agc ctg aat gag ctg ggg gac 1346 Asn Gln Ser Leu Arg Glu Leu Asp Leu Ser Leu Asn Glu Leu Gly Asp 430 435 440 ctc ggg gtg ctg ctg ctg tgt gag ggc ctc agg cat ccc acg tgc aag 1394 Leu Gly Val Leu Leu Leu Cys Glu Gly Leu Arg His Pro Thr Cys Lys 445 450 455 ctc cag acc ctg cgg ttg ggc atc tgc cgg ctg ggc tct gcc gcc tgt 1442 Leu Gln Thr Leu Arg Leu Gly Ile Cys Arg Leu Gly Ser Ala Ala Cys 460 465 470 475 gag ggt ctt tct gtg gtg ctc cag gcc aac cac aac ctc cgg gag ctg 1490 Glu Gly Leu Ser Val Val Leu Gln Ala Asn His Asn Leu Arg Glu Leu 480 485 490 gac ttg agt ttc aac gac ctg gga gac tgg ggc ctg tgg ttg ctg gct 1538 Asp Leu Ser Phe Asn Asp Leu Gly Asp Trp Gly Leu Trp Leu Leu Ala 495 500 505 gag ggg ctg caa cat ccc gcc tgc aga ctc cag aaa ctg tgg 1580 Glu Gly Leu Gln His Pro Ala Cys Arg Leu Gln Lys Leu Trp 510 515 520 tgagcatcgg ggagtgacgg ggtggcagtg gtcacgtttg gacagtggaa 1630 gcgccttctc atccttcatt tttctattta tgaactatcc tgcttcacta 1680 caa 1683 24 521 PRT Homo sapiens 24 Met Cys Phe Val Pro Leu Val Cys Trp Val Val Cys Thr Cys Leu Gln 1 5 10 15 Gln Gln Leu Glu Gly Gly Gly Leu Leu Arg Gln Thr Ser Arg Thr Thr 20 25 30 Thr Ala Val Tyr Met Leu Tyr Leu Leu Ser Leu Met Gln Pro Lys Pro 35 40 45 Gly Ala Pro Arg Leu Gln Pro Pro Pro Asn Gln Arg Gly Leu Cys Ser 50 55 60 Leu Ala Ala Asp Gly Leu Trp Asn Gln Lys Ile Leu Phe Glu Glu Gln 65 70 75 80 Asp Leu Arg Lys His Gly Leu Asp Gly Glu Asp Val Ser Ala Phe Leu 85 90 95 Asn Met Asn Ile Phe Gln Lys Asp Ile Asn Cys Glu Arg Tyr Tyr Ser 100 105 110 Phe Ile His Leu Ser Phe Gln Glu Phe Phe Ala Ala Met Tyr Tyr Ile 115 120 125 Leu Asp Glu Gly Glu Gly Gly Ala Gly Pro Asp Gln Asp Val Thr Arg 130 135 140 Leu Leu Thr Glu Tyr Ala Phe Ser Glu Arg Ser Phe Leu Ala Leu Thr 145 150 155 160 Ser Arg Phe Leu Phe Gly Leu Leu Asn Glu Glu Thr Arg Ser His Leu 165 170 175 Glu Lys Ser Leu Cys Trp Lys Val Ser Pro His Ile Lys Met Asp Leu 180 185 190 Leu Gln Trp Ile Gln Ser Lys Ala Gln Ser Asp Gly Ser Thr Leu Gln 195 200 205 Gln Gly Ser Leu Glu Phe Phe Ser Cys Leu Tyr Glu Ile Gln Glu Glu 210 215 220 Glu Phe Ile Gln Gln Ala Leu Ser His Phe Gln Val Ile Val Val Ser 225 230 235 240 Asn Ile Ala Ser Lys Met Glu His Met Val Ser Ser Phe Cys Leu Lys 245 250 255 Arg Cys Arg Ser Ala Gln Val Leu His Leu Tyr Gly Ala Thr Tyr Ser 260 265 270 Ala Asp Gly Glu Asp Arg Ala Arg Cys Ser Ala Gly Ala His Thr Leu 275 280 285 Leu Val Gln Leu Arg Pro Glu Arg Thr Val Leu Leu Asp Ala Tyr Ser 290 295 300 Glu His Leu Ala Ala Ala Leu Cys Thr Asn Pro Asn Leu Ile Glu Leu 305 310 315 320 Ser Leu Tyr Arg Asn Ala Leu Gly Ser Arg Gly Val Lys Leu Leu Cys 325 330 335 Gln Gly Leu Arg His Pro Asn Cys Lys Leu Gln Asn Leu Arg Leu Lys 340 345 350 Arg Cys Arg Ile Ser Ser Ser Ala Cys Glu Asp Leu Ser Ala Ala Leu 355 360 365 Ile Ala Asn Lys Asn Leu Thr Arg Met Asp Leu Ser Gly Asn Gly Val 370 375 380 Gly Phe Pro Gly Met Met Leu Leu Cys Glu Gly Leu Arg His Pro Gln 385 390 395 400 Cys Arg Leu Gln Met Ile Gln Leu Lys Ile Cys Arg Leu Thr Ala Ala 405 410 415 Ala Cys Asp Glu Leu Ala Ser Thr Leu Ser Val Asn Gln Ser Leu Arg 420 425 430 Glu Leu Asp Leu Ser Leu Asn Glu Leu Gly Asp Leu Gly Val Leu Leu 435 440 445 Leu Cys Glu Gly Leu Arg His Pro Thr Cys Lys Leu Gln Thr Leu Arg 450 455 460 Leu Gly Ile Cys Arg Leu Gly Ser Ala Ala Cys Glu Gly Leu Ser Val 465 470 475 480 Val Leu Gln Ala Asn His Asn Leu Arg Glu Leu Asp Leu Ser Phe Asn 485 490 495 Asp Leu Gly Asp Trp Gly Leu Trp Leu Leu Ala Glu Gly Leu Gln His 500 505 510 Pro Ala Cys Arg Leu Gln Lys Leu Trp 515 520 25 481 DNA Homo sapiens CDS (28)..(382) 25 cttgtcttgt tccagttctc agaggga atg ctt tca att ttt ctc tat tca 51 Met Leu Ser Ile Phe Leu Tyr Ser 1 5 gta tta tgt tgg ctg tgg gtt tgt cat aga ttg tgt gcc gtg agg gag 99 Val Leu Cys Trp Leu Trp Val Cys His Arg Leu Cys Ala Val Arg Glu 10 15 20 ttt act ttc ctg gcc aag aag cca ggc tgc agg ggc ctt cgg atc acc 147 Phe Thr Phe Leu Ala Lys Lys Pro Gly Cys Arg Gly Leu Arg Ile Thr 25 30 35 40 acg gat gcc tgc tgg ggt cgc tgt gag acc ttc tat cta tgg gga cag 195 Thr Asp Ala Cys Trp Gly Arg Cys Glu Thr Phe Tyr Leu Trp Gly Gln 45 50 55 aaa ccc att ctg gaa ccc ccc tat att gaa gcc cat cat cga gtc tgt 243 Lys Pro Ile Leu Glu Pro Pro Tyr Ile Glu Ala His His Arg Val Cys 60 65 70 acc tac aac gag acc aaa cag gtg act gtc aag ctg ccc aac tgt gcc 291 Thr Tyr Asn Glu Thr Lys Gln Val Thr Val Lys Leu Pro Asn Cys Ala 75 80 85 ccg gga gtc gac ccc ttc tac acc tat ccc gtg gcc atc cgc tgt gac 339 Pro Gly Val Asp Pro Phe Tyr Thr Tyr Pro Val Ala Ile Arg Cys Asp 90 95 100 tgc gga gcc tgc tcc act gcc acc acg gag tgt gag acc atc 381 Cys Gly Ala Cys Ser Thr Ala Thr Thr Glu Cys Glu Thr Ile 105 110 115 tgaggccgct agctgctctc tgcagaccca cctgtgtgag cagcacatgc 431 agttatactt cctggatgca agactgttta atttcgacca cacccatgga 481 26 118 PRT Homo sapiens 26 Met Leu Ser Ile Phe Leu Tyr Ser Val Leu Cys Trp Leu Trp Val Cys 1 5 10 15 His Arg Leu Cys Ala Val Arg Glu Phe Thr Phe Leu Ala Lys Lys Pro 20 25 30 Gly Cys Arg Gly Leu Arg Ile Thr Thr Asp Ala Cys Trp Gly Arg Cys 35 40 45 Glu Thr Phe Tyr Leu Trp Gly Gln Lys Pro Ile Leu Glu Pro Pro Tyr 50 55 60 Ile Glu Ala His His Arg Val Cys Thr Tyr Asn Glu Thr Lys Gln Val 65 70 75 80 Thr Val Lys Leu Pro Asn Cys Ala Pro Gly Val Asp Pro Phe Tyr Thr 85 90 95 Tyr Pro Val Ala Ile Arg Cys Asp Cys Gly Ala Cys Ser Thr Ala Thr 100 105 110 Thr Glu Cys Glu Thr Ile 115 27 682 DNA Homo sapiens CDS (1)..(673) 27 atg aag acc ctg ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg 48 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu 1 5 10 15 tcc ttc acc ctg gag gag gag gat gtg cat cca gaa gaa aat cct gat 96 Ser Phe Thr Leu Glu Glu Glu Asp Val His Pro Glu Glu Asn Pro Asp 20 25 30 gcg gaa tgg ggg cag gaa gct cat gta cct gca gga gct gcc cag gag 144 Ala Glu Trp Gly Gln Glu Ala

His Val Pro Ala Gly Ala Ala Gln Glu 35 40 45 gga cca cta cat ctt tta ctg caa aga cca gca cca tgg ggg cct gct 192 Gly Pro Leu His Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala 50 55 60 cca cat ggg aaa gct tgt ggg tgc tcc ctg cag ggc cgt gcc gct gtc 240 Pro His Gly Lys Ala Cys Gly Cys Ser Leu Gln Gly Arg Ala Ala Val 65 70 75 80 ccc acg tcg gct cac ctg gcc acc tca cct gca ggt agg aat tct gat 288 Pro Thr Ser Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Ser Asp 85 90 95 acc aac cgg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag cgc aag 336 Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys 100 105 110 gga ctc tcg gag gag gac att ttc acg ccc ctg cag acg ggt gag gat 384 Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro Leu Gln Thr Gly Glu Asp 115 120 125 ggc tgt gcc cag tcc cct gtg tcc ctc tgc tgt gtc tgt ctg cta tct 432 Gly Cys Ala Gln Ser Pro Val Ser Leu Cys Cys Val Cys Leu Leu Ser 130 135 140 cca gtg tcc cat gac ccc cat gtc ctc cca tgt ccc ccg cat tcc cca 480 Pro Val Ser His Asp Pro His Val Leu Pro Cys Pro Pro His Ser Pro 145 150 155 160 tgt gcc ccg agt ctc ctc gca ggg gct ccc ggg ccc tgt tta gcg tcc 528 Cys Ala Pro Ser Leu Leu Ala Gly Ala Pro Gly Pro Cys Leu Ala Ser 165 170 175 tcc tca ttg gag gct ctg tgc tct ggg ctg cga tgg ggt ctg ggg ctc 576 Ser Ser Leu Glu Ala Leu Cys Ser Gly Leu Arg Trp Gly Leu Gly Leu 180 185 190 cgc gct ctg ggc tgc gat ggg gtc tgg ggc tcc gca ctc tgg gct gcg 624 Arg Ala Leu Gly Cys Asp Gly Val Trp Gly Ser Ala Leu Trp Ala Ala 195 200 205 atg ggg tct ggg gct ccg cgc tct ggg ctg cga tgg gct ctg ggg ctc 672 Met Gly Ser Gly Ala Pro Arg Ser Gly Leu Arg Trp Ala Leu Gly Leu 210 215 220 tgagctctgg 682 28 224 PRT Homo sapiens 28 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu 1 5 10 15 Ser Phe Thr Leu Glu Glu Glu Asp Val His Pro Glu Glu Asn Pro Asp 20 25 30 Ala Glu Trp Gly Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu 35 40 45 Gly Pro Leu His Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala 50 55 60 Pro His Gly Lys Ala Cys Gly Cys Ser Leu Gln Gly Arg Ala Ala Val 65 70 75 80 Pro Thr Ser Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Ser Asp 85 90 95 Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys 100 105 110 Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro Leu Gln Thr Gly Glu Asp 115 120 125 Gly Cys Ala Gln Ser Pro Val Ser Leu Cys Cys Val Cys Leu Leu Ser 130 135 140 Pro Val Ser His Asp Pro His Val Leu Pro Cys Pro Pro His Ser Pro 145 150 155 160 Cys Ala Pro Ser Leu Leu Ala Gly Ala Pro Gly Pro Cys Leu Ala Ser 165 170 175 Ser Ser Leu Glu Ala Leu Cys Ser Gly Leu Arg Trp Gly Leu Gly Leu 180 185 190 Arg Ala Leu Gly Cys Asp Gly Val Trp Gly Ser Ala Leu Trp Ala Ala 195 200 205 Met Gly Ser Gly Ala Pro Arg Ser Gly Leu Arg Trp Ala Leu Gly Leu 210 215 220 29 1178 DNA Homo sapiens CDS (4)..(994) 29 ggg atg gga aaa cta tgc ctg ggg ccg acg ctc tgc ccg gct gct gcc 48 Met Gly Lys Leu Cys Leu Gly Pro Thr Leu Cys Pro Ala Ala Ala 1 5 10 15 gct gag gaa agc cgg gac gcg gag ccc cgc cga gag ctt ctt tgc tcc 96 Ala Glu Glu Ser Arg Asp Ala Glu Pro Arg Arg Glu Leu Leu Cys Ser 20 25 30 gga cgc ccc tgg acg tgg cgg gca gcc gcg agg gta acc acc atg atc 144 Gly Arg Pro Trp Thr Trp Arg Ala Ala Ala Arg Val Thr Thr Met Ile 35 40 45 ccc tgg gtg ctc ctg gcc tgt gcc ctc ccc tgt gct gct gac cca ctg 192 Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp Pro Leu 50 55 60 ctt ggc gcc ttt gct cgc agg gac ttc cgg aaa ggc tcc cct caa ctg 240 Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro Gln Leu 65 70 75 gtc tgc agc ctg cct ggc ccc cag ggc cca ccc ggc ccc cca gga gcc 288 Val Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro Gly Ala 80 85 90 95 cca ggg ccc tca gga atg atg gga cga atg ggc ttt cct ggc aaa gac 336 Pro Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly Lys Asp 100 105 110 ggc caa gat gga cac gac ggc gac cgg ggg gac agc gga gag gaa ggt 384 Gly Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu Glu Gly 115 120 125 cca cct ggc cgg aca ggt aac cgg gga aag cca gga cca aag ggc aaa 432 Pro Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys Gly Lys 130 135 140 gcc ggg gcc att ggg cgg gct ggc ccc cgt ggc ccc aag ggg gtc aac 480 Ala Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly Val Asn 145 150 155 ggt acc ccc ggg aag cat ggc aca cca ggc aag aag ggg ccc aag ggc 528 Gly Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro Lys Gly 160 165 170 175 aag aag ggg gag cca ggc ctc cca ggc ccc tgc agc tgt ggc agt ggc 576 Lys Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly Ser Gly 180 185 190 cat acc aag tca gct ttc tcg gtg gca gtg acc aag agc tac cca cgg 624 His Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr Pro Arg 195 200 205 gag cgg ctg ccc atc aag ttt gac aag att ctg atg aac gag ggt ggc 672 Glu Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu Gly Gly 210 215 220 cac tac aat gct tcc agc ggc aag ttc gtc tgc ggc gtg cct ggg atc 720 His Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro Gly Ile 225 230 235 tac tac ttc acc tac gac atc acg ctg gcc aac aag cac ctg gcc atc 768 Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile 240 245 250 255 ggc ctg gtg cac aac ggc cag tac cgc atc cgg acc ttt gat gcc aac 816 Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp Ala Asn 260 265 270 acc ggc aac cac gat gtg gcc tca ggc tcc acc atc ctg gct ctc aag 864 Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala Leu Lys 275 280 285 cag ggt gac gaa gtt tgg ctg cag atc ttc tac tca gag cag aac ggg 912 Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln Asn Gly 290 295 300 ctc ttc tat gac cct tac tgg aca gac agc ctc ttt acg ggc ttc cta 960 Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly Phe Leu 305 310 315 atc tat gcc gac cag gat gac ccc aac gag gta tagacatgcc 1003 Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val 320 325 330 acggcggtcc tccaggcagg gaacaagctt ctggacttgg gcttacagag 1053 caagacccca caactgtagg ctgggggtgg ggggtcgagt gagcggttct 1103 agcctcaggc tcacctcctc cgcctctttt ttttcccctt cattaaatcc 1153 aaaccttttt attcatccaa aaaaa 1178 30 330 PRT Homo sapiens 30 Met Gly Lys Leu Cys Leu Gly Pro Thr Leu Cys Pro Ala Ala Ala Ala 1 5 10 15 Glu Glu Ser Arg Asp Ala Glu Pro Arg Arg Glu Leu Leu Cys Ser Gly 20 25 30 Arg Pro Trp Thr Trp Arg Ala Ala Ala Arg Val Thr Thr Met Ile Pro 35 40 45 Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp Pro Leu Leu 50 55 60 Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro Gln Leu Val 65 70 75 80 Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro Gly Ala Pro 85 90 95 Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly Lys Asp Gly 100 105 110 Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu Glu Gly Pro 115 120 125 Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys Gly Lys Ala 130 135 140 Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly Val Asn Gly 145 150 155 160 Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro Lys Gly Lys 165 170 175 Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly Ser Gly His 180 185 190 Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr Pro Arg Glu 195 200 205 Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu Gly Gly His 210 215 220 Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro Gly Ile Tyr 225 230 235 240 Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile Gly 245 250 255 Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp Ala Asn Thr 260 265 270 Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala Leu Lys Gln 275 280 285 Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln Asn Gly Leu 290 295 300 Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly Phe Leu Ile 305 310 315 320 Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val 325 330 31 1611 DNA Homo sapiens CDS (42)..(1512) 31 ggagcgtctg ttgggtccgg gccgccggct tcgccctcgc c atg gcg ccc tgg 53 Met Ala Pro Trp 1 ctg cag ctc ctg tcg ctg ctg ggg ctg ctc ccg ggc gca gtg gcc gcc 101 Leu Gln Leu Leu Ser Leu Leu Gly Leu Leu Pro Gly Ala Val Ala Ala 5 10 15 20 ccc gcc cag ccc cga gcc gcc agc ttt cag gcc tgg ggg ccg ccg tcc 149 Pro Ala Gln Pro Arg Ala Ala Ser Phe Gln Ala Trp Gly Pro Pro Ser 25 30 35 ccg cag ctg ctg gcg ccc acc cgc ttc gcg ctg gag atg ttc aac cgc 197 Pro Gln Leu Leu Ala Pro Thr Arg Phe Ala Leu Glu Met Phe Asn Arg 40 45 50 ggc cgg gct gcg ggg acg cgg gcc gtg ctg ggc ctt gtg cgc gac cgt 245 Gly Arg Ala Ala Gly Thr Arg Ala Val Leu Gly Leu Val Arg Asp Arg 55 60 65 ccg cgc ctc acc tac tcc tct ctc cag gcg ggc cag ggg tcg ctg tac 293 Pro Arg Leu Thr Tyr Ser Ser Leu Gln Ala Gly Gln Gly Ser Leu Tyr 70 75 80 tcc ctg gag gcc acc ctg gag gag cca ccc tgc aac gac ccc atg gtg 341 Ser Leu Glu Ala Thr Leu Glu Glu Pro Pro Cys Asn Asp Pro Met Val 85 90 95 100 tgc cgg ctc ccc gtg tcc aag aaa acc ctg gtg act ttc aaa gtc ctg 389 Cys Arg Leu Pro Val Ser Lys Lys Thr Leu Val Thr Phe Lys Val Leu 105 110 115 gat gag ctc ggg ggg cgc gtg ctg ctg cgg aag gac tgt ggc cca gtg 437 Asp Glu Leu Gly Gly Arg Val Leu Leu Arg Lys Asp Cys Gly Pro Val 120 125 130 gac acc aag gtt cca ggt gct ggg gag ccc aag tca gcc ttc act cag 485 Asp Thr Lys Val Pro Gly Ala Gly Glu Pro Lys Ser Ala Phe Thr Gln 135 140 145 ggc tca gcc atg att tct tct ctg tcc caa aac cat cca gac aac aga 533 Gly Ser Ala Met Ile Ser Ser Leu Ser Gln Asn His Pro Asp Asn Arg 150 155 160 aac gag act ttc agc tca gtc att tcc ctg ttg aat gag gat ccc ctg 581 Asn Glu Thr Phe Ser Ser Val Ile Ser Leu Leu Asn Glu Asp Pro Leu 165 170 175 180 tcc cag gac ttg cct gtg aag atg gct tca atc ttc aag aac ttt gtc 629 Ser Gln Asp Leu Pro Val Lys Met Ala Ser Ile Phe Lys Asn Phe Val 185 190 195 att acc tat aac cgg aca tat gag tca aag gaa gaa gcc cgg tgg cgc 677 Ile Thr Tyr Asn Arg Thr Tyr Glu Ser Lys Glu Glu Ala Arg Trp Arg 200 205 210 ctg tcc gtc ttt gtc aat aac atg gtg cga gca cag aag atc cag gcc 725 Leu Ser Val Phe Val Asn Asn Met Val Arg Ala Gln Lys Ile Gln Ala 215 220 225 ctg gac cgt ggc aca gct cag tat gga gtc acc aag ttc agt gat ctc 773 Leu Asp Arg Gly Thr Ala Gln Tyr Gly Val Thr Lys Phe Ser Asp Leu 230 235 240 aca gag gag gag ttc cgc act atc tac ctg aat act ctc ctg aga aaa 821 Thr Glu Glu Glu Phe Arg Thr Ile Tyr Leu Asn Thr Leu Leu Arg Lys 245 250 255 260 gag cct ggc aac aag atg aag caa gcc aag tct gtg ggt gac ctc gcc 869 Glu Pro Gly Asn Lys Met Lys Gln Ala Lys Ser Val Gly Asp Leu Ala 265 270 275 cca cct gaa tgg gac tgg agg agt aag ggg gct gtc aca aaa gtc aaa 917 Pro Pro Glu Trp Asp Trp Arg Ser Lys Gly Ala Val Thr Lys Val Lys 280 285 290 gac cag ggc atg tgt ggc tcc tgc tgg gcc ttc tca gtc aca ggc aat 965 Asp Gln Gly Met Cys Gly Ser Cys Trp Ala Phe Ser Val Thr Gly Asn 295 300 305 gtg gag ggc cag tgg ttt ctc aac cag ggg acc ctg ctc tcc ctc tct 1013 Val Glu Gly Gln Trp Phe Leu Asn Gln Gly Thr Leu Leu Ser Leu Ser 310 315 320 gaa cag gag ctc ttg gac tgt gac aag atg gac aag gcc tgc atg ggc 1061 Glu Gln Glu Leu Leu Asp Cys Asp Lys Met Asp Lys Ala Cys Met Gly 325 330 335 340 ggc ttg ccc tcc aat gcc tac tcg gcc ata aag aat ttg gga ggg ctg 1109 Gly Leu Pro Ser Asn Ala Tyr Ser Ala Ile Lys Asn Leu Gly Gly Leu 345 350 355 gag aca gag gat gac tac agc tac cag ggt cac atg cag tcc tgc aac 1157 Glu Thr Glu Asp Asp Tyr Ser Tyr Gln Gly His Met Gln Ser Cys Asn 360 365 370 ttc tca gca gag aag gcc aag gtc tac atc aat gac tcc gtg gag ctg 1205 Phe Ser Ala Glu Lys Ala Lys Val Tyr Ile Asn Asp Ser Val Glu Leu 375 380 385 agc cag aac gag cag gag ctg gca gcc tgg ctg gcc aag aga ggc cca 1253 Ser Gln Asn Glu Gln Glu Leu Ala Ala Trp Leu Ala Lys Arg Gly Pro 390 395 400 atc tcc gtg gcc atc aat gcc ttt ggc atg cag ttt tac cgc cac ggg 1301 Ile Ser Val Ala Ile Asn Ala Phe Gly Met Gln Phe Tyr Arg His Gly 405 410 415 420 atc tcc cgc cct ctc cgg ccc ctc tgc agc cct tgc gtc att gac cat 1349 Ile Ser Arg Pro Leu Arg Pro Leu Cys Ser Pro Cys Val Ile Asp His 425 430 435 gcg gtg ttg ctt gtg ggc tac gga acc gtg agt tct gac gtt ccc ttt 1397 Ala Val Leu Leu Val Gly Tyr Gly Thr Val Ser Ser Asp Val Pro Phe 440 445 450 tgg gcc atc aag aac agc tgg ggc act gac tgg ggt gag aag ggt tac 1445 Trp Ala Ile Lys Asn Ser Trp Gly Thr Asp Trp Gly Glu Lys Gly Tyr 455 460 465 tac tac ttg cat cgc ggg tcc ggg gca tgt ggc gtg aac acc atg gcc 1493 Tyr Tyr Leu His Arg Gly Ser Gly Ala Cys Gly Val Asn Thr Met Ala 470 475 480 agc tcg gcg gtg gtg gac tgaagagggg cccccagctc gggacctggt 1541 Ser Ser Ala Val Val Asp 485 490 gctgatcaga gtggctgctg ccccagcctg acatgtgtcc aggcccctcc 1591 ccgggaggta cagctggcag 1611 32 490 PRT Homo sapiens 32 Met Ala Pro Trp Leu Gln Leu Leu Ser Leu Leu Gly Leu Leu Pro Gly 1 5 10 15 Ala Val Ala Ala Pro Ala Gln Pro Arg Ala Ala Ser Phe Gln Ala Trp 20 25 30 Gly Pro Pro Ser Pro Gln Leu Leu Ala Pro Thr Arg Phe Ala Leu Glu 35 40 45 Met Phe Asn Arg Gly Arg Ala Ala Gly Thr Arg Ala Val Leu Gly Leu 50 55 60 Val Arg Asp Arg Pro Arg Leu Thr Tyr Ser Ser Leu Gln Ala Gly Gln 65 70 75 80 Gly Ser Leu Tyr Ser Leu Glu Ala Thr Leu Glu Glu Pro Pro Cys Asn 85 90 95 Asp Pro Met Val Cys Arg Leu Pro Val Ser Lys Lys Thr Leu Val Thr 100 105 110 Phe Lys Val Leu Asp Glu Leu Gly Gly Arg Val Leu Leu Arg Lys Asp 115 120 125 Cys Gly Pro Val Asp Thr Lys Val Pro Gly Ala Gly Glu Pro Lys Ser 130 135 140 Ala Phe Thr Gln Gly Ser Ala Met Ile Ser Ser Leu Ser Gln Asn His 145 150 155

160 Pro Asp Asn Arg Asn Glu Thr Phe Ser Ser Val Ile Ser Leu Leu Asn 165 170 175 Glu Asp Pro Leu Ser Gln Asp Leu Pro Val Lys Met Ala Ser Ile Phe 180 185 190 Lys Asn Phe Val Ile Thr Tyr Asn Arg Thr Tyr Glu Ser Lys Glu Glu 195 200 205 Ala Arg Trp Arg Leu Ser Val Phe Val Asn Asn Met Val Arg Ala Gln 210 215 220 Lys Ile Gln Ala Leu Asp Arg Gly Thr Ala Gln Tyr Gly Val Thr Lys 225 230 235 240 Phe Ser Asp Leu Thr Glu Glu Glu Phe Arg Thr Ile Tyr Leu Asn Thr 245 250 255 Leu Leu Arg Lys Glu Pro Gly Asn Lys Met Lys Gln Ala Lys Ser Val 260 265 270 Gly Asp Leu Ala Pro Pro Glu Trp Asp Trp Arg Ser Lys Gly Ala Val 275 280 285 Thr Lys Val Lys Asp Gln Gly Met Cys Gly Ser Cys Trp Ala Phe Ser 290 295 300 Val Thr Gly Asn Val Glu Gly Gln Trp Phe Leu Asn Gln Gly Thr Leu 305 310 315 320 Leu Ser Leu Ser Glu Gln Glu Leu Leu Asp Cys Asp Lys Met Asp Lys 325 330 335 Ala Cys Met Gly Gly Leu Pro Ser Asn Ala Tyr Ser Ala Ile Lys Asn 340 345 350 Leu Gly Gly Leu Glu Thr Glu Asp Asp Tyr Ser Tyr Gln Gly His Met 355 360 365 Gln Ser Cys Asn Phe Ser Ala Glu Lys Ala Lys Val Tyr Ile Asn Asp 370 375 380 Ser Val Glu Leu Ser Gln Asn Glu Gln Glu Leu Ala Ala Trp Leu Ala 385 390 395 400 Lys Arg Gly Pro Ile Ser Val Ala Ile Asn Ala Phe Gly Met Gln Phe 405 410 415 Tyr Arg His Gly Ile Ser Arg Pro Leu Arg Pro Leu Cys Ser Pro Cys 420 425 430 Val Ile Asp His Ala Val Leu Leu Val Gly Tyr Gly Thr Val Ser Ser 435 440 445 Asp Val Pro Phe Trp Ala Ile Lys Asn Ser Trp Gly Thr Asp Trp Gly 450 455 460 Glu Lys Gly Tyr Tyr Tyr Leu His Arg Gly Ser Gly Ala Cys Gly Val 465 470 475 480 Asn Thr Met Ala Ser Ser Ala Val Val Asp 485 490 33 1226 DNA Homo sapiens CDS (15)..(1215) 33 gcttcgccct cgcc atg gcg ccc tgg ctg cag ctc ctg tcg ctg ctg ggg 50 Met Ala Pro Trp Leu Gln Leu Leu Ser Leu Leu Gly 1 5 10 ctg ctc ccg ggc gca gtg gcc gcc ccc gcc cag ccc caa gtc ctg gat 98 Leu Leu Pro Gly Ala Val Ala Ala Pro Ala Gln Pro Gln Val Leu Asp 15 20 25 gag ctc gga aga cac gtg ctg ctg cgg aag gac tgt ggc cca gtg gac 146 Glu Leu Gly Arg His Val Leu Leu Arg Lys Asp Cys Gly Pro Val Asp 30 35 40 acc aag gtt cca ggt gct ggg gag ccc aag tca gcc ttc act cag ggc 194 Thr Lys Val Pro Gly Ala Gly Glu Pro Lys Ser Ala Phe Thr Gln Gly 45 50 55 60 tca gcc atg att tct tct ctg tcc caa aac cat cca gac aac aga aac 242 Ser Ala Met Ile Ser Ser Leu Ser Gln Asn His Pro Asp Asn Arg Asn 65 70 75 gag act ttc agc tca gtc att tcc ctg ttg aat gag gat ccc ctg tcc 290 Glu Thr Phe Ser Ser Val Ile Ser Leu Leu Asn Glu Asp Pro Leu Ser 80 85 90 cag gac ttg cct gtg aag atg gct tca atc ttc aag aac ttt gtc att 338 Gln Asp Leu Pro Val Lys Met Ala Ser Ile Phe Lys Asn Phe Val Ile 95 100 105 acc tat aac cgg aca tat gag tca aag gaa gaa gcc cgg tgg cgc ctg 386 Thr Tyr Asn Arg Thr Tyr Glu Ser Lys Glu Glu Ala Arg Trp Arg Leu 110 115 120 tcc gtc ttt gtc aat aac atg gtg cga gca cag aag atc cag gcc ctg 434 Ser Val Phe Val Asn Asn Met Val Arg Ala Gln Lys Ile Gln Ala Leu 125 130 135 140 gac cgt ggc aca gct cag tat gga gtc acc aag ttc agt gat ctc aca 482 Asp Arg Gly Thr Ala Gln Tyr Gly Val Thr Lys Phe Ser Asp Leu Thr 145 150 155 gag gag gag ttc cgc act atc tac ctg aat act ctc ctg agg aaa gag 530 Glu Glu Glu Phe Arg Thr Ile Tyr Leu Asn Thr Leu Leu Arg Lys Glu 160 165 170 cct ggc aac aag atg aag caa gcc aag tct gtg ggt gac ctc gcc cca 578 Pro Gly Asn Lys Met Lys Gln Ala Lys Ser Val Gly Asp Leu Ala Pro 175 180 185 cct gaa tgg gac tgg agg agt aag ggg gct gtc aca aaa gtc aaa gac 626 Pro Glu Trp Asp Trp Arg Ser Lys Gly Ala Val Thr Lys Val Lys Asp 190 195 200 cag ggc atg tgt ggc tcc tgc tgg gcc ttc tca gtc aca ggc aat gtg 674 Gln Gly Met Cys Gly Ser Cys Trp Ala Phe Ser Val Thr Gly Asn Val 205 210 215 220 gag ggc cag tgg ttt ctc aac cag ggg acc ctg ctc tcc ctc tct gaa 722 Glu Gly Gln Trp Phe Leu Asn Gln Gly Thr Leu Leu Ser Leu Ser Glu 225 230 235 cag gag ctc ttg gac tgt gac aag atg gac aag gcc tgc atg ggc ggc 770 Gln Glu Leu Leu Asp Cys Asp Lys Met Asp Lys Ala Cys Met Gly Gly 240 245 250 ttg ccc tcc aat gcc tac tcg gcc ata aag aat ttg gga ggg ctg gag 818 Leu Pro Ser Asn Ala Tyr Ser Ala Ile Lys Asn Leu Gly Gly Leu Glu 255 260 265 aca gag gat gac tac agc tac cag ggt cac atg cag tcc tgc aac ttc 866 Thr Glu Asp Asp Tyr Ser Tyr Gln Gly His Met Gln Ser Cys Asn Phe 270 275 280 tca gca gag aag gcc aag gtc tac atc aat gac tcc gtg gag ctg agc 914 Ser Ala Glu Lys Ala Lys Val Tyr Ile Asn Asp Ser Val Glu Leu Ser 285 290 295 300 cag aac gag cag aag ctg gca gcc tgg ctg gcc aag aga ggc cca atc 962 Gln Asn Glu Gln Lys Leu Ala Ala Trp Leu Ala Lys Arg Gly Pro Ile 305 310 315 tcc gtg gcc atc aat gcc ttt ggc atg cag ttt tac cgc cac ggg atc 1010 Ser Val Ala Ile Asn Ala Phe Gly Met Gln Phe Tyr Arg His Gly Ile 320 325 330 tcc cgc cct ctc cgg ccc ctc tgc agc cct tgg ctc att gac cat gcg 1058 Ser Arg Pro Leu Arg Pro Leu Cys Ser Pro Trp Leu Ile Asp His Ala 335 340 345 gtg ttg ctt gtg ggc tac ggc aac cgc tct gac gtt ccc ttt tgg gcc 1106 Val Leu Leu Val Gly Tyr Gly Asn Arg Ser Asp Val Pro Phe Trp Ala 350 355 360 atc aag aac agc tgg ggc act gac tgg ggt gag aag ggt tac tac tac 1154 Ile Lys Asn Ser Trp Gly Thr Asp Trp Gly Glu Lys Gly Tyr Tyr Tyr 365 370 375 380 ttg cat cgc ggg tcc ggg gcc tgt ggc gtg aac acc atg gcc agc tcg 1202 Leu His Arg Gly Ser Gly Ala Cys Gly Val Asn Thr Met Ala Ser Ser 385 390 395 gcg gtg gtg gac tgaagagggg cc 1226 Ala Val Val Asp 400 34 400 PRT Homo sapiens 34 Met Ala Pro Trp Leu Gln Leu Leu Ser Leu Leu Gly Leu Leu Pro Gly 1 5 10 15 Ala Val Ala Ala Pro Ala Gln Pro Gln Val Leu Asp Glu Leu Gly Arg 20 25 30 His Val Leu Leu Arg Lys Asp Cys Gly Pro Val Asp Thr Lys Val Pro 35 40 45 Gly Ala Gly Glu Pro Lys Ser Ala Phe Thr Gln Gly Ser Ala Met Ile 50 55 60 Ser Ser Leu Ser Gln Asn His Pro Asp Asn Arg Asn Glu Thr Phe Ser 65 70 75 80 Ser Val Ile Ser Leu Leu Asn Glu Asp Pro Leu Ser Gln Asp Leu Pro 85 90 95 Val Lys Met Ala Ser Ile Phe Lys Asn Phe Val Ile Thr Tyr Asn Arg 100 105 110 Thr Tyr Glu Ser Lys Glu Glu Ala Arg Trp Arg Leu Ser Val Phe Val 115 120 125 Asn Asn Met Val Arg Ala Gln Lys Ile Gln Ala Leu Asp Arg Gly Thr 130 135 140 Ala Gln Tyr Gly Val Thr Lys Phe Ser Asp Leu Thr Glu Glu Glu Phe 145 150 155 160 Arg Thr Ile Tyr Leu Asn Thr Leu Leu Arg Lys Glu Pro Gly Asn Lys 165 170 175 Met Lys Gln Ala Lys Ser Val Gly Asp Leu Ala Pro Pro Glu Trp Asp 180 185 190 Trp Arg Ser Lys Gly Ala Val Thr Lys Val Lys Asp Gln Gly Met Cys 195 200 205 Gly Ser Cys Trp Ala Phe Ser Val Thr Gly Asn Val Glu Gly Gln Trp 210 215 220 Phe Leu Asn Gln Gly Thr Leu Leu Ser Leu Ser Glu Gln Glu Leu Leu 225 230 235 240 Asp Cys Asp Lys Met Asp Lys Ala Cys Met Gly Gly Leu Pro Ser Asn 245 250 255 Ala Tyr Ser Ala Ile Lys Asn Leu Gly Gly Leu Glu Thr Glu Asp Asp 260 265 270 Tyr Ser Tyr Gln Gly His Met Gln Ser Cys Asn Phe Ser Ala Glu Lys 275 280 285 Ala Lys Val Tyr Ile Asn Asp Ser Val Glu Leu Ser Gln Asn Glu Gln 290 295 300 Lys Leu Ala Ala Trp Leu Ala Lys Arg Gly Pro Ile Ser Val Ala Ile 305 310 315 320 Asn Ala Phe Gly Met Gln Phe Tyr Arg His Gly Ile Ser Arg Pro Leu 325 330 335 Arg Pro Leu Cys Ser Pro Trp Leu Ile Asp His Ala Val Leu Leu Val 340 345 350 Gly Tyr Gly Asn Arg Ser Asp Val Pro Phe Trp Ala Ile Lys Asn Ser 355 360 365 Trp Gly Thr Asp Trp Gly Glu Lys Gly Tyr Tyr Tyr Leu His Arg Gly 370 375 380 Ser Gly Ala Cys Gly Val Asn Thr Met Ala Ser Ser Ala Val Val Asp 385 390 395 400 35 1704 DNA Homo sapiens CDS (103)..(1666) 35 tggtagatgt ggcatttcca tgctgaggcc gcgagtcccg cctgaccccg 50 tcgctgcctc tccagggctt ctctgggccg cgcctctgca gactgcgcag 100 cc atg ctg cat ctg ctg gcg ctc ttc ctg cac tgc ctc cct ctg gcc 147 Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala 1 5 10 15 tct ggg gac tat gac atc tgc aaa tcc tgg gtg acc aca gat gag ggc 195 Ser Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly 20 25 30 ccc acc tgg gag ttc tac gcc tgc cag ccc aag gtg atg cgc ctg aag 243 Pro Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys 35 40 45 gac tac gtc aag gtg aag gtg gag ccc tca ggc atc aca tgt gga gac 291 Asp Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp 50 55 60 ccc cct gag agg ttc tgc tcc cat ccc tac cta tgc agc aac gag tgt 339 Pro Pro Glu Arg Phe Cys Ser His Pro Tyr Leu Cys Ser Asn Glu Cys 65 70 75 gac gcc tcc aac ccg gac ctg gcc cac ccg ccc agg ctc atg ttc gac 387 Asp Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe Asp 80 85 90 95 aag gag gag gag ggc ctg gcc acc tac tgg cag agc atc acc tgg agc 435 Lys Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp Ser 100 105 110 cgc tac ccc agc ccg ctg gaa gcc aac atc acc ctt tcg tgg aac aag 483 Arg Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn Lys 115 120 125 acc gtg gag ctg acc gac gac gtg gtg atg acc ttc gag tac ggc cgg 531 Thr Val Glu Leu Thr Asp Asp Val Val Met Thr Phe Glu Tyr Gly Arg 130 135 140 ccc acg gtc atg gtc ctg gag aag tcc ctg gac aac ggg cgc acc tgg 579 Pro Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr Trp 145 150 155 cag ccc tac cag ttc tac gcc gag gac tgc atg gag gcc ttc ggt atg 627 Gln Pro Tyr Gln Phe Tyr Ala Glu Asp Cys Met Glu Ala Phe Gly Met 160 165 170 175 tcc gcc cgc cgg gcc cgc gac atg tca tcc tcc agc gcg cac cgc gtg 675 Ser Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ser Ala His Arg Val 180 185 190 ctc tgc acc gag gag tac tcg cgc tgg gca ggc tcc aag aag gag aag 723 Leu Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu Lys 195 200 205 cac gtg cgc ttc gag gtg cgg gac cgc ttc gcc atc ttt gcc ggc ccc 771 His Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly Pro 210 215 220 gac ctg cgc aac atg gac aac ctc tac acg cgg ctg gag agc gcc aag 819 Asp Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala Lys 225 230 235 ggc ctc aag gag ttc ttc acc ctc acc gac ctg cgc atg cgg ctg ctg 867 Gly Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu Leu 240 245 250 255 cgc ccg gcg ctg ggc ggc acc tat gtg cag cgg gag aac ctc tac aag 915 Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr Lys 260 265 270 tac ttc tac gcc atc tcc aac atc gag gtc atc ggc agg tgc aag tgc 963 Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg Cys Lys Cys 275 280 285 aac ctg cac gcc aac ctg tgc tcc atg cgc gag ggc agc ctg cag tgc 1011 Asn Leu His Ala Asn Leu Cys Ser Met Arg Glu Gly Ser Leu Gln Cys 290 295 300 gag tgc gag cac aac acc acc ggc ccc gac tgc ggc aag tgc aag aag 1059 Glu Cys Glu His Asn Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys Lys 305 310 315 aat ttc cgc acc cgg tcc tgg cgg gcc ggc tcc tac ctg ccg ctg ccc 1107 Asn Phe Arg Thr Arg Ser Trp Arg Ala Gly Ser Tyr Leu Pro Leu Pro 320 325 330 335 cat ggc tct ccc aac gcc tgt gac tgc gaa tgc tac ggt cac tcc aac 1155 His Gly Ser Pro Asn Ala Cys Asp Cys Glu Cys Tyr Gly His Ser Asn 340 345 350 cgc tgc agc tac att gac ttc ctg aat gtg gtg acc tgc gtc agc tgc 1203 Arg Cys Ser Tyr Ile Asp Phe Leu Asn Val Val Thr Cys Val Ser Cys 355 360 365 aag cac aac acg cga ggt cag cac tgc cag cac tgc cgg ctg ggc tac 1251 Lys His Asn Thr Arg Gly Gln His Cys Gln His Cys Arg Leu Gly Tyr 370 375 380 tac cgc aac ggc tcg gca gag ctg gat gat gag aac gtc tgc att gag 1299 Tyr Arg Asn Gly Ser Ala Glu Leu Asp Asp Glu Asn Val Cys Ile Glu 385 390 395 tgt aac tgc aac cag ata ggc tcc gtg cac gac cgg tgc aac gag acc 1347 Cys Asn Cys Asn Gln Ile Gly Ser Val His Asp Arg Cys Asn Glu Thr 400 405 410 415 ggc ttc tgc gag tgc cgc gag ggc gcg gcg ggc ccc aag tgc gac gac 1395 Gly Phe Cys Glu Cys Arg Glu Gly Ala Ala Gly Pro Lys Cys Asp Asp 420 425 430 tgc ctc ccc acg cac tac tgg cgc cag ggc tgc tac ccc aac gtg tgc 1443 Cys Leu Pro Thr His Tyr Trp Arg Gln Gly Cys Tyr Pro Asn Val Cys 435 440 445 gac gac gac cag ctg ctg tgc cag aac gga ggc acc tgc ctg cag aac 1491 Asp Asp Asp Gln Leu Leu Cys Gln Asn Gly Gly Thr Cys Leu Gln Asn 450 455 460 cag cgc tgc gcc tgc ccg cgc ggc tac acc ggc gtg cgc tgc gag cag 1539 Gln Arg Cys Ala Cys Pro Arg Gly Tyr Thr Gly Val Arg Cys Glu Gln 465 470 475 ccc cgc tgc gac ccc gcc gac gat gac ggc ggt ctg gac tgc gac cgc 1587 Pro Arg Cys Asp Pro Ala Asp Asp Asp Gly Gly Leu Asp Cys Asp Arg 480 485 490 495 gcg ccc ggg gcc gcc ccg cgc ccc gcc acc ctg ctc ggc tgc ctg ctg 1635 Ala Pro Gly Ala Ala Pro Arg Pro Ala Thr Leu Leu Gly Cys Leu Leu 500 505 510 ctg ctg ggg ctg gcc gcc cgc ctg ggc cgc tgagccccgc ccggaggacg 1685 Leu Leu Gly Leu Ala Ala Arg Leu Gly Arg 515 520 ctccccgcac ccggaggcc 1704 36 521 PRT Homo sapiens 36 Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala Ser 1 5 10 15 Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly Pro 20 25 30 Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys Asp 35 40 45 Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp Pro 50 55 60 Pro Glu Arg Phe Cys Ser His Pro Tyr Leu Cys Ser Asn Glu Cys Asp 65 70 75 80 Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe Asp Lys 85 90 95 Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp Ser Arg 100 105 110 Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn Lys Thr 115 120 125 Val Glu Leu Thr Asp Asp Val Val Met Thr Phe Glu Tyr Gly Arg Pro 130 135 140 Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr Trp Gln 145 150 155 160 Pro Tyr Gln Phe Tyr Ala Glu

Asp Cys Met Glu Ala Phe Gly Met Ser 165 170 175 Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ser Ala His Arg Val Leu 180 185 190 Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu Lys His 195 200 205 Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly Pro Asp 210 215 220 Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala Lys Gly 225 230 235 240 Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu Leu Arg 245 250 255 Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr Lys Tyr 260 265 270 Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg Cys Lys Cys Asn 275 280 285 Leu His Ala Asn Leu Cys Ser Met Arg Glu Gly Ser Leu Gln Cys Glu 290 295 300 Cys Glu His Asn Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys Lys Asn 305 310 315 320 Phe Arg Thr Arg Ser Trp Arg Ala Gly Ser Tyr Leu Pro Leu Pro His 325 330 335 Gly Ser Pro Asn Ala Cys Asp Cys Glu Cys Tyr Gly His Ser Asn Arg 340 345 350 Cys Ser Tyr Ile Asp Phe Leu Asn Val Val Thr Cys Val Ser Cys Lys 355 360 365 His Asn Thr Arg Gly Gln His Cys Gln His Cys Arg Leu Gly Tyr Tyr 370 375 380 Arg Asn Gly Ser Ala Glu Leu Asp Asp Glu Asn Val Cys Ile Glu Cys 385 390 395 400 Asn Cys Asn Gln Ile Gly Ser Val His Asp Arg Cys Asn Glu Thr Gly 405 410 415 Phe Cys Glu Cys Arg Glu Gly Ala Ala Gly Pro Lys Cys Asp Asp Cys 420 425 430 Leu Pro Thr His Tyr Trp Arg Gln Gly Cys Tyr Pro Asn Val Cys Asp 435 440 445 Asp Asp Gln Leu Leu Cys Gln Asn Gly Gly Thr Cys Leu Gln Asn Gln 450 455 460 Arg Cys Ala Cys Pro Arg Gly Tyr Thr Gly Val Arg Cys Glu Gln Pro 465 470 475 480 Arg Cys Asp Pro Ala Asp Asp Asp Gly Gly Leu Asp Cys Asp Arg Ala 485 490 495 Pro Gly Ala Ala Pro Arg Pro Ala Thr Leu Leu Gly Cys Leu Leu Leu 500 505 510 Leu Gly Leu Ala Ala Arg Leu Gly Arg 515 520 37 910 DNA Homo sapiens CDS (31)..(826) 37 ggtccggggg ggctgccggt cccgggtacc atg tgt gac ggc gcc ctg ctg 51 Met Cys Asp Gly Ala Leu Leu 1 5 cct ccg ctc gtc ctg ccc gtg ctg ctg ctg ctg gtt tgg gga ctg gac 99 Pro Pro Leu Val Leu Pro Val Leu Leu Leu Leu Val Trp Gly Leu Asp 10 15 20 ccg ggc aca gct gtc ggc gac gcg gcg gcc gac gtg gag gtg gtg ctc 147 Pro Gly Thr Ala Val Gly Asp Ala Ala Ala Asp Val Glu Val Val Leu 25 30 35 ccg tgg cgg gtg cgc ccc gac gac gtg cac ctg ccg ccg ctg ccc gca 195 Pro Trp Arg Val Arg Pro Asp Asp Val His Leu Pro Pro Leu Pro Ala 40 45 50 55 gcc ccc ggg ccc cga cgg cgg cga cgc ccc cgc acg ccc cca gcc gcc 243 Ala Pro Gly Pro Arg Arg Arg Arg Arg Pro Arg Thr Pro Pro Ala Ala 60 65 70 ccg cgc gcc cgg ccc gga gag cgc gcc ctg ctg ctg cac ctg ccg gcc 291 Pro Arg Ala Arg Pro Gly Glu Arg Ala Leu Leu Leu His Leu Pro Ala 75 80 85 ttc ggg cgc gac ctg tac ctt cag ctg cgc cgc gac ctg cgc ttc ctg 339 Phe Gly Arg Asp Leu Tyr Leu Gln Leu Arg Arg Asp Leu Arg Phe Leu 90 95 100 tcc cga ggc ttc gag gtg gag gag gcg ggc gcg gcc cgg cgc cgc ggc 387 Ser Arg Gly Phe Glu Val Glu Glu Ala Gly Ala Ala Arg Arg Arg Gly 105 110 115 cgc ccc gcc gag ctg tgc ttc tac tcg ggc cgt gtg ctc ggc cac ccc 435 Arg Pro Ala Glu Leu Cys Phe Tyr Ser Gly Arg Val Leu Gly His Pro 120 125 130 135 ggc tcc ctc gtc tcg ctc agc gcc tgc ggc gcc gcc ggc ggc ctg gta 483 Gly Ser Leu Val Ser Leu Ser Ala Cys Gly Ala Ala Gly Gly Leu Val 140 145 150 ctg ccc gcg cca cct ccg ggt cgg ccc gtc cgg tct gtt gcg acg cag 531 Leu Pro Ala Pro Pro Pro Gly Arg Pro Val Arg Ser Val Ala Thr Gln 155 160 165 agt ggt cgc cgt gga ggg tgg ggg tgg ggc gcc tct gct gga agt cca 579 Ser Gly Arg Arg Gly Gly Trp Gly Trp Gly Ala Ser Ala Gly Ser Pro 170 175 180 gcc tcc agg gga acc gga ggg aac ccc ctg cct ttc cac ctc tcc cca 627 Ala Ser Arg Gly Thr Gly Gly Asn Pro Leu Pro Phe His Leu Ser Pro 185 190 195 tcc ccc acc ccg gcc ttc ggt acc ctc tat agg caa agg ggg tgg gag 675 Ser Pro Thr Pro Ala Phe Gly Thr Leu Tyr Arg Gln Arg Gly Trp Glu 200 205 210 215 ggg cag cat ccc agt cca gcg cct ctg cag ccc gtg gaa ccc gcg cgg 723 Gly Gln His Pro Ser Pro Ala Pro Leu Gln Pro Val Glu Pro Ala Arg 220 225 230 agc tgg ggt tgc gtg ggg gta tac gcc gcc cgc tct agg gag cgc aga 771 Ser Trp Gly Cys Val Gly Val Tyr Ala Ala Arg Ser Arg Glu Arg Arg 235 240 245 tct ggc agg gat gaa act gtc agg gcc ctg gac aga ggc gcc ttg gcc 819 Ser Gly Arg Asp Glu Thr Val Arg Ala Leu Asp Arg Gly Ala Leu Ala 250 255 260 cca atg tagagaacac tgcatctgca ccgccgtgtc aaagtgtatg tcacgggagt 875 Pro Met 265 acctgtgtac gtgtaggtgt tatgttcttg gactt 910 38 265 PRT Homo sapiens 38 Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu Leu 1 5 10 15 Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Ala Val Gly Asp Ala Ala 20 25 30 Ala Asp Val Glu Val Val Leu Pro Trp Arg Val Arg Pro Asp Asp Val 35 40 45 His Leu Pro Pro Leu Pro Ala Ala Pro Gly Pro Arg Arg Arg Arg Arg 50 55 60 Pro Arg Thr Pro Pro Ala Ala Pro Arg Ala Arg Pro Gly Glu Arg Ala 65 70 75 80 Leu Leu Leu His Leu Pro Ala Phe Gly Arg Asp Leu Tyr Leu Gln Leu 85 90 95 Arg Arg Asp Leu Arg Phe Leu Ser Arg Gly Phe Glu Val Glu Glu Ala 100 105 110 Gly Ala Ala Arg Arg Arg Gly Arg Pro Ala Glu Leu Cys Phe Tyr Ser 115 120 125 Gly Arg Val Leu Gly His Pro Gly Ser Leu Val Ser Leu Ser Ala Cys 130 135 140 Gly Ala Ala Gly Gly Leu Val Leu Pro Ala Pro Pro Pro Gly Arg Pro 145 150 155 160 Val Arg Ser Val Ala Thr Gln Ser Gly Arg Arg Gly Gly Trp Gly Trp 165 170 175 Gly Ala Ser Ala Gly Ser Pro Ala Ser Arg Gly Thr Gly Gly Asn Pro 180 185 190 Leu Pro Phe His Leu Ser Pro Ser Pro Thr Pro Ala Phe Gly Thr Leu 195 200 205 Tyr Arg Gln Arg Gly Trp Glu Gly Gln His Pro Ser Pro Ala Pro Leu 210 215 220 Gln Pro Val Glu Pro Ala Arg Ser Trp Gly Cys Val Gly Val Tyr Ala 225 230 235 240 Ala Arg Ser Arg Glu Arg Arg Ser Gly Arg Asp Glu Thr Val Arg Ala 245 250 255 Leu Asp Arg Gly Ala Leu Ala Pro Met 260 265 39 958 DNA Homo sapiens CDS (31)..(931) 39 gcagcacccg cagccagagc cgcgctcggc atg atg ccc ggg gcg ccg ctc 51 Met Met Pro Gly Ala Pro Leu 1 5 ctg cgg ctg ctg acc gcg gtc tct gcg gca gtg gca gtg gca gtg gcc 99 Leu Arg Leu Leu Thr Ala Val Ser Ala Ala Val Ala Val Ala Val Ala 10 15 20 ggg gcg ccc ggg acg gta atg ccc ccc acc acg ggg gac gcc acc ctg 147 Gly Ala Pro Gly Thr Val Met Pro Pro Thr Thr Gly Asp Ala Thr Leu 25 30 35 gcc ttc gtc ttc gac gtc acc ggc tcc atg tgg gac gaa ctg atg cag 195 Ala Phe Val Phe Asp Val Thr Gly Ser Met Trp Asp Glu Leu Met Gln 40 45 50 55 gtg atc gat ggc gcc tcg cgc att ctg gaa cgc agt ctg agc cgc cgc 243 Val Ile Asp Gly Ala Ser Arg Ile Leu Glu Arg Ser Leu Ser Arg Arg 60 65 70 agc cag gcc atc gcc aac tac gcg ctg gtg ccc ttc cac gac cca gat 291 Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val Pro Phe His Asp Pro Asp 75 80 85 att ggc cca gtg acc ctc acg gcg gac ccc aca gtg ttt cag agg gag 339 Ile Gly Pro Val Thr Leu Thr Ala Asp Pro Thr Val Phe Gln Arg Glu 90 95 100 ctg aga gaa ctc tac gtg cag gga ggt ggt gac tgc ccg gag atg agt 387 Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly Asp Cys Pro Glu Met Ser 105 110 115 gtg ggg gcc att aag gct gcc gtg gag gtt gcc aac ccc gga tcc ttc 435 Val Gly Ala Ile Lys Ala Ala Val Glu Val Ala Asn Pro Gly Ser Phe 120 125 130 135 atc tac gtc ttt tcg gat gcc cgc gcc aaa gac tat cac aag aag gaa 483 Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys Asp Tyr His Lys Lys Glu 140 145 150 gag ctg ctg cgg ctc ctg cag ctc aag caa tca cag gtg gtc ttt gtg 531 Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln Ser Gln Val Val Phe Val 155 160 165 ctg acg ggg gac tgt ggc gac cgc acc cat cct ggc tac ctg gct tat 579 Leu Thr Gly Asp Cys Gly Asp Arg Thr His Pro Gly Tyr Leu Ala Tyr 170 175 180 gag gag atc gct gcc acc agc tct ggg cag gtg ttc cac ctg gac aag 627 Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln Val Phe His Leu Asp Lys 185 190 195 cag caa gtg aca gag gtg ctg aag tgg gtg gag tca gcg atc cag gcc 675 Gln Gln Val Thr Glu Val Leu Lys Trp Val Glu Ser Ala Ile Gln Ala 200 205 210 215 tcc aag gtg cac ctg ctg tcc aca gac cac gag gag gag ggg gag cac 723 Ser Lys Val His Leu Leu Ser Thr Asp His Glu Glu Glu Gly Glu His 220 225 230 aca tgg aga ctc ccc ttt gac ccc agc ctg aag gag gtc acc atc tca 771 Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu Lys Glu Val Thr Ile Ser 235 240 245 ttg agt ggg cca ggg cct gag att gaa gtc caa gat ccg ctg ggt atg 819 Leu Ser Gly Pro Gly Pro Glu Ile Glu Val Gln Asp Pro Leu Gly Met 250 255 260 gac cac ccc ggg gct ggc ctc ctc ttt ggc ccc aag act gag gtg gaa 867 Asp His Pro Gly Ala Gly Leu Leu Phe Gly Pro Lys Thr Glu Val Glu 265 270 275 gcc cag gat ggg aca aag aaa gag acc aag ggt gac agg gct tca gac 915 Ala Gln Asp Gly Thr Lys Lys Glu Thr Lys Gly Asp Arg Ala Ser Asp 280 285 290 295 atg agg ctc cag gaa tagggaaata tggggtgggg gggacacg 958 Met Arg Leu Gln Glu 300 40 300 PRT Homo sapiens 40 Met Met Pro Gly Ala Pro Leu Leu Arg Leu Leu Thr Ala Val Ser Ala 1 5 10 15 Ala Val Ala Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro 20 25 30 Thr Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser 35 40 45 Met Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu 50 55 60 Glu Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu 65 70 75 80 Val Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp 85 90 95 Pro Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly 100 105 110 Gly Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu 115 120 125 Val Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala 130 135 140 Lys Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys 145 150 155 160 Gln Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp Arg Thr 165 170 175 His Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly 180 185 190 Gln Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp 195 200 205 Val Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp 210 215 220 His Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser 225 230 235 240 Leu Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu 245 250 255 Val Gln Asp Pro Leu Gly Met Asp His Pro Gly Ala Gly Leu Leu Phe 260 265 270 Gly Pro Lys Thr Glu Val Glu Ala Gln Asp Gly Thr Lys Lys Glu Thr 275 280 285 Lys Gly Asp Arg Ala Ser Asp Met Arg Leu Gln Glu 290 295 300 41 2916 DNA Homo sapiens CDS (31)..(2914) 41 gcagcacccg cagccagagc cgcgctcggc atg atg ccc ggg gcg ccg ctc 51 Met Met Pro Gly Ala Pro Leu 1 5 ctg cgg ctg ctg acc gcg gtc tct gcg gca gtg gca gtg gca gtg gcc 99 Leu Arg Leu Leu Thr Ala Val Ser Ala Ala Val Ala Val Ala Val Ala 10 15 20 ggg gcg ccc ggg acg gta atg ccc ccc acc acg ggg gac gcc acc ctg 147 Gly Ala Pro Gly Thr Val Met Pro Pro Thr Thr Gly Asp Ala Thr Leu 25 30 35 gcc ttc gtc ttc gac gtc acc ggc tcc atg tgg gac gaa ctg atg cag 195 Ala Phe Val Phe Asp Val Thr Gly Ser Met Trp Asp Glu Leu Met Gln 40 45 50 55 gtg atc gat ggc gcc tcg cgc att ctg gaa cgc agt ctg agc cgc cgc 243 Val Ile Asp Gly Ala Ser Arg Ile Leu Glu Arg Ser Leu Ser Arg Arg 60 65 70 agc cag gcc atc gcc aac tac gcg ctg gtg ccc ttc cac gac cca gat 291 Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val Pro Phe His Asp Pro Asp 75 80 85 att ggc cca gtg acc ctc acg gcg gac ccc aca gtg ttt cag agg gag 339 Ile Gly Pro Val Thr Leu Thr Ala Asp Pro Thr Val Phe Gln Arg Glu 90 95 100 ctg aga gaa ctc tac gtg cag gga ggt ggt gac tgc ccg gag atg agt 387 Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly Asp Cys Pro Glu Met Ser 105 110 115 gtg ggg gcc att aag gct gcc gtg gag gtt gcc aac ccc gga tcc ttc 435 Val Gly Ala Ile Lys Ala Ala Val Glu Val Ala Asn Pro Gly Ser Phe 120 125 130 135 atc tac gtc ttt tcg gat gcc cgc gcc aaa gac tat cac aag aag gaa 483 Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys Asp Tyr His Lys Lys Glu 140 145 150 gag ctg ctg cgg ctc ctg cag ctc aag caa tca cag gtg gtc ttt gtg 531 Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln Ser Gln Val Val Phe Val 155 160 165 ctg acg ggg gac tgt ggc gac cgc acc cat cct ggc tac ctg gct tat 579 Leu Thr Gly Asp Cys Gly Asp Arg Thr His Pro Gly Tyr Leu Ala Tyr 170 175 180 gag gag atc gct gcc acc agc tct ggg cag gtg ttc cac ctg gac aag 627 Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln Val Phe His Leu Asp Lys 185 190 195 cag caa gtg aca gag gca ggt gct tcc gtg ttt cca ggc aaa att gtg 675 Gln Gln Val Thr Glu Ala Gly Ala Ser Val Phe Pro Gly Lys Ile Val 200 205 210 215 cag gag cac agg atc ctt tca ggg gcc agc tgg gaa atg atg aac aac 723 Gln Glu His Arg Ile Leu Ser Gly Ala Ser Trp Glu Met Met Asn Asn 220 225 230 gct ctc tct gga aag gac aag cac acc cat ttc cgt ggt ata aat gct 771 Ala Leu Ser Gly Lys Asp Lys His Thr His Phe Arg Gly Ile Asn Ala 235 240 245 ccc acc tcg gct gat tcc aag tca gag ttg gga agt gac gct gac act 819 Pro Thr Ser Ala Asp Ser Lys Ser Glu Leu Gly Ser Asp Ala Asp Thr 250 255 260 cag ctt tcc gga gcc tac aca agt ggc tcc cac aca cca ctg gat ccc 867 Gln Leu Ser Gly Ala Tyr Thr Ser Gly Ser His Thr Pro Leu Asp Pro 265 270 275 gca cag gca cct ctc acc gcc agt tgg gtt aac gag agc ccc tac ctg 915 Ala Gln Ala Pro Leu Thr Ala Ser Trp Val Asn Glu Ser Pro Tyr Leu 280 285 290 295 gtg ctg aag tgg gtg gag tca gcg atc cag gcc tcc aag gtg cac ctg 963 Val Leu Lys Trp Val Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu 300 305 310 ctg tcc aca gac cac gag gag gag ggg gag cac aca tgg aga ctc ccc 1011 Leu Ser Thr Asp His Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro 315

320 325 ttt gac ccc agc ctg aag gag gtc acc atc tca ttg agt ggg cca ggg 1059 Phe Asp Pro Ser Leu Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly 330 335 340 cct gag att gaa gtc caa gat ccg ctg ggt atg gac cac ccc ggg gct 1107 Pro Glu Ile Glu Val Gln Asp Pro Leu Gly Met Asp His Pro Gly Ala 345 350 355 ggc ctc ctc ttt ggc ccc aag act gag gtg gaa gcc cag gat ggg aca 1155 Gly Leu Leu Phe Gly Pro Lys Thr Glu Val Glu Ala Gln Asp Gly Thr 360 365 370 375 aag aaa gag acc aag ggg agg atc ctg cag gag gac gag ggc ctc aac 1203 Lys Lys Glu Thr Lys Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn 380 385 390 gtg ctt ctc aac atc cct gac tcg gcc aag gtc gta gcc ttt aag cct 1251 Val Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro 395 400 405 gag cat ccg ggg ctg tgg tcc atc aag gtc tat agc agt ggc cgc cat 1299 Glu His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His 410 415 420 tca gtg agg atc aca ggc gtc agc aac att gac ttc cga gcc ggc ttc 1347 Ser Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe 425 430 435 tcc act cag ccc ttg ctg gac ctc aac cac acc ctc gag tgg ccc ttg 1395 Ser Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu 440 445 450 455 caa gga gtc ccc atc tcc ctg gtg atc aat tcc acg ggc ctg aag gca 1443 Gln Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala 460 465 470 ccc ggc cgc cta gac tcg gtg gag ctg gca caa agc tca ggg aag ccc 1491 Pro Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro 475 480 485 ctc ctg act ctg ccc acg aag ccc ctc tcc aat ggc tcc acc cat cag 1539 Leu Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln 490 495 500 ctg tgg ggc ggg ccg ccc ttc cac acc ccc aag gag cgc ttc tac ctc 1587 Leu Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu 505 510 515 aag gtg aag ggc aag gac cat gag gga aac ccc ctc ctt cgt gtc tct 1635 Lys Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser 520 525 530 535 gga gtg tcc tac agt ggg gtg gcc cca ggc gct ccc ctc gtc agc atg 1683 Gly Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met 540 545 550 gcc ccc agg atc cat ggc tac ctg cac cag ccc ctg ctg gtc tcc tgc 1731 Ala Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys 555 560 565 tcg gtg cac agt gcc ctt ccc ttc cgg ctg cag ctg cgg cga ggt gaa 1779 Ser Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu 570 575 580 gcc agg ctg ggc gaa gag agg cac ttt cag gag tcg gga aac agc agc 1827 Ala Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser 585 590 595 tgg gag atc ctg cgg gcc tcc aag gcc gag gag ggc acg tac gag tgc 1875 Trp Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys 600 605 610 615 aca gcc gtc agc agg gct ggg acc ggg cga gca aag gcc cag att gtt 1923 Thr Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val 620 625 630 gtc acc ctg cac ctc agg gtg ggg ttc ggg gca gca cca ggg ctt gca 1971 Val Thr Leu His Leu Arg Val Gly Phe Gly Ala Ala Pro Gly Leu Ala 635 640 645 cga aga ccc cct ccc ttg cct cag ctc ctt ggt tcc tcc tgt gct cat 2019 Arg Arg Pro Pro Pro Leu Pro Gln Leu Leu Gly Ser Ser Cys Ala His 650 655 660 gtc cct gca gac ccc ccg ccg cag ctg gtc cct gct ccc aac gtg acc 2067 Val Pro Ala Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr 665 670 675 gtg tcc cca ggg gag act gcc gtc cta tcc tgc cgg gtc cta ggc gag 2115 Val Ser Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu 680 685 690 695 gcc ccc tac aac ctg acg tgg gtc cgg gac tgg cga gtc ctg ccg gcc 2163 Ala Pro Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala 700 705 710 tcg acg ggc cga gtt gcc cag ctg gct gac ctg tcc ctg gag atc agt 2211 Ser Thr Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser 715 720 725 ggc atc atc ccc aca gac ggc ggg agg tac cag tgt gtg gcc agc aat 2259 Gly Ile Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn 730 735 740 gcc aat ggg gtc aca agg gca tcc gtc tgg ctc ctg gtg cga gag gcc 2307 Ala Asn Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Ala 745 750 755 cca cag gtc agc atc cac acc agc tcc cag cac ttc tcc caa ggt gtg 2355 Pro Gln Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val 760 765 770 775 gag gtg aag gtc agc tgc tca gcc tct gga tac ccc aca ccc cac atc 2403 Glu Val Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile 780 785 790 tcc tgg agc cgt gag agc caa gcc cta caa gag gac agc aga atc cat 2451 Ser Trp Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His 795 800 805 gtg gac gca cag gga acc ctg att att cag ggg gta gcc cca gag gat 2499 Val Asp Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp 810 815 820 gct ggg aat tac agc tgc cag gcg act aat gag gtt ggc act gac cag 2547 Ala Gly Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln 825 830 835 gag acg gtc acc ctc tac tac aca gac cca ccg tcg gtc tct gct gta 2595 Glu Thr Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Ala Val 840 845 850 855 aat gcc gtg gtg ctg gtg gcc gtt ggg gag gag gct gtg ttg gtg tgt 2643 Asn Ala Val Val Leu Val Ala Val Gly Glu Glu Ala Val Leu Val Cys 860 865 870 gag gca tct ggg gtt ccc ccg ccc cga gtc atc tgg tat cga ggg ggt 2691 Glu Ala Ser Gly Val Pro Pro Pro Arg Val Ile Trp Tyr Arg Gly Gly 875 880 885 ctt gaa atg atc ctg gcc cct gag ggc tcc agc tct ggg aag ctg cgg 2739 Leu Glu Met Ile Leu Ala Pro Glu Gly Ser Ser Ser Gly Lys Leu Arg 890 895 900 atc ccg gcg gct cag gag agg gat gct ggc acc tac acc tgc cgg gct 2787 Ile Pro Ala Ala Gln Glu Arg Asp Ala Gly Thr Tyr Thr Cys Arg Ala 905 910 915 gtc aat gag ttg ggt gac gcc tct gca gaa atc cag ctg gcg gtt gga 2835 Val Asn Glu Leu Gly Asp Ala Ser Ala Glu Ile Gln Leu Ala Val Gly 920 925 930 935 cat gcg ccc cag ctg acg gag ctg ccc cgg gat gtc act gtg gaa ctg 2883 His Ala Pro Gln Leu Thr Glu Leu Pro Arg Asp Val Thr Val Glu Leu 940 945 950 ggg agg agt gcc cag ctg cgg cgt ggg act taa 2916 Gly Arg Ser Ala Gln Leu Arg Arg Gly Thr 955 960 42 961 PRT Homo sapiens 42 Met Met Pro Gly Ala Pro Leu Leu Arg Leu Leu Thr Ala Val Ser Ala 1 5 10 15 Ala Val Ala Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro 20 25 30 Thr Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser 35 40 45 Met Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu 50 55 60 Glu Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu 65 70 75 80 Val Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp 85 90 95 Pro Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly 100 105 110 Gly Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu 115 120 125 Val Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala 130 135 140 Lys Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys 145 150 155 160 Gln Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp Arg Thr 165 170 175 His Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly 180 185 190 Gln Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Ala Gly Ala Ser 195 200 205 Val Phe Pro Gly Lys Ile Val Gln Glu His Arg Ile Leu Ser Gly Ala 210 215 220 Ser Trp Glu Met Met Asn Asn Ala Leu Ser Gly Lys Asp Lys His Thr 225 230 235 240 His Phe Arg Gly Ile Asn Ala Pro Thr Ser Ala Asp Ser Lys Ser Glu 245 250 255 Leu Gly Ser Asp Ala Asp Thr Gln Leu Ser Gly Ala Tyr Thr Ser Gly 260 265 270 Ser His Thr Pro Leu Asp Pro Ala Gln Ala Pro Leu Thr Ala Ser Trp 275 280 285 Val Asn Glu Ser Pro Tyr Leu Val Leu Lys Trp Val Glu Ser Ala Ile 290 295 300 Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His Glu Glu Glu Gly 305 310 315 320 Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu Lys Glu Val Thr 325 330 335 Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val Gln Asp Pro Leu 340 345 350 Gly Met Asp His Pro Gly Ala Gly Leu Leu Phe Gly Pro Lys Thr Glu 355 360 365 Val Glu Ala Gln Asp Gly Thr Lys Lys Glu Thr Lys Gly Arg Ile Leu 370 375 380 Gln Glu Asp Glu Gly Leu Asn Val Leu Leu Asn Ile Pro Asp Ser Ala 385 390 395 400 Lys Val Val Ala Phe Lys Pro Glu His Pro Gly Leu Trp Ser Ile Lys 405 410 415 Val Tyr Ser Ser Gly Arg His Ser Val Arg Ile Thr Gly Val Ser Asn 420 425 430 Ile Asp Phe Arg Ala Gly Phe Ser Thr Gln Pro Leu Leu Asp Leu Asn 435 440 445 His Thr Leu Glu Trp Pro Leu Gln Gly Val Pro Ile Ser Leu Val Ile 450 455 460 Asn Ser Thr Gly Leu Lys Ala Pro Gly Arg Leu Asp Ser Val Glu Leu 465 470 475 480 Ala Gln Ser Ser Gly Lys Pro Leu Leu Thr Leu Pro Thr Lys Pro Leu 485 490 495 Ser Asn Gly Ser Thr His Gln Leu Trp Gly Gly Pro Pro Phe His Thr 500 505 510 Pro Lys Glu Arg Phe Tyr Leu Lys Val Lys Gly Lys Asp His Glu Gly 515 520 525 Asn Pro Leu Leu Arg Val Ser Gly Val Ser Tyr Ser Gly Val Ala Pro 530 535 540 Gly Ala Pro Leu Val Ser Met Ala Pro Arg Ile His Gly Tyr Leu His 545 550 555 560 Gln Pro Leu Leu Val Ser Cys Ser Val His Ser Ala Leu Pro Phe Arg 565 570 575 Leu Gln Leu Arg Arg Gly Glu Ala Arg Leu Gly Glu Glu Arg His Phe 580 585 590 Gln Glu Ser Gly Asn Ser Ser Trp Glu Ile Leu Arg Ala Ser Lys Ala 595 600 605 Glu Glu Gly Thr Tyr Glu Cys Thr Ala Val Ser Arg Ala Gly Thr Gly 610 615 620 Arg Ala Lys Ala Gln Ile Val Val Thr Leu His Leu Arg Val Gly Phe 625 630 635 640 Gly Ala Ala Pro Gly Leu Ala Arg Arg Pro Pro Pro Leu Pro Gln Leu 645 650 655 Leu Gly Ser Ser Cys Ala His Val Pro Ala Asp Pro Pro Pro Gln Leu 660 665 670 Val Pro Ala Pro Asn Val Thr Val Ser Pro Gly Glu Thr Ala Val Leu 675 680 685 Ser Cys Arg Val Leu Gly Glu Ala Pro Tyr Asn Leu Thr Trp Val Arg 690 695 700 Asp Trp Arg Val Leu Pro Ala Ser Thr Gly Arg Val Ala Gln Leu Ala 705 710 715 720 Asp Leu Ser Leu Glu Ile Ser Gly Ile Ile Pro Thr Asp Gly Gly Arg 725 730 735 Tyr Gln Cys Val Ala Ser Asn Ala Asn Gly Val Thr Arg Ala Ser Val 740 745 750 Trp Leu Leu Val Arg Glu Ala Pro Gln Val Ser Ile His Thr Ser Ser 755 760 765 Gln His Phe Ser Gln Gly Val Glu Val Lys Val Ser Cys Ser Ala Ser 770 775 780 Gly Tyr Pro Thr Pro His Ile Ser Trp Ser Arg Glu Ser Gln Ala Leu 785 790 795 800 Gln Glu Asp Ser Arg Ile His Val Asp Ala Gln Gly Thr Leu Ile Ile 805 810 815 Gln Gly Val Ala Pro Glu Asp Ala Gly Asn Tyr Ser Cys Gln Ala Thr 820 825 830 Asn Glu Val Gly Thr Asp Gln Glu Thr Val Thr Leu Tyr Tyr Thr Asp 835 840 845 Pro Pro Ser Val Ser Ala Val Asn Ala Val Val Leu Val Ala Val Gly 850 855 860 Glu Glu Ala Val Leu Val Cys Glu Ala Ser Gly Val Pro Pro Pro Arg 865 870 875 880 Val Ile Trp Tyr Arg Gly Gly Leu Glu Met Ile Leu Ala Pro Glu Gly 885 890 895 Ser Ser Ser Gly Lys Leu Arg Ile Pro Ala Ala Gln Glu Arg Asp Ala 900 905 910 Gly Thr Tyr Thr Cys Arg Ala Val Asn Glu Leu Gly Asp Ala Ser Ala 915 920 925 Glu Ile Gln Leu Ala Val Gly His Ala Pro Gln Leu Thr Glu Leu Pro 930 935 940 Arg Asp Val Thr Val Glu Leu Gly Arg Ser Ala Gln Leu Arg Arg Gly 945 950 955 960 Thr 43 1023 DNA Homo sapiens CDS (628)..(1023) 43 ctcgagtgtg gaactcactc ttaacgtacc tgaggagtgt ccaacgtctt 50 tggacaaggc catactctca tgttcctttt cactcagctt tacccacaca 100 gaaattttgg ggacccatgg gggactcagc agttgccaag gtctgcagcc 150 tcctccaagg ggttcccatc tagttctcaa gaggaaggag ggggttctca 200 gtcgccaggt gggcatggca ctcccgaggc caggtgagca ggtcagtgcc 250 ttggggctca gggctgctcc ggttcttacc gaattgatcc agtcgttgta 300 gttggagacc cgcgtgaaga tggagggctt gtagtagtag ttgcaaccaa 350 ggaccgacgt gaggctgccg atgccatgca cctcccaccg gccgtcagat 400 gcctgacagt tcagcggccc accggagtct ccgttgcagg tgcatatcac 450 gccatcaccc ccagcacaga tcatattcgt cttcacggtg ctgccccacc 500 agccagagtt ggagcaggtg gcatagtcca caaccagcaa ccggccctgc 550 ttcaggtcat cagggagagc cccgttggtc tgcagccttc cccagcccgt 600 gacgtagcag gggtagttgt tgggtag aat ggt gcc ggc agg agg gag gca 651 Asn Gly Ala Gly Arg Arg Glu Ala 1 5 ggc cag ctg gat ctt gtc ggt gag gga gac ggg gtt agc cag ttt gag 699 Gly Gln Leu Asp Leu Val Gly Glu Gly Asp Gly Val Ser Gln Phe Glu 10 15 20 cag ggc aat gtc gtt ccc ttt gga gac ctg gtc gga gtt cca gtc ctt 747 Gln Gly Asn Val Val Pro Phe Gly Asp Leu Val Gly Val Pro Val Leu 25 30 35 40 gtg cac cac aat ctt aga gac act gac ggc cag cga gcc gga ctc tgc 795 Val His His Asn Leu Arg Asp Thr Asp Gly Gln Arg Ala Gly Leu Cys 45 50 55 aac gta gag gtt atg ctg gcc cag cat cac gcg gta gat ccc gga gga 843 Asn Val Glu Val Met Leu Ala Gln His His Ala Val Asp Pro Gly Gly 60 65 70 gct gat gca gtg ggc agc cgt cag gac cca gct gtt ggc tat cag gga 891 Ala Asp Ala Val Gly Ser Arg Gln Asp Pro Ala Val Gly Tyr Gln Gly 75 80 85 ccc tcc gca ggt gtg gta cca ctg gcc att gga gct gta ctg cag gga 939 Pro Ser Ala Gly Val Val Pro Leu Ala Ile Gly Ala Val Leu Gln Gly 90 95 100 gac ctg cca ggg ccg gct gtt ggg cct cgc ttc ttc acc tcc aag cat 987 Asp Leu Pro Gly Pro Ala Val Gly Pro Arg Phe Phe Thr Ser Lys His 105 110 115 120 cct aga cat atc agg cgc gta agt gga gac gga tcc 1023 Pro Arg His Ile Arg Arg Val Ser Gly Asp Gly Ser 125 130 44 132 PRT Homo sapiens 44 Asn Gly Ala Gly Arg Arg Glu Ala Gly Gln Leu Asp Leu Val Gly Glu 1 5 10 15 Gly Asp Gly Val Ser Gln Phe Glu Gln Gly Asn Val Val Pro Phe Gly 20 25 30 Asp Leu Val Gly Val Pro Val Leu Val His His Asn Leu Arg Asp Thr 35 40 45 Asp Gly Gln Arg Ala Gly Leu Cys Asn Val Glu Val Met Leu Ala Gln 50 55 60 His His Ala Val Asp Pro Gly Gly Ala Asp Ala Val Gly Ser Arg Gln 65 70 75 80 Asp Pro Ala Val Gly Tyr Gln Gly Pro Ser Ala Gly Val Val Pro Leu 85 90 95 Ala Ile Gly Ala Val Leu Gln Gly Asp Leu Pro Gly

Pro Ala Val Gly 100 105 110 Pro Arg Phe Phe Thr Ser Lys His Pro Arg His Ile Arg Arg Val Ser 115 120 125 Gly Asp Gly Ser 130 45 2058 DNA Homo sapiens CDS (1)..(2058) 45 aag ctt gtg gca gtg gcc ggg gcg ccc ggg acg gta atg ccc ccc acc 48 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 acg ggg gac gcc acc ctg gcc ttc gtc ttc gac gtc acc ggc tcc atg 96 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 tgg gac gaa ctg atg cag gtg atc gat ggc gcc tcg cgc att ctg gaa 144 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 cgc agt ctg agc cgc cgc agc cag gcc atc gcc aac tac gcg ctg gtg 192 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 ccc ttc cac gac cca gat att ggc cca gtg acc ctc acg gcg gac ccc 240 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 aca gtg ttt cag agg gag ctg aga gaa ctc tac gtg cag gga ggt ggt 288 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 gac tgc ccg gag atg agt gtg ggg gcc att aag gct gcc gtg gag gtt 336 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 gcc aac ccc gga tcc ttc atc tac gtc ttt tcg gat gcc cgc gcc aaa 384 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 gac tat cac aag aag gaa gag ctg ctg cgg ctc ctg cag ctc aag caa 432 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 tca cag gtg gtc ttt gtg ctg acg ggg gac tgt ggc gac cac acc cat 480 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 cct ggc tac ctg gct tat gag gag atc gct gcc acc agc tct ggg cag 528 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 gtg ttc cac ctg gac aag cag caa gtg aca gag gtg ctg aag tgg gtg 576 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 gag tca gcg atc cag gcc tcc aag gtg cac ctg ctg tcc aca gac cac 624 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 gag gag gag ggg gag cac aca tgg aga ctc ccc ttt gac ccc agc ctg 672 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 aag gag gtc acc atc tca ttg agt ggg cca ggg cct gag att gaa gtc 720 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 caa gat ccg ctg ggg agg atc ctg cag gag gac gag ggc ctc aac gtg 768 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 ctt ctc aac atc cct gac tcg gcc aag gtc gta gcc ttt aag cct gag 816 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 cat ccg ggg ctg tgg tcc atc aag gtc tat agc agt ggc cgc cat tca 864 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 gtg agg atc aca ggc gtc agc aac att gac ttc cga gcc ggc ttc tcc 912 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 act cag ccc ttg ctg gac ctc aac cac acc ctc gag tgg ccc ttg caa 960 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 gga gtc ccc atc tcc ctg gtg atc aat tcc acg ggc ctg aag gca ccc 1008 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 ggc cgc cta gac tcg gtg gag ctg gca caa agc tca ggg aag ccc ctc 1056 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 ctg act ctg ccc acg aag ccc ctc tcc aat ggc tcc acc cat cag ctg 1104 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 tgg ggc ggg cca ccc ttc cac acc ccc aag gag cgc ttc tac ctc aag 1152 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 gtg aag ggc aag gac cat gag gga aac ccc ctc ctt cgt gtc tct gga 1200 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 gtg tcc tac agt ggg gtg gcc cca ggc gct ccc ctc gtc agc atg gtc 1248 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Val 405 410 415 ccc agg atc cat ggc tac ctg cac cag ccc ctg ctg gtc tcc tgc tcg 1296 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 gtg cac agt gcc ctt ccc ttc cgg ctg cag ctg cgg cga ggt gaa gcc 1344 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 agg ctg ggc gaa gag agg cac ttt cag gag tcg gga aac agt agc tgg 1392 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 gag atc ctg cgg gcc tcc aag gcc gag gag ggc acg tac gag tgc aca 1440 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 gcc gtc agc agg gct ggg acc ggg cga gca aag gcc cag att gtt gtc 1488 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 aca gac ccc ccg ccg cag ctg gtc cct gct ccc aac gtg acc gtg tcc 1536 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 cca ggg gag act gcc gtc cta tcc tgc cgg gtc cta ggc gag gcc ccc 1584 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 tac aac ctg acg tgg gtc cgg gac tgg cga gtc ctg ccg gcc tcg acg 1632 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 ggc cga gtt gcc cag ctg gct gac ctg tcc ctg gag atc agt ggc atc 1680 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 atc ccc aca gac ggc ggg agg tac cag tgt gtg gcc agc aat gcc aat 1728 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 ggg gtc aca agg gca tcc gtc tgg ctc ctg gtg cga gag gtc cca cag 1776 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Val Pro Gln 580 585 590 gtc agc atc cac acc agc tcc cag cac ttc tcc caa ggt gtg gag gtg 1824 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 aag gtc agc tgc tca gcc tct gga tac ccc aca ccc cac atc tcc tgg 1872 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 agc cgt gag agc caa gcc cta caa gag gac agc aga atc cat gtg gac 1920 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 gca cag gga acc ctg att att cag ggg gta gcc cca gag gat gct ggg 1968 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 aat tac agc tgc cag gcg act aat gag gtt ggc act gac cag gag acg 2016 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 gtc acc ctc tac tac aca gac cca ccg tcg gtc tct gtc gac 2058 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 46 686 PRT Homo sapiens 46 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Val 405 410 415 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Val Pro Gln 580 585 590 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 47 2058 DNA Homo sapiens CDS (1)..(2058) 47 aag ctt gtg gca gtg gcc ggg gcg ccc ggg acg gta atg ccc ccc acc 48 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 acg ggg gac gcc acc ctg gcc ttc gtc ttc gac gtc acc ggc tcc atg 96 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 tgg gac gaa ctg atg cag gtg atc gat ggc gcc tcg cgc att ctg gaa 144 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 cgc agt ctg agc cgc cgc agc cag gcc atc gcc aac tac gcg ctg gtg 192 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 ccc ttc cac gac cca gat att ggc cca gtg acc ctc acg gcg gac ccc 240 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 aca gtg ttt cag agg gag ctg aga gaa ctc tac gtg cag gga ggt ggt 288 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 gac tgc ccg gag atg agt gtg ggg gcc att aag gct gcc gtg gag gtt 336 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 gcc aac ccc gga tcc ttc atc tac gtc ttt tcg gat gcc cgc gcc aaa 384 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 gac tat cac aag aag gaa gag ctg ctg cgg ctc ctg cag ctc aag caa 432 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 tca cag gtg gtc ttt gtg ctg acg ggg gac tgt ggc gac cac acc cat 480 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 cct ggc tac ctg gct tat gag gag atc gct gcc acc agc tct ggg cag 528 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 gtg ttc cac ctg gac aag cag caa gtg aca gag gtg ctg aag tgg gtg 576 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 gag tca gcg atc cag gcc tcc aag gtg cac ctg ctg tcc aca gac cac 624 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 gag gag gag ggg gag cac aca tgg aga ctc ccc ttt gac ccc agc ctg 672 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 aag gag gtc acc atc tca ttg agt ggg cca ggg cct gag att gaa gtc 720 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 caa gat ccg ctg ggg agg atc ctg cag gag gac gag ggc ctc aac gtg 768 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 ctt ctc aac atc cct gac tcg gcc aag gtc gta gcc ttt aag cct gag 816 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 cat ccg ggg ctg tgg tcc atc aag gtc tat agc agt ggc cgc cat tca 864 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 gtg agg atc aca ggc gtc agc aac att gac ttc cga gcc ggc ttc tcc 912 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 act cag ccc ttg ctg gac ctc aac cac acc ctc gag tgg ccc ttg caa 960 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 gga gtc ccc atc tcc ctg gtg atc aat tcc acg ggc ctg aag gca ccc 1008 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 ggc cgc cta gac tcg gtg gag ctg gca caa agc tca ggg aag ccc ctc 1056 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 ctg act ctg ccc acg aag ccc ctc tcc aat ggc tcc acc cat cag ctg 1104 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 tgg ggc ggg ccg ccc ttc cac acc ccc aag gag cgc ttc tac ctc aag 1152 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu

Lys 370 375 380 gtg aag ggc aag gac cat gag gga aac ccc ctc ctt cgt gtc tct gga 1200 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 gtg tcc tac agt ggg gtg gcc cca ggc gct ccc ctc gtc agc atg gcc 1248 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 ccc agg atc cat ggc tac ctg cac cag ccc ctg ctg gtc tcc tgc tcg 1296 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 gtg cac agt gcc ctt ccc ttc cgg ctg cag ctg cgg cga ggt gaa gcc 1344 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 agg ctg ggc gaa gag agg cac ttt cag gag tcg gga aac agc agc tgg 1392 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 gag atc ctg cgg gcc tcc aag gcc gag gag ggc acg tac gag tgc aca 1440 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 gcc gtc agc agg gct ggg acc ggg cga gca aag gcc cag att gtt gtc 1488 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 aca gac ccc ccg ccg cag ctg gtc cct gct ccc aac gtg acc gtg tcc 1536 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 cca ggg gag act gcc gtc cta tcc tgc cgg gtc cta ggc gag gcc ccc 1584 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 tac aac ctg acg tgg gtc cgg gac tgg cga gtc ctg ccg gcc tcg acg 1632 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 ggc cga gtt gcc cag ctg gct gac ctg tcc ctg gag atc agt ggc atc 1680 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 atc ccc aca gac ggc ggg agg tac cag tgt gtg gcc agc aat gcc aat 1728 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 ggg gtc aca agg gca tcc gtc tgg ctc ctg gtg cga gag gcc cca cag 1776 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 gtc agc atc cac acc agc tcc cag cac ttc tcc caa ggt gtg gag gtg 1824 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 aag gtc agc tgc tca gcc tct gga tac ccc aca ccc cac atc tcc tgg 1872 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 agc cgt gag agc caa gcc cta caa gag gac agc aga atc cat gtg gac 1920 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 gca cag gga acc ctg att att cag ggg gta gcc cca gag gat gct ggg 1968 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 aat tac agc tgc cag gcg act aat gag gtt ggc act gac cag gag acg 2016 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 gtc acc ctc tac gac aca gac cca ccg tcg gtc tct gtc gac 2058 Val Thr Leu Tyr Asp Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 48 686 PRT Homo sapiens 48 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 Val Thr Leu Tyr Asp Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 49 2058 DNA Homo sapiens CDS (1)..(2058) 49 aag ctt gtg gca gtg gcc ggg gcg ccc ggg acg gta atg ccc ccc acc 48 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 acg ggg gac gcc acc ctg gcc ttc gtc ttc gac gtc acc ggc tcc atg 96 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 tgg gac gaa ctg atg cag gtg atc gat ggc gcc tcg cgc att ctg gaa 144 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 cgc agt ctg agc cgc cgc agc cag gcc atc gcc aac tac gcg ctg gtg 192 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 ccc ttc cac gac cca gat att ggc cca gtg acc ctc acg gcg gac ccc 240 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 aca gtg ttt cag agg gag ctg aga gaa ctc tac gtg cag gga ggt ggt 288 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 gac tgc ccg gag atg agt gtg ggg gcc att aag gct gcc gtg gag gtt 336 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 gcc aac ccc gga tcc ttc atc tac gtc ttt tcg gat gcc cgc gcc aaa 384 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 gac tat cac aag aag gaa gag ctg ctg cgg ctc ctg cag ctc aag caa 432 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 tca cag gtg gtc ttt gtg ctg acg ggg gac tgt ggc gac cac acc cat 480 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 cct ggc tac ctg gct tat gag gag atc gct gcc acc agc tct ggg cag 528 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 gtg ttc cac ctg gac aag cag caa gtg aca gag gtg ctg aag tgg gtg 576 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 gag tca gcg atc cag gcc tcc aag gtg cac ctg ctg tcc aca gac cac 624 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 gag gag gag ggg gag cac aca tgg aga ctc ccc ttt gac ccc agc ctg 672 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 aag gag gtc acc atc tca ttg agt ggg cca ggg cct gag att gaa gtc 720 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 caa gat ccg ctg ggg agg atc ctg cag gag gac gag ggc ctc aac gtg 768 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 ctt ctc aac atc cct gac tcg gcc aag gtc gta gcc ttt aag cct gag 816 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 cat ccg ggg ctg tgg tcc atc aag gtc tat agc agt ggc cgc cat tca 864 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 gtg agg atc aca ggc gtc agc aac att gac ttc cga gcc ggc ttc tcc 912 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 act cag ccc ttg ctg gac ctc aac cac acc ctc gag tgg ccc ttg caa 960 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 gga gtc ccc atc tcc ctg gtg atc aat tcc acg ggc ctg aag gca ccc 1008 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 ggc cgc cta gac tcg gtg gag ctg gca caa agc tca ggg aag ccc ctc 1056 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 ctg act ctg ccc acg aag ccc ctc tcc aat ggc tcc acc cat cag ctg 1104 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 tgg ggc ggg ccg ccc ttc cac acc ccc aag gag cgc ttc tac ctc aag 1152 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 gtg aag ggc aag gac cat gag gga aac ccc ctc ctt cgt gtc tct gga 1200 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 gtg tcc tac agt ggg gtg gcc cca ggc gct ccc ctc gtc agc atg gcc 1248 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 ccc agg atc cat ggc tac ctg cac cag ccc ctg ctg gtc tcc tgc tcg 1296 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 gtg cac agt gcc ctt ccc ttc cgg ctg cag ctg cgg cga ggt gaa gcc 1344 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 agg ctg ggc gaa gag agg cac ttt cag gag tcg gga aac agc agc tgg 1392 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 gag atc ctg cgg gcc tcc aag gcc gag gag ggc acg tac gag tgc aca 1440 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 gcc gtc agc agg gct ggg acc ggg cga gca aag gcc cag att gtt gtc 1488 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 aca gac ccc ccg ccg cag ctg gtc cct gct ccc aac gtg acc gtg tcc 1536 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 cca ggg gag gct gcc gtc cta tcc tgc cgg gtc cta ggc gag gcc ccc 1584 Pro Gly Glu Ala Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 tac aac ctg acg tgg gtc cgg gac tgg cga gtc ctg ccg gcc tcg acg 1632 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 ggc cga gtt gcc cag ctg gct gac ctg tcc ctg gag atc agt ggc atc 1680 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 atc ccc aca gac ggc ggg agg tac cag tgt gtg gcc agc aat gcc aat 1728 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 ggg gtc aca agg gca tcc gtc tgg ctc ctg gtg cga gag gcc cca cag 1776 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 gtc agc atc cac acc agc tcc cag cac ttc tcc caa ggt gtg gag gtg 1824 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 aag gtc agc tgc tca gcc tct gga tac ccc aca ccc cac atc tcc tgg 1872 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 agc cgt gag agc caa gcc cta caa gag gac agc aga atc cat gtg gac 1920 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 gca cag gga acc ctg att att cag ggg gta gcc cca gag gat gct ggg 1968 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 aat tac agc tgc cag gcg act aat gag gtt ggc act gac cag gag acg 2016 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 gtc acc ctc tac tac aca gac cca ccg tcg gtc tct gtc gac 2058 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 50 686 PRT Homo sapiens 50 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 Ser Gln

Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 Pro Gly Glu Ala Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 Gly Val Thr Arg Ala Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 51 2058 DNA Homo sapiens CDS (1)..(2058) 51 aag ctt gtg gca gtg gcc ggg gcg ccc ggg acg gta atg ccc ccc acc 48 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 acg ggg gac gcc acc ctg gcc ttc gtc ttc gac gtc acc ggc tcc atg 96 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 tgg gac gaa ctg atg cag gtg atc gat ggc gcc tcg cgc att ctg gaa 144 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 cgc agt ctg agc cgc cgc agc cag gcc atc gcc aac tac gcg ctg gtg 192 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 ccc ttc cac gac cca gat att ggc cca gtg acc ctc acg gcg gac ccc 240 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 aca gtg ttt cag agg gag ctg aga gaa ctc tac gtg cag gga ggt ggt 288 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 gac tgc ccg gag atg agt gtg ggg gcc att aag gct gcc gtg gag gtt 336 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 gcc aac ccc gga tcc ttc atc tac gtc ttt tcg gat gcc cgc gcc aaa 384 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 gac tat cac aag aag gaa gag ctg ctg cgg ctc ctg cag ctc aag caa 432 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 tca cag gtg gtc ttt gtg ctg acg ggg gac tgt ggc gac cac acc cat 480 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 cct ggc tac ctg gct tat gag gag atc gct gcc acc agc tct ggg cag 528 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 gtg ttc cac ctg gac aag cag caa gtg aca gag gtg ctg aag tgg gtg 576 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 gag tca gcg atc cag gcc tcc aag gtg cac ctg ctg tcc aca gac cac 624 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 gag gag gag ggg gag cac aca tgg aga ctc ccc ttt gac ccc agc ctg 672 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 aag gag gtc acc atc tca ttg agt ggg cca ggg cct gag att gaa gtc 720 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 caa gat ccg ctg ggg agg atc ctg cag gag gac gag ggc ctc aac gtg 768 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 ctt ctc aac atc cct gac tcg gcc aag gtc gta gcc ttt aag cct gag 816 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 cat ccg ggg ctg tgg tcc atc aag gtc tat agc agt ggc cgc cat tca 864 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 gtg agg atc aca ggc gtc agc aac att gac ttc cga gcc ggc ttc tcc 912 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 act cag ccc ttg ctg gac ctc aac cac acc ctc gag tgg ccc ttg caa 960 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 gga gtc ccc atc tcc ctg gtg atc aat tcc acg ggc ctg aag gca ccc 1008 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 ggc cgc cta gac tcg gtg gag ctg gca caa agc tca ggg aag ccc ctc 1056 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 ctg act ctg ccc acg aag ccc ctc tcc aat ggc tcc acc cat cag ctg 1104 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 tgg ggc ggg ccg ccc ttc cac acc ccc aag gag cgc ttc tac ctc aag 1152 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 gtg aag ggc aag gac cat gag gga aac ccc ctc ctt cgt gtc tct gga 1200 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 gtg tcc tac agt ggg gtg gcc cca ggc gct ccc ctc gtc agc atg gcc 1248 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 ccc agg atc cat ggc tac ctg cac cag ccc ctg ctg gtc tcc tgc tcg 1296 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 gtg cac agt gcc ctt ccc ttc cgg ctg cag ctg cgg cga ggt gaa gcc 1344 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 agg ctg ggc gaa gag agg cac ttt cag gag tcg gga aac agc agc tgg 1392 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 gag atc ctg cgg gcc tcc aag gcc gag gag ggc acg tac gag tgc aca 1440 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 gcc gtc agc agg gct ggg acc ggg cga gca aag gcc cag att gtt gtc 1488 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 aca gac ccc ccg ccg cag ctg gtc cct gct ccc aac gtg acc gtg tcc 1536 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 cca ggg gag act gcc gtc cta tcc tgc cgg gtc cta ggc gag gcc ccc 1584 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 tac aac ctg acg tgg gtc cgg gac tgg cga gtc ctg ccg gcc tcg acg 1632 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 ggc cga gtt gcc cag ctg gct gac ctg tcc ctg gag atc agt ggc atc 1680 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 atc ccc aca gac ggc ggg agg tac cag tgt gtg gcc agc aat gcc aat 1728 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 ggg gtc aca agg aca tcc gtc tgg ctc ctg gtg cga gag gcc cca cag 1776 Gly Val Thr Arg Thr Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 gtc agc atc cac acc agc tcc cag cac ttc tcc caa ggt gtg gag gtg 1824 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 aag gtc agc tgc tca gcc tct gga tac ccc aca ccc cac atc tcc tgg 1872 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 agc cgt gag agc caa gcc cta caa gag gac agc aga atc cat gtg gac 1920 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 gca cag gga acc ctg att att cag ggg gta gcc cca gag gat gct ggg 1968 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 aat tac agc tgc cag gcg act aat gag gtt ggc act gac cag gag acg 2016 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 gtc acc ctc tac tac aca gac cca ccg tcg gtc tct gtc gac 2058 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 52 686 PRT Homo sapiens 52 Lys Leu Val Ala Val Ala Gly Ala Pro Gly Thr Val Met Pro Pro Thr 1 5 10 15 Thr Gly Asp Ala Thr Leu Ala Phe Val Phe Asp Val Thr Gly Ser Met 20 25 30 Trp Asp Glu Leu Met Gln Val Ile Asp Gly Ala Ser Arg Ile Leu Glu 35 40 45 Arg Ser Leu Ser Arg Arg Ser Gln Ala Ile Ala Asn Tyr Ala Leu Val 50 55 60 Pro Phe His Asp Pro Asp Ile Gly Pro Val Thr Leu Thr Ala Asp Pro 65 70 75 80 Thr Val Phe Gln Arg Glu Leu Arg Glu Leu Tyr Val Gln Gly Gly Gly 85 90 95 Asp Cys Pro Glu Met Ser Val Gly Ala Ile Lys Ala Ala Val Glu Val 100 105 110 Ala Asn Pro Gly Ser Phe Ile Tyr Val Phe Ser Asp Ala Arg Ala Lys 115 120 125 Asp Tyr His Lys Lys Glu Glu Leu Leu Arg Leu Leu Gln Leu Lys Gln 130 135 140 Ser Gln Val Val Phe Val Leu Thr Gly Asp Cys Gly Asp His Thr His 145 150 155 160 Pro Gly Tyr Leu Ala Tyr Glu Glu Ile Ala Ala Thr Ser Ser Gly Gln 165 170 175 Val Phe His Leu Asp Lys Gln Gln Val Thr Glu Val Leu Lys Trp Val 180 185 190 Glu Ser Ala Ile Gln Ala Ser Lys Val His Leu Leu Ser Thr Asp His 195 200 205 Glu Glu Glu Gly Glu His Thr Trp Arg Leu Pro Phe Asp Pro Ser Leu 210 215 220 Lys Glu Val Thr Ile Ser Leu Ser Gly Pro Gly Pro Glu Ile Glu Val 225 230 235 240 Gln Asp Pro Leu Gly Arg Ile Leu Gln Glu Asp Glu Gly Leu Asn Val 245 250 255 Leu Leu Asn Ile Pro Asp Ser Ala Lys Val Val Ala Phe Lys Pro Glu 260 265 270 His Pro Gly Leu Trp Ser Ile Lys Val Tyr Ser Ser Gly Arg His Ser 275 280 285 Val Arg Ile Thr Gly Val Ser Asn Ile Asp Phe Arg Ala Gly Phe Ser 290 295 300 Thr Gln Pro Leu Leu Asp Leu Asn His Thr Leu Glu Trp Pro Leu Gln 305 310 315 320 Gly Val Pro Ile Ser Leu Val Ile Asn Ser Thr Gly Leu Lys Ala Pro 325 330 335 Gly Arg Leu Asp Ser Val Glu Leu Ala Gln Ser Ser Gly Lys Pro Leu 340 345 350 Leu Thr Leu Pro Thr Lys Pro Leu Ser Asn Gly Ser Thr His Gln Leu 355 360 365 Trp Gly Gly Pro Pro Phe His Thr Pro Lys Glu Arg Phe Tyr Leu Lys 370 375 380 Val Lys Gly Lys Asp His Glu Gly Asn Pro Leu Leu Arg Val Ser Gly 385 390 395 400 Val Ser Tyr Ser Gly Val Ala Pro Gly Ala Pro Leu Val Ser Met Ala 405 410 415 Pro Arg Ile His Gly Tyr Leu His Gln Pro Leu Leu Val Ser Cys Ser 420 425 430 Val His Ser Ala Leu Pro Phe Arg Leu Gln Leu Arg Arg Gly Glu Ala 435 440 445 Arg Leu Gly Glu Glu Arg His Phe Gln Glu Ser Gly Asn Ser Ser Trp 450 455 460 Glu Ile Leu Arg Ala Ser Lys Ala Glu Glu Gly Thr Tyr Glu Cys Thr 465 470 475 480 Ala Val Ser Arg Ala Gly Thr Gly Arg Ala Lys Ala Gln Ile Val Val 485 490 495 Thr Asp Pro Pro Pro Gln Leu Val Pro Ala Pro Asn Val Thr Val Ser 500 505 510 Pro Gly Glu Thr Ala Val Leu Ser Cys Arg Val Leu Gly Glu Ala Pro 515 520 525 Tyr Asn Leu Thr Trp Val Arg Asp Trp Arg Val Leu Pro Ala Ser Thr 530 535 540 Gly Arg Val Ala Gln Leu Ala Asp Leu Ser Leu Glu Ile Ser Gly Ile 545 550 555 560 Ile Pro Thr Asp Gly Gly Arg Tyr Gln Cys Val Ala Ser Asn Ala Asn 565 570 575 Gly Val Thr Arg Thr Ser Val Trp Leu Leu Val Arg Glu Ala Pro Gln 580 585 590 Val Ser Ile His Thr Ser Ser Gln His Phe Ser Gln Gly Val Glu Val 595 600 605 Lys Val Ser Cys Ser Ala Ser Gly Tyr Pro Thr Pro His Ile Ser Trp 610 615 620 Ser Arg Glu Ser Gln Ala Leu Gln Glu Asp Ser Arg Ile His Val Asp 625 630 635 640 Ala Gln Gly Thr Leu Ile Ile Gln Gly Val Ala Pro Glu Asp Ala Gly 645 650 655 Asn Tyr Ser Cys Gln Ala Thr Asn Glu Val Gly Thr Asp Gln Glu Thr 660 665 670 Val Thr Leu Tyr Tyr Thr Asp Pro Pro Ser Val Ser Val Asp 675 680 685 53 621 DNA Homo sapiens CDS (4)..(598) 53 atc atg ccc cta ggt ctc ctg tgg ctg ggc cta gcc ctg ttg ggg gct 48 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala 1 5 10 15 ctg cat gcc cag gcc cag gac tcc acc tca gac ctg atc cca gcc cca 96 Leu His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro 20 25 30 cct ctg agc aag gtc cct ctg cag cag aac ttc cag gac aac caa ttc 144 Pro Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe 35 40 45 cag ggg aag tgg tat gtg gta ggc ctg gca ggg aat gca att ctc aga 192 Gln Gly Lys Trp Tyr Val Val Gly Leu Ala

Gly Asn Ala Ile Leu Arg 50 55 60 gaa gac aaa gac ccg caa aag atg tat gcc acc atc tat gag ctg aaa 240 Glu Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys 65 70 75 gaa gac aag agc tac aat gtc acc tcc gtc ctg ttt agg aaa aag aag 288 Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys 80 85 90 95 tgt gac tac tgg atc agg act ttt gtt cca ggt tgc cag ccc ggc gag 336 Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu 100 105 110 ttc acg ctg ggc aac att aag agt tac cct gga tta acg agt tac ctc 384 Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu 115 120 125 gtc cga gtg gtg agc acc aac tac aac cag cat gct atg gtg ttc ttc 432 Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe 130 135 140 aag aaa gtt tct caa aac agg gag tac ttc aag atc acc ctc tac ggt 480 Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly 145 150 155 aga acc aag gag ctg act tcg gaa cta aag gag aac ttc atc cgc ttc 528 Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe 160 165 170 175 tcc aaa tct ctg ggc ctc cct gaa aac cac atc gtc ttc cct gtc cca 576 Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro 180 185 190 atc ggt aat ggc cag tct gga tgaggggacg gggacatggg gact 621 Ile Gly Asn Gly Gln Ser Gly 195 54 198 PRT Homo sapiens 54 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Gly Asn Gly Gln Ser Gly 195 55 609 DNA Homo sapiens CDS (4)..(598) 55 atc atg ccc cta ggt ctc ctg tgg ctg ggc cta gcc ctg ttg ggg gct 48 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala 1 5 10 15 ctg cat gcc cag gcc cag gac tcc acc tca gac ctg atc cca gcc cca 96 Leu His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro 20 25 30 cct ctg agc aag gtc cct ctg cag cag aac ttc cag gac aac caa ttc 144 Pro Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe 35 40 45 cag ggg aag tgg tat gtg gta ggc ctg gca ggg aat gca att ctc aga 192 Gln Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg 50 55 60 gaa gac aaa gac ccg caa aag atg tat gcc acc atc tat gag ctg aaa 240 Glu Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys 65 70 75 gaa gac aag agc tac aat gtc acc tcc gtc ctg ttt agg aaa aag aag 288 Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys 80 85 90 95 tgt gac tac tgg atc agg act ttt gtt cca ggt tgc cag ccc ggc gag 336 Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu 100 105 110 ttc acg ctg ggc aac att aag agt tac cct gga tta acg agt tac ctc 384 Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu 115 120 125 gtc cga gtg gtg agc acc aac tac aac cag cat gct atg gtg ttc ttc 432 Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe 130 135 140 aag aaa gtt tct caa aac agg gag tac ttc aag atc acc ctc tac ggg 480 Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly 145 150 155 aga acc aag gag ctg act tcg gaa cta aag gag aac ttc atc cgc ttc 528 Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe 160 165 170 175 tcc aaa tct ctg ggc ctc cct gaa aac cac atc gtc ttc cct gtc cca 576 Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro 180 185 190 atc ggt aat ggc cag tct gga tgaggggacg gg 609 Ile Gly Asn Gly Gln Ser Gly 195 56 198 PRT Homo sapiens 56 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Gly Asn Gly Gln Ser Gly 195 57 477 DNA Homo sapiens CDS (1)..(477) 57 cgc gga tcc caa ttc cag ggg aag tgg tat gtg gta ggc ctg gca ggg 48 Arg Gly Ser Gln Phe Gln Gly Lys Trp Tyr Val Val Gly Leu Ala Gly 1 5 10 15 aat gca att ctc aga gga gac aaa gac ccg caa aag atg tat gcc acc 96 Asn Ala Ile Leu Arg Gly Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr 20 25 30 atc tat gag ctg aaa gaa gac aag agc tac aat gtc acc tcc gtc ctg 144 Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu 35 40 45 ttt agg aaa aag aag tgt gac tac tgg atc agg act ttt gtt cca ggt 192 Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly 50 55 60 tgc cag ccc ggc gag ttc acg ctg ggc aac att aag agt tac cct gga 240 Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly 65 70 75 80 tta acg agt tac ctc gtc cga gtg gtg agc acc aac tac aac cag cat 288 Leu Thr Ser Tyr Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln His 85 90 95 gct atg gtg ttc ttc aag aaa gtt tct caa aac agg gag tac ttc aag 336 Ala Met Val Phe Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys 100 105 110 atc acc ctc tac ggg aga acc aag gag ctg act tcg gaa cta aag gag 384 Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu 115 120 125 aac ttc atc cgc ttc tcc aaa tct ctg ggc ctc cct gaa aac cac atc 432 Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile 130 135 140 gtc ttc cct gtc cca atc ggt aat ggc cag tct gga ctc gag gcg 477 Val Phe Pro Val Pro Ile Gly Asn Gly Gln Ser Gly Leu Glu Ala 145 150 155 58 159 PRT Homo sapiens 58 Arg Gly Ser Gln Phe Gln Gly Lys Trp Tyr Val Val Gly Leu Ala Gly 1 5 10 15 Asn Ala Ile Leu Arg Gly Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr 20 25 30 Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu 35 40 45 Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly 50 55 60 Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly 65 70 75 80 Leu Thr Ser Tyr Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln His 85 90 95 Ala Met Val Phe Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys 100 105 110 Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu 115 120 125 Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile 130 135 140 Val Phe Pro Val Pro Ile Gly Asn Gly Gln Ser Gly Leu Glu Ala 145 150 155 59 2210 DNA Homo sapiens CDS (1)..(2194) 59 atg aca att tta aga gtg ttt aac caa gac tgt tcc ttt aaa tgt gtt 48 Met Thr Ile Leu Arg Val Phe Asn Gln Asp Cys Ser Phe Lys Cys Val 1 5 10 15 ctt ttg ctg ctg ttt aat tat aca tgt caa tta ttt aca gat cct gtg 96 Leu Leu Leu Leu Phe Asn Tyr Thr Cys Gln Leu Phe Thr Asp Pro Val 20 25 30 gta ttg tgg aaa ttc cca gag gac ttt gga gac cag gaa ata cta cag 144 Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp Gln Glu Ile Leu Gln 35 40 45 agt gtg cca aag ttc tgt ttt ccc ttt gac gtt gaa agg tac agt ata 192 Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val Glu Arg Tyr Ser Ile 50 55 60 agt caa gtt gga cag cac ttt acc ttt gta ctg aca gac att gaa agt 240 Ser Gln Val Gly Gln His Phe Thr Phe Val Leu Thr Asp Ile Glu Ser 65 70 75 80 aaa cag aga ttt gga ttc tgc aga ctg acg tca gga ggc aca att tgt 288 Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser Gly Gly Thr Ile Cys 85 90 95 tta tgc atc ctt agt tac ctt ccc tgg ttt gaa gtg tat tac aag ctt 336 Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu Val Tyr Tyr Lys Leu 100 105 110 cta aat act ctt gca gat tac ttg gct aag cat tcc tac ttc att gcc 384 Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys His Ser Tyr Phe Ile Ala 115 120 125 cct gat gta act gga ctc cca aca ata ccc gag agt aga aat ctt aca 432 Pro Asp Val Thr Gly Leu Pro Thr Ile Pro Glu Ser Arg Asn Leu Thr 130 135 140 gaa tat ttt gtt gcc gtg gat gtg aac aac atg ctg cag ctg tat gcc 480 Glu Tyr Phe Val Ala Val Asp Val Asn Asn Met Leu Gln Leu Tyr Ala 145 150 155 160 agt atg ctg cat gaa agg cgc atc gtg att atc tcg agc aaa tta agc 528 Ser Met Leu His Glu Arg Arg Ile Val Ile Ile Ser Ser Lys Leu Ser 165 170 175 act tta act gcc tgt atc cat gga tca gct gct ctt cta tac cca atg 576 Thr Leu Thr Ala Cys Ile His Gly Ser Ala Ala Leu Leu Tyr Pro Met 180 185 190 tat tgg caa cac ata tac atc cca gtg ctt cct cca cac ctg ctg gac 624 Tyr Trp Gln His Ile Tyr Ile Pro Val Leu Pro Pro His Leu Leu Asp 195 200 205 tac tgc agt gcc cca atg cca tac ctg att gga ata cac tcc agc ctc 672 Tyr Cys Ser Ala Pro Met Pro Tyr Leu Ile Gly Ile His Ser Ser Leu 210 215 220 ata gag aga gtg aaa aac aaa tca ttg gaa gat gtt gtt atg tta aat 720 Ile Glu Arg Val Lys Asn Lys Ser Leu Glu Asp Val Val Met Leu Asn 225 230 235 240 gtt gat aca aac aca tta gaa tca cca ttt agt gac ttg aac aac cta 768 Val Asp Thr Asn Thr Leu Glu Ser Pro Phe Ser Asp Leu Asn Asn Leu 245 250 255 cca agt gat gtg gta agt gcc ttg aaa aat aaa ctg aag aag cag tct 816 Pro Ser Asp Val Val Ser Ala Leu Lys Asn Lys Leu Lys Lys Gln Ser 260 265 270 aca gct acg ggt gat gga gta gct agg gcc ttt ctt aga gca cag gct 864 Thr Ala Thr Gly Asp Gly Val Ala Arg Ala Phe Leu Arg Ala Gln Ala 275 280 285 gct ttg ttt gga tcc tac aga gat gca ctg aga tac aaa cct ggt gag 912 Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu Arg Tyr Lys Pro Gly Glu 290 295 300 ccc atc act ttc tgt gag gag agt ttt gta aag cac cgc tca agc gtg 960 Pro Ile Thr Phe Cys Glu Glu Ser Phe Val Lys His Arg Ser Ser Val 305 310 315 320 atg aaa cag ttc ctg gaa act gcc att aac ctc cag ctt ttt aag cag 1008 Met Lys Gln Phe Leu Glu Thr Ala Ile Asn Leu Gln Leu Phe Lys Gln 325 330 335 gta ttt atc gat ggt cga ctg gca aaa cta aat gca gga agg ggt ttc 1056 Val Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn Ala Gly Arg Gly Phe 340 345 350 tct gat gta ttt gaa gaa gag atc act tca ggt ggc ttt tgt gga ggt 1104 Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly Gly Phe Cys Gly Gly 355 360 365 aaa gac aag tta caa tat aaa tat gtt tct gtt ttt ctt ttg cag aaa 1152 Lys Asp Lys Leu Gln Tyr Lys Tyr Val Ser Val Phe Leu Leu Gln Lys 370 375 380 gga ggt gca ctg ttc aac aca gca atg acc aaa gca acc cct gct gta 1200 Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr Pro Ala Val 385 390 395 400 cgg aca gca tat aaa ttt gca aaa aat cat gca aag ctg gga cta aag 1248 Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu Gly Leu Lys 405 410 415 gaa gtg aag agt aaa cta aaa cac aag gaa aat gaa gaa gat tat ggg 1296 Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu Asp Tyr Gly 420 425 430 acc tgt tct agt tct gta caa tat aca cca gtt tac aaa tta cac aat 1344 Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys Leu His Asn 435 440 445 gaa aag gga gga aac tca gaa aag cgt aag ctt gct cag gca cgc tta 1392 Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln Ala Arg Leu 450 455 460 aaa agg cct ctt aag agc ctt gat ggt gct cta tat gat gat gaa gat 1440 Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp Asp Glu Asp 465 470 475 480 gat gat gac att gaa aga gca agc aag tta tct tct gaa gat ggt gaa 1488 Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu Asp Gly Glu 485 490 495 gaa gct tct gct tat ctc tat gag agt gat gac tct gtt gaa aca aga 1536 Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val Glu Thr Arg 500 505 510 gtg aag act cct tac tca ggt gaa atg gac tta cta gga gag att ctt 1584 Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly Glu Ile Leu 515 520 525 gat aca ttg agc aca cac agc tca gat cag ggg aag ctg gca gct gca 1632 Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu Ala Ala Ala 530 535 540 aag agc ttg gat ttc ttt aga tca atg gat gac att gat tac aaa cct 1680 Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp Tyr Lys Pro 545 550 555 560 acg aat aaa tct aat gct cct agt gag aat aac ctg gct ttc ctc tgt 1728 Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala Phe Leu Cys 565 570 575 ggt ggt tct ggt gac caa gca gag tgg aat ctt ggg caa gac gat agt 1776 Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln Asp Asp Ser 580 585 590 gcc ctc cat ggc aaa cac ctc cct cca tct cct agg aag cgg gtt tcc 1824 Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys Arg Val Ser 595 600 605 tct agt ggt ttg aca gat tct ctg ttt atc ctg aga gag gaa aac agt 1872 Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Arg Glu Glu Asn Ser 610 615 620 aac aag cac ctc ggt gct gac aat gtg agt gac cct act tca gga ctg 1920 Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr Ser Gly Leu 625 630 635 640 gat ttc caa ctc act tcc cct gaa gtt tcc cag act gat aaa gga aaa 1968 Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp Lys Gly Lys 645 650 655 aca gaa aag agg

gaa aca cta agc cag att tca gat gat ctg ctt ata 2016 Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp Leu Leu Ile 660 665 670 ccc ggt ctt ggg cgg cat tca tcg act ttt gtt cct tgg gag aaa gaa 2064 Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp Glu Lys Glu 675 680 685 ggg aaa gaa gcc aaa gag act tca gaa gat att gga ctg ctc cat gaa 2112 Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu Leu His Glu 690 695 700 gta gtg tca tta tgt cat atg aca tct gac ttc caa caa agc ttg aac 2160 Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln Ser Leu Asn 705 710 715 720 att tca gac aaa aac aca aat gga aac caa act taaatcttgc 2203 Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr 725 730 atccaag 2210 60 731 PRT Homo sapiens 60 Met Thr Ile Leu Arg Val Phe Asn Gln Asp Cys Ser Phe Lys Cys Val 1 5 10 15 Leu Leu Leu Leu Phe Asn Tyr Thr Cys Gln Leu Phe Thr Asp Pro Val 20 25 30 Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp Gln Glu Ile Leu Gln 35 40 45 Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val Glu Arg Tyr Ser Ile 50 55 60 Ser Gln Val Gly Gln His Phe Thr Phe Val Leu Thr Asp Ile Glu Ser 65 70 75 80 Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser Gly Gly Thr Ile Cys 85 90 95 Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu Val Tyr Tyr Lys Leu 100 105 110 Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys His Ser Tyr Phe Ile Ala 115 120 125 Pro Asp Val Thr Gly Leu Pro Thr Ile Pro Glu Ser Arg Asn Leu Thr 130 135 140 Glu Tyr Phe Val Ala Val Asp Val Asn Asn Met Leu Gln Leu Tyr Ala 145 150 155 160 Ser Met Leu His Glu Arg Arg Ile Val Ile Ile Ser Ser Lys Leu Ser 165 170 175 Thr Leu Thr Ala Cys Ile His Gly Ser Ala Ala Leu Leu Tyr Pro Met 180 185 190 Tyr Trp Gln His Ile Tyr Ile Pro Val Leu Pro Pro His Leu Leu Asp 195 200 205 Tyr Cys Ser Ala Pro Met Pro Tyr Leu Ile Gly Ile His Ser Ser Leu 210 215 220 Ile Glu Arg Val Lys Asn Lys Ser Leu Glu Asp Val Val Met Leu Asn 225 230 235 240 Val Asp Thr Asn Thr Leu Glu Ser Pro Phe Ser Asp Leu Asn Asn Leu 245 250 255 Pro Ser Asp Val Val Ser Ala Leu Lys Asn Lys Leu Lys Lys Gln Ser 260 265 270 Thr Ala Thr Gly Asp Gly Val Ala Arg Ala Phe Leu Arg Ala Gln Ala 275 280 285 Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu Arg Tyr Lys Pro Gly Glu 290 295 300 Pro Ile Thr Phe Cys Glu Glu Ser Phe Val Lys His Arg Ser Ser Val 305 310 315 320 Met Lys Gln Phe Leu Glu Thr Ala Ile Asn Leu Gln Leu Phe Lys Gln 325 330 335 Val Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn Ala Gly Arg Gly Phe 340 345 350 Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly Gly Phe Cys Gly Gly 355 360 365 Lys Asp Lys Leu Gln Tyr Lys Tyr Val Ser Val Phe Leu Leu Gln Lys 370 375 380 Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr Pro Ala Val 385 390 395 400 Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu Gly Leu Lys 405 410 415 Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu Asp Tyr Gly 420 425 430 Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys Leu His Asn 435 440 445 Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln Ala Arg Leu 450 455 460 Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp Asp Glu Asp 465 470 475 480 Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu Asp Gly Glu 485 490 495 Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val Glu Thr Arg 500 505 510 Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly Glu Ile Leu 515 520 525 Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu Ala Ala Ala 530 535 540 Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp Tyr Lys Pro 545 550 555 560 Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala Phe Leu Cys 565 570 575 Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln Asp Asp Ser 580 585 590 Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys Arg Val Ser 595 600 605 Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Arg Glu Glu Asn Ser 610 615 620 Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr Ser Gly Leu 625 630 635 640 Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp Lys Gly Lys 645 650 655 Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp Leu Leu Ile 660 665 670 Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp Glu Lys Glu 675 680 685 Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu Leu His Glu 690 695 700 Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln Ser Leu Asn 705 710 715 720 Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr 725 730 61 2256 DNA Homo sapiens CDS (1)..(2256) 61 aga tct gat cct gtg gta ttg tgg aaa ttc cca gag gac ttt gga gac 48 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 cag gaa ata cta cag agt gtg cca aag ttc tgt ttt ccc ttt gac gtt 96 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 gaa agg gtg tct cag aat caa gtt gga cag cac ttt acc ttt gta ctg 144 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 aca gac att gaa agt aaa cag aga ttt gga ttc tgc aga ctg acg tca 192 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 gga ggc aca att tgt tta tgc atc ctt agt tac ctt ccc tgg ttt gaa 240 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 gtg tat tac aag ctt cta aat act ctt gca gat tac ttg gct aag gaa 288 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 ctg gaa aat gat ttg aat gaa act ctc aga tca ctg tat aac cac cca 336 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 gta cca aag gca aat act cct gta aat ttg agt gtg aac caa gag ata 384 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 ttt att acc tgt gag caa gtt ctg aaa gat cag cct gct cta cta ccg 432 Phe Ile Thr Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Leu Pro 130 135 140 cat tcc tac ttc att gcc cct gat gta act gga ctc cca aca ata ccc 480 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 gag agt aga aat ctt aca gaa tat ttt gtt gcc gtg gat gtg aac aac 528 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 atg ctg cag ctg tat gcc agt atg ctg cat gaa agg cgc atc gtg att 576 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 atc tcg agc aaa tta agc act tta act gcc tgt atc cat gga tca gct 624 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 gct ctt cta tac cca atg tat tgg caa cac ata tac atc cca gtg ctt 672 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 cct cca cac ctg ctg gac tac tgc tgt gcc cca atg cca tac ctg att 720 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 gga ata cac tcc agc ctc ata gag aga gtg aaa aac aaa tca ttg gaa 768 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 gat gtt gtt atg tta aat gtt gat aca aac aca tta gaa tca cca ttt 816 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 agt gac ttg aac aac cta cca agt gat gtg gtc tcg gcc ttg aaa aat 864 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 aaa ctg aag aag cag tct aca gct acg ggt gat gga gta gct agg gcc 912 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 ttt ctt aga gca cag gct gct ttg ttt gga tcc tac aga gat gca ctg 960 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 aga tac aaa cct ggt gag ccc atc act ttc tgt gag gag agt ttt gta 1008 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 aag cac cgc tca agc gtg atg aaa cag ttc ctg gaa act gcc att aac 1056 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 ctc cag ctt ttt aag cag ttt atc gat ggt cga ctg gca aaa cta aat 1104 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 gca gga agg ggt ttc tct gat gta ttt gaa gaa gag atc act tca ggt 1152 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 ggc ttt tgt gga ggg aac ccg agg tca tat caa caa tgg gtg cat aca 1200 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 gtc aag aaa gga ggt gca ctg ttc aac aca gca atg acc aaa gca acc 1248 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 cct gct gta cgg aca gca tat aaa ttt gca aaa aat cat gca aag ctg 1296 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 gga cta aag gaa gtg aag agt aaa cta aaa cac aag gaa aat gaa gaa 1344 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 gat tat ggg acc tgt tct agt tct gta caa tat aca cca gtt tac aaa 1392 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 tta cac aat gaa aag gga gga aac tca gaa aag cgt aag ctt gct cag 1440 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 gca cgc tta aaa agg cct ctt aag agc ctt gat ggt gct cta tat gat 1488 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 gat gaa gat gat gat gac att gaa aga gca agc aag tta tct tct gaa 1536 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 gat ggt gaa gaa gct tct gct tat ctc tat gag agt gat gac tct gtt 1584 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 gaa aca aga gtg aag act cct tac tca ggt gaa atg gac tta cta gga 1632 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 gag att ctt gat aca ttg agc aca cac agc tca gat cag ggg agg ctg 1680 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Arg Leu 545 550 555 560 gca gct gca aag agc ttg gat ttc ttt aga tca atg gac gac att gat 1728 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 tac aaa cct acg aat aaa tct aat gct cct agt gag aat aac ctg gct 1776 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 ttc ctc tgt ggt ggt tct ggt gac caa gca gag tgg aat ctt ggg caa 1824 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 gac gat agt gcc ctc cat ggc aaa cac ctc cct cca tct cct agg aag 1872 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 cgg gtt tcc tct agt ggt ttg aca gat tct ctg ttt atc ctg aaa gag 1920 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 gaa aac agt aac aag cac ctc ggt gct gac aat gtg agt gac cct act 1968 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 tca gga ctg gat ttc caa ctc act tcc cct gaa gtt tcc cag act gat 2016 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 aaa gga aaa aca gaa aag agg gaa aca cta agc cag att tca gat gat 2064 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 ctg ctt ata ccc ggt ctt ggg cgg cat tca tcg act ttt gtt cct tgg 2112 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 gag aaa gaa ggg aaa gaa gcc aaa gag act tca gaa gat att gga ctg 2160 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 ctc cat gaa gta gtg tca tta tgt cat atg aca tct gac ttc caa caa 2208 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 agc ttg aac att tca gac aaa aac aca aat gga aac caa act aga tct 2256 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 62 752 PRT Homo sapiens 62 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 Phe Ile Thr Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Leu Pro 130 135 140 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355

360 365 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Arg Leu 545 550 555 560 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 63 2256 DNA Homo sapiens CDS (1)..(2256) 63 aga tct gat cct gtg gta ttg tgg aaa ttc cca gag gac ttt gga gac 48 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 cag gaa ata cta cag agt gtg cca aag ttc tgt ttt ccc ttt gac gtt 96 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 gaa agg gtg tct cag aat caa gtt gga cag cac ttt acc ttt gta ctg 144 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 aca gac att gaa agt aaa cag aga ttt gga ttc tgc aga ctg acg tca 192 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 gga ggc aca att tgt tta tgc atc ctt agt tac ctt ccc tgg ttt gaa 240 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 gtg tat tac aag ctt cta aat act ctt gca gat tac ttg gct aag gaa 288 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 ctg gaa aat gat ttg aat gaa act ctc aga tca ctg tat aac cac cca 336 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 gta cca aag gca aat act cct gta aat ttg agt gtg aac caa gag ata 384 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 ttt att acc tgt gag caa gtt ctg aaa gat cag cct gct cta cta ccg 432 Phe Ile Thr Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Leu Pro 130 135 140 cat tcc tac ttc att gcc cct gat gta act gga ctc cca aca ata ccc 480 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 gag agt aga aat ctt aca gaa tat ttt gtt gcc gtg gat gtg aac aac 528 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 atg ctg cag ctg tat gcc agt atg ctg cat gaa agg cgc atc gtg att 576 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 atc tcg agc aaa tta agc act tta act gcc tgt atc cat gga tca gct 624 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 gct ctt cta tac cca atg tat tgg caa cac ata tac atc cca gtg ctt 672 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 cct cca cac ctg ctg gac tac tgc tgt gcc cca atg cca tac ctg att 720 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 gga ata cac tcc agc ctc ata gag aga gtg aaa aac aaa tca ttg gaa 768 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 gat gtt gtt atg tta aat gtt gat aca aac aca tta gaa tca cca ttt 816 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 agt gac ttg aac aac cta cca agt gat gtg gtc tcg gcc ttg aaa aat 864 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 aaa ctg aag aag cag tct aca gct acg ggt gat gga gta gct agg gcc 912 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 ttt ctt aga gca cag gct gct ttg ttt gga tcc tac aga gat gca ctg 960 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 aga tac aaa cct ggt gag ccc atc act ttc tgt gag gag agt ttt gta 1008 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 aag cac cgc tca agc gtg atg aaa cag ttc ctg gaa act gcc att aac 1056 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 ctc cag ctt ttt aag cag ttt atc gat ggt cga ctg gca aaa cta aat 1104 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 gca gga agg ggt ttc tct gat gta ttt gaa gaa gag atc act tca ggt 1152 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 ggc ttt tgt gga ggg aac ccg agg tca tat caa caa tgg gtg cat aca 1200 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 gtc aag aaa gga ggt gca ctg ttc aac aca gca atg acc aaa gca acc 1248 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 cct gct gta cgg aca gca tat aaa ttt gca aaa aat cat gca aag ctg 1296 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 gga cta aag gaa gtg aag agt aaa cta aaa cac aag gaa aat gaa gaa 1344 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 gat tat ggg acc tgt tct agt tct gta caa tat aca cca gtt tac aaa 1392 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 tta cac aat gaa aag gga gga aac tca gaa aag cgt aag ctt gct cag 1440 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 gca cgc tta aaa agg cct ctt aag agc ctt gat ggt gct cta tat gat 1488 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 gat gaa gat gat gat gac att gaa aga gca agc aag tta tct tct gaa 1536 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 gat ggt gaa gaa gct tct gct tat ctc tat gag agt gat gac tct gtt 1584 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 gaa aca aga gtg aag act cct tac tca ggt gaa atg gac tta cta gga 1632 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 gag att ctt gat aca ttg agc aca cac agc tca gat cag ggg agg ctg 1680 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Arg Leu 545 550 555 560 gca gct gca aag agc ttg gat ttc ttt aga tca atg gac gac att gat 1728 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 tac aaa cct acg aat aaa tct aat gct cct agt gag aat aac ctg gct 1776 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 ttc ctc tgt ggt ggt tct ggt gac caa gca gag tgg aat ctt ggg caa 1824 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 gac gat agt gcc ctc cat ggc aaa cac ctc cct cca tct cct agg aag 1872 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 cgg gtt tcc tct agt ggt ttg aca gat tct ctg ttt atc ctg aaa gag 1920 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 gaa aac agt aac aag cac ctc ggt gct gac aat gtg agt gac cct act 1968 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 tca gga ctg gat ttc caa ctc act tcc cct gaa gtt tcc cag act gat 2016 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 aaa gga aaa aca gaa aag agg gaa aca cta agc cag att tca gat gat 2064 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 ctg ctt ata ccc ggt ctt ggg cgg cat tca tcg act ttt gtt cct tgg 2112 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 gag aaa gaa ggg aaa gaa gcc aaa gag act tca gaa gat att gga ctg 2160 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 ctc cat gaa gta gtg tca tta tgt cat atg aca tct gac ttc caa caa 2208 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 agc ttg aac att tca gac aaa aac aca aat gga aac caa act aga tct 2256 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 64 752 PRT Homo sapiens 64 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 Phe Ile Thr Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Leu Pro 130 135 140 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Arg Leu 545 550 555 560 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 65 2259 DNA Homo sapiens CDS (1)..(2259) 65 aga tct gat cct gtg gta ttg tgg aaa ttc cca gag gac ttt gga gac 48 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 cag gaa ata cta cag agt gtg cca aag ttc tgt ttt ccc ttt gac gtt 96 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 gaa agg gtg tct cag aat caa gtt gga cag cac ttt acc ttt gta ctg 144 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 aca gac att gaa agt aaa cag

aga ttt gga ttc tgc aga ctg acg tca 192 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 gga ggc aca att tgt tta tgc atc ctt agt tac ctt ccc tgg ttt gaa 240 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 gtg tat tac aag ctt cta aat act ctt gca gat tac ttg gct aag gaa 288 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 ctg gaa aat gat ttg aat gaa act ctc aga tca ctg tat aac cac cca 336 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 gta cca aag gca aat act cct gta aat ttg agt gtg aac caa gag ata 384 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 ttt att gcc tgt gag caa gtt ctg aaa gat cag cct gct cta gta ccg 432 Phe Ile Ala Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Val Pro 130 135 140 cat tcc tac ttc att gcc cct gat gta act gga ctc cca aca ata ccc 480 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 gag agt aga aat ctt aca gaa tat ttt gtt gcc gtg gat gtg aac aac 528 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 atg ctg cag ctg tat gcc agt atg ctg cat gaa agg cgc atc gtg att 576 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 atc tcg agc aaa tta agc act tta act gcc tgt atc cat gga tca gct 624 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 gct ctt cta tac cca atg tat tgg caa cac ata tac atc cca gtg ctt 672 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 cct cca cac ctg ctg gac tac tgc tgt gcc cca atg cca tac ctg att 720 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 gga ata cac tcc agc ctc ata gag aga gtg aaa aac aaa tca ttg gaa 768 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 gat gtt gtt atg tta aat gtt gat aca aac aca tta gaa tca cca ttt 816 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 agt gac ttg aac aac cta cca agt gat gtg gtc tcg gcc ttg aaa aat 864 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 aaa ctg aag aag cag tct aca gct acg ggt gat gga gta gct agg gcc 912 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 ttt ctt aga gca cag gct gct ttg ttt gga tcc tac aga gat gca ctg 960 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 aga tac aaa cct ggt gag ccc atc act ttc tgt gag gag agt ttt gta 1008 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 aag cac cgc tca agc gtg atg aaa cag ttc ctg gaa act gcc att aac 1056 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 ctc cag ctt ttt aag cag ttt atc gat ggt cga ctg gca aaa cta aat 1104 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 gca gga agg ggt ttc tct gat gta ttt gaa gaa gag atc act tca ggt 1152 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 ggc ttt tgt gga ggg aac ccg agg tca tat caa caa tgg gtg cat aca 1200 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 gtc aag aaa gga ggt gca ctg ttc aac aca gca atg acc aaa gca acc 1248 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 cct gct gta cgg aca gca tat aaa ttt gca aaa aat cat gca aag ctg 1296 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 gga cta aag gaa gtg aag agt aaa cta aaa cac aag gaa aat gaa gaa 1344 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 gat tat ggg acc tgt tct agt tct gta caa tat aca cca gtt tac aaa 1392 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 tta cac aat gaa aag gga gga aac tca gaa aag cgt aag ctt gct cag 1440 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 gca cgc tta aaa agg cct ctt aag agc ctt gat ggt gct cta tat gat 1488 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 gat gaa gat gat gat gac att gaa aga gca agc aag tta tct tct gaa 1536 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 gat ggt gaa gaa gct tct gct tat ctc tat gag agt gat gac tct gtt 1584 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 gaa aca aga gtg aag act cct tac tca ggt gaa atg gac tta cta gga 1632 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 gag att ctt gat aca ttg agc aca cac agc tca gat cag ggg aag ctg 1680 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu 545 550 555 560 gca gct gca aag agc ttg gat ttc ttt aga tca atg gat gac att gat 1728 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 tac aaa cct acg aat aaa tct aat gct cct agt gag aat aac ctg gct 1776 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 ttc ctc tgt agt ggt tct ggt gac caa gca gag tgg aat ctt ggg caa 1824 Phe Leu Cys Ser Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 gac gat agt gcc ctc cat ggc aaa cac ctc cct cca tct cct agg aag 1872 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 cgg gtt tcc tct agt ggt ttg aca gat tct ctg tct atc ctg aaa gag 1920 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Ser Ile Leu Lys Glu 625 630 635 640 gaa aac agt aac aag cac ctc ggt gct gac aat gtg agt gac cct act 1968 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 tca gga ctg gat ttc caa ctc act tcc cct gaa gtt tcc cag act gat 2016 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 aaa gga aaa aca gaa aag agg gaa aca cta agc cag att tca gat gat 2064 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 ctg ctt ata ccc ggt ctt ggg cgg cat tca tcg act ttt gtt cct tgg 2112 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 gag aaa gaa ggg aaa gaa gcc aaa gag act tca gaa gat att gga ctg 2160 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 ctc cat gaa gta gtg tca tta tgt cat atg aca tct gac ttc caa gct 2208 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Ala 725 730 735 aaa gct tgg aac att tca gac aaa aac aca aat gga aac caa act aga 2256 Lys Ala Trp Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg 740 745 750 tct 2259 Ser 66 753 PRT Homo sapiens 66 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 Phe Ile Ala Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Val Pro 130 135 140 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu 545 550 555 560 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 Phe Leu Cys Ser Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Ser Ile Leu Lys Glu 625 630 635 640 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Ala 725 730 735 Lys Ala Trp Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg 740 745 750 Ser 67 2256 DNA Homo sapiens CDS (1)..(2256) 67 aga tct gat cct gtg gta ttg tgg aaa ttc cca gag gac ttt gga gac 48 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 cag gaa ata cta cag agt gtg cca aag ttc tgt ttt ccc ttt gac gtt 96 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 gaa agg gtg tct cag aat caa gtt gga cag cac ttt acc ttt gta ctg 144 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 aca gac att gaa agt aaa cag aga ttt gga ttc tgc aga ctg acg tca 192 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 gga ggc aca att tgt tta tgc atc ctt agt tac ctt ccc tgg ttt gaa 240 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 gtg tat tac aag ctt cta aat act ctt gca gat tac ttg gct aag gaa 288 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 ctg gaa aat gat ttg aat gaa act ctc aga tca ctg tat aac cac cca 336 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 gta cca aag gca aat act cct gta aat ttg agt gtg aac caa gag ata 384 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 ttt att gcc tgt gag caa gtt ctg aaa gat cag cct gct cta gta ccg 432 Phe Ile Ala Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Val Pro 130 135 140 cat tcc tac ttc att gcc cct gat gta act gga ctc cca aca ata ccc 480 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 gag agt aga aat ctt aca gaa tat ttt gtt gcc gtg gat gtg aac aac 528 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 atg ctg cag ctg tat gcc agt atg ctg cat gaa agg cgc atc gtg att 576 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 atc tcg agc aaa tta agc act tta act gcc tgt atc cat gga tca gct 624 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 gct ctt cta tac cca atg tat tgg caa cac ata tac atc cca gtg ctt 672 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 cct cca cac ctg ctg gac tac tgc tgt gcc cca atg cca tac ctg att 720 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 gga ata cac tcc agc ctc ata gag aga gtg aaa aac aaa tca ttg gaa 768 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 gat gtt gtt atg tta aat gtt gat aca aac aca tta gaa tca cca ttt 816 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 agt gac ttg aac aac cta cca agt gat gtg gtc tcg gcc ttg aaa aat 864 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 aaa ctg aag aag cag tct aca gct acg ggt gat gga gta gct agg gcc 912 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 ttt ctt aga gca cag gct gct ttg ttt gga tcc tac aga gat gca ctg 960 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 aga tac aaa cct ggt gag ccc atc act ttc tgt gag gag agt ttt gta 1008 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 aag cac cgc tca agc gtg atg aaa cag ttc ctg gaa

act gcc att aac 1056 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 ctc cag ctt ttt aag cag ttt atc gat ggt cga ctg gca aaa cta aat 1104 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 gca gga agg ggt ttc tct gat gta ttt gaa gaa gag atc act tca ggt 1152 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 ggc ttt tgt gga ggg aac ccg agg tca tat caa caa tgg gtg cat aca 1200 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 gtc aag aaa gga ggt gca ctg ttc aac aca gca atg acc aaa gca acc 1248 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 cct gct gta cgg aca gca tat aaa ttt gca aaa aat cat gca aag ctg 1296 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 gga cta aag gaa gtg aag agt aaa cta aaa cac aag gaa aat gaa gaa 1344 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 gat tat ggg acc tgt tct agt tct gta caa tat aca cca gtt tac aaa 1392 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 tta cac aat gaa aag gga gga aac tca gaa aag cgt aag ctt gct cag 1440 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 gca cgc tta aaa agg cct ctt aag agc ctt gat ggt gct cta tat gat 1488 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 gat gaa gat gat gat gac att gaa aga gca agc aag tta tct tct gaa 1536 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 gat ggt gaa gaa gct tct gct tat ctc tat gag agt gat gac tct gtt 1584 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 gaa aca aga gtg aag act cct tac tca ggt gaa atg gac tta cta gga 1632 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 gag att ctt gat aca ttg agc aca cac agc tca gat cag ggg aag ctg 1680 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu 545 550 555 560 gca gct gca aag agc ttg gat ttc ttt aga tca atg gat gac att gat 1728 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 tac aaa cct acg aat aaa tct aat gct cct agt gag aat aac ctg gct 1776 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 ttc ctc tgt ggt ggt tct ggt gac caa gca gag tgg aat ctt ggg caa 1824 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 gac gat agt gcc ctc cat ggc aaa cac ctc cct cca tct cct agg aag 1872 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 cgg gtt tcc tct agt ggt ttg aca gat tct ctg ttt atc ctg aaa gag 1920 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 gaa aac agt aac aag cac ctc ggt gct gac aat gtg agt gac cct act 1968 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 tca gga ctg gat ttc caa ctc act tcc cct gaa gtt tcc cag act gat 2016 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 aaa gga aaa aca gaa aag agg gaa aca cta agc cag att tca gat gat 2064 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 ctg ctt ata ccc ggt ctt ggg cgg cat tca tcg act ttt gtt cct tgg 2112 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 gag aaa gaa ggg aaa gaa gcc aaa gag act tca gaa gat att gga ctg 2160 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 ctc cat gaa gta gtg tca tta tgt cat atg aca tct gac ttc caa caa 2208 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 agc ttg aac att tca gac aaa aac aca aat gga aac caa act aga tct 2256 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 68 752 PRT Homo sapiens 68 Arg Ser Asp Pro Val Val Leu Trp Lys Phe Pro Glu Asp Phe Gly Asp 1 5 10 15 Gln Glu Ile Leu Gln Ser Val Pro Lys Phe Cys Phe Pro Phe Asp Val 20 25 30 Glu Arg Val Ser Gln Asn Gln Val Gly Gln His Phe Thr Phe Val Leu 35 40 45 Thr Asp Ile Glu Ser Lys Gln Arg Phe Gly Phe Cys Arg Leu Thr Ser 50 55 60 Gly Gly Thr Ile Cys Leu Cys Ile Leu Ser Tyr Leu Pro Trp Phe Glu 65 70 75 80 Val Tyr Tyr Lys Leu Leu Asn Thr Leu Ala Asp Tyr Leu Ala Lys Glu 85 90 95 Leu Glu Asn Asp Leu Asn Glu Thr Leu Arg Ser Leu Tyr Asn His Pro 100 105 110 Val Pro Lys Ala Asn Thr Pro Val Asn Leu Ser Val Asn Gln Glu Ile 115 120 125 Phe Ile Ala Cys Glu Gln Val Leu Lys Asp Gln Pro Ala Leu Val Pro 130 135 140 His Ser Tyr Phe Ile Ala Pro Asp Val Thr Gly Leu Pro Thr Ile Pro 145 150 155 160 Glu Ser Arg Asn Leu Thr Glu Tyr Phe Val Ala Val Asp Val Asn Asn 165 170 175 Met Leu Gln Leu Tyr Ala Ser Met Leu His Glu Arg Arg Ile Val Ile 180 185 190 Ile Ser Ser Lys Leu Ser Thr Leu Thr Ala Cys Ile His Gly Ser Ala 195 200 205 Ala Leu Leu Tyr Pro Met Tyr Trp Gln His Ile Tyr Ile Pro Val Leu 210 215 220 Pro Pro His Leu Leu Asp Tyr Cys Cys Ala Pro Met Pro Tyr Leu Ile 225 230 235 240 Gly Ile His Ser Ser Leu Ile Glu Arg Val Lys Asn Lys Ser Leu Glu 245 250 255 Asp Val Val Met Leu Asn Val Asp Thr Asn Thr Leu Glu Ser Pro Phe 260 265 270 Ser Asp Leu Asn Asn Leu Pro Ser Asp Val Val Ser Ala Leu Lys Asn 275 280 285 Lys Leu Lys Lys Gln Ser Thr Ala Thr Gly Asp Gly Val Ala Arg Ala 290 295 300 Phe Leu Arg Ala Gln Ala Ala Leu Phe Gly Ser Tyr Arg Asp Ala Leu 305 310 315 320 Arg Tyr Lys Pro Gly Glu Pro Ile Thr Phe Cys Glu Glu Ser Phe Val 325 330 335 Lys His Arg Ser Ser Val Met Lys Gln Phe Leu Glu Thr Ala Ile Asn 340 345 350 Leu Gln Leu Phe Lys Gln Phe Ile Asp Gly Arg Leu Ala Lys Leu Asn 355 360 365 Ala Gly Arg Gly Phe Ser Asp Val Phe Glu Glu Glu Ile Thr Ser Gly 370 375 380 Gly Phe Cys Gly Gly Asn Pro Arg Ser Tyr Gln Gln Trp Val His Thr 385 390 395 400 Val Lys Lys Gly Gly Ala Leu Phe Asn Thr Ala Met Thr Lys Ala Thr 405 410 415 Pro Ala Val Arg Thr Ala Tyr Lys Phe Ala Lys Asn His Ala Lys Leu 420 425 430 Gly Leu Lys Glu Val Lys Ser Lys Leu Lys His Lys Glu Asn Glu Glu 435 440 445 Asp Tyr Gly Thr Cys Ser Ser Ser Val Gln Tyr Thr Pro Val Tyr Lys 450 455 460 Leu His Asn Glu Lys Gly Gly Asn Ser Glu Lys Arg Lys Leu Ala Gln 465 470 475 480 Ala Arg Leu Lys Arg Pro Leu Lys Ser Leu Asp Gly Ala Leu Tyr Asp 485 490 495 Asp Glu Asp Asp Asp Asp Ile Glu Arg Ala Ser Lys Leu Ser Ser Glu 500 505 510 Asp Gly Glu Glu Ala Ser Ala Tyr Leu Tyr Glu Ser Asp Asp Ser Val 515 520 525 Glu Thr Arg Val Lys Thr Pro Tyr Ser Gly Glu Met Asp Leu Leu Gly 530 535 540 Glu Ile Leu Asp Thr Leu Ser Thr His Ser Ser Asp Gln Gly Lys Leu 545 550 555 560 Ala Ala Ala Lys Ser Leu Asp Phe Phe Arg Ser Met Asp Asp Ile Asp 565 570 575 Tyr Lys Pro Thr Asn Lys Ser Asn Ala Pro Ser Glu Asn Asn Leu Ala 580 585 590 Phe Leu Cys Gly Gly Ser Gly Asp Gln Ala Glu Trp Asn Leu Gly Gln 595 600 605 Asp Asp Ser Ala Leu His Gly Lys His Leu Pro Pro Ser Pro Arg Lys 610 615 620 Arg Val Ser Ser Ser Gly Leu Thr Asp Ser Leu Phe Ile Leu Lys Glu 625 630 635 640 Glu Asn Ser Asn Lys His Leu Gly Ala Asp Asn Val Ser Asp Pro Thr 645 650 655 Ser Gly Leu Asp Phe Gln Leu Thr Ser Pro Glu Val Ser Gln Thr Asp 660 665 670 Lys Gly Lys Thr Glu Lys Arg Glu Thr Leu Ser Gln Ile Ser Asp Asp 675 680 685 Leu Leu Ile Pro Gly Leu Gly Arg His Ser Ser Thr Phe Val Pro Trp 690 695 700 Glu Lys Glu Gly Lys Glu Ala Lys Glu Thr Ser Glu Asp Ile Gly Leu 705 710 715 720 Leu His Glu Val Val Ser Leu Cys His Met Thr Ser Asp Phe Gln Gln 725 730 735 Ser Leu Asn Ile Ser Asp Lys Asn Thr Asn Gly Asn Gln Thr Arg Ser 740 745 750 69 1357 DNA Homo sapiens CDS (1)..(1195) 69 atg aaa cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt 48 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 tta acc cag gaa tca cag tcc gag gaa att gat gac tgc aat gac aag 96 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 gat tta ttt aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa 144 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 aac caa agt aac aac cag ttt gta ttg tac cgc aaa acc tgg cag gac 192 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 tgt gag tac aag gat gct gca aaa gca gcc act gga gaa tgc aca gca 240 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 acc gtg ggg aag agg agc agt acg aaa ttc tcc gtg gct acc cag acc 288 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 tgc cag att act cca gcc gag ggc cct gtg gtg aca gcc cag tac gac 336 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 tgc ctc ggc tgt gtg cat cct ata tca acg cag agc cca gac ctg gag 384 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu 115 120 125 ccc att ctg aga cac ggc att cag tac ttt aac aac aac act caa cat 432 Pro Ile Leu Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His 130 135 140 tcc tcc ctc ttc acg ctt aat gaa gta aaa cgg gcc caa aga cag gtg 480 Ser Ser Leu Phe Thr Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val 145 150 155 160 gtg gct gga ttg aac ttt cga att acc tac tca att gtg caa acg aat 528 Val Ala Gly Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn 165 170 175 tgt tcc aaa gag aat ttt ctg ttc tta act cca gac tgc aag tcc ctt 576 Cys Ser Lys Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu 180 185 190 tgg aat ggt gat acc ggt gaa tgt aca gat aat gca tac atc gat att 624 Trp Asn Gly Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile 195 200 205 cag cta cga att gct tcc ttc tca cag aac tgt gac att tat cca ggg 672 Gln Leu Arg Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly 210 215 220 aag gat ttt gta caa cca cct acc aag att tgc gtg ggc tgc ccc aga 720 Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg 225 230 235 240 gat ata ccc acc aac agc cca gag ctg gag gag aca ctg act cac acc 768 Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 245 250 255 atc aca aag ctt aat gca gag aat aac gca act ttc tat ttc aag att 816 Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile 260 265 270 gac aat gtg aaa aaa gca aga gta cag gtg gtg gct ggc aag aaa tat 864 Asp Asn Val Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr 275 280 285 ttt att gac ttc gtg gcc agg gaa acc aca tgt tcc aag gaa agt aat 912 Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn 290 295 300 gaa gag ttg acc gaa agc tgt gag acc aaa aaa ctt ggc caa agc cta 960 Glu Glu Leu Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu 305 310 315 320 gat tgc aac gct gaa gtt tat gtg gta ccc tgg gag aaa aaa att tac 1008 Asp Cys Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr 325 330 335 cct act gtc aac tgt caa cca ctg gga atg atc tca ctg atg aaa agg 1056 Pro Thr Val Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg 340 345 350 cct cca ggt ttt tca cct ttc cga tca tca cga ata ggg gaa ata aaa 1104 Pro Pro Gly Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys 355 360 365 gaa gaa aca act agt cac cta agg tcc tgc gag tac aag ggt cga ccc 1152 Glu Glu Thr Thr Ser His Leu Arg Ser Cys Glu Tyr Lys Gly Arg Pro 370 375 380 cca aag gca ggg gca gag cca gca tct gag agg gag gtc tct 1194 Pro Lys Ala Gly Ala Glu Pro Ala Ser Glu Arg Glu Val Ser 385 390 395 tgaccaatgg gcagaatctt cactccaggc acatagcccc aaccacctct 1244 gccagcaacc ttgagaggaa ggacaagaag aaagatggga tagaatttaa 1294 atagagaaga atgccatttt atcactctgc ctctgggtga aataaagatc 1344 agtcttgatg ttc 1357 70 398 PRT Homo sapiens 70 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu 115 120 125 Pro Ile Leu Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His 130 135 140 Ser Ser Leu Phe Thr Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val 145 150 155 160 Val Ala Gly Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn 165 170 175 Cys Ser Lys Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu 180 185 190 Trp Asn Gly Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile 195 200 205 Gln Leu Arg Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly 210 215 220 Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg 225 230 235 240 Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 245 250 255 Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile 260 265 270 Asp Asn Val Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr 275 280 285 Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn 290 295 300 Glu Glu Leu Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu 305 310 315 320 Asp Cys Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr 325 330 335 Pro

Thr Val Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg 340 345 350 Pro Pro Gly Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys 355 360 365 Glu Glu Thr Thr Ser His Leu Arg Ser Cys Glu Tyr Lys Gly Arg Pro 370 375 380 Pro Lys Ala Gly Ala Glu Pro Ala Ser Glu Arg Glu Val Ser 385 390 395 71 1848 DNA Homo sapiens CDS (1)..(1846) 71 atg aaa cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt 48 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 tta acc cag gaa tca cag tcc gag gaa att gat gac tgc aat gac aag 96 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 gat tta ttt aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa 144 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 aac caa agt aac aac cag ttt gta ttg tac cgc aaa acc tgg cag gac 192 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 tgt gag tac aag gat gct gca aaa gca gcc act gga gaa tgc aca gca 240 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 acc gtg ggg aag agg agc agt acg aaa ttc tcc gtg gct acc cag acc 288 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 tgc cag att act cca gcc gag ggc cct gtg gtg aca gcc cag tac gac 336 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 tgc ctc ggc tgt gtg cat cct ata tca acg cag agc cca gac ctg gag 384 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu 115 120 125 ccc att ctg aga cac ggc att cag tac ttt aac aac aac act caa cat 432 Pro Ile Leu Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His 130 135 140 tcc tcc ctc ttc acg ctt aat gaa gta aaa cgg gcc caa aga cag gtg 480 Ser Ser Leu Phe Thr Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val 145 150 155 160 gtg gct gga ttg aac ttt cga att acc tac tca att gtg caa acg aat 528 Val Ala Gly Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn 165 170 175 tgt tcc aaa gag aat ttt ctg ttc tta act cca gac tgc aag tcc ctt 576 Cys Ser Lys Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu 180 185 190 tgg aat ggt gat acc ggt gaa tgt aca gat aat gca tac atc gat att 624 Trp Asn Gly Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile 195 200 205 cag cta cga att gct tcc ttc tca cag aac tgt gac att tat cca ggg 672 Gln Leu Arg Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly 210 215 220 aag gat ttt gta caa cca cct acc aag att tgc gtg ggc tgc ccc aga 720 Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg 225 230 235 240 gat ata ccc acc aac agc cca gag ctg gag gag aca ctg act cac acc 768 Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 245 250 255 atc aca aag ctt aat gca gag aat aac gca act ttc tat ttc aag att 816 Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile 260 265 270 gac aat gtg aaa aaa gca aga gta cag gtg gtg gct ggc aag aaa tat 864 Asp Asn Val Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr 275 280 285 ttt att gac ttc gtg gcc agg gaa acc aca tgt tcc aag gaa agt aat 912 Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn 290 295 300 gaa gag ttg acc gaa agc tgt gag acc aaa aaa ctt ggc caa agc cta 960 Glu Glu Leu Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu 305 310 315 320 gat tgc aac gct gaa gtt tat gtg gta ccc tgg gag aaa aaa att tac 1008 Asp Cys Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr 325 330 335 cct act gtc aac tgt caa cca ctg gga atg atc tca ctg atg aaa agg 1056 Pro Thr Val Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg 340 345 350 cct cca ggt ttt tca cct ttc cga tca tca cga ata ggg gaa ata aaa 1104 Pro Pro Gly Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys 355 360 365 gaa gaa aca act gta agt cca ccc cac act tcc atg gca cct gca caa 1152 Glu Glu Thr Thr Val Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln 370 375 380 gat gaa gag cgg gat tca gga aaa gaa caa ggg cat act cgt aga cat 1200 Asp Glu Glu Arg Asp Ser Gly Lys Glu Gln Gly His Thr Arg Arg His 385 390 395 400 gac tgg ggc cat gaa aaa caa aga aaa cat aat ctt ggc cat ggc cat 1248 Asp Trp Gly His Glu Lys Gln Arg Lys His Asn Leu Gly His Gly His 405 410 415 aaa cat gaa cgt gac caa ggg cat ggg cac caa aga gga cat ggc ctt 1296 Lys His Glu Arg Asp Gln Gly His Gly His Gln Arg Gly His Gly Leu 420 425 430 ggc cat gga cac gaa caa cag cat ggt ctt ggt cat gga cat aag ttc 1344 Gly His Gly His Glu Gln Gln His Gly Leu Gly His Gly His Lys Phe 435 440 445 aaa ctt gat gat gat ctt gaa cac caa ggg ggc cat gtc ctt gac cat 1392 Lys Leu Asp Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His 450 455 460 gga cat aag cat aag cat ggt cat ggc cac gga aaa cat aaa aat aaa 1440 Gly His Lys His Lys His Gly His Gly His Gly Lys His Lys Asn Lys 465 470 475 480 ggc aaa aag aat gga aag cac aat ggt tgg aaa aca gag cat ttg gca 1488 Gly Lys Lys Asn Gly Lys His Asn Gly Trp Lys Thr Glu His Leu Ala 485 490 495 agc tct tct gaa gac agt act aca cct tct gca cag aca caa gag aag 1536 Ser Ser Ser Glu Asp Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys 500 505 510 aca gaa ggg cca aca ccc atc cct tcc cta gcc aag cca ggt gta aca 1584 Thr Glu Gly Pro Thr Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr 515 520 525 gtt acc ttt tct gac ttt cag gac tct gat ctc att gca act atg atg 1632 Val Thr Phe Ser Asp Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met 530 535 540 cct cct ata tca cca gct ccc ata cag agt gat gac gat tgg atc cct 1680 Pro Pro Ile Ser Pro Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro 545 550 555 560 gat atc cag aca gac cca aat ggc ctt tca ttt aac cca ata tca gat 1728 Asp Ile Gln Thr Asp Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp 565 570 575 ttt cca gac acg acc tcc cca aaa tgt cct gga cgc ccc tgg aag tca 1776 Phe Pro Asp Thr Thr Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser 580 585 590 gtt agt gaa att aat cca acc aca caa atg aaa gaa tct tat tat ttc 1824 Val Ser Glu Ile Asn Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe 595 600 605 gat ctc act gat ggc ctt tct taa 1848 Asp Leu Thr Asp Gly Leu Ser 610 615 72 615 PRT Homo sapiens 72 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu 115 120 125 Pro Ile Leu Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His 130 135 140 Ser Ser Leu Phe Thr Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val 145 150 155 160 Val Ala Gly Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn 165 170 175 Cys Ser Lys Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu 180 185 190 Trp Asn Gly Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile 195 200 205 Gln Leu Arg Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly 210 215 220 Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg 225 230 235 240 Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 245 250 255 Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile 260 265 270 Asp Asn Val Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr 275 280 285 Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn 290 295 300 Glu Glu Leu Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu 305 310 315 320 Asp Cys Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr 325 330 335 Pro Thr Val Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg 340 345 350 Pro Pro Gly Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys 355 360 365 Glu Glu Thr Thr Val Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln 370 375 380 Asp Glu Glu Arg Asp Ser Gly Lys Glu Gln Gly His Thr Arg Arg His 385 390 395 400 Asp Trp Gly His Glu Lys Gln Arg Lys His Asn Leu Gly His Gly His 405 410 415 Lys His Glu Arg Asp Gln Gly His Gly His Gln Arg Gly His Gly Leu 420 425 430 Gly His Gly His Glu Gln Gln His Gly Leu Gly His Gly His Lys Phe 435 440 445 Lys Leu Asp Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His 450 455 460 Gly His Lys His Lys His Gly His Gly His Gly Lys His Lys Asn Lys 465 470 475 480 Gly Lys Lys Asn Gly Lys His Asn Gly Trp Lys Thr Glu His Leu Ala 485 490 495 Ser Ser Ser Glu Asp Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys 500 505 510 Thr Glu Gly Pro Thr Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr 515 520 525 Val Thr Phe Ser Asp Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met 530 535 540 Pro Pro Ile Ser Pro Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro 545 550 555 560 Asp Ile Gln Thr Asp Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp 565 570 575 Phe Pro Asp Thr Thr Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser 580 585 590 Val Ser Glu Ile Asn Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe 595 600 605 Asp Leu Thr Asp Gly Leu Ser 610 615 73 1981 DNA Homo sapiens CDS (50)..(1981) 73 aattccggtt gaaaccatcc ctcagctcct agagggagat tgttagatc atg aaa 55 Met Lys 1 cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt tta acc 103 Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser Leu Thr 5 10 15 cag gaa tca cag tcc gag gaa att gac tgc aat gac aag gat tta ttt 151 Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp Leu Phe 20 25 30 aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa aac caa agt 199 Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn Gln Ser 35 40 45 50 aac aac cag ttt gta ttg tac cgc ata act gaa gcc act aag acg gtt 247 Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys Thr Val 55 60 65 ggc tct gac acg ttt tat tcc ttc aag tac gaa atc aag gag ggg gat 295 Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu Gly Asp 70 75 80 tgt cct gtt caa agt ggc aaa acc tgg cag gac tgt gag tac aag gat 343 Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr Lys Asp 85 90 95 gct gca aaa gca gcc act gga gaa tgc acg gca acc gtg ggg aag agg 391 Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Lys Arg 100 105 110 agc agt acg aaa ttc tcc gtg gct acc cag acc tgc cag att act cca 439 Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile Thr Pro 115 120 125 130 gcc gag ggc cct gtg gtg aca gcc cag tac gac tgc ctc ggc tgt gtg 487 Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly Cys Val 135 140 145 cat cct ata tca acg cag agc cca gac ctg gag ccc att ctg aga cac 535 His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu Arg His 150 155 160 ggc att cag tac ttt aac aac aac act caa cat tcc tcc ctc ttc atg 583 Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu Phe Met 165 170 175 ctt aat gaa gta aaa cgg gcc caa aga cag gtg gtg gct gga ttg aac 631 Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly Leu Asn 180 185 190 ttt cga att acc tac tca att gtg caa acg aat tgt tcc aaa gag aat 679 Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys Glu Asn 195 200 205 210 ttt ctg ttc tta act cca gac tgc aag tcc ctt tgg aat ggt gat acc 727 Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu Trp Asn Gly Asp Thr 215 220 225 ggt gaa tgt aca gat aat gca tac atc gat att cag cta cga att gct 775 Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg Ile Ala 230 235 240 tcc ttc tca cag aac tgt gac att tat cca ggg aag gat ttt gta caa 823 Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe Val Gln 245 250 255 cca cct acc aag att tgc gtg ggc tgc ccc aga gat ata ccc acc aac 871 Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro Thr Asn 260 265 270 agc cca gag ctg gag gag aca ctg act cac acc atc aca aag ctt aat 919 Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys Leu Asn 275 280 285 290 gca gag aat aac gca act ttc tat ttc aag att gac aat gtg aaa aaa 967 Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val Lys Lys 295 300 305 gca aga gta cag gtg gtg gct ggc aag aaa tat ttt att gac ttc gtg 1015 Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp Phe Val 310 315 320 gcc agg gaa acc aca tgt tcc aag gaa agt aat gaa gag ttg acc gaa 1063 Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu Thr Glu 325 330 335 agc tgt gag acc aaa aaa ctt ggc caa agc cta gat tgc aac gct gaa 1111 Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn Ala Glu 340 345 350 gtt tat gtg gta ccc tgg gag aaa aaa att tac cct act gtc aac tgt 1159 Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val Asn Cys 355 360 365 370 caa cca ctg gga atg atc tca ctg atg aaa agg cct cca ggt ttt tca 1207 Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly Phe Ser 375 380 385 cct ttc cga tca tca cga ata ggg gaa ata aaa gaa gaa aca act gta 1255 Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Val 390 395 400 agt cca ccc cac act tcc atg gca cct gca caa gat gaa gag cgg gat 1303 Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln Asp Glu Glu Arg Asp 405 410 415 tca gga aaa gaa caa ggg cat act cgt aga cat gac tgg ggc cat gaa 1351 Ser Gly Lys Glu Gln Gly His Thr Arg Arg His Asp Trp Gly His Glu 420 425 430 aaa caa aga aaa cat aat ctt ggc cat ggc cat aaa cat gaa cgt gac 1399 Lys Gln Arg Lys His Asn Leu Gly His Gly His Lys His Glu Arg Asp 435 440 445 450 caa ggg cat ggg cac caa aga gga cat ggc ctt ggc cat gga cac gaa 1447 Gln Gly His Gly His Gln Arg Gly His Gly Leu Gly His Gly

His Glu 455 460 465 caa cag cat ggt ctt ggt cat gga cat aag ttc aaa ctt gat gat gat 1495 Gln Gln His Gly Leu Gly His Gly His Lys Phe Lys Leu Asp Asp Asp 470 475 480 ctt gaa cac caa ggg ggc cat gtc ctt gac cat gga cat aag cat aag 1543 Leu Glu His Gln Gly Gly His Val Leu Asp His Gly His Lys His Lys 485 490 495 cat ggt cat ggc cac gga aaa cat aaa aat aaa ggc aaa aag aat gga 1591 His Gly His Gly His Gly Lys His Lys Asn Lys Gly Lys Lys Asn Gly 500 505 510 aag cac aat ggt tgg aaa aca gag cat ttg gca agc tct tct gaa gac 1639 Lys His Asn Gly Trp Lys Thr Glu His Leu Ala Ser Ser Ser Glu Asp 515 520 525 530 agt act aca cct tct gca cag aca caa gag aag aca gaa ggg cca aca 1687 Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys Thr Glu Gly Pro Thr 535 540 545 ccc atc cct tcc cta gcc aag cca ggt gta aca gtt acc ttt tct gac 1735 Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr Val Thr Phe Ser Asp 550 555 560 ttt cag gac tct gat ctc att gca act atg atg cct cct ata tca cca 1783 Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile Ser Pro 565 570 575 gct ccc ata cag agt gat gac gat tgg atc cct gat atc cag ata gac 1831 Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln Ile Asp 580 585 590 cca aat ggc ctt tca ttt aac cca ata tca gat ttt cca gac acg acc 1879 Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp Thr Thr 595 600 605 610 tcc cca aaa tgt cct gga cgc ccc tgg aag tca gtt agt gaa att aat 1927 Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu Ile Asn 615 620 625 cca acc aca caa atg aaa gaa tct tat tat ttc gat ctc act gat ggc 1975 Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe Asp Leu Thr Asp Gly 630 635 640 ctt tct 1981 Leu Ser 74 644 PRT Homo sapiens 74 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 Thr Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu 65 70 75 80 Gly Asp Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr 85 90 95 Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly 100 105 110 Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile 115 120 125 Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly 130 135 140 Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu 145 150 155 160 Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu 165 170 175 Phe Met Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly 180 185 190 Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys 195 200 205 Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu Trp Asn Gly 210 215 220 Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg 225 230 235 240 Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe 245 250 255 Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro 260 265 270 Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys 275 280 285 Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val 290 295 300 Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp 305 310 315 320 Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu 325 330 335 Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn 340 345 350 Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val 355 360 365 Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly 370 375 380 Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr 385 390 395 400 Thr Val Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln Asp Glu Glu 405 410 415 Arg Asp Ser Gly Lys Glu Gln Gly His Thr Arg Arg His Asp Trp Gly 420 425 430 His Glu Lys Gln Arg Lys His Asn Leu Gly His Gly His Lys His Glu 435 440 445 Arg Asp Gln Gly His Gly His Gln Arg Gly His Gly Leu Gly His Gly 450 455 460 His Glu Gln Gln His Gly Leu Gly His Gly His Lys Phe Lys Leu Asp 465 470 475 480 Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His Gly His Lys 485 490 495 His Lys His Gly His Gly His Gly Lys His Lys Asn Lys Gly Lys Lys 500 505 510 Asn Gly Lys His Asn Gly Trp Lys Thr Glu His Leu Ala Ser Ser Ser 515 520 525 Glu Asp Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys Thr Glu Gly 530 535 540 Pro Thr Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr Val Thr Phe 545 550 555 560 Ser Asp Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile 565 570 575 Ser Pro Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln 580 585 590 Ile Asp Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp 595 600 605 Thr Thr Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu 610 615 620 Ile Asn Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe Asp Leu Thr 625 630 635 640 Asp Gly Leu Ser 75 1297 DNA Homo sapiens CDS (50)..(1295) 75 aattccggtt gaaaccatcc ctcagctcct agagggagat tgttagatc atg aaa 55 Met Lys 1 cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt tta acc 103 Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser Leu Thr 5 10 15 cag gaa tca cag tcc gag gaa att gac tgc aat gac aag gat tta ttt 151 Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp Leu Phe 20 25 30 aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa aac caa agt 199 Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn Gln Ser 35 40 45 50 aac aac cag ttt gta ttg tac cgc ata act gaa gcc act aag acg gtt 247 Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys Thr Val 55 60 65 ggc tct gac acg ttt tat tcc ttc aag tac gaa atc aag gag ggg gat 295 Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu Gly Asp 70 75 80 tgt cct gtt caa agt ggc aaa acc tgg cag gac tgt gag tac aag gat 343 Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr Lys Asp 85 90 95 gct gca aaa gca gcc act gga gaa tgc aca gca acc gtg ggg aag agg 391 Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Lys Arg 100 105 110 agc agt acg aaa ttc tcc gtg gct acc cag acc tgc cag att act cca 439 Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile Thr Pro 115 120 125 130 gcc gag ggc cct gtg gtg aca gcc cag tac gac tgc ctc ggc tgt gtg 487 Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly Cys Val 135 140 145 cat cct ata tca acg cag agc cca ggt ttt tca cct ttc cga tca tca 535 His Pro Ile Ser Thr Gln Ser Pro Gly Phe Ser Pro Phe Arg Ser Ser 150 155 160 cga ata ggg gaa ata aaa gaa gaa aca act gta agt cca ccc cac act 583 Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Val Ser Pro Pro His Thr 165 170 175 tcc atg gca cct gca caa gat gaa gag cgg gat tca gga aaa gaa caa 631 Ser Met Ala Pro Ala Gln Asp Glu Glu Arg Asp Ser Gly Lys Glu Gln 180 185 190 ggg cat act cgt aga cat gac tgg ggc cat gaa aaa caa aga aaa cat 679 Gly His Thr Arg Arg His Asp Trp Gly His Glu Lys Gln Arg Lys His 195 200 205 210 aat ctt ggc cat ggc cat aaa cat gaa cgt gac caa ggg cat ggg cac 727 Asn Leu Gly His Gly His Lys His Glu Arg Asp Gln Gly His Gly His 215 220 225 caa aga gga cat ggc ctt ggc cat gga cac gaa caa cag cat ggt ctt 775 Gln Arg Gly His Gly Leu Gly His Gly His Glu Gln Gln His Gly Leu 230 235 240 ggt cat gga cat aag ttc aaa ctt gat gat gat ctt gaa cac caa ggg 823 Gly His Gly His Lys Phe Lys Leu Asp Asp Asp Leu Glu His Gln Gly 245 250 255 ggc cat gtc ctt gac cat gga cat aag cat aag cat ggt cat ggc cac 871 Gly His Val Leu Asp His Gly His Lys His Lys His Gly His Gly His 260 265 270 gga aaa cat aaa aat aaa ggc aaa aag aat gga aag cac aat ggt tgg 919 Gly Lys His Lys Asn Lys Gly Lys Lys Asn Gly Lys His Asn Gly Trp 275 280 285 290 aaa aca gag cat ttg gca agc tct tct gaa gac agt act aca cct tct 967 Lys Thr Glu His Leu Ala Ser Ser Ser Glu Asp Ser Thr Thr Pro Ser 295 300 305 gca cag aca caa gag aag aca gaa ggg cca aca ccc atc cct tcc cta 1015 Ala Gln Thr Gln Glu Lys Thr Glu Gly Pro Thr Pro Ile Pro Ser Leu 310 315 320 gcc aag cca ggt gta aca gtt acc ttt tct gac ttt cag gac tct gat 1063 Ala Lys Pro Gly Val Thr Val Thr Phe Ser Asp Phe Gln Asp Ser Asp 325 330 335 ctc att gca act atg atg cct cct ata tca cca gct ccc ata cag agt 1111 Leu Ile Ala Thr Met Met Pro Pro Ile Ser Pro Ala Pro Ile Gln Ser 340 345 350 gat gac gat tgg atc cct gat atc cag ata gac cca aat ggc ctt tca 1159 Asp Asp Asp Trp Ile Pro Asp Ile Gln Ile Asp Pro Asn Gly Leu Ser 355 360 365 370 ttt aac cca ata tca gat ttt cca gac acg acc tcc cca aaa tgt cct 1207 Phe Asn Pro Ile Ser Asp Phe Pro Asp Thr Thr Ser Pro Lys Cys Pro 375 380 385 gga cgc ccc tgg aag tca gtt agt gaa att aat cca acc aca caa atg 1255 Gly Arg Pro Trp Lys Ser Val Ser Glu Ile Asn Pro Thr Thr Gln Met 390 395 400 aaa gaa tct tat tat ttc gat ctc act gat ggc ctt tct taa 1297 Lys Glu Ser Tyr Tyr Phe Asp Leu Thr Asp Gly Leu Ser 405 410 415 76 415 PRT Homo sapiens 76 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 Thr Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu 65 70 75 80 Gly Asp Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr 85 90 95 Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly 100 105 110 Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile 115 120 125 Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly 130 135 140 Cys Val His Pro Ile Ser Thr Gln Ser Pro Gly Phe Ser Pro Phe Arg 145 150 155 160 Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Val Ser Pro Pro 165 170 175 His Thr Ser Met Ala Pro Ala Gln Asp Glu Glu Arg Asp Ser Gly Lys 180 185 190 Glu Gln Gly His Thr Arg Arg His Asp Trp Gly His Glu Lys Gln Arg 195 200 205 Lys His Asn Leu Gly His Gly His Lys His Glu Arg Asp Gln Gly His 210 215 220 Gly His Gln Arg Gly His Gly Leu Gly His Gly His Glu Gln Gln His 225 230 235 240 Gly Leu Gly His Gly His Lys Phe Lys Leu Asp Asp Asp Leu Glu His 245 250 255 Gln Gly Gly His Val Leu Asp His Gly His Lys His Lys His Gly His 260 265 270 Gly His Gly Lys His Lys Asn Lys Gly Lys Lys Asn Gly Lys His Asn 275 280 285 Gly Trp Lys Thr Glu His Leu Ala Ser Ser Ser Glu Asp Ser Thr Thr 290 295 300 Pro Ser Ala Gln Thr Gln Glu Lys Thr Glu Gly Pro Thr Pro Ile Pro 305 310 315 320 Ser Leu Ala Lys Pro Gly Val Thr Val Thr Phe Ser Asp Phe Gln Asp 325 330 335 Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile Ser Pro Ala Pro Ile 340 345 350 Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln Ile Asp Pro Asn Gly 355 360 365 Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp Thr Thr Ser Pro Lys 370 375 380 Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu Ile Asn Pro Thr Thr 385 390 395 400 Gln Met Lys Glu Ser Tyr Tyr Phe Asp Leu Thr Asp Gly Leu Ser 405 410 415 77 1892 DNA Homo sapiens CDS (50)..(458) 77 aattccggtt gaaaccatcc ctcagctcct agagggagat tgttagatc atg aaa 55 Met Lys 1 cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt tta acc 103 Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser Leu Thr 5 10 15 cag gaa tca cag tcc gag gaa att gac tgc aat gac aag gat tta ttt 151 Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp Leu Phe 20 25 30 aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa aac caa agt 199 Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn Gln Ser 35 40 45 50 aac aac cag ttt gta ttg tac cgc ata act gaa gcc act aag acg gtt 247 Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys Thr Val 55 60 65 ggc tct gac acg ttt tat tcc ttc aag tac gaa atc aag gag ggg gat 295 Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu Gly Asp 70 75 80 tgt cct gtt caa agt ggc aaa acc tgg cag gac tgt gag tac aag gat 343 Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr Lys Asp 85 90 95 gct gca aaa gca gcc act gga gaa tgc aca gca acc gtg gga aga gga 391 Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Arg Gly 100 105 110 gca gta cga aat tct ccg tgg cta ccc aga cct gga gcc cat tct gag 439 Ala Val Arg Asn Ser Pro Trp Leu Pro Arg Pro Gly Ala His Ser Glu 115 120 125 130 aca cgg cat tca gta ctt taacaacaac actcaacatt cctccctctt 487 Thr Arg His Ser Val Leu 135 cacgcttaat gaagtaaaac gggcccaaag acaggtggtg gctggattga 537 actttcgaat tacctactca attgtgcaaa cgaattgttc caaagagaat 587 tttctgttct taactccaga ctgcaagtcc ctttggaatg gtgataccgg 637 tgaatgtaca gataatgcat acatcgatat tcagctacga attgcttcct 687 tctcacagaa ctgtgacatt tatccaggga aggattttgt acaaccacct 737 accaagattt gcgtgggctg ccccagagat atacccacca acagcccaga 787 gctggaggag acactgactc acaccatcac aaagcttaat gcagagaata 837 acgcaacttt ctatttcaag attgacaatg tgaaaaaagc aagagtacag 887 gtggtggctg gcaagaaata ttttattgac ttcgtggcca gggaaaccac 937 atgttccaag gaaagtaatg aagagttgac cgaaagctgt gagaccaaaa 987 aacttggcca aagcctagat tgcaacgctg aagtttatgt ggtaccctgg 1037 gagaaaaaaa tttaccctac tgtcaactgt caaccactgg gaatgatctc 1087 actgatgaaa aggcctccag gtttttcacc tttccgatca tcacgaatag 1137

gggaaataaa agaagaaaca actgtaagtc caccccacac ttccatggca 1187 cctgcacaag atgaagagcg ggattcagga aaagaacaag ggcatactcg 1237 tagacatgac tggggccatg aaaaacaaag aaaacataat cttggccatg 1287 gccataaaca tgaacgtgac caagggcatg ggcaccaaag aggacatggc 1337 cttggccatg gacacgaaca acagcatggt cttggtcatg gacataagtt 1387 caaacttgat gatgatcttg aacaccaagg gggccatgtc cttgaccatg 1437 gacataagca taagcatggt catggccacg gaaaacataa aaataaaggc 1487 aaaaagaatg gaaagcacaa tggttggaaa acagagcatt tggcaagctc 1537 ttctgaagac agtactacac cttctgcaca gacacaagag aagacagaag 1587 ggccaacacc catcccttcc ctagccaagc caggtgtaac agttaccttt 1637 tctgactttc aggactctga tctcattgca actatgatgc ctcctatatc 1687 accagctccc atacagagtg atgacgattg gatccctgat atccagatag 1737 acccaaatgg cctttcattt aacccaatat cagattttcc agacacgacc 1787 tccccaaaat gtcctggacg cccctggaag tcagttagtg aaattaatcc 1837 aaccacacaa atgaaagaat cttattattt cgatctcact gatggccttt 1887 cttaa 1892 78 136 PRT Homo sapiens 78 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 Thr Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu 65 70 75 80 Gly Asp Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr 85 90 95 Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly 100 105 110 Arg Gly Ala Val Arg Asn Ser Pro Trp Leu Pro Arg Pro Gly Ala His 115 120 125 Ser Glu Thr Arg His Ser Val Leu 130 135 79 670 DNA Homo sapiens CDS (1)..(508) 79 atg aaa cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt 48 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 tta acc cag gaa tca cag tcc gag gaa att gat gac tgc aat gac aag 96 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 gat tta ttt aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa 144 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 aac caa agt aac aac cag ttt gta ttg tac cgc aaa acc tgg cag gac 192 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 tgt gag tac aag gat gct gca aaa gca gcc act gga gaa tgc aca gca 240 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 acc gtg ggg aag agg agc agt acg aaa ttc tcc gtg gct acc cag acc 288 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 tgc cag att act cca gcc gag ggc cct gtg gtg aca gcc cag tac gac 336 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 tgc ctc ggc tgt gtg cat cct ata tca acg cag agc cca ggt ttt tca 384 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Gly Phe Ser 115 120 125 cct ttc cga tca tca cga ata ggg gaa ata aaa gaa gaa aca act agt 432 Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Ser 130 135 140 cac cta agg tcc tgc gag tac aag ggt cga ccc cca aag gca ggg gca 480 His Leu Arg Ser Cys Glu Tyr Lys Gly Arg Pro Pro Lys Ala Gly Ala 145 150 155 160 gag cca gca tct gag agg gag gtc tct tgaccaatgg gcagaatctt 527 Glu Pro Ala Ser Glu Arg Glu Val Ser 165 cactccaggc acatagcccc aaccacctct gccagcaacc ttgagaggaa 577 ggacaagaag aaagatggga tagaatttaa atagagaaga atgccatttt 627 atcactctgc ctctgggtga aataaagatc agtcttgatg ttc 670 80 169 PRT Homo sapiens 80 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Asp Cys Asn Asp Lys 20 25 30 Asp Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln 35 40 45 Asn Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Lys Thr Trp Gln Asp 50 55 60 Cys Glu Tyr Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala 65 70 75 80 Thr Val Gly Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr 85 90 95 Cys Gln Ile Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp 100 105 110 Cys Leu Gly Cys Val His Pro Ile Ser Thr Gln Ser Pro Gly Phe Ser 115 120 125 Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Ser 130 135 140 His Leu Arg Ser Cys Glu Tyr Lys Gly Arg Pro Pro Lys Ala Gly Ala 145 150 155 160 Glu Pro Ala Ser Glu Arg Glu Val Ser 165 81 1193 DNA Homo sapiens CDS (1)..(1171) 81 atg aaa cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt 48 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 tta acc cag gaa tca cag tcc gag gaa att gac tgc aat gac aag gat 96 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 tta ttt aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa aac 144 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 caa agt aac aac cag ttt gta ttg tac cgc ata act gaa gcc act aag 192 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 acg gcc act gga gaa tgc acg gca acc gtg ggg aag agg agc agt acg 240 Thr Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Lys Arg Ser Ser Thr 65 70 75 80 aaa ttc tcc gtg gct acc cag acc tgc cag att act cca gcc gag ggc 288 Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile Thr Pro Ala Glu Gly 85 90 95 cct gtg gtg aca gcc cag tac gac tgc ctc ggc tgt gtg cat cct ata 336 Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly Cys Val His Pro Ile 100 105 110 tca acg cag agc cca gac ctg gag ccc att ctg aga cac ggc att cag 384 Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu Arg His Gly Ile Gln 115 120 125 tac ttt aac aac aac act caa cat tcc tcc ctc ttc acg ctt aat gaa 432 Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu Phe Thr Leu Asn Glu 130 135 140 gta aaa cgg gcc caa aga cag gtg gtg gct gga ttg aac ttt cga att 480 Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly Leu Asn Phe Arg Ile 145 150 155 160 acc tac tca att gtg caa acg aat tgt tcc aaa gag aat ttt ctg ttc 528 Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys Glu Asn Phe Leu Phe 165 170 175 tta act cca gac tgc gag tcc ctt tgg aat ggt gat acc ggt gaa tgt 576 Leu Thr Pro Asp Cys Glu Ser Leu Trp Asn Gly Asp Thr Gly Glu Cys 180 185 190 aca gat aat gca tac atc gat att cag cta cga att gct tcc ttc tca 624 Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg Ile Ala Ser Phe Ser 195 200 205 cag aac tgt gac att tat cca ggg aag gat ttt gta caa cca cct acc 672 Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe Val Gln Pro Pro Thr 210 215 220 aag att tgc gtg ggc tgc ccc aga gat ata ccc acc aac agc cca gag 720 Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro Thr Asn Ser Pro Glu 225 230 235 240 ctg gag gag aca ctg act cac acc atc aca aag ctt aat gca gag aat 768 Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys Leu Asn Ala Glu Asn 245 250 255 aac gca act ttc tat ttc aag att gac aat gtg aaa aaa gca aga gta 816 Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val Lys Lys Ala Arg Val 260 265 270 cag gtg gtg gct ggc aag aaa tat ttt att gac ttc gtg gcc agg gaa 864 Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp Phe Val Ala Arg Glu 275 280 285 acc aca tgt tcc aag gaa agt aat gaa gag ttg acc gaa agc tgt gag 912 Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu Thr Glu Ser Cys Glu 290 295 300 acc aaa aaa ctt ggc caa agc cta gat tgc aac gct gaa gtt tat gtg 960 Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn Ala Glu Val Tyr Val 305 310 315 320 gta ccc tgg gag aaa aaa att tac cct act gtc aac tgt caa cca ctg 1008 Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val Asn Cys Gln Pro Leu 325 330 335 gga atg atc tca ctg atg aaa agg cct cca ggt ttt tca cct ttc cga 1056 Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg 340 345 350 tca tca cga ata ggg gaa ata aaa gaa gaa aca act agt cac cta agg 1104 Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Ser His Leu Arg 355 360 365 tcc tgc gag tac aag ggt cga ccc cca aag gca ggg gca gag cca gta 1152 Ser Cys Glu Tyr Lys Gly Arg Pro Pro Lys Ala Gly Ala Glu Pro Val 370 375 380 tct gag agg gag gtc tct tgaccaatgg gcagaatctt cac 1193 Ser Glu Arg Glu Val Ser 385 390 82 390 PRT Homo sapiens 82 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 Thr Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Lys Arg Ser Ser Thr 65 70 75 80 Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile Thr Pro Ala Glu Gly 85 90 95 Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly Cys Val His Pro Ile 100 105 110 Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu Arg His Gly Ile Gln 115 120 125 Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu Phe Thr Leu Asn Glu 130 135 140 Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly Leu Asn Phe Arg Ile 145 150 155 160 Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys Glu Asn Phe Leu Phe 165 170 175 Leu Thr Pro Asp Cys Glu Ser Leu Trp Asn Gly Asp Thr Gly Glu Cys 180 185 190 Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg Ile Ala Ser Phe Ser 195 200 205 Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe Val Gln Pro Pro Thr 210 215 220 Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro Thr Asn Ser Pro Glu 225 230 235 240 Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys Leu Asn Ala Glu Asn 245 250 255 Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val Lys Lys Ala Arg Val 260 265 270 Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp Phe Val Ala Arg Glu 275 280 285 Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu Thr Glu Ser Cys Glu 290 295 300 Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn Ala Glu Val Tyr Val 305 310 315 320 Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val Asn Cys Gln Pro Leu 325 330 335 Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg 340 345 350 Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Ser His Leu Arg 355 360 365 Ser Cys Glu Tyr Lys Gly Arg Pro Pro Lys Ala Gly Ala Glu Pro Val 370 375 380 Ser Glu Arg Glu Val Ser 385 390 83 1984 DNA Homo sapiens CDS (50)..(1982) 83 aattccggtt gaaaccatcc ctcagctcct agagggagat tgttagatc atg aaa 55 Met Lys 1 cta att acc atc ctt ttc ctc tgc tcc agg cta cta cta agt tta acc 103 Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser Leu Thr 5 10 15 cag gaa tca cag tcc gag gaa att gac tgc aat gac aag gat tta ttt 151 Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp Leu Phe 20 25 30 aaa gct gtg gat gct gct ctg aag aaa tat aac agt caa aac caa agt 199 Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn Gln Ser 35 40 45 50 aac aac cag ttt gta ttg tac cgc ata act gaa gcc act aag acg gtt 247 Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys Thr Val 55 60 65 ggc tct gac acg ttt tat tcc ttc aag tac gaa atc aag gag ggg gat 295 Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu Gly Asp 70 75 80 tgt cct gtt caa agt ggc aaa acc tgg cag gac tgt gag tac aag gat 343 Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr Lys Asp 85 90 95 gct gca aaa gca gcc act gga gaa tgc acg gca acc gtg ggg aag agg 391 Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly Lys Arg 100 105 110 agc agt acg aaa ttc tcc gtg gct acc cag acc tgc cag att act cca 439 Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile Thr Pro 115 120 125 130 gcc gag ggc cct gtg gtg aca gcc cag tac gac tgc ctc ggc tgt gtg 487 Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly Cys Val 135 140 145 cat cct ata tca acg cag agc cca gac ctg gag ccc att ctg aga cac 535 His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu Arg His 150 155 160 ggc att cag tac ttt aac aac aac act caa cat tcc tcc ctc ttc atg 583 Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu Phe Met 165 170 175 ctt aat gaa gta aaa cgg gcc caa aga cag gtg gtg gct gga ttg aac 631 Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly Leu Asn 180 185 190 ttt cga att acc tac tca att gtg caa acg aat tgt tcc aaa gag aat 679 Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys Glu Asn 195 200 205 210 ttt ctg ttc tta act cca gac tgc aag tcc ctt tgg aat ggt gat acc 727 Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu Trp Asn Gly Asp Thr 215 220 225 ggt gaa tgt aca gat aat gca tac atc gat att cag cta cga att gct 775 Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg Ile Ala 230 235 240 tcc ttc tca cag aac tgt gac att tat cca ggg aag gat ttt gta caa 823 Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe Val Gln 245 250 255 cca cct acc aag att tgc gtg ggc tgc ccc aga gat ata ccc acc aac 871 Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro Thr Asn 260 265 270 agc cca gag ctg gag gag aca ctg act cac acc atc aca aag ctt aat 919 Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys Leu Asn 275 280 285 290 gca gag aat aac gca act ttc tat ttc aag att gac aat gtg aaa aaa 967 Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val Lys Lys 295 300 305 gca aga gta cag gtg gtg gct ggc aag aaa tat ttt att gac ttc gtg 1015 Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp Phe Val 310 315 320 gcc agg gaa acc aca tgt tcc aag gaa agt aat gaa gag ttg acc gaa 1063 Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu Thr Glu 325 330 335 agc tgt gag acc aaa aaa ctt ggc caa agc cta gat tgc aac gct gaa 1111 Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn Ala Glu 340 345 350 gtt tat gtg gta ccc tgg gag aaa aaa att tac cct act gtc aac tgt 1159 Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val Asn Cys 355 360 365 370 caa cca ctg gga atg atc tca ctg atg aaa agg cct cca ggt ttt tca 1207 Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly

Phe Ser 375 380 385 cct ttc cga tca tca cga ata ggg gaa ata aaa gaa gaa aca act gta 1255 Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr Thr Val 390 395 400 agt cca ccc cac act tcc atg gca cct gca caa gat gaa gag cgg gat 1303 Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln Asp Glu Glu Arg Asp 405 410 415 tca gga aaa gaa caa ggg cat act cgt aga cat gac tgg ggc cat gaa 1351 Ser Gly Lys Glu Gln Gly His Thr Arg Arg His Asp Trp Gly His Glu 420 425 430 aaa caa aga aaa cat aat ctt ggc cat ggc cat aaa cat gaa cgt gac 1399 Lys Gln Arg Lys His Asn Leu Gly His Gly His Lys His Glu Arg Asp 435 440 445 450 caa ggg cat ggg cac caa aga gga cat ggc ctt ggc cat gga cac gaa 1447 Gln Gly His Gly His Gln Arg Gly His Gly Leu Gly His Gly His Glu 455 460 465 caa cag cat ggt ctt ggt cat gga cat aag ttc aaa ctt gat gat gat 1495 Gln Gln His Gly Leu Gly His Gly His Lys Phe Lys Leu Asp Asp Asp 470 475 480 ctt gaa cac caa ggg ggc cat gtc ctt gac cat gga cat aag cat aag 1543 Leu Glu His Gln Gly Gly His Val Leu Asp His Gly His Lys His Lys 485 490 495 cat ggt cat ggc cac gga aaa cat aaa aat aaa ggc aaa aag aat gga 1591 His Gly His Gly His Gly Lys His Lys Asn Lys Gly Lys Lys Asn Gly 500 505 510 aag cac aat ggt tgg aaa aca gag cat ttg gca agc tct tct gaa gac 1639 Lys His Asn Gly Trp Lys Thr Glu His Leu Ala Ser Ser Ser Glu Asp 515 520 525 530 agt act aca cct tct gca cag aca caa gag aag aca gaa ggg cca aca 1687 Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys Thr Glu Gly Pro Thr 535 540 545 ccc atc cct tcc cta gcc aag cca ggt gta aca gtt acc ttt tct gac 1735 Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr Val Thr Phe Ser Asp 550 555 560 ttt cag gac tct gat ctc att gca act atg atg cct cct ata tca cca 1783 Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile Ser Pro 565 570 575 gct ccc ata cag agt gat gac gat tgg atc cct gat atc cag ata gac 1831 Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln Ile Asp 580 585 590 cca aat ggc ctt tca ttt aac cca ata tca gat ttt cca gac acg acc 1879 Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp Thr Thr 595 600 605 610 tcc cca aaa tgt cct gga cgc ccc tgg aag tca gtt agt gaa att aat 1927 Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu Ile Asn 615 620 625 cca acc aca caa atg aaa gaa tct tat tat ttc gat ctc act gat ggc 1975 Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe Asp Leu Thr Asp Gly 630 635 640 ctt tct taa 1984 Leu Ser 84 644 PRT Homo sapiens 84 Met Lys Leu Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser 1 5 10 15 Leu Thr Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30 Leu Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45 Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60 Thr Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu 65 70 75 80 Gly Asp Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr 85 90 95 Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly 100 105 110 Lys Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile 115 120 125 Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly 130 135 140 Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu 145 150 155 160 Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu 165 170 175 Phe Met Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly 180 185 190 Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys 195 200 205 Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu Trp Asn Gly 210 215 220 Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg 225 230 235 240 Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe 245 250 255 Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg Asp Ile Pro 260 265 270 Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys 275 280 285 Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val 290 295 300 Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp 305 310 315 320 Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu 325 330 335 Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn 340 345 350 Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val 355 360 365 Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly 370 375 380 Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu Glu Thr 385 390 395 400 Thr Val Ser Pro Pro His Thr Ser Met Ala Pro Ala Gln Asp Glu Glu 405 410 415 Arg Asp Ser Gly Lys Glu Gln Gly His Thr Arg Arg His Asp Trp Gly 420 425 430 His Glu Lys Gln Arg Lys His Asn Leu Gly His Gly His Lys His Glu 435 440 445 Arg Asp Gln Gly His Gly His Gln Arg Gly His Gly Leu Gly His Gly 450 455 460 His Glu Gln Gln His Gly Leu Gly His Gly His Lys Phe Lys Leu Asp 465 470 475 480 Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His Gly His Lys 485 490 495 His Lys His Gly His Gly His Gly Lys His Lys Asn Lys Gly Lys Lys 500 505 510 Asn Gly Lys His Asn Gly Trp Lys Thr Glu His Leu Ala Ser Ser Ser 515 520 525 Glu Asp Ser Thr Thr Pro Ser Ala Gln Thr Gln Glu Lys Thr Glu Gly 530 535 540 Pro Thr Pro Ile Pro Ser Leu Ala Lys Pro Gly Val Thr Val Thr Phe 545 550 555 560 Ser Asp Phe Gln Asp Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile 565 570 575 Ser Pro Ala Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln 580 585 590 Ile Asp Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp 595 600 605 Thr Thr Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu 610 615 620 Ile Asn Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe Asp Leu Thr 625 630 635 640 Asp Gly Leu Ser 85 1272 DNA Homo sapiens CDS (220)..(1249) 85 cttccccagg actccaggag acataaaact tgaaacggga gacttcgtgc 50 aaatcctgct ccggacgctg ctgaagctca gatttctccc actgcctgca 100 cagggtgctg cctgctggcg aatgtgactc tcctcctgtt cacccacaag 150 gctgattttt ccgtgttcct cctctggaaa gagcattgct ttctctcttc 200 cagcacttta cctacattc atg tct ttc agg tgg ctg ctt ctc tat tat 249 Met Ser Phe Arg Trp Leu Leu Leu Tyr Tyr 1 5 10 gct ctg tgc ttc tcc ctg tca aag gct tca gcc cac acc gtg gag cta 297 Ala Leu Cys Phe Ser Leu Ser Lys Ala Ser Ala His Thr Val Glu Leu 15 20 25 aac aat atg ttt ggc cag atc cag tcg cct ggt tat cca gac tcc tat 345 Asn Asn Met Phe Gly Gln Ile Gln Ser Pro Gly Tyr Pro Asp Ser Tyr 30 35 40 ccc agt gat tca gag gtg act tgg aat atc act gtc cca gat ggg ttt 393 Pro Ser Asp Ser Glu Val Thr Trp Asn Ile Thr Val Pro Asp Gly Phe 45 50 55 cgg atc aag ctt tac ttc atg cac ttc aac ttg gaa tcc tcc tac ctt 441 Arg Ile Lys Leu Tyr Phe Met His Phe Asn Leu Glu Ser Ser Tyr Leu 60 65 70 tgt gaa tat gac tat gtg aag gta gaa act gag gac act tcg aga gtg 489 Cys Glu Tyr Asp Tyr Val Lys Val Glu Thr Glu Asp Thr Ser Arg Val 75 80 85 90 cca aat gac aag tgg ttt ggg agt ggg gcc ctg ctc tct gcg tcc tgg 537 Pro Asn Asp Lys Trp Phe Gly Ser Gly Ala Leu Leu Ser Ala Ser Trp 95 100 105 atc ctc aca gca gct cat gtg ctg cgc tcc cag cgt aga gac acc acg 585 Ile Leu Thr Ala Ala His Val Leu Arg Ser Gln Arg Arg Asp Thr Thr 110 115 120 gtg ata cca gtc tcc aag gag cat gtc acc gtc tac ctg ggc ttg cat 633 Val Ile Pro Val Ser Lys Glu His Val Thr Val Tyr Leu Gly Leu His 125 130 135 gat gtg cga gac aaa tcg ggg gca gtc aac agc tca gct gcc cga gtg 681 Asp Val Arg Asp Lys Ser Gly Ala Val Asn Ser Ser Ala Ala Arg Val 140 145 150 gtg ctc cac cca gac ttc aac atc caa aac tac aac cac gat ata gct 729 Val Leu His Pro Asp Phe Asn Ile Gln Asn Tyr Asn His Asp Ile Ala 155 160 165 170 ctg gtg cag ctg cag gag cct gtg ccc ctg gga ccc cac gtt atg cct 777 Leu Val Gln Leu Gln Glu Pro Val Pro Leu Gly Pro His Val Met Pro 175 180 185 gtc tgc ctg cca agg ctt gag cct gaa ggc ccg gcc ccc cac atg ctg 825 Val Cys Leu Pro Arg Leu Glu Pro Glu Gly Pro Ala Pro His Met Leu 190 195 200 ggc ctg gtg gcc ggc tgg ggc atc tcc aat ccc aat gtg aca gtg gat 873 Gly Leu Val Ala Gly Trp Gly Ile Ser Asn Pro Asn Val Thr Val Asp 205 210 215 gag atc atc agc agt ggc aca cgg acc ttg tca gat gtc ctg cag tat 921 Glu Ile Ile Ser Ser Gly Thr Arg Thr Leu Ser Asp Val Leu Gln Tyr 220 225 230 gtc aag tta ccc gtg gtg cct cac gct gag tgc aaa act agc tat gag 969 Val Lys Leu Pro Val Val Pro His Ala Glu Cys Lys Thr Ser Tyr Glu 235 240 245 250 tcc cgc tcg ggc aat tac agc gtc acg gag aac atg ttc tgt gct ggc 1017 Ser Arg Ser Gly Asn Tyr Ser Val Thr Glu Asn Met Phe Cys Ala Gly 255 260 265 tac tac gag ggc ggc aaa gac acg tgc ctt gga gat agc ggt ggg gcc 1065 Tyr Tyr Glu Gly Gly Lys Asp Thr Cys Leu Gly Asp Ser Gly Gly Ala 270 275 280 ttt gtc atc ttt gat gac ttg agc cag cgc tgg gtg gtg caa ggc ctg 1113 Phe Val Ile Phe Asp Asp Leu Ser Gln Arg Trp Val Val Gln Gly Leu 285 290 295 gtg tcc tgg ggg gga cct gaa gaa tgc ggc agc aag cag gtc tat gga 1161 Val Ser Trp Gly Gly Pro Glu Glu Cys Gly Ser Lys Gln Val Tyr Gly 300 305 310 gtc tac aca aag gtc tcc aat tac gtg gac tgg gtg tgg gag cag atg 1209 Val Tyr Thr Lys Val Ser Asn Tyr Val Asp Trp Val Trp Glu Gln Met 315 320 325 330 ggc tta cca caa agt gtt gtg gag ccc cag gtg gaa cgg tgagctgact 1258 Gly Leu Pro Gln Ser Val Val Glu Pro Gln Val Glu Arg 335 340 tacttcctcg cggg 1272 86 343 PRT Homo sapiens 86 Met Ser Phe Arg Trp Leu Leu Leu Tyr Tyr Ala Leu Cys Phe Ser Leu 1 5 10 15 Ser Lys Ala Ser Ala His Thr Val Glu Leu Asn Asn Met Phe Gly Gln 20 25 30 Ile Gln Ser Pro Gly Tyr Pro Asp Ser Tyr Pro Ser Asp Ser Glu Val 35 40 45 Thr Trp Asn Ile Thr Val Pro Asp Gly Phe Arg Ile Lys Leu Tyr Phe 50 55 60 Met His Phe Asn Leu Glu Ser Ser Tyr Leu Cys Glu Tyr Asp Tyr Val 65 70 75 80 Lys Val Glu Thr Glu Asp Thr Ser Arg Val Pro Asn Asp Lys Trp Phe 85 90 95 Gly Ser Gly Ala Leu Leu Ser Ala Ser Trp Ile Leu Thr Ala Ala His 100 105 110 Val Leu Arg Ser Gln Arg Arg Asp Thr Thr Val Ile Pro Val Ser Lys 115 120 125 Glu His Val Thr Val Tyr Leu Gly Leu His Asp Val Arg Asp Lys Ser 130 135 140 Gly Ala Val Asn Ser Ser Ala Ala Arg Val Val Leu His Pro Asp Phe 145 150 155 160 Asn Ile Gln Asn Tyr Asn His Asp Ile Ala Leu Val Gln Leu Gln Glu 165 170 175 Pro Val Pro Leu Gly Pro His Val Met Pro Val Cys Leu Pro Arg Leu 180 185 190 Glu Pro Glu Gly Pro Ala Pro His Met Leu Gly Leu Val Ala Gly Trp 195 200 205 Gly Ile Ser Asn Pro Asn Val Thr Val Asp Glu Ile Ile Ser Ser Gly 210 215 220 Thr Arg Thr Leu Ser Asp Val Leu Gln Tyr Val Lys Leu Pro Val Val 225 230 235 240 Pro His Ala Glu Cys Lys Thr Ser Tyr Glu Ser Arg Ser Gly Asn Tyr 245 250 255 Ser Val Thr Glu Asn Met Phe Cys Ala Gly Tyr Tyr Glu Gly Gly Lys 260 265 270 Asp Thr Cys Leu Gly Asp Ser Gly Gly Ala Phe Val Ile Phe Asp Asp 275 280 285 Leu Ser Gln Arg Trp Val Val Gln Gly Leu Val Ser Trp Gly Gly Pro 290 295 300 Glu Glu Cys Gly Ser Lys Gln Val Tyr Gly Val Tyr Thr Lys Val Ser 305 310 315 320 Asn Tyr Val Asp Trp Val Trp Glu Gln Met Gly Leu Pro Gln Ser Val 325 330 335 Val Glu Pro Gln Val Glu Arg 340 87 861 DNA Homo sapiens CDS (10)..(775) 87 cagctcagc atg gct agg gta ctg gga gca ccc gtt gca ctg ggg ttg 48 Met Ala Arg Val Leu Gly Ala Pro Val Ala Leu Gly Leu 1 5 10 tgg agc cta tgc tgg tct ctg gcc att gcc acc cct ctt cct ccg act 96 Trp Ser Leu Cys Trp Ser Leu Ala Ile Ala Thr Pro Leu Pro Pro Thr 15 20 25 agt gcc cat ggg aat gtt gct gaa ggc gag acc aag cca gac cca gac 144 Ser Ala His Gly Asn Val Ala Glu Gly Glu Thr Lys Pro Asp Pro Asp 30 35 40 45 gtg act gaa cgc tgc tca gat ggc tgg agc ttt gat gct acc acc ctg 192 Val Thr Glu Arg Cys Ser Asp Gly Trp Ser Phe Asp Ala Thr Thr Leu 50 55 60 gat gac aat gga acc atg ctg ttt ttt aaa ggg acc cac tac tgg cgt 240 Asp Asp Asn Gly Thr Met Leu Phe Phe Lys Gly Thr His Tyr Trp Arg 65 70 75 ctg gac acc agc cgg gat ggc tgg cat agc tgg ccc att gct cat cag 288 Leu Asp Thr Ser Arg Asp Gly Trp His Ser Trp Pro Ile Ala His Gln 80 85 90 tgg ccc cag ggt cct tca gca gtg gat gct gcc ttt tcc tgg gaa gaa 336 Trp Pro Gln Gly Pro Ser Ala Val Asp Ala Ala Phe Ser Trp Glu Glu 95 100 105 aaa ctc tat ctg gtc cag ggc acc cag gta tat gtc ttc ctg aca aag 384 Lys Leu Tyr Leu Val Gln Gly Thr Gln Val Tyr Val Phe Leu Thr Lys 110 115 120 125 gga ggc tat acc cta gta agc ggt tat ccg aag cgg ctg gag aag gaa 432 Gly Gly Tyr Thr Leu Val Ser Gly Tyr Pro Lys Arg Leu Glu Lys Glu 130 135 140 gtc ggg acc cct cat ggg att atc ctg gac tct gtg gat gcg gcc ttt 480 Val Gly Thr Pro His Gly Ile Ile Leu Asp Ser Val Asp Ala Ala Phe 145 150 155 atc tgc cct ggg tct tct cgg ctc cat atc atg gca gga cgg cgg ctg 528 Ile Cys Pro Gly Ser Ser Arg Leu His Ile Met Ala Gly Arg Arg Leu 160 165 170 tgg tgg ctg gac ctg aag tca gga gcc caa gcc acg tgg aca gag ctt 576 Trp Trp Leu Asp Leu Lys Ser Gly Ala Gln Ala Thr Trp Thr Glu Leu 175 180 185 cct tgg ccc cat gag aag gta gac gga gcc ttg tgt atg gaa aag tcc 624 Pro Trp Pro His Glu Lys Val Asp Gly Ala Leu Cys Met Glu Lys Ser 190 195 200 205 ctt ggc cct aac tca tgt tcc gcc aat ggt ccc ggc ttg tac ctc atc 672 Leu Gly Pro Asn Ser Cys Ser Ala Asn Gly Pro Gly Leu Tyr Leu Ile 210 215 220 cat ggt ccc aat ttg tac tgc tac agt gat gtg gag aaa ctg aat gca 720 His Gly Pro Asn Leu Tyr Cys Tyr Ser Asp Val Glu Lys Leu Asn Ala 225 230 235 gcc aag gcc ctt ccg caa ccc cag aat gtg acc agt ctc ctg ggc tgc 768 Ala Lys Ala Leu Pro Gln

Pro Gln Asn Val Thr Ser Leu Leu Gly Cys 240 245 250 act cac tgaggggcct tctgacatga gtctggcctg gccccacctc ctagttcctc 824 Thr His 255 ataataaaga cagattgctt cttcgcttct cactgag 861 88 255 PRT Homo sapiens 88 Met Ala Arg Val Leu Gly Ala Pro Val Ala Leu Gly Leu Trp Ser Leu 1 5 10 15 Cys Trp Ser Leu Ala Ile Ala Thr Pro Leu Pro Pro Thr Ser Ala His 20 25 30 Gly Asn Val Ala Glu Gly Glu Thr Lys Pro Asp Pro Asp Val Thr Glu 35 40 45 Arg Cys Ser Asp Gly Trp Ser Phe Asp Ala Thr Thr Leu Asp Asp Asn 50 55 60 Gly Thr Met Leu Phe Phe Lys Gly Thr His Tyr Trp Arg Leu Asp Thr 65 70 75 80 Ser Arg Asp Gly Trp His Ser Trp Pro Ile Ala His Gln Trp Pro Gln 85 90 95 Gly Pro Ser Ala Val Asp Ala Ala Phe Ser Trp Glu Glu Lys Leu Tyr 100 105 110 Leu Val Gln Gly Thr Gln Val Tyr Val Phe Leu Thr Lys Gly Gly Tyr 115 120 125 Thr Leu Val Ser Gly Tyr Pro Lys Arg Leu Glu Lys Glu Val Gly Thr 130 135 140 Pro His Gly Ile Ile Leu Asp Ser Val Asp Ala Ala Phe Ile Cys Pro 145 150 155 160 Gly Ser Ser Arg Leu His Ile Met Ala Gly Arg Arg Leu Trp Trp Leu 165 170 175 Asp Leu Lys Ser Gly Ala Gln Ala Thr Trp Thr Glu Leu Pro Trp Pro 180 185 190 His Glu Lys Val Asp Gly Ala Leu Cys Met Glu Lys Ser Leu Gly Pro 195 200 205 Asn Ser Cys Ser Ala Asn Gly Pro Gly Leu Tyr Leu Ile His Gly Pro 210 215 220 Asn Leu Tyr Cys Tyr Ser Asp Val Glu Lys Leu Asn Ala Ala Lys Ala 225 230 235 240 Leu Pro Gln Pro Gln Asn Val Thr Ser Leu Leu Gly Cys Thr His 245 250 255 89 2671 DNA Homo sapiens CDS (15)..(2652) 89 cccgccgggc gagc atg ggg cgc ctg gcc tcg agg ccg ctg ctg ctg gcg 50 Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala 1 5 10 ctc ctg tcg ttg gct ctt tgc cga ggg cgt gtg gtg aga gtc ccc aca 98 Leu Leu Ser Leu Ala Leu Cys Arg Gly Arg Val Val Arg Val Pro Thr 15 20 25 gcg acc ctg gtt cga gtg gtg ggc act gag ctg gtc atc ccc tgc aac 146 Ala Thr Leu Val Arg Val Val Gly Thr Glu Leu Val Ile Pro Cys Asn 30 35 40 gtc agt gac tat gat ggc ccc agc gag caa aac ttt gac tgg agc ttc 194 Val Ser Asp Tyr Asp Gly Pro Ser Glu Gln Asn Phe Asp Trp Ser Phe 45 50 55 60 tca tct ttg ggg agc agc ttt gtg gag ctt gca agc acc tgg gag gtg 242 Ser Ser Leu Gly Ser Ser Phe Val Glu Leu Ala Ser Thr Trp Glu Val 65 70 75 ggg ttc cca gcc caa ctg tac cag gag cgg ctg cag agg ggc gag atc 290 Gly Phe Pro Ala Gln Leu Tyr Gln Glu Arg Leu Gln Arg Gly Glu Ile 80 85 90 ctg tta agg cgg act gcc aac gac gcc gtg gag ctc cac ata aag aac 338 Leu Leu Arg Arg Thr Ala Asn Asp Ala Val Glu Leu His Ile Lys Asn 95 100 105 gtc cag cct tca gac caa ggc cac tac aaa tgt tca acc ccc agc aca 386 Val Gln Pro Ser Asp Gln Gly His Tyr Lys Cys Ser Thr Pro Ser Thr 110 115 120 gat gcc act gtc cag gga aac tat gag gac aca gtg cag gtt aaa gtg 434 Asp Ala Thr Val Gln Gly Asn Tyr Glu Asp Thr Val Gln Val Lys Val 125 130 135 140 ctg gcc gac tcc ctg cac gtg ggc ccc agc gcg cgg ccc ccg ccg agc 482 Leu Ala Asp Ser Leu His Val Gly Pro Ser Ala Arg Pro Pro Pro Ser 145 150 155 ctg agc ctg cgg gag ggg gag ccc ttc gag ctg cgc tgc acc gcc gcc 530 Leu Ser Leu Arg Glu Gly Glu Pro Phe Glu Leu Arg Cys Thr Ala Ala 160 165 170 tcc gcc tcg ccg ctg cac acg cac ctg gcg ctg ctg tgg gag gtg cac 578 Ser Ala Ser Pro Leu His Thr His Leu Ala Leu Leu Trp Glu Val His 175 180 185 cgc ggc ccg gcc agg cgg agc gtc ctc gcc ctg acc cac gag ggc agg 626 Arg Gly Pro Ala Arg Arg Ser Val Leu Ala Leu Thr His Glu Gly Arg 190 195 200 ttc cac ccg ggc ctg ggg tac gag cag cgc tac cac agt ggg gac gtg 674 Phe His Pro Gly Leu Gly Tyr Glu Gln Arg Tyr His Ser Gly Asp Val 205 210 215 220 cgc ctc gac acc gtg ggc agc gac gcc tac cgc ctc tca gtg tcc cgg 722 Arg Leu Asp Thr Val Gly Ser Asp Ala Tyr Arg Leu Ser Val Ser Arg 225 230 235 gct ctg tct gcc gac cag ggc tcc tac agg tgt atc gtc agc gag tgg 770 Ala Leu Ser Ala Asp Gln Gly Ser Tyr Arg Cys Ile Val Ser Glu Trp 240 245 250 atc gcc gag cag ggc aac tgg cag gaa atc caa gaa aag gcc gtg gaa 818 Ile Ala Glu Gln Gly Asn Trp Gln Glu Ile Gln Glu Lys Ala Val Glu 255 260 265 gtt gcc acc gtg gtg atc cag ccg aca gtt ctg cga gca gcc gtg ccc 866 Val Ala Thr Val Val Ile Gln Pro Thr Val Leu Arg Ala Ala Val Pro 270 275 280 aag aat gtg tct gtg gct gaa gga aag gaa ctg gac ctg acc tgt aac 914 Lys Asn Val Ser Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn 285 290 295 300 atc aca aca gac cga gcc gat gac gtc cgg ccc gag gtg acg tgg tcc 962 Ile Thr Thr Asp Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser 305 310 315 ttc agc agg atg cct gac agc acc cta cct ggc tcc cgc gtg ttg gcg 1010 Phe Ser Arg Met Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala 320 325 330 cgg ctt gac cgt gat tcc ctg gtg cac agc tcg cct cat gtt gct ttg 1058 Arg Leu Asp Arg Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu 335 340 345 agt cat gtg gat gca cgc tcc tac cat tta ctg gtt cgg gat gtt agc 1106 Ser His Val Asp Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser 350 355 360 aaa gaa aac tct ggc tac tat tac tgc cac gtg tcc ctg tgg gca ccc 1154 Lys Glu Asn Ser Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro 365 370 375 380 gga cac aac agg agc tgg cac aaa gtg gca gag gcc gtg tct tcc cca 1202 Gly His Asn Arg Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro 385 390 395 gct ggt gtg ggt gtg acc tgg cta gaa cca gac tac cag gtg tac ctg 1250 Ala Gly Val Gly Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu 400 405 410 aat gct tcc aag gtc ccc ggg ttt gcg gat gac ccc aca gag ctg gca 1298 Asn Ala Ser Lys Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala 415 420 425 tgc cgg gtg gtg gac acg aag agt ggg gag gcg aat gtc cga ttc acg 1346 Cys Arg Val Val Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr 430 435 440 gtt tcg tgg tac tac agg atg aac cgg cgc agc gac aat gtg gtg acc 1394 Val Ser Trp Tyr Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr 445 450 455 460 agc gag ctg ctt gca gtc atg gac ggg gac tgg acg cta aaa tat gga 1442 Ser Glu Leu Leu Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly 465 470 475 gag agg agc aag cag cgg gcc cag gat gga gac ttt att ttt tct aag 1490 Glu Arg Ser Lys Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys 480 485 490 gaa cat aca gac acg ttc aat ttc cgg atc caa agg act aca gag gaa 1538 Glu His Thr Asp Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu 495 500 505 gac aga ggc aat tat tac tgt gtt gtg tct gcc tgg acc aaa cag cgg 1586 Asp Arg Gly Asn Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg 510 515 520 aac aac agc tgg gtg aaa agc aag gat gtc ttc tcc aag cct gtt aac 1634 Asn Asn Ser Trp Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn 525 530 535 540 ata ttt tgg gca tta gaa gat tcc gtg ctt gtg gtg aag gcg agg cag 1682 Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln 545 550 555 cca aag cct ttc ttt gct gcc gga aat aca ttt gag atg act tgc aaa 1730 Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys 560 565 570 gta tct tcc aag aat att aag tcg cca cgc tac tct gtt ctc atc atg 1778 Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met 575 580 585 gct gag aag cct gtc ggc gac ctc tcc agt ccc aat gaa acg aag tac 1826 Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr 590 595 600 atc atc tct ctg gac cag gat tct gtg gtg aag ctg gag aat tgg aca 1874 Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr 605 610 615 620 gat gca tca cgg gtg gat ggc gtt gtt tta gaa aaa gtg cag gag gat 1922 Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp 625 630 635 gag ttc cgc tat cga atg tac cag act cag gtc tca gac gca ggg ctg 1970 Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu 640 645 650 tac cgc tgc atg gtg aca gcc tgg tct cct gtc agg ggc agc ctt tgg 2018 Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp 655 660 665 cga gaa gca gca acc agt ctc tcc aat cct att gag ata gac ttc caa 2066 Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln 670 675 680 acc tca ggt cct ata ttt aat gct tct gtg cat tca gac aca cca tca 2114 Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser 685 690 695 700 gta att cgg gga gat ctg atc aaa ttg ttc tgt atc atc act gtc gag 2162 Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu 705 710 715 gga gca gca ctg gat cca gat gac atg gcc ttt gat gtg tcc tgg ttt 2210 Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe 720 725 730 gcg gtg cac tct ttt ggc ctg gac aag gct cct gtg ctc ctg tct tcc 2258 Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser 735 740 745 ctg gat cgg aag ggc atc gtg acc acc tcc cgg agg gac tgg aag agc 2306 Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser 750 755 760 gac ctc agc ctg gag cgc gtg agt gtg ctg gaa ttc ttg ctg caa gtg 2354 Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val 765 770 775 780 cat ggc tcc gag gac cag gac ttt ggc aac tac tac tgt tcc gtg act 2402 His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr 785 790 795 cca tgg gtg aag tca cca aca ggt tcc tgg cag aag gag gca gag atc 2450 Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile 800 805 810 cac tcc aag ccc gtt ttt ata act gtg aag atg gat gtg ctg aac gcc 2498 His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala 815 820 825 ttc aag tat ccc ttg ctg atc ggc gtc ggt ctg tcc acg gtc atc ggg 2546 Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly 830 835 840 ctc ctg tcc tgt ctc atc ggg tac tgc agc tcc cac tgg tgt tgt aag 2594 Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys 845 850 855 860 aag gag gtt cag gag aca cgg cgc gag cgc cgc agg ctc atg tcg atg 2642 Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met 865 870 875 gag atg gac taggctggcc cgggagggga 2671 Glu Met Asp 90 879 PRT Homo sapiens 90 Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala Leu Leu Ser Leu 1 5 10 15 Ala Leu Cys Arg Gly Arg Val Val Arg Val Pro Thr Ala Thr Leu Val 20 25 30 Arg Val Val Gly Thr Glu Leu Val Ile Pro Cys Asn Val Ser Asp Tyr 35 40 45 Asp Gly Pro Ser Glu Gln Asn Phe Asp Trp Ser Phe Ser Ser Leu Gly 50 55 60 Ser Ser Phe Val Glu Leu Ala Ser Thr Trp Glu Val Gly Phe Pro Ala 65 70 75 80 Gln Leu Tyr Gln Glu Arg Leu Gln Arg Gly Glu Ile Leu Leu Arg Arg 85 90 95 Thr Ala Asn Asp Ala Val Glu Leu His Ile Lys Asn Val Gln Pro Ser 100 105 110 Asp Gln Gly His Tyr Lys Cys Ser Thr Pro Ser Thr Asp Ala Thr Val 115 120 125 Gln Gly Asn Tyr Glu Asp Thr Val Gln Val Lys Val Leu Ala Asp Ser 130 135 140 Leu His Val Gly Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg 145 150 155 160 Glu Gly Glu Pro Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro 165 170 175 Leu His Thr His Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala 180 185 190 Arg Arg Ser Val Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly 195 200 205 Leu Gly Tyr Glu Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr 210 215 220 Val Gly Ser Asp Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala 225 230 235 240 Asp Gln Gly Ser Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln 245 250 255 Gly Asn Trp Gln Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val 260 265 270 Val Ile Gln Pro Thr Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser 275 280 285 Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp 290 295 300 Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met 305 310 315 320 Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg 325 330 335 Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu Ser His Val Asp 340 345 350 Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser 355 360 365 Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg 370 375 380 Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly 385 390 395 400 Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys 405 410 415 Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val 420 425 430 Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr 435 440 445 Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu 450 455 460 Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys 465 470 475 480 Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp 485 490 495 Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn 500 505 510 Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp 515 520 525 Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala 530 535 540 Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe 545 550 555 560 Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys 565 570 575 Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro 580 585 590 Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu 595 600 605 Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg 610 615 620 Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr 625 630 635 640 Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met 645 650 655 Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala 660 665 670 Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro 675 680 685 Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly 690 695 700 Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu 705 710 715

720 Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser 725 730 735 Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys 740 745 750 Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu 755 760 765 Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu 770 775 780 Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys 785 790 795 800 Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro 805 810 815 Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro 820 825 830 Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys 835 840 845 Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln 850 855 860 Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp 865 870 875 91 1565 DNA Homo sapiens CDS (4)..(1549) 91 gga atg ctc tcc cgc ctg agc ctg ctc cag gaa ttg gac ctc agc tac 48 Met Leu Ser Arg Leu Ser Leu Leu Gln Glu Leu Asp Leu Ser Tyr 1 5 10 15 aac cag ctc tca acc ctt gag cct ggg gcc ttc cat ggc cta caa agc 96 Asn Gln Leu Ser Thr Leu Glu Pro Gly Ala Phe His Gly Leu Gln Ser 20 25 30 cta ctc acc ctg agg ctg cag ggc aat cgg ctc aga atc atg ggg cct 144 Leu Leu Thr Leu Arg Leu Gln Gly Asn Arg Leu Arg Ile Met Gly Pro 35 40 45 ggg gtc ttc tca ggc ctc tct gct ctg acc ctg ctg gac ctc cgc ctc 192 Gly Val Phe Ser Gly Leu Ser Ala Leu Thr Leu Leu Asp Leu Arg Leu 50 55 60 aac cag att gtt ctc ttc cta gat gga gct ttt ggg gag cta ggc agc 240 Asn Gln Ile Val Leu Phe Leu Asp Gly Ala Phe Gly Glu Leu Gly Ser 65 70 75 ctc cag aag ctg gag gtt ggg gac aac cac ctg gta ttt gtg gct ccg 288 Leu Gln Lys Leu Glu Val Gly Asp Asn His Leu Val Phe Val Ala Pro 80 85 90 95 ggg gcc ttt gca ggg cta gcc aag ttg agc acc ctc acc ctg gag cgc 336 Gly Ala Phe Ala Gly Leu Ala Lys Leu Ser Thr Leu Thr Leu Glu Arg 100 105 110 tgc aac ctc agc aca gtg cct ggc cta gcc ctt gcc cgt ctc ccg gca 384 Cys Asn Leu Ser Thr Val Pro Gly Leu Ala Leu Ala Arg Leu Pro Ala 115 120 125 cta gtg gcc cta agg ctt aga gaa ctg gat att ggg agg ctg cca gct 432 Leu Val Ala Leu Arg Leu Arg Glu Leu Asp Ile Gly Arg Leu Pro Ala 130 135 140 ggg gcc ctg cgg ggg ctg ggg cag ctc aag gag ctg gag atc cac ctc 480 Gly Ala Leu Arg Gly Leu Gly Gln Leu Lys Glu Leu Glu Ile His Leu 145 150 155 tgg cca tct ctg gag gct ctg gac cct ggg agc ctg gtt ggg ctc aat 528 Trp Pro Ser Leu Glu Ala Leu Asp Pro Gly Ser Leu Val Gly Leu Asn 160 165 170 175 ctc agc agc ctg gcc atc act cgc tgc aat ctg agc tcg gtg ccc ttc 576 Leu Ser Ser Leu Ala Ile Thr Arg Cys Asn Leu Ser Ser Val Pro Phe 180 185 190 caa gca ctg tac cac ctc agc ttc ctc agg gtc ctg gat ctg tcc cag 624 Gln Ala Leu Tyr His Leu Ser Phe Leu Arg Val Leu Asp Leu Ser Gln 195 200 205 aat ccc atc tca gcc atc cca gcc cga agg ctc agc ccc ctg gtg cgg 672 Asn Pro Ile Ser Ala Ile Pro Ala Arg Arg Leu Ser Pro Leu Val Arg 210 215 220 ctc cag gag cta cgc ctg tca ggg gca tgc ctc acc tcc att gct gcc 720 Leu Gln Glu Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala 225 230 235 cat gcc ttc cat ggc ttg act gcc ttc cac ctc ctg gat gtg gca gat 768 His Ala Phe His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp 240 245 250 255 aac gcc ctt cag aca cta gag gaa aca gct ttc cct tct cca gac aaa 816 Asn Ala Leu Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys 260 265 270 ctg gtc acc ttg agg ctg tct ggc aac ccc cta acc tgt gac tgc cgc 864 Leu Val Thr Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg 275 280 285 ctc ctc tgg ctg ctc cgg ctc cgc cgc cac ctg gac ttt ggc atg tcc 912 Leu Leu Trp Leu Leu Arg Leu Arg Arg His Leu Asp Phe Gly Met Ser 290 295 300 ccc cct gcc tgt gct ggc ccc cat cat gtc cag ggg aag agc ctg aag 960 Pro Pro Ala Cys Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys 305 310 315 gag ttt tca gac atc ctg cct cca ggg cac ttc acc tgc aaa cca gcc 1008 Glu Phe Ser Asp Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala 320 325 330 335 ctg atc cga aag tcg ggg cct cga tgg gtc att gca gag gag ggc ggg 1056 Leu Ile Arg Lys Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly 340 345 350 cat gcg gtt ttc tcc tgc tct gga gat gga gac cca gcc ccc act gtc 1104 His Ala Val Phe Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val 355 360 365 tcc tgg atg agg cct cat ggg gct tgg ctg ggc agg gct ggg aga gta 1152 Ser Trp Met Arg Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val 370 375 380 agg gtc cta gag gat ggg aca ctg gag atc cgc tca gtg cag cta cgg 1200 Arg Val Leu Glu Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg 385 390 395 gac aga ggg gcc tat gtc tgt gtg gtt agc aat gtc gct ggg aat gac 1248 Asp Arg Gly Ala Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp 400 405 410 415 tcc ctg agg acc tgg ctg gaa gtc atc cag gtg gaa cca cca aac ggc 1296 Ser Leu Arg Thr Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly 420 425 430 aca ctt tct gac ccc aac atc acc gtg cca ggg atc cca ggg cct ttt 1344 Thr Leu Ser Asp Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe 435 440 445 ttt ctg gat agc aga ggt gtg gcc atg gtg ctg gca gtc ggc ttc ctc 1392 Phe Leu Asp Ser Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu 450 455 460 ccc ttc ctc acc tca gtg acc ctc tgc ttt ggc ctg att gcc ctt tgg 1440 Pro Phe Leu Thr Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp 465 470 475 agc aag ggc aaa ggt cgg gtc aaa cat cac atg acc ttt gac ttt gtg 1488 Ser Lys Gly Lys Gly Arg Val Lys His His Met Thr Phe Asp Phe Val 480 485 490 495 gca cct cgg ccc tct ggg gat aaa aac tct ggg ggt aac cgg gtc act 1536 Ala Pro Arg Pro Ser Gly Asp Lys Asn Ser Gly Gly Asn Arg Val Thr 500 505 510 gcc aag ctc ttc tgacctttcc ttcccca 1565 Ala Lys Leu Phe 515 92 515 PRT Homo sapiens 92 Met Leu Ser Arg Leu Ser Leu Leu Gln Glu Leu Asp Leu Ser Tyr Asn 1 5 10 15 Gln Leu Ser Thr Leu Glu Pro Gly Ala Phe His Gly Leu Gln Ser Leu 20 25 30 Leu Thr Leu Arg Leu Gln Gly Asn Arg Leu Arg Ile Met Gly Pro Gly 35 40 45 Val Phe Ser Gly Leu Ser Ala Leu Thr Leu Leu Asp Leu Arg Leu Asn 50 55 60 Gln Ile Val Leu Phe Leu Asp Gly Ala Phe Gly Glu Leu Gly Ser Leu 65 70 75 80 Gln Lys Leu Glu Val Gly Asp Asn His Leu Val Phe Val Ala Pro Gly 85 90 95 Ala Phe Ala Gly Leu Ala Lys Leu Ser Thr Leu Thr Leu Glu Arg Cys 100 105 110 Asn Leu Ser Thr Val Pro Gly Leu Ala Leu Ala Arg Leu Pro Ala Leu 115 120 125 Val Ala Leu Arg Leu Arg Glu Leu Asp Ile Gly Arg Leu Pro Ala Gly 130 135 140 Ala Leu Arg Gly Leu Gly Gln Leu Lys Glu Leu Glu Ile His Leu Trp 145 150 155 160 Pro Ser Leu Glu Ala Leu Asp Pro Gly Ser Leu Val Gly Leu Asn Leu 165 170 175 Ser Ser Leu Ala Ile Thr Arg Cys Asn Leu Ser Ser Val Pro Phe Gln 180 185 190 Ala Leu Tyr His Leu Ser Phe Leu Arg Val Leu Asp Leu Ser Gln Asn 195 200 205 Pro Ile Ser Ala Ile Pro Ala Arg Arg Leu Ser Pro Leu Val Arg Leu 210 215 220 Gln Glu Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala His 225 230 235 240 Ala Phe His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp Asn 245 250 255 Ala Leu Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys Leu 260 265 270 Val Thr Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg Leu 275 280 285 Leu Trp Leu Leu Arg Leu Arg Arg His Leu Asp Phe Gly Met Ser Pro 290 295 300 Pro Ala Cys Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys Glu 305 310 315 320 Phe Ser Asp Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala Leu 325 330 335 Ile Arg Lys Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly His 340 345 350 Ala Val Phe Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val Ser 355 360 365 Trp Met Arg Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val Arg 370 375 380 Val Leu Glu Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg Asp 385 390 395 400 Arg Gly Ala Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp Ser 405 410 415 Leu Arg Thr Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly Thr 420 425 430 Leu Ser Asp Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe Phe 435 440 445 Leu Asp Ser Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu Pro 450 455 460 Phe Leu Thr Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp Ser 465 470 475 480 Lys Gly Lys Gly Arg Val Lys His His Met Thr Phe Asp Phe Val Ala 485 490 495 Pro Arg Pro Ser Gly Asp Lys Asn Ser Gly Gly Asn Arg Val Thr Ala 500 505 510 Lys Leu Phe 515 93 1780 DNA Homo sapiens CDS (26)..(1772) 93 ccaaccctct gcccggccgg tgccc atg ctt ctg tgg ctg ctg ctg ctg atc 52 Met Leu Leu Trp Leu Leu Leu Leu Ile 1 5 ctg act cct gga aga gaa caa tca ggg gtg gcc cca aaa gct gta ctt 100 Leu Thr Pro Gly Arg Glu Gln Ser Gly Val Ala Pro Lys Ala Val Leu 10 15 20 25 ctc ctc aat cct cca tgg tcc aca gcc ttc aaa gga gaa aaa gtg gct 148 Leu Leu Asn Pro Pro Trp Ser Thr Ala Phe Lys Gly Glu Lys Val Ala 30 35 40 ctc ata tgc agc agc ata tca cat tcc cta gcc cag gga gac aca tat 196 Leu Ile Cys Ser Ser Ile Ser His Ser Leu Ala Gln Gly Asp Thr Tyr 45 50 55 tgg tat cac gat gag aag ttg ttg aaa ata aaa cat gac aag atc caa 244 Trp Tyr His Asp Glu Lys Leu Leu Lys Ile Lys His Asp Lys Ile Gln 60 65 70 att aca gag cct gga aat tac caa tgt aag acc cga gga tcc tcc ctc 292 Ile Thr Glu Pro Gly Asn Tyr Gln Cys Lys Thr Arg Gly Ser Ser Leu 75 80 85 agt gat gcc gtg cat gtg gaa ttt tca cct gac tgg ctg atc ctg cag 340 Ser Asp Ala Val His Val Glu Phe Ser Pro Asp Trp Leu Ile Leu Gln 90 95 100 105 gct tta cat cct gtc ttt gaa gga gac aat gtc att ctg aga tgt cag 388 Ala Leu His Pro Val Phe Glu Gly Asp Asn Val Ile Leu Arg Cys Gln 110 115 120 ggg aaa gac aac aaa aac act cat caa aag gtt tac tac aag gat gga 436 Gly Lys Asp Asn Lys Asn Thr His Gln Lys Val Tyr Tyr Lys Asp Gly 125 130 135 aaa cag ctt cct aat agt tat aat tta gag aag atc aca gtg aat tca 484 Lys Gln Leu Pro Asn Ser Tyr Asn Leu Glu Lys Ile Thr Val Asn Ser 140 145 150 gtc tcc agg gat aat agc aaa tat cat tgt act gct tat agg aag ttt 532 Val Ser Arg Asp Asn Ser Lys Tyr His Cys Thr Ala Tyr Arg Lys Phe 155 160 165 tac ata ctt gac att gaa gta act tca aaa ccc cta aat atc caa gtt 580 Tyr Ile Leu Asp Ile Glu Val Thr Ser Lys Pro Leu Asn Ile Gln Val 170 175 180 185 caa gag ctg ttt cta cat cct gtg ctg aga gcc agc tct tcc acg ccc 628 Gln Glu Leu Phe Leu His Pro Val Leu Arg Ala Ser Ser Ser Thr Pro 190 195 200 ata gag ggg agt ccc atg acc ctg acc tgt gag acc cag ctc tct cca 676 Ile Glu Gly Ser Pro Met Thr Leu Thr Cys Glu Thr Gln Leu Ser Pro 205 210 215 cag agg cca gat gtc cag ctg caa ttc tcc ctc ttc aga gat agc cag 724 Gln Arg Pro Asp Val Gln Leu Gln Phe Ser Leu Phe Arg Asp Ser Gln 220 225 230 acc ctc gga ttg ggc tgg agc agg tcc ccc aga ctc cag atc cct gcc 772 Thr Leu Gly Leu Gly Trp Ser Arg Ser Pro Arg Leu Gln Ile Pro Ala 235 240 245 atg tgg act gaa gac tca ggg tct tac tgg tgt gag gtg gag aca gtg 820 Met Trp Thr Glu Asp Ser Gly Ser Tyr Trp Cys Glu Val Glu Thr Val 250 255 260 265 act cac agc atc aaa aaa agg agc ctg aga tct cag ata cgt gta cag 868 Thr His Ser Ile Lys Lys Arg Ser Leu Arg Ser Gln Ile Arg Val Gln 270 275 280 aga gtc cct gtg tct aat gtg aat cta gag atc cgg ccc acc gga ggg 916 Arg Val Pro Val Ser Asn Val Asn Leu Glu Ile Arg Pro Thr Gly Gly 285 290 295 cag ctg att gaa gga gaa aat atg gtc ctt att tgc tca gta gcc cag 964 Gln Leu Ile Glu Gly Glu Asn Met Val Leu Ile Cys Ser Val Ala Gln 300 305 310 ggt tca ggg act gtc aca ttc tcc tgg cac aaa gaa gga aga gta aga 1012 Gly Ser Gly Thr Val Thr Phe Ser Trp His Lys Glu Gly Arg Val Arg 315 320 325 agc ctg ggt aga aag acc cag cgt tcc ctg ttg gca gag ctg cat gtt 1060 Ser Leu Gly Arg Lys Thr Gln Arg Ser Leu Leu Ala Glu Leu His Val 330 335 340 345 ctc acc gtg aag gag agt gat gca ggg aga tac tac tgt gca gct gat 1108 Leu Thr Val Lys Glu Ser Asp Ala Gly Arg Tyr Tyr Cys Ala Ala Asp 350 355 360 aac gtt cac agc ccc atc ctc agc acg tgg att cga gtc acc gtg aga 1156 Asn Val His Ser Pro Ile Leu Ser Thr Trp Ile Arg Val Thr Val Arg 365 370 375 att ccg gta tct cac cct gtc ctc acc ttc agg gct ccc agg gcc cac 1204 Ile Pro Val Ser His Pro Val Leu Thr Phe Arg Ala Pro Arg Ala His 380 385 390 act gtg gtg ggg gac ctg ctg gag ctt cac tgt gag tcc ctg aga ggc 1252 Thr Val Val Gly Asp Leu Leu Glu Leu His Cys Glu Ser Leu Arg Gly 395 400 405 tct ccc ccg atc ctg tac cga ttt tat cat gag gat gtc acc ctg ggg 1300 Ser Pro Pro Ile Leu Tyr Arg Phe Tyr His Glu Asp Val Thr Leu Gly 410 415 420 425 aac agc tca gcc ccc tct gga gga gga gcc tcc ttc aac ctc tct ctg 1348 Asn Ser Ser Ala Pro Ser Gly Gly Gly Ala Ser Phe Asn Leu Ser Leu 430 435 440 act gca gaa cat tct gga aac tac tcc tgt gat gca gac aat ggc ctg 1396 Thr Ala Glu His Ser Gly Asn Tyr Ser Cys Asp Ala Asp Asn Gly Leu 445 450 455 ggg gcc cag cac agt cat gga gtg agt ctc agg gtc aca gtt ccg gtg 1444 Gly Ala Gln His Ser His Gly Val Ser Leu Arg Val Thr Val Pro Val 460 465 470 tct cgc ccc gtc ctc acc ctc agg gct ccc ggg gcc cag gct gtg gtg 1492 Ser Arg Pro Val Leu Thr Leu Arg Ala Pro Gly Ala Gln Ala Val Val 475 480 485 ggg gac ctg ctg gag ctt cac tgt gag tcc ctg aga ggc tcc ttc ccg 1540 Gly Asp Leu Leu Glu Leu His Cys Glu Ser Leu Arg Gly Ser Phe Pro 490 495 500 505 atc ctg tac tgg ttt tat cac gag gat gac acc ttg ggg aac atc tcg 1588 Ile Leu Tyr Trp Phe Tyr His Glu Asp Asp Thr Leu Gly Asn Ile Ser 510 515 520 gcc cac tct gga gga ggg gca tcc ttc aac ctc tct ctg act aca gaa 1636 Ala His Ser Gly Gly Gly Ala Ser Phe Asn Leu Ser Leu Thr Thr Glu 525 530 535 cat tct gga aac tac tca tgt gag gct gac aat ggc ctg ggg gcc cag 1684 His Ser Gly Asn Tyr Ser Cys Glu Ala Asp Asn Gly Leu Gly Ala Gln 540 545 550 cac agt aaa gtg gtg aca ctc aat gtt aca ggt gtg tta ata gta cct 1732 His Ser Lys Val Val Thr Leu Asn Val Thr Gly Val

Leu Ile Val Pro 555 560 565 ggg cta gag gtc aca gtt atg gta aat aaa ata gtt atc tgacagatt 1780 Gly Leu Glu Val Thr Val Met Val Asn Lys Ile Val Ile 570 575 580 94 582 PRT Homo sapiens 94 Met Leu Leu Trp Leu Leu Leu Leu Ile Leu Thr Pro Gly Arg Glu Gln 1 5 10 15 Ser Gly Val Ala Pro Lys Ala Val Leu Leu Leu Asn Pro Pro Trp Ser 20 25 30 Thr Ala Phe Lys Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser 35 40 45 His Ser Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu 50 55 60 Leu Lys Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr 65 70 75 80 Gln Cys Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu 85 90 95 Phe Ser Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu 100 105 110 Gly Asp Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr 115 120 125 His Gln Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr 130 135 140 Asn Leu Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys 145 150 155 160 Tyr His Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val 165 170 175 Thr Ser Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro 180 185 190 Val Leu Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr 195 200 205 Leu Thr Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu 210 215 220 Gln Phe Ser Leu Phe Arg Asp Ser Gln Thr Leu Gly Leu Gly Trp Ser 225 230 235 240 Arg Ser Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly 245 250 255 Ser Tyr Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg 260 265 270 Ser Leu Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val 275 280 285 Asn Leu Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn 290 295 300 Met Val Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe 305 310 315 320 Ser Trp His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln 325 330 335 Arg Ser Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp 340 345 350 Ala Gly Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu 355 360 365 Ser Thr Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val 370 375 380 Leu Thr Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu 385 390 395 400 Glu Leu His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg 405 410 415 Phe Tyr His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly 420 425 430 Gly Gly Ala Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn 435 440 445 Tyr Ser Cys Asp Ala Asp Asn Gly Leu Gly Ala Gln His Ser His Gly 450 455 460 Val Ser Leu Arg Val Thr Val Pro Val Ser Arg Pro Val Leu Thr Leu 465 470 475 480 Arg Ala Pro Gly Ala Gln Ala Val Val Gly Asp Leu Leu Glu Leu His 485 490 495 Cys Glu Ser Leu Arg Gly Ser Phe Pro Ile Leu Tyr Trp Phe Tyr His 500 505 510 Glu Asp Asp Thr Leu Gly Asn Ile Ser Ala His Ser Gly Gly Gly Ala 515 520 525 Ser Phe Asn Leu Ser Leu Thr Thr Glu His Ser Gly Asn Tyr Ser Cys 530 535 540 Glu Ala Asp Asn Gly Leu Gly Ala Gln His Ser Lys Val Val Thr Leu 545 550 555 560 Asn Val Thr Gly Val Leu Ile Val Pro Gly Leu Glu Val Thr Val Met 565 570 575 Val Asn Lys Ile Val Ile 580 95 1263 DNA Homo sapiens CDS (1)..(1263) 95 aag ctt gga gaa aaa gtg gct ctc ata tgc agc agc ata tca cat tcc 48 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 cta gcc cag gga gac aca tat tgg tat cac gat gag aag ttg ttg aaa 96 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys 20 25 30 ata aaa cat gac aag atc caa att aca gag cct gga aat tac caa tgt 144 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 aag acc cga gga tcc tcc ctc agt gat gcc gtg cat gtg gaa ttt tca 192 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 cct gac tgg ctg atc ctg cag gct tta cat cct gtc ttt gaa gga gac 240 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 aat gtc att ctg aga tgt cag ggg aaa gac aac aaa aac act cat caa 288 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 aag gtt tac tac aag gat gga aaa cag ctt cct aat agt tat aat tta 336 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 gag aag atc aca gtg aat tca gtc tcc agg gat aat agc aaa tat cat 384 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 tgt act gct tat agg aag ttt tac ata ctt gac att gaa gta act tca 432 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 aaa ccc cta aat atc caa gtt caa gag ctg ttt cta cat cct gtg ctg 480 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 aga gcc agc tct tcc acg ccc ata gag ggg agt ccc atg acc ctg acc 528 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 tgt gag acc cag ctc tct cca cag agg cca gat gtc cag ctg caa ttc 576 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 tcc ctc ttc aga gat agc cag acc ctc gga ttg ggc tgg agt agg tcc 624 Ser Leu Phe Arg Asp Ser Gln Thr Leu Gly Leu Gly Trp Ser Arg Ser 195 200 205 ccc aga ctc cag atc cct gcc atg tgg act gaa gac tca ggg tct tac 672 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 tgg tgt gag gtg gag aca gtg act cac agc atc aaa aaa agg agc ctg 720 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 aga tct cag ata cgt gta cag aga gtc cct gtg tct aat gtg aat cta 768 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 gag atc cgg ccc acc gga ggg cag ctg att gaa gga gaa aat atg gtc 816 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 ctt att tgc tca gta gcc cag ggt tca ggg act gtc aca ttc tcc tgg 864 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 cac aaa gaa gga aga gta aga agc ctg ggt aga aag acc cag cgt tcc 912 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 ctg ttg gca gag ctg cat gtt ctc acc gtg aag gag agt gat gca ggg 960 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 aga tac tac tgt gca gct gat aac gtt cac agc ccc atc ctc agc acg 1008 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 tgg att cga gtc acc gtg aga att ccg gta tct cac cct gtc ctc acc 1056 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Leu Thr 340 345 350 ttc agg gct ccc agg gcc cac act gtg gtg ggg gac ctg ctg gag ctt 1104 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 cac tgt gag tcc ctg aga ggc tct ccc ccg atc ctg tac cga ttt tat 1152 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 cat gag gat gtc acc ctg ggg aac agc tca gcc ccc tct gga gga gga 1200 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 gcc tcc ttc aac ctc tct ctg act gca gaa cat tct gga aac tac tca 1248 Ala Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 tgt gag gct ctc gag 1263 Cys Glu Ala Leu Glu 420 96 421 PRT Homo sapiens 96 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys 20 25 30 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 Ser Leu Phe Arg Asp Ser Gln Thr Leu Gly Leu Gly Trp Ser Arg Ser 195 200 205 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Leu Thr 340 345 350 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 Ala Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 Cys Glu Ala Leu Glu 420 97 1263 DNA Homo sapiens CDS (1)..(1263) 97 aag ctt gga gaa aaa gtg gct ctc ata tgc agc agc ata tca cat tcc 48 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 cta gcc cag gga gac aca tat tgg tat cac gat gag aag ttg ttg aaa 96 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys 20 25 30 ata aaa cat gac aag atc caa att aca gag cct gga aat tac caa tgt 144 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 aag acc cga gga tcc tcc ctc agt gat gcc gtg cat gtg gaa ttt tca 192 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 cct gac tgg ctg atc ctg cag gct tta cat cct gtc ttt gaa gga gac 240 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 aat gtc att ctg aga tgt cag ggg aaa gac aac aaa aac act cat caa 288 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 aag gtt tac tac aag gat gga aaa cag ctt cct aat agt tat aat tta 336 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 gag aag atc aca gtg aat tca gtc tcc agg gat aat agc aaa tat cat 384 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 tgt act gct tat agg aag ttt tac ata ctt gac att gaa gta act tca 432 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 aaa ccc cta aat atc caa gtt caa gag ctg ttt cta cat cct gtg ctg 480 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 aga gcc agc tct tcc acg ccc ata gag ggg agt ccc atg acc ctg acc 528 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 tgt gag acc cag ctc tct cca cag agg cca gat gtc cag ctg caa ttc 576 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 tcc ctc ttc aga gat agc cag acc ctc gga ttg ggc tgg agc agg tcc 624 Ser Leu Phe Arg Asp Ser Gln Thr Leu Gly Leu Gly Trp Ser Arg Ser 195 200 205 ccc aga ctc cag atc cct gcc atg tgg act gaa gac tca ggg tct tac 672 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 tgg tgt gag gtg gag aca gtg act cac agc atc aaa aaa agg agc ctg 720 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 aga tct cag ata cgt gta cag aga gtc cct gtg tct aat gtg aat cta 768 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 gag atc cgg ccc acc gga ggg cag ctg att gaa gga gaa aat atg gtc 816 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 ctt att tgc tca gta gcc cag ggt tca ggg act gtc aca ttc tcc tgg 864 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 cac aaa gaa gga aga gta aga agc ctg ggt aga aag acc cag cgt tcc 912 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 ctg ttg gca gag ctg cat gtt ctc acc gtg aag gag agt gat gca ggg 960 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 aga tac tac tgt gca gct gat aac gtt cac agc ccc atc ctc agc acg 1008 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 tgg att cga gtc acc gtg aga att ccg gta tct cac cct gtc ctc acc 1056 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Leu Thr 340 345 350 ttc agg gct ccc agg gcc cac act gtg gtg ggg gac ctg ctg gag ctt 1104 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 cac tgt gag tcc ctg aga ggc tct ccc ccg atc ctg tac cga ttt tat 1152 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 cat gag gat gtc acc ctg ggg aac agc tca gcc ccc tct gga gga gga 1200 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 gcc tcc ttc aac ctc tct ctg act gca gaa cat tct gga aac tac tca 1248 Ala Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 tgt gag gct ctc gag 1263 Cys Glu Ala Leu Glu 420 98 421 PRT Homo sapiens 98 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys

20 25 30 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 Ser Leu Phe Arg Asp Ser Gln Thr Leu Gly Leu Gly Trp Ser Arg Ser 195 200 205 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Leu Thr 340 345 350 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 Ala Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 Cys Glu Ala Leu Glu 420 99 1263 DNA Homo sapiens CDS (1)..(1263) 99 aag ctt gga gaa aaa gtg gct ctc ata tgc agc agc ata tca cat tcc 48 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 cta gcc cag gga gac aca tat tgg tat cac gat gag aag ttg ttg aaa 96 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys 20 25 30 ata aaa cat gac aag atc caa att aca gag cct gga aat tac caa tgt 144 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 aag acc cga gga tcc tcc ctc agt gat gcc gtg cat gtg gaa ttt tca 192 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 cct gac tgg ctg atc ctg cag gct tta cat cct gtc ttt gaa gga gac 240 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 aat gtc att ctg aga tgt cag ggg aaa gac aac aaa aac act cat caa 288 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 aag gtt tac tac aag gat gga aaa cag ctt cct aat agt tat aat tta 336 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 gag aag atc aca gtg aat tca gtc tcc agg gat aat agc aaa tat cat 384 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 tgt act gct tat agg aag ttt tac ata ctt gac att gaa gta act tca 432 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 aaa ccc cta aat atc caa gtt cag gag ctg ttt cta cat cct gtg ctg 480 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 aga gcc agc tct tcc acg ccc ata gag ggg agt ccc atg acc ctg acc 528 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 tgt gag acc cag ctc tct cca cag agg cca gat gtc cag ctg caa ttc 576 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 tcc ctc ttc aga gat agc cag acc ccc gga ttg ggc tgg agc agg tcc 624 Ser Leu Phe Arg Asp Ser Gln Thr Pro Gly Leu Gly Trp Ser Arg Ser 195 200 205 ccc aga ctc cag atc cct gcc atg tgg act gaa gac tca ggg tct tac 672 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 tgg tgt gag gtg gag aca gtg act cac agc atc aaa aaa agg agc ctg 720 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 aga tct cag ata cgt gta cag aga gtc cct gtg tct aat gtg aat cta 768 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 gag atc cgg ccc acc gga ggg cag ctg att gaa gga gaa aat atg gtc 816 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 ctt att tgc tca gta gcc cag ggt tca ggg act gtc aca ttc tcc tgg 864 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 cac aaa gaa gga aga gta aga agc ctg ggt aga aag acc cag cgt tcc 912 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 ctg ttg gca gag ctg cat gtt ctc acc gtg aag gag agt gat gca ggg 960 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 aga tac tac tgt gca gct gat aac gtt cac agc ccc atc ctc agc acg 1008 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 tgg att cga gtc acc gtg aga att ccg gta tct cac cct gtc ccc acc 1056 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Pro Thr 340 345 350 ttc agg gct ccc agg gcc cac act gtg gtg ggg gac ctg ctg gag ctt 1104 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 cac tgt gag tcc ctg aga ggc tct ccc ccg atc ctg tac cga ttt tat 1152 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 cat gag gat gtc acc ctg ggg aac agc tca gcc ccc tct gga gga gga 1200 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 gac tcc ttc aac ctc tct ctg act gca gaa cat tct gga aac tac tca 1248 Asp Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 tgt gag gct ctc gag 1263 Cys Glu Ala Leu Glu 420 100 421 PRT Homo sapiens 100 Lys Leu Gly Glu Lys Val Ala Leu Ile Cys Ser Ser Ile Ser His Ser 1 5 10 15 Leu Ala Gln Gly Asp Thr Tyr Trp Tyr His Asp Glu Lys Leu Leu Lys 20 25 30 Ile Lys His Asp Lys Ile Gln Ile Thr Glu Pro Gly Asn Tyr Gln Cys 35 40 45 Lys Thr Arg Gly Ser Ser Leu Ser Asp Ala Val His Val Glu Phe Ser 50 55 60 Pro Asp Trp Leu Ile Leu Gln Ala Leu His Pro Val Phe Glu Gly Asp 65 70 75 80 Asn Val Ile Leu Arg Cys Gln Gly Lys Asp Asn Lys Asn Thr His Gln 85 90 95 Lys Val Tyr Tyr Lys Asp Gly Lys Gln Leu Pro Asn Ser Tyr Asn Leu 100 105 110 Glu Lys Ile Thr Val Asn Ser Val Ser Arg Asp Asn Ser Lys Tyr His 115 120 125 Cys Thr Ala Tyr Arg Lys Phe Tyr Ile Leu Asp Ile Glu Val Thr Ser 130 135 140 Lys Pro Leu Asn Ile Gln Val Gln Glu Leu Phe Leu His Pro Val Leu 145 150 155 160 Arg Ala Ser Ser Ser Thr Pro Ile Glu Gly Ser Pro Met Thr Leu Thr 165 170 175 Cys Glu Thr Gln Leu Ser Pro Gln Arg Pro Asp Val Gln Leu Gln Phe 180 185 190 Ser Leu Phe Arg Asp Ser Gln Thr Pro Gly Leu Gly Trp Ser Arg Ser 195 200 205 Pro Arg Leu Gln Ile Pro Ala Met Trp Thr Glu Asp Ser Gly Ser Tyr 210 215 220 Trp Cys Glu Val Glu Thr Val Thr His Ser Ile Lys Lys Arg Ser Leu 225 230 235 240 Arg Ser Gln Ile Arg Val Gln Arg Val Pro Val Ser Asn Val Asn Leu 245 250 255 Glu Ile Arg Pro Thr Gly Gly Gln Leu Ile Glu Gly Glu Asn Met Val 260 265 270 Leu Ile Cys Ser Val Ala Gln Gly Ser Gly Thr Val Thr Phe Ser Trp 275 280 285 His Lys Glu Gly Arg Val Arg Ser Leu Gly Arg Lys Thr Gln Arg Ser 290 295 300 Leu Leu Ala Glu Leu His Val Leu Thr Val Lys Glu Ser Asp Ala Gly 305 310 315 320 Arg Tyr Tyr Cys Ala Ala Asp Asn Val His Ser Pro Ile Leu Ser Thr 325 330 335 Trp Ile Arg Val Thr Val Arg Ile Pro Val Ser His Pro Val Pro Thr 340 345 350 Phe Arg Ala Pro Arg Ala His Thr Val Val Gly Asp Leu Leu Glu Leu 355 360 365 His Cys Glu Ser Leu Arg Gly Ser Pro Pro Ile Leu Tyr Arg Phe Tyr 370 375 380 His Glu Asp Val Thr Leu Gly Asn Ser Ser Ala Pro Ser Gly Gly Gly 385 390 395 400 Asp Ser Phe Asn Leu Ser Leu Thr Ala Glu His Ser Gly Asn Tyr Ser 405 410 415 Cys Glu Ala Leu Glu 420 101 360 DNA Homo sapiens CDS (3)..(279) 101 cg ctg ctc ctg ctg ctg ctg gcg ctg tac acc gcg cgt gtg gac ggg 47 Leu Leu Leu Leu Leu Leu Ala Leu Tyr Thr Ala Arg Val Asp Gly 1 5 10 15 tcc aaa tgc aag tgc tcc cgg aag gga ccc aag atc cgc tac agc gac 95 Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp 20 25 30 gtg aag aag ctg gaa atg aag cca aag tac ccg cac tgc gag gag aag 143 Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys 35 40 45 atg gtt atc atc acc acc aag agc gtg tcc agg tac cga ggt cag gag 191 Met Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu 50 55 60 cac tgc ctg cac ccc aag ctg cag agc acc aag cgc ttc atc aag tgg 239 His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp 65 70 75 tac aac gcc tgg aac gag aag cgc agg gtc tac gaa gaa tagggtgaaa 288 Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 80 85 90 aacctcagaa gggaaaactc caaaccagtt gggagacttg tgcaaaggac 338 tttgcagatt aaaaaaaaaa aa 360 102 92 PRT Homo sapiens 102 Leu Leu Leu Leu Leu Leu Ala Leu Tyr Thr Ala Arg Val Asp Gly Ser 1 5 10 15 Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp Val 20 25 30 Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met 35 40 45 Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His 50 55 60 Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr 65 70 75 80 Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 85 90 103 228 DNA Homo sapiens CDS (1)..(228) 103 aaa tgc aag tgc tcc cgg aag gga ccc aag atc cgc tac agc gac gtg 48 Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp Val 1 5 10 15 aag aag ctg gaa atg aag cca aag tac ccg cac tgc gag gag aag atg 96 Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met 20 25 30 gtt atc atc acc acc aag agc gtg tcc agg tac cga ggt cag gag cac 144 Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His 35 40 45 tgc ctg cac ccc aag ctg cag agc acc aag cgc ttc atc aag tgg tac 192 Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr 50 55 60 aac gcc tgg aac gag aag cgc agg gtc tac gaa gaa 228 Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 65 70 75 104 76 PRT Homo sapiens 104 Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp Val 1 5 10 15 Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met 20 25 30 Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His 35 40 45 Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr 50 55 60 Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 65 70 75 105 228 DNA Homo sapiens CDS (1)..(228) 105 aaa tgc aag tgc tcc cgg aag gga ccc aag atc cgc tac agc gac gtg 48 Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp Val 1 5 10 15 aag aag ctg gaa atg aag cca aag tac ccg cac tgc gag gag aag atg 96 Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met 20 25 30 gtt atc atc acc acc aag agc gtg tcc agg tac cga ggt cag gag cac 144 Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His 35 40 45 tgc ctg cac ccc aag ctg cag agc acc aag cgc ttc atc aag tgg tac 192 Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr 50 55 60 aac gcc tgg aac gag aag cgc agg gtc tac gaa gaa 228 Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 65 70 75 106 76 PRT Homo sapiens 106 Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp Val 1 5 10 15 Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys Met 20 25 30 Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu His 35 40 45 Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp Tyr 50 55 60 Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu 65 70 75 107 619 DNA Homo sapiens CDS (1)..(604) 107 gct gcc tgc ctc ctc atg ttc ccc tcc acc aca gcg gac tgc ctg tcg 48 Ala Ala Cys Leu Leu Met Phe Pro Ser Thr Thr Ala Asp Cys Leu Ser 1 5 10 15 cgg tgc tcc ttg tgt gct gta aag acc cag gat ggt ccc aaa cct atc 96 Arg Cys Ser Leu Cys Ala Val Lys Thr Gln Asp Gly Pro Lys Pro Ile 20 25 30 aat ccc ctg att tgc tcc ctg caa tgc cag gct gcc ctg ctg ccc tct 144 Asn Pro Leu Ile Cys Ser Leu Gln Cys Gln Ala Ala Leu Leu Pro Ser 35 40 45 gag gaa tgg gag aga tgc cag agc ttt ctg tct ttt ttc acc ccc tcc 192 Glu Glu Trp Glu Arg Cys Gln Ser Phe Leu Ser Phe Phe Thr Pro Ser 50 55 60 acc ctt ggg ctc aat gac aag gag gac ttg ggg agc aag tcg gtt ggg 240 Thr Leu Gly Leu Asn Asp Lys Glu Asp Leu Gly Ser Lys Ser Val Gly 65 70 75 80 gaa ggg ccc tac agt gag ctg gcc aag ctc tct ggg tca ttc ctg aag 288 Glu Gly Pro Tyr Ser Glu Leu Ala Lys Leu Ser Gly Ser Phe Leu Lys 85 90 95 gag ctg aac gat ggt gcc atg gag act ggc aca ctc tat ctc gct gag 336 Glu Leu Asn Asp Gly Ala Met Glu Thr Gly Thr Leu Tyr Leu Ala Glu 100 105 110 gag gac ccc aag gag cag gtc aaa cgc tat ggg ggc ttt ttg cgc aaa 384 Glu Asp Pro Lys Glu Gln Val Lys Arg Tyr Gly Gly Phe Leu Arg Lys 115 120 125 tac ccc aag agg agc tca gag gtg gct ggg gag ggg gac ggg gat agc 432 Tyr Pro Lys Arg Ser Ser Glu Val Ala Gly Glu Gly Asp Gly Asp Ser 130 135 140 atg ggc cat gag gac ctg tac aaa cgc tat ggg ggc ttc ttg cgg cgc 480 Met Gly

His Glu Asp Leu Tyr Lys Arg Tyr Gly Gly Phe Leu Arg Arg 145 150 155 160 att cgt ccc aag ctc aag tgg gac aac cag aag cgc tat ggc ggt ttt 528 Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln Lys Arg Tyr Gly Gly Phe 165 170 175 ctc cgg cgc cag ttc aag gtg gtg act cgg tct cag gaa gat ccg aat 576 Leu Arg Arg Gln Phe Lys Val Val Thr Arg Ser Gln Glu Asp Pro Asn 180 185 190 gct tac tct gga gag ctt ttt gat gca taagcacttc ttttca 619 Ala Tyr Ser Gly Glu Leu Phe Asp Ala 195 200 108 201 PRT Homo sapiens 108 Ala Ala Cys Leu Leu Met Phe Pro Ser Thr Thr Ala Asp Cys Leu Ser 1 5 10 15 Arg Cys Ser Leu Cys Ala Val Lys Thr Gln Asp Gly Pro Lys Pro Ile 20 25 30 Asn Pro Leu Ile Cys Ser Leu Gln Cys Gln Ala Ala Leu Leu Pro Ser 35 40 45 Glu Glu Trp Glu Arg Cys Gln Ser Phe Leu Ser Phe Phe Thr Pro Ser 50 55 60 Thr Leu Gly Leu Asn Asp Lys Glu Asp Leu Gly Ser Lys Ser Val Gly 65 70 75 80 Glu Gly Pro Tyr Ser Glu Leu Ala Lys Leu Ser Gly Ser Phe Leu Lys 85 90 95 Glu Leu Asn Asp Gly Ala Met Glu Thr Gly Thr Leu Tyr Leu Ala Glu 100 105 110 Glu Asp Pro Lys Glu Gln Val Lys Arg Tyr Gly Gly Phe Leu Arg Lys 115 120 125 Tyr Pro Lys Arg Ser Ser Glu Val Ala Gly Glu Gly Asp Gly Asp Ser 130 135 140 Met Gly His Glu Asp Leu Tyr Lys Arg Tyr Gly Gly Phe Leu Arg Arg 145 150 155 160 Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln Lys Arg Tyr Gly Gly Phe 165 170 175 Leu Arg Arg Gln Phe Lys Val Val Thr Arg Ser Gln Glu Asp Pro Asn 180 185 190 Ala Tyr Ser Gly Glu Leu Phe Asp Ala 195 200 109 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 109 tcttccagaa ggacatcaac tg 22 110 26 DNA Artificial Sequence Description of Artificial Sequence probe 110 cagcttcatc cacttgagtt tccagg 26 111 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 111 cccctcgtcc aggatatagt ac 22 112 30 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 112 gtagtgaagc aggatagttc ataaatagaa 30 113 26 DNA Artificial Sequence Description of Artificial Sequence probe 113 agtggaagcg ccttctcatc cttcat 26 114 18 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 114 gcagtggtca cgtttgga 18 115 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 115 gtgaggcggc agatcttc 18 116 25 DNA Artificial Sequence Description of Artificial Sequence probe 116 agctgaatca tctgcagcct gcatt 25 117 18 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 117 attcccaggc atgatgct 18 118 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 118 gtgaggcggc agatcttc 18 119 25 DNA Artificial Sequence Description of Artificial Sequence probe 119 agctgaatca tctgcagcct gcatt 25 120 18 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 120 attcccaggc atgatgct 18 121 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 121 gtgaggcggc agatcttc 18 122 25 DNA Artificial Sequence Description of Artificial Sequence probe 122 agctgaatca tctgcagcct gcatt 25 123 18 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 123 attcccaggc atgatgct 18 124 23 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 124 acaacgagac caaacaggtg act 23 125 22 DNA Artificial Sequence Description of Artificial Sequence probe 125 tcaagctgcc caactgtgcc cc 22 126 20 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 126 ggccacggga taggtgtaga 20 127 23 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 127 acaacgagac caaacaggtg act 23 128 22 DNA Artificial Sequence Description of Artificial Sequence probe 128 caactgtgcc ccgggagtcg ac 22 129 20 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 129 ggccacggga taggtgtaga 20 130 21 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 130 actctcggag gaggacattt t 21 131 23 DNA Artificial Sequence Description of Artificial Sequence probe 131 cagtcccctg tgtccctctg ctg 23 132 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 132 cactggagat agcagacaga ca 22 133 21 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 133 actctcggag gaggacattt t 21 134 23 DNA Artificial Sequence Description of Artificial Sequence probe 134 cagtcccctg tgtccctctg ctg 23 135 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 135 cactggagat agcagacaga ca 22 136 19 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 136 ccagccccaa gtcctggat 19 137 24 DNA Artificial Sequence Description of Artificial Sequence probe 137 aaccttggtg tccactgggc caca 24 138 20 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 138 atcatggctg agccctgagt 20 139 20 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 139 ggtcatggtc ctggagaagt 20 140 25 DNA Artificial Sequence Description of Artificial Sequence probe 140 acctggcagc cctaccagtt ctacg 25 141 19 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 141 acataccgaa ggcctccat 19 142 19 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 142 ggcagggatg aaactgtca 19 143 26 DNA Artificial Sequence Description of Artificial Sequence probe 143 ccttggcccc aatgtagaga acactg 26 144 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 144 ctcccgtgac atacactttg ac 22 145 20 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 145 catggagact cccctttgac 20 146 26 DNA Artificial Sequence Description of Artificial Sequence probe 146 cctgaaggag gtcaccatct cattga 26 147 21 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 147 cggatcttgg acttcaatct c 21 148 21 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 148 tgggacaaag aaagagacca a 21 149 24 DNA Artificial Sequence Description of Artificial Sequence probe 149 ttgctgacgc ctgtgatcct cact 24 150 19 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 150 caagggctga gtggagaag 19 151 20 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 151 cttcatccgc ttctccaaat 20 152 26 DNA Artificial Sequence Description of Artificial Sequence probe 152 cctgaaaacc acatcgtctt ccctgt 26 153 21 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 153 ctcatccaga ctggccatta c 21 154 20 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 154 ggagaacttc atccgcttct 20 155 26 DNA Artificial Sequence Description of Artificial Sequence probe 155 cctgaaaacc acatcgtctt ccctgt 26 156 21 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 156 ctcatccaga ctggccatta c 21 157 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 157 cctttgacgt tgaaaggtac ag 22 158 26 DNA Artificial Sequence Description of Artificial Sequence probe 158 tcaagttgga cagcacttta cctttg 26 159 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 159 tctgcagaat ccaaatctct gt 22 160 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 160 gattgcaacg ctgaagttta tg 22 161 26 DNA Artificial Sequence Description of Artificial Sequence probe 161 ctgtcaactg tcaaccactg ggaatg 26 162 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 162 gaggcctttt catcagtgag at 22 163 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 163 aatcttcact ccaggcacat ag 22 164 24 DNA Artificial Sequence Description of Artificial Sequence probe 164 acctctgcca gcaaccttga gagg 24 165 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 165 tcccatcttt cttcttgtcc tt 22 166 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 166 acgcagagcc caggtttt 18 167 27 DNA Artificial Sequence Description of Artificial Sequence probe 167 tcacctttcc gatcatcacg aataggg 27 168 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 168 cgcaggacct taggtgacta gt 22 169 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 169 gattgcaacg ctgaagttta tg 22 170 26 DNA Artificial Sequence Description of Artificial Sequence probe 170 ctgtcaactg tcaaccactg ggaatg 26 171 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 171 gaggcctttt catcagtgag at 22 172 19 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 172 acagagcatt tggcaagct 19 173 27 DNA Artificial Sequence Description of Artificial Sequence probe 173 cagtactaca ccttctgcac agacaca 27 174 20 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 174 gttggccctt ctgtcttctc 20 175 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 175 cagccactgg agaatgca 18 176 27 DNA Artificial Sequence Description of Artificial Sequence probe 176 agcagtacga aattctccgt ggctacc 27 177 18 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 177 gaatgggctc caggtctg 18 178 18 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 178 acgcagagcc caggtttt 18 179 27 DNA Artificial Sequence Description of Artificial Sequence probe 179 cacctttccg atcatcacga atagggg 27 180 25 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 180 gggtggactt acagttgttt cttct 25 181 24 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 181 ctttacttca tgcacttcaa cttg 24 182 30 DNA Artificial Sequence Description of Artificial Sequence probe 182 cctcctacct ttgtgaatat gactatgtga 30 183 23 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 183 actctcgaag tgtcctcagt ttc 23 184 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 184 ttttaaaggg acccactact gg 22 185 25 DNA Artificial Sequence Description of Artificial Sequence probe 185 ctggcatagc tggcccattg ctcat 25 186 19 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 186 gaaaaggcag catccactg 19 187 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 187 agaccaaggc cactacaaat gt 22 188 23 DNA Artificial Sequence Description of Artificial Sequence probe 188 cacagatgcc actgtccagg gaa 23 189 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 189 acctgcactg tgtcctcata gt 22 190 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 190 tcacatgacc tttgactttg tg 22 191 23 DNA Artificial Sequence Description of Artificial Sequence probe 191 acctcggccc tctggggata aaa 23 192 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 192 gaaggaaagg tcagaagagc tt 22 193 21 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 193 cctcaaggtg accagtttgt c 21 194 26 DNA Artificial Sequence Description of Artificial Sequence probe 194 cgcccttcag acactagagg aaacag 26 195 20 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 195 ctcctggatg tggcagataa 20 196 22 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 196 agagcctgga aattaccaat gt 22 197 26 DNA Artificial Sequence Description of Artificial Sequence probe 197 agacccgagg atcctccctc agtgat 26 198 22 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 198 cagtcaggtg aaaattccac at 22 199 19 DNA Artificial Sequence Description of Artificial Sequence Forward Primer 199 ccaagagcgt gtccaggta 19 200 25 DNA Artificial Sequence Description of Artificial Sequence probe 200 agagcaccaa gcgcttcatc aagtg 25 201 19 DNA Artificial Sequence Description of Artificial Sequence Reverse Primer 201 ctcgttccag gcgttgtac 19

Claims

1. An isolated polypeptide comprising an amino acid sequenced selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 54

2. An isolated polypeptide comprising a mature form of the amino acid sequence of claim 1.

3. (canceled)

4. An isolated polypeptide comprising an amino acid sequence having one or more conservative substitutions in the amino acid sequence of claim 1.

5. (canceled)

6. A composition comprising the polypeptide of claim 1 and a carrier.

7.-19. (canceled)

20. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide of claim 1.

21. (canceled)

22. A nucleic acid molecule, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence of claim 20.

23. An isolated nucleic acid molecule encoding the polypeptide of claim 2.

24. (canceled)

25. (canceled)

26. A vector comprising the nucleic acid molecule of claim 20.

27. (canceled)

28. A cell comprising the vector of claim 26.

29. An antibody that immunospecifically binds to the polypeptide of claim 1.

30. The antibody of claim 29, wherein the antibody is a monoclonal antibody.

31. The antibody of claim 29, wherein the antibody is a humanized antibody.

32.-40. (canceled)

41. A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 54.

42.-45. (canceled)

46. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 48.

47. The isolated polypeptide of claim 46 consisting of amino acid sequence of SEQ ID NO: 48.

48. An isolated polypeptide comprising an amino acid sequence having one or more conservative substitutions to SEQ ID NO: 48.

49. An isolated polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 48.

50. A pharmaceutical composition comprising the polypeptide of claim 46, and a pharmaceutically acceptable carrier.

51. A pharmaceutical composition comprising the polypeptide of claim 48, and a pharmaceutically acceptable carrier.

52. A pharmaceutical composition comprising the polypeptide of claim 49, and a pharmaceutically acceptable carrier.